Biaryl amide compounds as kinase inhibitors

ABSTRACT

The present invention provides compounds of Formula (I) 
     
       
         
         
             
             
         
       
     
     as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

RELATED APPLICATIONS

This application is a Divisional of U.S. patent application Ser. No.15/601,423, filed on May 22, 2017, which is a Divisional of U.S. patentapplication Ser. No. 14/774,431, filed on Sep. 10, 2015, now U.S. Pat.No. 9,694,016, which is a 371 of international applicationPCT/US2014/026107, filed on Mar. 13, 2014, which claims benefit ofprovisional U.S. Application No. 61/783,558, filed on Mar. 14, 2013. Theentire contents of these applications are incorporated herein byreference in their entireties.

FIELD OF THE INVENTION

The invention provides compounds that inhibit Raf kinases, and areaccordingly useful for treating certain disorders associated withexcessive Raf kinase activity, including cell proliferation disorderssuch as cancers. The invention further provides pharmaceuticalcompositions containing these compounds and methods of using thesecompounds to treat conditions including cancer.

BACKGROUND

Protein Kinases are involved in very complex signaling cascades thatregulate most cellular functions, including cell survival andproliferation. These signaling pathways have been heavily studied,particularly in the context of disorders caused by dysregulated cellularfunction, such as cancer. The mitogen-activated protein kinase (MAPK)cascade has been studied extensively, for example, and kinases in thispathway (e.g., RAS, RAF, MEK, and ERK) have been exploited as targetsites for drug discovery. Mutated B-Raf is found in a significantfraction of malignancies (over 30% of all tumors and 40% of melanomas),and several drug candidates that inhibit a common B-Raf mutant (V600E,an activating mutation found in many cancers, particularly in cutaneousmalignant melanoma, thyroid cancer, colorectal cancer, and ovariancancer) have been reported, including GDC-0879, PLX4032, and PLX4720,while other inhibitors targeting C-Raf or B-Raf (or both) includesorafenib, XL281 RAF265, and BAY43-9006. These examples demonstrate thatcompounds that inhibit B-Raf or C-Raf are useful to treat variouscancers.

The MAPK signaling cascade includes RAS, Raf, MEK and ERK kinases, eachof which is actually a group of related proteins. Because they functioncollectively as a signal transduction cascade, the number of distinctkinases and their varying substrate specificities create a complex andhighly branched pathway. Roskoski, Biochem. Biophys. Res. Comm., 399,313-17 (2010). Raf, for example, consists of monomers referred to asA-Raf, B-Raf, and C-Raf (also called Raf-1), each of which functionsprimarily as a dimer. The RAF complex includes heterodimers as well ashomodimers of these three species, bringing the total number of dimericspecies in the Raf group to six, and each of these has a number of siteswhere phosphorylation at serine, threonine or tyrosine can cause eitheractivation or inhibition. Matallanas, et al., Genes and Cancer 2:232(2011, published online 10 May 2011). Due to the complexity of thepathway and its regulation, it has been reported that inhibitors ofB-Raf can cause paradoxical activation of the pathway, apparently due toconformational effects on the kinase domain of Raf that affectdimerization, membrane localization, and interaction with RAS-GTP.Hatzivassiliou, et al., Nature, vol. 464, 431-36 (18 Mar. 2010). Inparticular, ATP-competitive inhibitors can exhibit opposing effects onthe signaling pathway, as either inhibitors or activators, depending onthe cellular context. As a result, B-Raf inhibitors effective againsttumors having the activating B-Raf mutation V600E may not be aseffective as expected in tumors having wild-type B-Raf or KRasmutations. Id.

SUMMARY OF THE INVENTION

The present invention provides novel inhibitors of Raf kinases,including A-Raf, B-Raf and/or C-Raf, and use of these compounds to treatdisorders associated with excessive or undesired levels of Raf activity,such as certain cancers. The compounds of the invention minimizeundesired pathway activation effects, and thus can be more efficaciousand more predictable in vivo than the B-Raf inhibitors that causeparadoxical pathway activation even when they have similar in vitropotency. The compounds of the invention bind in a DFG-out mode, makingthem type 2 inhibitors, which have been reported to be less prone toinduce paradoxical activation. They are also quite different instructure from known type 2 inhibitors like sorafenib and RAF265. J.Med. Chem. 2012, vol. 55, 3452-78. The compounds are thus suited fortreatment of BRaf wild-type and KRas mutant tumors, as well as B-RafV600E mutant tumors.

In one aspect, the invention provides compounds of the formula (I):

as further described herein, including the pharmaceutically acceptablesalts of these compounds. The compounds of Formula (I) are inhibitors ofRaf kinases as shown by data herein, and are accordingly useful to treatconditions such as melanoma, breast cancer, sarcoma, GI tumors such asgastrointestinal stromal tumors, ovarian cancer, sarcoma, GI tumors suchas gastrointestinal stromal tumors, and other malignancies associatedwith excessive Raf pathway activity, particularly in cancers driven byRas mutations. In addition, the compounds of the invention exhibit lowlevels of paradoxical activation of the Raf pathway.

In another aspect, the invention provides pharmaceutical compositionscomprising a compound of Formula (I) admixed with at least onepharmaceutically acceptable carrier or excipient, optionally admixedwith two or more pharmaceutically acceptable carriers or excipients. Inaddition, the invention includes combinations of a compound of Formula(I) with a co-therapeutic agent, optionally including one or morepharmaceutically acceptable carriers, and methods of treatment using acompound of Formula (I) in combination with a co-therapeutic agent.Suitable co-therapeutic agents for use in the invention include, forexample, cancer chemotherapeutics including but not limited toinhibitors of PI3K, other inhibitors of the Raf pathway, paclitaxel,docetaxel, temozolomide, platins, doxorubicins, vinblastins,cyclophosphamide, topotecan, gemcitabine, ifosfamide, etoposide,irinotecan, and the like.

In another aspect, the invention provides a method to treat a conditioncharacterized by excessive or undesired levels of activity of Raf,especially B-Raf and/or C-Raf, which comprises administering to asubject in need of such treatment an effective amount of a compound ofFormula (I) or any subgenus thereof as described herein, or apharmaceutical composition comprising such compound. The subject can bea mammal, and is preferably a human. Conditions treatable by thecompounds and methods described herein include various forms of cancer,such as solid tumors, melanoma, breast cancer, lung cancer (e.g.,non-small cell lung cancer), sarcoma, GI tumors such as gastrointestinalstromal tumors, ovarian cancer, colorectal cancer, thyroid cancer, andpancreatic cancer. The invention thus includes compounds of Formula (I)and the subgenera thereof that are disclosed herein, including eachspecies disclosed herein, for use in therapy, particularly for use totreat cancers such as melanoma, breast cancer, lung cancer, livercancer, sarcoma, GI tumors such as gastrointestinal stromal tumors,sarcoma, GI tumors such as gastrointestinal stromal tumors, ovariancancer, colorectal cancer, thyroid cancer, and pancreatic cancer. Theinvention also includes use of such compounds for manufacture of amedicament for treating these conditions.

The invention includes compounds of Formula (I) and the subgenera ofFormula (I) described herein, and all stereoisomers (includingdiastereoisomers and enantiomers), tautomers and isotopically enrichedversions thereof (including deuterium substitutions), as well aspharmaceutically acceptable salts of these compounds. In particular,where a heteroaryl ring containing N as a ring atom is optionallysubstituted with hydroxyl, e.g., a 2-hydroxypyridine ring, tautomerswhere the hydroxyl is depicted as a carbonyl (e.g., 2-pyridone) areincluded. Compounds of the present invention also comprise polymorphs ofcompounds of formula I (or sub-formulae thereof) and salts thereof.

DETAILED DESCRIPTION

The following definitions apply unless otherwise expressly provided.

As used herein, the term “halogen” (or halo) refers to fluorine,bromine, chlorine or iodine, in particular fluorine or chlorine.Halogen-substituted groups and moieties, such as alkyl substituted byhalogen (haloalkyl) can be mono-, poly- or per-halogenated.

As used herein, the term “hetero atoms” refers to nitrogen (N), oxygen(O) or sulfur (S) atoms, in particular nitrogen or oxygen, unlessotherwise provided.

As used herein, the term “alkyl” refers to a fully saturated branched orunbranched hydrocarbon moiety having up to 20 carbon atoms. Unlessotherwise provided, alkyl refers to hydrocarbon moieties having 1 to 10carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. Typically,alkyl groups have 1-6 carbon atoms. “Lower alkyl” refers to alkyl groupshaving 1-4 carbon atoms. Representative examples of alkyl include, butare not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl,sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl,n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl,n-heptyl, n-octyl, n-nonyl, n-decyl and the like.

A substituted alkyl is an alkyl group containing one or moresubstituents in place of hydrogen, such as one, two or threesubstituents, or 1-4 substituents, up to the number of hydrogens presenton the unsubstituted alkyl group. Suitable substituents for alkylgroups, if not otherwise specified, may be selected from halogen, CN,oxo, hydroxy, substituted or unsubstituted C₁₋₄ alkoxy, substituted orunsubstituted C₃₋₆ cycloalkyl, substituted or unsubstituted C₃₋₆heterocycloalkyl, substituted or unsubstituted phenyl, amino, (C₁₋₄alkyl)amino, di(C₁₋₄ alkyl)amino, C₁₋₄ alkylthio, C₁₋₄ alkylsulfonyl,—C(═O)— C₁₋₄ alkyl, COOH, COO(C₁₋₄ alkyl), —O(C═O)— C₁₋₄ alkyl,—NHC(═O)C₁₋₄ alkyl and —NHC(═O)OC₁₋₄ alkyl groups; wherein thesubstituents for substituted C₁₋₄ alkoxy, substituted C₃₋₆ cycloalkyl,C₃₋₆ heterocycloalkyl, and substituted phenyl are up to three groupsselected from halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, amino,hydroxy, and CN. Preferred substituents for alkyl groups includehalogen, CN, oxo, hydroxy, C₁₋₄ alkoxy, C₃₋₆ cycloalkyl, phenyl, amino,(C₁₋₄ alkyl)amino, di(C₁₋₄ alkyl)amino, C₁₋₄ alkylthio, C₁₋₄alkylsulfonyl, —C(═O)— C₁₋₄ alkyl, COOH, —COO(C₁₋₄ alkyl), —O(C═O)— C₁₋₄alkyl, —NHC(═O) C₁₋₄ alkyl and —NHC(═O)O C₁₋₄ alkyl groups.

As used herein, the term “alkylene” refers to a divalent alkyl grouphaving 1 to 10 carbon atoms, and two open valences to attach to otherfeatures. Unless otherwise provided, alkylene refers to moieties having1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms.Representative examples of alkylene include, but are not limited to,methylene, ethylene, n-propylene, iso-propylene, n-butylene,sec-butylene, iso-butylene, tert-butylene, n-pentylene, isopentylene,neopentylene, n-hexylene, 3-methylhexylene, 2,2-dimethylpentylene,2,3-dimethylpentylene, n-heptylene, n-octylene, n-nonylene, n-decyleneand the like. A substituted alkylene is an alkylene group containing oneor more, such as one, two or three substituents; unless otherwisespecified, suitable and preferred substituents are selected from thesubstituents described as suitable and preferred for alkyl groups.

As used herein, the term “haloalkyl” refers to an alkyl as definedherein, which is substituted by one or more halo groups as definedherein. The haloalkyl can be monohaloalkyl, dihaloalkyl, trihaloalkyl,or polyhaloalkyl including perhaloalkyl. A monohaloalkyl can have oneiodo, bromo, chloro or fluoro within the alkyl group. Chloro and fluoroare preferred on alkyl or cycloalkyl groups; fluoro, chloro and bromoare often preferred on aryl or heteroaryl groups. Dihaloalkyl andpolyhaloalkyl groups can have two or more of the same halo atoms or acombination of different halo groups within the alkyl. Typically thepolyhaloalkyl contains up to 12, or 10, or 8, or 6, or 4, or 3, or 2halo groups. Non-limiting examples of haloalkyl include fluoromethyl,difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,trichloromethyl, pentafluoroethyl, heptafluoropropyl,difluorochloromethyl, dichlorofluoromethyl, difluoroethyl,difluoropropyl, dichloroethyl and dichloropropyl. A perhalo-alkyl refersto an alkyl having all hydrogen atoms replaced with halo atoms, e.g,trifluoromethyl.

As used herein, the term “alkoxy” refers to alkyl-O—, wherein alkyl isdefined above. Representative examples of alkoxy include, but are notlimited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy,pentyloxy, hexyloxy, and the like. Typically, alkoxy groups have 1-10,or 1-6 carbons, more commonly 1-4 carbon atoms.

A “substituted alkoxy” is an alkoxy group containing one or more, suchas one, two or three substituents on the alkyl portion of the alkoxy.Unless otherwise specified, suitable and preferred substituents areselected from the substituents listed above for alkyl groups, exceptthat hydroxyl and amino are not normally present on the carbon that isdirectly attached to the oxygen of the substituted ‘alkyl-O’ group.

Similarly, each alkyl part of other groups like “alkylaminocarbonyl”,“alkoxyalkyl”, “alkoxycarbonyl”, “alkoxy-carbonylalkyl”,“alkylsulfonyl”, “alkylsulfoxyl”, “alkylamino”, “haloalkyl” shall havethe same meaning as described in the above-mentioned definition of“alkyl”. When used in this way, unless otherwise indicated, the alkylgroup is often a 1-4 carbon alkyl and is not further substituted bygroups other than the component named. When such alkyl groups aresubstituted, suitable substituents are selected from the suitable orpreferred substituents named above for alkyl groups unless otherwisespecified.

As used herein, the term “haloalkoxy” refers to haloalkyl-O—, whereinhaloalkyl is defined above. Representative examples of haloalkoxyinclude, but are not limited to, fluoromethoxy, difluoromethoxy,trifluoromethoxy, trichloromethoxy, 2-chloroethoxy,2,2,2-trifluoroethoxy, 1,1,1,3,3,3-hexafluoro-2-propoxy, and the like.Typically, haloalkyl groups have 1-4 carbon atoms.

As used herein, the term “cycloalkyl” refers to saturated or unsaturatednon-aromatic monocyclic, bicyclic, tricyclic or spirocyclic hydrocarbongroups of 3-12 carbon atoms: the cycloalkyl group may be unsaturated,and may be fused to another ring that can be saturated, unsaturated oraromatic, provided the ring atom of the cycloalkyl group that isconnected to the molecular formula of interest is not an aromatic ringatom. Unless otherwise provided, cycloalkyl refers to cyclic hydrocarbongroups having between 3 and 9 ring carbon atoms or between 3 and 7 ringcarbon atoms. Preferably, cycloalkyl groups are saturated monocyclicrings having 3-7 ring atoms unless otherwise specified.

A substituted cycloalkyl is a cycloalkyl group substituted by one, ortwo, or three, or more than three substituents, up to the number ofhydrogens on the unsubstituted group. Typically, a substitutedcycloalkyl will have 1-4 or 1-2 substituents. Suitable substituents,unless otherwise specified, are independently selected from the groupconsisting of halogen, hydroxyl, thiol, cyano, nitro, oxo,C₁₋₄-alkylimino, C₁₋₄-alkoximino, hydroxyimino, C₁₋₄-alkyl,C₂₋₄-alkenyl, C₂₋₄-alkynyl, C₁₋₄-alkoxy, C₁₋₄-thioalkyl,C₂₋₄-alkenyloxy, C₂₋₄-alkynyloxy, C₁₋₄-alkylcarbonyl, carboxy,C₁₋₄-alkoxycarbonyl, amino, C₁₋₄-alkylamino, di-C₁₋₄-alkylamino,C₁₋₄-alkylaminocarbonyl, di-C₁₋₄-alkylaminocarbonyl,C₁₋₄-alkylcarbonylamino, C₁₋₄-alkylcarbonyl(C₁₋₄-alkyl)amino,C₁₋₄-alkylsulfonyl, C₁₋₄-alkylsulfamoyl, and C₁₋₄-alkylaminosulfonyl,where each of the aforementioned hydrocarbon groups (e.g., alkyl,alkenyl, alkynyl, alkoxy residues) may be further substituted by one ormore groups independently selected at each occurrence from the list ofsubstituents for ‘alkyl’ groups herein. Preferred substituents includeC₁₋₄ alkyl and the substituent groups listed above as preferredsubstituents for alkyl groups.

Exemplary monocyclic hydrocarbon groups include, but are not limited to,cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl andcyclohexenyl and the like. Exemplary bicyclic hydrocarbon groups includebornyl, indyl, hexahydroindyl, tetrahydronaphthyl, decahydronaphthyl,bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl,6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl,bicyclo[2.2.2]octyl and the like. Exemplary tricyclic hydrocarbon groupsinclude adamantyl and the like.

Similarly, each cycloalkyl part of other groups like “cycloalkyloxy”,“cycloalkoxyalkyl”, “cycloalkoxycarbonyl”, “cycloalkoxy-carbonylalkyl”,“cycloalkylsulfonyl”, “halocycloalkyl” shall have the same meaning asdescribed in the above-mentioned definition of “cycloalkyl”. When usedin these terms, the cycloalkyl is typically a monocyclic 3-7 carbonring, that is unsubstituted or substituted with 1-2 groups. Whenoptionally substituted, the substituents are typically selected fromC₁₋₄ alkyl and those set forth above as suitable or preferredsubstituents for alkyl groups.

As used herein, the term “aryl” refers to an aromatic hydrocarbon grouphaving 6-14 carbon atoms in the ring portion. Typically, aryl ismonocyclic, bicyclic or tricyclic aryl having 6-14 carbon atoms, often6-10 carbon atoms, e.g., phenyl or naphthyl. Furthermore, the term“aryl” as used herein, refers to an aromatic substituent which can be asingle aromatic ring, or multiple aromatic rings that are fusedtogether. Non-limiting examples include phenyl, naphthyl and1,2,3,4-tetrahydronaphthyl, provided the tetrahydronaphthyl is connectedto the formula being described through a carbon of the aromatic ring ofthe tetrahydronaphthyl group.

A substituted aryl is an aryl group substituted by 1-5 (such as one, ortwo, or three) substituents independently selected from the groupconsisting of hydroxyl, thiol, cyano, nitro, C₁₋₄-alkyl, C₂₋₄-alkenyl,C₂₋₄-alkynyl, C₁₋₄-alkoxy, C₁₋₄-thioalkyl, C₂₋₄-alkenyloxy,C₂₋₄-alkynyloxy, halogen, C₁₋₄-alkylcarbonyl, carboxy,C₁₋₄-alkoxycarbonyl, amino, C₁₋₄-alkylamino, di-C₁₋₄-alkylamino,C₁₋₄-alkylaminocarbonyl, di-C₁₋₄-alkylaminocarbonyl,C₁₋₄-alkylcarbonylamino, C₁₋₄-alkylcarbonyl(C₁₋₄-alkyl)amino,C₁₋₄-alkylsulfonyl, sulfamoyl, C₁₋₄-alkylsulfamoyl, andC₁₋₄-alkylaminosulfonyl where each of the afore-mentioned hydrocarbongroups (e.g., alkyl, alkenyl, alkynyl, alkoxy residues) may be furthersubstituted by one or more groups independently selected at eachoccurrence from the groups listed above as suitable substituents foralkyl groups. Preferred substituents for a substituted aryl group areC₁₋₄ alkyl, halogen, CN, hydroxy, substituted or unsubstituted C₁₋₄alkyl, substituted or unsubstituted C₁₋₄ alkoxy, substituted orunsubstituted C₃₋₆ cycloalkyl, substituted or unsubstituted C₃₋₆heterocycloalkyl, amino, (C₁₋₄ alkyl)amino, di(C₁₋₄ alkyl)amino, C₁₋₄alkylthio, C₁₋₄ alkylsulfonyl, —C(═O)— C₁₋₄ alkyl, COOH, COO(C₁₋₄alkyl), —O(C═O)— C₁₋₄ alkyl, —NHC(═O)C₁₋₄ alkyl and —NHC(═O)OC₁₋₄ alkylgroups; wherein the substituents for substituted C₁₋₄ alkoxy,substituted C₃₋₆ cycloalkyl, C₃₋₆ heterocycloalkyl, and substitutedalkyl are up to three groups selected from halo, oxo, C₁₋₄ alkyl, C₁₋₄haloalkyl, C₁₋₄ alkoxy, amino, hydroxy, and CN.

Similarly, each aryl part of other groups like “aryloxy”,“aryloxyalkyl”, “aryloxycarbonyl”, “aryloxy-carbonylalkyl” shall havethe same meaning as described in the above-mentioned definition of“aryl”.

As used herein, the term “heterocyclyl” or “heterocycloalkyl” refers toa heterocyclic radical that is saturated or partially unsaturated butnot aromatic, and can be a monocyclic or a polycyclic ring, including abicyclic, tricyclic or spirocyclic ring system; and has 3 to 14, morecommonly 4 to 10, and most preferably 5 to 7 ring atoms; wherein one ormore, preferably one to four, especially one or two ring atoms areheteroatoms independently selected from O, S and N (the remaining ringatoms therefore being carbon). Even though described as, e.g., a C₅₋₆atom ring, a heterocycle contains at least one heteroatom as a ring atomand has the total number of ring atoms stated, e.g. 5 or 6 in thisexample. Preferably, a heterocyclyl group has one or two suchheteroatoms as ring atoms, and preferably the heteroatoms are notdirectly connected to each other. The bonding ring (i.e. the ringconnecting to the Formula of interest) preferably has 4 to 12,especially 5 to 7 ring atoms. The heterocyclic group can be fused to anaromatic ring, provided the atom of the heterocyclic group attached tothe Formula of interest is not aromatic. The heterocyclic group can beattached to the Formula of interest via a heteroatom (typicallynitrogen) or a carbon atom of the heterocyclic group. The heterocyclylcan comprise fused or bridged rings as well as spirocyclic ring systems(e.g., 2-oxa-6-azaspiro[3.3]heptane), and only one ring of a polycyclicheterocyclic group needs to contain a heteroatom as a ring atom.Examples of heterocycles include tetrahydrofuran (THF), dihydrofuran,1,4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine,1,3-dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine,tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane,1,3-dithiane, oxathiane, thiomorpholine, and the like.

A substituted heterocyclyl is a heterocyclyl group independentlysubstituted by 1-5 (such as one, or two, or three) substituents selectedfrom the substituents described above as suitable or preferred for acycloalkyl group.

Similarly, each heterocyclyl part of other groups like“heterocyclyloxy”, “heterocyclyloxyalkyl”, “heterocyclyloxycarbonyl”shall have the same meaning as described in the above-mentioneddefinition of “heterocyclyl”.

As used herein, the term “heteroaryl” refers to a 5-14 memberedmonocyclic- or bicyclic- or tricyclic-aromatic ring system, having 1 to8 heteroatoms as ring members; the heteroatoms are selected from N, Oand S. Typically, the heteroaryl is a 5-10 membered ring system, e.g., a5-6 membered monocyclic or an 8-10 membered bicyclic group. Typicalheteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 1-, 3-, 4-, or 5-pyrazolyl, 2-, 4-,or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-,4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2, 3-triazolyl,1- or 2-tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-,or 5-pyrazinyl, 2-pyrazinyl, and 2-, 4-, or 5-pyrimidinyl.

The term “heteroaryl” also refers to a group in which a heteroaromaticring is fused to one or more aryl, cycloalkyl, or heterocyclyl rings,where the radical or point of attachment to the Formula of interest ison a heteroaromatic ring. Nonlimiting examples include 1-, 2-, 3-, 5-,6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-,4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-,5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl,2-, 3-, 4-, 5-, 6-, 7-, or 8-quinoliyl, 1-, 3-, 4-, 5-, 6-, 7-, or8-isoquinoliyl, 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl, 2-, 3-, 4-, 5-,or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7-, or 8-quinazolinyl, 3-, 4-, 5-,6-, 7-, or 8-cinnolinyl, 2-, 4-, 6-, or 7-pteridinyl, 1-, 2-, 3-, 4-,5-, 6-, 7-, or 8-4aH carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or8-carbzaolyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbolinyl, 1-, 2-, 3-,4-, 6-, 7-, 8-, 9-, or 10-phenanthridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-,8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-perimidinyl, 2-,3-, 4-, 5-, 6-, 8-, 9-, or 10-phenathrolinyl, 1-, 2-, 3-, 4-, 6-, 7-,8-, or 9-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or10-phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenoxazinyl,2-, 3-, 4-, 5-, 6-, or I-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or10-benzisoqinolinyl, 2-, 3-, 4-, or thieno[2,3-b]furanyl, 2-, 3-, 5-,6-, 7-, 8-, 9-, 10-, or 11-7H-pyrazino[2,3-c]carbazolyl, 2-, 3-, 5-, 6-,or 7-2H-furo[3,2-b]-pyranyl, 2-, 3-, 4-, 5-, 7-, or8-5H-pyrido[2,3-d]-o-oxazinyl, 1-, 3-, or 5-1H-pyrazolo[4,3-d]-oxazolyl,2-, 4-, or 54H-imidazo[4,5-d] thiazolyl, 3-, 5-, or8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5-, or 6-imidazo[2,1-b] thiazolyl,1-, 3-, 6-, 7-, 8-, or 9-furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-,8-, 9-, 10, or 11-4H-pyrido[2,3-c]carbazolyl, 2-, 3-, 6-, or7-imidazo[1,2-b][1,2,4]triazinyl, 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 4-, 5-, 6-,or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-benzoxapinyl, 2-,4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-,or 11-1H-pyrrolo[1,2-b][2]benzazapinyl. Typical fused heteroaryl groupsinclude, but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl,1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, and 2-, 4-, 5-, 6-,or 7-benzothiazolyl.

A substituted heteroaryl is a heteroaryl group containing one or moresubstituents, typically 1, 2 or 3 substituents, selected from thesubstituents described above as suitable or preferred for an aryl group.

Similarly, each heteroaryl part of other groups like “heteroaryloxy”,“heteroaryloxyalkyl”, “heteroaryloxycarbonyl” shall have the samemeaning as described in the above-mentioned definition of “heteroaryl”.

Various embodiments of the invention are described herein. It will berecognized that features specified in each embodiment may be combinedwith other specified features to provide further embodiments of thepresent invention. The following enumerated embodiments arerepresentative of the invention:

1. In certain embodiments, the invention provides a compound of Formula(I)

or a pharmaceutically acceptable salt thereof, wherein:

-   -   Z¹ is O, S, S(═O) or SO₂;    -   Z² is N, S or CR^(a), where R^(a) is H, halo, C₁₋₄ alkyl or C₁₋₄        haloalkyl;    -   R¹ is CN, halo, OH, C₁₋₄ alkoxy, or C₁₋₄ alkyl that is        optionally substituted with one to three groups selected from        halo, C₁₋₄ alkoxy, CN, and hydroxyl;    -   Ring B is selected from phenyl, pyridine, pyrimidine, pyrazine,        pyridazine, pyridone, pyrimidone, pyrazinone, pyridazinone, and        thiazole, each of which is optionally substituted with up to two        groups selected from halo, OH, CN, C₁₋₄ alkyl, C₂₋₄ alkenyl,        —O—(C₁₋₄alkyl), NH₂, NH—(C₁₋₄alkyl), —N(C₁₋₄ alkyl)₂, —SO₂R²,        NHSO₂R², NHC(O)R², NHCO₂R², C₃₋₆ cycloalkyl, 5-6 membered        heteroaryl, —O—C₃₋₆ cycloalkyl, —O-(5-6-membered heteroaryl),        C₄₋₈ heterocycloalkyl, and —O-(4-8 membered heterocycloalkyl),        where each heterocycloalkyl and heteroaryl contains up to three        heteroatoms selected from N, O and S as ring members,        -   where each C₁₋₄ alkyl, C₂₋₄ alkenyl, C₃₋₆ cycloalkyl, 5-6            membered heteroaryl, and 4-8 membered heterocycloalkyl is            each optionally substituted with up to three groups selected            from oxo, hydroxyl, halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄            alkoxy, and —(CH₂)₁₋₂Q where Q is OH, C₁₋₄ alkoxy, —CN, NH₂,            —NHR³, —N(R³)₂, —SO₂R³, NHSO₂R³, NHC(O)OR³, or NHC(O)R³;            each R² and R³ is independently C₁. 4 alkyl; and    -   Ring B is optionally fused to a 5-6 membered aromatic or        nonaromatic ring containing up to two heteroatoms selected from        N, O and S, where the 5-6 membered ring can be substituted with        halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, or C₁₋₄ alkoxy, and        optionally, if the fused ring is non-aromatic the substituent        options can further include oxo;    -   each Y is independently selected from C₁₋₄ alkyl, C₁₋₄ alkoxy,        CN, halo, oxo, —(CH₂)_(p)OR⁴, —(CH₂)_(p)N(R⁴)₂,        —(CH₂)_(p)NHC(O)R⁴, —(CH₂)_(p)NHCOO(C₁₋₄ alkyl), and imidazole,    -   or two Y groups on Ring A are optionally taken together to form        a ring fused to or bridging Ring A, where said fused or bridging        ring optionally contains a heteroatom selected from N, O and S        as a ring member, and is optionally substituted with up to two        groups selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, CN, halo, oxo,        —(CH₂)_(p)OR⁴, —(CH₂)_(p) N(R⁴)₂, —(CH₂)_(p)NHC(O)R⁴, and        —(CH₂)_(p)NHCOO(C₁₋₄ alkyl);    -   each R⁴ is independently H or C₁₋₄ alkyl;    -   each p is independently 0, 1, or 2;    -   q is 0, 1 or 2;    -   Z³, Z⁴, and Z⁵ are independently selected from CH and N and        optionally NO;    -   L is —C(═O)—NR⁴—[CY] or —NR⁴—C(═O)—[CY], where [CY] indicates        which atom of L is attached to CY; and    -   CY is an aromatic ring selected from phenyl, pyridine,        pyrimidine, pyrazine, pyridazine, pyridone, thiazole,        isothiazole, oxazole, pyrazole, and isoxazole, wherein the ring        is optionally fused to a thiophene, imidazole, oxazolone, or        pyrrole ring;    -   and CY is substituted with up to two groups selected from halo,        CN, R⁵, OR⁵, SO₂R⁵, —S(═NH)(═O)R⁵, OH, NH₂, NHR⁵, and —N(R⁵)₂,        -   wherein each R⁵ is independently C₁₋₄ alkyl, C₂₋₄ alkenyl,            C₄₋₆ heterocyclyl, 5-membered heteroaryl containing up to            three heteroatoms selected from N, O and S as ring members,            or C₃₋₈ cycloalkyl, and R⁵ is optionally substituted with up            to four groups selected from oxo, halo, CN, R⁶, OH, OR⁶,            SO₂R⁶, NH₂, NHR⁶, N(R⁶)₂, NHSO₂R⁶, NHCOOR⁶, NHC(═O)R⁶,            —CH₂OR⁷, —CH₂N(R⁷)₂, wherein each R⁶ is independently C₁₋₄            alkyl, and each R⁷ is independently H or C₁₋₄ alkyl;        -   and two R⁴, R⁵, R⁶, or R⁷ on the same nitrogen atom can be            taken together to form a 5-6 membered heterocyclic ring            optionally containing an additional N, O or S as a ring            member and optionally substituted with up to two groups            selected from C₁₋₄ alkyl, oxo, halo, OH, and C₁₋₄ alkoxy.

In certain embodiments, the compound is a compound of the formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

-   -   Z¹ is O, S, S(═O) or SO₂;    -   Z² is N, S or CR^(a), where R^(a) is H, C₁₋₄ alkyl or C₁₋₄        haloalkyl;    -   R¹ is CN, halo, OH, C₁₋₄ alkoxy, or C₁₋₄ alkyl that is        optionally substituted with one to three groups selected from        halo, C₁₋₄ alkoxy, CN, and hydroxyl;    -   Ring B is selected from phenyl, pyridine, pyrimidine, pyrazine,        pyridone, pyrimidone, pyrazinone, pyridazinone, and thiazole,        each of which is optionally substituted with up to two groups        selected from halo, OH, CN, C₁₋₄ alkyl, C₂₋₄ alkenyl,        —O—(C₁₋₄alkyl), NH₂, NH—(C₁₋₄alkyl), —N(C₁₋₄ alkyl)₂, —SO₂R²,        NHSO₂R², NHC(O)R², NHCO₂R², C₃₋₆ cycloalkyl, 5-6 membered        heteroaryl, —O—C₃₋₆ cycloalkyl, —O-(5-6-membered heteroaryl),        C₄₋₈ heterocycloalkyl, and —O-(4-8 membered heterocycloalkyl),        where each heterocycloalkyl and heteroaryl contains up to three        heteroatoms selected from N, O and S as ring members,        -   where each C₁₋₄ alkyl, C₂₋₄ alkenyl, C₃₋₆ cycloalkyl, 5-6            membered heteroaryl, and 4-8 membered heterocycloalkyl is            each optionally substituted with up to three groups selected            from oxo, hydroxyl, halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄            alkoxy, and —(CH₂)₁₋₂Q where Q is OH, C₁₋₄ alkoxy, —CN, NH₂,            —NHR³, —N(R³)₂, —SO₂R³, NHSO₂R³, NHC(O)OR³, or NHC(O)R³;        -   each R² and R³ is independently C₁₋₄ alkyl; and        -   Ring B is optionally fused to a 5-6 membered aromatic or            nonaromatic ring containing up to two heteroatoms selected            from N, O and S, where the 5-6 membered ring can be            substituted with halo, C₁₋₄ alkyl, C₁₋₄ haloalkyl, or C₁₋₄            alkoxy;    -   each Y is independently selected from C₁₋₄ alkyl, C₁₋₄ alkoxy,        CN, halo, oxo, —(CH₂)_(p)OR⁴, —(CH₂)_(p) N(R⁴)₂,        —(CH₂)_(p)NHC(O)R⁴, —(CH₂)_(p)NHCOO(C₁₋₄ alkyl),    -   or two Y groups on Ring A are optionally taken together to form        a ring fused to or bridging Ring A, where said fused or bridging        ring optionally contains a heteroatom selected from N, O and S        as a ring member, and is optionally substituted with up to two        groups selected from C₁₋₄ alkyl, C₁₋₄ alkoxy, CN, halo, oxo,        —(CH₂)_(p)OR⁴, —(CH₂)_(p) N(R⁴)₂, —(CH₂)_(p)NHC(O)R⁴, and        —(CH₂)_(p)NHCOO(C₁₋₄ alkyl);    -   each R⁴ is independently H or C₁₋₄ alkyl;    -   each p is independently 0, 1, or 2;    -   q is 0, 1 or 2;    -   Z³, Z⁴, and Z⁵ are independently selected from CH and N;    -   L is —C(═O)—NH—[CY] or —NH—C(═O)—[CY], where [CY] indicates        which atom of L is attached to CY; and    -   CY is an aromatic ring selected from phenyl, pyridine,        pyrimidine, pyrazine, pyridazine, pyridone, thiazole,        isothiazole, oxazole, pyrazole, and isoxazole, wherein the ring        is optionally fused to a thiophene, imidazole, oxazolone, or        pyrrole ring;    -   and CY is substituted with up to two groups selected from halo,        CN, R⁵, OR⁵, SO₂R⁵, OH, NH₂, NHR⁵, and —N(R⁵)₂,        -   wherein each R⁵ is independently C₁₋₄ alkyl, C₄₋₆            heterocyclyl, or C₃₋₈ cycloalkyl, and R⁵ is optionally            substituted with up to three groups selected from oxo, halo,            CN, R⁶, OH, OR⁶, SO₂R⁶, NH₂, NHR⁶, N(R⁶)₂, NHSO₂R⁶, NHCOOR⁶,            NHC(═O)R⁶, —CH₂OR⁷, —CH₂N(R⁷)₂, wherein each R⁶ is            independently C₁₋₄alkyl, and each R⁷ is independently H or            C₁₋₄ alkyl;        -   and two R⁴, R⁵, R⁶, or R⁷ on the same nitrogen atom can be            taken together to form a 5-6 membered heterocyclic ring            optionally containing an additional N, O or S as a ring            member and optionally substituted with up to two groups            selected from C₁₋₄ alkyl, oxo, halo, OH, and C₁₋₄ alkoxy.

2. A compound according to embodiment 1 or a pharmaceutically acceptablesalt thereof, wherein Z¹ is O.

3 (a). A compound according to embodiment 1 or embodiment 2 or apharmaceutically acceptable salt thereof, wherein Z² is CH.

3 (b). In an alternative, a compound according to embodiment 1 orembodiment 2 or a pharmaceutically acceptable salt thereof, wherein, Z²is N.

4. A compound according to any one of embodiments 1 to 3 or apharmaceutically acceptable salt thereof, wherein CY is selected fromphenyl, pyridine, pyrimidine, pyrazine, pyridazine, pyridone, thiazole,isothiazole, oxazole, and isoxazole, each of which is optionallysubstituted as described for embodiment 1. In some of these embodiments,CY is phenyl or 4-pyridinyl.

5. A compound according to any of the preceding embodiments or apharmaceutically acceptable salt thereof, wherein R¹ is methyl or CF₃.

6. A compound according to any of the preceding embodiments or apharmaceutically acceptable salt thereof, wherein Ring B is pyridine orpyrimidine or pyridone.

7. A compound according to any of the preceding embodiments or apharmaceutically acceptable salt thereof, wherein CY is phenyl orpyridin-4-yl, and is optionally substituted with one or two groupsselected from methyl, ethyl, isopropyl, CF₃, —CHF₂, CH₂F, CF₂CH₃,CH₂CF₃, 1-piperazinyl, 4-methyl-1-piperazinyl, 4-ethyl-1-piperazinyl,cyclopropyl, 1-cyanocyclopropyl, —CH₂CN, —CHMeCN, —CMe₂CN, OMe, OEt, F,Cl, —SO₂Me, —SO₂NMe₂, —CH₂NH₂, —CH₂NMe₂, —CH₂NHMe, and —CH₂OMe. In someof these embodiments, CY has one or two substituents at ring atom 3 orring atom 5 relative to the point of attachment of CY to L.

8. A compound according to any of the preceding embodiments or apharmaceutically acceptable salt thereof, wherein CY is substituted withat least one group selected from CF₃, OCF₃, t-butyl, —C(Me)₂CN, and—SO₂Me.

In some embodiments, CY is substituted with —CF(Me)₂ or —CHF₂.

In some of these embodiments, CY has one or two substituents at ringatom 3 or ring atom 5 relative to the point of attachment of CY to L.

9. A compound according to any of the preceding embodiments or apharmaceutically acceptable salt thereof, wherein Z⁴ is CH.

10. A compound according to any of embodiments 1-8 or a pharmaceuticallyacceptable salt thereof, wherein Z⁴ is N.

11. A compound according to any of the preceding embodiments or apharmaceutically acceptable salt thereof, wherein L is —C(═O)—NH—[CY],where [CY] indicates which atom of L is attached to ring CY.

12. A compound according to any of embodiments 1-10 or apharmaceutically acceptable salt thereof, wherein L is —NH—C(═O)—[CY],where [CY] indicates which atom of L is attached to ring CY.

13. A compound according to any of the preceding embodiments or apharmaceutically acceptable salt thereof, wherein Z³ is N.

14. A compound of any of the preceding embodiments, wherein ring B isselected from

wherein [Z¹] indicates where the ring containing Z¹ is attached to ringB, and [Z³] indicates where the ring containing Z³ is attached to ringB,and R¹⁵, R¹⁶, R¹⁷ and R¹⁸ are each selected from CN, halo, R²⁰,—N(R²⁰)₂, —OR²⁰, and C₄₋₈ heterocycloalkyl optionally substituted withup to two groups selected from hydroxyl, C₁₋₄ alkyl, oxo, and halo;where each R²⁰ is independently H or C₁₋₄ alkyl optionally substitutedwith up to three groups independently selected from halo, oxo, C₁₋₄alkoxy, hydroxyl, amino, and CN.

15. A compound of any of the preceding embodiments, wherein q is 0.

16. A compound of any of the preceding embodiments, wherein ring B isselected from

17. A compound of any of the preceding embodiments, wherein Z³ and Z⁵are both CH.

18. A compound of any of the preceding embodiments wherein Z⁴ is N andR¹ is methyl.

19. A compound of any of embodiments 1-17, wherein Z⁴ is CH and R¹ ismethyl.

20. A compound of any of the preceding embodiments, wherein L is—NH—C(═O)—[CY] and CY is phenyl or 4-pyridinyl, and CY is substitutedwith one or two groups selected from halo, CF₃, CF₂H, CFH₂, CFMe₂, and—CH₂NMe₂.

21. A compound of embodiment 1, which is selected from the compounds ofExamples 1-1175 and compounds in Table A and the pharmaceuticallyacceptable salts thereof.

22. A pharmaceutical composition comprising a compound of any of thepreceding embodiments or a pharmaceutically acceptable salt thereof andone or more pharmaceutically acceptable carriers.

23. A combination comprising a therapeutically effective amount of acompound according to any one of embodiments 1 to 21 or apharmaceutically acceptable salt thereof and one or more therapeuticallyactive co-agents.

24. A method of treating a proliferative disorder, comprisingadministering to a subject in need thereof a therapeutically effectiveamount of a compound of any of embodiments 1-21 or a pharmaceuticallyacceptable salt thereof. In some embodiments, the proliferative disorderis a cancer, e.g., a condition selected from solid tumors, melanoma,breast cancer, lung cancer (e.g., non-small cell lung cancer, lungadenocarcinoma), sarcoma, GI tumors such as gastrointestinal stromaltumors, ovarian cancer, colorectal cancer, thyroid cancer, andpancreatic cancer.

25. A compound according to any one of embodiments 1 to 21 or apharmaceutically acceptable salt thereof, for use as a medicament.

26. A compound according to any one of embodiments 1 to 21 or apharmaceutically acceptable salt thereof, for use in the treatment ofcancer. In some embodiments, the cancer is selected from solid tumors,melanoma, breast cancer, lung cancer (e.g., non-small cell lung cancer,lung adenocarcinoma), sarcoma, GI tumors such as gastrointestinalstromal tumors, ovarian cancer, colorectal cancer, thyroid cancer, andpancreatic cancer.

27. Use of a compound according to any one of embodiments 1 to 21 or apharmaceutically acceptable salt thereof in the manufacture of amedicament for the treatment of cancer. In some embodiments, the canceris selected from solid tumors, melanoma, breast cancer, lung cancer(e.g., non-small cell lung cancer, lung adenocarcinoma), sarcoma, GItumors such as gastrointestinal stromal tumors, ovarian cancer,colorectal cancer, thyroid cancer, and pancreatic cancer.

Each of the Example compounds having a measured IC-50 (B-Raf) of lessthan or equal to 0.01 μM, and a measured IC-50 (c-Raf) of less than0.005 μM as shown in Table 2 is a preferred compound of the invention.The compounds of Examples having a measured IC-50 (B-Raf) of less thanor equal to 0.01 μM and measured IC-50 (c-Raf) less than or equal to0.002 μM according to Table 2 are especially preferred. Thus the use ofany one of these compounds for treatment of a condition selected frommelanoma, breast cancer, lung cancer (e.g., non-small cell lung cancer,lung adenocarcinoma), sarcoma, GI tumors such as gastrointestinalstromal tumors, ovarian cancer, colorectal cancer, thyroid cancer, andpancreatic cancer is an embodiment of the invention.

Unless otherwise specified, in any of the foregoing enumeratedembodiments, Ring A can be unsubstituted morpholine or a substitutedmorpholine derivative as described for Formula (I) above. In specificembodiments, Ring A is selected from the following morpholinic groups

In certain embodiments, Ring A is unsubstituted morpholine.

In the foregoing enumerated embodiments, unless otherwise stated, Ring Bis selected from phenyl, pyridine, pyrimidine, pyrazine, pyridone,pyrimidone, pyrazinone, pyridazinone, and thiazole. In certain of theseembodiments, Ring B is selected from pyrazine, pyridazine, pyridone,pyrimidone, pyrazinone, and pyridazinone. Ring B in any of theseembodiments can be substituted as described above for Formula (I); insome embodiments, Ring B is a six-membered ring that is substituted atpositions 1, 3 and 5, where the N of ring A is at position 1 and Z² isat position 6. Where Ring B includes an oxo group (pyridone,pyridazinone, pyrazinone), oxo is sometimes at position 2 using thisnumbering. In some embodiments, Ring B is substituted by a groupselected from methyl, ethyl, isopropyl, amino, hydroxyl, —NHMe,—NHEt,—NMe₂, —NHSO₂Me, —NH—CH₂CH₂OH, 4-tetrahydropyranyl,—O-4-tetrahydropyranyl, 1-pyrrolidinyl, 1-morpholinyl, —NH—CH(CH₂OH)₂,1-pyrrolidin-2-one, 4-morpholin-3-one, 2-oxa-6-aza[3.3]heptan-6-yl,—CH₂CH₂OH, CF₃, SO₂Me, 2-propenyl, —CH₂CN, and —CH₂CH₂NHCOOMe.

Preferably, Ring B is selected from pyridine, pyrimidine, pyrazine,pyridone, pyrimidone, pyrazinone, and pyridazinone, optionallysubstituted and/or fused as described for Formula (I). When Ring B isfused, the additional fused ring can be substituted as described,typically with up to two (0, 1 or 2) of the substituents describedabove.

Where Ring B is pyridone, it is preferably a 2-pyridone (pyridin-2-one),and optionally is N-alkylated with a C₁₋₄ alkyl, which may besubstituted with one to three groups selected from OH, OMe, halo, andCN. In some embodiments, Ring B is substituted by a group selected frommethyl, ethyl, isopropyl, amino, hydroxyl, —NHMe,—NHEt, —NMe₂, —NHSO₂Me,—NH—CH₂CH₂OH, 4-tetrahydropyranyl, —O-4-tetrahydropyranyl,1-pyrrolidinyl, 1-morpholinyl, —NH—CH(CH₂OH)₂, 1-pyrrolidin-2-one,4-morpholin-3-one, 2-oxa-6-aza[3.3]heptan-6-yl, 1-imidazolyl,4-methyl-1,2,3-triazol-1-yl, 4-ethyl-1,2,3-triazol-1-yl,4-isopropyl-1,2,3-triazol-1-yl,4-(1-hydroxy-2-propyl)-1,2,3-triazol-1-yl, —CH₂CH₂OH, CF₃, SO₂Me,2-propenyl, —CH₂CN, and —CH₂CH₂NHCOOMe.

Preferred embodiments of Ring B include

where [N] indicates the position attached to Ring A; R^(B) is selectedfrom amino, hydroxyl, —NHMe,—NHEt, —NMe₂, —NHSO₂Me, —NH—CH₂CH₂OH,—O-4-tetrahydropyranyl, 1-pyrrolidinyl, 1-morpholinyl, —NH—CH(CH₂OH)₂,1-pyrrolidin-2-one, 4-morpholin-3-one, and 2-oxa-6-aza[3.3]heptan-6-yl;and R^(B2) is selected from methyl, ethyl, isopropyl, —CH₂CH₂OH,4-tetrahydropyranyl, CH₂CN, and —CH₂CH₂NHCOOMe.

In some of the foregoing embodiments, Ring C is phenyl or pyridine. WhenRing C is pyridine, preferably Z⁴ is N. Unless otherwise stated, R¹ isoften methyl or CF₃. The presence of R¹, a substituent such as methylrather than hydrogen, significantly affects the conformation of thecompound, favoring a highly active conformation. The methyl groupthereby enhances in vitro activity significantly.

In the enumerated embodiments where not otherwise specified, CY can besubstituted with 1 or 2 groups selected from methyl, ethyl, isopropyl,CF₃, —CHF₂, CH₂F, CF₂CH₃, CH₂CF₃, 1-piperazinyl, 4-methyl-1-piperazinyl,4-ethyl-1-piperazinyl, cyclopropyl, 1-cyanocyclopropyl, —CH₂CN, —CHMeCN,—CMe₂CN, OMe, OEt, F, Cl, —SO₂Me, —SO₂NMe₂, —CH₂NH₂, —CH₂NMe₂, —CH₂NHMe,and —CH₂OMe. It some of these embodiments, CY is phenyl or 4-pyridinyl,and at least one substituent is at position 3.

In some embodiments, CY is a group of the formula

where [L] indicates which position is attached to L in Formula (I);Z^(CY) is N or CH; R* is

selected from methyl, ethyl, isopropyl, CF₃, —CHF₂, CH₂F, CF₂CH₃,CH₂CF₃, 1-piperazinyl, 4-methyl-1-piperazinyl, 4-ethyl-1-piperazinyl,cyclopropyl, 1-cyanocyclopropyl, —CH₂CN, —CHMeCN, —CMe₂CN, OMe, OEt, F,Cl, —SO₂Me, —SO₂NMe₂, —CH₂NH₂, —CH₂NMe₂, —CH₂NHMe, and —CH₂OMe; andR^(CY) is selected from CF₃, OCF₃, t-butyl, —C(Me)₂CN, and —SO₂Me.

In certain embodiments, the compound of Formula (I) has this formula:

wherein Z² is N or CH;

Z⁴ is N or CH;

Z⁶ is C═O and Z⁷ is NR^(Q), where R^(Q) is H or C₁₋₄ alkyl optionallysubstituted by OH, CN, OMe, SO₂Me, or 1-3 halogens;

-   -   or Z⁶ is CH and Z⁷ is C-Q;        Z⁸ is CH or N (and preferably Z⁸ and Z² are not both        simultaneously N);        Q is selected from H, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆        cycloalkyl, C₅₋₆ heteroaryl, C₄₋₇ heterocycloalkyl, including        morpholine or any of the morpholinic groups shown above as        options for Ring A, as well as 2-oxa-6-azaspiro[3.3]heptane,        e.g.,

and other spirocyclic systems; where the, C₁₋₄ alkyl, C₃₋₆ cycloalkyl,C₅₋₆ heteroaryl, or C₄₋₇ heterocycloalkyl is optionally substituted witha group selected from OH, NH₂, CN, OMe, SO₂Me, and NMe₂;and R₁, Y, q, L, and CY are as defined for Formula (I) or any of thesubgenera of Formula (I) described herein.

In a particular embodiment, the invention provides compounds of thisformula:

wherein:

-   -   Y is oxo, C₁₋₄ alkyl, or —CH₂T, where T is selected from        hydroxyl, C₁₋₄ alkoxy, amino, C₁₋₄ alkylamino, di(C₁₋₄        alkyl)amino, —NHC(═O)(C₁₋₄ alkyl) and —NHC(═O)—O(C₁₋₄ alkyl);    -   q is 0, 1 or 2;    -   Z² is CH or N;    -   Z⁴ is CH or N;    -   Z⁶ is C═O, Z⁷ is NR²⁰, and Z⁸ is CH;        -   or Z⁶ is N, Z⁷ is CR²¹, and Z⁸ is CH;        -   or Z⁶ is N, Z⁷ is CR²², and Z⁸ is N, provided Z² and Z⁸ are            not both N;    -   Z⁹ is N or CH;    -   R¹ is Me or CF₃;    -   L is —C(═O)NH— or —NH—C(═O)—;    -   R¹⁰ is selected from C₁₋₄ alkyl, —O—C₁₋₃ alkyl, —SO₂—C₁₋₃ alkyl,        and C₃₋₄ cycloalkyl, wherein each C₁₋₃ alkyl, —O—C₁₋₃ alkyl,        —SO₂—C₁₋₃ alkyl, and C₃₋₄ cycloalkyl is optionally substituted        with up to three groups selected from halo, CN, Me, CF₃, OH and        OMe; and    -   R²⁰, R²¹, and R²² are each selected from H, C₁₋₄ alkyl and C₄₋₈        heterocycloalkyl, wherein the C₁₋₄ alkyl and C₄₋₈        heterocycloalkyl are each optionally substituted with 1-2 groups        selected from C₁₋₄ alkyl, oxo, halo, and —(CH₂)₁₋₂Q wherein Q is        OH, C₁₋₄ alkoxy, —CN, NH₂, —NHR³, —N(R³)₂, —SO₂R³, NHSO₂R³, or        NHC(O)R³;

or a pharmaceutically acceptable salt thereof.

In specific embodiments of these compounds, Z⁶ is C═O, Z⁷ is NR²⁰, andZ⁸ is CH. In some such embodiments, L is —NH—C(═O)—; in alternativeembodiments, L is —C(═O)NH—. In some of these embodiments, Z⁴ is N; inalternative embodiments, Z⁴ is CH. In some of these embodiments, Z⁹ isN; in other embodiments, Z⁹ is CH. In some of these embodiments, R¹⁰ istrifluoromethyl. In preferred embodiments of these compounds, R¹ ismethyl.

In another particular embodiment, the compound of Formula (I) is of thisformula:

wherein Z⁴ is CH or N;

-   -   Z⁶ is CH or N;    -   R¹⁰ is selected from F, CN, OH, —OMe, and —NMe₂;    -   each R¹¹ is independently selected from H, F, and Me;    -   R¹² is selected from H, halo, CF₃, and —CH₂R¹³, where R¹³ is        selected from F, —OH, —OMe, NH₂, NHMe, NMe₂; and    -   Ring B is selected from

where [N] indicates the point of attachment of Ring B to the morpholinering and [Z⁴] indicates the point where Ring B is attached to the ringcontaining Z⁴;

R¹³ is selected from C₁₋₄ alkyl, tetrahydropyranyl, and C₁₋₄ haloalkyl,wherein the C₁₋₄ alkyl group is optionally substituted with up to threegroups selected from halo, CN, —N(R¹⁵)₂, and —OR¹⁵;

R¹⁴ is C₁₋₆ alkyl optionally substituted with up to three groupsselected from halo, CN, —N(R¹⁵)₂, and —OR¹⁵; and

each R¹⁵ is selected from H and Me,

including the pharmaceutically acceptable salts of these compounds.

As used herein, the term “an optical isomer” or “a stereoisomer” refersto any of the various stereo isomeric configurations which may exist fora given compound of the present invention and includes geometricisomers. It is understood that a substituent may be attached at a chiralcenter of a carbon atom. The term “chiral” refers to molecules whichhave the property of non-superimposability on their mirror imagepartner, while the term “achiral” refers to molecules which aresuperimposable on their mirror image partner. Therefore, the inventionincludes enantiomers, diastereomers or racemates of the compound.“Enantiomers” are a pair of stereoisomers that are non-superimposablemirror images of each other. A 1:1 mixture of a pair of enantiomers is a“racemic” mixture. The term is used to designate a racemic mixture whereappropriate. “Diastereoisomers” are stereoisomers that have at least twoasymmetric atoms, but which are not mirror-images of each other. Theabsolute stereochemistry is specified according to theCahn-lngold-Prelog ‘R-S’ system. When a compound is a pure enantiomer,the stereochemistry at each chiral carbon may be specified by either Ror S. Resolved compounds whose absolute configuration is unknown can bedesignated (+) or (−) depending on the direction (dextro- orlevorotatory) which they rotate plane polarized light at the wavelengthof the sodium D line. Certain compounds described herein contain one ormore asymmetric centers or axes and may thus give rise to enantiomers,diastereomers, and other stereoisomeric forms that may be defined, interms of absolute stereochemistry, as (R)- or (S)-.

Depending on the choice of the starting materials and synthesisprocedures, the compounds can be present in the form of one of thepossible isomers or as mixtures thereof, for example as pure opticalisomers, or as isomer mixtures, such as racemates and diastereoisomermixtures, depending on the number of asymmetric carbon atoms. Thepresent invention is meant to include all such possible isomers,including racemic mixtures, diasteriomeric mixtures and optically pureforms. Optically active (R)- and (S)-isomers may be prepared usingchiral synthons or chiral reagents, or resolved using conventionaltechniques. If the compound contains a double bond, the substituent maybe E or Z configuration unless specified. If the compound contains adisubstituted cycloalkyl, the cycloalkyl substituent may have a cis- ortrans-configuration, unless otherwise specified. All tautomeric formsare also intended to be included.

In many cases, the compounds of the present invention are capable offorming acid and/or base salts by virtue of the presence of amino and/orcarboxyl groups or groups similar thereto. As used herein, the terms“salt” or “salts” refers to an acid addition or base addition salt of acompound of the invention. “Salts” include in particular “pharmaceuticalacceptable salts”. The term “pharmaceutically acceptable salts” refersto salts that retain the biological effectiveness and properties of thecompounds of this invention and, which typically are not biologically orotherwise undesirable.

Pharmaceutically acceptable acid addition salts can be formed withinorganic acids and organic acids, e.g., acetate, aspartate, benzoate,besylate, bromide/hydrobromide, bicarbonate/carbonate,bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride,chlorotheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate,gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate,lactate, lactobionate, laurylsulfate, malate, maleate, malonate,mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate,nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate,phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate,propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate andtrifluoroacetate salts. Lists of additional suitable salts can be found,e.g., in “Remington's Pharmaceutical Sciences”, 20th ed., MackPublishing Company, Easton, Pa., (1985); and in “Handbook ofPharmaceutical Salts: Properties, Selection, and Use” by Stahl andWermuth (Wiley-VCH, Weinheim, Germany, 2002).

Inorganic acids from which salts can be derived include, for example,hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like.

Organic acids from which salts can be derived include, for example,acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid,malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid,benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid,toluenesulfonic acid, sulfosalicylic acid, and the like.

Pharmaceutically acceptable base addition salts can be formed withinorganic or organic bases and can have inorganic or organiccounterions.

Inorganic counterions for such base salts include, for example, ammoniumsalts and metals from columns I to XII of the periodic table. In certainembodiments, the counterion is selected from sodium, potassium,ammonium, alkylammonium having one to four C1-C4 alkyl groups, calcium,magnesium, iron, silver, zinc, and copper; particularly suitable saltsinclude ammonium, potassium, sodium, calcium and magnesium salts.

Organic bases from which salts can be derived include, for example,primary, secondary, and tertiary amines, substituted amines includingnaturally occurring substituted amines, cyclic amines, basic ionexchange resins, and the like. Suitable organic amines includeisopropylamine, benzathine, cholinate, diethanolamine, diethylamine,lysine, meglumine, piperazine and tromethamine.

The pharmaceutically acceptable salts of the present invention can besynthesized from a basic or acidic moiety, by conventional chemicalmethods. Generally, such salts can be prepared by reacting free acidforms of these compounds with a stoichiometric amount of the appropriatebase (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or thelike), or by reacting free base forms of these compounds with astoichiometric amount of the appropriate acid. Such reactions aretypically carried out in water or in an organic solvent, or in a mixtureof the two. Generally, use of non-aqueous media like ether, ethylacetate, tetrahydrofuran, toluene, chloroform, dichloromethane,methanol, ethanol, isopropanol, or acetonitrile is desirable, wherepracticable.

Any formula given herein is also intended to represent unlabeled forms(i.e., compounds wherein all atoms are present at natural isotopicabundances, and not isotopically enriched) as well as isotopicallyenriched or labeled forms of the compounds. Isotopically enriched orlabeled compounds have structures depicted by the formulas given hereinexcept that at least one atom of the compound is replaced by an atomhaving an atomic mass or mass number different from the atomic mass orthe atomic mass distribution that occurs naturally. Examples of isotopesthat can be incorporated into enriched or labeled compounds of theinvention include isotopes of hydrogen, carbon, nitrogen, oxygen,phosphorous, fluorine, and chlorine, such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N,¹⁸F ³¹P, ³²P, ³⁵S, ³⁶Cl, ¹²⁵I respectively. The invention includesvarious isotopically labeled compounds as defined herein, for examplethose in which radioactive isotopes, such as ³H and ¹⁴C, or those inwhich non-radioactive isotopes, such as ²H and ¹³C, are present atlevels significantly above the natural abundance for these isotopes.These isotopically labeled compounds are useful in metabolic studies(with ¹⁴C), reaction kinetic studies (with, for example ²H or ³H),detection or imaging techniques, such as positron emission tomography(PET) or single-photon emission computed tomography (SPECT) includingdrug or substrate tissue distribution assays, or in radioactivetreatment of patients. In particular, an ¹⁸F or labeled compound may beparticularly desirable for PET or SPECT studies. Isotopically-labeledcompounds of formula (I) can generally be prepared by conventionaltechniques known to those skilled in the art or by processes analogousto those described in the accompanying Examples and Preparations usingan appropriate isotopically-labeled reagents in place of the non-labeledreagent previously employed.

Further, substitution with heavier isotopes, particularly deuterium(i.e., ²H or D) may afford certain therapeutic advantages resulting fromgreater metabolic stability, for example increased in vivo half-life orreduced dosage requirements or an improvement in therapeutic index. Itis understood that deuterium in this context is regarded as asubstituent of a compound of the formula (I). The concentration of sucha heavier isotope, specifically deuterium, may be defined by theisotopic enrichment factor. The term “isotopic enrichment factor” asused herein means the ratio between the isotopic abundance and thenatural abundance of a specified isotope. If a substituent in a compoundof this invention is denoted deuterium, such compound has an isotopicenrichment factor for each designated deuterium atom of at least 3500(52.5% deuterium incorporation at each designated deuterium atom), atleast 4000 (60% deuterium incorporation), at least 4500 (67.5% deuteriumincorporation), at least 5000 (75% deuterium incorporation), at least5500 (82.5% deuterium incorporation), at least 6000 (90% deuteriumincorporation), at least 6333.3 (95% deuterium incorporation), at least6466.7 (97% deuterium incorporation), at least 6600 (99% deuteriumincorporation), or at least 6633.3 (99.5% deuterium incorporation).

Pharmaceutically acceptable solvates in accordance with the inventioninclude those wherein the solvent of crystallization may be isotopicallysubstituted, e.g. D₂O, d⁶-acetone, d⁶-DMSO, as well as solvates withnon-enriched solvents.

Compounds of the invention, i.e. compounds of formula (I) that containgroups capable of acting as donors and/or acceptors for hydrogen bondsmay be capable of forming co-crystals with suitable co-crystal formers.These co-crystals may be prepared from compounds of formula (I) by knownco-crystal forming procedures. Such procedures include grinding,heating, co-subliming, co-melting, or contacting in solution compoundsof formula (I) with the co-crystal former under crystallizationconditions and isolating co-crystals thereby formed. Suitable co-crystalformers include those described in WO 2004/078163. Hence the inventionfurther provides co-crystals comprising a compound of formula (I).

As used herein, the term “pharmaceutically acceptable carrier” includesany and all solvents, dispersion media, coatings, surfactants,antioxidants, preservatives (e.g., antibacterial agents, antifungalagents), isotonic agents, absorption delaying agents, salts,preservatives, drug stabilizers, binders, excipients, disintegrationagents, lubricants, sweetening agents, flavoring agents, dyes, and thelike and combinations thereof, as would be known to those skilled in theart (see, for example, Remington's Pharmaceutical Sciences, 18th Ed.Mack Printing Company, 1990, pp. 1289-1329). Except insofar as anyconventional carrier is incompatible with the active ingredient, its usein the therapeutic or pharmaceutical compositions is contemplated.

The term “a therapeutically effective amount” of a compound of thepresent invention refers to an amount of the compound of the presentinvention that will elicit the biological or medical response of asubject, for example, reduction or inhibition of an enzyme or a proteinactivity, or ameliorate symptoms, alleviate conditions, slow or delaydisease progression, or prevent a disease, etc. In one non-limitingembodiment, the term “a therapeutically effective amount” refers to theamount of the compound of the present invention that, when administeredto a subject, is effective to (1) at least partially alleviate, inhibit,prevent and/or ameliorate a condition, or a disorder or a diseasemediated by a Raf kinase such as B-Raf or C-Raf, or associated withactivity of a kinase such as B-Raf or C-Raf, or (2) reduce or inhibitthe activity of a kinase such as B-Raf or C-Raf in vivo.

In another non-limiting embodiment, the term “a therapeuticallyeffective amount” refers to the amount of the compound of the presentinvention that, when administered to a cell, or a tissue, or anon-cellular biological material, or a medium, is effective to at leastpartially reduce or inhibit the activity of a kinase such as B-Raf orC-Raf, or at least partially reduce or alleviate a symptom or acondition associated with excessive Raf kinase activity.

As used herein, the term “subject” refers to an animal. Typically theanimal is a mammal. A subject also refers to for example, primates(e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats,rabbits, rats, mice, fish, birds and the like. In certain embodiments,the subject is a primate. In specific embodiments, the subject is ahuman.

As used herein, the term “inhibit”, “inhibition” or “inhibiting” refersto the reduction or suppression of a given condition, symptom, ordisorder, or disease, or a significant decrease in the baseline activityof a biological activity or process.

As used herein, the term “treat”, “treating” or “treatment” of anydisease or disorder refers in one embodiment, to ameliorating thedisease or disorder (i.e., slowing or arresting or reducing thedevelopment of the disease or at least one of the clinical symptomsthereof). In another embodiment “treat”, “treating” or “treatment”refers to alleviating or ameliorating at least one physical parameterincluding those which may not be discernible by the patient. In yetanother embodiment, “treat”, “treating” or “treatment” refers tomodulating the disease or disorder, either physically, (e.g.,stabilization of a discernible symptom), physiologically, (e.g.,stabilization of a physical parameter), or both. In yet anotherembodiment, “treat”, “treating” or “treatment” refers to preventing ordelaying the development or progression of the disease or disorder.

As used herein, a subject is “in need of” a treatment if such subjectwould benefit biologically, medically or in quality of life from suchtreatment.

As used herein, the term “a,” “an,” “the” and similar terms used in thecontext of the present invention (especially in the context of theclaims) are to be construed to cover both the singular and plural unlessotherwise indicated herein or clearly contradicted by the context.

All methods described herein can be performed in any suitable orderunless otherwise indicated herein or otherwise clearly contradicted bycontext. The use of any and all examples, or exemplary language (e.g.“such as”) provided herein is intended merely to better illuminate theinvention and does not pose a limitation on the scope of the inventionotherwise claimed.

Any asymmetric atom (e.g., carbon or the like) of the compound(s) of thepresent invention can be present in racemic or enantiomericallyenriched, for example the (R)-, (S)- or (R,S)-configuration. In certainembodiments, each asymmetric atom has at least 50% enantiomeric excess,at least 60% enantiomeric excess, at least 70% enantiomeric excess, atleast 80% enantiomeric excess, at least 90% enantiomeric excess, atleast 95% enantiomeric excess, or at least 99% enantiomeric excess ofeither the (R)- or (S)-configuration; i.e., for optically activecompounds, it is often preferred to use one enantiomer to thesubstantial exclusion of the other enantiomer. Substituents at atomswith unsaturated double bonds may, if possible, be present in cis-(Z)-or trans-(E)-form.

Accordingly, as used herein a compound of the present invention can bein the form of one of the possible isomers, rotamers, atropisomers,tautomers or mixtures thereof, for example, as substantially puregeometric (cis or trans) isomers, diastereomers, optical isomers(antipodes), racemates or mixtures thereof. ‘Substantially pure’ or‘substantially free of other isomers’ as used herein means the productcontains less than 5%, and preferably less than 2%, of other isomersrelative to the amount of the preferred isomer, by weight.

Any resulting mixtures of isomers can be separated on the basis of thephysicochemical differences of the constituents, into the pure orsubstantially pure geometric or optical isomers, diastereomers,racemates, for example, by chromatography and/or fractionalcrystallization.

Any resulting racemates of final products or intermediates can beresolved into the optical antipodes by known methods, e.g., byseparation of the diastereomeric salts thereof, obtained with anoptically active acid or base, and liberating the optically activeacidic or basic compound. In particular, a basic moiety may thus beemployed to resolve the compounds of the present invention into theiroptical antipodes, e.g., by fractional crystallization of a salt formedwith an optically active acid, e.g., tartaric acid, dibenzoyl tartaricacid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelicacid, malic acid or camphor-10-sulfonic acid. Racemic products can alsobe resolved by chiral chromatography, e.g., high pressure liquidchromatography (HPLC) using a chiral adsorbent.

Furthermore, the compounds of the present invention, including theirsalts, can also be obtained in the form of their hydrates, or includeother solvents used for their crystallization. The compounds of thepresent invention may inherently or by design form solvates withpharmaceutically acceptable solvents (including water); therefore, it isintended that the invention embrace both solvated and unsolvated forms.The term “solvate” refers to a molecular complex of a compound of thepresent invention (including pharmaceutically acceptable salts thereof)with one or more solvent molecules. Such solvent molecules are thosecommonly used in the pharmaceutical art, which are known to be innocuousto the recipient, e.g., water, ethanol, and the like. The term “hydrate”refers to the complex where the solvent molecule is water.

The compounds of the present invention, including salts, hydrates andsolvates thereof, may inherently or by design form polymorphs.

In another aspect, the present invention provides a pharmaceuticalcomposition comprising a compound of the present invention, or apharmaceutically acceptable salt thereof, and at least onepharmaceutically acceptable carrier. The pharmaceutical composition canbe formulated for particular routes of administration such as oraladministration, parenteral administration, and rectal administration,and the like. In addition, the pharmaceutical compositions of thepresent invention can be made up in a solid form (including withoutlimitation capsules, tablets, pills, granules, powders orsuppositories), or in a liquid form (including without limitationsolutions, suspensions or emulsions). The pharmaceutical compositionscan be subjected to conventional pharmaceutical operations such assterilization and/or can contain conventional inert diluents,lubricating agents, or buffering agents, as well as adjuvants, such aspreservatives, stabilizers, wetting agents, emulsifiers and buffers,etc.

Typically, the pharmaceutical compositions for compounds of Formula (I)are tablets or gelatin capsules comprising an active ingredient ofFormula (I) together with at least one of the following pharmaceuticallyacceptable excipients:

-   -   a) diluents, e.g., lactose, dextrose, sucrose, mannitol,        sorbitol, cellulose and/or glycine;    -   b) lubricants, e.g., silica, talcum, stearic acid, its magnesium        or calcium salt and/or polyethyleneglycol; for tablets also    -   c) binders, e.g., magnesium aluminum silicate, starch paste,        gelatin, tragacanth, methylcellulose, sodium        carboxymethylcellulose and/or polyvinylpyrrolidone; if desired    -   d) disintegrants, e.g., starches, agar, alginic acid or its        sodium salt, or effervescent mixtures; and/or    -   e) absorbents, colorants, flavors and sweeteners.

Tablets may be either film coated or enteric coated according to methodsknown in the art.

Suitable compositions for oral administration include an effectiveamount of a compound of the invention in the form of tablets, lozenges,aqueous or oily suspensions, dispersible powders or granules, emulsion,hard or soft capsules, or syrups or elixirs. Compositions intended fororal use are prepared according to any method known in the art for themanufacture of pharmaceutical compositions and such compositions cancontain one or more agents selected from the group consisting ofsweetening agents, flavoring agents, coloring agents and preservingagents in order to provide pharmaceutically elegant and palatablepreparations. Tablets may contain the active ingredient in admixturewith nontoxic pharmaceutically acceptable excipients which are suitablefor the manufacture of tablets. These excipients are, for example, inertdiluents, such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for example,starch, gelatin or acacia; and lubricating agents, for example magnesiumstearate, stearic acid or talc. The tablets are uncoated or coated byknown techniques to delay disintegration and absorption in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate can be employed. Formulations fororal use can be presented as hard gelatin capsules wherein the activeingredient is mixed with an inert solid diluent, for example, calciumcarbonate, calcium phosphate or kaolin, or as soft gelatin capsuleswherein the active ingredient is mixed with water or an oil medium, forexample, peanut oil, liquid paraffin or olive oil.

Certain injectable compositions are aqueous isotonic solutions orsuspensions, and suppositories are advantageously prepared from fattyemulsions or suspensions. Said compositions may be sterilized and/orcontain adjuvants, such as preserving, stabilizing, wetting oremulsifying agents, solution promoters, salts for regulating the osmoticpressure and/or buffers. In addition, they may also contain othertherapeutically valuable substances. Said compositions are preparedaccording to conventional mixing, granulating or coating methods,respectively, and contain about 0.1-75%, or contain about 1-50%, of theactive ingredient.

Suitable compositions for transdermal application include an effectiveamount of a compound of the invention with a suitable carrier. Carrierssuitable for transdermal delivery include absorbable pharmacologicallyacceptable solvents to assist passage through the skin of the host. Forexample, transdermal devices are in the form of a bandage comprising abacking member, a reservoir containing the compound optionally withcarriers, optionally a rate controlling barrier to deliver the compoundof the skin of the host at a controlled and predetermined rate over aprolonged period of time, and means to secure the device to the skin.

Suitable compositions for topical application, e.g., to the skin andeyes, include aqueous solutions, suspensions, ointments, creams, gels orsprayable formulations, e.g., for delivery by aerosol or the like. Suchtopical delivery systems will in particular be appropriate for dermalapplication, e.g., for the treatment of skin cancer, e.g., forprophylactic use in sun creams, lotions, sprays and the like. They arethus particularly suited for use in topical, including cosmetic,formulations well-known in the art. Such may contain solubilizers,stabilizers, tonicity enhancing agents, buffers and preservatives.

As used herein a topical application may also pertain to an inhalationor to an intranasal application. They may be conveniently delivered inthe form of a dry powder (either alone, as a mixture, for example a dryblend with lactose, or a mixed component particle, for example withphospholipids) from a dry powder inhaler or an aerosol spraypresentation from a pressurized container, pump, spray, atomizer ornebulizer, with or without the use of a suitable propellant.

The present invention further provides anhydrous pharmaceuticalcompositions and dosage forms comprising the compounds of the presentinvention as active ingredients, since water may facilitate thedegradation of certain compounds.

Anhydrous pharmaceutical compositions and dosage forms of the inventioncan be prepared using anhydrous or low moisture containing ingredientsand low moisture or low humidity conditions. An anhydrous pharmaceuticalcomposition may be prepared and stored such that its anhydrous nature ismaintained. Accordingly, anhydrous compositions are packaged usingmaterials known to prevent exposure to water such that they can beincluded in suitable formulary kits. Examples of suitable packaginginclude, but are not limited to, hermetically sealed foils, plastics,unit dose containers (e. g., vials), blister packs, and strip packs.

The invention further provides pharmaceutical compositions and dosageforms that comprise one or more agents that reduce the rate by which thecompound of the present invention as an active ingredient willdecompose. Such agents, which are referred to herein as “stabilizers,”include, but are not limited to, antioxidants such as ascorbic acid, pHbuffers, or salt buffers, etc.

The compounds of formula I in free form or in salt form, exhibitvaluable pharmacological activities, e.g. they modulate or inhibitactivity of A-Raf, B-Raf and/or C-Raf, as indicated by test dataprovided in the next sections, and are therefore indicated for therapyor for use as research chemicals, e.g. as tool compounds. Thesecompounds are especially useful for treatment of cancers driven bymutations in the Raf/Raf/MEK/ERK pathway, including cancerscharacterized by an activating Raf mutation such as Raf V600E, includingbut not limited to melanoma (e.g., malignant melanoma), breast cancer,lung cancer (e.g., non-small cell lung cancer), sarcoma, GI tumors suchas gastrointestinal stromal tumors, ovarian cancer, colorectal cancer,thyroid cancer, and pancreatic cancer.

Thus, as a further embodiment, the present invention provides the use ofa compound of formula (I) or any of the embodiments within the scope ofFormula (I) as described herein, in therapy. In a further embodiment,the therapy is for a disease which may be treated by inhibition ofA-Raf, B-Raf or C-Raf. In another embodiment, the compounds of theinvention are useful to treat cancers, including but not limited tomelanoma, breast cancer, lung cancer, sarcoma, GI tumors such asgastrointestinal stromal tumors, ovarian cancer, colorectal cancer,thyroid cancer, and pancreatic cancer.

In another embodiment, the invention provides a method of treating adisease which is treatable by inhibition of A-Raf, B-Raf or C-Raf, or acombination thereof, comprising administration of a therapeuticallyeffective amount of a compound of formula (I) or any of the embodimentswithin the scope of Formula (I) as described herein. In a furtherembodiment, the disease is selected from the afore-mentioned list,suitably melanoma, breast cancer, lung cancer, sarcoma, GI tumors suchas gastrointestinal stromal tumors, ovarian cancer, colorectal cancer,thyroid cancer, and pancreatic cancer. The method typically comprisesadministering an effective amount of a compound as described herein or apharmaceutical composition comprising such compound to a subject in needof such treatment. The compound may be administered by any suitablemethod such as those described herein, and the administration may berepeated at intervals selected by a treating physician.

Thus, as a further embodiment, the present invention provides the use ofa compound of formula (I) or any of the embodiments of such compoundsdescribed herein for the manufacture of a medicament. In a furtherembodiment, the medicament is for treatment of a disease which may betreated by inhibition of A-Raf, B-Raf or C-Raf. In another embodiment,the disease is a cancer, e.g., a cancer selected from theafore-mentioned list, including melanoma, breast cancer, lung cancer,sarcoma, GI tumors such as gastrointestinal stromal tumors, ovariancancer, colorectal cancer, thyroid cancer, and pancreatic cancer.

The pharmaceutical composition or combination of the present inventioncan be in unit dosage of about 1-1000 mg of active ingredient(s) for asubject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients.The therapeutically effective dosage of a compound, the pharmaceuticalcomposition, or the combinations thereof, is dependent on the species ofthe subject, the body weight, age and individual condition, the disorderor disease or the severity thereof being treated. A physician, clinicianor veterinarian of ordinary skill can readily determine the effectiveamount of each of the active ingredients necessary to prevent, treat orinhibit the progress of the disorder or disease.

The above-cited dosage properties are demonstrable in vitro and in vivotests using advantageously mammals, e.g., mice, rats, dogs, monkeys orisolated organs, tissues and preparations thereof. The compounds of thepresent invention can be applied in vitro in the form of solutions,e.g., aqueous solutions, and in vivo either enterally, parenterally,advantageously intravenously, e.g., as a suspension or in aqueoussolution. The dosage in vitro may range between about 10⁻³ molar and10⁻⁹ molar concentrations. A therapeutically effective amount in vivomay range depending on the route of administration, between about0.1-500 mg/kg, or between about 1-100 mg/kg.

The compound of the present invention may be administered eithersimultaneously with, or before or after, one or more therapeuticco-agent(s) (co-therapeutic agents). Suitable co-therapeutic agents foruse in the invention include, for example, cancer chemotherapeuticsincluding but not limited to inhibitors of PI3K, other inhibitors of theRaf pathway, paclitaxel, docetaxel, temozolomide, platins, doxorubicins,vinblastins, cyclophosphamide, topotecan, gemcitabine, ifosfamide,etoposide, irinotecan, and the like. The compound of the presentinvention may be administered separately, by the same or different routeof administration, or together in the same pharmaceutical composition asthe co-agent(s).

In one embodiment, the invention provides a product comprising acompound of formula (I) and at least one other therapeutic co-agent as acombined preparation for simultaneous, separate or sequential use intherapy. In one embodiment, the therapy is the treatment of a disease orcondition mediated by B-Raf or C-Raf, such as cancer. Products providedas a combined preparation include a composition comprising the compoundof formula (I) and the other therapeutic co-agent(s) together in thesame pharmaceutical composition, or the compound of formula (I) and theother therapeutic co-agent(s) in separate form, e.g. in the form of akit.

In one embodiment, the invention provides a pharmaceutical compositioncomprising a compound of formula (I) and another therapeuticco-agent(s). Optionally, the pharmaceutical composition may comprise apharmaceutically acceptable carrier, as described above.

In one embodiment, the invention provides a kit comprising two or moreseparate pharmaceutical compositions, at least one of which contains acompound of formula (I). In one embodiment, the kit comprises means forseparately retaining said compositions, such as a container, dividedbottle, or divided foil packet. An example of such a kit is a blisterpack, as typically used for the packaging of tablets, capsules and thelike.

The kit of the invention may be used for administering different dosageforms, for example, oral and parenteral, for administering the separatecompositions at different dosage intervals, or for titrating theseparate compositions against one another. To assist compliance, the kitof the invention typically comprises directions for administration.

In the combination therapies of the invention, the compound of theinvention and the other therapeutic co-agent may be manufactured and/orformulated by the same or different manufacturers. Moreover, thecompound of the invention and the other therapeutic may be broughttogether into a combination therapy: (i) prior to release of thecombination product to physicians (e.g. in the case of a kit comprisingthe compound of the invention and the other therapeutic agent); (ii) bythe physician themselves (or under the guidance of the physician)shortly before administration; (iii) in the patient themselves, e.g.during sequential administration of the compound of the invention andthe other therapeutic agent.

Accordingly, the invention provides the use of a compound of formula (I)for treating a disease or condition mediated by B-Raf or C-Raf, whereinthe medicament is prepared for administration with another therapeuticagent. The invention also provides the use of another therapeuticco-agent for treating a disease or condition, wherein the medicament isadministered with a compound of formula (I).

The invention also provides a compound of formula (I) for use in amethod of treating a disease or condition mediated by B-Raf or C-Raf,wherein the compound of formula (I) is prepared for administration withanother therapeutic agent. The invention also provides anothertherapeutic co-agent for use in a method of treating a disease orcondition mediated by B-Raf or C-Raf, wherein the other therapeuticco-agent is prepared for administration with a compound of formula (I).The invention also provides a compound of formula (I) for use in amethod of treating a disease or condition mediated by B-Raf or C-Raf,wherein the compound of formula (I) is administered with anothertherapeutic co-agent. The invention also provides another therapeuticco-agent for use in a method of treating a disease or condition mediatedby B-Raf or C-Raf, wherein the other therapeutic co-agent isadministered with a compound of formula (I).

The invention also provides the use of a compound of formula (I) fortreating a disease or condition mediated by B-Raf or C-Raf, wherein thepatient has previously (e.g. within 24 hours) been treated with anothertherapeutic agent. The invention also provides the use of anothertherapeutic agent for treating a disease or condition mediated by B-Rafor C-Raf, wherein the patient has previously (e.g. within 24 hours) beentreated with a compound of formula (I).

General Synthesis Methods

The following Schemes and Examples illustrate representative methodsuseful for making the compounds of Formula (I).

Compounds of Formula (I) where ring B is a pyrimidine can be preparedfrom known halopyrimidine intermediates, introducing ring C by a Suzukior similar arylation reactions. The group -L-CY can be attached to RingC before it is installed, or a protected amine can be present at theposition corresponding to L for the Suzuki, and can be converted intothe amide linker to form -L-CY after the Suzuki reaction.

Compounds having different groups on Ring B, instead of two morpholinegroups, can be prepared by using thioalkyl-substituted pyrimidines, asexemplified in the following scheme. A desired A-ring morpholine group(see Formula (I)) can be attached using nucleophilic aromaticsubstitution chemistry, and a Suzuki or similar arylation can be used toattach Ring C. The thioalkyl group can then be activated towardnucleophilic displacement by oxidation to an alkylsulfonyl group, whichcan be displaced by various nucleophilic groups.

Alternatively, the oxidation can be done before the Suzuki reaction.This sequence can be used to install a heterocyclic or heteroaryl groupon the B ring, or it can be used to introduce other nucleophiles such asalkoxy, amine or azide at this position. These can then be furthermodified as exemplified by amine alkylation (above) or, e.g., if azideis used as the nucleophile, a cycloaddition reaction can be used to makea heteroaryl substituent on Ring B as shown below.

Other compounds of Formula (I) wherein Ring B is pyrimidine can be madefrom 2,4,6-trichloropyrimidine by starting with a Suzuki reaction tointroduce one group (R₁), providing a mixture of isomeric products, asshown in Scheme 4. A morpholine A-ring can then be attached by aromaticnucleophilic substitution chemistry, followed by another Suzukireaction.

Compounds of Formula (I) wherein Ring B is pyridine can be made by thefollowing

general methods, which provide various pyridine isomers.Bromo-fluoropyridines allow selective use of nucleophilic aromaticsubstitution and Suzuki or similar arylation chemistry.

Various other substituent groups can be introduced onto pyridinyl B-ringcompounds by introducing only one optionally substituted morpholine on a2,4,6-trihalopyridine, then sequentially replacing the other twohalogens with suitable groups as illustrated in the following schemes.Scheme 6 illustrates introduction of an aryl or heteroaryl group on theB ring, using Suzuki chemistry; Scheme 7 illustrates use of aromaticnucleophilic substitution chemistry to introduce other nucleophilicsubstituents such as amines, alkoxy groups, and alkylthio groups.

The following schemes illustrate additional routes to make compoundswhere ring B is pyridine, as demonstrated by the Examples below.

The following scheme illustrates a general route for synthesis ofcompound of Formula (I) wherein the B-ring is pyridone. The sequencealso produces alkoxy-substituted pyridine B-ring compounds of Formula(I).

Compounds of Formula (I) wherein the B-ring is pyridazine can be madesimilarly, using known halogenated pyridazine starting materials withnucleophilic aromatic substitution reactions to attach Ring A (and/orother substituents on the B-ring), and Suzuki chemistry to attach RingC.

Salts of compounds of the present invention having at least onesalt-forming group may be prepared in a manner known to those skilled inthe art. For example, salts of compounds of the present invention havingacid groups may be formed, for example, by treating the compounds withmetal compounds, such as alkali metal salts of suitable organiccarboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, withorganic alkali metal or alkaline earth metal compounds, such as thecorresponding hydroxides, carbonates or hydrogen carbonates, such assodium or potassium hydroxide, carbonate or hydrogen carbonate, withcorresponding calcium compounds or with ammonia or a suitable organicamine, stoichiometric amounts or only a small excess of the salt-formingagent preferably being used. Acid addition salts of compounds of thepresent invention are obtained in customary manner, e.g. by treating thecompounds with an acid or a suitable anion exchange reagent. Internalsalts of compounds of the present invention containing acid and basicsalt-forming groups, e.g. a free carboxy group and a free amino group,may be formed, e.g. by the neutralization of salts, such as acidaddition salts, to the isoelectric point, e.g. with weak bases, or bytreatment with ion exchangers.

Salts can be converted into the free compounds in accordance withmethods known to those skilled in the art. Metal and ammonium salts canbe converted, for example, by treatment with suitable acids, and acidaddition salts, for example, by treatment with a suitable basic agent.

Mixtures of isomers obtainable according to the invention can beseparated in a manner known to those skilled in the art into theindividual isomers; diastereoisomers can be separated, for example, bypartitioning between polyphasic solvent mixtures, recrystallizationand/or chromatographic separation, for example over silica gel or bye.g. medium pressure liquid chromatography over a reversed phase column,and racemates can be separated, for example, by the formation of saltswith optically pure salt-forming reagents and separation of the mixtureof diastereoisomers so obtainable, for example by means of fractionalcrystallization, or by chromatography over optically active columnmaterials.

Intermediates and final products can be worked up and/or purifiedaccording to standard methods, e.g. using chromatographic methods,distribution methods, (re-) crystallization, and the like.

Compounds of the invention and intermediates can also be converted intoeach other according to methods generally known to those skilled in theart.

Terms used herein have their ordinary meaning to those of skill in theart unless otherwise defined. The following abbreviations may be usedherein:

DAST (diethylamino)sulfurtrifluoride DCM Dichloromethane DIADdiisopropylazodicarboxylate DIEA diisopropylethylamine DMADimethylacetamide DMAP 4-dimethylaminopyridine DME 1,2-dimethoxyethaneDMF N,N-dimethylformamide DPPF 1,1′-bis(diphenylphosphino)ferrocene EDC1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EtOAc ethylacetate EtOH Ethanol HOAT Hydroxyazabenzotriazole HOBtHydroxybenzotriazole K₂CO₃ Potassium carbonate MeCN Acetonitrile MgSO₄Magnesium sulfate MeOH Methanol Na₂CO₃ sodium carbonate NaCl Sodiumchloride NaHCO₃ sodium bicarbonate NBS N-bromosuccinimide NMPN-methyl-2-pyrrolidone Pd₂(dba)₃Tris(dibenzylideneacetone)dipalladium(0) Pd(PPh₃)₄Tetrakis(triphenylphospine)palladium(0) Pd(dppf)Cl₂—DCMDichloro-(1,2-bis(diphenylphosphino)ethan)-Palladium(II)-dichloromothethane adduct RT or rt room temperatureTBDMSCl tert-butyldimethylsilylchloride TEA Triethylamine THFtetrahydrofuran

The following examples are intended to illustrate the invention and arenot to be construed as being limitations thereon. Temperatures are givenin degrees Celsius. If not mentioned otherwise, all evaporations areperformed under reduced pressure, typically between about 15 mm Hg and100 mm Hg (=20-133 mbar). The structure of final products, intermediatesand starting materials is confirmed by standard analytical methods,e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR,NMR. Abbreviations used are those conventional in the art.

Mass spectrometric analysis was performed on LCMS instruments: WatersSystem (Acuity UPLC and a Micromass ZQ mass spectrometer; Column: AcuityHSS C18 1.8-micron, 2.1×50 mm; gradient: 5-95% acetonitrile in waterwith 0.05% TFA over a 1.8 min period; flow rate 1.2 mL/min; molecularweight range 200-1500; cone Voltage 20 V; column temperature 50° C.).All masses were reported as those of the protonated parent ions.

Nuclear magnetic resonance (NMR) analysis was performed on some of thecompounds with a Varian 400 MHz NMR (Palo Alto, Calif.). The spectralreference was either TMS or the known chemical shift of the solvent.

All starting materials, building blocks, reagents, acids, bases,dehydrating agents, solvents, and catalysts utilized to synthesize thecompounds of the present invention are either commercially available orcan be produced by organic synthesis methods known to one of ordinaryskill in the art (Houben-Weyl 4th Ed. 1952, Methods of OrganicSynthesis, Thieme, Volume 21). Further, the compounds of the presentinvention can be produced by organic synthesis methods known to one ofordinary skill in the art in view of the following examples.

Compounds of the invention can be prepared using methods known in theart, along with methods disclosed herein, starting with known materials.

The syntheses of certain intermediates are outlined here, followed bydescription of syntheses of examples of compounds of Formula (I).

Synthesis of 4-(2-cyanopropan-2-yl)picolinic acid

To a suspension of 4-chloropicolinic acid (1.0 equiv.) in THF (0.95 M)at rt was added isobutyronitrile (3.2 equiv.) and LiHMDS (1M solution inTHF, 3.1 equiv.). The mixture was stirred at 100° C. for 10 min in themicrowave. The cooled solution was quenched with sat. ammonium chlorideand acidified with 6N HCl to pH=4. The solution was extracted withIPA/Chloroform (1:3) three times. The combined organic layer was washedwith brine, dried over sodium sulfate, filtered and concentrated to give4-(2-cyanopropan-2-yl)picolinic acid in 72% yield. ¹H NMR (400 MHz,<dmso>) δ ppm 1.71 (s, 6H) 7.76 (dd, J=5.48, 1.96 Hz, 1H) 8.12 (d,J=1.57 Hz, 1H) 8.73 (d, J=5.09 Hz, 1H). LCMS m/z (M+H)=190.9, Rt=0.31min.

Synthesis of 4-(2-hydroxypropan-2-yl)picolinic acid

Step 1

To a solution of ethyl 2-oxopropanoate (15 equiv.) at 0° C. was addeddropwise H₂O₂ (10 equiv.). The cold mixture (still stirred at 0° C.) wascannulated into a mixture of 1-(pyridin-4-yl)ethanone (1.0 equiv.),H₂SO₄ (1.0 equiv.) and FeSO₄.7H₂O (10 equiv.) in DCM/water (15:1, 0.08M) at rt over 3 h. The resulting reaction mixture was stirred at rt foradditional 30 min. The aqueous layer was extracted with DCM and thecombined organic DCM layers were washed with 5% sodium sulfite, brine,dried over sodium sulfate and concentrated. Purification via silica gelcolumn chromatography (ISCO, 0-60% EtOAc/Heptane) gave ethyl4-acetylpicolinate in 46% yield. LCMS m/z (M+H)=193.9, Rt=0.51 min.

Step 2

Ethyl 4-acetylpicolinate (1.0 equiv.) was dissolved in THF (0.1 M) andthe solution was cooled to −78° C. Methyllithium (1.2 equiv.) was addedover the period of 5 min and the mixture was stirred at −78° C. for anadditional 5 min. The reaction was poured into ice-water and extractedtwice with ethyl acetate. The organic layer was washed with brine, driedover sodium sulfate, filtered and concentrated. The residue was purifiedvia silica gel chromatography (ISCO, 0-100% ethyl acetate/heptanes) togive ethyl 4-(2-hydroxypropan-2-yl)picolinate in 47% yield. LCMS m/z(M+H)=210.2, Rt=0.43 min.

Step 3

To a solution of ethyl 4-(2-hydroxypropan-2-yl)picolinate (1.0 equiv.)in THF (0.13 M) was added LiOH (3.0 equiv.). The mixture was stirred atrt for 4 hr. Concentrated to remove most of THF and the residue wasneutralized with 6 N HCl to pH=3. Dilute the mixture with water andMeCN, then lyophilized give 4-(2-hydroxypropan-2-yl)picolinic acidcontaining 3.0 equiv. of LiCl. LCMS m/z (M+H)=181.9, Rt=0.18 min.

Synthesis of 4-(2-fluoropropan-2-yl)picolinic acid

Step 1

To a solution of ethyl 4-(2-hydroxypropan-2-yl)picolinate (1.0 equiv.)in DCM (0.1 M) at −78° C. was added DAST (1.2 equiv.). The mixture wasstirred at −78° C. for 1 h and warmed up to rt and stirred at rt for 1h. LC-Ms indicated completed conversion. An aqueous saturated NaHCO₃solution was added and the mixture was stirred for 15 minutes, then themixture was extracted with EtOAc. The organic layer was washed withbrine, dried over sodium sulfate and concentrated to give ethyl4-(2-fluoropropan-2-yl)picolinate in 98% yield. LCMS m/z (M+H)=211.9,Rt=0.69 min.

Step 2

To a solution of ethyl 4-(2-fluoropropan-2-yl)picolinate (1.0 equiv.) inTHF (0.19 M) was added LiOH (3.8 equiv.). The mixture was stirred at rtfor 4 hr. Concentrated to remove most of THF and the residue wasneutralized with 6 N HCl to pH=3 and extracted with EtOAc. The organiclayer was washed with brine, dried over sodium sulfate and concentratedto yield 4-(2-fluoropropan-2-yl)picolinic acid in 71% yield. LCMS m/z(M+H)=183.9, Rt=0.32 min.

Synthesis of 4-(1,1-difluoroethyl)picolinic acid

Step 1

A solution of ethyl 4-acetylpicolinate (1.0 equiv.) in 1.0 equiv. ofDeoxoFluor (50% in toluene) was stirred for 12 h at 85° C. The reactionmixture was then added to a NaCl(sat) solution. The aqueous mixture wasextracted with EtOAc. The organics were dried, and the resultingmaterial was purified by column chromatography utilizing an ISCO system(heptane-EtOAc) to yield ethyl 4-(1,1-difluoroethyl)picolinate in 72%yield. LCMS m/z (M+H)=216.1, Rt=0.70 min.

Step 2

To a solution of ethyl 4-(1,1-difluoroethyl)picolinate (1.0 equiv.) inTHF (0.2 M) was added LiOH (3.9 equiv.). The mixture was stirred at rtfor 4 hr. Concentrated to remove most of THF and the residue wasneutralized with 6N HCl to pH=3 and extracted with EtOAc. The organiclayer was washed with brine, dried with sodium sulfate and concentratedto yield 4-(1,1-difluoroethyl)picolinic acid in 86% yield. LCMS m/z(M+H)=187.9, Rt=0.41 min.

Synthesis of 3-(S-methylsulfonimidoyl)benzoic acid

Step 1

A solution of NalO₄ (1.0 equiv.) in Water (0.11 M) was prepared and thenadded dropwise to a stirred solution of 3-(methylthio)benzoic acid (1.0equiv.) in MeOH (0.11 M) at 0° C. After the addition was complete themixture was allowed to warm to 25° C. and stirred for 1 h. LCMS showsabout 20% complete, clean conversion to product. Stirring was continuedat 25° C. overnight. The reaction mixture was filtered, the filter cakewashed with MeOH. The filtrate was concentrated to a peach solid and3-(methylsulfinyl)benzoic acid was obtained in quantitative yield. LCMS(m/z) (M+H)=185.1, Rt=0.35 min.

Step 2

To solution of 3-(methylsulfinyl)benzoic acid (1.0 equiv.) in THF (0.2M) at 25° C. was added CDI (1.2 equiv.) and the mixture was stirred for15 min. MeOH (8.0 equiv.) was then added and the reaction was brieflywarmed to near reflux and then allowed to cool back to room temperature.LCMS shows about near complete, clean conversion to product. Thereaction mixture was poured onto a mix of saturated aqueous sodiumbicarbonate and brine and extracted two times with ethyl acetate. Thecombined organics were washed with brine, dilute HCl, and brine again,and then dried over magnesium sulfate, filtered, and concentrated. Thecrude reside was purified by Grace flash column chromatography oversilica gel eluting with heptane and 0-100% EtOAc gradient. Productfractions elute around 75% EtOAc and were concentrated to give methyl3-(methylsulfinyl)benzoate as a pale yellow oil in 70% yield. ¹H NMR(400 MHz, <cdcl3>) δ ppm 2.76 (s, 3H) 3.96 (s, 3H) 7.65 (t, J=7.83 Hz,1H) 7.90 (d, J=7.83 Hz, 1H) 8.18 (d, J=7.83 Hz, 1H) 8.28 (s, 1H). LCMS(m/z) (M+H)=198.9, Rt=0.47 min.

Step 3

To solution of methyl 3-(methylsulfinyl)benzoate (1.0 equiv.) in DCM(0.1 M) at 25° C. under Ar were added 2,2,2-trifluoroacetamide (2.0equiv.), MgO (4.0 equiv.), rhodium(II) acetate dimer (0.05 equiv.), anddiacetoxyiodobenzene (1.5 equiv.) and the mixture was stirred overnight.LCMS shows near complete consumption of starting material and cleanconversion to product (M+1=310, R_(t)=0.76). The reaction mixture wasfiltered through Celite, washing with DCM, and concentrated. The residuewas purified by Grace flash column chromatography over silica gel,eluting with heptane and 0-75% EtOAc gradient. Product fractions elutearound 40% EtOAc and were concentrated to give methyl3-(S-methyl-N-(2,2,2-trifluoroacetyl)sulfonimidoyl)benzoate in 90% yieldas a colorless oil. ¹H NMR (400 MHz, <cdcl3>) δ ppm 3.50 (s, 3H) 4.00(s, 3H) 7.78 (t, J=8.02 Hz, 1H) 8.17-8.23 (m, 1H) 8.41 (d, J=7.83 Hz,1H) 8.63 (s, 1H). LCMS (m/z) (M+H)=310.0, Rt=0.76 min.

Step 4

To a stirred solution of methyl 3-(S-methyl-N-(2,2,2trifluoroacetyl)sulfonimidoyl)benzoate (1.0 equiv.) in THF and MeOH(2:1, 0.09 M) at 25° C. was added LiOH (2 M aq.) (3.5 equiv.) and themixture was stirred for 3 h. LCMS shows complete consumption of startingmaterial and clean conversion to product. Most of the THF/MeOH wasremoved by concentration and then the mixture was acidified using 1 MHCl. Product could not be extracted from the aqueous with organicsolvents, so the acidic aqueous layer was diluted with some acetonitrileand then lyophilized to give 3-(S-methylsulfonimidoyl)benzoic acid as awhite solid which likely contains approx. 3.5 eq of LiCl. Thiscalculates to a 99% calculated yield of desired product. LCMS (m/z)(M+H)=199.9, Rt=0.25 min

Synthesis of 3-(2,2,2-trifluoro-1-hydroxyethyl)benzoic acid

Step 1

Trimethyl(trifluoromethyl)silane (1.3 quiv.) and cesium fluoride (0.1equiv.) were added to a solution of methylformylbenzoate (1.0 equiv.) inTHF (0.3 M) at room temperature under nitrogen and the mixture wassonicated for 30 min to initiate the reaction, which was indicated bythe appearance of a pale yellow colour. The mixture was stirred at roomtemp for 5 h, after which HCl(aq) (1M) was added and the mixture stirredfor a further 15 min. The mixture was then extracted with EtOAc, washed(saturated NaHCO₃, brine), dried (MgSO₄) and evaporated in vacuo. Theproduct was purified by ISCO and eluted with 0 to 70% ethyl acetate inheptane to give methyl 3-(2,2,2-trifluoro-1-hydroxyethyl)benzoate in 81%yield. LCMS (m/z) (M+H)=234.9, Rt=0.74 min.

Step 2

Lithium hydroxide (5.0 equiv, 2M aqueous solution) was added to methyl3-(2,2,2-trifluoro-1-hydroxyethyl)benzoate (1.0 equiv.) in Acetonitrileand Water (2:1, 0.001M) at 0° C. and then the mixture was brought to RTand stirred for 6 h. The mixture was acidified with 1N HCl and extractedwith ethyl acetate to give 3-(2,2,2-trifluoro-1-hydroxyethyl)benzoicacid in 91% yield. LCMS (m/z) (M+H)=219.1, Rt=0.3 min.

Synthesis of 5-fluoro-2-(trifluoromethyl)pyridin-4-amine

2-(trifluoromethyl)pyridin-4-amine (1.0 equiv.) was dissolved in ACN(0.06). Selectfluor (2.2 equiv.) was added and the reaction mixture wasstirred at rt for 2 days. Sat. sodium bicarbonate solution added toquench reaction, partitioned with ethyl acetate, the organic phase wasconcentrated to dryness and purified by ISCO flash chromatograph (0-70%ethyl acetate in heptane) to yield5-fluoro-2-(trifluoromethyl)pyridin-4-amine in 23% yield. ¹H NMR (400MHz, <cdcl3>) δ ppm 4.52 (br. s., 2H) 6.97-7.16 (m, 1H) 8.27 (d, J=2.35Hz, 1H).

Synthesis of 2-(1,1-difluoroethyl)pyridin-4-amine

Step 1

To a solution of 2-(1,1-difluoroethyl)isonicotinic acid (1.0 equiv.) inDioxane (0.3 M) was added diphenyl phosphoryl azide (1.8 equiv.),t-butyl alcohol (6.0 equiv.), and TEA (1.8 equiv.). The rxn was degassedfor 1 min, then heated at 110° C. for 3.0 hr. The dioxane was evaporatedin vacuo, and the residue partioned between EtOAc and 10% citric acid.The organic layer was separated and the aqueous layer further extractedwith EtOAc. The combined organics were dried over Na₂SO₄, filtered andconcentrated. The crude was loaded onto silica gel and purified bycolumn chromatography (ISCO, 0-50% EtOAc in Heptanes). Pure fractionswere combined and concentrated to yield tert-butyl(2-(1,1-difluoroethyl)pyridin-4-yl)carbamate in 44% yield as a clearoil. LCMS (m/z) (M+H)=259, Rt=0.68.

Step 2

To a solution of tert-butyl (2-(1,1-difluoroethyl)pyridin-4-yl)carbamate(1.0 equiv.) in DCM (0.25 M) was added TFA (10 equiv.) and allowed tostir at RT for 6 hrs. The volaties were removed in vacuo, and theresidue was taken up in DCM and pushed through a carbonate column toremove the TFA salt, the column was washed several times with DCM. Thecombined organics were concentrated to yield2-(1,1-difluoroethyl)pyridin-4-amine in 54% yield. LCMS (m/z)(M+H)=158.9, Rt=0.29.

Synthesis ofN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide

To a solution of4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.) in THF (0.1 M) at 0° C. was added3-trifluoromethylbenzoylchloride (1.0 equiv.) and the reaction wasstirred at room temperature for 3 h. The solution was concentrated anddried under vacuo to giveN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamideas a tan solid in 96% yield.

LCMS (m/z) (M+H)=406.2, Rt=1.24 min.

Synthesis ofN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

To a 0.4 M solution of 5-bromo-6-methylpyridin-3-amine (1.00 equiv.) inDCM was added DIEA (1.00 equiv.) and 3-(trifluoromethyl)benzoyl chloride(1.00 equiv.). The mixture was stirred at ambient temperature for 3 hr.The reaction mixture was diluted with DCM, washed with saturated aqueoussodium bicarbonate, dried over sodium sulfate, filtered, andconcentrated to giveN-(5-bromo-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide as anoff-white solid in 98% yield. LCMS (m/z) (M+H)=359.0/361.0, Rt=0.86 min.

Step 2

To a 0.27 M solutionN-(5-bromo-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide (1.00equiv.) in 1,4-dioxane was added bis(pinacolato)diboron (1.50 equiv.),potassium acetate (2.00 equiv.) and PdCl₂(dppf).CH₂Cl₂ adduct (0.10equiv.). The reaction was irradiated at 120° C. for 20 min. The cooledreaction mixture was diluted with ethyl acetate and filtered throughCelite. The filtrate was concentrated to giveN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamideas a dark brown tacky solid in quantitative yield. LCMS (m/z)(M+H)=325.0, Rt=0.59 min.

Synthesis of2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide

Step 1

To a mixture of 2-fluoro-4-methylpyridine (1.0 equiv.) andisobutyronitrile (4.0 equiv.) was cannulated KHMDS (1.2 equiv.) intoluene. The mixture was heated to reflux for 1.5 hours at which timethe reaction was cooled to RT, quenched with NH₄Cl (aq), extracted withEtOAc, dried over Na₂SO₄, filtered, and concentrated. The crude materialwas used in next step. LCMS (m/z) (M+H)=161.1, Rt=0.48 min.

Step 2

To a solution of 2-methyl-2-(4-methylpyridin-2-yl)propanenitrile (1.0equiv.) in water (0.38 M) was added potassium permanganate (6.0 equiv.).The mixture was heated at 60° C. for 1 hr. The mixture was cooled to rt,acidified with 2 M HCl to pH 4 and extracted with EtOAc. The organiclayer was washed with brine, dried over Na₂SO₄ and concentrated. LC-MSshowed the crude yellowish solid still contained 15% of diacid.Redissolved the crude in EtOAc and washed with acidic water (pH 4). Theorganic layer was washed with brine, dried over Na₂SO₄ and concentratedto yield off white solid. NO diacid left. Used as is in next step. LCMS(m/z) (M+H)=191.0, Rt=0.53 min.

Step 3

EDC (1.3 equiv.) was added to a solution of4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.), 2-(2-cyanopropan-2-yl)isonicotinic acid (1.2 equiv.), HOAt (1.3equiv.) in DMF (0.19 M). The mixture was stirred at ambient temperature3 hrs. The reaction mixture was diluted with water and extracted withethyl acetate. The combined extracts were washed sequentially with 1Maqueous sodium hydroxide and brine, dried over sodium sulfate, filtered,and concentrated to yield2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamidein 97% yield. LCMS (m/z) (M+H)=406.2, Rt=1.10 min.

Synthesis ofN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of 3-bromo-4-methylbenzoic acid (1.0 equiv.) in DMF (1.2M)was added EDC (1.0 equiv.) and HOBt (1.0 equiv.) followed by3-trifluoromethylaniline (1.0 equiv.) and the reaction was stirred atambient temperature for 48 h. The reaction mixture was partitionedbetween ethyl acetate and water. The separated organic layer was driedwith sodium sulfate and concentrated under vacuo. The concentrated crudewas purified via silica gel chromatography and eluted with 0 to 100%ethyl acetate in heptanes to give3-bromo-4-methyl-N-(3-(trifluoromethyl) phenyl) benzamide in 83% yield.LCMS (m/z) (M+H)=358/360, Rt=1.1 min.

Step 2

To 3-bromo-4-methyl-N-(3-(trifluoromethyl) phenyl) benzamide (1.0equiv.) in a microwave vial equipped with a stir bar was added dioxane(0.5M) was added4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (3 equiv.)and potassium acetate (6 equiv.) and nitrogen was bubbled through thereaction mixture for 5 min. To it was added PdCl₂(dppf)-DCM adduct (0.1equiv) and the vial was sealed and heated to 120° C. for 16 h. Thereaction mixture was filtered and the filter paper was washed withdichloromethane and the filtrate was concentrated under vacuo. It wasthen loaded on celite and purified via silica gel chromatography elutingwith 0-100% ethyl acetate in heptanes to affordN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamidein quantitative yield. LCMS (m/z) (M+H)=406.2, Rt=1.2 min.

Synthesis ofN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

To a mixture of4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.) and 3-(trifluoromethyl)benzoic acid (1.1 equiv.) in DMF (0.27 M)was added HOAt (1.3 equiv.) and EDC (1.3 equiv.) After 3 h the reactionmixture was diluted with water and then extracted with EtOAc. Theorganic phase was washed sequentially with 1 M aqueous sodium hydroxideand brine and was then dried over sodium sulfate. The solution wasconcentrated and dried under vacuo to giveN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-(trifluoromethyl)isonicotinamidein 91% yield. LCMS (m/z) (M+H)=407.1, Rt=1.13 min.

2-(tert-butyl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide

A solution of 5-amino-2-methylphenylboronic acid, pinacol ester (1.0equiv.), 2-(tert-butyl)isonicotinic acid (1.0 equiv.), EDC (1.0 equiv.)and 1-hydroxy-7-azabenzotriazole (0.380 g, 1.0 equiv.) in DMF (0.3 M)was stirred at RT for 68 hr. The reaction mixture was then diluted withEtOAc and water, the organic layer was isolated and the aqueous layerwas extracted twice with EtOAc. The combined organics were dried overMgSO₄, filtered and concentrated in vacuo to yield2-(tert-butyl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamideas a white solid in 91%. LCMS (m/z) (M+H)=395.1, Rt=0.71 min.

Synthesis of2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)isonicotinamide

Step 1

EDC (1.3 equiv.) was added to a solution of5-bromo-6-methylpyridin-3-amine (1.05 equiv),2-(2-cyanopropan-2-yl)isonicotinic acid (1.0 equiv), HOAt (1.3 equiv) inDMF (0.17 M). The mixture was stirred at ambient temperature 3 hrs. Thereaction mixture was diluted with water and extracted with ethylacetate. The combined extracts were washed sequentially with 1M aqueoussodium hydroxide and brine, dried over sodium sulfate, filtered, andconcentrated. The crude was purified by ISCO (50% EtOAc/Heptane).Combined fractions still contained 17% 5-bromo-6-methylpyridin-3-amine.Add 2-(2-cyanopropan-2-yl)isonicotinic acid (0.3 equiv), EDC (0.3equiv), HOAt (0.3 equiv) in DMF (0.17 M). After stirred at rt overnight,the reaction mixture was diluted with water and extracted with ethylacetate. The combined extracts were washed sequentially with 1M aqueoussodium hydroxide and brine, dried over sodium sulfate, filtered, andconcentrated to yieldN-(5-bromo-6-methylpyridin-3-yl)-2-(2-cyanopropan-2-yl)isonicotinamidein 71% over three steps. LCMS (m/z) (M+H)=359.0, Rt=0.73 min.

Step 2

To a solution ofN-(5-bromo-6-methylpyridin-3-yl)-2-(2-cyanopropan-2-yl)isonicotinamide(1.0 equiv.) in dioxane (0.18 M) was added potassium acetate (5.0equiv.) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane)(1.5 equiv.). The solution was degassed with nitrogen andPd(dppf)Cl₂-DCM was added. The reaction was then heated to 80° C.overnight. The mixture was concentrated and diluted with EtOAc, washedwith H₂O, brine. The organic layer was dried over Na₂SO₄ andconcentrated. The residue was then titrated in hexane. Filtered and thesolid was collected to yield2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)isonicotinamidein 82% yield. LCMS (m/z) (M+H)=325.1, Rt=0.49 min. 1H NMR (400 MHz,<cdcl3>) δ ppm 1.27 (s, 6H), 1.32-1.40 (m, 12H), 1.82 (s, 6H), 2.75 (s,3H), 7.69 (d, J=3.91 Hz, 1H), 7.86-7.95 (m, 1H), 7.98 (s, 1H), 8.28 (br.s., 1H), 8.79 (d, J=5.09 Hz, 1H), 8.89 (br. s., 1H).

Synthesis of Amine-substituted 4-Pyridinyl-Phenyl/3-Pyridinyl Amines asIntermediates

Synthesis of2-((5-amino-2-methyl-6′-morpholino-[3,4′-bipyridin]-2′-yl)amino)ethanolStep 1

To a 0.3M solution of 5-bromo-6-methylpyridin-3-amine (1.00 equiv.) inDME was added (2,6-difluoropyridin-4-yl)boronic acid (1.30 equiv.),PdCl2(dppf).CH2Cl2 adduct (0.05 equiv.), and 2M aqueous sodium carbonate(3.00 equiv.). The reaction mixture was heated at 60° C. for 18 hrs inan oil bath. The cooled reaction mixture was partitioned between waterand EtOAc (3×100 mL). The combined organics were washed with brine,dried over MgSO₄, filtered and concentrated. The crude was purified byflash chromatography over silica gel (ethyl acetate in heptane, 0-100%gradient) to give 2′,6′-difluoro-2-methyl-[3,4′-bipyridin]-5-amine(90.0% yield) as an orange solid. ¹H NMR (400 MHz, <dmso>) δ ppm 2.27(s, 3H) 5.31 (s, 2H) 6.84 (d, J=2.35 Hz, 1H), 7.23 (s, 2H) 7.94 (d,J=2.74 Hz, 1H). LCMS (m/z) (M+H)=222.1, Rt=0.41 min.

Step 2

To a 0.35M suspension of2′,6′-difluoro-2-methyl-[3,4′-bipyridin]-5-amine (1.00 eq) and potassiumcarbonate (1.20 eq) in DMSO was added 2-aminoethanol (5.10 eq) dropwise. The reaction was mixture was heated to 35° C. for 18 hrs in an oilbath. The reaction was partition between water and EtOAc. The aqueouswas further washed with EtOAc (3×75 mL). The combined organics weredried over MgSO₄, filtered, and concentrated to yield2-((5-amino-6′-fluoro-2-methyl-[3,4′-bipyridin]-2′-yl)amino)ethanol(95%). No further purification was performed. LCMS (m/z) (M+H)=263.0,Rt=0.38 min.

Step 3

To a 0.5M suspension of2-((5-amino-6′-fluoro-2-methyl-[3,4′-bipyridin]-2′-yl)amino)ethanol(1.00 equiv.) and potassium carbonate (1.20 eq) in DMSO was addedmorpholine (5 eq). The reaction mixture was irradiated at 150° C. for 30min in the microwave. The cooled reaction mixture was partitionedbetween water and EtOAc (3×75 mL). The combined organics were washedwith brine, dried over MgSO₄, filtered and concentrated. The crude waspurified by flash chromatography over silica gel (MeOH in DCM 0-15%gradient) to give2-((5-amino-2-methyl-6′-morpholino-[3,4′-bipyridin]-2′-yl)amino)ethanol(58.0% yield) as a tan solid. ¹H NMR (400 MHz, <dmso>) δ ppm 2.22 (s,3H) 3.26-3.30 (m, 2H) 3.37 (t, J=4.50 Hz, 4H) 3.52 (q, J=6.00 Hz, 2H)3.64-3.69 (m, 4H) 4.63 (t, J=5.48 Hz, 1H) 5.11 (s, 2H) 5.72-5.80 (m, 2H)6.24 (t, J=5.48 Hz, 1H) 6.71 (d, J=2.35 Hz, 1H) 7.81 (d, J=2.74 Hz, 1H).LCMS (m/z) (M+H)=330.1, Rt=0.32 min.

Synthesis of 3-(difluoromethyl)benzoic acid

Step 1

In a high pressure vial, a solution of methyl 3-formylbenzoate (1equiv.) in DCM/EtOH (867:1, 0.40M) was added DeoxoFluor (2.0 equiv.).The reaction was purged with N₂, the vessel was sealed and heated at 60°C. After 18 hrs of stirring additional DeoxoFluor (2.0 equiv.) was addedand allowed to stir for 42 hrs. The reaction was followed by TLC (25%EtOAc in heptanes). The reaction was partitioned between brine andEtOAc. The aqueous layer was further washed with EtOAc (3×) and thecombined organics were dried over Na₂SO₄, filtered, and concentrated.The crude material was purified via flash chromatography over silica geleluting with heptanes and 0-25% ethyl acetate gradient. Isolated methyl3-(difluoromethyl)benzoate as a yellow oil in 62% yield. 1H NMR (400MHz, <cdcl3>) bb ppm 3.94 (s, 3H) 6.53-6.84 (m, 1H) 7.54 (t, J=7.83 Hz,1H) 7.71 (d, J=7.83 Hz, 1H) 8.15 (d, J=7.83 Hz, 1H) 8.18 (s, 1H).

Step 2

To a solution of methyl 3-(difluoromethyl)benzoate (1 equiv.) in THF(0.25M) was added 1M LiOH (2.5 equiv.) and allowed to stir at RT. Uponinitial addition of LiOH, the solution turned from clear to a burntorange, and after 2 hrs the solution is light yellow. The reactionstirred for 18 hrs at RT. The volatiles were removed in vacuo, and theaqueous phase was acidified to ˜pH 3. A white precipitate was formed,filtered and dried. Isolated 3-(difluoromethyl)benzoic acid in 78%yield. LCMS (m/z) (M+H)=245.1, Rt=0.73). 1H NMR (400 MHz, <dmso>) 5 ppm6.97-7.30 (m, 1H) 7.63-7.71 (m, 1H) 7.83 (d, J=7.43 Hz, 1H) 8.06-8.16(m, 1H)

Synthesis of 2-(1,1-difluoroethyl)isonicotinic acid

Step 1

In a high pressure vial charged with a solution of1-(4-methylpyridin-2-yl)ethanone (1.0 equiv.) and EtOH (0.1 equiv) inDCM (2.0M) was added DAST (2.5 equiv.). The reaction was heated to 30°C. and heated for 48 hrs. LCMS analysis indicated the formation of thedesired product (MH+—157.9, Rt—0.54 min). The reaction was diluted withDCM and quenched with NaHCO₃, slowly at 0° C. The phases were separatedand the aqueous layer was washed with DCM (2×). The combined organicswere dried over MgSO4, filtered, and concentrated. The crude materialwas purified via flash chromatography over silica gel eluting withheptanes and 0-100% ethyl acetate gradient. Isolated2-(1,1-difluoroethyl)-4-methylpyridine in 27% yield. LCMS (m/z)(M+H)=157.9, Rt=0.54.

Step 2

To a solution of 2-(1,1-difluoroethyl)-4-methylpyridine (1 equiv.) inwater (2.0 M) was added KMnO₄ (3.0 equiv) and heated to 80° C. for 4hrs. LCMS analysis indicated the formation of the desired product(MH⁺—188.0, Rt—0.52 min). The reaction was acidified to pH 3 with 1MHCl. The white precipitate was filtered and dried. Isolated2-(1,1-difluoroethyl)isonicotinic acid in 12% yield. LCMS (m/z)(M+H)=188.0, Rt=0.52). 1H NMR (400 MHz, <cd3od>) bb ppm 2.01 (t, J=18.78Hz, 3H) 8.00 (d, J=4.70 Hz, 1H) 8.16 (s, 1H) 8.80 (d, J=5.09 Hz, 1H).

Synthesis of 2-(difluoromethyl)isonicotinic acid

Procedure follows exactly as that of 2-(1,1-difluoroethyl)isonicotinicacid. Isolated 2-(difluoromethyl)isonicotinic acid in 23%. LCMS (m/z)(M+H)=174.0, Rt=0.48).

Synthesis of 3-(2-cyanopropan-2-yl)benzoic acid

Step 1

To a vial with a stir bar was added methyl 3-bromobenzoate (1.0 equiv.)4-isoxazoleboronic acid (1.2 equiv.), PdCl₂(dppf).CH₂Cl₂ adduct (0.1equiv.), 1M KF (2.0) and DMSO (0.10 M). The reaction mixture wasdegassed with bubbling nitrogen and the vial capped and heated at 130°C. for 18 hr. LCMS analysis indicated the formation of the desiredproduct (MH⁺—176, Rt—0.62 min). The reaction mixture was diluted with asaturated solution of NH₄Cl and extracted with EtOAc (2×). The combinedorganics were washed with water and brine, dried over MgSO₄, filteredand concentrated. The crude material was purified via flashchromatography over silica gel eluting with heptanes and 0-100% ethylacetate gradient. Isolated methyl 3-(cyanomethyl)benzoate in 69% yield.LCMS (m/z) (M+H)=176.1, Rt=0.62). 1H NMR (400 MHz, <cd3od>) 5 ppm 3.92(s, 3H), 3.99 (s, 2H), 7.49-7.55 (m, 1H), 7.62 (d, J=7.83 Hz, 1H), 7.99(d, J=7.83 Hz, 1H), 8.04 (s, 1H).

Step 2

To a solution of methyl 3-(cyanomethyl)benzoate (1.0 equiv.) in DMSO(0.50) was slowly added NaH (3 equiv.) at 0° C. and allowed to stir for20 mins. To the mixture was added Mel (3.0 equiv.) and allowed to stir18 hrs at RT. LCMS analysis indicated the formation of the desiredproduct (MH⁺—204, Rt—0.78 min). Under ice-cooling, the reaction mixturewas diluted with water and extracted with EtOAc. The organics werewashed with water and brine, dried over MgSO₄, filtered, andconcentrated. The crude material was purified via flash chromatographyover silica gel eluting with heptanes and 0-50% ethyl acetate gradient.Isolated methyl 3-(2-cyanopropan-2-yl)benzoate in 63% yield. LCMS (m/z)(M+H)=204.1, Rt=0.78).

Step 3

To a solution of methyl 3-(2-cyanopropan-2-yl)benzoate (1 equiv.) in THF(0.10 M) was added 1M LiOH (2.5 equiv.) and allowed to stir at RT for 18hrs. LCMS analysis indicated the formation of the desired product(MH⁺—190, Rt—0.60 min). The volatiles were removed in vacuo, and theaqueous phase was acidified to ˜pH3 with 1M HCl. A white precipitate wasformed, filtered and dried. Isolated 3-(2-cyanopropan-2-yl)benzoic acidin 63% yield. LCMS (m/z) (M+H)=190.1, Rt=0.60. 1H NMR (400 MHz, <cd3od>)b ppm 1.76 (s, 6H) 7.54 (t, J=7.83 Hz, 1H) 7.74-7.80 (m, 1H) 8.00 (d,J=7.43 Hz, 1H) 8.16-8.21 (m, 1H).

Synthesis of (R)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate Step1

A solution of (S)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate(1.0 equiv.), tosyl chloride (1.10 equiv.), triethylamine (1.40 equiv.)and N,N-dimethylpyridin-4-amine (0.1 equiv.) in dichloromethane (0.1 M)at RT. The resulting mixture was stirred at RT for 2 hours. The reactionmixture was then diluted with water and the aqueous layer was separatedand washed sequentially with NaOH (1 M), water, brine dried over sodiumsulfate then concentrated in vacuo to yield (S)-tert-butyl2-((tosyloxy)methyl)morpholine-4-carboxylate as a pale yellow oil in 99%yield. LCMS (m/z) (M+H)=390.2, Rt=0.84 min.

Step 2

To a solution of (S)-tert-butyl2-((tosyloxy)methyl)morpholine-4-carboxylate (1.0 equiv.) in DMF (0.1 M)at RT was added sodium azide (2.00). The resulting mixture was heated to60° C. for 24 h. The reaction then cooled to RT and partitioned betweenwater and diethyl ether. The organic layer was separated then washedwith water followed by brine then dried over sodium sulfate. The organiclayer was then concentrated in vacuo to yield (S)-tert-butyl2-(azidomethyl)morpholine-4-carboxylates a white solid oil in 83% yield.

Step 3

A solution of (S)-tert-butyl 2-(azidomethyl)morpholine-4-carboxylates(1.0 equiv.) in ethanol (0.1 M) was evacuated and back filled with argon(×3). To the solution was then added Pd/C (0.20 eq.) and the mixture wasevacuated and back filled with hydrogen (×3). The mixture was thenstirred at RT under a positive pressure of atmospheric hydrogen(balloon) for 24 h. The hydrogen gas was removed by evacuation and thereaction backfilled with argon. The reaction mixture was then filteredthrough a pad of celite and then concentrated in vacuo to afford(R)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate as a white solidin 91% yield. LCMS (m/z) (M+H)=217.1, Rt=0.43 min.

Synthesis of (S)-methyl (morpholin-2-ylmethyl)carbamate Step 1

To a solution of (R)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate(1.0 equiv.) and triethylamine (3.0 equiv.) in dichloromethane (0.1 M)was added methyl chloroformate (1.1 equiv.). The resulting mixture wasstirred at RT for 45 min. After concentration, the residue waspartitioned between EtOAc and water. The organic phase was washed withwater and then with brine. After drying over sodium sulfate the solutionwas concentrated in vacuo to give crude (R)-tert-butyl2-(((methoxycarbonyl)amino)methyl)morpholine-4-carboxylate which wasused in the next step without further purification. LCMS (m/z)(M+H)=175.1 (-Boc), Rt=0.63 min.

Step 2

To a 4:1 solution of dichloromethane and TFA (0.1 M) was added(R)-tert-butyl2-(((methoxycarbonyl)amino)methyl)morpholine-4-carboxylate. After 1 hthe solution was then concentrated in vacuo to give crude (S)-methyl(morpholin-2-ylmethyl)carbamate which was used in the next step withoutfurther purification. LCMS (m/z) (M+H)=175.0, Rt=0.11 min.

Synthesis of (S)-N-(morpholin-2-ylmethyl)acetamide Step 1

To a solution of (R)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate(1.0 equiv.) and triethylamine (1.5 equiv.) in dichloromethane (0.1 M)was added acetic anhydride (1.1 equiv.). The resulting mixture wasstirred at RT for 45 min. After concentration, the residue waspartitioned between EtOAc and water. The organic phase was washed withwater and then with brine. After drying over sodium sulfate the solutionwas concentrated in vacuo to give crude (R)-tert-butyl2-(acetamidomethyl)morpholine-4-carboxylate which was used in the nextstep without further purification. LCMS (m/z) (M+H)=159.1 (-Boc),Rt=0.53 min.

Step 2

To a 4:1 solution of dichloromethane and TFA (0.1 M) was added(R)-tert-butyl 2-(acetamidomethyl)morpholine-4-carboxylate. After 1 hthe solution was then concentrated in vacuo to give crude(S)-N-(morpholin-2-ylmethyl)acetamide which was used in the next stepwithout further purification. LCMS (m/z) (M+H)=159.0, Rt=0.11 min.

Synthesis of (S)-2-hydroxy-N-(morpholin-2-ylmethyl)acetamide Step 1

A mixture of (R)-tert-butyl 2-(aminomethyl)morpholine-4-carboxylate (1.0equiv.), 2-hydroxyacetic acid (1.80 equiv.),N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (2.0 equiv.), and N,N-dimethylpyridin-4-amine (0.20equiv.) was stirred in DCM (0.1 M) at room temperature overnight. Thereaction was quenched with water and washed (3×) with water. Thecombined aqueous fractions were then back-extracted with chloroform (4×)and the combined organics were dried over Na₂SO₄, filtered, andconcentrated. The resulting oil was passed through a pad of SiO₂ gelusing 5-50% MeOH/DCM and concentrated to yield (R)-tert-butyl2-((2-hydroxyacetamido)methyl)morpholine-4-carboxylate as an oil. LCMS(m/z) (M+H)=175.1 (-Boc), Rt=0.55 min.

Step 2

(R)-tert-butyl 2-((2-hydroxyacetamido)methyl)morpholine-4-carboxylate(1.0 equiv.) was dissolved in DCM:TFA (4:1, 0.5 M) and stirred at roomtemperature. After one hour the solution was concentrated to yield(S)-2-hydroxy-N-(morpholin-2-ylmethyl)acetamide. LCMS (m/z) (M+H)=175.1,Rt=0.12 min.

(R)-1-(4-(4-bromopyridin-2-yl)morpholin-2-yl)-N-methylmethanamine Step 1

To a 4:1 solution of dichloromethane and TFA (0.1 M) was added(S)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate. After 1 h thesolution was then concentrated in vacuo to give crude(S)-morpholin-2-ylmethanol which was used in the next step withoutfurther purification. LCMS (m/z) (M+H)=60.0, Rt=0.11 min.

Step 2

Refer to standard.

Step 3

A solution of (S)-(4-(4-bromopyridin-2-yl)morpholin-2-yl)methanol (1.0equiv.), tosyl chloride (1.0 equiv.), triethylamine (1.40 equiv.) andN,N-dimethylpyridin-4-amine (0.1 equiv.) in dichloromethane (0.1 M) atRT. The resulting mixture was stirred at RT for 18 hours. The reactionmixture was then diluted with water and the aqeuous layer was separatedand washed sequentially with NaOH (1 M), water, brine dried over sodiumsulfate then concentrated in vacuo to yield(S)-(4-(4-bromopyridin-2-yl)morpholin-2-yl)methyl4-methylbenzenesulfonate in 56% yield. LCMS (m/z) (M+H)=427.1/429.0,Rt=0.77 min.

Step 4

To a 2 M solution of methylamine in methanol was added(S)-(4-(4-bromopyridin-2-yl)morpholin-2-yl)methyl4-methylbenzenesulfonate (1.0 eq). This solution was microwave heated at80° C. After 1 h the solution was then concentrated in vacuo and waterwas added. The resulting suspension was sonicated and centrifuged. Thewater soluble portion was separated from the solids. The resultingaqueous solution of(R)-1-(4-(4-bromopyridin-2-yl)morpholin-2-yl)-N-methylmethanamine wasused in the next step without further purification. LCMS (m/z)(M+H)=286.0/288.0, Rt=0.34 min.

Synthesis of 5-bromo-3-morpholinopyridin-2(1H)-one

Step 1

To a solution of 5-bromo-2-methoxypyridin-3-amine (1.0 equiv.) in DMFwas added 1-bromo-2-(2-bromoethoxy)ethane (1.2 equiv.), followed by DIEA(3.0 equiv.). The solution was heated at 120° C. for 24 hours. Cooled toroom temperature and partitioned between ethyl acetate and water. Theorganic phase was washed with brine, dried over sodium sulfate, filteredand concentrated. The crude material was purified via flashchromatography over silica gel eluting with heptanes and 0-25% ethylacetate gradient). Isolated 4-(5-bromo-2-methoxypyridin-3-yl)morpholineas a yellow solid in 69% yield. LCMS (m/z) (M+H)=273.0/274.9, Rt=0.82min. ¹H NMR (400 MHz, <cdcl3>) 6 ppm 2.90-3.18 (m, 4H) 3.76-3.91 (m, 4H)3.97 (s, 3H) 7.14 (d, J=1.96 Hz, 1H) 7.84 (d, J=1.96 Hz, 1H).

Step 2

To a solution of 4-(5-bromo-2-methoxypyridin-3-yl)morpholine (1.0equiv.) in 1,4-dioxane (0.3 M) was added concentrated HCl (5 equiv.) andthe solution was heated to 100° C. for 1 h. Upon cooling to roomtemperature, the solution was concentrated to dryness under vacuo, thendissolved in water and neutralized with solid sodium bicarbonate. Theprecipitate was filtered, washed with water and dried under vacuo togive 5-bromo-3-morpholinopyridin-2(1H)-one as a beige solid in 93%yield. LCMS m/z (M+H)=258.9/260.9, Rt=0.48 min.

Synthesis of 4-(6-chloropyrazin-2-yl)morpholine

To a solution of 2,6-dichloropyrazine (1.0 equiv.) in acetonitrile (0.3M) was added morpholine (3.5 equiv.) and the reaction was stirred atroom temperature for 20 h. The resulting precipitate was filtered offand the filtrate was concentrated under vacuo. The crude material waspartitioned between water and ethyl acetate, the organic phase was driedwith sodium sulfate, filtered and concentrated to afford4-(6-chloropyrazin-2-yl)morpholine in 75% yield. LCMS m/z (M+H)=200.0,Rt=0.61 min.

Synthesis of 5-bromo-3-morpholinopyridin-2(1H)-one

Step 1

A solution of 3,5-dibromopyrazin-2(1H)-one (1.0 equiv.) in morpholine (5equiv.) was heated to 100° C. for 24 h. Cooled to room temperature andfiltered off the precipitate. The filtrate was partitioned between waterand ethyl acetate. The organic phase was dried with sodium sulfate,filtered and concentrated. The crude material was purified via silicagel column chromatography eluting with ethyl acetate and heptanes(0-50%). The pure fractions were concentrated to yield5-bromo-3-morpholinopyrazin-2(1H)-one as a white solid in 43% yield.LCMS m/z (M+H)=259.9, Rt=0.41 min.

Step 2

To a solution of 5-bromo-3-morpholinopyrazin-2(1H)-one (1.0 equiv.) inDMF (0.1 M) was added potassium carbonate (2.0 equiv.) and iodomethane(1.0 equiv.) at 0° C. and the solution was allowed to warm to roomtemperature and stirred for 2 hours. Upon completion, the reaction waspartitioned between water and ethyl acetate, the organic phase waswashed with brine, dried with sodium sulfate, filtered and concentrated.The crude material was used for the next step without furtherpurification. Isolated 5-bromo-1-methyl-3-morpholinopyrazin-2(1H)-one in91% yield. LCMS m/z (M+H)=274/276, Rt=0.60 min. ¹H NMR (400 MHz,<cdcl3>) δ ppm 3.42 (s, 3H) 3.66-3.83 (m, 4H) 3.85-4.00 (m, 4H), 6.77(s, 1H).

Synthesis of 3-bromo-1-methyl-5-morpholinopyridin-2(1H)-one

Step 1

To a solution of 5-bromo-6-methoxypyridin-3-amine (1.0 equiv.) in DMFwas added DIEA (3.0 equiv.) and 1-bromo-2-(2-bromoethoxy)ethane (1.0equiv.). The solution was heated to 120° C. for 24 hours. Upon coolingto room temperature, the reaction was partitioned between water andethyl acetate, the aqueous phase was extracted three times with ethylacetate, the organics were combined, dried with sodium sulfate, filteredand concentrated. The crude material was purified via silica gel columnchromatography eluting with 0-50% ethyl acetate in heptanes. The purefractions were concentrated to yield4-(5-bromo-6-methoxypyridin-3-yl)morpholine in 53% yield as an orangeoil. LCMS m/z (M+H)=273/275, Rt=0.61 min. ¹H NMR (400 MHz, <cdcl3>) bppm 2.93-3.18 (m, 4H) 3.80-4.05 (m, 7H) 7.50 (d, J=2.74 Hz, 1H) 7.74 (d,J=2.74 Hz, 1H).

Step 2

A solution of 4-(5-bromo-6-methoxypyridin-3-yl)morpholine (1.0 equiv.)in 4M HCl in dioxane (20 equiv.) was heated to 110° C. for 24 hours.Upon cooling to room temperature, the reaction was neutralized withaqueous NaOH to pH ˜6 then extracted with ethyl acetate three times. Theorganic phase was dried with sodium sulfate, filtered and concentrated.Isolated 3-bromo-5-morpholinopyridin-2-ol as the desired product in 32%yield. LCMS (m/z) (M+H)=259.0/261/0, Rt=0.36 min.

Step 3

To a solution of 3-bromo-5-morpholinopyridin-2-ol (1.0 equiv.) in DMF(0.1M) was added potassium carbonate (2.0 equiv.) and iodomethane (1.0equiv.). The solution was stirred at room temperature for 3 hours.Partitioned between water and ethyl acetate, the organic phase waswashed with brine, dried with sodium sulfate, filtered and concentratedto dryness. Isolated 3-bromo-1-methyl-5-morpholinopyridin-2(1H)-one in87% yield.

LCMS (m/z) (M+H)=273.0/275.0, Rt=0.41 min.

Synthesis of 4-bromo-1-methyl-6-morpholinopyridin-2(1H)-one and6-chloro-1-methyl-4-morpholinopyridin-2(1H)-one

Step 1

A solution of 4-bromo-2,6-dichloropyridine (1.0 equiv.) in dioxane andaqueous sodium hydroxide (15% by weight solution, 1:1 ratio, 0.55 M) washeated in the microwave for 30 min at 150° C. The solution was cooled toroom temperature and neutralized with concentrated HCl (pH=˜6) andextracted with ethyl acetate three times. The organic phase was driedwith sodium sulfate, filtered and concentrated. The crude material wasdried under vacuo to give 4-bromo-6-chloropyridin-2-ol as an off-whitesolid in 76% yield. LCMS (m/z) (M+H)=207.9/209.9, Rt=0.60 min.

Step 2

To a solution of 4-bromo-6-chloropyridin-2-ol (1.0 equiv.) in DMF (0.16M) was added potassium carbonate (2.0 equiv.) and iodomethane (1.2equiv.) at room temperature. The solution was stirred for 2 hours, thenpartitioned between water and ethyl acetate. The aqueous phase wasextracted with ethyl acetate two more times, the organic phase waswashed with brine, dried with sodium sulfate, filtered and concentrated.The crude material was purified via silica gel column chromatographyeluting with ethyl acetate and heptanes (0-50% ethyl acetate). The purefractions were concentrated to yield4-bromo-6-chloro-1-methylpyridin-2(1H)-one in 38% yield. LCMS (m/z)(M+H)=221.9/223.9, Rt=0.64 min.

Step 3

To a solution of 4-bromo-6-chloro-1-methylpyridin-2(1H)-one (1.0 equiv.)in NMP (0.18 M) was added morpholine (1.1 equiv.) and DIEA (1.1 equiv).The solution was stirred at 100° C. for 4 hours. Upon cooling to roomtemperature, the solution was partitioned between water and ethylacetate. The organic phase was washed with water, then brine, dried withsodium sulfate, filtered and concentrated. The crude material waspurified via silica gel column chromatography eluting with ethyl acetateand heptanes (0-100% ethyl acetate then 90% ethyl acetate and 10%methanol). Isolated 4-bromo-1-methyl-6-morpholinopyridin-2(1H)-one in51% yield and 6-chloro-1-methyl-4-morpholinopyridin-2(1H)-one in 15%yield. LCMS (m/z) (M+H)=273/274.9, Rt=0.53 min and LCMS (m/z)(M+H)=229.1/230.9, Rt=0.47 min respectively.

Synthesis of 6-chloro-2-methyl-4-morpholinopyridazin-3(2H)-one

Step 1

To a solution of 6-chloropyridazin-3-amine (1.0 equiv) in MeOH (1M) atroom temperature was added sodium bicarbonate (2.0 equiv.) and theresulting suspension was stirred at room temperature for 30 min beforethe dropwise addition of bromine (1.0 equiv.). The reaction mixture wasstirred for 20 h. Upon concentration under vacuo, the crude residue waspurified via silica gel column chromatography eluting with 100% heptanesto 80% ethyl acetate:heptanes to yield 4-bromo-6-chloropyridazin-3-aminein 50% yield. LCMS (m/z) (M+H)=207.8/209.8, Rt=0.47 min. ¹H NMR (400MHz, <cdcl3>) ppm 5.31-5.63 (m, 2H) 7.46-7.61 (m, 1H).

Step 2

To a cooled solution (0-5° C.) of NaNO₂ (2.4 equiv.) in H₂SO₄ conc. (23equiv.) was added 4-bromo-6-chloropyridazin-3-amine (1.0 equiv.) inacetic acid (0.25 M). The reaction mixture was stirred at 0° C. for 30min before warming to room temperature and stirring for 1 hour. Waterwas added and stirred at room temperature for a further 4 hours. Thereaction mixture was then extracted with ethyl acetate, dried over MgSO₄and concentrated in vacuo to yield a brown oil. The oil was furtherpurified by silica gel column chromatography eluting with 100% heptanesto 80% ethyl acetate/heptanes to yield4-bromo-6-chloropyridazin-3(2H)-one as an off-white solid in 83% yield.LCMS (m/z) (M+H)=208.9/210.9, Rt=0.42 min. ¹H NMR (400 MHz, <dmso>) δppm 8.08-8.32 (m, 1H) 13.25-13.71 (m, 1H).

Step 3

To a solution of 4-bromo-6-chloropyridazin-3(2H)-one (1.0 equiv.) andCs₂CO₃ (1.2 equiv.) in DMF (0.07 M) was added iodomethane (1.5 equiv.)drop-wise over 20 min. The resulting mixture was stirred for 3 h. Thereaction mixture was then diluted with ammonium chloride, then extractedwith ethyl acetate, dried over MgSO₄ and concentrated in vacuo to yieldas a brown solid. The oil was further purified via silica gel columnchromatography eluting with 100% heptanes to 80% ethyl acetate:heptanesto yield 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one as an off-whitesolid in 79% yield. LCMS (m/z) (M+H)=222.9/224.9, Rt=0.54 min. ¹H NMR(400 MHz, <cdcl3>) δ ppm 3.77-3.86 (m, 3H) 7.56-7.69 (m, 1H).

Step 4

To a solution of 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (1.0equiv.) in DMF (0.3 M) was added DIEA (1.0 equiv.) and morpholine (1.0equiv.) at room temperature. The resulting mixture was heated to 120° C.for 5 h and 30 min. The reaction mixture was diluted with water,extracted with ethyl acetate, dried over MgSO₄ and concentrated in vacuoto yield. 6-chloro-2-methyl-4-morpholinopyridazin-3(2H)-one as anoff-white solid in 97% yield. LCMS (m/z) (M+H)=230.0/232.0, Rt=0.63 min.

Synthesis of4-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)morpholine AND5-bromo-3-morpholino-1-(tetrahydro-2H-pyran-4-yl)pyridin-2(1H)-one

To a 0.45 M solution of triphenylphosphine (1.50 equiv.) in DMF wasadded DIAD (1.50 equiv.). The mixture was stirred at ambient temperaturefor 10 min. Tetrahydro-2H-pyran-4-ol (2.00 equiv.) was added, and themixture was stirred for 15 min. 5-Bromo-3-morpholinopyridin-2(1H)-one(1.00 equiv.) was added. The mixture was stirred for 2 hr. The reactionmixture was diluted with water and extracted with ethyl acetate. Thecombined organics were washed with brine, dried over sodium sulfate,filtered and concentrated with silica gel. The material was purified byflash chromatography over silica gel (heptanes with 0-100% ethyl acetategradient) to give both the O-alkylated isomer (88% yield) and theN-alkylated isomer (11% yield).

4-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)morpholine: ¹HNMR (400 MHz, <cdcl3>) δ ppm 1.82 (td, J=8.51, 4.30 Hz, 2H) 2.09 (dt,J=8.99, 4.33 Hz, 2H) 3.02-3.17 (m, 4H) 3.56-3.73 (m, 2H) 3.77-3.89 (m,4H) 3.90-4.03 (m, 2H) 5.29 (dt, J=8.01, 3.99 Hz, 1H) 7.13 (d, J=2.10 Hz,1H) 7.78 (d, J=2.20 Hz, 1H). LCMS (m/z) (M+H)=343.0/345.0, Rt=0.92 min.

5-bromo-3-morpholino-1-(tetrahydro-2H-pyran-4-yl)pyridin-2(1H)-one: ¹HNMR (400 MHz, <cdcl3>) δ ppm 1.26 (s, 2H) 1.72-1.96 (m, 4H) 3.08-3.24(m, 4H) 3.47-3.67 (m, 2H) 3.79-3.95 (m, 4H) 4.04-4.19 (m, 2H) 5.14 (s,1H) 6.64 (d, J=2.40 Hz, 1H) 7.13 (d, J=2.40 Hz, 1H). LCMS (m/z)(M+H)=342.9/344.9, Rt=0.63 min.

Synthesis of 4-(5-bromo-2-isopropoxypyridin-3-yl)morpholine AND5-bromo-1-isopropyl-3-morpholinopyridin-2(1H)-one

A 0.3 M solution of 5-bromo-3-morpholinopyridin-2(1H)-one (1.00 equiv.)in DMF was treated with sodium hydride (1.20 equiv.). The mixture wasstirred for 20 min at ambient temperature. 2-bromopropane (1.20 equiv.)was added. The mixture was stirred at 70° C. for 18 hr. The cooledreaction mixture was diluted with water and extracted with ethylacetate. The combined extracts were washed with brine, dried over sodiumsulfate, filtered, and concentrated. The crude material was purified byflash chromatography over silica gel (heptanes with 20-100% ethylacetate gradient) to give both the O-alkylated isomer (56% yield) andthe N-alkylated isomer (26% yield).

4-(5-bromo-2-isopropoxypyridin-3-yl)morpholine: ¹H NMR (400 MHz,<cdcl3>) δ ppm 1.39 (d, J=6.16 Hz, 6H) 3.04-3.15 (m, 4H) 3.82-3.93 (m,4H) 5.24-5.44 (m, 1H) 7.12 (d, J=2.10 Hz, 1H) 7.82 (d, J=2.15 Hz, 1H).LCMS (m/z) (M+H)=301.0/303.0, Rt=0.99 min.

5-bromo-1-isopropyl-3-morpholinopyridin-2(1H)-one: ¹H NMR (400 MHz,<cdcl3>) δ ppm 1.30-1.40 (m, 6H) 3.12-3.21 (m, 4H) 3.82-3.93 (m, 4H)5.19-5.33 (m, 1H) 6.62 (d, J=2.35 Hz, 1H) 7.11 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=301.0/303.0, Rt=0.70 min.

Synthesis of tert-butyl(2-(5-bromo-3-morpholino-2-oxopyridin-1(2H)-yl)ethyl)carbamate

A 0.3 M solution of 5-bromo-3-morpholinopyridin-2(1H)-one (1.00 equiv.)in DMF was treated with sodium hydride (1.20 equiv.). The mixture wasstirred for 15 min at ambient temperature. Tert-butyl(2-bromoethyl)carbamate (1.20 equiv.) was added. The mixture was stirredat 60° C. for 3 hr. The cooled reaction mixture was diluted with waterand extracted with ethyl acetate. The combined organics were washed withsaturated aqueous sodium bicarbonate, dried over sodium sulfate,filtered, and concentrated to give tert-butyl(2-(5-bromo-3-morpholino-2-oxopyridin-1 (2H)-yl)ethyl)carbamate. LCMS(m/z) (M+H)=402.1/404.1, Rt=0.78 min.

Method 1:

To a solution of the starting pyridone or pyrazinone (1.0 equiv.) in DMF(0.1-0.2 M) was added the electrophile (1.0-1.5 equiv.) followed bypotassium carbonate or cesium carbonate (1.0-2.0 equiv.). The solutionwas stirred at room temperature (or alternatively heated up to 80° C.)for 2-24 hours. Upon cooling to room temperature, the solution waspartitioned between water and ethyl acetate, the organic phase waswashed with water, then brine, dried over sodium sulfate, filtered andconcentrated under vacuo. The crude material was a mixture of N-alkyland O-alkyl products. The material could be used for the next stepwithout further purification as a mixture of isomers or it could bepurified via silica gel column chromatography eluting with 0-100% ethylacetate in heptanes.

Synthesis of 5-bromo-1-methyl-3-morpholinopyridin-2(1H)-one AND4-(5-bromo-2-methoxypyridin-3-yl)morpholine

To a solution of 5-bromo-3-morpholinopyridin-2(1H)-one (1.0 equiv.) inDMF (0.2 M) was added potassium carbonate (2.0 equiv.), followed byiodomethane (1.0 equiv.). The solution was stirred at room temperaturefor 3 hours. The solution was partitioned between water and ethylacetate, the organic phase was washed with brine, dried with sodiumsulfate, filtered and concentrated. The crude material was a mixture ofN-methylated and O-methylated products (90:10). The material could beused for the next step without further purification as a mixture ofisomers or it could be purified via silica gel column chromatographyeluting with 0-100% ethyl acetate in heptanes to afford5-bromo-1-methyl-3-morpholinopyridin-2(1H)-one in 71% yield LCMS (m/z)(M+H)=273/275, Rt=0.55 min and4-(5-bromo-2-methoxypyridin-3-yl)morpholine in 10% yield. LCMS (m/z)(M+H)=273/275, Rt=0.82 min.

The intermediates listed below were prepared using methods similar tothose described for the preparation of5-bromo-1-methyl-3-morpholinopyridin-2(1H)-one AND4-(5-bromo-2-methoxypyridin-3-yl)morpholine (Method 1) using theappropriate starting materials.

Synthesis of 5-bromo-1-(2-hydroxyethyl)-3-morpholinopyridin-2(1H)-oneand 2-((5-bromo-3-morpholinopyridin-2-yl)oxy)ethanol

Method 1 was followed using 5-bromo-3-morpholinopyridin-2(1H)-one (1.0equiv.), 2-iodoethanol (1.0 equiv.) and potassium carbonate (2.0 equiv.)at room temperature to give5-bromo-1-(2-hydroxyethyl)-3-morpholinopyridin-2(1H)-one and2-((5-bromo-3-morpholinopyridin-2-yl)oxy)ethanol as a mixture of twoisomers (˜5:1 ratio). LCMS (m/z) (M+H)=303/305, Rt=0.47 min and 0.62min.

Synthesis of5-bromo-1-(2-(methylsulfonyl)ethyl)-3-morpholinopyridin-2(1H)-one

Method 1 was followed using 5-bromo-3-morpholinopyridin-2(1H)-one (1.0equiv.), (methylsulfonyl)ethene (1.2 equiv.) and cesium carbonate (1.2equiv.) at room temperature to give5-bromo-1-(2-(methylsulfonyl)ethyl)-3-morpholinopyridin-2(1H)-one in 98%yield. ¹H NMR (400 MHz, <cdcl3>) δ ppm 2.92 (s, 3H) 3.09-3.23 (m, 4H)3.53 (t, J=6.65 Hz, 2H) 3.78-3.96 (m, 4H) 4.32 (t, J=6.65 Hz, 2H) 6.69(s, 1H) 7.23 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=365.1/366.9, Rt=0.57min.

Synthesis of 5-bromo-1-ethyl-3-morpholinopyridin-2(1H)-one and4-(5-bromo-2-ethoxypyridin-3-yl)morpholine

Method 1 was followed using 5-bromo-3-morpholinopyridin-2(1H)-one (1.0equiv.), iodoethane (1.0 equiv.) and cesium carbonate (1.0 equiv.) at50° C. to afford a mixture of5-bromo-1-ethyl-3-morpholinopyridin-2(1H)-one and4-(5-bromo-2-ethoxypyridin-3-yl)morpholine in about 2:1 ratio. LCMS(m/z) (M+H)=286.9/288.9, Rt=0.62 min and 0.88 min.

Synthesis of 2-(5-bromo-3-morpholino-2-oxopyridin-1 (2H)-yl)acetonitrileand 2-((5-bromo-3-morpholinopyridin-2-yl)oxy)acetonitrile

Method 1 was followed using 5-bromo-3-morpholinopyridin-2(1H)-one (1.0equiv.), 2-bromoacetonitrile (1.2 equiv.) and potassium carbonate (1.0equiv.) at 80° C. and the isomers were purified via silica gel columnchromatography (0-50% ethyl acetate and heptanes). Isolated2-(5-bromo-3-morpholino-2-oxopyridin-1(2H)-yl)acetonitrile in 61% yield.LCMS (m/z) (M+H)=298/299.8, Rt=0.60 min. And2-((5-bromo-3-morpholinopyridin-2-yl)oxy)acetonitrile in 12% yield. LCMS(m/z) (M+H)=298/299.8, Rt=0.82 min.

Synthesis of 2-(5-bromo-3-morpholino-2-oxopyridin-1(2H)-yl)propanenitrile and2-((5-bromo-3-morpholinopyridin-2-yl)oxy)propanenitrile

Method 1 was followed using 5-bromo-3-morpholinopyridin-2(1H)-one (1.0equiv.), 2-bromopropanenitrile (1.2 equiv.) and potassium carbonate (1.0equiv.) at 80° C. and the isomers were purified via silica gel columnchromatography (0-50% ethyl acetate and heptanes). Isolated2-(5-bromo-3-morpholino-2-oxopyridin-1(2H)-yl)propanenitrile in 50%yield. LCMS (m/z) (M+H)=312/314, Rt=0.63 min. And2-((5-bromo-3-morpholinopyridin-2-yl)oxy)propanenitrile in 39% yield.LCMS (m/z) (M+H)=312/314, Rt=0.84 min.

Synthesis of(R)-2-(5-bromo-3-morpholino-2-oxopyridin-1(2H)-yl)propanenitrile and(S)-2-(5-bromo-3-morpholino-2-oxopyridin-1 (2H)-yl)propanenitrile

2-(5-bromo-3-morpholino-2-oxopyridin-1(2H)-yl)propanenitrile was furtherpurified via chiral HPLC (SFC, Methanol, AD-column) to give: Peak 1(Rt=1.13 min, 99% ee) and Peak 2 (Rt=1.74 min, 95% ee).

Synthesis of (R)-2-((5-bromo-3-morpholinopyridin-2-yl)oxy)propanenitrileand (S)-2-((5-bromo-3-morpholinopyridin-2-yl)oxy)propanenitrile

2-((5-bromo-3-morpholinopyridin-2-yl)oxy)propanenitrile was furtherpurified via chiral HPLC (Heptanes/ethanol 95:5, AD-H column) to give:Peak 1 (Rt=4.808 min, 99% ee) and Peak 2 (Rt=7.274 min, 99% ee).

Method 2:

To a solution of the aryl halide (1.0 equiv.) and the boronic ester(Intermediate A-G, 1.0-1.2 equiv.) in DME and 2M sodium carbonate (3:1,0.1 M) was added PdCl₂(dppf)-DCM adduct (0.1-0.5 equiv.) in a microwavevial equipped with a stir bar. The reaction was heated to 120° C. for10-20 min in the microwave. The solution was partitioned between ethylacetate and water, the organic phase was dried with sodium sulfate ormagnesium sulfate, filtered and concentrated. The crude material waspurified via preparative reverse HPLC. Upon lyophilization, the TFA saltof the product was obtained.

Compounds of Formula (I) were prepared by the synthetic schemes shownabove, using the intermediates depicted above and analogs madesimilarly. Other compounds of the invention can be made by the samemethods, based on the Examples described herein and known startingmaterials, in combination with methods known in the art.

Synthesis of 2-(difluoromethyl)isonicotinic acid

Step 1

To a solution of ethyl isonicotinate (1.0 eq) andbis(((difluoromethyl)sulfinyl)oxy)zinc (2.7 eq) in DCM/Water (1:0.4) wascooled to 0° C. followed by the slow addition of t-butylhydroperoxide(6M in decane) (5 eq) with vigorous stirring. The reaction was warmed toRT and stirred for 18 hrs. TLC (4:1 EtOAc in Heptanes) indicates competeconsumption of SM. The reaction was partitioned between DCM andNaHCO_(3(sat)). The organic phase was separated and the aqueous layerwas extracted with DCM (3×). The combined organics were dried overMgSO₄, filtered and concentrated. The crude was loaded onto silica geland purified via ISCO (0-30% EtOAc in heptanes). Pure fractions werecombined and concentrated to yield ethyl 2-(difluoromethyl)isonicotinatein 95% as a colorless oil. ¹H NMR (400 MHz, <cdcl3>) b ppm 1.44 (t,J=7.24 Hz, 3H) 4.46 (q, J=7.30 Hz, 2H) 6.70 (t, J=55.60 Hz, 1H) 7.98 (d,J=4.70 Hz, 1H) 8.19 (s, 1H) 8.82 (d, J=5.09 Hz, 1H).

Step 2

To a solution of 2-(difluoromethyl)isonicotinate (1 eq) in THF (0.25 M)was added 2M LiOH (2.5 eq) and allowed to stir at RT. Upon initialaddition of LiOH, the solution turned from clear to burnt orange. After2 hrs of stirring, the solution is light yellow in color. The reactionstirred for 18 hrs. The volatiles were removed in vacuo, and the aqueousphase was acidified to ˜pH 3. A white ppt formed and was filtered anddried. Some product remained in the aqueous layer which was extractedwith BuOH (2×). The organics were dried over MgSO₄, filtered,concentrated and dried on the high-vacuum for 2 days to yield2-(difluoromethyl)isonicotinic acid in 99% as a white solid. ¹H NMR (400MHz, <dmso>) δ ppm 7.05 (t, J=54.00 Hz, 1H) 7.97 (d, J=4.70 Hz, 1H) 8.05(s, 1H) 8.82 (d, J=4.70 Hz, 1H)

Synthesis of 2-(2-fluoropropan-2-yl)isonicotinic acid

Step 1

To a solution of 2-bromo-4-methylpyridine (1.0 equiv) in toluene (0.3 M)at −78° C. was slowly added n-BuLi (1.15 equiv) and the mixture wasallowed to stir for 45 min. Acetone (3 equiv) was then added, and thereaction was allowed to warm to 25° C. over 30 min. The reaction wasquenched with saturated aqueous ammonium chloride and extracted threetimes with ethyl acetate The combined organics were washed with brine,dried over magnesium sulfate, filtered and concentrated. The cruderesidue was purified via flash chromatography over silica gel elutingwith heptanes and 0-50% ethyl acetate gradient. Isolated2-(4-methylpyridin-2-yl)propan-2-ol as a pale yellow oil in 72% yield.LCMS (m/z) (M+H)=151.9, Rt=0.28 min.

Step 2

To a solution of 2-(4-methylpyridin-2-yl)propan-2-ol (1.0 equiv.) in DCM(0.2 M) at −78° C. was added DAST (1.4 equiv.). The reaction was allowedto warm to 0° C. over 30 min and then slowly quenched with saturatedaqueous sodium bicarbonate and extracted two times with DCM. Thecombined organics were washed with brine, dried over magnesium sulfate,filtered and concentrated. The crude residue was purified via flashchromatography over silica gel eluting with pentane and 0-20% diethylether gradient. Isolated 2-(2-fluoropropan-2-yl)-4-methylpyridine as apale yellow oil in 61% yield. LCMS (m/z) (M+H)=153.9, Rt=0.32 min.

Step 3

To a solution of 2-(2-fluoropropan-2-yl)-4-methylpyridine (1.0 equiv.)in water (0.2 M) was added KMnO₄ (3.0 equiv) and the reaction heated to80° C. for 1.5 hrs. More KMnO₄ (1.5 equiv) was added and the reactionheated at 80° C. for an additional 1.5 hrs. The reaction was cooled toroom temperature, acidified to pH 3 with 1 M HCl, and then extractedthree times with ethyl acetate. The combined organics were dried overmagnesium sulfate, filtered and concentrated. Isolated2-(2-fluoropropan-2-yl)isonicotinic acid as a white solid in 43% yield.LCMS (m/z) (M+H)=184.0, Rt=0.45. ¹H NMR (400 MHz, <dmso>) δ ppm 1.65 (s,3H) 1.70 (s, 3H) 7.76 (dd, J=5.09, 1.57 Hz, 1H) 7.93 (s, 1H) 8.75 (d,J=5.09 Hz, 1H)

Synthesis of 3-(1,3,4-oxadiazol-2-yl)benzoic acid

Step 1

Monomethyl isophthalate (1.0 equiv) and hydrazine hydrate (4 equiv) werecombined in MeOH (1.0 M) and heated to reflux for 4 h. More hydrazinehydrate (4 equiv) was added and the reaction was continued refluxing foranother 3 h. The mixture was cooled and concentrated, providing3-(hydrazinecarbonyl)benzoic acid which was used without furtherpurification. LCMS (m/z) (M+H)=181.0, Rt=0.27 min.

Step 2

A mixture of 3-(hydrazinecarbonyl)benzoic acid (1.0 equiv), triethylorthoformate (12 equiv), and TsOH.H₂O (0.1 equiv) was heated at 60° C.overnight, and then further heated to 120° C. for 1.5 h. The mixture wascooled to room temp and poured onto water. The precipitated solid wasfiltered, washed with water, and dried to give3-(1,3,4-oxadiazol-2-yl)benzoic acid as a white solid in 61% yield. LCMS(m/z) (M+H)=191.0, Rt=0.44 min. ¹H NMR (400 MHz, <dmso>) δ ppm 7.74 (t,J=7.83 Hz, 1H) 8.16 (d, J=7.83 Hz, 1H) 8.25 (d, J=7.43 Hz, 1H) 8.51 (s,1H) 9.38 (s, 1H) 13.39 (br. s., 1H)

Synthesis of1-ethyl-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxylic acid

Step 1

In a round bottom flask equipped with a stir bar and purged withnitrogen was added 5-bromo-3-(trifluoromethyl)pyridin-2-ol (1.0 equiv.),potassium carbonate (2.0 equiv.) and DMF (0.2 M). The mixture wasstirred at room temperature and iodoethane (1.2 equiv.) was added viasyringe. The mixture was warmed to 30° C. for 4 hours at which time LCMSindicated full conversion. The reaction was worked up by partitioningbetween water and ethyl acetate, the aqueous phase was extracted 3 moretimes with ethyl acetate, the organics were combined, washed with brine,dried with sodium sulfate, filtered and concentrated to yield5-bromo-1-ethyl-3-(trifluoromethyl)pyridin-2(1H)-one (83%). ¹H NMR (400MHz, <cdcl3>) δ ppm 1.32-1.50 (m, 3H) 4.04 (q, J=7.17 Hz, 2H) 7.63 (br.s., 1H) 7.78 (br. s., 1H). LCMS (m/z) (M+H)=269.1/271.1, Rt=0.72 minStep 2: In a 2.0 mL microwave tube was added5-bromo-1-ethyl-3-(trifluoromethyl)pyridin-2(1H)-one (1.0 equiv.),PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.), Mo(CO)₆ (1.0 equiv.), methanol(10.0 equiv.) and THF (0.4 M). The mixture was capped and stirred whileDBU (3.0 equiv) was added, fizzing occured and the tube was vented andsubsequently heated in the microwave at 120° C. for 20 min at which timeLCMS indicated full conversion to product (M+H=250). The reaction wasfiltered through Celite, concentrated, and purified via ISCO to yieldmethyl1-ethyl-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxylate (52%yield). LCMS (m/z) (M+H)=250.0, Rt=0.69 min.

Step 3

To a solution of methyl1-ethyl-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxylate (1.0equiv.) in THF (0.25 M) was added lithium hydroxide (1.0 M, 3.0 equiv.)and allowed to stir at RT. Upon initial addition of LiOH, the solutionturned from clear to burnt orange. The rxn stirred overnight at whichtime LCMS indicated conversion to M+H=236. The volatiles were removed invacuo, and the aqueous phase was acidified to ˜pH 3. A tan ppt formedand was filtered and dried. A significant amount of the product remainedin the aqueous layer so it was extracted 3× with EtOAc, dried, filteredand concentrated. The solids were combined to yield1-ethyl-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxylic acid(97% yield). ¹³C NMR (400 MHz, <cdcl3>) δ ppm 166.2, 160.1, 148.3,140.0, 125.5, 122.8, 110.6, 47.4, 14.7. LCMS (m/z) (M+H)=236.0, Rt=0.53min.

Synthesis of 2-(1,1-difluoropropyl)isonicotinic acid

Step 1

To a flame dried flask and 2-cyano-4-methylpyridine (1.0 equiv.) in THF(0.5 M) at −78° C. was added 3M ethylmagnesiumbromide in diethyl ether(1.2 equiv.) and the mixture was stirred at that temperature for 20 minsand then warmed to room temperature. The reaction mixture was acidifiedwith aqueous citric acid and then partitioned between ethyl acetate andwater. The separated organic layer was dried with sodium sulfate andconcentrated under vacuo. The concentrated crude was purified via silicagel chromatography and eluted with 0 to 100% ethyl acetate in heptanesto give 1-(4-methylpyridinyl-2-yl)propan-1-one in 78% yield. LCMS m/z(M+H)=150.1, Rt=0.35 min.

Step 2

To 1-(4-methylpyridinyl-2-yl)propan-1-one (1 eq) in DCM (0.46 M) wasadded DAST (3 eq) and ethanol (0.8 eq) and the mixture was refluxedunder nitrogen atmosphere. After 5 h another portion of ethanol (0.8 eq)was added and the mixture was refluxed for 16 h. The reaction mixturewas partitioned between ethyl acetate and saturated sodium bicarbonatesolution and the separated organic layer was dried with sodium sulfateand concentrated under vacuo. The concentrated crude was purified viasilica gel chromatography and eluted with 0 to 100% ethyl acetate inheptanes to give 2-(1,1-difluoropropyl)-4-methylpyridine in 70% yield.LCMS m/z (M+H)=172.1, Rt=0.68 min.

Step 3

To 2-(1,1-difluoropropyl)-4-methylpyridine (1 eq) in water (0.36M) wasadded potassium permanganate (3 eq) and the mixture was heated to 80° C.for 6 h. To the reaction mixture was added another portion of potassiumpermanganate (1.5 eq) and after 1 h the reaction mixture was cooled toambient temperature and was then acidified with 6N HCl and the productwas extracted with ethyl acetate and the separated organic layer wasdried with sodium sulfate and concentrated under vacuo to give2-(1,1-difluoropropyl)isonicotinic acid in 23% yield. LCMS m/z(M+H)=202.1, Rt=0.64 min.

Synthesis of 2-(2-hydroxypropan-2-yl)isonicotinic acid

Step 1

To a solution of methyl-2-acetylisonicotinate (1.0 equiv.) in THF(0.089M) at −78° C. was added 3M solution of methyl magnesiumbromide indiethyl ether (6 eq) drop-wise over 10 min. The reaction mixture wasquenched with water at that temperature and brought to ambienttemperature. The reaction mixture was partitioned between ethyl acetateand water. The separated organic layer was dried with sodium sulfate andconcentrated under vacuo. The concentrated crude was purified via silicagel chromatography and eluted with 0 to 100% ethyl acetate in heptanesto give methyl 2-(2-hydroxypropan-2-yl)isonicotinate in 38% yield. LCMSm/z (M+H)=196 Rt=0.3 min.

Step 2

To methyl 2-(2-hydroxypropan-2-yl)isonicotinate (1.0 equiv.) in THF (0.3M) was added 2M Lithium hydroxide (2 eq) and the reaction mixture wasstirred at ambient temperature for 1 h. The reaction mixture wasconcentrated and to it was added 6M HCl (2 eq) (pH=4) and then extractedwith 3:1 chloroform:IPA mixture and the separated organic layer wasdried with sodium sulfate and concentrated under vacuo to give2-(2-hydroxypropan-2-yl)isonicotinic acid in 91% yield. LCMS (m/z)(M+H)=182, Rt=0.12 min. 1H NMR (400 MHz, <dmso>) δ ppm 1.40 (d, J=5.09Hz, 16H) 5.08-5.23 (m, 1H) 7.15-7.29 (m, 1H) 7.67-7.78 (m, 1H) 8.28-8.43(m, 1H)

Synthesis of 6-cyclopropylpyridazine-4-carboxylic acid

Step 1

To a dry round bottom flask was added a solution of ZnCl₂ (0.5 M in THF)(1.50 equiv.) followed by cyclopropylmagnesium bromide (0.5 M in THF)(1.50 equiv.) at room temperature under Argon. The resulting solutionwas stirred for 30 min before the addition of methyl6-chloropyridazine-4-carboxylate (1.0 equiv.), PdCl₂(dppf)-DCM (0.05equiv.), and zinc dust (0.15 equiv.). The resulting mixture was thenheated to 55° C. overnight. LCMS indicated 90% conversion and thereaction was cooled, quenched with H₂O, filtered through Celite,extracted with EtOAc (3×), dried, concentrated, and purified on a ISCOSiO₂ cartridge using 0-100% EtOAc/Heptanes to yield methyl6-cyclopropylpyridazine-4-carboxylate (39% yield). 1H NMR (400 MHz,<cdcl3>) 5 ppm 1.12-1.34 (m, 4H) 2.11-2.36 (m, 1H) 4.01 (s, 3H) 7.73 (d,J=1.96 Hz, 1H) 9.43 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=178.9, Rt=0.46min.

Step 2

To a solution of methyl 6-cyclopropylpyridazine-4-carboxylate (1.0equiv.) in THF (0.25 M) was added lithium hydroxide (1.0 M, 3.0 equiv.)and allowed to stir at room temperature. The rxn stirred overnight atwhich time LCMS indicated conversion to M+H=165. The volatiles (THF)were removed in vacuo, and the aqueous phase was acidified to ˜pH 3-4with HCl. The reaction was diluted with H₂O and brine, extracted withEtOAc (3×), dried over MgSO₄, filtered, and concentrated to yield6-cyclopropylpyridazine-4-carboxylic acid (83% yield). LCMS (m/z)(M+H)=164.8, Rt=0.27 min.

Synthesis of 2-cyclopropylisonicotinic acid

Step 1

To an oven dried round-bottomed flask was added a solution of zincchloride (0.5 M in THF, 1.5 equiv.) followed by cyclopropylmagnesiumbromide (0.5 M in THF, 1.5 equiv.) at room temperature and the resultingsolution was stirred at room temperature for 30 min before theportionwise sequential addition of 2-chloroisonicotinonitrile (1.0equiv.), dppf (0.12 equiv.) and Pd₂(dba)₃ (0.06 equiv.) at roomtemperature. The resulting mixture was heated to 60° C. for 23 hours. Atthis point, LC/MS indicated complete consumption of the startingmaterial and formation of the desired product. The reaction mixture wasquenched by the addition of ammonium chloride and diluted with diethylether. Extracted with ethyl acetate three times, the combined organicswere dried over magnesium sulfate and concentrated in vacuo to yield abrown oil. The oil was further purified by flash column chromatographyeluting with 100% heptanes to 50% ethyl acetate:heptanes to yield2-cyclopropylisonicotinonitrile as the desired product as a yellow oilin 75% yield. LCMS (m/z) (M+H)=145.0, Rt=0.53 min.

Step 2

To a solution of 2-cyclopropylisonicotinonitrile (1.0 equiv.) in ethanoland water (2:3, 1.7 M) was added sodium hydroxide (2.0 equiv.). Theresulting mixture was then heated to 80° C. for 90 min. Cooled to roomtemperature and concentrated under vacuo. The residue was diluted withwater and 2M HCl to pH=5. The aqueous layer was separated and extractedwith ethyl acetate three times. The combined organics were then driedover magnesium sulfate, filtered, and concentrated under vacuo to yield2-cyclopropylisonicotinic acid as a white solid in 99% yield. LCMS (m/z)(M+H)=164.0, Rt=0.26 min.

Synthesis of 2-(oxetan-3-yl)isonicotinic acid

Step 1

To a solution of ethyl isonicotinate (1.0 equiv.) in DMSO (0.1M) wasadded sulphuric acid (2.0 equiv.), iron(II) sulfate heptahydrate (0.3equiv.), 3-iodooxetane (2.0 equiv.). Heated to 40° C. and then addedhydrogen peroxide (30% in water, 3.0 equiv.). After 2 min, another 0.3equiv. of iron (II) sulfate heptahydrate was added and stirred for 30min. After 30 min, added additional hydrogen peroxide (3.0 equiv.) andiron (II) sulfate heptahydrate (0.3 equiv.) and stirred for 15 min at40° C. After 2 hours, LC/MS indicated complete conversion to product.Quenched by the addition of 1M NaOH and diluted with diethyl ether.Extracted three more times with diethyl ether, the organics werecombined, dried over magnesium sulfate, filtered and concentrated invacuo to yield an orange oil. This material was further purified viaflash column chromatography eluting with 100% heptanes to 20% ethylacetate:heptanes to 80% ethyl acetate:heptanes to yield ethyl2-(oxetan-3-yl)isonicotinate as a colorless oil in 14% yield. LCMS (m/z)(M+H)=208.1, Rt=0.48 min.

Step 2

To a solution of ethyl 2-(oxetan-3-yl)isonicotinate (1.0 equiv.) in THFand Water (1:1, 0.45 M) was added lithium hydroxide (2.0 equiv.) at roomtemperature. The mixture was stirred for 4 hours at rt. The reaction wasquenched with 2M HCl and diluted with ethyl acetate. The organic phasewas dried over magnesium sulfate, filtered and concentrated under vacuoto yield 2-(oxetan-3-yl)isonicotinic acid as an off-white solid in 41%yield. LCMS (m/z) (M+H)=180.0, Rt=0.22.

Synthesis of 6-(trifluoromethyl)pyridazine-4-carboxylic acid

Step 1

To a solution of methyl 6-chloropyridazine-4-carboxylate (1.0 equiv.) inHI (57% w/w in water) (1.35 M was added NaI (1.3 equiv.). The reactionwas heated at 40° C. for 20 hrs. The reaction mixture was cooled to roomtemperature, neutralized with sat. NaHCO₃ and extracted with EtOAc. Thecombined organic solution was washed with sat NH₄Cl, brine, dried andconcentrated in vacuo to give methyl 6-iodopyridazine-4-carboxylate in87% yield. LCMS (m/z) (M+H)=264.9, Rt=0.48 min.

Step 2

To a mixture of methyl 6-iodopyridazine-4-carboxylate (1.0 equiv.) and[(phen)CuCF₃] (1.5 equiv.) at rt was added DMF (0.28 M). The mixture wasstirred at rt overnight, diluted with ether and filtered through Celite.The organics were washed with H₂O, Brine and dried over Na₂SO₄ andconcentrated to yield methyl 6-(trifluoromethyl)pyridazine-4-carboxylatein 99% yield. LCMS (m/z) (M+H)=206.9, Rt=0.53 min.

Step 3

To a solution of methyl 6-(trifluoromethyl)pyridazine-4-carboxylate (1.0equiv.) in THF/water (1:1, 0.20 M) was added LiOH (6.0 equiv.). After itstirred at rt for 3 hr, the mixture was concentrated to remove most ofTHF and the residue was diluted with EtOAc and neutralized with 6N HClto pH=2. The organic layer was washed with brine, dried with Na₂SO₄,filtered and concentrated to yield6-(trifluoromethyl)pyridazine-4-carboxylic acid in 69% yield. LCMS (m/z)(M+H)=192.8, Rt=0.37 min. 1H NMR (400 MHz, <dmso>) δ ppm 8.42 (d, J=1.57Hz, 1H), 9.81 (d, J=1.57 Hz, 1H).

Synthesis of 2-(1-cyanocyclopropyl)isonicotinic acid

Step 1

To a mixture of cyclopropanecarbonitrile (4.0 equiv.) and2-fluoro-4-methylpyridine (1.0 equiv.) was added KHMDS in PhMe (1.3equiv.) to give a dark suspension. The mixture was heated to reflux for1.5 hours at which time the reaction was cooled to RT, quenched withNH₄Cl (aq), extracted with EtOAc (3×), dried over Na₂SO₄, filtered, andconcentrated to yield 1-(4-methylpyridin-2-yl)cyclopropanecarbonitrilein 38% yield. LCMS (m/z) (M+H)=158.8, Rt=0.43 min. The crude materialwas used in next step.

Step 2

To a solution of 1-(4-methylpyridin-2-yl)cyclopropanecarbonitrile (1.0equiv.) in water (0.16 M) was added potassium permanganate (6.0 equiv.).The mixture was heated at 60° C. for 4 hr. The mixture was cooled to rt,acidified with 2 M HCl to pH=4 and extracted with EtOAc. The organiclayer was washed with brine, dried over Na₂SO₄ and concentrated to yield2-(1-cyanocyclopropyl)isonicotinic acid in 34% yield. LCMS (m/z)(M+H)=189.1, Rt=0.53 min.

Synthesis of 6-(1-cyanocyclopropyl)pyridazine-4-carboxylic acid

Step 1

A solution of 5-methylpyridazin-3(2H)-one (1.0 equiv.) in POCl₃ (2.3 M)was heated at 90° C. for 2 h. The reaction mixture was poured intocrushed ice and neutralized with sodium bicarbonate. After threeextractions with EtOAc, the combined organic phase was washed with brineand then dried over sodium sulfate. After concentration, the crudematerial was purified via normal phase chromatography eluting with 30%EtOAc in heptanes. 3-chloro-5-methylpyridazine was isolated in 93%yield. LCMS (m/z) (M+H)=128.9, Rt=0.37 min.

Step 2

To a solution of tert-butyl 2-cyanoacetate (1.0 equiv.) in THF (0.25 M)in a flame dried flask under Ar and cooled in an ice-water bath wasadded sodium hydride (2.7 eq). After 30 min, 3-chloro-5-methylpyridazinein THF (2 M) was added dropwise. After several min, the solution waswarmed to room temperature and then microwave heated at 120° C. for 60min. The reaction mixture was then partitioned between water and EtOAc.The organic phase was then washed with water and brine and then driedover sodium sulfate. After concentration, the crude material waspurified via normal phase chromatography. tert-butyl2-cyano-2-(5-methylpyridazin-3-yl)acetate was isolated in 44% yield.LCMS (m/z) (M+H)=178.1, Rt=0.90 min.

Step 3

To a solution of tert-butyl 2-cyano-2-(5-methylpyridazin-3-yl)acetate(1.0 equiv.) in DCM (0.1 M) was added 2,2,2-trifluoroacetic acid (24eq). After 1 h 45 min, the reaction mixture was concentrated and wasthen purified via normal phase chromatography. Product eluted at 90%EtOAc in heptanes. 2-(5-Methylpyridazin-3-yl)acetonitrile was isolatedin 81% yield. LCMS (m/z) (M+H)=134.0, Rt=0.25 min.

Step 4

In a flame dried flask under Ar, 2-(5-methylpyridazin-3-yl)acetonitrilewas dissolved in DMF (0.1 M) and then cooled in an ice-water bath.Sodium hydride (3 eq) was added. After 30 min, 1,2-dibromoethane (1 eq)was added. After 2 h, the reaction mixture was warmed to roomtemperature and was then poured into water. The product was extractedwith three portions of EtOAc. The combined organics were washed withbrine and dried over sodium sulfate. The organics were concentrated andwere then purified via normal phase chromatography. Product eluted at20% EtOAc in heptanes.1-(5-Methylpyridazin-3-yl)cyclopropanecarbonitrile was isolated in 65%yield. LCMS (m/z) (M+H)=160.2, Rt=0.40 min.

Step 5

To a solution of 1-(5-methylpyridazin-3-yl)cyclopropanecarbonitrile (1.0equiv.) in pyridine (0.38 M) under Ar was added selenium dioxide (4 eq).After heating at 90° C. for 2 days, the reaction mixture was cooled inan ice bath and water was added. After washing with ethyl acetate, theaqueous phase was acidified to pH 3 with 6 N HCl and then extracted withethyl acetate. The combined organics were dried over Na₂SO₄ andconcentrated to give 6-(1-cyanocyclopropyl)pyridazine-4-carboxylic acidin 36% yield. LCMS (m/z) (M+H)=190.2, Rt=0.36 min.

Synthesis of 3-(2-(methylsulfonyl)propan-2-yl)benzoic acid

Step 1

To methyl 3-(bromomethyl)benzoate (1.0 equiv.) in THF (0.44M) at rt wasadded sodium methanesulfonate (2.0 equiv.). The mixture was stirred atrt for 18 h. The reaction mixture was poured onto ice-water. The solidwas collected by filtration and dried overnight under vacuo to givemethyl 3-((methylsulfonyl)methyl)benzoate in 95% yield. LCMS m/z(M+H)=229.2, Rt=0.52 min.

Step 2

To methyl 3-((methylsulfonyl)methyl)benzoate (1.0 equiv.) in THF (0.16M)at rt was added sodium t-butoxide (3.0 equiv.) and 2.0 M methyl iodidein diethyl ether (2.2 equiv.). The reaction mixture was stirred at rtfor 18 h. The reaction mixture was partitioned between ethyl acetate andwater. The separated organic layer was dried with sodium sulfate andconcentrated under vacuo. The concentrated crude was purified via silicagel chromatography and eluted with 0 to 50% ethyl acetate in heptanes togive methyl 3-(2-(methylsulfonyl)propan-2-yl)benzoate in 70% yield. LCMSm/z (M+H)=257.2, Rt=0.60 min.

Step 3

To methyl 3-(2-(methylsulfonyl)propan-2-yl)benzoate (1.0 equiv.) in 10:1mixture of THF and water (0.5M) at rt was added lithium hydroxide. Thereaction mixture was stirred at rt for 1 h then concentrated. Theresidue was dissolved in water then acidified with 1.0N HCl to pH=3. Theprecipitate was collected by filtration and dried under vacuo to give3-(2-(methylsulfonyl)propan-2-yl)benzoic acid in 95% yield. LCMS m/z(M+H)=243.2, Rt=0.54 min.

Synthesis of 6-(2-fluoropropan-2-yl)pyridazine-4-carboxylic acid

Step 1

To 3-chloro-5-methylpyridazine (1.0 equiv.) in DME (0.5M) at rt wasadded 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (1.4equiv.), 2.0 M sodium carbonate (3.0 equiv.), Pd(PPh₃)₄(0.02 equiv.).The mixture was stirred at 70° C. for 18 h then cooled to ambienttemperature. The reaction mixture was partitioned between ethyl acetateand water. The separated organic layer was dried with sodium sulfate andconcentrated under vacuo. The concentrated crude was purified via silicagel chromatography and eluted with 0 to 30% ethyl acetate in heptanes togive 5-methyl-3-(prop-1-en-2-yl)pyridazine in 58% yield. LCMS m/z(M+H)=134.8, Rt=0.44 min.

Step 2

To 5-methyl-3-(prop-1-en-2-yl)pyridazine in dichloromethane (0.5M) at−78° C. was bubbled with ozone for 10 min. The reaction mixture waswarmed to rt then concentrated. The concentrated crude was purified viasilica gel chromatography and eluted with 0 to 50% ethyl acetate inheptanes to give 1-(5-methylpyridazin-3-yl)ethanone in 50% yield. LCMSm/z (M+H)=136.8, Rt=0.36 min.

Step 3

To 1-(5-methylpyridazin-3-yl)ethanone (1.0 equiv.) in THF (0.5M) at −0°C. was added 3.0 M methylmagnesiumbromide in diethyl ether (1.1 eq) andthe mixture was stirred at that temperature for 2 h. The reactionmixture was acidified with aqueous citric acid and then partitionedbetween ethyl acetate and water. The separated organic layer was driedwith sodium sulfate and concentrated under vacuo. The concentrated crudewas purified via silica gel chromatography and eluted with 0 to 40%ethyl acetate in heptanes to give 2-(5-methylpyridazin-3-yl)propan-2-olin 49% yield. LCMS m/z (M+H)=152.9, Rt=0.76 min.

Step 4

To 2-(5-methylpyridazin-3-yl)propan-2-ol (1 equiv.) in DCM (0.46M) at−15° C. was added DAST (1.2 equiv.) and the mixture was stirred at thattemperature for 1 h under argon atmosphere. The reaction mixture wasneutralized with saturated sodium bicarbonate solution to pH=8 andpartitioned between water and dichloromethane. The separated organiclayer was dried with sodium sulfate and concentrated under vacuo. Theconcentrated crude was purified via silica gel chromatography and elutedwith 0 to 50% ethyl acetate in heptanes to give3-(2-fluoropropan-2-yl)-5-methylpyridazine in 52% yield. LCMS m/z(M+H)=154.8, Rt=0.42 min.

Step 5

To 3-(2-fluoropropan-2-yl)-5-methylpyridazine (1 equiv.) in pyridine(0.38 M) was added selenium dioxide (2.5 equiv.) and the mixture washeated to 70° C. for 18 h. The reaction mixture was cooled to ambienttemperature and concentrated. The concentrated crude was dissolved inwater and then acidified with 1N HCl to pH=3. The mixture waspartitioned between ethyl acetate and water. The separated organic layerwas dried with sodium sulfate and concentrated under vacuo to give2-(1,1-difluoropropyl)isonicotinic acid in 89% yield. LCMS m/z(M+H)=184.9, Rt=0.63 min.

Synthesis of 6-(2-cyanopropan-2-yl)pyridazine-4-carboxylic acid

Step 1

A solution of 5-methylpyridazin-3(2H)-one (1.0 equiv.) in POCl₃ (2 M)was heated up to 90° C. for 2 h. After completion of the reaction (TLCmonitoring), reaction mass was poured into crushed ice and pH wasneutralized by using solid NaHCO₃. The compound was extracted with EtOAc(3×); combined organics were washed with brine and dried over anhydrousNa₂SO₄. The solvent was evaporated and crude residue was purified oversilica gel by using eluents 30% EtOAc:hexanes to afford3-chloro-5-methylpyridazine as yellowish liquid in 93% yield. ¹H-NMR(400 MHz, CDCl₃): δ 8.96 (s, 1H), 7.36 (s, 1H) and 2.39 (s, 3H). LCMSm/z (M+H)=129.13.

Step 2

A solution of LDA (2M in THF, 2.5 equiv.) in THF (1 M) was cooled up to−78° C. followed by the drop wise addition of isobutyronitrile (2.5equiv.). The resulting reaction mixture was stirred at 0° C. for 30minutes and again cooled up to −78° C. followed by the addition of asolution of 3-chloro-5-methylpyridazine (1.0 equiv.) in THF. Theresulting reaction mixture temperature was slowly raised up to roomtemperature and left for stirring for 16 h. After completion of thereaction (TLC monitoring), reaction mass was quenched with saturatedsolution of NH₄Cl followed by the extraction with EtOAc (3×). Thecombined organics were washed with brine, dried over anhydrous Na₂SO₄.The solvent was evaporated and crude residue was purified over silicagel by using eluents 50% EtOAc: hexanes to afford2-methyl-2-(5-methylpyridazin-3-yl)propanenitrile as the desired productas off-white low melting solid (76%). ¹H-NMR (400 MHz, CDCl₃): δ 9.01(s, 1H), 7.61 (s, 1H), 2.42 (s, 3H) and 1.87 (s, 6H). LCMS m/z(M+H)=162.42.

Step 3

To a solution of 2-methyl-2-(5-methylpyridazin-3-yl)propanenitrile (1.0equiv.) in pyridine (1.2 M) was added SeO₂ (2.5 equiv.). The resultingreaction mass was stirred at 90° C. for 24 h. After completion of thereaction (TLC monitoring), reaction mixture was cooled up to roomtemperature and poured into crushed ice followed by the extraction withEtOAc (2×). The organics were discarded and the pH of the aqueous layerwas adjusted up to 3-4 by using 6N HCl followed by the extraction withEtOAc (3×). The combined organics were washed with brine, dried overanhydrous Na₂SO₄, filtered and evaporated under reduced pressure. Thecrude compound was finally triturated with n-pentane to get6-(2-cyanopropan-2-yl)pyridazine-4-carboxylic acid as the desiredproduct as light yellow solid (51%). ¹H-NMR (400 MHz, DMSO-d₆): δ 9.55(s, 1H), 8.21 (s, 1H) and 1.82 (s, 6H). LCMS m/z (M+H)=192.28.

Synthesis of 4-(5-bromo-2-ethoxypyridin-3-yl)morpholine

Step 1

To a solution of 5-bromo-2-chloro-3-nitropyridine (1.0 equiv) in EtOH(0.25 M) at 25° C. was added sodium ethoxide (21 wt % solution in EtOH,1.2 equiv) and the mixture was heated to 75° C. for 1 h. The reactionwas poured onto a 1:1 mix of 1 M citric acid and water and the ethanolwas removed by concentration. The residue was extracted with three timeswith ethyl acetate. The combined organics were washed with brine, driedover magnesium sulfate, filtered and concentrated. Isolated5-bromo-2-ethoxy-3-nitropyridine as a brown oil which was used withoutfurther purification. LCMS (m/z) (M+H)=246.8/248.8, Rt=0.95 min.

Step 2

To a solution of 5-bromo-2-ethoxy-3-nitropyridine (1.0 equiv) in MeOHand DCM (1:10; 0.3 M) at 25° C. were added zinc (5.5 equiv) and ammoniumchloride (5 equiv) and the mixture was heated to 75° C. and stirred for4 hours. The reaction was cooled to room temperature and filteredthrough a short plug of Celite, washing with DCM, and then concentrated.The residue was taken up in ethyl acetate, washed with water and brineand then dried over magnesium sulfate, filtered and concentrated. Thecrude residue was purified via flash chromatography over silica geleluting with heptanes and 0-50% ethyl acetate gradient. Isolated5-bromo-2-ethoxypyridin-3-amine as a brown solid in 79% yield. LCMS(m/z) (M+H)=216.9/218.9, Rt=0.75 min.

Step 3

To a solution of 5-bromo-2-ethoxypyridin-3-amine (1.0 equiv.) in DMF(0.5 M) at 0° C. was slowly added NaH (1.5 equiv.) and the mixture wasallowed to warm to room temperature over 15 min followed by the additionof bis(2-bromoethyl) ether (4 equiv.). The mixture was heated to 90° C.and stirred for 48 hours. The mixture was poured onto ice water andextracted three times with ethyl acetate. The combined organics werewashed with water, brine, dried over magnesium sulfate, filtered andconcentrated. The crude residue was purified via flash chromatographyover silica gel eluting with heptanes and 0-25% acetone gradient.Isolated 4-(5-bromo-2-ethoxypyridin-3-yl)morpholine as an orange solidin 76% yield. LCMS (m/z) (M+H)=286.9/288.9, Rt=0.93 min.

Synthesis of 4-(5-bromo-2-chloropyridin-3-yl)morpholine

Step 1

To a solution of 5-bromo-2-chloro-3-nitropyridine (1.0 equiv) in MeOHand DCM (1:10; 0.45 M) at 25° C. were added zinc (5.5 equiv) andammonium chloride (5 equiv) and the mixture was heated to 65° C. andstirred for 5 hours. More zinc (2.5 equiv) and ammonium chloride (2.5equiv) was added and the mixture was stirred at 65° C. for an additional3 hours. The reaction was cooled to room temperature and filteredthrough a short plug of Celite. The filtrate was washed with water andbrine and then dried over magnesium sulfate, filtered and concentrated.Isolated 5-bromo-2-chloropyridin-3-amine as an off-white solid in 35%yield which was used without further purification. LCMS (m/z)(M+H)=206.8/208.8, Rt=0.62 min.

Step 2

To a solution of 5-bromo-2-chloropyridin-3-amine (1.0 equiv.) in DMF(0.2 M) at 0° C. was slowly added NaH (1.5 equiv.) and the mixture wasallowed to warm to room temperature over 15 min followed by the additionof bis(2-bromoethyl) ether (3 equiv.). The mixture was heated to 80° C.and stirred for 2 hours. The mixture was poured onto water and extractedthree times with ethyl acetate. The combined organics were washed withwater, brine, dried over magnesium sulfate, filtered and concentrated.The crude residue was purified via flash chromatography over silica geleluting with heptanes and 0-50% acetone gradient. Isolated4-(5-bromo-2-chloropyridin-3-yl)morpholine as a yellow solid in 71%yield. LCMS (m/z) (M+H)=276.9/278.9, Rt=0.81 min.

Synthesis of 4-(5-bromo-2-fluoropyridin-3-yl)morpholine

To an ice-bath cooled solution of NaH (60% in mineral oil, 3.0 equiv.)in DMF (1.4 M) was added 3-amino-5-bromo-2-fluoropyridine (1.0 equiv.).The mixture was allowed to warm to room temperature over 15 min and thentreated with bis(2-bromoethyl) ether (1.5 equiv.). The mixture washeated to 80° C. and stirred for 35 min. The cooled reaction mixture waspoured into four volumes of water. The resulting precipitate wascollected by vacuum filtration. The filter cake was rinsed twice withwater and twice with heptanes. The tan solid was dried under high vacuumto give 4-(5-bromo-2-fluoropyridin-3-yl)morpholine in 83% yield. LCMS(m/z) (M+H)=260.9/262.9, Rt=0.74 min.

Synthesis of 4-(5-bromopyridin-3-yl)morpholine

To a solution of 3-amino-5-bromopyridine (1.0 equiv.) in DMF (0.6 M) at0° C. was slowly added NaH (1.5 equiv.) and the mixture was allowed towarm to room temperature over 15 min followed by the addition ofbis(2-bromoethyl) ether (3 equiv.). The mixture was heated to 80° C. andstirred for 18 hours. The mixture was poured onto water and extractedthree times with DCM. The combined organics were washed with water,brine, dried over magnesium sulfate, filtered and concentrated. Thecrude residue was purified via flash chromatography over silica geleluting with heptanes and 0-75% ethyl acetate gradient. Isolated4-(5-bromopyridin-3-yl)morpholine as a yellow solid in 40% yield. LCMS(m/z) (M+H)=242.9/244.9, Rt=0.39 min.

Synthesis of 5-bromo-3-morpholinopicolinonitrile

A solution of 5-bromo-3-fluoropicolinonitrile (1.0 equiv.) inacetonitrile (0.5 M) was treated with morpholine (1.1 equiv.), and DIEA(2.0 equiv.). The mixture was stirred at 90° C. for 22 hr. The cooledreaction mixture was diluted with water (12 mL) and filtered. Theprecipitate was air-dried to give 5-bromo-3-morpholinopicolinonitrile asa yellow crystalline solid in 87% yield. LCMS (m/z) (M+H)=267.9/269.9,Rt=0.79 min.

Synthesis of 5-bromo-N,N-dimethyl-3-morpholinopyridin-2-amine

To a solution of 4-(5-bromo-2-fluoropyridin-3-yl)morpholine (1.0 equiv.)in DMF (0.3 M) was added dimethylamine, 5.6M in ethanol (4.0 equiv.).The reaction mixture was stirred at 90° C. overnight. The cooledreaction mixture was partially concentrated in vacuo. Four volumes ofwater were added. The mixture was stirred for 1 hr and filtered. Thepinkish solid was air-dried to give5-bromo-N,N-dimethyl-3-morpholinopyridin-2-amine in 69% yield. LCMS(m/z) (M+H)=285.8/287.8, Rt=0.50 min.

Synthesis of 4-(5-bromo-2-(difluoromethoxy)pyridin-3-yl)morpholine

To a solution of 5-bromo-3-morpholinopyridin-2-ol (1.0 equiv) in DMF(0.38 M) was added sodium 2-chloro-2,2-difluoroacetate (2 equiv.) andsodium hydroxide (1.1 equiv.) and the reaction was heated to 55° C. for16 h. The reaction mixture was further heated to 90° C. for 16 h. Thereaction mixture was partitioned between water and ethyl acetate, andthe organic phase was dried with sodium sulfate, filtered andconcentrated. The crude material was redissolved in DCM and a few dropsof methanol and filtered. The filtrate was concentrated and purified viaflash column chromatography over silica gel eluting with heptane and 0to 100% ethyl acetate gradient. Isolated4-(5-bromo-2-(difluoromethoxy)pyridin-3-yl)morpholine. ¹H NMR (500 MHz,DMSO-d6) b 2.95-3.14 (m, 4H), 3.54-3.93 (m, 4H), 7.58 (d, J=2.2 Hz, 1H),7.74 (t, J=72.4 Hz, 1H), 7.95 (d, J=2.1 Hz, 1H), LCMS (m/z)(M+H)=308.9/310.9, Rt=0.87 min.

Synthesis of8-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-3-oxa-8-azabicyclo[3.2.1]octane

Step 1

To a solution of 5-bromo-3-iodo-2-hydroxypyridine (1.0 equiv.) in THF(0.18 M) at 25° C. were added 4-hydroxytetrahydropyran (1.2 equiv.),PPh₃ (1.25 equiv.) and DIAD (1.2 equiv.) and the mixture was stirred for2 hours. More 4-hydroxytetrahydropyran (1.2 equiv.), PPh₃ (1.25 equiv.),and DIAD (1.2 equiv.) was added, and the reaction was stirred foranother 2 hours. The reaction mixture was concentrated, and the cruderesidue was purified via flash chromatography over silica gel elutingwith heptanes and 0-20% ethyl acetate gradient. Isolated5-bromo-3-iodo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridine as a colorlessoil in 55% yield. LCMS (m/z) (M+H)=384.0/386.0, Rt=0.88 min.

Step 2

To a solution of5-bromo-3-iodo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridine (1.0 equiv.) intoluene (0.15 M) in a microwave vial was added3-oxa-8-azabicyclo[3.2.1]octane (1.3 equiv.), NaOtBu (3 equiv.), andXantphos (0.1 equiv.) and the mixture was degassed with Ar. Pd(dba)₂(0.05 equiv) was added, and the mixture was degassed again and thensealed and heated at 90° C. for 18 hours. The mixture was poured ontosaturated aqueous sodium bicarbonate and extracted three times withethyl acetate. The combined organics were washed with brine, dried overmagnesium sulfate, filtered and concentrated. The crude residue waspurified via flash chromatography over silica gel eluting with heptanesand 0-30% ethyl acetate gradient. Isolated8-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-3-oxa-8-azabicyclo[3.2.1]octaneas a pale yellow solid in 67% yield. LCMS (m/z) (M+H)=369.1/371.1,Rt=0.95 min.

Synthesis of 5-bromo-2-ethoxy-3-iodopyridine

To a solution of 5-bromo-2-ethoxypyridin-3-amine (1.0 equiv.) in amixture of concentrated HCl and water (1:1.3, 0.2 M) at 0° C. was slowlyadded NaNO2 (1.4 equiv.) and the mixture was stirred for 30 min. A 0.3 Msolution of KI in water (3 equiv.) was slowly added to the mixture,which was then allowed to warm to 25° C. and stirred for 30 min. Themixture was poured into a separatory funnel and extracted three timeswith ethyl acetate. The combined organics were washed with saturatedaqueous sodium sulfite, saturated aqueous sodium bicarbonate, dried overmagnesium sulfate, filtered, and concentrated. The crude residue waspurified via flash chromatography over silica gel eluting with heptanesand 0-15% ethyl acetate gradient. Isolated5-bromo-2-ethoxy-3-iodopyridine as a white solid in 71% yield. LCMS(m/z) (M+H)=327.9/329.9, Rt=1.10 min.

Method 4:

To a solution of the starting iodide (1.0 equiv.) in toluene (0.15 M) ina microwave vial was added the amine (1.3 equiv.), NaOtBu (3 equiv.),and Xantphos (0.1 equiv.) and the mixture was degassed with Ar. Pd(dba)₂(0.05 equiv) was added, and the mixture was degassed again and thensealed and heated at 90° C. for 18 hours. The mixture was poured ontosaturated aqueous sodium bicarbonate and extracted three times withethyl acetate. The combined organics were washed with brine, dried overmagnesium sulfate, filtered and concentrated. The crude residue waspurified via flash chromatography over silica gel eluting with heptanesand 0-30% ethyl acetate gradient.

Synthesis of8-(5-bromo-2-ethoxypyridin-3-yl)-3-oxa-8-azabicyclo[3.2.1]octane

Method 4 was followed using 5-bromo-2-ethoxy-3-iodopyridine and3-oxa-8-azabicyclo[3.2.1]octane to give8-(5-bromo-2-ethoxypyridin-3-yl)-3-oxa-8-azabicyclo[3.2.1]octane as apale orange oil in 46% yield. LCMS (m/z) (M+H)=312.9/314.9, Rt=0.97 min.

Synthesis of (S)-4-(5-bromo-2-ethoxypyridin-3-yl)-3-methylmorpholine

Method 4 was followed using 5-bromo-2-ethoxy-3-iodopyridine and(S)-3-methylmorpholine to give(S)-4-(5-bromo-2-ethoxypyridin-3-yl)-3-methylmorpholine as a pale orangeoil in 12% yield. LCMS (m/z) (M+H)=300.9/302.9, Rt=0.91 min.

Synthesis of (R)-4-(5-bromo-2-ethoxypyridin-3-yl)-3-methylmorpholine

Method 4 was followed using 5-bromo-2-ethoxy-3-iodopyridine and(R)-3-methylmorpholine to give(R)-4-(5-bromo-2-ethoxypyridin-3-yl)-3-methylmorpholine as a pale yellowoil in 17% yield. LCMS (m/z) (M+H)=300.9/302.9, Rt=0.92 min.

Synthesis of 4-(5-bromo-2-methoxypyridin-3-yl)morpholine

To a solution of 4-(5-bromo-2-fluoropyridin-3-yl)morpholine (1.0 equiv.)in dioxane (0.13 M) at 25° C. was added NaOMe (5 equiv.) and thereaction was heated to 105° C. and stirred for 2 hours. The reaction wascooled to room temperature, poured onto water, and extracted three timeswith ethyl acetate. The combined organics were washed with water, brine,dried over magnesium sulfate and concentrated. Isolated4-(5-bromo-2-methoxypyridin-3-yl)morpholine as a pale orange solid in95% yield which was used without further purification. LCMS (m/z)(M+H)=272.9/274.9, Rt=0.78 min.

Synthesis of4-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)ox)pyridin-3-yl)morpholine

To a solution of 4-hydroxytetrahydropyran (2 equiv.) in dioxane (0.2 M)at 25° C. was added NaH (2.1 equiv.) and the reaction was stirred for 30min. 4-(5-bromo-2-fluoropyridin-3-yl)morpholine (1.0 equiv.) was thenadded and the reaction was heated to 105° C. and stirred for 5 h. Thereaction was cooled to room temperature, poured onto water, andextracted three times with ethyl acetate. The combined organics weredried over sodium sulfate, filtered, and concentrated. The crude residuewas purified by flash chromatography over silica gel eluting withheptane and 50-100% ethyl acetate gradient. Isolated4-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)morpholine as alight yellow oil in 83% yield. LCMS (m/z) (M+H)=343.0/344.9, Rt=0.86min.

Synthesis of 4-(5-bromo-2-(2,2-difluoroethoxy)pyridin-3-yl)morpholine

To a solution of 2,2-difluroethanol (2.0 equiv.) in dioxane (0.13 M) wasadded sodium hydride (2.0 equiv.) under nitrogen. The reaction wasstirred for 15 min at room temperature, then4-(5-bromo-2-fluoropyridin-3-yl)morpholine (1.0 equiv.) was added. Thesolution was allowed to stir at room temperature overnight. The mixturewas partitioned between water and ethyl acetate, and the organic phasewas dried over sodium sulfate, filtered and concentrated. The crudematerial was used for the next step without further purification. LCMS(m/z) (M+H)=322.9/324.9, Rt=0.89 min.

Synthesis of4-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine

Step 1

To a solution of 4-(5-bromo-2-methoxypyridin-3-yl)morpholine (1.0equiv.) in 1,4-dioxane (0.15 M) was added bis(pinacolato)diboron (1.5equiv.), PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.), and 2M aqueous sodiumcarbonate (3.0 equiv.). The reaction mixture was irradiated at 120° C.for 18 min in the microwave. The cooled reaction mixture was dilutedwith DCM and filtered. The filtrate was concentrated to give crude4-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine(assumed 100% yield) as a brown residue which was used without furtherpurification. LCMS (m/z) (M+H)=321.0, Rt=0.81 min.

Step 2

To a solution of4-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine(1.0 equiv.) in DME (0.15 M) was added 5-bromo-6-chloropyridin-3-amine(1.0 equiv.), PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.), and 2M aqueoussodium carbonate (3.0 equiv.). The reaction mixture was irradiated at120° C. for 15 min in the microwave. The cooled reaction mixture wasdiluted with 2:1 DCM:MeOH and filtered. The filtrate was concentratedand purified by flash chromatography over silica gel eluting withheptane and 50-100% ethyl acetate gradient. Isolated2-chloro-6′-methoxy-5′-morpholino-[3,3′-bipyridin]-5-amine as a brownresidue in 73% yield. LCMS (m/z) (M+H)=321.0, Rt=0.60 min.

Method 5:

A solution of the aryl bromide (1.0 equiv.) and the boronic ester (1.2equiv.) in DME (0.15 M) and 2 M aqueous sodium carbonate (3 equiv.) waspurged with Ar for 5 min. PdCl₂(dppf).CH₂Cl₂ adduct (0.05 equiv.) wasthen added, and the mixture was purged with Ar again and then heated at100° C. for 1 h. The mixture was poured onto water and extracted threetimes with ethyl acetate. The combined organics were washed with brine,dried over magnesium sulfate, filtered and concentrated. The cruderesidue was purified via flash chromatography over silica gel elutingwith either heptane and 0-100% ethyl acetate gradient or DCM and 0-15%methanol gradient, or in other cases the crude residue was used withoutfurther purification.

Synthesis of 3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylaniline

Method 5 was followed using 4-(5-bromo-2-ethoxypyridin-3-yl)morpholineand 5-amino-2-methylphenylboronic acid, pinacol ester. The crude residuewas purified via flash chromatography over silica gel eluting withheptane and 0-100% ethyl acetate gradient. Isolated3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylaniline as a pale yellowoil in 91% yield. LCMS (m/z) (M+H)=314.1, Rt=0.60 min.

Synthesis of 6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

Method 5 was followed using 4-(5-bromo-2-ethoxypyridin-3-yl)morpholineand6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. Isolated6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine as a lightbrown solid in 96% yield. LCMS (m/z) (M+H)=315.1, Rt=0.52 min.

Synthesis of 3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylbenzoic acid

Step 1

Method 5 was followed using 4-(5-bromo-2-ethoxypyridin-3-yl)morpholineand methyl4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate. Thecrude residue was purified via flash chromatography over silica geleluting with heptane and 0-100% ethyl acetate gradient. Isolated methyl3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylbenzoate as a white solidin 57% yield. LCMS (m/z) (M+H)=357.1, Rt=1.01 min.

Step 2

To a stirred solution of methyl3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylbenzoate (1.0 equiv.) inTHF/MeOH (2:1, 0.1 M) was added 2.0 M aqueous LiOH (6 equiv.) and themixture was heated at 45° C. for 2 h. The mixture was cooled to roomtemperature and acidified with 1 M HCl. The mixture was extracted threetimes with ethyl acetate. The combined organics were dried overmagnesium sulfate, filtered, and concentrated. Isolated3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylbenzoic acid as a paleorange solid which was used without further purification. LCMS (m/z)(M+H)=343.1, Rt=0.81 min.

Synthesis ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

Method 5 was followed using 4-(5-bromo-2-fluoropyridin-3-yl)morpholineandN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. IsolatedN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideas a light brown solid in 100% yield. LCMS (m/z) (M+H)=461.1, Rt=0.75min.

Synthesis of 6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

Method 5 was followed using 4-(5-bromo-2-fluoropyridin-3-yl)morpholineand6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. Isolated6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine as a lightbrown oil in 100% yield. LCMS (m/z) (M+H)=289.0, Rt=0.45 min.

Synthesis of5′-amino-2′-methyl-5-morpholino-[3,3′-bipyridine]-6-carbonitrile

Method 5 was followed using 5-bromo-3-morpholinopicolinonitrile and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. Isolated5′-amino-2′-methyl-5-morpholino-[3,3′-bipyridine]-6-carbonitrile as atan solid. LCMS (m/z) (M+H)=296.0, Rt=0.46 min.

Synthesis ofN6′,N6′,2-trimethyl-5′-morpholino-[3,3′-bipyridine]-5,6′-diamine

Method 5 was followed using5-bromo-N,N-dimethyl-3-morpholinopyridin-2-amine and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amineThe crude residue was purified via flash chromatography over silica geleluting with ethyl acetate and 0-5% methanol IsolatedN6′,N6′,2-trimethyl-5′-morpholino-[3,3′-bipyridine]-5,6′-diamine as abrown residue in 69% yield. LCMS (m/z) (M+H)=314.1, Rt=0.32 min.

Synthesis of5′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-methyl-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-amine

Method 5 was followed using8-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-3-oxa-8-azabicyclo[3.2.1]octaneand6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. Isolated5′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-methyl-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-amineas a light brown oil in 98% yield. LCMS (m/z) (M+H)=397.0, Rt=0.56 min.

Synthesis of2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-amine

Method 5 was followed using4-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)morpholine and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. Isolated2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-amineas a brown residue in 46% yield. LCMS (m/z) (M+H)=371.1, Rt=0.51 min.

Synthesis of4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)aniline

Method 5 was followed using4-(5-bromo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)morpholine and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.15equiv.). The crude residue was purified via flash chromatography oversilica gel eluting with DCM and 0-15% methanol gradient. Isolated4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)anilineas a brown residue in 76% yield. LCMS (m/z) (M+H)=370.2, Rt=0.59 min.

Synthesis of5′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6′-ethoxy-2-methyl-[3,3′-bipyridin]-5-amine

Method 5 was followed using8-(5-bromo-2-ethoxypyridin-3-yl)-3-oxa-8-azabicyclo[3.2.1]octane and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. Isolated5′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6′-ethoxy-2-methyl-[3,3′-bipyridin]-5-amineas a light brown oil in 92% yield. LCMS (m/z) (M+H)=341.0, Rt=0.58 min.

Synthesis of(S)-6′-ethoxy-2-methyl-5′-(3-methylmorpholino)-[3,3′-bipyridin]-5-amine

Method 5 was followed using(S)-4-(5-bromo-2-ethoxypyridin-3-yl)-3-methylmorpholine and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue used without further purification. Isolated(S)-6′-ethoxy-2-methyl-5′-(3-methylmorpholino)-[3,3′-bipyridin]-5-amineas a light brown oil. LCMS (m/z) (M+H)=329.1.0, Rt=0.53 min.

Synthesis of(R)-6′-ethoxy-2-methyl-5′-(3-methylmorpholino)-[3,3′-bipyridin]-5-amine

Method 5 was followed using(R)-4-(5-bromo-2-ethoxypyridin-3-yl)-3-methylmorpholine and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with heptane and 0-100% ethyl acetate gradient. Isolated(R)-6′-ethoxy-2-methyl-5′-(3-methylmorpholino)-[3,3′-bipyridin]-5-amineas a pale yellow solid. LCMS (m/z) (M+H)=329.1.0, Rt=0.53 min.

Synthesis of 6′-chloro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

Method 5 was followed using 4-(5-bromo-2-chloropyridin-3-yl)morpholineand6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. Isolated6′-chloro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine as a paleyellow foam in 100% yield. LCMS (m/z) (M+H)=305.0, Rt=0.47 min.

Synthesis of 2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

Method 5 was followed using 4-(5-bromopyridin-3-yl)morpholine and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine.The crude residue was purified via flash chromatography over silica geleluting with DCM and 0-15% methanol gradient. Isolated2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine as a light brown oil in69% yield. LCMS (m/z) (M+H)=271.0, Rt=0.27 min.

6′-methoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

¹H NMR (400 MHz, <cd3od>) 6 ppm 2.40 (s, 3H) 3.05-3.18 (m, 4H) 3.84-3.95(m, 4H) 4.05 (s, 3H) 6.89 (br. s., 1H) 7.02 (d, J=1.96 Hz, 1H) 7.76 (d,J=1.96 Hz, 1H) 8.04 (d, J=2.74 Hz, 1H). LCMS (m/z) (M+H)=301.0, Rt=0.45min.

Synthesis of2-((5′-amino-2′-methyl-5-morpholino-[3,3′-bipyridin]-6-yl)oxy)ethanol

To a solution of ethylene glycol (5 equiv.) in dioxane (0.1 M) at 25° C.was added NaH (5 equiv) and the reaction was stirred for 15 min6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine (1.0 equiv.)was then added and the reaction was heated to 105° C. and stirred for 24h. More ethylene glycol (5 equiv.) and NaH (5 equiv) was added and themixture was stirred at 105° C. for an additional 24 h. The reaction wascooled to room temperature, poured onto water, and extracted three timeswith ethyl acetate. The combined organics were washed with brine, driedover magnesium sulfate and concentrated. Isolated2-((5′-amino-2′-methyl-5-morpholino-[3,3′-bipyridin]-6-yl)oxy)ethanol asa light brown oil in 95% yield which was used without furtherpurification. LCMS (m/z) (M+H)=331.1 Rt=0.39 min.

Method 6:

To a solution of the amine (1.0 equiv) and the acid (1.1 equiv.) in DMA(0.15 M) at 25° C. were added HOAT (1.3 equiv.), i-Pr₂NEt (3 equiv.),and EDC (1.3 equiv) and the mixture was stirred for 4 h at 25° C. Themixture was poured onto water and extracted three times with ethylacetate. The combined organics were washed with water, brine, dried overmagnesium sulfate, filtered and concentrated. The crude residue was usedwithout further purification.

Method 7: Synthesis of5′-amino-2′-chloro-1-methyl-5-morpholino-[3,3′-bipyridin]-6(1H)-one

To a 0.15M solution of1-methyl-3-morpholino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one(1.00 equiv.) in DME was added 5-bromo-6-chloropyridin-3-amine (1.00equiv.), PdCl₂(dppf).CH₂Cl₂ adduct (0.10 equiv.), and 2M aqueous sodiumcarbonate (3.00 equiv.). The reaction mixture was irradiated at 120° C.for 15 min in the microwave. The cooled reaction mixture was dilutedwith 2:1 DCM:MeOH and filtered. The filtrate was concentrated andpurified by flash chromatography over silica gel (ethyl acetate with0-10% methanol gradient) to give5′-amino-2′-chloro-1-methyl-5-morpholino-[3,3′-bipyridin]-6(1H)-one(56.6% yield) as a brown residue. LCMS (m/z) (M+H)=321.0, Rt=0.45 min.

Synthesis of5-(5-amino-2-fluorophenyl)-1-methyl-3-morpholinopyridin-2(1H)-one

Following the preparation in Method 7 using the appropriate startingmaterials gave5-(5-amino-2-fluorophenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (52.2%yield) as a brown residue. LCMS (m/z) (M+H)=304.0, Rt=0.40 min.

Synthesis of5-(5-amino-2-chlorophenyl)-1-methyl-3-morpholinopyridin-2(1H)-one

Following the preparation in Method 7 using the appropriate startingmaterials gave5-(5-amino-2-chlorophenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (52.1%yield) as a brown residue. LCMS (m/z) (M+H)=320.1, Rt=0.46 min.

Synthesis of4-amino-2-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzonitrile

Following the preparation in Method 7 using the appropriate startingmaterials gave4-amino-2-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzonitrile(63.4% yield) as a tan solid. LCMS (m/z) (M+H)=310.9, Rt=0.56 min.

Method 8:

Synthesis of2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylicacid

Step 1

To a 0.15M solution of1-methyl-3-morpholino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one(1.00 equiv.) in DME was added methyl 5-bromo-6-chloronicotinate (1.00equiv.), PdCl₂(dppf).CH₂Cl₂ adduct (0.10 equiv.), and 2M aqueous sodiumcarbonate (3.00 equiv.). The reaction mixture was irradiated at 120° C.for 15 min in the microwave. The cooled reaction mixture was dilutedwith 2:1 DCM:MeOH and filtered. The filtrate was concentrated andpurified by flash chromatography over silica gel (ethyl acetate with0-10% methanol gradient) to give methyl2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylate(29.0% yield) as a yellow solid. LCMS (m/z) (M+H)=364.1, Rt=0.62 min.

Step 2

To a 0.23M solution of methyl2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylate(1.00 equiv.) in THF was added 2.0M aqueous lithium hydroxide (3.00equiv.). The mixture was stirred at ambient temperature for 1.5 hr. Thereaction mixture was acidified to pH 3 with aqueous HCl and concentratedto give crude2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylicacid as a yellow solid (assumed 100% yield). LCMS (m/z) (M+H)=350.0,Rt=0.52 min.

Synthesis of2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylicacid

Following the preparation of Method 8 using the appropriate startingmaterials gave4-chloro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzoicacid as a yellow solid (assumed 100% yield). LCMS (m/z) (M+H)=349.1,Rt=0.61 min.

Synthesis of4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzoicacid

Step 1

To a solution of 5-bromo-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.) in DME (0.18 M) was added methyl4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.5equiv.), PdCl₂(dppf).CH₂Cl₂ adduct (0.10 equiv.), and 2M aqueous sodiumcarbonate (3.00 equiv.). The reaction was heated to 90 C for 2 hours.Cooled to room temperature, partitioned between water and ethyl acetate,the organic phase was dried with sodium sulfate, filtered andconcentrated. The crude material was purified via silica gel columnchromatography eluting with 0-100% ethyl acetate in heptanes followed by10% methanol in ethyl acetate. The pure fractions were concentrated toyield methyl4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzoatein 76% yield. LCMS (m/z) (M+H)=343.2, Rt=0.70 min.

Step 2

To a solution of methyl4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzoate(1.0 equiv.) in THF was added lithium hydroxide (2M solution, 3.0equiv.). The reaction was stirred at room temperature overnight.Acidified with 1N HCl to pH=2 and extracted with ethyl acetate. Theorganic phase was separated, and the precipitate was filtered off toyield4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzoicacid as the desired product in 91% yield. LCMS (m/z) (M+H)=329.1,Rt=0.60 min.

Synthesis ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-isopropylisonicotinamide

Method 6 was followed using6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine and2-isopropylisonicotinic acid. IsolatedN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-isopropylisonicotinamideas a light brown oil. LCMS (m/z) (M+H)=436.3, Rt=0.52 min.

Synthesis ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

Method 6 was followed using6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine and2-(trifluoromethyl)pyridine-4-carboxylic acid. IsolatedN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamideas a light brown oil. LCMS (m/z) (M+H)=462.2, Rt=0.65 min.

Synthesis of6′-chloro-3′-fluoro-2-methyl-2′-morpholino-[3,4′-bipyridin]-5-amine

Step 1

4-(4-bromo-6-chloropyridin-2-yl)morpholine (1.0 equiv.) was dissolved inacetonitrile (0.1 M). Selectfluor (1.1 equiv.) was added at rt andstirred for 18 hours. The reaction was diluted with ethyl acetate andwashed with water, brine, dried over sodium sulfate, filtered andconcentrated. The residue was purified by silica gel chromatography(ISCO, 0-10% ethyl acetate/heptanes) to give4-(4-bromo-6-chloro-3-fluoropyridin-2-yl)morpholine in 42% yield and4-(4-bromo-6-chloro-5-fluoropyridin-2-yl)morpholine in 14% yield. LCMS(m/z) (M+H)=294.7, Rt=0.95 and 0.99 min.

Step 2

To a solution of 4-(4-bromo-6-chloro-3-fluoropyridin-2-yl)morpholine(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.7 equiv.) in DME (0.04 M) and sodium carbonate (2M, 3.0 equiv.) wasadded Pd(PPh₃)₄(0.03 equiv.) and the reaction was heated at 100° C. for2 hours. The mixture was poured onto ice water and extracted with ethylacetate. The combined organics were washed with brine, dried overmagnesium sulfate, filtered and concentrated. The mixture was purifiedvia silica gel chromatography (10% methanol:ethyl acetate:heptanes) togive 6′-chloro-3′-fluoro-2-methyl-2′-morpholino-[3,4′-bipyridin]-5-amineas a yellow solid in 39% yield. ¹H NMR (400 MHz, <cdcl3>) 6 ppm 2.32 (s,3H) 3.52-3.59 (m, 4H) 3.66 (br. s., 2H) 3.80-3.85 (m, 4H) 6.63 (d,J=3.91 Hz, 1H) 6.79-6.84 (m, 1H) 8.08 (d, J=2.74 Hz, 1H)

Synthesis of2′-chloro-3′-fluoro-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-amine

To a solution of 4-(4-bromo-6-chloro-5-fluoropyridin-2-yl)morpholine(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.4 equiv.) in DME (0.02 M)) and Na₂CO₃ (2 M aq.) (3.0 equiv.) wasadded Pd(PPh₃)₄ and heated (thermally) at 100° C. for 2 h. LCMS showscomplete consumption of starting material with fairly clean conversionto desired product. The mixture was poured onto ice-water and extractedwith EtOAc (3×). The combined organics were washed with brine, dried(MgSO₄) and concentrated. The mixture was adsorbed onto Celite andpurified by ISCO flash column chromatography (silica gel, 10% methanolin EtOAc:heptane). Product fractions eluted around 40% EtOAc and wereconcentrated to give2′-chloro-3′-fluoro-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-amine in77% yield as a pale yellow solid. LCMS (m/z) (M+H)=322.9, Rt=0.62 min.

Synthesis of2-((4-(5-amino-2-methylphenyl)-3-fluoro-6-morpholinopyridin-2-yl)amino)ethanol

Step 1

To a solution of 4-(4-bromo-6-chloro-5-fluoropyridin-2-yl)morpholine(1.0 equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.2equiv.) in DME (0.1 M) and Na₂CO₃ (2 M aq.) (3.0 equiv.) was addedPd(PPh₃)₄ and heated (thermally) at 100° C. for 2 h. LCMS shows completeconsumption of starting material with fairly clean conversion to desiredproduct. The mixture was poured onto ice-water and extracted with EtOAc(3×). The combined organics were washed with brine, dried (MgSO₄) andconcentrated. The mixture was adsorbed onto Celite and purified by ISCOflash column chromatography (silica gel, 10% methanol in EtOAc:heptane).Product fractions eluted around 40% EtOAc and were concentrated to give3-(2-chloro-3-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline in 87%yield. LCMS (m/z) (M+H)=322, Rt=0.62 min.

Step 2

In a microwave vial was added3-(2-chloro-3-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline (1.0equiv.), 2-aminoethanol (50 equiv.), DIPEA (2.0 equiv.) in NMP (0.2).The vial was sealed with a crimp top. The reaction was then heated to250° C. for 30 min heated by microwave. LC-MS showed completion of thereaction. The reaction mixture was diluted with ethyl acetate, washedwith water, brine then dried over sodium sulfate. Concentrated to yieldcrude. Purified by 10% methanol in ethyl acetate to yield2-((4-(5-amino-2-methylphenyl)-3-fluoro-6-morpholinopyridin-2-yl)amino)ethanolin 43% yield. LCMS (m/z) (M+H)=347.0, Rt=0.50 min.

Example 1: Synthesis ofN-(4-methyl-3-(6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of 4,6-dichloropyrimidine (1.0 equiv.) in EtOH (0.44 M)was added morpholine (1.0 equiv.) followed by triethylamine (1.10equiv.). The resulting mixture was stirred at RT for 16 hours. Thereaction mixture was then concentrated in vacuo and dried under highvacuum over 20 h to yield 4-(6-chloropyrimidin-4-yl)morpholine as awhite solid in 93% yield. LCMS (m/z) (M+H)=200.0/201.8, Rt=0.35 min. ¹HNMR (400 MHz, <cdcl3>) δ ppm 3.53-3.71 (m, 4H) 3.72-3.83 (m, 4H) 6.51(s, 1H) 8.39 (s, 1H) 11.75 (br. s., 1H).

Step 2

To a solution of 4-(6-chloropyrimidin-4-yl)morpholine (1.0 equiv.) andIntermediate A (1.1 equiv.) in DME and 2M sodium carbonate (3:1, 0.2 M)was added PdCl₂(dppf)-DCM adduct (0.500 equiv.) in a microwave vialequipped with a stir bar. The reaction was heated to 120° C. for 20 minin the microwave. The organic phase was dried with sodium sulfate,filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(4-methyl-3-(6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 52% yield. ¹H NMR (400 MHz, <cd3od>) δppm 2.28 (s, 3H) 3.67-4.02 (m, 8H) 7.09 (s, 1H) 7.35 (d, J=8.22 Hz, 1H)7.65 (s, 2H) 7.78-7.84 (m, 1H) 7.92 (d, J=2.35 Hz, 1H) 8.16 (s, 2H) 8.64(s, 1H). LCMS (m/z) (M+H)=443.2, Rt=0.77 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 1 using the appropriatestarting materials.

Example 2:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(6-morpholinopyrimidin-4-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.70-1.81 (m, 6H) 2.30 (s, 3H) 3.67-3.92(m, 8H) 7.11-7.22 (m, 1H) 7.34-7.45 (m, 1H) 7.73-7.83 (m, 1H) 7.83-7.92(m, 2H) 7.99 (s, 1H) 8.73-8.86 (m, 2H) 10.70 (s, 1H). LCMS (m/z)(M+H)=443.2, Rt=0.64 min.

Example 3: Synthesis ofN-(4-methyl-3-(2-morpholino-6-(3-oxomorpholino)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution 4-(4,6-dichloropyrimidin-2-yl)morpholine (1.0 equiv.),morpholin-3-one (1.2 equiv.), tribasic potassium phosphate (4.00 equiv),(9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (0.16 equiv)and Pd₂(dba)₃.HCCl₃ (20 mol %) in dioxane (0.5 M) was heated to 100° C.for 90 min. The reaction mixture was then cooled to room temperature anddiluted with EtOAc (20 ml) and water (20 ml). The aqueous layer wasseparated and extracted with EtOAc (×2, 20 ml). The combined organiclayer was dried over magnesium sulfate, filtered and concentrated invacuo. The compound was utilized in the subsequent reactions withoutfurther purification. LCMS (m/z) (M+H)=299.2/300.9, Rt=0.77 min.

Step 2

To a solution of 4-(6-chloro-2-morpholinopyrimidin-4-yl)morpholin-3-one(1.0 equiv.) and Intermediate A (1.1 equiv.) in DME and 2M sodiumcarbonate (3:1, 0.2 M) was added PdCl₂(dppf)-DCM adduct (0.500 equiv.)in a microwave vial equipped with a stir bar. The reaction was heated to120° C. for 20 min in the microwave. The organic phase was dried withsodium sulfate, filtered and concentrated. The crude material waspurified via preparative reverse phase HPLC. Upon lyophilization of thepure fractions,N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 19% yield. LCMS (m/z) (M+H)=542.4,Rt=1.04 min. ¹H NMR (400 MHz, <dmso>) δ ppm 2.36 (s, 3H) 3.56-3.81 (m,8H) 4.01 (d, J=5.09 Hz, 4H) 4.28 (s, 5H) 7.31 (d, J=8.22 Hz, 1H)7.72-7.82 (m, 2H) 7.85 (d, J=1.96 Hz, 1H) 7.97 (d, J=7.83 Hz, 1H)8.20-8.35 (m, 2H) 10.53 (s, 1H).

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 3 using the appropriatestarting materials.

Example 4:4-methyl-3-(2-morpholino-6-(3-oxomorpholino)pyrimidin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

¹H NMR (400 MHz, <dmso>) 5 ppm 2.45 (s, 3H) 3.69 (d, J=4.70 Hz, 5H) 3.74(d, J=4.70 Hz, 5H) 4.01 (d, J=5.09 Hz, 3H) 4.29 (s, 2H) 7.36-7.54 (m,3H) 7.60 (t, J=8.02 Hz, 2H) 7.93-8.02 (m, 2H) 8.05 (d, J=8.22 Hz, 1H)8.24 (s, 1H) 10.55 (s, 1H) LCMS (m/z) (M+H)=542.3, Rt=1.08 min.

Example 5:N-(6-methyl-5-(2-morpholino-6-(3-oxomorpholino)pyrimidin-4-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 3.61-3.72 (m, 6H) 3.75 (d, J=4.70 Hz, 5H)3.88-4.08 (m, 9H) 4.29 (s, 3H) 7.41-7.51 (m, 4H) 7.51-7.58 (m, 3H)7.77-7.88 (m, 3H) 8.01 (t, J=6.46 Hz, 3H) 8.22-8.32 (m, 4H) 9.01 (dd,J=4.30, 2.35 Hz, 2H) 10.83 (s, 1H) 10.88 (s, 1H), LCMS (m/z)(M+H)=543.3, Rt=0.78 min.

Example 6: Synthesis ofN-(3-(6-(1,1-dioxidothiomorpholino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of 4-(4,6-dichloropyrimidin-2-yl)morpholine (1.0 equiv.)in EtOH:THF (1:1, 0.25 M) was added thiomorpholine 1,1-dioxide (1.0equiv.) in one portion. The resulting mixture was heated to 100° C. for42 h. The resulting mixture was then cooled to RT and concentrated invacuo to yield an off white solid in The reaction mixture was thenconcentrated in vacuo and dried under high vacuum over 20 h to yield4-(6-chloropyrimidin-4-yl)morpholine as a white solid in 97% yield. LCMS(m/z) (M+H)=333.0/334.9, Rt=0.68 min.

Step 2

To a solution of 4-(6-chloro-2-morpholinopyrimidin-4-yl)thiomorpholine1,1-dioxide (1.0 equiv.) and Intermediate A (1.1 equiv.) in DME and 2Msodium carbonate (3:1, 0.2 M) was added PdCl₂(dppf)-DCM adduct (0.500equiv.) in a microwave vial equipped with a stir bar. The reaction washeated to 120° C. for 20 min in the microwave. The organic phase wasdried with sodium sulfate, filtered and concentrated. The crude materialwas purified via preparative reverse phase HPLC. Upon lyophilization ofthe pure fractions,N-(3-(6-(1,1-dioxidothiomorpholino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 35% yield. LCMS (m/z) (M+H)=576.3,Rt=0.79 min, ¹H NMR (400 MHz, <dmso>) δ ppm 2.33 (s, 3H) 2.54 (s, 1H)3.21 (br. s., 4H) 3.70 (d, J=10.56 Hz, 8H) 4.16 (br. s., 4H) 6.56 (br.s., 1H) 7.32 (d, J=7.83 Hz, 1H) 7.67-7.87 (m, 3H) 7.98 (d, J=7.83 Hz,1H) 8.21-8.44 (m, 2H) 10.55 (br. s., 1H).

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 6 using the appropriatestarting materials.

Example 7: Synthesis of3-(6-(1,1-dioxidothiomorpholino)-2-morpholinopyrimidin-4-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide

LCMS (m/z) (M+H)=576.3, Rt=0.78 min, ¹H NMR (400 MHz, <dmso>) δ ppm 2.44(s, 3H) 3.08-3.30 (m, 4H) 3.41-3.88 (m, 46H) 4.15 (br. s., 4H) 6.49-6.68(m, 1H) 7.39-7.52 (m, 2H) 7.56-7.66 (m, 1H) 7.91-8.00 (m, 1H) 8.01 (d,J=1.57 Hz, 1H) 8.06 (d, J=8.22 Hz, 1H) 8.25 (s, 1H) 10.40-10.60 (m, 1H).

Example 8: Synthesis ofN-(3-(2-(1,1-dioxidothiomorpholino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

LCMS (m/z) (M+H)=576.3, Rt=0.78 min, ¹H NMR (400 MHz, <dmso>) δ ppm 2.32(s, 3H) 2.54 (s, 2H) 3.20 (br. s., 4H) 3.69 (br. s., 8H) 4.01-4.30 (m,4H) 6.45 (br. s., 1H) 7.32 (d, J=8.22 Hz, 1H) 7.71-7.80 (m, 2H) 7.82 (d,J=4.30 Hz, 1H) 7.98 (d, J=7.43 Hz, 1H) 8.27 (d, J=8.22 Hz, 1H) 8.30 (s,1H) 10.55 (s, 1H).

Example 9: Synthesis of3-(2-(1,1-dioxidothiomorpholino)-6-morpholinopyrimidin-4-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide

LCMS (m/z) (M+H)=576.3, Rt=0.80 min, ¹H NMR (400 MHz, <dmso>) 5 ppm 2.43(s, 3H) 2.54 (s, 2H) 3.04-3.23 (m, 4H) 3.68 (br. s., 10H) 4.20 (br. s.,4H) 6.46 (br. s., 1H) 7.26-7.53 (m, 2H) 7.60 (t, J=7.83 Hz, 1H) 7.98 (d,J=7.83 Hz, 1H) 8.00 (s, 1H) 8.06 (d, J=8.22 Hz, 1H) 8.25 (s, 1H) 10.52(s, 1H).

Example 10: Synthesis ofN-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of 4,4′-(6-chloropyrimidine-2,4-diyl)dimorpholine (1.0equiv.) and Intermediate A (1.1 equiv.) in DME and 2M sodium carbonate(3:1, 0.2 M) was added PdCl₂(dppf)-DCM adduct (0.500 equiv.) in amicrowave vial equipped with a stir bar. The reaction was heated to 120°C. for 20 min in the microwave. The organic phase was dried with sodiumsulfate, filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 37% yield. LCMS (m/z) (M+H)=528.3,Rt=0.80 min, ¹H NMR (400 MHz, <dmso>) 5 ppm 2.21-2.35 (m, 3H) 3.68 (br.s., 8H) 3.71 (d, J=4.30 Hz, 8H) 6.50 (br. s., 1H) 7.34 (d, J=8.22 Hz,1H) 7.70-7.89 (m, 3H) 7.97 (d, J=7.83 Hz, 1H) 8.26 (d, J=7.83 Hz, 1H)8.29 (s, 1H) 10.59 (br. s., 1H).

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 10 using the appropriatestarting materials.

Example 11:3-(2,6-dimorpholinopyrimidin-4-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide

LCMS (m/z) (M+H)=528.3, Rt=0.80 min. ¹H NMR (400 MHz, <dmso>) 5 ppm2.29-2.37 (m, 3H) 3.42-3.72 (m, 19H) 3.84 (br. s., 8H) 7.35-7.50 (m, 2H)7.54 (t, J=8.02 Hz, 1H) 7.95 (s, 2H) 8.00 (d, J=8.22 Hz, 1H) 8.18 (s,1H) 10.47 (s, 1H).

Example 12:N-(5-(2,6-dimorpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) 5 ppm 10.86 (s, 1H), 8.99 (d, J=2.3 Hz, 1H),8.24-8.40 (m, 3H), 8.01 (d, J=7.8 Hz, 1H), 7.75-7.89 (m, 1H), 6.51 (br.s., 1H), 3.68 (d, J=6.6 Hz, 16H), 2.56 (s, 3H). LCMS (m/z) (M+H)=529.4,Rt=0.70 min.

Example 13: Synthesis ofN-(3-(4,6-dimorpholinopyrimidin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

To a solution of 4,4′-(2-chloropyrimidine-4,6-diyl)dimorpholine (1.0equiv.) and Intermediate A (1.1 equiv.) in DME and 2M sodium carbonate(3:1, 0.2 M) was added PdCl₂(dppf)-DCM adduct (0.500 equiv.) in amicrowave vial equipped with a stir bar. The reaction was heated to 120°C. for 20 min in the microwave. The organic phase was dried with sodiumsulfate, filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(3-(4,6-dimorpholinopyrimidin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 35% yield. LCMS (m/z) (M+H)=528.3,Rt=0.82 min, ¹H NMR (400 MHz, <dmso>) δ ppm 2.35-2.45 (m, 3H) 3.40-3.63(m, 9H) 3.66 (d, J=4.30 Hz, 9H) 5.97 (s, 1H) 7.26 (d, J=8.22 Hz, 1H)7.69-7.84 (m, 2H) 7.95 (d, J=7.83 Hz, 1H) 8.04 (d, J=2.35 Hz, 1H)8.21-8.31 (m, 2H) 10.49 (s, 1H).

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 13 using the appropriatestarting materials.

Example 14: Synthesis of3-(4,6-dimorpholinopyrimidin-2-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide

LCMS (m/z) (M+H)=528.3, Rt=0.84 min, ¹H NMR (400 MHz, <dmso>) 6 ppm2.51-2.62 (m, 4H) 3.58 (d, J=4.30 Hz, 9H) 3.62-3.77 (m, 9H) 5.96 (s, 1H)7.30-7.47 (m, 2H) 7.51-7.65 (m, 2H) 7.92 (dd, J=8.02, 1.76 Hz, 1H) 8.03(d, J=8.22 Hz, 1H) 8.16-8.34 (m, 2H) 10.53 (s, 1H).

Example 15: Synthesis of2-(2-cyanopropan-2-yl)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

Step 1

To a solution of 4,4′-(6-chloropyrimidine-2,4-diyl)dimorpholine (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.5equiv.) in DME and 2M sodium carbonate (3:1, 0.2 M) was addedPdCl₂(dppf)-DCM adduct (0.100 equiv.) in a microwave vial equipped witha stir bar. The reaction was heated to 120° C. for 20 min in themicrowave. The reaction mixture gas quenched with water and the aqueouslayer was separated and extracted with EtOAc (×3). The combined organiclayer was dried over magnesium sulfate, filtered and concentrated invacuo. The material was purified via silica gel column chromatographyeluting with 100% DCM to 10% MeOH/DCM to afford3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylaniline in 96% yield. LCMS(m/z) (M+H)=356.2, Rt=0.44 min.

Step 2

To a solution of 3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylaniline (1.0equiv.) in DMF (0.10 M) was added 2-(2-cyanopropan-2-yl)isonicotinicacid (1.2 equiv.), ED-HCl and 2M (1.2 equiv.) and aza-HOBt (1.2 equiv.).The reaction was stirred at room temperature for 6 hours. Uponcompletion, the solution was filtered through a HPLC filter and purifiedvia reverse phase preparative HPLC. Upon lyophilization of the purefractions,2-(2-cyanopropan-2-yl)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamidewas isolated as the TFA salt in 40% yield. ¹H NMR (400 MHz, <cd3od>) δppm 1.81 (s, 6H) 2.38 (s, 3H) 3.79 (s, 13H) 3.89 (br. s., 3H) 6.57 (s,1H) 7.43 (d, J=8.41 Hz, 1H) 7.65 (dd, J=8.27, 2.30 Hz, 1H) 7.81 (dd,J=5.04, 1.57 Hz, 1H) 7.97 (d, J=2.25 Hz, 1H) 8.04-8.10 (m, 1H) 8.78 (dd,J=5.04, 0.78 Hz, 1H). LCMS (m/z) (M+H)=528.3, Rt=0.69 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 15 using the appropriatestarting materials.

Example 16:3-(2-cyanopropan-2-yl)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 1.79 (s, 7H) 2.38 (s, 3H) 3.80 (s, 13H)6.58 (s, 1H) 7.41 (d, J=8.36 Hz, 1H) 7.53-7.68 (m, 2H) 7.78 (ddd,J=7.92, 2.05, 1.03 Hz, 1H) 7.86-7.99 (m, 2H) 8.10 (t, J=1.71 Hz, 1H).LCMS (m/z) (M+H)=527.3, Rt=0.75 min.

Example 17:2-chloro-3-(1-cyanocyclopropyl)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.31-1.41 (m, 2H) 1.65-1.76 (m, 2H) 2.26(s, 3H) 3.69 (s, 17H) 6.47 (s, 1H) 7.30 (d, J=8.36 Hz, 1H) 7.35-7.41 (m,1H) 7.44-7.50 (m, 2H) 7.53 (dd, J=7.65, 1.74 Hz, 1H) 7.87 (d, J=2.30 Hz,1H). LCMS (m/z) (M+H)=560.2, Rt=0.72 min.

Example 18:5-(dimethylamino)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)nicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.38 (s, 3H) 3.17 (s, 6H) 3.71-3.99 (m,16H) 6.56 (s, 1H) 7.43 (d, J=8.36 Hz, 1H) 7.67 (dd, J=8.31, 2.30 Hz, 1H)7.95 (d, J=2.35 Hz, 1H) 8.03 (dd, J=2.86, 1.54 Hz, 1H) 8.26 (d, J=2.84Hz, 1H) 8.44 (d, J=1.22 Hz, 1H). LCMS (m/z) (M+H)=504.3, Rt=0.53 min.

Example 19:5-(tert-butyl)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)nicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.40-1.48 (m, 9H) 2.38 (s, 3H) 3.80 (s,13H) 6.58 (s, 1H) 7.43 (d, J=8.41 Hz, 1H) 7.62-7.68 (m, 1H) 7.72 (d,J=5.28 Hz, 1H) 7.97 (d, J=2.15 Hz, 2H) 8.69 (d, J=5.18 Hz, 1H). LCMS(m/z) (M+H)=517.3, Rt=0.60 min.

Example 20:3-((dimethylamino)methyl)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 2.38 (s, 3H) 2.92 (s, 6H) 3.68-3.98 (m,16H) 4.51 (s, 2H) 6.53 (s, 1H) 7.42 (d, J=8.41 Hz, 1H) 7.66-7.73 (m, 1H)7.93 (d, J=2.15 Hz, 1H) 8.12 (s, 1H) 8.38 (s, 1H) 8.43 (s, 1H). LCMS(m/z) (M+H)=585.3, Rt=0.61 min.

Example 21:N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)-3-(4-ethylpiperazin-1-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 1.41 (t, J=7.34 Hz, 3H) 2.38 (s, 3H)3.70-3.93 (m, 15H) 6.52 (s, 1H) 7.40 (d, J=8.36 Hz, 1H) 7.52 (s, 1H)7.66 (dd, J=8.39, 1.98 Hz, 1H) 7.79 (s, 1H) 7.82 (d, J=2.01 Hz, 1H) 7.91(d, J=2.25 Hz, 1H). LCMS (m/z) (M+H)=640.3, Rt=0.66 min.

Example 22:N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethoxy)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 2.38 (s, 3H) 3.72-3.94 (m, 15H) 6.57 (s,1H) 7.42 (d, J=8.36 Hz, 1H) 7.51-7.57 (m, 1H) 7.60-7.69 (m, 2H) 7.87 (s,1H) 7.94-8.00 (m, 1H). LCMS (m/z) (M+H)=544.3, Rt=0.84 min.

Example 23:N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamide

¹H NMR (400 MHz, <cd3od>) ppm 2.38 (s, 3H) 3.19 (s, 3H) 3.65-4.06 (m,16H) 6.58 (s, 1H) 7.42 (d, J=8.22 Hz, 1H) 7.65 (dd, J=8.41, 2.15 Hz, 1H)7.81 (t, J=7.83 Hz, 1H) 7.97 (d, J=2.35 Hz, 1H) 8.19 (d, J=7.83 Hz, 1H)8.28 (d, J=7.83 Hz, 1H) 8.51 (s, 1H). LCMS (m/z) (M+H)=538.3, Rt=0.64min.

Example 24:3-(tert-butyl)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)isoxazole-5-carboxamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 1.42 (s, 9H) 2.37 (s, 3H) 3.80 (m, 16H)6.52 (s, 1H) 7.10 (s, 1H) 7.42 (d, J=5.28 Hz, 1H) 7.71 (d, J=5.28 Hz,1H) 7.92 (s, 1H). LCMS (m/z) (M+H)=507.3, Rt=0.79 min.

Example 25:5-(tert-butyl)-N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)isoxazole-3-carboxamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 1.39 (s, 9H) 2.30 (s, 3H) 3.80 (m, 16H)6.52 (m, 2H) 7.40 (d, J=5.28 Hz, 1H) 7.71 (d, J=5.28 Hz, 1H) 7.87 (s,1H). LCMS (m/z) (M+H)=507.3, Rt=0.84 min.

Example 26N-(3-(2,6-dimorpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)thiazole-4-carboxamide

LCMS (m/z) (M+H)=535.2, Rt=0.78 min. 1H NMR (400 MHz, <cd3od>) 5 ppm2.37 (s, 3H) 3.71-4.00 (m, 16H) 6.57 (s, 1H) 7.42 (d, J=8.22 Hz, 1H)7.77 (dd, J=8.22, 2.35 Hz, 1H) 7.92 (d, J=1.96 Hz, 1H) 8.70 (s, 1H).

Example 27N-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of 4,6-dichloro-2-(methylthio)pyrimidine (1.0 equiv.) andtriethylamine (0.8 equiv.) in EtOH (0.256 M) at RT was added morpholine(1.0 equiv.) in one portion. The resulting mixture was stirred at RT for6 hours; a precipitate formed during this time. LCMS analysis indicatedthe formation of the desired product. The precipitate was filtered andwashed with EtOH. Isolated4-(6-chloro-2-(methylthio)pyrimidin-4-yl)morpholine as a white solid in76% yield. LCMS (m/z) (M+H)=245.1, Rt=0.73 min.

Step 2

To a solution of 4-(6-chloro-2-(methylthio)pyrimidin-4-yl)morpholine(1.0 equiv.),N-(4methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.05 equiv.) in DME/2M sodium carbonate (3:1, 0.20M) was addedPdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.). The reaction was purged with N₂for 5 mins, the vial was sealed and subjected to microwave irradiationfor 10 min at 120° C. LCMS shows complete formation of desired product.The reaction was partitioned between water and EtOAc. The aqueous layerwas further washed EtOAc (2×100 mL). The combined organics were driedover MgSO₄, filtered and concentrated. The crude material was purifiedvia flash chromatography over silica gel eluting with heptanes and 0-60%ethyl acetate gradient. IsolatedN-(4-methyl-3-(2-(methylthio)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamideas a white solid in 60% yield. LCMS (m/z) (M+H)=489.1, Rt=0.81 min.

Step 3

To a solution ofN-(4-methyl-3-(2-(methylthio)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.1 M) was added m-CPBA (2.2 equiv.) portion wise.The reaction was stirred at RT for 4 hours. After which time LCMS showscomplete oxidation to desired product. The reaction was diluted with DCMand washed with 0.5M Na₂CO₃. The resulting emulsion was filtered througha pad of celite and the cake was washed with DCM. The organics weredried over MgSO₄, filtered and concentrated. The material was purifiedvia preparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 33% yield. LCMS (m/z) (M+H)=521.2,Rt=0.97 min. 1H NMR (400 MHz, <dmso>) δ ppm 2.36 (s, 3H) 3.68-3.81 (m,9H) 4.03 (br. s., 2H) 7.14 (s, 1H) 7.35 (d, J=9.00 Hz, 1H) 7.76-7.82 (m,1H) 7.82-7.87 (m, 2H) 7.98 (d, J=7.83 Hz, 1H) 8.28 (d, J=7.83 Hz, 1H)8.31 (s, 1H) 10.57 (s, 1H).

Example 28 Synthesis ofN-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution ofN-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and 2-oxa-6-azaspiro[3.3]heptane (1.0 equiv.) in THF(0.20M) was added triethylamine (3.5 equiv.) and the allowed to stir at75° C. for 48 hours. LCMS analysis indicated formation of the desiredproduct. The volatiles were removed in vacuo. The crude material waspurified via preparative reverse phase HPLC. Upon lyophilization of thepure fractions,N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 21% yield. 1H NMR (400 MHz, <cd3od>) δppm 1.28 (t, J=7.24 Hz, 3H) 2.38 (s, 3H) 3.52 (q, J=6.65 Hz, 2H) 3.80(br. s., 6H) 4.05 (br. s., 2H) 6.50 (s, 1H) 7.41 (d, J=8.61 Hz, 1H) 7.66(dd, J=8.22, 2.35 Hz, 1H) 7.72-7.78 (m, 1H) 7.91 (d, J=7.83 Hz, 1H) 7.96(d, J=2.35 Hz, 1H) 8.21 (d, J=7.83 Hz, 1H) 8.26 (s, 1H). LCMS (m/z)(M+H)=486.3, Rt=0.86 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 28 using the appropriatestarting materials.

Example 29N-(4-methyl-3-(6-morpholino-2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

LCMS (m/z) (M+H)=540.3, Rt=0.81 min. 1H NMR (400 MHz, <cd3od>) δ ppm2.36 (s, 3H) 3.69-3.83 (m, 12H) 4.44 (s, 4H) 6.51 (s, 1H) 7.41 (d,J=8.61 Hz, 1H) 7.63 (dd, J=8.22, 2.35 Hz, 1H) 7.72-7.78 (m, 1H) 7.92 (d,J=7.83 Hz, 1H) 7.95 (d, J=1.96 Hz, 1H) 8.21 (d, J=7.83 Hz, 1H) 8.26 (s,1H).

Example 30N-(4-methyl-3-(2-(methylamino)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) 5 ppm 2.37 (s, 3H) 3.03 (s, 3H) 3.80 (br. s.,6H) 4.08 (br. s., 2H) 6.50 (s, 1H) 7.41 (d, J=8.22 Hz, 1H) 7.66 (dd,J=8.22, 2.35 Hz, 1H) 7.71-7.78 (m, 1H) 7.91 (d, J=7.83 Hz, 1H) 7.96 (d,J=2.35 Hz, 1H) 8.21 (d, J=7.83 Hz, 1H) 8.26 (s, 1H). LCMS (m/z)(M+H)=472.3, Rt=0.82 min.

Example 31N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) 5 ppm 2.02-2.26 (m, 2H) 2.38 (s, 3H) 3.62-3.85(m, 9H) 4.04 (br. s., 2H) 4.56 (br. s., 1H) 6.52 (s, 1H) 7.41 (d, J=8.22Hz, 1H) 7.66 (dd, J=8.22, 2.35 Hz, 1H) 7.72-7.78 (m, 1H) 7.92 (d, J=7.83Hz, 1H) 7.94 (d, J=1.96 Hz, 1H) 8.21 (d, J=7.83 Hz, 1H) 8.26 (s, 1H).LCMS (m/z) (M+H)=502.3, Rt=0.77 min.

Example 32N-(3-(2-(3-hydroxypyrrolidin-1-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.02-2.27 (m, 2H) 2.38 (s, 3H) 3.63-3.87(m, 10H) 4.05 (br. s., 2H) 4.56 (br. s., 1H) 6.52 (s, 1H) 7.41 (d,J=8.61 Hz, 1H) 7.66 (dd, J=8.41, 2.15 Hz, 1H) 7.72-7.78 (m, 1H) 7.92 (d,J=7.83 Hz, 1H) 7.94 (d, J=2.35 Hz, 1H) 8.21 (d, J=7.83 Hz, 1H) 8.26 (s,1H). LCMS (m/z) (M+H)=528.3, Rt=0.79 min.

Example 33N-(3-(2-(1H-imidazol-1-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.46 (s, 3H) 3.78-3.93 (m, 8H) 6.99 (s,1H) 7.36 (d, J=8.22 Hz, 1H) 7.60 (s, 1H) 7.63 (dd, J=8.22, 2.35 Hz, 1H)7.71-7.78 (m, 1H) 7.91 (d, J=7.83 Hz, 1H) 7.99 (d, J=1.96 Hz, 1H) 8.22(d, J=7.83 Hz, 1H) 8.27 (s, 1H) 8.36 (s, 1H) 9.61 (s, 1H). LCMS (m/z)(M+H)=509.4, Rt=0.84 min.

Example 34 Synthesis ofN-(3-(2-(2-hydroxyethoxy)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

To a solution ofN-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and ethylene glycol (1.0 equiv.) in acetonitrile (0.10M)was added potassium carbonate (1.0 equiv.) and the allowed to stir at120° C. for 24 hours. LCMS analysis indicated formation of the desiredproduct. The volatiles were removed in vacuo. The crude material waspurified via preparative reverse phase HPLC. Upon lyophilization of thepure fractions,N-(4-methyl-3-(2-(methylsulfonamido)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 6% yield. LCMS (m/z) (M+H)=536.3,Rt=0.80 min, 1H NMR (400 MHz, <cd3od>) b ppm 2.37 (s, 3H) 3.79-3.85 (m,4H) 3.86-3.97 (m, 6H) 4.60-4.65 (m, 2H) 6.78 (s, 1H) 7.41 (d, J=8.22 Hz,1H) 7.67 (dd, J=8.22, 2.35 Hz, 1H) 7.74 (t, J=7.83 Hz, 1H) 7.91 (d,J=8.22 Hz, 1H) 7.94 (d, J=1.96 Hz, 1H) 8.21 (d, J=7.83 Hz, 1H) 8.26 (s,1H). LCMS (m/z) (M+H)=503.1, Rt=0.73 min.

The compounds listed below were prepared using methods similar to thosedescribed above using the appropriate starting materials.

Example 35N-(4-methyl-3-(2-(methylsulfonamido)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

LCMS (m/z) (M+H)=536.3, Rt=0.80 min. 1H NMR (400 MHz, <cd3od>) δ ppm2.37 (s, 3H) 3.23 (s, 3H) 3.76-3.83 (m, 4H) 3.86 (br. s., 4H) 6.50 (s,1H) 7.38 (d, J=8.22 Hz, 1H) 7.68-7.78 (m, 2H) 7.84 (d, J=2.35 Hz, 1H)7.91 (d, J=7.83 Hz, 1H) 8.21 (d, J=7.83 Hz, 1H) 8.26 (s, 1H).

Example 36 Synthesis ofN-(4-methyl-3-(6-morpholino-2-(2-oxopyrrolidin-1-yl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

To a solution ofN-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and pyrrolidin-2-one (2.0 equiv.) in dioxane (0.10M) wasadded cesium carbonate (1.0 equiv.) and the allowed to stir at 120° C.for 24 hours. LCMS analysis indicated formation of the desired product.The volatiles were removed in vacuo. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(4-methyl-3-(6-morpholino-2-(2-oxopyrrolidin-1-yl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 12% yield. LCMS (m/z) (M+H)=526.3,Rt=0.83 min. 1H NMR (400 MHz, <cd3od>) b ppm 2.25 (quin, J=7.73 Hz, 2H)2.47 (s, 3H) 2.81 (t, J=8.02 Hz, 2H) 3.82-3.87 (m, 8H) 4.15 (t, J=7.43Hz, 2H) 7.03 (s, 1H) 7.47 (d, J=8.61 Hz, 1H) 7.71 (dd, J=8.41, 2.15 Hz,1H) 7.75 (t, J=7.83 Hz, 1H) 7.92 (d, J=7.83 Hz, 1H) 8.11 (d, J=2.35 Hz,1H) 8.22 (d, J=7.83 Hz, 1H) 8.27 (s, 1H).

Example 37 Synthesis ofN-(3-(2-(4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Step 1

A solution ofN-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and Sodium azide in DMF (0.2 M) was heated at 90° C. for 3hours. The reaction mixture was then cooled to room temperature andquenched with water then the aqueous layer was separated and extractedwith EtOAc (×2). The combined organic layer was dried over sodiumsulfate, filtered and concentrated in vacuo to affordN-(3-(2-azido-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide.The compound was utilized in the subsequent reaction without furtherpurification. LCMS (m/z) (M+H)=484.0/485.1, Rt=0.96 min.

Step 2

To a mixture ofN-(3-(2-azido-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.), 2-methylbut-3-yn-2-ol (5.0 equiv.) and triethylamine (2.0equiv.) in dioxane (0.25 M) was added Copper (I) Oxide on carbon (0.2equiv.). The resulting mixture was heated to 90° C. for 3 hours. Thereaction mixture was then cooled to room temperature and filtered,concentrated in vacuo. The crude material was purified via preparativereverse phase HPLC. Upon lyophilization of the pure fractions,N-(3-(2-(4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 14% yield. 1H NMR (400 MHz, <cd3od>) δppm 1.66 (s, 6H) 2.55 (s, 3H) 2.66 (s, 1H) 3.71-4.06 (m, 8H) 6.99 (s,1H) 7.43 (d, J=7.83 Hz, 1H) 7.47-7.61 (m, 2H) 7.92-8.02 (m, 2H) 8.11 (d,J=1.96 Hz, 1H) 8.17 (s, 1H) 8.62 (s, 1H). LCMS (m/z) (M+H)=568.3,Rt=0.96 min.

Example 38 Synthesis ofN-(3-(2-amino-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

To a solution ofN-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DMSO (0.05M) was added ammonium acetate (2 equiv.) in amicrowave vial equipped with a stir bar. The reaction was heated to 100°C. for 15 min in the microwave. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(3-(2-amino-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 23% yield. LCMS (m/z) (M+H)=458.0,Rt=0.79 min. 1H NMR (400 MHz, <cd3od>) 5 ppm 2.48 (s, 3H) 3.79 (br. s.,8H) 6.57 (s, 1H) 7.45 (d, J=7.83 Hz, 1H) 7.54-7.60 (m, 2H) 7.94 (d,J=8.61 Hz, 1H) 8.03 (d, J=1.57 Hz, 1H) 8.08 (dd, J=8.02, 1.76 Hz, 1H)8.17 (s, 1H).

Example 39 Synthesis ofN-(3-(2-((1,3-dihydroxypropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

To a solution ofN-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and 2-aminopropane-1,3-diol (1.0 equiv.) in DMF (0.05M) wasadded 60% sodium hydride (1.0 equiv.) at 00° C. The reaction was allowedto warm to room temperature and stir for 24 hours. LCMS analysisindicated the formation of the desired product. The crude material waspurified via preparative reverse phase HPLC. Upon lyophilization of thepure fractions,N-(3-(2-((1,3-dihydroxypropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 28% yield. LCMS (m/z) (M+H)=532.1,Rt=0.68 min. 1H NMR (400 MHz, <cd3od>) δ ppm 2.45 (s, 3H) 3.64-3.71 (m,1H) 3.79 (s, 10H) 3.85-3.91 (m, 1H) 4.53-4.59 (m, 1H) 4.63-4.69 (m, 1H)6.67 (s, 1H) 7.44 (d, J=7.43 Hz, 1H) 7.51 (d, J=7.83 Hz, 1H) 7.56 (t,J=8.02 Hz, 1H) 7.93 (d, J=8.22 Hz, 1H) 7.96-8.01 (m, 3H) 8.16 (s, 1H).

Step 2

To a solution of 4-(6-chloro-2-(methylthio)pyrimidin-4-yl)morpholine(1.0 equiv.) in DCM (0.10 M) was added mCPBA (2.2 equiv.) portion-wise.The reaction was stirred at RT for 3 hours. After which time LCMS showscomplete oxidation to desired product. The reaction was diluted with DCM(150 mL) and washed with 0.5M Na₂CO₃. The organics were dried overMgSO₄, filtered and concentrated. Isolated4-(6-chloro-2-(methylsulfonyl)pyrimidin-4-yl)morpholine in 100% yield.LCMS (m/z) (M+H)=277.9, Rt=0.49 min.

Step 3

To a solution of 4-(6-chloro-2-(methylsulfonyl)pyrimidin-4-yl)morpholine(1.0 equiv) in dioxane (0.20M) was added ethane-1,2-diol (90 equiv.). Tothis stirring solution was added 60% NaH (1.0 equiv.) at 0° C. Thereaction was allowed to warm to room temperature stirring for 24 hours.LCMS analysis indicated the formation of the desired product. Thereaction was partitioned between NH₄Cl and EtOAc. The organics werewashed with brine, water, then dried over MgSO₄ filtered andconcentrated. Isolated2-((4-chloro-6-morpholinopyrimidin-2-yl)oxy)ethanol in 75% yield. LCMS(m/z) (M+H)=260.0, Rt=0.49 min. ¹H NMR (400 MHz, <cdcl3>) δ ppm3.71-3.82 (m, 8H) 3.91-3.98 (m, 2H) 4.40-4.47 (m, 2H) 6.18-6.24 (m, 1H).

Example 40N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

To a solution of 2-((4-chloro-6-morpholinopyrimidin-2-yl)oxy)ethanol(1.0 equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)phenyl)-3-(trifluoromethyl)benxamide(1.2 equiv.) in DME and 2M sodium carbonate (3:1, 0.2 M) was addedPdCl₂(dppf)-DCM adduct (0.1 equiv.) in a microwave vial equipped with astir bar. The reaction was heated to 120° C. for 20 min in themicrowave. The reaction was partitioned between water and ethyl acetate,the organic phase was washed with brine, was dried with sodium sulfate,filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 18% yield. 1H NMR (400 MHz, <cd3od>) δppm 2.37 (s, 3H) 3.79-3.85 (m, 4H) 3.86-3.97 (m, 6H) 4.60-4.65 (m, 2H)6.78 (s, 1H) 7.41 (d, J=8.22 Hz, 1H) 7.67 (dd, J=8.22, 2.35 Hz, 1H) 7.74(t, J=7.83 Hz, 1H) 7.91 (d, J=8.22 Hz, 1H) 7.94 (d, J=1.96 Hz, 1H) 8.21(d, J=7.83 Hz, 1H) 8.26 (s, 1H). LCMS (m/z) (M+H)=503.1, Rt=0.73 min.

Example 42 and Example 43: Synthesis ofN-(4-methyl-3-(2-morpholino-6-(prop-1-en-2-yl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamideandN-(4-methyl-3-(4-morpholino-6-(prop-1-en-2-yl)pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of 2,4,6-trichloropyrimidine (1.0 equiv.) and4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (1.05 equiv.)in dioxane and 2M sodium carbonate (3:1, 0.31 M) was addedPdCl₂(dppf)-DCM adduct (0.05 equiv.). The reaction mixture was heated to110° C. for 45 min. The reaction mixture was then cooled to roomtemperature and diluted with EtOAc and water. The aqueous layer wasseparated and extracted with EtOAc (×2). The combined organic layer wasdried over sodium sulfate, filtered and concentrated in vacuo. Themixture of regioisomers was utilized in the subsequent reactions withoutfurther purification. LCMS (m/z) (M+H)=189.0/191.1, Rt=0.92 min twooverlapping.

Step 2

To a solution of 2,4-dichloro-6-(prop-1-en-2-yl)pyrimidine and4,6-dichloro-2-(prop-1-en-2-yl)pyrimidine (total 1.0 equiv.) int-Butanol (0.2 M) was added morpholine (1.0 equiv.) followed byN,N-diisopropylethylamine (1.20 equiv.). The resulting mixture washeated to 120 at ° C. for 45 min. The reaction mixture was then cooledto RT, concentrated in vacuo and utilized in the subsequent reactionswithout further purification. LCMS Major (m/z) (M+H)=240.1/242.1,Rt=0.74 min and Minor (m/z) (M+H)=240.1/242.1, 0.94 min.

Step 3

To a solution of 4-(2-chloro-6-(prop-1-en-2-yl)pyrimidin-4-yl)morpholineand 4-(4-chloro-6-(prop-1-en-2-yl)pyrimidin-2-yl)morpholine (total 1.0equiv.) and Intermediate A (1.1 equiv.) in dioxane and 2M sodiumcarbonate (4:1, 0.17 M) was added PdCl₂(dppf)-DCM adduct (0.150 equiv.)in a microwave vial equipped with a stir bar. The reaction was heated to120° C. for 20 min in the microwave. The organic phase was dried withsodium sulfate, filtered and concentrated. The crude material waspurified via preparative reverse phase HPLC. Upon lyophilization of thepure fractions, two regioisomers were isolated in order of elution,majorN-(4-methyl-3-(4-morpholino-6-(prop-1-en-2-yl)pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 4% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.13 (s, 3H)3.30 (s, 3H) 3.69 (s, 8H) 5.38 (s, 1H) 6.15 (d, J=0.78 Hz, 1H) 6.83 (s,1H) 7.26 (d, J=8.61 Hz, 1H) 7.72-7.84 (m, 2H) 7.95 (d, J=7.83 Hz, 1H)8.16 (d, J=2.35 Hz, 1H) 8.22-8.34 (m, 2H) 10.48 (s, 1H). LCMS (m/z)(M+H)=483.2, Rt=0.87 min and minorN-(4-methyl-3-(2-morpholino-6-(prop-1-en-2-yl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide2% as the TFA salt in 2% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.11 (s,3H) 2.35 (s, 3H) 3.75 (d, J=4.70 Hz, 8H) 5.45 (s, 1H) 6.12 (s, 1H) 6.99(s, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.73-7.87 (m, 3H) 7.95 (s, 1H) 8.21-8.35(m, 2H) 10.49 (s, 1H). LCMS (m/z) (M+H)=483.2, Rt=1.22 min.

Example 44: Synthesis ofN-(3-(4-isopropyl-6-morpholinopyrimidin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

A solution ofN-(4-methyl-3-(4-morpholino-6-(prop-1-en-2-yl)pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamidein Methanol (0.083 M) was evacuated and back filled with argon (×3). Tothe solution was then added Pd/C (1.00 eq.) and the mixture wasevacuated and back filled with hydrogen (×3). The mixture was thenstirred at RT under a positive pressure of atmospheric hydrogen(balloon) for 2 h. The hydrogen gas was removed by evacuation and thereaction backfilled with argon. The reaction mixture was thenconcentrated in vacuo. The crude material was purified via preparativereverse phase HPLC. Upon lyophilization of the pure fractionsN-(3-(4-isopropyl-6-morpholinopyrimidin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 30% yield. 1H NMR (400 MHz, <dmso>) b ppm 1.29 (d,J=6.65 Hz, 6H) 2.38 (br. s., 3H) 2.91-3.07 (m, 1H) 3.71 (br. s., 8H)7.27-7.47 (m, 1H) 7.74-7.88 (m, 2H) 7.93-8.01 (m, 1H) 8.06 (s, 1H) 8.28(s, 2H) 10.54-10.70 (m, 1H). LCMS (m/z) (M+H)=485.4, Rt=0.85 min.

Example 45: Synthesis ofN-(3-(6-isopropyl-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

A solution ofN-(4-methyl-3-(2-morpholino-6-(prop-1-en-2-yl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamidein Methanol (0.083 M) was evacuated and back filled with argon (×3). Tothe solution was then added Pd/C (1.00 eq.) and the mixture wasevacuated and back filled with hydrogen (×3). The mixture was thenstirred at RT under a positive pressure of atmospheric hydrogen(balloon) for 2 h. The hydrogen gas was removed by evacuation and thereaction backfilled with argon. The reaction mixture was thenconcentrated in vacuo. The crude material was purified via preparativereverse phase HPLC. Upon lyophilization of the pure fractionsN-(3-(6-isopropyl-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide was obtained as the TFA salt in 43% yield. 1H NMR (400 MHz,<dmso>) δ ppm 1.22 (d, J=6.65 Hz, 6H) 2.34 (s, 3H) 2.86 (dt, J=13.69,6.85 Hz, 1H) 3.62-3.79 (m, 8H) 6.70 (s, 1H) 7.29 (d, J=8.22 Hz, 1H)7.74-7.84 (m, 3H) 7.95 (d, J=7.83 Hz, 1H) 8.21-8.33 (m, 2H) 10.49 (s,1H). LCMS (m/z) (M+H)=485.4, Rt=1.09 min.

Example 46 Synthesis ofN-(3-(6-(2,2-dimethylmorpholino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Step 1

A mixture of 2,2-dimethylmorpholine (2.0 equiv.),4-(4,6-dichloropyrimidin-2-yl)morpholine (1 equiv.) and triethylamine (6equiv.) in EtOH (0.2 M) were heated to 110° C. for 25 min in themicrowave. The reaction mixture was partitioned between EtOAc and water.The organic phase was dried over sodium sulfate. The resulting solutionwas concentrated and dried under vacuo to give4-(6-chloro-2-morpholinopyrimidin-4-yl)-2,2-dimethylmorpholine and wasused in the next step without further purification. LCMS (m/z)(M+H)=313.2, Rt=0.86 min.

Step 2

A mixture of4-(6-chloro-2-morpholinopyrimidin-4-yl)-2,2-dimethylmorpholine (1.0equiv.),N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.2 equiv.), sodium carbonate (2 M, 8 equiv.) and PdCl₂(dppf) (0.5equiv.) in DME (0.1 M) were heated to 108° C. for 13 min in themicrowave. After removing the DME soluble portion and concentrating, theresulting solid was partitioned between EtOAc and water. The organicphase was washed with brine, dried over sodium sulfate and then purifiedvia preparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(3-(6-(2,2-dimethylmorpholino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 36% yield. ¹H NMR (400 MHz, <dmso>) δppm 1.08-1.18 (m, 6H) 2.29 (s, 3H) 3.39-3.90 (m, 14H) 7.34 (d, J=6.26Hz, 1H) 7.45-7.65 (m, 1H) 7.70-7.88 (m, 3H) 7.92-8.03 (m, 1H) 8.18-8.36(m, 2H) 10.58 (br. s., 1H). LCMS (m/z) (M+H)=556.4, Rt=0.87 min.

The compounds listed below were prepared using methods similar to thosedescribed above using the appropriate starting materials.

Example 47:N-(4-methyl-3-(2-morpholino-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

LCMS (m/z) (M+H)=540.2, Rt=0.79 min.

Example 48:(R)-N-(3-(6-(3-(hydroxymethyl)morpholino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.29 (s, 3H) 3.16 (br. s., 1H) 3.36-3.55(m, 3H) 3.68 (d, J=7.43 Hz, 10H) 3.85-4.04 (m, 3H) 6.43 (br. s., 1H)7.34 (d, J=6.65 Hz, 1H) 7.69-7.88 (m, 3H) 7.97 (d, J=7.83 Hz, 1H)8.20-8.35 (m, 2H) 10.57 (br. s., 1H). LCMS (m/z) (M+H)=558.3, Rt=0.75min.

Example 49:N-(3-(6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) 5 ppm 1.82-2.06 (m, 4H) 2.31 (s, 3H) 3.58-3.73(m, 14H) 7.33 (br. s., 1H) 7.45-7.67 (m, 1H) 7.71-7.88 (m, 3H) 7.91-8.02(m, 1H) 8.16-8.39 (m, 2H) 10.55 (br. s., 1H). LCMS (m/z) (M+H)=554.3,Rt=0.85 min.

Example 50:N-(4-methyl-3-(2-morpholino-6-(1,4-oxazepan-4-yl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) 5 ppm 1.85 (br. s., 2H) 2.30 (s, 3H) 3.58-3.80(m, 16H) 7.35 (br. s., 1H) 7.44-7.69 (m, 1H) 7.72-7.90 (m, 3H) 7.97 (d,J=7.83 Hz, 1H) 8.18-8.36 (m, 2H) 10.57 (br. s., 1H). LCMS (m/z)(M+H)=542.3, Rt=0.85 min.

Example 51:N-(3-(6-(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

LCMS (m/z) (M+H)=540.4 Rt=0.79 min.

Example 52:N-(3-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluofomethl)benzamide

¹H NMR (400 MHz, <dmso>) 5 ppm 1.58-1.72 (m, 2H) 1.74-1.92 (m, 2H) 2.29(s, 3H) 2.94-3.29 (m, 2H) 3.68 (d, J=7.04 Hz, 8H) 4.42 (br. s., 2H) 7.33(d, J=7.04 Hz, 1H) 7.46-7.68 (m, 1H) 7.70-7.86 (m, 3H) 7.97 (d, J=7.83Hz, 1H) 8.19-8.34 (m, 2H) 10.56 (br. s., 1H). LCMS (m/z) (M+H)=554.4,Rt=0.83 min.

Example 53:(R)-N-(4-methyl-3-(6-(2-methylmorpholino)-2-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) 5 ppm 1.00-1.26 (m, 3H) 2.29 (s, 3H) 3.41-3.57(m, 2H) 3.68 (d, J=8.61 Hz, 8H) 3.89 (d, J=10.96 Hz, 1H) 7.32 (br. s.,1H) 7.42-7.66 (m, 1H) 7.70-7.87 (m, 3H) 7.92-8.02 (m, 1H) 8.19-8.33 (m,2H) 10.54 (br. s., 1H). LCMS (m/z) (M+H)=542.3, Rt=0.85 min.

Example 54:(S)-N-(4-methyl-3-(6-(2-methylmorpholino)-2-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) 5 ppm 1.13 (d, J=6.26 Hz, 3H) 2.29 (s, 3H) 2.52(s, 2H) 3.41-3.61 (m, 2H) 3.68 (d, J=9.39 Hz, 8H) 3.90 (d, J=10.17 Hz,1H) 7.33 (d, J=6.26 Hz, 1H) 7.42-7.62 (m, 1H) 7.69-7.88 (m, 3H)7.93-8.03 (m, 1H) 8.20-8.35 (m, 2H) 10.57 (br. s., 1H). LCMS (m/z)(M+H)=542.4, Rt=0.85 min.

Example 55:N-(3-(6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.82-2.06 (m, 4H) 2.31 (s, 3H) 3.58-3.73(m, 14H) 7.33 (br. s., 1H) 7.45-7.67 (m, 1H) 7.71-7.88 (m, 3H) 7.91-8.02(m, 1H) 8.16-8.39 (m, 2H) 10.55 (br. s., 1H). LCMS (m/z) (M+H)=554.3,Rt=0.79 min.

Example 56: Synthesis ofN-(4-methyl-3-(2-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

A mixture of4-(4-chloro-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-2-yl)morpholine(prepared according to WO2007/084786) (1.0 equiv.),N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.2 equiv.), sodium carbonate (2 M, 8 equiv.) and PdCl₂(dppf) (0.5equiv.) in DME (0.1 M) were heated to 108° C. for 13 min in themicrowave. After removing the DME soluble portion and concentrating, theresulting solid was partitioned between EtOAc and water. The organicphase was washed with brine, dried over sodium sulfate and then purifiedvia preparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(3-(6-(2,2-dimethylmorpholino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 44% yield. ¹H NMR (400 MHz, <dmso>) δppm 1.59-1.71 (m, 2H) 1.95-2.09 (m, 2H) 2.35 (s, 3H) 3.64-3.72 (m, 10H)3.80-3.91 (m, 2H) 5.24 (dt, J=8.71, 4.45 Hz, 1H) 6.18 (s, 1H) 7.27 (d,J=8.22 Hz, 1H) 7.72-7.87 (m, 3H) 7.96 (d, J=7.43 Hz, 1H) 8.18-8.38 (m,2H) 10.45 (s, 1H). LCMS (m/z) (M+H)=543.3, Rt=0.96 min.

Example 57: Synthesis ofN-(4-methyl-3-(5-methyl-2,6-dimorpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of 4-(4,6-dichloro-5-methylpyrimidin-2-yl)morpholine inEtOH (0.15 M) was added morpholine (2.0 equiv.) followed bytriethylamine (4.00 equiv.). The resulting mixture was heated undermicrowave irradiation at 125° C. for 50 min (2×25 min). The reactionmixture was then concentrated in vacuo to yield4,4′-(6-chloro-5-methylpyrimidine-2,4-diyl)dimorpholine as a white solidin 96% yield which was utilized without further purification in thesubsequent reaction. LCMS (m/z) (M+H)=299.1, Rt=0.85 min.

Step 2

To a solution of 4,4′-(6-chloro-5-methylpyrimidine-2,4-diyl)dimorpholine(1.0 equiv.) and Intermediate A (1.20 equiv.) in DME and 2M sodiumcarbonate (3:1, 0.2 M) was added PdCl₂(dppf)-DCM adduct (0.500 equiv.)in a microwave vial equipped with a stir bar. The reaction was heated to110° C. for 10 min under microwave irradiation. The organic phase wasdried with sodium sulfate, filtered and concentrated. The crude materialwas purified via preparative reverse phase HPLC. Upon lyophilization ofthe pure fractions,N-(4-methyl-3-(5-methyl-2,6-dimorpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 6% yield. ¹H NMR (400 MHz, <dmso>) δ ppm1.81 (s, 3H) 2.10 (br. s., 3H) 3.63 (br. s., 11H) 3.70 (d, J=3.91 Hz,5H) 7.30 (br. s., 1H) 7.65-7.82 (m, 2H) 7.95 (d, J=7.43 Hz, 1H)8.15-8.35 (m, 3H) 10.48 (br. s., 1H). LCMS (m/z) (M+H)=542.2, Rt=0.85min.

Example 58: Synthesis ofN-(6-methyl-5-(6-morpholinopyridazin-4-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

A mixture of 5-bromo-3-chloropyridazine (1.0 equiv.),N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.2 equiv.), sodium carbonate (2 M, 8 equiv.) and PdCl₂(dppf) (0.5equiv.) in DME (0.1 M) were heated to 108° C. for 13 min in themicrowave. After removing the DME soluble portion and concentrating, theresulting solid was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over sodium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Volatiles were removed by rotary evaporation and theremaining aqueous solution was basified with sodium bicarbonate. Thissolution was extracted with EtOAc, washed with brine and dried oversodium sulfate. The solution was concentrated and dried under vacuo togive crudeN-(5-(6-chloropyridazin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamideand was used in the next step without further purification. LCMS (m/z)(M+H)=393.1, Rt=0.73 min.

Step 2

A mixture ofN-(5-(6-chloropyridazin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.), morpholine (5 equiv.) and potassium carbonate (10 equiv.)in NMP (0.15 M) were heated to 130° C. for 18 h in an oil bath. Thereaction mixture was centrifuged and the soluble portion was removedfrom solids. The soluble portion was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,N-(6-methyl-5-(6-morpholinopyridazin-4-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide was isolated as the TFA saltin 1% yield. LCMS (m/z) (M+H)=444.2, Rt=0.63 min.

Example 59: Synthesis ofN-(4-methyl-3-(5-morpholinopyridazin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

A mixture of 5-bromo-3-chloropyridazine (1.0 equiv.), morpholine (1equiv.) and potassium carbonate (6 equiv.) in NMP (0.2 M) were heated to110° C. for 4 hours in an oil bath. The reaction mixture was partitionedbetween EtOAc and water. The organic phase was dried over sodiumsulfate, concentrated and purified by normal phase chromatography. Thecombined fractions were concentrated and dried under vacuo to give crude4-(6-chloropyridazin-4-yl)morpholine and was used in the next stepwithout further purification. LCMS (m/z) (M+H)=200.0, Rt=0.34 min.

Step 2

A mixture of 4-(6-chloropyridazin-4-yl)morpholine (1.0 equiv.),N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.), sodium carbonate (2 M, 10 equiv.) and PdCl₂(dppf) (0.5equiv.) in DME (0.1 M) were heated to 110° C. for 15 min in themicrowave. After removing the DME soluble portion and concentrating, theresulting solid was partitioned between EtOAc and water. The organicphase was washed with brine, dried over sodium sulfate and then purifiedvia preparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(4-methyl-3-(5-morpholinopyridazin-3-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 14% yield. ¹H NMR (400 MHz, <dmso>) δppm 2.37 (s, 3H) 3.73-3.86 (m, 8H) 7.46 (d, J=7.83 Hz, 1H) 7.51 (d,J=2.35 Hz, 1H) 7.55-7.69 (m, 2H) 8.01-8.10 (m, 2H) 8.14 (d, J=8.22 Hz,1H) 8.21 (s, 1H) 9.07 (d, J=2.74 Hz, 1H) 10.60 (s, 1H). LCMS (m/z)(M+H)=443.1, Rt=0.74 min.

The compound listed below were prepared using methods similar to thosedescribed above using the appropriate starting materials.

Example 60:N-(6-methyl-5-(5-morpholinopyridazin-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.46 (s, 3H) 3.73-3.90 (m, 9H) 7.55 (br.s., 1H) 7.76-7.88 (m, 1H) 8.01 (d, J=7.83 Hz, 1H) 8.28 (d, J=7.83 Hz,1H) 8.32 (s, 1H) 8.38 (d, J=2.35 Hz, 1H) 8.95 (d, J=1.96 Hz, 1H) 9.07(d, J=3.13 Hz, 1H) 10.87 (s, 1H). LCMS (m/z) (M+H)=444.0, Rt=0.62 min.

Example 61:N-(4-methyl-3-(2-morpholino-6-(trifluoromethyl)pyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) 5 ppm 2.40 (s, 3H) 3.65-3.85 (m, 8H) 7.19 (s,1H) 7.35 (d, J=8.22 Hz, 1H) 7.75-7.83 (m, 1H) 7.87 (dd, J=8.22, 1.96 Hz,1H) 7.91 (d, J=1.96 Hz, 1H) 7.97 (d, J=7.43 Hz, 1H) 8.22-8.34 (m, 2H)10.54 (s, 1H). LCMS (m/z) (M+H)=511.2, Rt=1.23 min.

Example 62: Synthesis ofN-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

Synthesis of 4-(4-bromopyridin-2-yl)morpholine

To a solution of triethylamine (1.0 equiv.) and 2-fluoro-4-bromopyridine(1.0 equiv.) at RT was added morpholine (1.0 equiv) in one portion, theresulting mixture was then heated in an oil bath at 100° C. for 66 hr.LCMS analysis indicated the formation of the desired product (m/z=244.9,Rt=0.36 min). The reaction mixture was concentrated in vacuo to yield4-(4-bromopyridin-2-yl)morpholine as a light brown solid, (>100%, TEAimpurity). LCMS (m/z) (M+H)=244.9, Rt=0.36 min. ¹H NMR (400 MHz, <dmso>)δ ppm 3.39-3.55 (m, 4H) 3.59-3.75 (m, 4H) 6.87 (dd, J=5.28, 1.37 Hz, 1H)7.05 (d, J=1.17 Hz, 1H) 8.00 (d, J=5.48 Hz, 1H).

Synthesis of4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine

4-(4-bromopyridin-2-yl)morpholine (1.10 equiv), bis(pinacolato)diboron(1.0 equiv.), potassium acetate (4.0 equiv), and PdCl₂(dppf)CH₂Cl₂ (0.05equiv.) were added to a rb flask which was purged with nitrogen. DMF(0.20 M) was added and the mixture was heated to 80° C. overnight. Thereaction was cooled to rt, quenched with water, and the product wasextracted into EtOAc (3×). The combined organics were dried over Na₂SO₄,filtered, and concentrated. The crude was loaded onto silica gel andpurified via ISCO to yield4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholineas a light brown foam (56%). 1H NMR (400 MHz, <cdcl3>) δ ppm 1.33 (s,12H) 3.49-3.55 (m, 4H) 3.79-3.83 (m, 4H) 6.98 (d, J=4.70 Hz, 1H) 7.03(s, 1H) 8.21 (d, J=4.70 Hz, 1H).

Synthesis of 2-methyl-2′-morpholino-[3,4′-bipyridin]-5-amine

To a solution of 5-bromo-6-methylpyridin-3-amine (1.0 equiv.) and4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine(1.7 equiv.) in DME and 2M sodium carbonate (4:1, 0.14 M) was addedPdCl₂(dppf)-DCM adduct (0.1 equiv.) in a microwave vial equipped with astir bar. The reaction was heated to 110° C. for 15 min in themicrowave. The cooled reaction mixture was partitioned between water andethyl acetate. The organic phase was dried with sodium sulfate, filteredand concentrated. The crude material was purified by flashchromatography over silica gel (DCM with a 0-20% methanol gradient). Thepure fractions were concentrated in vacuo to afford2-methyl-2′-morpholino-[3,4′-bipyridin]-5-amine in quantitative yield.LCMS (m/z) (M+H)=271.1, Rt=0.26 min.

Synthesis ofN-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

To a solution of 4-(4-bromopyridin-2-yl)morpholine (1.0 equiv.) andIntermediate A (1.2 equiv.) in DME and 2M sodium carbonate (3:1, 0.08 M)was added PdCl₂(dppf)-DCM adduct (0.1 equiv.) in a microwave vialequipped with a stir bar. The reaction was heated to 120° C. for 20 minin the microwave. The reaction was quenched with water and extractedwith ethyl acetate. The combined organic phase was dried with sodiumsulfate, filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 16% yield. LCMS (m/z) (M+H)=442.3,Rt=0.76 min. 1H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 3.44-3.59 (m,5H) 3.64-3.87 (m, 22H) 6.82 (d, J=5.48 Hz, 1H) 7.00 (s, 1H) 7.27-7.41(m, 1H) 7.67-7.82 (m, 3H) 7.90-8.03 (m, 1H) 8.17 (d, J=5.48 Hz, 1H) 8.26(d, J=7.83 Hz, 1H) 8.30 (s, 1H) 10.40-10.61 (m, 1H).

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 62 using the appropriatestarting materials.

Example 63:4-Methyl-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

1H NMR (400 MHz, <dmso>) 5 ppm 2.28-2.38 (m, 3H) 3.50-3.58 (m, 5H)3.61-3.93 (m, 36H) 6.83 (d, J=5.09 Hz, 1H) 6.97 (br. s., 1H) 7.37-7.69(m, 6H) 7.89 (d, J=1.57 Hz, 1H) 7.96 (dd, J=7.83, 1.57 Hz, 1H) 8.06 (d,J=8.22 Hz, 1H) 8.20 (d, J=5.48 Hz, 1H) 8.23 (s, 1H) 10.50 (s, 1H). LCMS(m/z) (M+H)=442.3, Rt=0.79 min.

Example 64:4-methyl-3-(4-morpholinopyridin-2-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.36 (s, 3H) 2.54 (s, 1H) 7.27 (dd,J=7.24, 2.54 Hz, 1H) 7.32 (d, J=2.74 Hz, 1H) 7.48 (d, J=7.83 Hz, 1H)7.56-7.65 (m, 2H) 8.03-8.10 (m, 2H) 8.14 (dd, J=8.02, 1.76 Hz, 1H) 8.23(s, 1H) 8.36 (d, J=7.04 Hz, 1H) 10.50-10.65 (m, 1H) 13.75 (br. s., 1H).LCMS (m/z) (M+H)=442.3, Rt=0.74 min.

Example 65:N-(3-(2,6-dimorpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.14-2.27 (m, 3H) 3.28-3.51 (m, 8H)3.54-3.82 (m, 8H) 5.97-6.12 (m, 2H) 7.21-7.33 (m, 1H) 7.56-7.63 (m, 2H)7.68-7.74 (m, 1H) 7.78 (t, J=7.83 Hz, 1H) 7.96 (d, J=7.83 Hz, 1H)8.17-8.27 (m, 1H) 8.29 (s, 1H) 10.36-10.50 (m, 1H), LCMS (m/z)(M+H)=527.4, Rt=1.04 min.

Example 66:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 3.45-3.61 (m, 4H) 3.67-3.79(m, 4H) 6.81 (d, J=5.48 Hz, 1H) 6.98 (br. s., 1H) 7.35 (d, J=8.22 Hz,1H) 7.69 (s, 1H) 7.73 (dd, J=8.22, 1.96 Hz, 1H) 7.86 (dd, J=5.09, 1.17Hz, 1H) 8.00 (s, 1H) 8.17 (d, J=5.87 Hz, 1H) 8.81 (d, J=5.09 Hz, 1H)10.60 (s, 1H), LCMS (m/z) (M+H)=442.4, Rt=0.67 min.

Example 67:N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)pyridazine-3-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 2.17-2.34 (m, 3H) 3.49-3.65 (m, 4H)3.69-3.82 (m, 4H) 6.88 (d, J=5.48 Hz, 1H) 7.09 (s, 1H) 7.27-7.44 (m, 1H)7.86-7.95 (m, 2H) 7.98 (dd, J=8.61, 5.09 Hz, 1H) 8.13-8.22 (m, 1H)8.27-8.37 (m, 1H) 9.38-9.55 (m, 1H) 11.03-11.24 (m, 1H), LCMS (m/z)(M+H)=376.3.0, Rt=0.56 min.

Example 68:N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)-3-(methylsulfonyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.17-2.30 (m, 3H) 3.23-3.35 (m, 3H)3.52-3.64 (m, 4H) 3.69-3.85 (m, 4H) 6.85 (d, J=5.48 Hz, 1H), 7.06 (br.s., 1H) 7.35 (d, J=8.22 Hz, 1H) 7.65-7.79 (m, 2H) 7.79-7.89 (m, 1H)8.09-8.20 (m, 2H) 8.29 (d, J=7.83 Hz, 1H) 8.43-8.53 (m, 1H) 10.50-10.65(m, 1H), LCMS (m/z) (M+H)=452.1, Rt=0.61 min.

Example 69:2-(tert-butyl)-N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) 5 ppm 1.29-1.42 (m, 9H) 2.25 (s, 3H) 3.51-3.65(m, 4H) 3.69-3.81 (m, 4H) 6.85 (d, J=5.48 Hz, 1H) 6.95-7.13 (m, 1H) 7.35(d, J=8.22 Hz, 1H) 7.59-7.78 (m, 3H) 7.86 (s, 1H) 8.16 (d, J=5.48 Hz,1H) 8.72 (d, J=5.09 Hz, 1H) 10.52 (s, 1H), LCMS (m/z) (M+H)=431.3,Rt=0.54 min.

Example 70:N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)pyrazine-2-carboxamide

1H NMR (400 MHz, <dmso>) 5 ppm 2.18-2.31 (m, 3H) 3.48-3.65 (m, 4H)3.68-3.83 (m, 4H) 6.85 (d, J=5.48 Hz, 1H) 6.95-7.13 (m, 1H), 7.27-7.39(m, 1H) 7.79-7.92 (m, 2H) 8.05-8.22 (m, 1H) 8.81 (dd, J=2.35, 1.57 Hz,1H) 8.94 (d, J=2.35 Hz, 1H) 9.23-9.37 (m, 1H) 10.79 (s, 1H), LCMS (m/z)(M+H)=376.2, Rt=0.57 min.

Example 71:N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)pyrimidine-5-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 2.19-2.28 (m, 3H) 3.49-3.63 (m, 4H)3.68-3.81 (m, 4H) 6.85 (d, J=5.48 Hz, 1H) 6.97-7.12 (m, 1H) 7.32-7.41(m, 1H) 7.65-7.78 (m, 2H) 8.11 (dd, J=5.28, 2.15 Hz, 1H) 8.17 (d, J=5.48Hz, 1H) 9.50 (dd, J=5.48, 0.78 Hz, 1H) 9.64 (d, J=0.78 Hz, 1H)10.68-10.86 (m, 1H), LCMS (m/z) (M+H)=376.2, Rt=0.52 min.

Example 72:N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 2.19-2.29 (m, 3H) 3.58 (d, J=3.91 Hz, 4H)3.67-3.82 (m, 4H) 6.83 (d, J=5.09 Hz, 1H) 7.03 (br. s., 1H), 7.29-7.42(m, 1H) 7.64-7.76 (m, 2H) 8.10-8.24 (m, 1H) 9.27 (s, 2H) 9.37 (s, 1H)10.66 (s, 1H), LCMS (m/z) (M+H)=376.2, Rt=0.50 min.

Example 73:N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.18-2.34 (m, 3H) 3.35 (s, 3H) 3.47-3.63(m, 4H) 3.69-3.84 (m, 4H) 6.72-6.88 (m, 1H) 6.95-7.07 (m, 1H) 7.37 (d,J=8.22 Hz, 1H) 7.72 (s, 1H) 7.76 (dd, J=8.22, 2.35 Hz, 1H) 8.17 (d,J=5.48 Hz, 1H) 8.20-8.26 (m, 1H) 8.53 (s, 1H) 8.94-9.05 (m, 1H)10.75-10.90 (m, 1H), LCMS (m/z) (M+H)=453.3, Rt=0.57 min.

Example 74:3-(4-ethylpiperazin-1-yl)-N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)-5-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) 5 ppm 1.27 (t, J=7.24 Hz, 4H) 2.24 (s, 3H) 2.54(s, 1H) 3.13 (d, J=8.22 Hz, 5H) 3.18-3.28 (m, 3H) 3.44-3.56 (m, 6H) 3.61(d, J=6.26 Hz, 3H) 3.66-3.81 (m, 6H) 4.11 (d, J=8.61 Hz, 3H) 6.76 (d,J=5.09 Hz, 1H) 6.89 (s, 1H) 7.33 (d, J=8.61 Hz, 1H) 7.52 (s, 1H) 7.65(d, J=1.96 Hz, 1H) 7.73 (s, 2H) 7.75-7.81 (m, 2H) 8.18 (d, J=5.48 Hz,1H) 9.72 (br. s., 1H) 10.42 (s, 1H), LCMS (m/z) (M+H)=554.4, Rt=0.61min.

Example 75:3-(difluoromethyl)-N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.54 (s, 1H) 3.46-3.63 (m, 4H) 3.66-3.82(m, 4H) 6.84 (d, J=5.09 Hz, 1H) 7.01 (s, 1H) 7.03 (br. s., 1H), 7.15 (s,1H) 7.28 (s, 1H) 7.33 (d, J=8.22 Hz, 1H) 7.62-7.84 (m, 4H) 8.06-8.20 (m,3H) 10.46 (s, 1H), LCMS (m/z) (M+H)=424.1, Rt=0.73 min.

Example 76:N-(3-(2-(dimethylamino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, DMSO-d₆) δ ppm 2.21 (s, 3H) 2.99 (s, 6H) 3.30-3.49 (m,4H) 5.89 (d, J=19.95 Hz, 2H) 7.12-7.32 (m, 1H) 7.63-7.84 (m, 2H)7.90-8.04 (m, 1H) 8.17-8.35 (m, 2H) 10.30-10.53 (m, 1H). LCMS (m/z)(M+H) 485.4, Rt=0.93 min.

Example 77:N-(2-methyl-2′,6′-dimorpholino-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, DMSO-d₆) b 2.13-2.32 (m, 1H) 2.54-2.66 (m, 2H)3.54-3.70 (m, 9H) 7.65-8.11 (m, 4H) 7.83-8.02 (m, 3H) 8.26 (s, 3H)8.76-8.94 (m, 1H) 10.53-10.79 (m, 1H). LCMS (m/z) (M+H) 528.3, Rt=0.8min.

Example 78:(S)-N-(3-(2-(2-(hydroxymethyl)morpholino)pyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 2.33 (s, 3H) 3.13 (t, J=11.54 Hz, 1H)3.60-3.73 (m, 3H) 3.77 (td, J=11.74, 2.74 Hz, 1H) 4.02 (d, J=13.30 Hz,1H) 4.11 (d, J=12.91 Hz, 2H) 7.02 (d, J=6.26 Hz, 1H) 7.29 (s, 1H) 7.37(d, J=8.61 Hz, 1H) 7.61 (dd, J=8.22, 2.35 Hz, 1H) 7.70-7.76 (m, 1H) 7.81(d, J=2.35 Hz, 1H) 7.90 (d, J=7.83 Hz, 1H) 8.04 (d, J=6.26 Hz, 1H) 8.20(d, J=7.83 Hz, 1H) 8.26 (s, 1H). LCMS (m/z) (M+H)=472.3, Rt=0.74 min.

Example 79:2-(2-cyanopropan-2-yl)-N-(3-(2-((2R,5R)-2-((dimethylamino)methyl)-5-methylmorpholino)pyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.18 (d, J=6.26 Hz, 3H) 1.75 (s, 6H) 2.23(s, 3H) 2.81 (br. s., 6H) 3.11 (br. s., 1H) 3.43 (dd, J=13.69, 4.70 Hz,1H) 3.52 (dd, J=11.74, 2.35 Hz, 1H) 3.70-3.80 (m, 1H) 3.91 (d, J=12.91Hz, 1H) 4.04 (dd, J=11.93, 3.33 Hz, 1H) 4.22-4.31 (m, 1H) 4.37 (d,J=10.56 Hz, 1H) 6.70 (d, J=5.09 Hz, 1H) 6.75 (s, 1H) 7.33 (d, J=8.22 Hz,1H) 7.62-7.76 (m, 2H) 7.80-7.88 (m, 1H) 7.99 (s, 1H) 8.19 (d, J=5.09 Hz,1H) 8.80 (d, J=5.09 Hz, 1H) 10.56-10.66 (m, 1H). LCMS (m/z) (M+H)=513.5,Rt=0.59 min.

Example 80:2-(2-cyanopropan-2-yl)-N-(3-(2-((2S,5S)-2-((dimethylamino)methyl)-5-methylmorpholino)pyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.14 (d, J=6.65 Hz, 3H) 1.75 (s, 6H) 2.22(s, 3H) 2.75-2.89 (m, 7H) 3.23-3.36 (m, 2H) 3.79-3.85 (m, 2H) 3.92 (t,J=9.78 Hz, 1H) 4.11 (d, J=12.52 Hz, 1H) 4.40 (d, J=6.26 Hz, 1H) 6.68 (d,J=5.48 Hz, 1H) 6.74 (s, 1H) 7.32 (d, J=8.61 Hz, 1H) 7.64-7.72 (m, 2H)7.84 (d, J=4.70 Hz, 1H) 7.98 (s, 1H) 8.18 (d, J=5.09 Hz, 1H) 8.79 (d,J=5.09 Hz, 1H) 10.57 (s, 1H). LCMS (m/z) (M+H)=513.4, Rt=0.57 min.

Example 81:5-(dimethylamino)-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)nicotinamide

¹H NMR (400 MHz, <dmso>) 5 ppm 2.49 (s, 9H) 3.50-3.62 (m, 4H) 3.68-3.77(m, 4H) 6.86 (d, J=5.48 Hz, 1H) 7.07 (s, 1H) 7.87 (br. s., 1H) 8.18 (d,J=2.35 Hz, 1H) 8.22 (d, J=5.48 Hz, 1H) 8.34 (d, J=2.74 Hz, 1H) 8.50 (s,1H) 8.97 (d, J=2.35 Hz, 1H) 10.96 (s, 1H). LCMS (m/z) (M+H)=419.3,Rt=0.37 min.

Example 82:(R)-2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(3-methylmorpholino)pyridin-4-yl)phenyl)isonicotinamide

LCMS (m/z) (M+H)=456.3, Rt=0.66 min.

Example 83:(S)-2-(2-cyanopropan-2-yl)-N-(3-(2-(2-(hydroxymethyl)morpholino)pyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 2.23 (s, 3H) 2.76 (t,J=11.35 Hz, 1H) 2.99 (t, J=10.96 Hz, 1H) 3.36-3.66 (m, 4H) 3.96 (dd,J=11.54, 2.15 Hz, 1H) 4.07 (d, J=12.91 Hz, 1H) 4.19 (d, J=12.52 Hz, 1H)6.81 (d, J=5.09 Hz, 1H) 6.99 (br. s., 1H) 7.34 (d, J=8.61 Hz, 1H) 7.68(d, J=1.57 Hz, 1H) 7.72 (dd, J=8.41, 2.15 Hz, 1H) 7.85 (dd, J=5.09, 1.17Hz, 1H) 7.99 (s, 1H) 8.15 (d, J=5.48 Hz, 1H) 8.80 (d, J=5.09 Hz, 1H)10.59 (s, 1H).

LCMS (m/z) (M+H)=472.1, Rt=0.63 min.

Example 84:(R)-2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(2-((methylamino)methyl)morpholino)pyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) 5 ppm 1.75 (s, 7H) 2.22 (s, 3H) 2.58 (t, J=5.28Hz, 3H) 2.62-2.73 (m, 2H) 2.87-2.99 (m, 1H) 3.00-3.22 (m, 2H) 3.76-3.87(m, 2H) 4.01 (d, J=11.35 Hz, 1H) 4.11 (d, J=12.52 Hz, 1H) 4.26 (d,J=12.13 Hz, 1H) 6.72 (d, J=5.09 Hz, 1H) 6.81 (s, 1H) 7.33 (d, J=9.00 Hz,1H) 7.61-7.72 (m, 2H) 7.84 (dd, J=5.09, 1.17 Hz, 1H) 7.98 (s, 1H) 8.19(d, J=5.09 Hz, 1H) 8.80 (d, J=5.09 Hz, 1H) 10.57 (s, 1H). LCMS (m/z)(M+H)=485.3, Rt=0.60 min.

Example 85:(R)-N-(3-(2-(2-(acetamidomethyl)morpholino)pyridin-4-yl)-4-methylphenyl)-2-(2-cyanopropan-2-yl)isonicotinamide

LCMS (m/z) (M+H)=513.2, Rt=0.64 min.

Example 86: (R)-methyl((4-(2-methyl-5-(3-(trifluoromethyl)benzamido)-[3,4′-bipridin]-2′-yl)morpholin-2-yl)methyl)carbamate

LCMS (m/z) (M+H)=530.2, Rt=0.65 min.

Example 87: (R)-N-(2′-(2-((2-hydroxyacetamido) methyl)morpholino)-2-methyl-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of (S)-2-hydroxy-N-(morpholin-2-ylmethyl)acetamide (1.0equiv.) andN-(2′-fluoro-2-methyl-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(2.0 equiv.) in NMP (0.13 M) was added potassium carbonate (6.0 equiv.).The mixture was heated at 120° C. overnight. The reaction mixture wasthen filtered, and purified via reverse phase HPLC to yield(R)-N-(2′-(2-((2-hydroxyacetamido)methyl)morpholino)-2-methyl-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(5%, 99% purity by LC) as a white crystalline solid. LCMS (m/z)(M+H)=530.1, Rt=0.56 min.

Example 88:2-(2-cyanopropan-2-yl)-N-(2-methoxy-2′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 3.53 (t, J=4.30 Hz, 4H)3.67-3.76 (m, 4H) 3.90 (s, 3H) 6.98 (d, J=5.48 Hz, 1H) 7.15 (br. s., 1H)7.88 (dd, J=4.89, 1.37 Hz, 1H) 8.02 (s, 1H) 8.11-8.23 (m, 2H) 8.58 (d,J=2.35 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 10.73 (s, 1H). LCMS (m/z)(M+H)=459.2, Rt=0.69 min.

Example 89:2-(1,1-difluoroethyl)-N-(2′-morpholino-2-oxo-1,2-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) ppm 1.94-2.12 (m, 3H) 3.54 (d, J=4.70 Hz, 4H)3.68-3.79 (m, 4H) 7.19 (d, J=5.48 Hz, 1H) 7.56 (br. s., 1H) 8.00 (d,J=4.70 Hz, 1H) 8.04-8.15 (m, 3H) 8.17 (s, 1H) 8.88 (d, J=5.09 Hz, 1H)10.54 (s, 1H). LCMS (m/z) (M+H)=442.2, Rt=0.60 min.

Example 90:N-(2′-morpholino-2-oxo-1,2-dihydro-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 3.53 (d, J=4.30 Hz, 4H) 3.68-3.77 (m, 4H)7.17 (d, J=4.70 Hz, 1H) 7.52 (br. s., 1H) 8.00-8.14 (m, 3H) 8.17 (d,J=4.70 Hz, 1H) 8.34 (s, 1H) 9.00 (d, J=5.09 Hz, 1H) 10.59 (s, 1H). LCMS(m/z) (M+H)=446.2, Rt=0.61 min.

Example 91:2-(2-cyanopropan-2-yl)-N-(2′-morpholino-2-oxo-1,2-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 3.69-3.79 (m, 4H) 7.05-7.21(m, 1H) 7.50 (br. s., 1H) 7.84 (dd, J=5.09, 1.57 Hz, 1H) 7.99 (s, 1H)8.03 (br. s., 1H) 8.06-8.15 (m, 2H) 8.81 (d, J=5.09 Hz, 1H) 10.45 (s,1H). LCMS (m/z) (M+H)=445.2, Rt=0.59 min.

Example 92:N-(3-(6-amino-4-morpholinopyridin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.34 (s, 3H) 3.49-3.60 (m, 4H) 3.75-3.86(m, 4H) 6.07 (d, J=2.35 Hz, 1H) 6.61 (d, J=2.35 Hz, 1H) 7.40 (d, J=8.61Hz, 1H) 7.65 (dd, J=8.41, 2.15 Hz, 1H) 7.70-7.79 (m, 1H) 7.87-7.96 (m,2H) 8.21 (d, J=7.83 Hz, 1H) 8.26 (s, 1H). LCMS (m/z) (M+H)=447.2,Rt=0.87 min.

Example 93:N-(3-(2-amino-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.32 (s, 3H) 3.44-3.55 (m, 4H) 3.80-3.88(m, 4H) 6.13-6.24 (m, 1H) 7.34 (d, J=8.22 Hz, 1H) 7.58 (dd, J=8.22, 2.35Hz, 1H) 7.69-7.81 (m, 2H) 7.90 (d, J=7.83 Hz, 1H) 8.20 (d, J=7.83 Hz,1H) 8.26 (s, 1H). LCMS (m/z) (M+H)=447.2, Rt=0.87 min.

Example 94:1-ethyl-N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.41 (t, J=7.24 Hz, 3H) 2.32 (s, 3H)3.61-3.74 (m, 4H) 3.80-3.94 (m, 4H) 4.16 (q, J=7.04 Hz, 2H) 7.02 (d,J=5.87 Hz, 1H) 7.28 (s, 1H) 7.36 (d, J=8.61 Hz, 1H) 7.55 (dd, J=8.22,1.96 Hz, 1H) 7.76 (d, J=1.96 Hz, 1H) 8.04 (d, J=6.26 Hz, 1H) 8.48 (s,1H) 8.70 (d, J=2.74 Hz, 1H). LCMS (m/z) (M+H)=487.2, Rt=0.72 min.

Example 95: Synthesis of2-(2-cyanopropan-2-yl)-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

To a 0.2 M solution of 2-methyl-2′-morpholino-[3,4′-bipyridin]-5-amine(1.0 equiv.) in DMF was added 2-(2-cyanopropan-2-yl)isonicotinic acid(1.0 equiv.), EDC-HCl (1.1 equiv.) and aza-HOBt (1.1 equiv.). Thereaction was stirred at room temperature for 4 hours. The solution wasfiltered through a syringe filter and purified via reverse phasepreparative HPLC. Upon lyophilization of the pure fractions,2-(2-cyanopropan-2-yl)-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamidewas isolated as the TFA salt in 51% yield. ¹H NMR (400 MHz, <dmso>) δppm 1.75 (s, 6H) 2.47 (br. s., 3H) 3.45-3.63 (m, 4H) 3.64-3.79 (m, 4H)6.84 (d, J=5.09 Hz, 1H) 7.03 (br. s., 1H) 7.87 (dd, J=5.09, 1.17 Hz, 1H)8.02 (s, 1H) 8.14 (d, J=2.35 Hz, 1H) 8.20 (d, J=5.48 Hz, 1H) 8.83 (d,J=5.09 Hz, 1H) 8.92 (d, J=2.35 Hz, 1H) 10.90 (s, 1H); LCMS (m/z)(M+H)=443.2, Rt=0.50 min.

Synthesis of 3-bromo-4-(bromomethyl)benzoic acid

To a solution of 3-bromo-4-methylbenzoic acid (1.0 equiv.) and AIBN(0.05 equiv.) in trfluorotoluene (0.28 M) was added NBS (1.1 equiv.).The mixture was heated at 90° C. overnight. The reaction mixture waspartitioned between EtOAc and H₂O. The organic layer was washed withNaCl(sat.), dried over MgSO₄, filtered, concentrated to yield3-bromo-4-(bromomethyl)benzoic acid in 60% yield. LC/MS (m/z)=294.8(MH⁺), Rt=0.80 min.

Synthesis of 3-bromo-4-(hydroxymethyl)benzoic acid

To a solution of yield 3-bromo-4-(bromomethyl)benzoic acid (1.0 equiv.)in Water (0.56 M) at 95° C. was added potassium carbonate K₂CO₃ (5.0equiv.). The homogenous reaction mixture was stirred at 95° C. in an oilbath for 1 hr. The reaction mixture was COOLED OFF TO RT, neutralizedwith 6 M HCl. diluted with EtOAc and washed with brine. The organiclayer was dried over Na₂SO₄, filtered and concentrated. The crude wasused in next step. LC/MS (m/z)=294.8 (MH⁺), Rt=0.80 min.

Synthesis of3-bromo-4-(hydroxymethyl)-N-(3-(trifluoromethyl)phenyl)benzamide

EDC (1.3 equiv.) was added to a solution of3-bromo-4-(hydroxymethyl)benzoic acid (1.0 equiv),3-(trifluoromethyl)aniline (1.1 equiv.), HOAt (1.3 equiv.) in DMF (0.43M). The mixture was stirred at ambient temperature 3 hrs. The reactionmixture was diluted with water and extracted with ethyl acetate. Thecombined extracts were washed sequentially with 1M aqueous sodiumhydroxide and brine, dried over sodium sulfate, filtered, andconcentrated. The residue was purified by ISCO (50% EtOAc/Heptane) toyield 3-bromo-4-(hydroxymethyl)-N-(3-(trifluoromethyl)phenyl)benzamidein 35% yield. LC/MS (m/z)=374.0 (MH⁺), Rt=0.93 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 95 using the appropriatestarting materials.

Example 96:N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.47 (br. s., 3H) 3.49-3.59 (m, 4H)3.67-3.75 (m, 4H) 6.85 (d, J=4.65 Hz, 1H) 7.03 (s, 1H) 7.81 (t, J=7.83Hz, 1H) 8.00 (d, J=7.87 Hz, 1H) 8.18 (d, J=2.40 Hz, 1H) 8.21 (d, J=5.67Hz, 1H) 8.27 (d, J=7.92 Hz, 1H) 8.32 (s, 1H) 8.96 (d, J=2.40 Hz, 1H)10.82 (s, 1H). LCMS (m/z) (M+H)=443.3, Rt=0.61 min.

Example 97:4-methoxy-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.60 (s, 3H) 3.63-3.73 (m, 4H) 3.81-3.91(m, 4H) 4.01 (s, 3H) 6.98-7.06 (m, 1H) 7.29 (s, 1H) 7.36 (d, J=8.22 Hz,1H) 8.14 (d, J=5.87 Hz, 1H) 8.22-8.33 (m, 2H) 8.42 (d, J=2.35 Hz, 1H)9.04 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=473.3, Rt=0.59 min.

Example 98:4-fluoro-3-methoxy-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.59 (s, 3H) 3.62-3.73 (m, 4H) 3.81-3.91(m, 4H) 3.97 (s, 3H) 7.01 (dd, J=6.06, 0.98 Hz, 1H) 7.20-7.33 (m, 2H)7.60 (ddd, J=8.41, 4.11, 2.35 Hz, 1H) 7.73 (dd, J=8.02, 2.15 Hz, 1H)8.14 (d, J=6.26 Hz, 1H) 8.39 (d, J=2.35 Hz, 1H) 9.02 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=423.3, Rt=0.51 min.

Example 99:3-(difluoromethyl)-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)benzamide

1H NMR (400 MHz, <cd3od>) 5 ppm 2.59 (s, 3H) 3.65-3.70 (m, 4H) 3.84-3.89(m, 4H) 6.75 (s, 1H) 6.89 (s, 1H) 7.01 (s, 1H) 7.03 (d, J=3.13 Hz, 1H)7.27 (s, 1H) 7.66-7.72 (m, 1H) 7.81 (d, J=7.83 Hz, 1H) 8.11-8.16 (m, 2H)8.19 (s, 1H) 8.41 (d, J=2.35 Hz, 1H) 9.01 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=425.1, Rt=0.56 min.

Example 100:2-(1,1-difluoroethyl)-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) 5 ppm 2.05 (t, J=18.78 Hz, 3H) 2.59 (s, 3H)3.67-3.73 (m, 4H) 3.84-3.91 (m, 4H) 7.05 (dd, J=6.26, 1.17 Hz, 1H) 7.34(s, 1H) 8.00 (d, J=3.91 Hz, 1H) 8.13 (d, J=6.26 Hz, 1H) 8.23 (s, 1H)8.41 (d, J=2.35 Hz, 1H) 8.85 (d, J=5.09 Hz, 1H) 8.98 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=440.1, Rt=0.51 min.

Example 101:3-(1,1-difluoroethyl)-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 1.99 (t, J=18.39 Hz, 3H) 2.60 (s, 3H)3.66-3.71 (m, 4H) 3.84-3.89 (m, 4H) 7.03 (dd, J=6.26, 1.17 Hz, 1H) 7.30(s, 1H) 7.63-7.69 (m, 1H) 7.81 (d, J=7.43 Hz, 1H) 8.09 (d, J=7.83 Hz,1H) 8.15 (d, J=6.26 Hz, 1H) 8.18 (s, 1H) 8.44 (d, J=2.35 Hz, 1H) 9.05(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=439.1, Rt=0.59 min.

Example 102:N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) 5 ppm 3.27-3.42 (m, 3H) 3.48-3.64 (m, 4H)3.67-3.84 (m, 4H) 6.90 (d, J=5.09 Hz, 1H) 7.12 (s, 1H) 8.10-8.34 (m, 3H)8.57 (s, 1H) 8.99 (d, J=2.35 Hz, 1H) 9.04 (d, J=5.09 Hz, 1H) 11.19 (s,1H), LCMS (m/z) (M+H)=454.2, Rt=0.40 min.

Example 103:N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)-3-(methylsulfonyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.53 (s, 3H) 3.45-3.63 (m, 4H) 3.66-3.82(m, 4H) 5.67 (br. s., 1H) 6.81-6.96 (m, 1H) 7.14 (s, 1H) 7.87 (t, J=7.83Hz, 1H) 8.13-8.26 (m, 2H) 8.27-8.37 (m, 2H) 8.53 (s, 1H) 9.00-9.13 (m,1H) 10.96-11.11 (m, 1H), LCMS (m/z) (M+H)=453.2, Rt=0.43 min.

Example 104:2-(tert-butyl)-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.38 (s, 9H) 2.51-2.54 (m, 3H) 3.52-3.63(m, 4H) 3.68-3.79 (m, 4H) 6.85-6.97 (m, 1H) 7.10-7.17 (m, 1H) 7.74 (dd,J=5.09, 1.57 Hz, 1H) 7.87-7.95 (m, 1H) 8.23 (d, J=5.48 Hz, 1H) 8.25-8.30(m, 1H) 8.77 (d, J=5.09 Hz, 1H) 9.00-9.06 (m, 1H) 10.98 (s, 1H), LCMS(m/z) (M+H)=432.3, Rt=0.46 min.

Example 106:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-morpholino-6-(tetrahydro-2H-pyran-4-yl)pyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 1.85-2.01 (m, 4H) 2.31 (s,3H) 3.02-3.17 (m, 1H) 3.48-3.61 (m, 2H) 3.65-3.76 (m, 3H) 3.80-3.92 (m,4H) 4.01-4.14 (m, 2H) 6.87 (s, 1H) 7.02 (s, 1H) 7.37 (d, J=8.22 Hz, 1H)7.61 (dd, J=8.22, 1.96 Hz, 1H) 7.73-7.86 (m, 2H) 8.06 (s, 1H) 8.76 (d,J=5.09 Hz, 1H). LCMS (m/z) (M+H)=526.3, Rt=0.76 min.

Example 107:N-(4-methyl-3-(2-morpholino-6-(tetrahydro-2H-pyran-4-yl)pyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 1.81-2.02 (m, 4H) 2.31 (s, 3H) 3.05-3.18(m, 1H) 3.45-3.62 (m, 2H) 3.66-3.75 (m, 4H) 3.81-3.91 (m, 4H) 4.03-4.15(m, 2H) 6.89 (s, 1H) 7.06 (s, 1H) 7.36 (d, J=8.22 Hz, 1H) 7.60 (dd,J=8.22, 2.35 Hz, 1H) 7.69-7.83 (m, 2H) 7.90 (d, J=7.83 Hz, 1H) 8.20 (d,J=7.83 Hz, 1H) 8.26 (s, 1H). LCMS (m/z) (M+H)=526.2, Rt=0.86 min.

Example 108:4-(hydroxymethyl)-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

The method used to prepare example 62 was followed using3-bromo-4-(hydroxymethyl)-N-(3-(trifluoromethyl)phenyl)benzamide and4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholineto afford4-(hydroxymethyl)-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide in a 91% yield. ¹H NMR (400 MHz, <cd3od>) 5 ppm3.61-3.73 (m, 4H), 3.83-3.90 (m, 4H), 4.63 (s, 2H), 7.09-7.15 (m, 1H),7.39-7.47 (m, 2H), 7.53-7.60 (m, 1H), 7.75-7.82 (m, 1H), 7.91-7.99 (m,2H), 8.04-8.13 (m, 2H), 8.14-8.19 (m, 1H). LC/MS (m/z)=458.1 (MH⁺),R_(t)=0.73 min.

4-formyl-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

MnO₂ (8.0 equiv.) was added into a solution of4-(hydroxymethyl)-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (1.0 equiv.) in DCM (0.05 M). The suspension wasstirred at rt for 1 hr. The mixture was filtered over celite andconcentrated to yield4-formyl-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamidein 100% yield. LC/MS (m/z)=456.1 (MH⁺), R_(t)=0.76 min.

Example 109:4-(difluoromethyl)-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

To a cooled solution of4-formyl-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide (1.0 equiv.) in dry CH₂Cl₂ (0.05 M), (diethylamino)sulfurtrifluoride (3.5 equiv.) was added under vigorous stirring. Theresulting reaction mixture was stirred at 0° C. for 2 hrs. Quenched thereaction with sat NaHCO₃ and extracted with DCM. The organic layer waswashed with Brine, filtered over Na₂SO₄ and concentrated. The crude waspurified by prep HPLC to yield4-(difluoromethyl)-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamidein 12% yield. ¹H NMR (400 MHz, <cd3od>) δ ppm 2.65 (s, 1H), 3.63-3.73(m, 4H), 3.80-3.90 (m, 4H), 6.70-7.05 (m, 2H), 7.27 (s, 1H), 7.43-7.49(m, 1H), 7.53-7.61 (m, 1H), 7.91-7.99 (m, 2H), 8.01-8.05 (m, 1H),8.08-8.14 (m, 1H), 8.15-8.23 (m, 2H). LC/MS (m/z)=478.1 (MH⁺),R_(t)=0.85 min.

Example 110: Synthesis of4-(fluoromethyl)-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

To a cooled solution of4-(difluoromethyl)-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide(1.0 equiv.) in dry CH₂Cl₂ (0.05 M), (diethylamino)sulfur trifluoride(3.5 equiv.) was added portionwise under vigorous stirring. Theresulting reaction mixture was stirred at −78° C. for 3 hrs, Quenchedthe reaction with sat NaHCO₃ and extracted with DCM. The organic layerwas washed with Brine, filtered over Na₂SO₄ and concentrated. Theresidue was purified by PREP HPLC to yield4-(fluoromethyl)-3-(2-morpholinopyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamidein 16% yield. ¹H NMR (400 MHz, <cd3od>) δ ppm 3.68 (d, J=5.09 Hz, 4H),3.86 (d, J=5.09 Hz, 4H), 5.40 (s, 1H), 5.52 (s, 1H), 7.01-7.11 (m, 1H),7.24-7.31 (m, 1H), 7.41-7.48 (m, 1H), 7.52-7.60 (m, 1H), 7.77-7.83 (m,1H), 7.91-7.98 (m, 1H), 7.99-8.04 (m, 1H), 8.07-8.19 (m, 3H). LC/MS(m/z)=460.1 (MH⁺), R_(t)=0.85 min.

Synthesis of 4-(2-chloropyridin-4-yl)morpholine

To a solution of triethylamine (1.0 equiv.) and 2,4-dichloropyridine(1.0 equiv.) at RT was added morpholine (1.0 equiv) in one portion, theresulting mixture was then stirred at RT for 45 hr. LCMS analysisindicated the formation of the desired product (M+H=199, Rt=0.29 min,major) and the undesired isomer (M+H=199, Rt=0.33 min, minor). Thereaction mixture was concentrated in vacuo and purified via ISCO toyield 4-(2-chloropyridin-4-yl)morpholine as a light brown solid (28%).LCMS (m/z) (M+H)=299.0, Rt=0.29 min. 1H NMR (400 MHz, <cdcl3>) δ ppm3.18-3.37 (m, 4H) 3.72-3.91 (m, 4H) 6.51-6.61 (m, 1H) 6.61-6.69 (m, 1H)8.05 (d, J=6.26 Hz, 1H)

Example 111:N-(4-methyl-3-(4-morpholinopyridin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

To a solution of 4-(2-chloropyridin-4-yl)morpholine (1.0 equiv.) andIntermediate A (1.2 equiv.) in DME and 2M sodium carbonate (3:1, 0.08 M)was added PdCl₂(dppf)-DCM adduct (0.1 equiv.) in a microwave vialequipped with a stir bar. The reaction was heated to 120° C. for 20 minin the microwave. The reaction was quenched with water and extractedwith ethyl acetate. The combined organic phase was dried with sodiumsulfate, filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(4-methyl-3-(4-morpholinopyridin-2-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 16% yield. ¹H NMR (400 MHz, <dmso>) δppm 2.17-2.30 (m, 3H) 7.17-7.29 (m, 2H) 7.44 (d, J=8.22 Hz, 1H)7.74-7.86 (m, 2H) 7.93 (d, J=1.96 Hz, 1H) 7.99 (d, J=7.83 Hz, 1H)8.17-8.41 (m, 3H) 10.68 (s, 1H) 13.74 (br. s., 1H). LCMS (m/z)(M+H)=442.3, Rt=0.73 min.

Synthesis of 4,4′-(4-bromopyridine-2,6-diyl)dimorpholine

To a solution of Morpholine (5.0 equiv.) and4-bromo-2,6-dichloropyridine (1.0 equiv.) in DMF (0.275 M) was addedcesium carbonate (2.0 equiv.). The mixture was heated at 100° C. for 45hours. LCMS analysis indicated formation of several products includingthe desired (M+H=288, Rt=0.87 min). The reaction mixture was thenconcentrated in vacuo to yield a glassy foam. Water was then added, andthe mixture was extracted with ethyl acetate, and the combined extractswere washed with brine, dried over magnesium sulfate, filtered, andconcentrated. The residue was chromatographed via ISCO to provide4,4′-(4-bromopyridine-2,6-diyl)dimorpholine (44%, 80% purity by LC) as awhite crystalline solid. LCMS (m/z) (M+H)=288.0, Rt=0.87 min.

Example 112:3-(2,6-dimorpholinopyridin-4-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide

To a solution of 4-bromo-2,6-dichloropyridine (1.0 equiv.) andIntermediate D (1.2 equiv.) in DME and 2M sodium carbonate (3:1, 0.08 M)was added PdCl₂(dppf)-DCM adduct (0.1 equiv.) in a microwave vialequipped with a stir bar. The reaction was heated to 120° C. for 20 minin the microwave. The reaction was quenched with water and extractedwith ethyl acetate. The combined organic phase was dried with sodiumsulfate, filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,3-(2,6-dimorpholinopyridin-4-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamidewas isolated as the TFA salt in 8% yield. LCMS (m/z) (M+H)=527.3,Rt=1.07 min. 1H NMR (400 MHz, <dmso>) δ ppm 1.27 (s, 2H) 2.31 (s, 3H)3.53-3.71 (m, 16H) 6.08 (s, 2H) 7.30-7.72 (m, 6H) 7.80-7.98 (m, 2H) 8.22(s, 2H) 10.44 (s, 1H).

Synthesis of 4-(6-chloro-4-iodopyridin-2-yl)morpholine

To a solution of triethylamine (1.0 equiv.) and2,6-dichloro-4-iodopyridine (1.0 equiv.) at RT was added morpholine (1.0equiv) in one portion, the resulting mixture was then heated in an oilbath at 100° C. for 18 hours. LCMS analysis indicated the formation ofthe desired product (M+H=324.9/326.8, Rt=0.98 min). Water was thenadded, and the mixture was extracted with ethyl acetate, and thecombined extracts were washed with brine, dried over magnesium sulfate,filtered, and concentrated. The residue was chromatographed via ISCO toyield 4-(6-chloro-4-iodopyridin-2-yl)morpholine as a light brown solid(63%). LCMS (m/z) (M+H)=324.9/326.8, Rt=0.98 min.

Synthesis ofN-(3-(2-chloro-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

To a solution of 4-(6-chloro-4-iodopyridin-2-yl)morpholine (1.0 equiv.)and Intermediate A (1.2 equiv.) in DME and 2M sodium carbonate (3:1,0.08 M) was added PdCl₂(dppf)-DCM adduct (0.1 equiv.) in a vial equippedwith a stir bar. The reaction was heated to 80° C. for 18 hours. Thereaction was quenched with water and extracted with ethyl acetate. Thecombined organic phase was dried with sodium sulfate, filtered andconcentrated. The residue was chromatographed via ISCO to yieldN-(3-(2-chloro-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamideas a light brown solid (>100%, 90% purity by UV). LCMS (m/z)(M+H)=476.0, Rt=1.16 min.

Example 113:N-(4-methyl-3-(2-(1-methyl-1H-pyrazol-4-yl)-6-morpholinopyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

To a solution ofN-(3-(2-chloro-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.), 1-methyl-4-pyrazole-1H-boronic acid pinacol ester (2.0equiv.), potassium fluoride (3.0 equiv.), and P(t-Bu)₃ (0.1 equiv./1.0 Min PhMe) in THF and water (1:1, 0.12 M) was added Pd₂(dba)₃ (0.1 equiv.)in a nitrogen purged microwave vial equipped with a stir bar. Thereaction was heated to 80° C. for 2 hours. The reaction was quenchedwith water and extracted with ethyl acetate. The combined organic phasewas dried with sodium sulfate, filtered and concentrated. The crudematerial was purified via preparative reverse phase HPLC. Uponlyophilization of the pure fractions,N-(4-methyl-3-(2-(1-methyl-1H-pyrazol-4-yl)-6-morpholinopyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 6% yield. 1H NMR (400 MHz, <cd3od>) δppm 2.33 (s, 3H) 3.64-3.69 (m, 4H) 3.82-3.88 (m, 4H) 3.96 (s, 3H) 6.79(s, 1H) 7.08 (s, 1H) 7.35 (d, J=8.61 Hz, 1H) 7.62 (dd, J=8.41, 2.15 Hz,1H) 7.70-7.77 (m, 2H) 7.90 (d, J=7.83 Hz, 1H) 8.04 (s, 1H) 8.18-8.24 (m,2H) 8.26 (s, 1H). LCMS (m/z) (M+H)=522.1, Rt=0.89 min.

Synthesis of3-(2-(3,6-dihydro-2H-pyran-4-yl)-6-morpholinopyridin-4-yl)-4-methylaniline

Step 1

To a solution of 3-(2-chloro-6-morpholinopyridin-4-yl)-4-methylaniline(1.0 equiv.) and2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1.2 equiv.) in DME and 2M sodium carbonate (3:1, 0.1 M) was addedPdCl2(dppf)-DCM adduct (0.1 equiv.). The solution was heated to 100 Cfor 5 hours. Upon cooling to room temperature, the solution waspartitioned between water and ethyl acetate, the organic phase was driedwith sodium sulfate, filtered and concentrated. The crude material waspurified via silica gel column chromatography eluting with 0-50% ethylacetate and heptanes). The pure fractions were concentrated to yield3-(2-(3,6-dihydro-2H-pyran-4-yl)-6-morpholinopyridin-4-yl)-4-methylanilinein 69% yield. LCMS (m/z) (M+H)=352.3, Rt=0.50 min.

Step 2

To a solution of3-(2-(3,6-dihydro-2H-pyran-4-yl)-6-morpholinopyridin-4-yl)-4-methylaniline(1.0 equiv.) in degassed ethanol (0.09 M) was added Pd/C (0.1 equiv.)and the solution was stirred under a hydrogen balloon for 1 h. Uponcompletion, the solution was filtered through Celite, and the filtratewas concentrated to dryness to give4-methyl-3-(2-morpholino-6-(tetrahydro-2H-pyran-4-yl)pyridin-4-yl)anilineas desired product in 87% yield. LCMS (m/z) (M+H)=354.3, Rt=0.42 min.

Example 114:3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-morpholino-6-(tetrahydro-2H-pyran-4-yl)pyridin-4-yl) phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.79 (s, 6H) 1.85-1.96 (m, 4H) 2.31 (s,3H) 3.05-3.17 (m, 1H) 3.48-3.62 (m, 2H) 3.66-3.76 (m, 4H) 3.82-3.92 (m,4H) 4.07 (d, J=11.35 Hz, 2H) 6.89 (s, 1H) 7.06 (s, 1H) 7.36 (d, J=8.22Hz, 1H) 7.54-7.64 (m, 2H) 7.77 (d, J=5.09 Hz, 2H) 7.91 (d, J=7.83 Hz,1H) 8.09 (s, 1H). LCMS (m/z) (M+H)=525.3, Rt=0.82 min.

Synthesis ofN-(3-(2,6-difluoropyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

To a solution of (2,6-difluoropyridin-4-yl)boronic acid (1.5 equiv.) andIntermediate X (1.0 equiv.) in DME and 2M sodium carbonate (3:1, 0.2 M)was added PdCl₂(dppf)-DCM adduct (0.1 equiv.) in a vial equipped with astir bar. The reaction was heated to 80° C. for 18 hours. The reactionwas quenched with water and extracted with ethyl acetate. The combinedorganic phase was dried with sodium sulfate, filtered and concentrated.The residue was chromatographed via ISCO to yieldN-(3-(2,6-difluoropyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamideas a light brown solid (37%). LCMS (m/z) (M+H)=393.0, Rt=1.09 min.

Synthesis ofN-(3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

To a solution of triethylamine (3.0 equiv.) andN-(3-(2,6-difluoropyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) at RT in MeOH (0.12 M) was added morpholine (2.0 equiv) inone portion, the resulting mixture was then heated at 55° C. for 8hours. LCMS analysis indicated 90% conversion to the desired product(M+H=460.1, Rt=0.43 min/non-polar). Water was then added, and themixture was extracted with ethyl acetate, and the combined extracts werewashed with brine, dried over magnesium sulfate, filtered, andconcentrated to yieldN-(3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamideas a light brown solid (>100%). LCMS (m/z) (M+H)=460.1, Rt=0.43min/non-polar.

Example 115:N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

In a nitrogen purged microwave vial equipped with a stir barN-(3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.), in ethanolamine (276 equiv.) was heated to 180° C. for 15minutes. The reaction was quenched with water and extracted with ethylacetate. The combined organic phase was dried with sodium sulfate,filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 27% yield. ¹H NMR (400 MHz, <cd3od>) δppm 2.23 (s, 3H) 3.35-3.50 (m, 6H) 3.63-3.81 (m, 6H) 6.08-6.18 (m, 1H)7.24 (d, J=8.22 Hz, 1H) 7.47 (dd, J=8.22, 2.35 Hz, 1H) 7.59-7.71 (m, 2H)7.80 (d, J=7.83 Hz, 1H) 8.10 (d, J=7.83 Hz, 1H) 8.16 (s, 1H). LCMS (m/z)(M+H)=501.1, Rt=0.80 min.

Synthesis of 5-bromo-1-ethyl-3-(trifluoromethyl)pyridin-2(1H)-one

In a round bottom flask equipped with a stir bar and purged withnitrogen was added 5-bromo-3-(trifluoromethyl)pyridin-2-ol (1.0 equiv.),potassium carbonate (2.0 equiv.) and DMF (0.2 M). The mixture wasstirred at room temperature and iodoethane (1.2 equiv.) was added viasyringe. The mixture was warmed to 35° C. for 4 hours at which time LCMSindicated full conversion. The reaction was worked up by partitioningbetween water and ethyl acetate, the aqueous phase was extracted 3 moretimes with ethyl acetate, the organics were combined, washed with brine,dried with sodium sulfate, filtered and concentrated to yield5-bromo-1-ethyl-3-(trifluoromethyl)pyridin-2(1H)-one (67%). ¹H NMR (400MHz, <cdcl3>) δ ppm 1.32-1.50 (m, 3H) 4.04 (q, J=7.17 Hz, 2H) 7.63 (br.s., 1H) 7.78 (br. s., 1H). LCMS (m/z) (M+H)=269.1/271.1, Rt=0.72 min

Example 116:1-ethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

In a microwave tube was added5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.), 5-bromo-1-ethyl-3-(trifluoromethyl)pyridin-2(1H)-one (2.0equiv.), PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.), Mo(CO)6 (1.0 equiv.),and THF (0.3 M). The mixture was capped and stirred while DBU (3.0equiv.) was added, fizzing occured and the tube was subsequently heatedin the microwave at 150° C. for 15 min at which time LCMS indicated fullconversion to product (M+H=517). The reaction was filtered,concentrated, and purified via preparative HPLC to yield1-ethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide(15% yield). ¹H NMR (400 MHz, <cd3od>) δ ppm 1.42 (t, J=7.24 Hz, 3H)2.30 (s, 3H) 3.08-3.21 (m, 4H) 3.64 (s, 3H) 3.80-3.92 (m, 4H) 4.16 (q,J=7.04 Hz, 2H) 6.93 (d, J=1.96 Hz, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.34 (d,J=1.96 Hz, 1H) 7.47-7.60 (m, 2H) 8.48 (d, J=1.96 Hz, 1H) 8.70 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=517.1, Rt=0.81 min.

Example 117: Synthesis ofN-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

To a solution of 5-bromo-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.) and Intermediate A (1.2 equiv.) in DME and 2M sodium carbonate(3:1, 0.08 M) was added PdCl₂(dppf)-DCM adduct (0.1 equiv.) in amicrowave vial equipped with a stir bar. The reaction was heated to 120°C. for 10 min in the microwave. The organic phase was dried with sodiumsulfate, filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 11% yield. LCMS (m/z) (M+H)=472.2,Rt=0.87 min. ¹H NMR (400 MHz, <cd3od>) δ ppm 2.30 (s, 3H) 3.13-3.21 (m,4H) 3.64 (s, 3H) 3.81-3.92 (m, 4H) 7.01 (d, J=2.35 Hz, 1H) 7.29 (d,J=8.61 Hz, 1H) 7.39 (d, J=2.35 Hz, 1H) 7.57 (dd, J=8.22, 1.96 Hz, 1H)7.62 (d, J=1.96 Hz, 1H) 7.69-7.77 (m, 1H) 7.89 (d, J=7.83 Hz, 1H) 8.19(d, J=7.43 Hz, 1H) 8.25 (s, 1H).

The compounds listed below were prepared by methods similar to thosedescribed for the preparation of Example 117 using the correspondingaryl halide and intermediates (A-G).

Example 118:N-(4-methyl-3-(6-morpholinopyrazin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 2.40 (s, 3H) 3.60-3.73 (m, 4H) 3.75-3.88(m, 4H) 7.33 (d, J=8.22 Hz, 1H) 7.59-7.78 (m, 2H) 7.81-7.96 (m, 2H) 8.02(s, 1H) 8.14-8.40 (m, 3H). LCMS (m/z) (M+H)=443.2, Rt=0.93 min.

Example 119:N-(4-methyl-3-(4-methyl-6-morpholino-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 2.39 (s, 3H) 3.56 (s, 3H) 3.80 (s, 9H)7.18 (s, 1H) 7.26 (d, J=8.22 Hz, 1H) 7.56 (dd, J=8.22, 2.35 Hz, 1H)7.67-7.80 (m, 2H) 7.89 (d, J=7.83 Hz, 1H) 8.20 (d, J=7.83 Hz, 1H) 8.25(s, 1H). LCMS (m/z) (M+H)=473.1, Rt=0.92 min.

Example 120: N-(4-methyl-3-(6-morpholino-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.29 (s, 3H) 3.72 (d, J=4.70 Hz, 9H)6.85 (s, 1H) 7.16 (d, J=8.22 Hz, 1H) 7.47 (dd, J=8.22, 2.35 Hz, 1H)7.58-7.69 (m, 2H) 7.79 (d, J=7.83 Hz, 1H) 8.05-8.20 (m, 1H). LCMS (m/z)(M+H)=459.3, Rt=0.86 min.

Example 121: N-(6-methyl-5-(6-morpholino-5-oxo-4,5-dihydropyrazin-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 2.71 (s, 3H) 3.59-3.91 (m, 9H) 7.11 (s,1H) 7.69 (t, J=7.83 Hz, 1H) 7.86 (d, J=7.83 Hz, 1H) 8.08-8.30 (m, 2H)8.54 (d, J=2.35 Hz, 1H) 9.11 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=460.2,Rt=0.66 min.

Example 122:N-(3-(2-methoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.11 (s, 3H) 3.21 (dd, J=5.48, 3.91 Hz,4H) 3.81-3.92 (m, 7H) 7.27 (d, J=8.22 Hz, 1H) 7.45 (d, J=2.74 Hz, 1H)7.52-7.62 (m, 2H) 7.68-7.77 (m, 1H) 7.83-7.97 (m, 2H) 8.10-8.36 (m, 2H).LCMS (m/z) (M+H)=472.2, Rt=0.93 min.

Example 123:N-(4-methyl-3-(1-methyl-5-morpholino-2-oxo-1,2-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.17 (s, 3H) 2.87-3.06 (m, 4H) 3.63 (s,3H) 3.74-3.87 (m, 4H) 7.14-7.30 (m, 2H) 7.43-7.63 (m, 3H) 7.67-7.77 (m,1H) 7.88 (d, J=7.83 Hz, 1H) 8.12-8.28 (m, 1H). LCMS (m/z) (M+H)=472.3,Rt=0.80 min.

Example 124:N-(1′,2-dimethyl-5′-morpholino-2′-oxo-1′,2′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 2.61 (s, 3H) 2.92-3.08 (m, 4H) 3.67 (s,3H) 3.77-3.92 (m, 4H) 7.42 (d, J=3.13 Hz, 1H) 7.68-7.83 (m, 2H) 7.96 (d,J=7.83 Hz, 1H) 8.17-8.37 (m, 2H) 8.47 (d, J=2.35 Hz, 1H) 9.37 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=473.2, Rt=0.63 min.

Example 125:N-(4-methyl-3-(5-morpholino-2-oxo-1,2-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.11 (s, 3H) 2.84-2.98 (m, 4H) 3.66-3.79(m, 4H) 6.93 (d, J=3.13 Hz, 1H) 7.18 (d, J=8.22 Hz, 1H) 7.39-7.55 (m,3H) 7.57-7.68 (m, 1H) 7.79 (d, J=7.43 Hz, 1H) 8.02-8.22 (m, 1H). LCMS(m/z) (M+H)=458.2, Rt=0.78 min.

Example 126:N-(3-(6-methoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.27 (s, 3H) 3.04-3.22 (m, 4H) 3.81-3.93(m, 4H) 4.04 (s, 3H) 7.27-7.34 (m, 2H) 7.61 (dd, J=4.11, 2.15 Hz, 2H)7.68-7.76 (m, 1H) 7.80 (d, J=1.96 Hz, 1H) 7.88 (d, J=7.83 Hz, 1H) 8.20(d, J=7.83 Hz, 1H) 8.25 (s, 1H).

LCMS (m/z) (M+H)=472.4, Rt=1.04 min.

Example 127:N-(6′-methoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.67 (s, 3H) 3.09-3.18 (m, 4H) 3.80-3.91(m, 4H) 4.05 (s, 3H) 7.31 (d, J=1.96 Hz, 1H) 7.78 (t, J=7.83 Hz, 1H)7.88 (d, J=1.96 Hz, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.28 (d, J=8.22 Hz, 1H)8.34 (s, 1H) 8.43 (d, J=2.35 Hz, 1H) 9.32 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=473.3, Rt=0.72 min.

Example 128:2-(2-cyanopropan-2-yl)-N-(3-(6-methoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) 5 ppm 1.81 (s, 6H) 2.27 (s, 3H) 3.09-3.17 (m,4H) 3.81-3.89 (m, 4H) 4.02 (s, 3H) 7.24 (d, J=1.96 Hz, 1H) 7.32 (d,J=8.22 Hz, 1H) 7.60 (d, J=1.96 Hz, 1H) 7.63 (dd, J=8.22, 2.35 Hz, 1H)7.76 (d, J=1.96 Hz, 1H) 7.81 (dd, J=4.89, 1.37 Hz, 1H) 8.06 (s, 1H) 8.75(d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=472.4, Rt=0.87 min.

Example 129:2-(2-cyanopropan-2-yl)-N-(6′-methoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) ppm 1.82 (s, 6H) 2.69 (s, 3H) 3.07-3.21 (m,4H) 3.78-3.92 (m, 4H) 4.05 (s, 3H) 7.31 (d, J=1.96 Hz, 1H) 7.82-7.94 (m,2H) 8.14 (s, 1H) 8.45 (d, J=2.35 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 9.34(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=473.3, Rt=0.62 min.

Example 130:N-(2-methyl-5′-morpholino-6′-oxo-1′-(tetrahydro-2H-pyran-4-yl)-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.87 (dd, J=11.98, 2.15 Hz, 2H) 2.01(qd, J=12.22, 4.52 Hz, 2H) 3.09-3.21 (m, 4H) 3.62 (td, J=11.77, 1.83 Hz,2H) 3.79-3.91 (m, 4H) 4.10 (dd, J=11.27, 4.33 Hz, 2H) 5.19 (tt, J=12.06,4.00 Hz, 1H) 6.94 (d, J=2.25 Hz, 1H) 7.55 (d, J=2.30 Hz, 1H) 7.74-7.83(m, 1H) 7.96 (dd, J=7.87, 0.68 Hz, 1H) 8.27 (d, J=7.92 Hz, 1H) 8.34 (d,J=0.64 Hz, 1H) 8.40 (d, J=2.40 Hz, 1H) 9.22 (d, J=2.40 Hz, 1H). LCMS(m/z) (M+H)=543.1, Rt=0.70 min.

Example 131:N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.77-1.91 (m, 2H) 2.06-2.20 (m, 2H) 2.71(s, 3H) 3.12-3.22 (m, 4H) 3.67 (ddd, J=11.59, 8.22, 3.28 Hz, 2H)3.81-3.91 (m, 4H) 3.92-4.03 (m, 2H) 5.45 (tt, J=7.92, 3.91 Hz, 1H) 7.33(d, J=2.20 Hz, 1H) 7.74-7.82 (m, 1H) 7.87 (d, J=2.15 Hz, 1H) 7.93-8.00(m, 1H) 8.29 (d, J=7.87 Hz, 1H) 8.35 (d, J=1.22 Hz, 1H) 8.50 (d, J=2.30Hz, 1H) 9.40 (d, J=2.40 Hz, 1H). LCMS (m/z) (M+H)=543.1, Rt=0.80 min.

Example 132:N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) b 1.84 (dtd, J=12.67, 8.34, 8.34, 3.91 Hz, 2H)2.03-2.20 (m, 2H) 2.27 (s, 3H) 3.06-3.22 (m, 4H) 3.67 (ddd, J=11.64,8.31, 3.13 Hz, 2H) 3.78-3.91 (m, 4H) 3.92-4.04 (m, 2H) 5.39 (tt, J=7.83,3.91 Hz, 1H) 7.24 (d, J=1.96 Hz, 1H) 7.30 (d, J=7.83 Hz, 1H) 7.56-7.66(m, 2H) 7.68-7.78 (m, 2H) 7.88 (d, J=7.83 Hz, 1H) 8.20 (d, J=7.83 Hz,1H) 8.25 (s, 1H). LCMS (m/z) (M+H)=542.1, Rt=1.06 min.

Example 133:N-(1′-isopropyl-2-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (d, J=6.80 Hz, 6H) 2.70 (s, 3H)3.12-3.23 (m, 4H) 3.81-3.95 (m, 4H) 5.35 (quin, J=6.87 Hz, 1H) 6.95 (d,J=2.15 Hz, 1H) 7.56 (d, J=2.10 Hz, 1H) 7.80 (t, J=7.73 Hz, 1H) 7.98 (d,J=7.19 Hz, 1H) 8.30 (d, J=7.87 Hz, 1H) 8.36 (s, 1H) 8.41 (d, J=2.35 Hz,1H) 9.26 (d, J=2.20 Hz, 1H). LCMS (m/z) (M+H)=501.3, Rt=0.78 min.

Example 134:N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.16 Hz, 6H) 2.69 (s, 3H)3.12-3.22 (m, 4H) 3.82-3.92 (m, 4H) 5.47 (quin, J=6.17 Hz, 1H) 7.30 (d,J=2.10 Hz, 1H) 7.76-7.84 (m, 1H) 7.87 (d, J=2.01 Hz, 1H) 7.98 (d, J=7.87Hz, 1H) 8.30 (d, J=7.68 Hz, 1H) 8.36 (s, 1H) 8.43 (d, J=2.35 Hz, 1H)9.31 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=501.3, Rt=0.90 min.

Example 135:N-(3-(1-isopropyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.44 (d, J=6.80 Hz, 6H) 2.32 (s, 3H)3.12-3.23 (m, 4H) 3.84-3.93 (m, 4H) 5.35 (quin, J=6.86 Hz, 1H) 6.98 (d,J=2.10 Hz, 1H) 7.32 (d, J=8.02 Hz, 1H) 7.39 (d, J=2.10 Hz, 1H) 7.58-7.66(m, 2H) 7.71-7.79 (m, 1H) 7.91 (d, J=7.92 Hz, 1H) 8.23 (d, J=7.92 Hz,1H) 8.28 (s, 1H). LCMS (m/z) (M+H)=500.3, Rt=1.02 min.

Example 136:N-(3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.16 Hz, 6H) 2.29 (s, 3H)3.15-3.25 (m, 4H) 3.83-3.94 (m, 4H) 5.42 (spt, J=6.18 Hz, 1H) 7.27-7.35(m, 2H) 7.59-7.66 (m, 2H) 7.70-7.77 (m, 1H) 7.79 (d, J=1.86 Hz, 1H) 7.90(d, J=7.87 Hz, 1H) 8.22 (d, J=7.68 Hz, 1H) 8.27 (s, 1H). LCMS (m/z)(M+H)=500.4, Rt=1.17 min.

Example 137:4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.42 (s, 3H) 3.12-3.22 (m, 4H) 3.67 (s,3H) 3.83-3.94 (m, 4H) 6.99 (d, J=2.25 Hz, 1H) 7.42 (d, J=2.25 Hz, 1H)7.43-7.50 (m, 2H) 7.57 (t, J=8.02 Hz, 1H) 7.85 (d, J=2.01 Hz, 1H) 7.89(dd, J=7.92, 2.01 Hz, 1H) 7.95 (d, J=8.22 Hz, 1H) 8.17 (s, 1H). LCMS(m/z) (M+H)=472.1, Rt=0.91 min.

Example 138:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.71 (s, 3H) 3.12-3.21 (m, 4H) 3.65 (s,3H) 3.82-3.90 (m, 4H) 6.96 (d, J=2.35 Hz, 1H) 7.53 (d, J=1.96 Hz, 1H)7.74-7.83 (m, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.28 (d, J=7.83 Hz, 1H) 8.34(s, 1H) 8.45 (d, J=2.35 Hz, 1H) 9.27 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=473.3, Rt=0.64 min.

Example 139:2-(tert-butyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.50 (s, 9H) 2.31 (s, 3H) 3.08-3.19 (m,4H) 3.64 (s, 3H) 3.79-3.94 (m, 4H) 6.93 (d, J=1.96 Hz, 1H) 7.24-7.38 (m,2H) 7.57-7.71 (m, 2H) 7.98 (d, J=5.48 Hz, 1H) 8.20 (s, 1H) 8.76 (d,J=5.87 Hz, 1H). LCMS (m/z) (M+H)=461.4, Rt=0.66 min.

Example 140:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.31 (s, 3H) 3.10-3.23 (m,4H) 3.64 (s, 3H) 3.82-3.95 (m, 4H) 7.01 (d, J=1.96 Hz, 1H) 7.30 (d,J=8.22 Hz, 1H) 7.40 (d, J=1.96 Hz, 1H) 7.58 (dd, J=8.22, 2.35 Hz, 1H)7.63 (d, J=1.96 Hz, 1H) 7.80 (dd, J=5.09, 1.17 Hz, 1H) 8.06 (s, 1H) 8.76(d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=472.2, Rt=0.73 min.

Example 141:2-(2-cyanopropan-2-yl)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.78-1.86 (m, 6H) 2.70 (s, 3H) 3.16 (br.s., 4H) 3.65 (s, 3H) 3.85 (br. s., 4H) 6.90-6.99 (m, 1H) 7.49-7.56 (m,1H) 7.82-7.89 (m, 1H) 8.09-8.16 (m, 1H) 8.38-8.45 (m, 1H) 8.78-8.85 (m,1H) 9.20-9.26 (m, 1H). LCMS (m/z) (M+H)=473.2, Rt=0.54 min.

Example 142:N-(3-(1-(2-hydroxyethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) β ppm 2.31 (s, 3H) 3.13 (d, J=3.91 Hz, 4H)3.80-3.95 (m, 6H) 4.17 (t, J=5.28 Hz, 2H) 6.93 (d, J=1.96 Hz, 1H)7.26-7.33 (m, 2H) 7.54-7.63 (m, 2H) 7.72 (t, J=7.83 Hz, 1H) 7.89 (d,J=7.83 Hz, 1H) 8.20 (d, J=8.22 Hz, 1H) 8.25 (s, 1H). LCMS (m/z)(M+H)=502.2, Rt=0.78 min.

Example 143:2-(2-cyanopropan-2-yl)-N-(3-(1-(2-hydroxyethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.80 (s, 6H) 2.32 (s, 3H) 2.97-3.18 (m,4H) 3.74-3.94 (m, 7H) 4.17 (t, J=5.28 Hz, 2H) 6.98 (d, J=2.35 Hz, 1H)7.24-7.42 (m, 2H) 7.54-7.65 (m, 2H) 7.80 (dd, J=5.09, 1.17 Hz, 1H) 8.06(s, 1H) 8.75 (d, J=5.09 Hz, 1H).

LCMS (m/z) (M+H)=502.2, Rt=0.71 min.

Example 144:N-(1′-(2-hydroxyethyl)-2-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.72 (s, 3H) 3.07-3.20 (m, 4H) 3.80-3.99(m, 6H) 4.19 (t, J=5.09 Hz, 2H) 6.98 (d, J=2.35 Hz, 1H) 7.50 (d, J=2.35Hz, 1H) 7.78 (t, J=7.83 Hz, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.28 (d, J=7.83Hz, 1H) 8.34 (s, 1H) 8.47 (d, J=2.35 Hz, 1H) 9.30 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=503.2, Rt=0.63 min.

Example 145:N-(6′-(2-hydroxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.67 (s, 3H) 3.12-3.22 (m, 4H) 3.80-3.89(m, 4H) 3.91-3.99 (m, 2H) 4.47-4.58 (m, 2H) 7.32 (d, J=1.96 Hz, 1H)7.68-7.82 (m, 1H) 7.85 (d, J=1.96 Hz, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.28(d, J=7.83 Hz, 1H) 8.34 (s, 1H) 8.42 (d, J=1.96 Hz, 1H) 9.30 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=503.2, Rt=0.67 min.

Example 146:N-(4-methyl-3-(5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.20 (s, 3H) 2.98-3.12 (m, 4H) 3.67-3.84(m, 4H) 6.89 (d, J=1.96 Hz, 1H) 6.99 (d, J=1.96 Hz, 1H) 7.20 (d, J=8.22Hz, 1H) 7.45-7.54 (m, 2H) 7.59-7.67 (m, 1H) 7.79 (d, J=7.83 Hz, 1H) 8.10(d, J=7.83 Hz, 1H) 8.16 (s, 1H). LCMS (m/z) (M+H)=458.3, Rt=0.82 min.

Example 147:N-(3-(1-(cyanomethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.11-3.22 (m, 4H) 3.80-3.89(m, 4H) 5.05 (s, 2H) 6.93 (d, J=1.96 Hz, 1H) 7.30 (d, J=8.22 Hz, 1H)7.39 (d, J=1.96 Hz, 1H) 7.59 (dd, J=8.22, 1.96 Hz, 1H) 7.64 (d, J=1.96Hz, 1H) 7.69-7.76 (m, 1H) 7.89 (d, J=7.83 Hz, 1H) 8.20 (d, J=7.83 Hz,1H) 8.25 (s, 1H). LCMS (m/z) (M+H)=497.3, Rt=0.95 min.

Example 148:(R)-N-(3-(1-(1-cyanoethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.72 (d, J=7.04 Hz, 6H) 2.25 (s, 6H) 3.11(br. s., 8H) 3.71 (br. s., 8H) 5.87 (q, J=7.04 Hz, 2H) 6.73 (d, J=1.17Hz, 2H) 7.28 (d, J=8.22 Hz, 2H) 7.43 (d, J=1.57 Hz, 2H) 7.63 (s, 2H)7.71 (d, J=8.22 Hz, 2H) 7.77 (t, J=7.83 Hz, 2H) 7.95 (d, J=7.43 Hz, 2H)8.21-8.32 (m, 5H) 10.45 (s, 1H). LCMS (m/z) (M+H)=511.2, Rt=1.00 min.

Example 149:(S)-N-(3-(1-(1-cyanoethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.80 (d, J=7.43 Hz, 3H) 2.33 (s, 3H) 3.20(br. s., 4H) 3.78 (d, J=4.30 Hz, 4H) 5.95 (q, J=7.04 Hz, 1H) 6.81 (d,J=1.56 Hz, 1H) 7.36 (d, J=8.22 Hz, 1H) 7.51 (d, J=1.57 Hz, 1H) 7.71 (d,J=1.96 Hz, 1H) 7.79 (dd, J=8.22, 1.96 Hz, 1H) 7.83-7.90 (m, 1H) 8.04 (d,J=7.83 Hz, 1H) 8.28-8.44 (m, 2H) 10.53 (s, 1H). LCMS (m/z) (M+H)=511.3,Rt=1.01 min.

Example 150:N-(4-methyl-3-(1-(2-(methylsulfonyl)ethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.02 (s, 3H) 3.14-3.24 (m,4H) 3.67 (t, J=6.46 Hz, 2H) 3.83-3.90 (m, 4H) 4.50 (t, J=6.46 Hz, 2H)6.99 (d, J=1.96 Hz, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.42 (d, J=1.96 Hz, 1H)7.57 (dd, J=8.22, 1.96 Hz, 1H) 7.61 (s, 1H) 7.69-7.76 (m, 1H) 7.89 (d,J=7.43 Hz, 1H) 8.20 (d, J=7.83 Hz, 1H) 8.25 (s, 1H). LCMS (m/z)(M+H)=564.3, Rt=0.90 min.

Example 151:N-(2-methyl-1′-(2-(methylsulfonyl)ethyl)-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.71 (s, 3H) 3.04 (s, 3H) 3.12-3.22 (m,4H) 3.70 (t, J=6.06 Hz, 2H) 3.80-3.95 (m, 4H) 4.53 (t, J=6.06 Hz, 2H)6.94 (d, J=1.96 Hz, 1H) 7.56 (d, J=1.96 Hz, 1H) 7.78 (t, J=8.02 Hz, 1H)7.96 (d, J=7.43 Hz, 1H) 8.27 (d, J=7.43 Hz, 1H) 8.33 (s, 1H) 8.44 (d,J=2.35 Hz, 1H) 9.28 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=565.2, Rt=0.68min.

Example 152:(S)-N-(3-(6-(1-cyanoethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.73 (d, J=7.04 Hz, 3H) 2.22 (s, 3H) 3.06(d, J=5.09 Hz, 4H) 3.74 (t, J=4.50 Hz, 4H) 5.78 (q, J=6.91 Hz, 1H) 7.26(d, J=1.57 Hz, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.65 (d, J=1.57 Hz, 1H)7.70-7.82 (m, 3H) 7.95 (d, J=7.83 Hz, 1H) 8.22-8.30 (m, 2H) 10.44 (s,1H). LCMS (m/z) (M+H)=511.5, Rt=1.13 min.

Example 153:(R)-N-(3-(6-(1-cyanoethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) ppm 1.73 (d, J=7.04 Hz, 3H) 2.22 (s, 3H) 3.06(d, J=5.09 Hz, 4H) 3.74 (t, J=4.50 Hz, 4H) 5.78 (q, J=6.65 Hz, 1H) 7.26(d, J=1.57 Hz, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.65 (d, J=1.96 Hz, 1H)7.69-7.83 (m, 3H) 7.95 (d, J=7.83 Hz, 1H) 8.19-8.32 (m, 2H) 10.44 (s,1H). LCMS (m/z) (M+H)=511.2, Rt=1.00 min.

Example 154:4-methyl-3-(1-(2-(methylsulfonyl)ethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.40 (s, 3H) 3.03 (s, 3H) 3.10-3.22 (m,4H) 3.68 (t, J=6.46 Hz, 2H) 3.81-3.92 (m, 4H) 4.51 (t, J=6.46 Hz, 2H)7.00 (d, J=1.96 Hz, 1H) 7.36-7.48 (m, 2H) 7.54 (t, J=8.02 Hz, 1H)7.81-7.88 (m, 2H) 7.93 (d, J=8.22 Hz, 1H) 8.15 (s, 1H). LCMS (m/z)(M+H)=564.3, Rt=0.93 min.

Example 155:N-(3-(1-ethyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.38 (t, J=7.04 Hz, 3H) 2.31 (s, 3H)3.11-3.21 (m, 4H) 3.82-3.91 (m, 4H) 4.11 (q, J=7.30 Hz, 2H) 6.96 (d,J=1.96 Hz, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.38 (d, J=1.96 Hz, 1H) 7.58 (d,J=8.22 Hz, 1H) 7.62 (s, 1H) 7.69-7.76 (m, 1H) 7.89 (d, J=7.83 Hz, 1H)8.20 (d, J=7.83 Hz, 1H) 8.25 (s, 1H). LCMS (m/z) (M+H)=486.2, Rt=0.95min.

Example 156:N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 2.27 (s, 3H)3.12-3.23 (m, 4H) 3.81-3.96 (m, 4H) 4.47 (q, J=7.04 Hz, 2H) 7.24-7.33(m, 2H) 7.57-7.64 (m, 2H) 7.69-7.75 (m, 1H) 7.76 (d, J=1.96 Hz, 1H) 7.88(d, J=7.83 Hz, 1H) 8.20 (d, J=7.83 Hz, 1H) 8.25 (s, 1H). LCMS (m/z)(M+H)=486.3, Rt=1.09 min.

Example 157:N-(1′-ethyl-2-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.39 (t, J=7.24 Hz, 3H) 2.72 (s, 3H)3.07-3.21 (m, 4H) 3.76-3.89 (m, 4H) 4.13 (q, J=7.30 Hz, 2H) 6.95 (d,J=1.96 Hz, 1H) 7.55 (d, J=2.35 Hz, 1H) 7.74-7.83 (m, 1H) 7.97 (d, J=7.83Hz, 1H) 8.28 (d, J=7.83 Hz, 1H) 8.34 (s, 1H) 8.46 (d, J=2.35 Hz, 1H)9.30 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=487.2, Rt=0.70 min.

Example 158:N-(3-(1-ethyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.29 (t, J=7.24 Hz, 3H) 2.22 (s, 3H)3.03-3.13 (m, 4H) 3.71-3.82 (m, 4H) 4.03 (q, J=7.04 Hz, 2H) 6.93 (d,J=1.96 Hz, 1H) 7.22 (d, J=8.22 Hz, 1H) 7.32 (d, J=1.96 Hz, 1H) 7.51 (dd,J=8.22, 2.35 Hz, 1H) 7.56 (d, J=2.35 Hz, 1H) 8.02 (d, J=5.09 Hz, 1H)8.20 (s, 1H) 8.81 (d, J=4.69 Hz, 1H). LCMS (m/z) (M+H)=487.2, Rt=0.89min.

Example 159:N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 2.27 (s, 3H)3.01-3.22 (m, 4H) 3.75-3.99 (m, 4H) 4.47 (q, J=7.04 Hz, 2H) 7.25 (d,J=1.96 Hz, 1H) 7.32 (d, J=8.22 Hz, 1H) 7.50-7.67 (m, 2H) 7.74 (d, J=1.96Hz, 1H) 8.12 (d, J=5.09 Hz, 1H) 8.29 (s, 1H) 8.90 (d, J=5.09 Hz, 1H).LCMS (m/z) (M+H)=487.2, Rt=1.03 min.

Example 160:2-(2-cyanopropan-2-yl)-N-(3-(1-ethyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.38 (t, J=7.04 Hz, 3H) 1.81 (s, 6H)2.31 (s, 3H) 3.20 (d, J=3.91 Hz, 4H) 3.80-3.94 (m, 4H) 4.12 (q, J=7.04Hz, 2H) 7.02 (d, J=1.96 Hz, 1H) 7.31 (d, J=8.61 Hz, 1H) 7.41 (d, J=1.96Hz, 1H) 7.59 (d, J=8.22 Hz, 1H) 7.63 (s, 1H) 7.81 (d, J=4.70 Hz, 1H)8.06 (s, 1H) 8.76 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=486.3, Rt=0.79min.

Example 161:2-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.46 (t, J=7.04 Hz, 3H) 1.81 (s, 6H)2.27 (s, 3H) 3.12-3.25 (m, 4H) 3.75-3.94 (m, 4H) 4.49 (q, J=7.04 Hz, 2H)7.24-7.36 (m, 2H) 7.47-7.67 (m, 2H) 7.75-7.90 (m, 2H) 8.06 (s, 1H) 8.75(d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=486.3, Rt=0.93 min.

Example 162:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.30 (s, 3H) 3.05 (d, J=3.91 Hz, 4H)3.66 (s, 3H) 3.82-3.91 (m, 4H) 6.13 (d, J=0.78 Hz, 1H) 6.31 (s, 1H) 7.31(d, J=9.00 Hz, 1H) 7.61-7.67 (m, 2H) 7.72 (t, J=7.83 Hz, 1H) 7.89 (d,J=7.83 Hz, 1H) 8.20 (d, J=7.83 Hz, 1H) 8.25 (s, 1H). LCMS (m/z)(M+H)=472.3, Rt=0.96 min.

Example 163:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.64 (s, 3H) 2.99-3.11 (m, 4H) 3.65 (s,3H) 3.80-3.96 (m, 4H) 6.12 (d, J=1.57 Hz, 1H) 6.35 (d, J=1.56 Hz, 1H)7.73-7.81 (m, 1H) 7.95 (d, J=7.83 Hz, 1H) 8.26 (d, J=7.83 Hz, 1H) 8.33(s, 1H) 8.36 (d, J=2.35 Hz, 1H) 9.21 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=473.2, Rt=0.69 min.

Example 164:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.29 (s, 3H) 3.37-3.51 (m, 4H) 3.67 (s,3H) 3.68-3.77 (m, 5H) 6.59 (s, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.69-7.83 (m,3H) 7.95 (d, J=7.83 Hz, 1H) 8.21-8.27 (m, 1H) 8.29 (s, 1H) 10.47 (s,1H). LCMS (m/z) (M+H)=473.1, Rt=0.94 min.

Example 165:4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.34 (s, 3H) 3.26 (br. s., 12H) 3.43 (br.s., 4H) 3.64 (br. s., 7H) 6.62 (s, 1H) 7.32-7.46 (m, 3H) 7.48-7.59 (m,2H) 7.89 (d, J=8.22 Hz, 1H) 7.92 (s, 1H) 8.00 (d, J=7.83 Hz, 1H) 8.18(s, 1H) 10.46 (s, 1H). LCMS (m/z) (M+H)=473.1, Rt=1.00 min.

Example 166:N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.56 (s, 3H) 3.40-3.54 (m, 4H) 3.62-3.77(m, 8H) 6.72 (s, 1H) 7.75-7.87 (m, 1H) 8.00 (d, J=7.83 Hz, 1H) 8.25-8.31(m, 2H) 8.33 (s, 1H) 8.99 (d, J=2.35 Hz, 1H) 10.84 (s, 1H). LCMS (m/z)(M+H)=474.3, Rt=0.72 min.

Example 167:2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.76 (s, 6H) 2.54 (s, 3H) 3.39-3.53 (m,4H) 3.65-3.75 (m, 7H) 6.71 (s, 1H) 7.81-7.92 (m, 1H) 8.04 (s, 1H) 8.22(d, J=2.35 Hz, 1H) 8.83 (d, J=5.09 Hz, 1H) 8.94 (d, J=1.96 Hz, 1H) 10.90(s, 1H). LCMS (m/z) (M+H)=474.2, Rt=0.68 min.

Example 168:2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.29 (s, 3H) 3.43-3.52 (m, 8H) 3.67 (s,3H) 3.68-3.76 (m, 4H) 6.59 (s, 1H) 7.31 (d, J=8.22 Hz, 1H) 7.69-7.79 (m,2H) 8.18 (d, J=4.30 Hz, 1H) 8.36 (s, 1H) 8.98 (d, J=5.09 Hz, 1H) 10.69(s, 1H). LCMS (m/z) (M+H)=474.2, Rt=0.94 min.

The compounds listed below were prepared using methods similar to thosedescribed in Method 1 using the appropriate starting materials andpurified via preparative HPLC to yield the corresponding TFA salt uponlyophilization.

Example 169:N-(3-(4-ethyl-6-morpholino-5-oxo-4,5-dihydropyrazin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Method 1 was followed usingN-(4-methyl-3-(6-morpholino-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.), iodoethane (1.2 equiv.) and potassium carbonate (2.0equiv.) at room temperature. ¹H NMR (400 MHz, <cd3od>) b ppm 1.38 (t,J=7.24 Hz, 3H) 2.39 (s, 3H) 3.80 (s, 8H) 4.02 (q, J=7.30 Hz, 2H)7.02-7.31 (m, 2H) 7.57 (dd, J=8.22, 1.96 Hz, 1H) 7.65-7.81 (m, 2H) 7.89(d, J=7.83 Hz, 1H) 8.13-8.38 (m, 1H). LCMS (m/z) (M+H)=487.4, Rt=1.02min.

Example 170:N-(3-(4-(2,2-difluoroethyl)-6-morpholino-5-oxo-4,5-dihydropyrazin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Method 1 was followed usingN-(4-methyl-3-(6-morpholino-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.), 1,1-difluoro-2-iodoethane (1.2 equiv.) and potassiumcarbonate (2.0 equiv.) at 60° C. ¹H NMR (400 MHz, <cd3od>) δ ppm 2.39(s, 3H) 3.81 (d, J=5.09 Hz, 8H) 4.38 (td, J=14.09, 3.91 Hz, 2H)6.02-6.44 (m, 1H) 7.14 (s, 1H) 7.26 (d, J=8.22 Hz, 1H) 7.59 (dd, J=8.22,1.96 Hz, 1H) 7.67-7.79 (m, 2H) 7.89 (d, J=7.83 Hz, 1H) 8.16-8.34 (m,1H). LCMS (m/z) (M+H)=523.3, Rt=1.05 min.

Synthesis of5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one

To a solution of 5-bromo-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.2equiv.) in DME and 2M sodium carbonate (3:1, 0.14 M) was addedPdCl₂(dppf)-DCM adduct (0.1 equiv.) in a microwave vial equipped with astir bar. The reaction was heated to 120° C. for 15 min in themicrowave. The solution was partitioned between water and ethyl acetate,the organic phase was dried with sodium sulfate, filtered andconcentrated. The crude material was purified via silica gel columnchromatography eluting with 100% ethyl acetate followed by 10% methanolin ethyl acetate. The pure fractions were concentrated and dried undervacuo to afford5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one in 31%yield. LCMS (m/z) (M+H)=300.2, Rt=0.41 min.

Synthesis of5′-amino-1,2′-dimethyl-5-morpholino-[3,3′-bipyridin]-6(1H)-one

Step 1

To a 0.18 M solution of 5-bromo-1-methyl-3-morpholinopyridin-2(1H)-one(1.00 equiv.) in 1,4-dioxane was added bis(pinacolato)diboron (1.50equiv.), potassium acetate (2.00 equiv.), and PdCl₂(dppf).CH₂Cl₂ adduct(0.10 equiv.). The reaction was irradiated at 120° C. for 20 min. Thereaction was diluted with DCM (20 mL) and filtered. The filtrate wasconcentrated to give5′-amino-1,2′-dimethyl-5-morpholino-[3,3′-bipyridin]-6(1H)-one as amixture with the corresponding boronic acid as a dark brown tacky solidin quantitative yield. LCMS (m/z) (M+H)=321.0, Rt=0.65 min.

Step 2

To a 0.18 M solution of5′-amino-1,2′-dimethyl-5-morpholino-[3,3′-bipyridin]-6(1H)-one (1.00equiv.) in DME and 5-bromo-6-methylpyridin-3-amine (1.00 equiv.) wasadded PdCl₂(dppf).CH₂Cl₂ adduct (0.10 equiv.) and 2M aqueous sodiumcarbonate (3.00 equiv.). The reaction mixture was irradiated at 125° C.for 20 min. LC-MS showed primarily conversion to P. The cooled reactionmixture was diluted with 2:1 DCM:MeOH and filtered. The filtrate wasconcentrated and purified by flash chromatography over silica gel (ethylacetate with a 0-15% methanol gradient) to give5′-amino-1,2′-dimethyl-5-morpholino-[3,3′-bipyridin]-6(1H)-one as abrown solid. LCMS (m/z) (M+H)=301.0, Rt=0.33 min.

Synthesis of6-(5-amino-2-methylphenyl)-2-methyl-4-morpholinopyridazin-3(2H)-one

To a solution of 6-chloro-2-methyl-4-morpholinopyridazin-3(2H)-one (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.1equiv.) in DME and water (2:1, 0.2 M) was added PdCl₂(dppf).CH₂Cl₂adduct (0.5 equiv.) and sodium carbonate (6.6 equiv.). The solution washeated in the microwave for 40 min at 120° C. Upon cooling to roomtemperature, the solution was diluted with ethyl acetate and water, theaqueous layer was extracted with ethyl acetate two more times, theorganics were combined, dried over magnesium sulfate, filtered andconcentrated to yield a brown solid. Isolated6-(5-amino-2-methylphenyl)-2-methyl-4-morpholinopyridazin-3(2H)-one asthe desired product. LCMS (m/z) (M+H)=301.1, Rt=0.49 min.

Method 3:

To a solution of the amine (1.0 equiv.) and the corresponding carboxylicacid (1.0-1.2 equiv.) in DMF (0.1 M) was added EDC (1.0-1.2 equiv.) andHOAt (1.0-1.2 equiv.) and the reaction was stirred at room temperaturefor 6-24 hours. Upon completion, the solution was filtered through aHPLC filter and purified via reverse phase preparative HPLC.Alternatively, the solution was partitioned between water and ethylacetate, the organic phase was dried over sodium sulfate or magnesiumsulfate, filtered and concentrated to yield a crude material that wasfurther purified via reverse phase preparative HPLC. Upon lyophilizationof the pure fractions, the desired product was isolated as the TFA salt.

Example 171: Synthesis of3-(difluoromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

To a solution of5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.) in DMF (0.07 M) was added 3-(difluoromethyl)benzoic acid (1.2equiv.), EDC-HCl (1.2 equiv.) and HOAt (1.2 equiv.). The reaction wasstirred at room temperature for 6 hours. Upon completion, the solutionwas filtered through a HPLC filter and purified via reverse phasepreparative HPLC. Upon lyophilization of the pure fractions,3-(difluoromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamidewas isolated as the TFA salt in 45% yield. LCMS (m/z) (M+H)=454.2,Rt=0.79 min. ¹H NMR (400 MHz, <cd3od>) δ ppm 2.30 (s, 3H) 3.08-3.22 (m,4H) 3.64 (s, 3H) 3.81-3.94 (m, 4H) 6.66-7.05 (m, 2H) 7.29 (d, J=8.61 Hz,1H) 7.40 (d, J=2.35 Hz, 1H) 7.56 (dd, J=8.41, 2.15 Hz, 1H) 7.60-7.68 (m,2H) 7.76 (d, J=7.43 Hz, 1H) 8.05-8.15 (m, 1H).

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 171 (Method 3) using theappropriate starting materials.

Example 172:3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.78 (s, 6H) 2.30 (s, 3H) 3.08-3.25 (m,4H) 3.64 (s, 3H) 3.82-3.95 (m, 4H) 7.03 (d, J=1.96 Hz, 1H) 7.29 (d,J=8.22 Hz, 1H) 7.41 (d, J=1.96 Hz, 1H) 7.51-7.66 (m, 3H) 7.76 (d, J=9.00Hz, 1H) 7.90 (d, J=7.83 Hz, 1H) 8.08 (s, 1H). LCMS (m/z) (M+H)=471.3,Rt=0.80 min.

Example 173:3-((dimethylamino)methyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide

To a solution of 3-((dimethylamino)methyl)-5-(trifluoromethyl)benzoicacid (1.1 equiv.),N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.1 equiv.), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-olhydrate (1.1 equiv.) in DMF (0.3 M) was added5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.) and the reaction was stirred overnight at rt. Diluted with 0.4 Maqueous sodium carbonate and extracted with ethyl acetate. The combinedorganics were dried over sodium sulfate, filtered and concentrated withsilica gel to give the crude product. The material was purified by flashchromatography over silica gel (heptanes with 50-100% 90:10:1.5 ethylacetate:methanol:triethylamine gradient) to give3-((dimethylamino)methyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamideas a pale yellow-green solid in 46% yield. ¹H NMR (400 MHz, <cd3od>) δppm 2.31 (s, 3H) 2.92 (s, 6H) 3.07-3.20 (m, 4H) 3.63 (s, 3H) 3.79-3.91(m, 4H) 4.51 (s, 2H) 6.92 (d, J=1.96 Hz, 1H) 7.22-7.40 (m, 2H) 7.53-7.72(m, 2H) 8.10 (s, 1H) 8.30-8.46 (m, 1H). LCMS (m/z) (M+H)=529.4, Rt=0.65min.

Example 174:3-(4-ethylpiperazin-1-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.41 (t, J=7.24 Hz, 3H) 2.30 (s, 3H)3.14 (d, J=4.30 Hz, 5H) 3.21 (d, J=18.00 Hz, 4H) 3.63 (s, 3H) 3.70 (br.s., 2H) 3.81-3.91 (m, 4H) 4.09 (d, J=12.13 Hz, 2H) 6.91 (d, J=1.96 Hz,1H) 7.29 (d, J=7.83 Hz, 1H) 7.33 (d, J=1.96 Hz, 1H) 7.50 (s, 1H)7.54-7.62 (m, 2H) 7.79 (d, J=4.70 Hz, 2H). LCMS (m/z) (M+H)=584.4,Rt=0.70 min.

Example 175:5-(dimethylamino)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)nicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.01-3.16 (m, 4H) 3.20 (s,6H) 3.63 (s, 3H) 3.78-3.92 (m, 4H) 6.91 (d, J=2.35 Hz, 1H) 7.23-7.37 (m,2H) 7.54-7.75 (m, 2H) 8.14-8.30 (m, 2H) 8.45 (s, 1H). LCMS (m/z)(M+H)=448.3, Rt=0.57 min.

Example 176: Synthesis ofN-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(methylsulfonyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.32 (s, 3H) 3.06-3.19 (m, 4H) 3.27 (s,4H) 3.64 (s, 3H) 3.77-3.93 (m, 4H) 6.92 (d, J=1.96 Hz, 1H) 7.23-7.39 (m,2H) 7.53-7.71 (m, 2H) 8.45 (s, 1H) 8.60 (s, 1H) 8.78 (s, 1H). LCMS (m/z)(M+H)=550.1, Rt=0.83.

Example 177: Synthesis of3-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.98 (t, J=18.39 Hz, 3H) 2.31 (s, 3H)3.13-3.23 (m, 4H) 3.65 (s, 3H) 3.82-3.93 (m, 4H) 7.01 (d, J=1.96 Hz, 1H)7.29 (d, J=8.22 Hz, 1H) 7.40 (d, J=1.96 Hz, 1H) 7.53-7.67 (m, 3H) 7.76(d, J=7.83 Hz, 1H) 8.03 (d, J=7.83 Hz, 1H) 8.11 (s, 1H). LCMS (m/z)(M+H)=468.1, Rt=0.85.

Example 178:2-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.04 (t, J=18.78 Hz, 3H) 2.31 (s, 3H)3.10-3.23 (m, 4H) 3.65 (s, 3H) 3.81-3.93 (m, 4H) 7.00 (d, J=1.96 Hz, 1H)7.31 (d, J=8.22 Hz, 1H) 7.39 (d, J=1.96 Hz, 1H) 7.55-7.68 (m, 2H) 7.96(d, J=4.30 Hz, 1H) 8.17 (s, 1H) 8.81 (d, J=5.09 Hz, 1H). LCMS (m/z)(M+H)=469.1, Rt=0.78.

Example 179:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.10-3.22 (m, 4H) 3.65 (s,3H) 3.80-3.93 (m, 4H) 6.98 (d, J=1.96 Hz, 1H) 7.31 (d, J=8.22 Hz, 1H)7.38 (d, J=2.35 Hz, 1H) 7.60 (dd, J=8.22, 2.35 Hz, 1H) 7.65 (d, J=1.96Hz, 1H) 8.12 (d, J=5.09 Hz, 1H) 8.30 (s, 1H) 8.91 (d, J=5.09 Hz, 1H).LCMS (m/z) (M+H)=473.1, Rt=0.83.

Example 181:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-4-methoxy-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.69 (s, 3H) 3.10-3.21 (m, 4H) 3.65 (s,3H) 3.79-3.91 (m, 4H) 4.02 (s, 3H) 6.95 (d, J=1.96 Hz, 1H) 7.37 (d,J=8.61 Hz, 1H) 7.52 (d, J=1.96 Hz, 1H) 8.22-8.34 (m, 2H) 8.42 (d, J=2.35Hz, 1H) 9.24 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=503.1, Rt=0.67 min.

Example 182:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-4-fluoro-3-methoxybenzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.70 (s, 3H) 3.12-3.20 (m, 4H) 3.65 (s,3H) 3.80-3.89 (m, 4H) 3.97 (s, 3H) 6.95 (d, J=2.35 Hz, 1H) 7.27 (dd,J=10.96, 8.61 Hz, 1H) 7.53 (d, J=2.35 Hz, 1H) 7.62 (ddd, J=8.41, 4.11,1.96 Hz, 1H) 7.75 (dd, J=8.22, 1.96 Hz, 1H) 8.43 (d, J=2.35 Hz, 1H) 9.25(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=453.0, Rt=0.58 min.

Example 184:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.27 (s, 3H) 3.11 (br. s., 4H) 3.35 (s,5H) 3.50 (s, 5H) 3.72 (br. s., 4H) 6.70 (s, 1H) 7.30 (d, J=8.22 Hz, 1H)7.41 (s, 1H) 7.64 (s, 1H) 7.69 (d, J=8.22 Hz, 1H) 8.22 (d, J=4.69 Hz,1H) 8.53 (s, 1H) 9.00 (d, J=5.09 Hz, 1H) 10.76 (s, 1H). LCMS (m/z)(M+H)=483.3, Rt=0.65.

Example 185:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(methylsulfonyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.27 (s, 3H) 3.11 (br. s., 4H) 3.29 (s,3H) 3.50 (s, 4H) 3.68-3.77 (m, 5H) 6.71 (d, J=1.96 Hz, 1H) 7.28 (d,J=8.22 Hz, 1H) 7.41 (d, J=1.96 Hz, 1H) 7.63 (d, J=1.96 Hz, 1H) 7.69 (dd,J=8.22, 1.96 Hz, 1H) 7.83 (t, J=7.83 Hz, 1H) 8.14 (d, J=7.83 Hz, 1H)8.29 (d, J=8.22 Hz, 1H) 8.48 (s, 1H) 10.49 (s, 1H). LCMS (m/z)(M+H)=482.3, Rt=0.68.

Example 189:2-(difluoromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.31 (br. s., 1H) 3.42-3.49 (m, 5H) 3.67(s, 3H) 3.68-3.74 (m, 4H) 6.59 (s, 1H) 7.07 (s, 1H) 7.30 (d, J=8.22 Hz,1H) 7.74 (s, 2H) 8.05 (d, J=5.09 Hz, 1H) 8.17 (s, 1H) 8.89 (d, J=5.09Hz, 1H) 10.65 (s, 1H), LCMS (m/z) (M+H)=456.0, Rt=0.76 min.

Example 190:3-(difluoromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.23-2.33 (m, 3H) 3.37-3.52 (m, 4H)3.61-3.77 (m, 7H) 6.59 (s, 1H) 7.23-7.32 (m, 1H) 7.60-7.71 (m, 1H)7.71-7.80 (m, 3H) 8.07-8.18 (m, 2H) 10.41 (s, 1H), LCMS (m/z)(M+H)=455.0, Rt=0.87 min.

Example 191:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 2.29 (s, 3H) 3.36-3.51 (m,4H) 3.57-3.76 (m, 7H) 6.59 (s, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.65-7.78 (m,2H) 7.85 (d, J=3.91 Hz, 1H) 7.94-8.06 (m, 1H) 8.79 (d, J=5.09 Hz, 1H)10.56 (s, 1H), LCMS (m/z) (M+H)=473.4, Rt=0.84 min.

Example 192: Synthesis of4-(difluoromethyl)-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

Step 1

MnO₂ (8.0 equiv.) was added into a solution of3-bromo-4-(hydroxymethyl)-N-(3-(trifluoromethyl)phenyl)benzamide (1.0equiv.) in DCM (0.14 M). The suspension was stirred at rt for 1 hr. Themixture was filtered over celite and concentrated to yield3-bromo-4-formyl-N-(3-(trifluoromethyl)phenyl)benzamide in 100% yield.LC/MS (m/z)=373.9 (MH⁺), R_(t)=0.0.94 min.

Step 2

To a cooled solution of3-bromo-4-formyl-N-(3-(trifluoromethyl)phenyl)benzamide (1.0 equiv.) indry CH₂Cl₂ (0.18 M), (diethylamino)sulfur trifluoride (3.5 equiv.) wasadded under vigorous stirring. The resulting reaction mixture wasstirred at 0° C. for 2 hrs. Quenched the reaction with sat NaHCO₃ andextracted with DCM. The organic layer was washed with Brine, filteredover Na₂SO₄ and concentrated to yield3-bromo-4-(difluoromethyl)-N-(3-(trifluoromethyl)phenyl)benzamide in 47%yield. LC/MS (m/z)=393.9 (MH⁺), Rt=1.11 min.

Step 3

Method 2 was followed using1-methyl-3-morpholino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-oneand 3-bromo-4-(difluoromethyl)-N-(3-(trifluoromethyl)phenyl)benzamide togive4-(difluoromethyl)-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamidin8% yield. LC/MS (m/z)=508.1 (MH+), Rt=0.98 min. ¹H NMR (400 MHz,<cd3od>) δ ppm 3.12-3.21 (m, 4H), 3.64 (s, 3H), 3.80-3.90 (m, 4H), 6.96(d, J=1.96 Hz, 2H), 7.41 (d, J=1.96 Hz, 2H), 7.52-7.62 (m, 1H),7.84-7.92 (m, 1H), 7.97 (br. s., 2H), 8.05-8.12 (m, 1H), 8.14-8.20 (m,1H).

Example 193: Synthesis of methyl(2-(2′-methyl-5-morpholino-6-oxo-5′-(3-(trifluoromethyl)benzamido)-[3,3′-bipyridin]-1(6H)-yl)ethyl)carbamate

Step 1

A 0.3 M solution of 5-bromo-3-morpholinopyridin-2(1H)-one (1.00 equiv.)in DMF was treated with sodium hydride (1.20 equiv.). The mixture wasstirred for 15 min at ambient temperature. Tert-butyl(2-bromoethyl)carbamate (1.20 equiv.) was added. The mixture was stirredat 60° C. for 3 hr. The cooled reaction mixture was diluted with waterand extracted with ethyl acetate. The combined organics were washed withsaturated aqueous sodium bicarbonate, dried over sodium sulfate,filtered, and concentrated to give tert-butyl(2-(5-bromo-3-morpholino-2-oxopyridin-1 (2H)-yl)ethyl)carbamate. LCMS(m/z) (M+H)=402.1/404.1, Rt=0.78 min.

Step 2

Tert-butyl(2-(2′-methyl-5-morpholino-6-oxo-5′-(3-(trifluoromethyl)benzamido)-[3,3′-bipyridin]-1(6H)-yl)ethyl)carbamate was prepared using methods similar to thosedescribed for the preparation of Example 192 using the appropriatestarting materials. LCMS (m/z) (M+H)=602.2, Rt=0.78 min.

Step 3

A 0.1 M solution of tert-butyl(2-(2′-methyl-5-morpholino-6-oxo-5′-(3-(trifluoromethyl)benzamido)-[3,3′-bipyridin]-1(6H)-yl)ethyl)carbamate(1.00 equiv.) in 1:1 DCM:TFA was stirred for 15 min at ambienttemperature. The reaction mixture was concentrated. The residue wasbasified with aqueous sodium carbonate and extracted with DCM. Thecombined extracts were dried over sodium sulfate, filtered, andconcentrated to give crudeN-(1′-(2-aminoethyl)-2-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewhich was used without further purification. LCMS (m/z) (M+H)=502.2,Rt=0.58 min.

Step 4

To a 0.2 M solution ofN-(1′-(2-aminoethyl)-2-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM was added and triethylamine (3.00 equiv.) and methylchloroformate (1.10 equiv.). The reaction was stirred at ambienttemperature for 20 min. The reaction was quenched by the addition ofwater and concentrated. The crude material was purified via preparativereverse phase HPLC. Upon lyophilization of the pure fractions, methyl(2-(2′-methyl-5-morpholino-6-oxo-5′-(3-(trifluoromethyl)benzamido)-[3,3′-bipyridin]-1(6H)-yl)ethyl)carbamatewas isolated as the TFA salt in 7% yield. ¹H NMR (400 MHz (400 MHz,<cd3od>) δ ppm 2.69 (s, 3H) 3.10-3.21 (m, 5H) 3.47-3.62 (m, 5H)3.80-3.90 (m, 4H) 4.10-4.20 (m, 2H) 6.93 (d, J=2.05 Hz, 1H) 7.41 (d,J=2.10 Hz, 1H) 7.73-7.83 (m, 1H) 7.96 (dd, J=7.87, 0.68 Hz, 1H) 8.27 (d,J=7.87 Hz, 1H) 8.33 (s, 1H) 8.43 (d, J=2.20 Hz, 1H) 9.18 (d, J=2.15 Hz,1H). LCMS (m/z) (M+H)=560.3, Rt=0.68 min.

The compound listed below was prepared using methods similar to thosedescribed for the preparation of Example 193 using the appropriatestarting materials.

Example 194: Methyl(2-(5-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-3-morpholino-2-oxopyridin-1(2H)-yl)ethyl)carbamate

¹H NMR (400 MHz, <cd3od>) δ ppm 2.30 (s, 3H) 3.16 (br. s., 4H) 3.48-3.55(m, 2H) 3.56 (s, 3H) 3.81-3.91 (m, 4H) 4.08-4.19 (m, 2H) 6.97 (d, J=1.57Hz, 1H) 7.24 (d, J=1.56 Hz, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.55 (d, J=8.22Hz, 1H) 7.62 (s, 1H) 7.69-7.78 (m, 1H) 7.89 (d, J=7.83 Hz, 1H) 8.20 (d,J=7.83 Hz, 1H) 8.25 (s, 1H). LCMS (m/z) (M+H)=559.3, Rt=0.89 min.

Synthesis of 5-bromo-1-ethyl-3-(trifluoromethyl)pyridin-2(1H)-one

In a round bottom flask equipped with a stir bar and purged withnitrogen was added 5-bromo-3-(trifluoromethyl)pyridin-2-ol (1.0 equiv.),potassium carbonate (2.0 equiv.) and DMF (0.2 M). The mixture wasstirred at room temperature and iodoethane (1.2 equiv.) was added viasyringe. The mixture was warmed to 35° C. for 4 hours at which time LCMSindicated full conversion. The reaction was worked up by partitioningbetween water and ethyl acetate, the aqueous phase was extracted 3 moretimes with ethyl acetate, the organics were combined, washed with brine,dried with sodium sulfate, filtered and concentrated to yield5-bromo-1-ethyl-3-(trifluoromethyl)pyridin-2(1H)-one (67%). ¹H NMR (400MHz, <cdcl3>) δ ppm 1.32-1.50 (m, 3H) 4.04 (q, J=7.17 Hz, 2H) 7.63 (br.s., 1H) 7.78 (br. s., 1H). LCMS (m/z) (M+H)=269.1/271.1, Rt=0.72 min

Example 196:N-(3-(4-methoxy-6-morpholinopyridin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Step 1

A mixture of 2,6-dichloro-4-nitropyridine (1.0 equiv.), potassiumcarbonate (3 equiv.) and methanol (20 equiv.) were heated to 70° C. for25 min in the microwave. The reaction mixture was diluted with methanoland was decanted from remaining solids. After concentration, the mixturewas partitioned between water and EtOAc. The organic phase was washedwith brine and dried over sodium sulfate. The solution was concentratedand dried under vacuo to give 2,6-dichloro-4-methoxypyridine in 88%yield. LCMS (m/z) (M+H)=177.9/179.9, Rt=0.72 min.

Step 2

A mixture of 2,6-dichloro-4-methoxypyridine (1.0 equiv.) and morpholine(20 equiv.) were heated to 130° C. for 40 min in the microwave. Thereaction mixture was centrifuged and the soluble portion was removedfrom solids. Water was added to the soluble portion which resulted inprecipitation of product. This mixture was centrifuged and the solubleportion was discarded. The remaining solids were partitioned betweenwater and EtOAc. The organic phase was washed with brine and dried oversodium sulfate. The solution was concentrated and dried under vacuo togive 4-(6-chloro-4-methoxypyridin-2-yl)morpholine in 43% yield. LCMS(m/z) (M+H)=229.1, Rt=0.76 min.

Step 3

A mixture of 4-(6-chloro-4-methoxypyridin-2-yl)morpholine (1.0 equiv.),N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.2 equiv.), sodium carbonate (2 M, 8 equiv.) and PdCl₂(dppf) (0.5equiv.) in DME (0.1 M) were heated to 108° C. for 13 min in themicrowave. After removing the DME soluble portion and concentrating, theresulting solid was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,N-(3-(4-methoxy-6-morpholinopyridin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 34% yield. LCMS (m/z) (M+H)=472.4,Rt=0.81 min.

Example 197:N-(4-methyl-3-(6-morpholino-4-oxo-1,4-dihydropyridin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

A mixture of 2,6-dichloro-4-nitropyridine (1.0 equiv.), potassiumcarbonate (2 equiv.) and benzyl alcohol (2.4 equiv.) in NMP (4 M) wereheated to 90° C. for 2 h in the microwave. The mixture was partitionedbetween water and EtOAc. The organic phase was washed with brine anddried over sodium sulfate. The solution was concentrated and dried undervacuo to give crude 4-(benzyloxy)-2,6-dichloropyridine and was used inthe next step without further purification. LCMS (m/z)(M+H)=254.0/256.0, Rt=1.05 min.

Step 2

A mixture of 4-(benzyloxy)-2,6-dichloropyridine (1.0 equiv.) andmorpholine (1.2 equiv.) in NMP (2 M) were heated to 130° C. for 1 h inthe microwave. The reaction mixture was partitioned between water andEtOAc. The organic phase was washed with brine and dried over sodiumsulfate. The solution was concentrated and dried under vacuo to givecrude 4-(4-(benzyloxy)-6-chloropyridin-2-yl)morpholine and was used inthe next step without further purification. LCMS (m/z) (M+H)=305.0,Rt=1.10 min.

Step 3

A mixture of 4-(4-(benzyloxy)-6-chloropyridin-2-yl)morpholine (1.0equiv.),N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.2 equiv.), sodium carbonate (2 M, 8 equiv.) and PdCl₂(dppf) (0.5equiv.) in DME (0.1 M) were heated to 108° C. for 13 min in themicrowave. After removing the DME soluble portion and concentrating, theresulting solid was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Thesolution was concentrated and dried under vacuo to give crudeN-(3-(4-(benzyloxy)-6-morpholinopyridin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamideand was used in the next step without further purification. LCMS (m/z)(M+H)=548.2, Rt=0.99 min.

Step 4

ToN-(3-(4-(benzyloxy)-6-morpholinopyridin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in EtOH flushed with nitrogen was added Pd—C (0.2 equiv.).This mixture was then exposed to an atmosphere of hydrogen. Afterstirring for 4 h, the hydrogen atmosphere was replaced with nitrogen andthe mixture was filtered over celite. After concentration, the crudematerial was purified via preparative reverse phase HPLC. Uponlyophilization of the pure fractions,N-(4-methyl-3-(6-morpholino-4-oxo-1,4-dihydropyridin-2-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 10% yield over four steps. ¹H NMR (400MHz, <dmso>) δ ppm 2.26 (s, 3H) 3.69 (br. s., 4H) 6.20-6.50 (m, 1H) 7.30(br. s., 1H) 7.61-7.85 (m, 3H) 7.96 (d, J=7.83 Hz, 1H) 8.17-8.37 (m, 2H)10.50 (br. s., 1H). LCMS (m/z) (M+H)=458.1, Rt=0.78 min.

Example 198:N-(4-methyl-3-(2-morpholinothiazol-5-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

A solution of 2,5-dibromothiazole (1.0 equiv.), morpholine (1.5 equiv.)and triethylamine (4 equiv.) were heated to 150° C. for 2 h in themicrowave. After concentration, the mixture was partitioned betweenwater and EtOAc. The organic phase was washed with brine and dried oversodium sulfate. The solution was concentrated and dried under vacuo togive crudeN-(4-methyl-3-(2-morpholinothiazol-5-yl)phenyl)-3-(trifluoromethyl)benzamideand was used in the next step without further purification. LCMS (m/z)(M+H)=448.2, Rt=0.83 min.

Step 2

A mixture of 4-(5-bromothiazol-2-yl)morpholine (1.0 equiv.),N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.2 equiv.), sodium carbonate (2 M, 8 equiv.) and PdCl₂(dppf) (0.5equiv.) in DME (0.1 M) were heated to 108° C. for 13 min in themicrowave. After removing the DME soluble portion and concentrating, theresulting solid was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,N-(4-methyl-3-(2-morpholinothiazol-5-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 15% yield. ¹H NMR (400 MHz, <dmso>) δppm 2.36 (s, 3H) 3.40-3.43 (m, 4H) 3.70-3.74 (m, 4H) 7.22-7.33 (m, 2H)7.63 (dd, J=8.22, 1.96 Hz, 1H) 7.72-7.84 (m, 2H) 7.95 (d, J=7.43 Hz, 1H)8.19-8.33 (m, 2H) 10.45 (s, 1H). LCMS (m/z) (M+H)=448.2, Rt=0.83 min.

Example 199:N-(4-methyl-3-(2-morpholinothiazol-4-yl)phenyl)-3-(trifluoromethyl)benzamide

Starting with 2,4-dibromothiazole, the product was synthesized using thesame procedure as forN-(4-methyl-3-(2-morpholinothiazol-5-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.39 (s, 3H) 3.68-3.77 (m, 4H) 6.94 (s,1H) 7.17-7.27 (m, 1H) 7.68 (dd, J=8.41, 2.15 Hz, 1H) 7.77 (t, J=7.83 Hz,1H) 7.89-8.00 (m, 2H) 8.19-8.34 (m, 2H) 10.43 (s, 1H). LCMS (m/z)(M+H)=448.2, Rt=0.85 min.

Synthesis ofN-(2′-fluoro-2-methyl-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of 4-bromo-2-fluoropyridine (1.0 equiv.) andN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DME and 2M sodium carbonate (3:1, 0.08 M) was addedPdCl₂(dppf)-DCM adduct (0.1 equiv.) in a microwave vial equipped with astir bar. The reaction was heated to 110° C. for 15 min in themicrowave. The reaction was quenched with water and extracted with ethylacetate. The combined organic phase was dried with sodium sulfate,filtered and concentrated. The crude materialN-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamidewas isolated as a solid and used in the subsequent step withoutpurification. LCMS (m/z) (M+H)=376.0, Rt=0.71 min.

Example 215:2-(difluoromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.17-3.22 (m, 4H) 3.65 (s,3H) 3.85-3.91 (m, 4H) 6.67-6.98 (m, 1H) 7.02 (d, J=1.96 Hz, 1H) 7.31 (d,J=8.22 Hz, 1H) 7.40 (d, J=1.96 Hz, 1H) 7.59 (dd, J=8.41, 2.15 Hz, 1H)7.65 (d, J=1.96 Hz, 1H) 8.01 (d, J=5.09 Hz, 1H) 8.17 (s, 1H) 8.83 (d,J=5.09 Hz, 1H). LCMS (m/z) (M+H)=455.1, Rt=0.75 min.

Example 222: Synthesis ofN-(6′-cyano-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of5′-amino-2′-methyl-5-morpholino-[3,3′-bipyridine]-6-carbonitrile (1.0equiv.) andN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.2 equiv.) in DME (0.1 M) and 2 M sodium carbonate (3 equiv.) wasadded PdCl₂(dppf)-DCM adduct (0.1 equiv.) in a microwave vial equippedwith a stir bar. The reaction was heated to 120° C. for 10 min in themicrowave. The organic phase was dried with sodium sulfate, filtered andconcentrated. The crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,N-(6′-cyano-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 23% yield. ¹H NMR (400 MHz, <cd3od>) δppm 2.62 (s, 3H) 3.36-3.43 (m, 4H) 3.87-3.98 (m, 4H) 7.75 (d, J=1.57 Hz,1H) 7.80 (t, J=7.83 Hz, 1H) 7.97 (d, J=7.43 Hz, 1H) 8.28 (d, J=7.83 Hz,1H) 8.35 (s, 1H) 8.38 (d, J=1.57 Hz, 1H) 8.42 (d, J=1.96 Hz, 1H) 9.20(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=468.1, Rt=0.74 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 222 using the correspondingbromides and boronic esters.

Example 223:2-(2-cyanopropan-2-yl)-N-(3-(6-(difluoromethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.74 (s, 6H) 2.12-2.27 (m, 3H) 2.99-3.15(m, 3H) 3.63-3.84 (m, 3H) 7.29-7.34 (m, 1H) 7.36-7.39 (m, 1H) 7.61-7.64(m, 1H) 7.68-7.72 (m, 1H) 7.78-7.81 (m, 1H) 7.82-7.86 (m, 1H) 7.93-8.00(m, 1H) 8.69-8.87 (m, 1H) 10.47-10.60 (m, 1H), LCMS (m/z) (M+H)=508.3,Rt=1.08 min.

Example 224:N-(6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.97-3.11 (m, 4H) 3.69-3.72 (m, 4H)7.43-7.49 (m, 1H) 7.69-7.81 (m, 2H) 7.83-7.87 (m, 1H) 7.89-7.99 (m, 1H)8.10-8.17 (m, 1H) 8.21-8.30 (m, 2H) 8.87-8.95 (m, 1H) 10.73-10.86 (m,1H) LCMS (m/z) (M+H)=509.2, Rt=0.86 min.

Example 225:2-(2-cyanopropan-2-yl)-N-(6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) ™ppm 1.74 (s, 6H) 2.12-2.27 (m, 3H) 2.99-3.15(m, 3H) 3.63-3.84 (m, 3H) 7.29-7.34 (m, 1H) 7.36-7.39 (m, 1H) 7.61-7.64(m, 1H) 7.68-7.72 (m, 1H) 7.78-7.81 (m, 1H) 7.82-7.86 (m, 1H) 7.93-8.00(m, 1H) 8.69-8.87 (m, 1H) 10.47-10.60 (m, 1H), LCMS (m/z) (M+H)=508.3,Rt=1.04 min.

Example 226N-(3-(6-(difluoromethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)-2-(2-hydroxypropan-2-yl)isonicotinamide

LCMS (m/z) (M+H)=499.2, Rt=0.79 min.

Example 227:N-(6′-(2,2-difluoroethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.69 (s, 3H) 3.05-3.20 (m, 4H) 3.76-3.96(m, 4H) 4.67 (td, J=14.18, 3.72 Hz, 2H) 6.02-6.59 (m, 1H) 7.36 (d,J=1.96 Hz, 1H) 7.69-7.84 (m, 1H) 7.97 (d, J=7.83 Hz, 2H) 8.23-8.38 (m,2H) 8.47 (d, J=2.35 Hz, 1H) 9.37 (d, J=2.35 Hz, 1H).

LCMS (m/z) (M+H)=523.1, Rt=0.82 min.

Example 228:2-(2-cyanopropan-2-yl)-N-(6′-(2,2-difluoroethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.67 (s, 3H) 2.98-3.24 (m,4H) 3.71-4.16 (m, 4H) 4.67 (td, J=14.18, 3.72 Hz, 2H) 6.03-6.57 (m, 1H)7.36 (d, J=1.96 Hz, 1H) 7.80-7.92 (m, 2H) 8.13 (s, 1H) 8.42 (d, J=2.35Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 9.30 (d, J=1.96 Hz, 1H). LCMS (m/z)(M+H)=523.2, Rt=0.72 min.

Example 229: Synthesis ofN-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamide

To a solution of 3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylaniline(1.0 equiv) and 3-(methylsulfonyl)benzoic acid (1.1 equiv.) in DMA (0.1M) at 25° C. were added HOAT (1.3 equiv.), i-Pr₂NEt (3 equiv.), and EDC(1.3 equiv) and the mixture was stirred for 20 h at 25° C. The mixturewas quenched with a small amount of water, diluted with DMSO, filtered,and purified via preparative reverse phase HPLC. Upon lyophilization ofthe pure fractions,N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamidewas isolated as the TFA salt in 63% yield. ¹H NMR (400 MHz, <dmso>) δppm 1.35 (t, J=7.04 Hz, 3H) 2.21 (s, 3H) 3.05 (br. s., 4H) 3.27 (s, 3H)3.66-3.82 (m, 4H) 4.38 (q, J=7.04 Hz, 2H) 7.12 (d, J=1.57 Hz, 1H) 7.29(d, J=8.61 Hz, 1H) 7.62 (d, J=1.57 Hz, 1H) 7.68-7.74 (m, 2H) 7.81 (t,J=7.83 Hz, 1H) 8.12 (d, J=7.83 Hz, 1H) 8.27 (d, J=7.83 Hz, 1H) 8.46 (s,1H) 10.48 (s, 1H). LCMS (m/z) (M+H)=496.1, Rt=0.88 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 229 using the correspondingamines and acids:

Example 230:N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(1,3,4-oxadiazol-2-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=6.85 Hz, 3H) 2.22 (s, 3H)2.99-3.12 (m, 4H) 3.63-3.80 (m, 4H) 4.38 (q, J=6.78 Hz, 2H) 7.13 (d,J=1.57 Hz, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.65 (d, J=1.57 Hz, 1H) 7.70-7.81(m, 3H) 8.21 (t, J=7.43 Hz, 2H) 8.59 (s, 1H) 9.41 (s, 1H) 10.47 (s, 1H).LCMS (m/z) (M+H)=486.1, Rt=0.89 min.

Example 231:3-(difluoromethyl)-N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=7.04 Hz, 3H) 2.21 (s, 3H) 3.05(br. s., 4H) 3.69-3.79 (m, 4H) 4.38 (q, J=7.04 Hz, 2H) 6.97-7.25 (m, 2H)7.27 (d, J=7.83 Hz, 1H) 7.60-7.73 (m, 4H) 7.75-7.81 (m, 1H) 8.09-8.16(m, 2H) 10.36 (s, 1H). LCMS (m/z) (M+H)=468.1, Rt=1.02 min.

Example 232:N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=7.04 Hz, 3H) 2.22 (s, 3H) 3.05(br. s., 4H) 3.33 (s, 3H) 3.67-3.79 (m, 4H) 4.38 (q, J=7.04 Hz, 2H) 7.12(d, J=1.57 Hz, 1H) 7.31 (d, J=8.22 Hz, 1H) 7.63 (d, J=1.96 Hz, 1H)7.68-7.75 (m, 2H) 8.17-8.24 (m, 1H) 8.52 (s, 1H) 8.98 (d, J=5.09 Hz, 1H)10.75 (s, 1H). LCMS (m/z) (M+H)=497.1, Rt=0.87 min.

Example 233:2-(1,1-difluoroethyl)-N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=7.04 Hz, 3H) 2.03 (t, J=19.17Hz, 3H) 2.22 (s, 3H) 3.05 (br. s., 4H) 3.64-3.80 (m, 4H) 4.38 (q, J=6.91Hz, 2H) 7.12 (d, J=1.57 Hz, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.62 (d, J=1.96Hz, 1H) 7.68-7.74 (m, 2H) 8.01 (d, J=4.70 Hz, 1H) 8.16 (s, 1H) 8.86 (d,J=5.09 Hz, 1H) 10.60 (s, 1H). LCMS (m/z) (M+H)=483.1, Rt=1.00 min.

Example 234:N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-1-ethyl-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.29 (t, J=7.04 Hz, 3H) 1.35 (t, J=6.85Hz, 3H) 2.20 (s, 3H) 3.04 (br. s., 4H) 3.72 (d, J=3.91 Hz, 4H) 4.06 (q,J=6.91 Hz, 2H) 4.38 (q, J=6.91 Hz, 2H) 7.11 (d, J=1.57 Hz, 1H) 7.27 (d,J=8.22 Hz, 1H) 7.52 (d, J=1.57 Hz, 1H) 7.63 (dd, J=8.22, 1.96 Hz, 1H)7.70 (d, J=1.57 Hz, 1H) 8.45 (d, J=1.96 Hz, 1H) 8.79 (d, J=2.35 Hz, 1H)10.12 (s, 1H). LCMS (m/z) (M+H)=531.1, Rt=0.99 min.

Example 235:3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=7.04 Hz, 3H) 2.32 (s, 3H) 3.07(d, J=3.91 Hz, 4H) 3.68-3.77 (m, 4H) 4.39 (q, J=7.04 Hz, 2H) 7.18 (d,J=1.57 Hz, 1H) 7.45 (dd, J=15.85, 8.02 Hz, 2H) 7.58 (t, J=8.02 Hz, 1H)7.78 (d, J=1.57 Hz, 1H) 7.85-7.92 (m, 2H) 8.05 (d, J=8.22 Hz, 1H) 8.22(s, 1H) 10.45 (s, 1H). LCMS (m/z) (M+H)=486.1, Rt=1.13 min.

Example 236:3-(6-ethoxy-5-morpholinopyridin-3-yl)-N-(3-(2-hydroxypropan-2-yl)phenyl)-4-methylbenzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=7.04 Hz, 3H) 1.41 (s, 6H) 2.31(s, 3H) 3.06 (br. s., 4H) 3.69-3.77 (m, 4H) 4.39 (q, J=7.04 Hz, 2H)7.13-7.20 (m, 2H) 7.21-7.27 (m, 1H) 7.44 (d, J=8.22 Hz, 1H) 7.67 (d,J=8.22 Hz, 1H) 7.78 (d, J=1.57 Hz, 1H) 7.80 (s, 1H) 7.84-7.90 (m, 2H)10.11 (s, 1H). LCMS (m/z) (M+H)=476.2, Rt=0.91 min.

Example 237:2-(difluoromethyl)-N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=7.04 Hz, 3H) 2.21 (s, 3H) 3.05(br. s., 4H) 3.68-3.79 (m, 4H) 4.38 (q, J=7.04 Hz, 2H) 6.88-7.22 (m, 2H)7.30 (d, J=8.22 Hz, 1H) 7.62 (d, J=1.96 Hz, 1H) 7.67-7.75 (m, 2H) 8.04(d, J=4.70 Hz, 1H) 8.16 (s, 1H) 8.88 (d, J=5.09 Hz, 1H) 10.61 (s, 1H).LCMS (m/z) (M+H)=469.1, Rt=0.95 min.

Example 238:3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methyl-N-(3-(methylsulfonyl)phenyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=7.04 Hz, 3H) 2.32 (s, 3H) 3.06(br. s., 4H) 3.19 (s, 3H) 3.69-3.78 (m, 4H) 4.39 (q, J=7.04 Hz, 2H) 7.19(d, J=1.96 Hz, 1H) 7.47 (d, J=8.61 Hz, 1H) 7.58-7.66 (m, 2H) 7.78 (d,J=1.96 Hz, 1H) 7.87-7.93 (m, 2H) 8.12 (dt, J=5.97, 2.69 Hz, 1H) 8.39 (s,1H) 10.52 (s, 1H). LCMS (m/z) (M+H)=496.1, Rt=0.90 min.

Example 239:2-(2-cyanopropan-2-yl)-N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.36 (t, J=7.04 Hz, 3H) 1.75 (s, 6H) 2.49(s, 3H) 2.99-3.12 (m, 4H) 3.66-3.78 (m, 4H) 4.39 (q, J=7.04 Hz, 2H) 7.23(d, J=1.57 Hz, 1H) 7.80 (d, J=1.96 Hz, 1H) 7.86-7.92 (m, 1H) 8.02 (s,1H) 8.14 (s, 1H) 8.83 (d, J=5.09 Hz, 1H) 8.93 (s, 1H) 10.90 (s, 1H).LCMS (m/z) (M+H)=487.1, Rt=0.70 min.

Example 240:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-hydroxypropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.36 (t, J=7.04 Hz, 3H) 1.48 (s, 6H) 2.53(s, 3H) 3.07 (br. s., 4H) 3.63-3.82 (m, 4H) 4.40 (q, J=7.04 Hz, 2H) 7.26(d, J=1.57 Hz, 1H) 7.75 (dd, J=5.09, 1.17 Hz, 1H) 7.83 (d, J=1.57 Hz,1H) 8.20 (s, 1H) 8.28 (s, 1H) 8.72 (d, J=5.09 Hz, 1H) 9.04 (s, 1H) 11.00(s, 1H). LCMS (m/z) (M+H)=478.1, Rt=0.55 min.

Example 241:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-1-ethyl-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.29 (t, J=7.04 Hz, 3H) 1.35 (t, J=7.04Hz, 3H) 2.48 (s, 3H) 3.06 (br. s., 4H) 3.65-3.80 (m, 4H) 4.08 (q, J=7.17Hz, 2H) 4.39 (q, J=7.04 Hz, 2H) 7.22 (d, J=1.96 Hz, 1H) 7.79 (d, J=1.57Hz, 1H) 8.05 (s, 1H) 8.48 (d, J=1.96 Hz, 1H) 8.78-8.91 (m, 2H) 10.47 (s,1H). LCMS (m/z) (M+H)=532.2, Rt=0.72 min.

Example 242:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(methylsulfonyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.36 (t, J=7.04 Hz, 3H) 2.52 (s, 3H) 3.07(br. s., 4H) 3.29 (s, 3H) 3.63-3.81 (m, 4H) 4.40 (q, J=7.04 Hz, 2H) 7.25(d, J=1.57 Hz, 1H) 7.82 (d, J=1.96 Hz, 1H) 7.86 (t, J=7.83 Hz, 1H) 8.18(d, J=7.83 Hz, 1H) 8.23 (s, 1H) 8.31 (d, J=7.83 Hz, 1H) 8.52 (s, 1H)9.01 (d, J=1.57 Hz, 1H) 10.95 (s, 1H). LCMS (m/z) (M+H)=497.1, Rt=0.64min.

Example 243:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.36 (t, J=7.04 Hz, 3H) 2.48 (br. s., 3H)3.00-3.11 (m, 4H) 3.35 (s, 3H) 3.68-3.78 (m, 4H) 4.40 (q, J=7.04 Hz, 2H)7.23 (d, J=1.96 Hz, 1H) 7.81 (d, J=1.96 Hz, 1H) 8.16 (s, 1H) 8.20-8.26(m, 1H) 8.56 (s, 1H) 8.95 (s, 1H) 9.03 (d, J=5.09 Hz, 1H) 11.12 (s, 1H).LCMS (m/z) (M+H)=498.1, Rt=0.60 min.

Example 244:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(1,3,4-oxadiazol-2-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.36 (t, J=7.04 Hz, 3H) 2.52 (s, 3H) 3.07(br. s., 4H) 3.68-3.79 (m, 4H) 4.40 (q, J=6.91 Hz, 2H) 7.26 (d, J=1.96Hz, 1H) 7.78-7.85 (m, 2H) 8.21-8.30 (m, 3H) 8.65 (s, 1H) 9.03 (s, 1H)9.43 (s, 1H) 10.93 (s, 1H). LCMS (m/z) (M+H)=487.1, Rt=0.65 min.

Example 245:5-cyclopropyl-N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isoxazole-3-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.91 (dd, J=4.89, 2.15 Hz, 2H) 1.07 (dd,J=8.41, 2.54 Hz, 2H) 1.30 (t, J=7.04 Hz, 3H) 2.12-2.22 (m, 1H) 2.41 (br.s., 3H) 3.01 (br. s., 4H) 3.63-3.74 (m, 4H) 4.34 (q, J=7.04 Hz, 2H) 6.59(s, 1H) 7.16 (d, J=1.96 Hz, 1H) 7.73 (d, J=1.96 Hz, 1H) 8.10 (br. s.,1H) 8.87 (d, J=1.57 Hz, 1H) 10.93 (s, 1H). LCMS (m/z) (M+H)=450.1,Rt=0.73 min.

Example 246:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.35 (t, J=7.04 Hz, 3H) 2.46 (br. s., 3H)3.01-3.13 (m, 4H) 3.51-3.83 (m, 4H) 4.39 (q, J=7.04 Hz, 2H) 7.21 (d,J=1.96 Hz, 1H) 7.79 (d, J=1.96 Hz, 1H) 8.08 (s, 1H) 8.20 (d, J=5.09 Hz,1H) 8.38 (s, 1H) 8.89 (d, J=1.96 Hz, 1H) 9.01 (d, J=4.70 Hz, 1H) 10.94(s, 1H). LCMS (m/z) (M+H)=488.1, Rt=0.74 min.

Example 247:2-(difluoromethyl)-N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.36 (t, J=7.04 Hz, 3H) 2.49 (s, 3H) 3.06(br. s., 4H) 3.62-3.80 (m, 4H) 4.40 (q, J=7.04 Hz, 2H) 6.90-7.28 (m, 2H)7.81 (d, J=1.96 Hz, 1H) 8.07 (d, J=4.70 Hz, 1H) 8.14-8.27 (m, 2H) 8.93(d, J=5.09 Hz, 1H) 8.95 (d, J=1.57 Hz, 1H) 10.99 (s, 1H). LCMS (m/z)(M+H)=470.1, Rt=0.67 min.

Example 248:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.36 (t, J=6.85 Hz, 3H) 2.50 (br. s., 3H)3.07 (br. s., 4H) 3.62-3.81 (m, 4H) 4.40 (q, J=7.04 Hz, 2H) 7.24 (d,J=1.96 Hz, 1H) 7.77-7.87 (m, 2H) 8.01 (d, J=7.83 Hz, 1H) 8.20 (s, 1H)8.28 (d, J=7.83 Hz, 1H) 8.33 (s, 1H) 8.99 (d, J=1.57 Hz, 1H) 10.85 (s,1H). LCMS (m/z) (M+H)=487.2, Rt=0.81 min.

Example 249:N-(6′-cyano-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-((dimethylamino)methyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.56 (s, 3H) 2.95 (s, 6H) 3.35-3.40 (m,4H) 3.88-3.96 (m, 4H) 4.54 (s, 2H) 7.73 (d, J=1.57 Hz, 1H) 8.16 (s, 1H)8.30 (d, J=2.35 Hz, 1H) 8.35 (d, J=1.57 Hz, 1H) 8.44 (s, 1H) 8.51 (s,1H) 9.02 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=525.1, Rt=0.60 min.

Example 250:N-(6′-cyano-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.09 (t, J=18.78 Hz, 3H) 2.54 (s, 3H)3.28-3.41 (m, 4H) 3.89-4.01 (m, 4H) 7.33 (d, J=1.57 Hz, 1H) 7.86 (d,J=4.70 Hz, 1H) 8.07 (s, 1H) 8.22 (s, 1H) 8.30-8.36 (m, 2H) 8.69 (d,J=2.35 Hz, 1H) 8.88 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=468.1, Rt=0.74min.

Example 251:N-(6′-cyano-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <cd3od>) ppm 1.43 (d, J=7.04 Hz, 6H) 2.61 (s, 3H)3.25-3.30 (m, 1H) 3.35-3.41 (m, 4H) 3.88-3.96 (m, 4H) 7.74 (d, J=1.57Hz, 1H) 7.97 (dd, J=5.48, 1.57 Hz, 1H) 8.09 (s, 1H) 8.36 (d, J=1.57 Hz,1H) 8.39 (d, J=2.35 Hz, 1H) 8.78 (d, J=5.48 Hz, 1H) 9.13 (d, J=2.35 Hz,1H). LCMS (m/z) (M+H)=443.2, Rt=0.55 min.

Example 252:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.29 (d, J=7.04 Hz, 6H) 1.36 (t, J=7.04Hz, 3H) 2.54 (s, 3H) 3.07 (br. s., 4H) 3.16 (dt, J=13.69, 6.85 Hz, 1H)3.66-3.79 (m, 4H) 4.40 (q, J=7.04 Hz, 2H) 7.26 (d, J=1.96 Hz, 1H) 7.75(dd, J=5.28, 1.37 Hz, 1H) 7.80-7.88 (m, 2H) 8.29 (d, J=1.57 Hz, 1H) 8.75(d, J=5.48 Hz, 1H) 9.05 (d, J=1.57 Hz, 1H) 11.00 (s, 1H). LCMS (m/z)(M+H)=462.1, Rt=0.58 min.

Example 253:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

Step 1

To a solution of 4-(5-bromo-2-ethoxypyridin-3-yl)morpholine (1.0 equiv.)and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.7 equiv.) in DME (0.3 M) and sodium carbonate (2M aqueous solution,3.0 equiv.) was added PdCl₂(dppf)-DCM adduct (0.02 equiv.) and thesolution was heated at 100° C. for 2 hours. The cooled mixture waspoured into ice-water and extracted with ethyl acetate (3×). Thecombined organics were washed with brine, dried over MgSO₄, filtered andconcentrated. The mixture was adsorbed onto Celite and purified bysilica gel chromatography (ISCO, 0-70% ethyl acetate in heptanes). Thepure fractions were concentrated to give6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine as a paleyellow solid in 78% yield. ¹H NMR (400 MHz, <cdcl3>) δ ppm 1.47 (t,J=7.04 Hz, 3H) 3.08-3.19 (m, 4H) 3.49 (s, 3H) 3.64 (br. s., 2H)3.84-3.96 (m, 4H) 4.48 (q, J=7.04 Hz, 2H) 6.86 (d, J=2.35 Hz, 1H) 7.01(d, J=1.96 Hz, 1H) 7.73 (d, J=1.96 Hz, 1H) 8.03 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=315.1, Rt=0.50 min.

Step 2

To a solution of 2-(2-fluoropropan-2-yl)isonicotinic acid (1.3 equiv.),6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine (1.0 equiv.)and N-ethyl-N-isopropylpropan-2-amine (2.5 equiv.) in DCM (0.12 M) wasadded 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide(1.3 quiv.) and the mixture was stirred at rt over the weekend. Thereaction was diluted with DCM and washed with sat. sodium bicarbonate,the organic phase was concentrated to dryness and purified via silicagel chromatography (ISCO, 0-8% methanol in ethyl acetate) to giveN-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide.¹H NMR (400 MHz, <cdcl3>) b ppm 1.48 (t, J=7.04 Hz, 3H) 1.71-1.77 (m,6H) 2.51 (s, 3H) 3.09-3.21 (m, 4H) 3.85-3.96 (m, 4H) 4.49 (q, J=7.04 Hz,2H) 7.05 (d, J=1.96 Hz, 1H) 7.69 (dd, J=5.09, 1.57 Hz, 1H) 7.78 (d,J=1.96 Hz, 1H) 7.94 (s, 1H) 8.13 (d, J=2.35 Hz, 1H) 8.23 (s, 1H) 8.64(d, J=2.35 Hz, 1H) 8.73 (d, J=4.70 Hz, 1H). LCMS (m/z) (M+H)=480.3,Rt=0.68 min.

Example 254:2-cyclopropyl-N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.10-1.19 (m, 2H) 1.23 (dt, J=7.92, 3.08Hz, 2H) 1.45 (t, J=7.04 Hz, 3H) 2.23-2.34 (m, 1H) 2.70 (s, 3H) 3.07-3.19(m, 4H) 3.82-3.91 (m, 4H) 4.50 (d, J=7.04 Hz, 2H) 7.31 (d, J=1.96 Hz,1H) 7.81 (dd, J=5.48, 1.57 Hz, 1H) 7.86 (d, J=1.96 Hz, 2H) 8.46 (d,J=2.35 Hz, 1H) 8.65 (d, J=5.48 Hz, 1H) 9.35 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=460.1, Rt=0.57 min.

Example 255:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(oxetan-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 2.71 (s, 3H)3.10-3.21 (m, 4H) 3.82-3.89 (m, 4H) 4.50 (q, J=7.04 Hz, 2H) 4.53-4.62(m, 1H) 4.97 (t, J=6.26 Hz, 2H) 5.11 (dd, J=8.61, 5.87 Hz, 2H) 7.31 (d,J=1.96 Hz, 2H) 7.82-7.89 (m, 3H) 7.95 (s, 1H) 8.48 (d, J=1.96 Hz, 1H)8.83 (d, J=5.09 Hz, 1H) 9.38 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=476.3,Rt=0.59 min.

Example 256:3-(6-ethoxy-5-morpholinopyridin-3-yl)-N-(2-fluoro-5-(prop-1-en-2-yl)phenyl)-4-methylbenzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 2.15 (s, 3H)2.36 (s, 3H) 3.13-3.19 (m, 4H) 3.82-3.90 (m, 4H) 4.47 (d, J=7.04 Hz, 2H)5.08-5.12 (m, 1H) 5.34-5.39 (m, 1H) 7.11-7.20 (m, 1H) 7.24-7.29 (m, 1H)7.34-7.41 (m, 1H) 7.43-7.49 (m, 1H) 7.75-7.80 (m, 1H) 7.80-7.91 (m, 1H).LCMS (m/z) (M+H)=476.3, Rt=1.12 min.

Example 257:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(4-ethylpiperazin-1-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (dt, J=16.04, 7.24 Hz, 6H) 2.67 (s,3H) 3.12-3.19 (m, 4H) 3.20-3.28 (m, 2H) 3.72 (br. s., 1H) 3.82-3.90 (m,4H) 4.10 (br. s., 1H) 4.50 (q, J=7.04 Hz, 2H) 7.30 (d, J=2.35 Hz, 1H)7.56 (s, 1H) 7.82-7.88 (m, 2H) 7.89 (s, 1H) 8.44 (d, J=2.35 Hz, 1H) 9.29(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=599.4, Rt=0.67 min.

Example 258:3-((dimethylamino)methyl)-N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.46 (t, J=7.04 Hz, 3H) 2.68 (s, 3H)2.93 (s, 6H) 3.11-3.23 (m, 4H) 3.81-3.91 (m, 4H) 4.47-4.56 (m, 4H) 7.30(d, J=2.35 Hz, 1H) 7.85 (d, J=1.96 Hz, 1H) 8.16 (s, 1H) 8.45-8.50 (m,2H) 8.51 (s, 1H) 9.32 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=544.3,Rt=0.62 min.

Example 259:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 2.64 (s, 3H)3.08-3.21 (m, 4H) 3.80-3.95 (m, 4H) 4.50 (q, J=7.04 Hz, 2H) 7.29 (d,J=1.96 Hz, 1H) 7.83 (d, J=1.96 Hz, 1H) 8.33 (d, J=2.35 Hz, 1H) 8.63 (d,J=1.96 Hz, 1H) 9.17 (d, J=2.35 Hz, 1H) 9.92 (d, J=1.96 Hz, 1H). LCMS(m/z) (M+H)=489.2, Rt=0.69 min.

Example 260:N-(2-chloro-6′-methoxy-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(1-cyanocyclopropyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.78-1.93 (m, 4H) 3.13-3.25 (m, 4H)3.82-3.95 (m, 4H) 4.06 (s, 3H) 7.43 (d, J=2.35 Hz, 1H) 7.77 (dd, J=5.09,1.17 Hz, 1H) 7.94 (d, J=1.96 Hz, 1H) 8.13 (s, 1H) 8.32 (d, J=2.74 Hz,1H) 8.69 (d, J=5.09 Hz, 1H) 8.80 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=491.1, Rt=0.86 min.

Example 261:N-(2-chloro-6′-methoxy-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.05 (t, J=18.78 Hz, 3H) 3.11-3.25 (m,4H) 3.83-3.94 (m, 4H) 4.06 (s, 3H) 7.42 (d, J=1.96 Hz, 1H) 7.93 (d,J=1.96 Hz, 1H) 8.01 (d, J=4.69 Hz, 1H) 8.24 (s, 1H) 8.32 (d, J=2.35 Hz,1H) 8.81 (d, J=2.35 Hz, 1H) 8.85 (d, J=5.09 Hz, 1H). LCMS (m/z)(M+H)=490.1, Rt=0.89 min.

Example 262:N-(2-chloro-6′-methoxy-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) β ppm 1.68-1.83 (m, 6H) 3.10-3.22 (m, 4H)3.81-3.93 (m, 4H) 4.06 (s, 3H) 7.43 (d, J=2.35 Hz, 1H) 7.85 (dd, J=5.09,1.57 Hz, 1H) 7.93 (d, J=1.96 Hz, 1H) 8.14 (s, 1H) 8.32 (d, J=2.74 Hz,1H) 8.75 (d, J=5.09 Hz, 1H) 8.80 (d, J=2.74 Hz, 1H). LCMS (m/z)(M+H)=486.1, Rt=0.88 min.

Example 263:N-(2-chloro-6′-methoxy-5′-morpholino-[3,3′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.11-3.20 (m, 4H) 3.82-3.93 (m, 4H) 4.06(s, 3H) 7.41 (d, J=1.96 Hz, 1H) 7.91 (d, J=1.96 Hz, 1H) 8.33 (d, J=2.35Hz, 1H) 8.64 (d, J=1.96 Hz, 1H) 8.82 (d, J=2.74 Hz, 1H) 9.92 (d, J=1.96Hz, 1H). LCMS (m/z) (M+H)=495.1, Rt=0.84 min.

Example 264:N-(2-chloro-6′-methoxy-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-cyanopropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.84 (s, 6H) 3.11-3.21 (m, 4H) 3.82-3.93(m, 4H) 4.06 (s, 3H) 7.40 (d, J=1.96 Hz, 1H) 7.87 (dd, J=4.89, 1.37 Hz,1H) 7.92 (d, J=1.96 Hz, 1H) 8.12 (s, 1H) 8.32 (d, J=2.74 Hz, 1H)8.77-8.84 (m, 2H). LCMS (m/z) (M+H)=493.1, Rt=0.86 min.

Example 265:2-(2-cyanopropan-2-yl)-N-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) ppm 1.83 (s, 6H) 2.65 (s, 3H) 3.02-3.12 (m,4H) 3.33 (s, 6H) 3.87-3.96 (m, 4H) 7.65 (d, J=1.96 Hz, 1H) 7.85-7.92 (m,2H) 8.13 (s, 1H) 8.47 (d, J=2.35 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 9.13(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=486.2, Rt=0.54 min.

Example 266:2-(1-cyanocyclopropyl)-N-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) ppm 1.77-1.92 (m, 4H) 2.65 (s, 3H) 3.02-3.11(m, 4H) 3.33 (s, 6H) 3.86-3.96 (m, 4H) 7.65 (d, J=1.96 Hz, 1H) 7.77 (dd,J=5.09, 1.57 Hz, 1H) 7.89 (d, J=1.56 Hz, 1H) 8.14 (s, 1H) 8.48 (d,J=2.35 Hz, 1H) 8.69 (d, J=4.70 Hz, 1H) 9.15 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=484.2, Rt=0.54 min.

Example 267:2-(1,1-difluoroethyl)-N-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.05 (t, J=18.78 Hz, 3H) 2.66 (s, 3H)3.02-3.11 (m, 4H) 3.34 (s, 6H) 3.87-3.96 (m, 4H) 7.66 (d, J=1.96 Hz, 1H)7.89 (d, J=1.96 Hz, 1H) 8.02 (d, J=3.91 Hz, 1H) 8.24 (s, 1H) 8.50 (d,J=2.35 Hz, 1H) 8.86 (d, J=5.09 Hz, 1H) 9.17 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=483.2, Rt=0.55 min.

Example 268:N-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.69-1.83 (m, 6H) 2.65 (s, 3H) 3.03-3.13(m, 4H) 3.32 (s, 6H) 3.88-3.98 (m, 4H) 7.63 (d, J=1.96 Hz, 1H) 7.83 (dd,J=5.09, 1.96 Hz, 1H) 7.89 (d, J=1.56 Hz, 1H) 8.13 (s, 1H) 8.47 (d,J=2.35 Hz, 1H) 8.76 (d, J=5.09 Hz, 1H) 9.14 (d, J=1.96 Hz, 1H). LCMS(m/z) (M+H)=479.3, Rt=0.55 min.

Example 269:N-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-((dimethylamino)methyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.64 (s, 3H) 2.94 (s, 6H) 3.05-3.12 (m,4H) 3.31 (s, 6H) 3.88-3.96 (m, 4H) 4.54 (s, 2H) 7.61 (d, J=1.96 Hz, 1H)7.89 (d, J=1.57 Hz, 1H) 8.17 (s, 1H) 8.44 (d, J=2.35 Hz, 1H) 8.49 (d,J=9.39 Hz, 2H) 9.14 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=543.3, Rt=0.49min.

Example 270:N-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.61 (s, 3H) 3.05-3.13 (m, 4H) 3.33 (s,6H) 3.88-3.97 (m, 4H) 7.64 (d, J=1.96 Hz, 1H) 7.85 (d, J=1.96 Hz, 1H)8.38 (d, J=2.35 Hz, 1H) 8.63 (d, J=1.96 Hz, 1H) 8.99 (d, J=2.35 Hz, 1H)9.92 (d, J=1.57 Hz, 1H). LCMS (m/z) (M+H)=488.1, Rt=0.52 min.

Example 271:6-cyclopropyl-N-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.18-1.37 (m, 4H) 2.36-2.46 (m, 1H) 2.63(s, 3H) 3.03-3.13 (m, 4H) 3.33 (br. s., 6H) 3.85-3.98 (m, 4H) 7.64 (d,J=1.96 Hz, 1H) 7.87 (d, J=1.96 Hz, 1H) 7.98 (d, J=1.96 Hz, 1H) 8.42 (d,J=2.35 Hz, 1H) 9.05 (d, J=2.35 Hz, 1H) 9.42 (d, J=1.96 Hz, 1H). LCMS(m/z) (M+H)=460.2, Rt=0.47 min.

Example 272:2-(2-cyanopropan-2-yl)-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.81-1.93 (m, 8H) 2.08-2.23 (m, 2H) 2.71(s, 3H) 3.16-3.25 (m, 4H) 3.69 (ddd, J=11.54, 8.22, 3.33 Hz, 2H)3.82-3.93 (m, 4H) 3.94-4.04 (m, 2H) 5.46 (tt, J=7.92, 3.81 Hz, 1H) 7.34(d, J=1.96 Hz, 1H) 7.84-7.93 (m, 2H) 8.15 (s, 1H) 8.47 (d, J=2.35 Hz,1H) 8.84 (d, J=5.09 Hz, 1H) 9.36 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=543.3, Rt=0.68 min.

Example 273:2-(2-fluoropropan-2-yl)-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.67-1.80 (m, 6H) 1.86 (dtd, J=12.72,8.31, 8.31, 3.91 Hz, 2H) 2.09-2.23 (m, 2H) 2.72 (s, 3H) 3.15-3.24 (m,4H) 3.69 (ddd, J=11.64, 8.31, 3.13 Hz, 2H) 3.81-3.93 (m, 4H) 3.94-4.06(m, 2H) 5.46 (dt, J=7.83, 3.91 Hz, 1H) 7.34 (d, J=1.96 Hz, 1H) 7.85 (dd,J=5.09, 1.57 Hz, 1H) 7.88 (d, J=1.96 Hz, 1H) 8.15 (s, 1H) 8.50 (d,J=2.35 Hz, 1H) 8.77 (d, J=5.09 Hz, 1H) 9.38 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=536.3, Rt=0.69 min.

Example 274:N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)phenyl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.77-1.94 (m, 2H) 2.08-2.21 (m, 2H) 2.29(s, 3H) 3.16-3.23 (m, 4H) 3.31 (s, 3H) 3.69 (ddd, J=11.64, 8.31, 3.13Hz, 2H) 3.82-3.94 (m, 4H) 3.94-4.07 (m, 2H) 5.41 (tt, J=7.97, 3.96 Hz,1H) 7.27 (d, J=1.57 Hz, 1H) 7.34 (d, J=8.22 Hz, 1H) 7.60-7.69 (m, 2H)7.76 (d, J=1.96 Hz, 1H) 8.17 (dd, J=5.09, 1.57 Hz, 1H) 8.56 (s, 1H) 8.94(d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=553.2, Rt=0.83 min.

Example 275:N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)phenyl)-6-(trifluoromethyl) pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.86 (dtd, J=12.67, 8.34, 8.34, 3.91 Hz,2H) 2.07-2.22 (m, 2H) 2.29 (s, 3H) 3.14-3.25 (m, 4H) 3.68 (ddd, J=11.44,8.31, 3.33 Hz, 2H) 3.82-3.94 (m, 4H) 3.95-4.06 (m, 2H) 5.41 (dt, J=7.92,4.06 Hz, 1H) 7.27 (d, J=1.96 Hz, 1H) 7.34 (d, J=8.22 Hz, 1H) 7.61-7.72(m, 2H) 7.76 (d, J=1.96 Hz, 1H) 8.59 (d, J=1.96 Hz, 1H) 9.88 (d, J=1.96Hz, 1H). LCMS (m/z) (M+H)=544.3, Rt=0.93 min.

Example 276:6-cyclopropyl-N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.18-1.39 (m, 4H) 1.85 (dtd, J=12.81,8.46, 8.46, 3.91 Hz, 2H) 2.06-2.19 (m, 2H) 2.28 (s, 3H) 2.35-2.50 (m,1H) 3.14-3.22 (m, 4H) 3.68 (ddd, J=11.44, 8.31, 3.33 Hz, 2H) 3.81-3.92(m, 4H) 3.93-4.04 (m, 2H) 5.40 (tt, J=7.92, 3.81 Hz, 1H) 7.25 (d, J=1.96Hz, 1H) 7.33 (d, J=8.22 Hz, 1H) 7.57-7.69 (m, 2H) 7.74 (d, J=1.96 Hz,1H) 8.05 (d, J=1.96 Hz, 1H) 9.44 (d, J=1.96 Hz, 1H). LCMS (m/z)(M+H)=516.2, Rt=0.84 min.

Example 277:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)phenyl) isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.69 (s, 6H) 1.85 (dtd, J=12.77, 8.39,8.39, 3.72 Hz, 2H) 2.07-2.21 (m, 2H) 2.30 (s, 3H) 3.09-3.21 (m, 4H) 3.69(ddd, J=11.64, 8.31, 3.13 Hz, 2H) 3.81-3.93 (m, 4H) 3.94-4.06 (m, 2H)5.41 (tt, J=7.92, 3.81 Hz, 1H) 7.23 (d, J=1.96 Hz, 1H) 7.35 (d, J=8.22Hz, 1H) 7.63 (d, J=2.35 Hz, 1H) 7.67 (dd, J=8.22, 2.35 Hz, 1H) 7.74 (d,J=1.96 Hz, 1H) 8.10 (dd, J=5.48, 1.56 Hz, 1H) 8.40 (s, 1H) 8.77 (d,J=5.48 Hz, 1H). LCMS (m/z) (M+H)=533.3, Rt=0.73 min.

Example 278:N-(5′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-methyl-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.79-1.92 (m, 2H) 1.95-2.10 (m, 4H)2.10-2.20 (m, 2H) 2.68 (s, 3H) 3.59-3.72 (m, 4H) 3.89-4.01 (m, 4H) 4.21(br. s., 2H) 5.43 (dt, J=7.83, 3.91 Hz, 1H) 7.24 (d, J=1.96 Hz, 1H) 7.73(d, J=2.35 Hz, 1H) 8.18 (d, J=5.09 Hz, 1H) 8.36 (s, 1H) 8.40 (d, J=2.35Hz, 1H) 8.97 (d, J=5.09 Hz, 1H) 9.27 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=570.2, Rt=0.75 min.

Example 279:N-(5′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-methyl-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.71 (s, 3H) 1.77 (s, 3H) 1.84 (dtd,J=12.67, 8.34, 8.34, 3.91 Hz, 2H) 1.95-2.10 (m, 4H) 2.10-2.21 (m, 2H)2.71 (s, 3H) 3.60-3.74 (m, 4H) 3.88-4.03 (m, 4H) 4.22 (br. s., 2H) 5.43(dt, J=7.83, 3.91 Hz, 1H) 7.25 (d, J=1.96 Hz, 1H) 7.75 (d, J=1.96 Hz,1H) 7.84 (dd, J=5.09, 1.57 Hz, 1H) 8.14 (s, 1H) 8.49 (d, J=2.35 Hz, 1H)8.76 (d, J=5.09 Hz, 1H) 9.38 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=562.2,Rt=0.74 min.

Example 280:N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.46 (t, J=7.04 Hz, 3H) 2.28 (s, 3H)3.14-3.21 (m, 4H) 3.83-3.91 (m, 4H) 4.47 (q, J=7.04 Hz, 2H) 7.26 (d,J=1.96 Hz, 1H) 7.33 (d, J=8.22 Hz, 1H) 7.63-7.71 (m, 2H) 7.75 (d, J=1.96Hz, 1H) 8.58 (d, J=1.96 Hz, 1H) 9.87 (d, J=1.57 Hz, 1H). LCMS (m/z)(M+H)=488.1, Rt=0.94 min.

Example 281:N-(6′-methoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.71 (s, 3H) 1.77 (s, 3H) 2.71 (s, 3H)3.09-3.19 (m, 4H) 3.83-3.90 (m, 4H) 4.06 (s, 3H) 7.32 (d, J=1.96 Hz, 1H)7.84 (dd, J=5.09, 1.57 Hz, 1H) 7.90 (d, J=1.96 Hz, 1H) 8.15 (s, 1H) 8.50(d, J=2.35 Hz, 1H) 8.76 (d, J=5.09 Hz, 1H) 9.40 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=466.3, Rt=0.64 min.

Example 282:N-(5′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6′-ethoxy-2-methyl-[3,3′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 1.96-2.13 (m,4H) 2.69 (s, 3H) 3.61 (d, J=10.17 Hz, 2H) 3.91 (d, J=10.56 Hz, 2H) 4.22(br. s., 2H) 4.48 (q, J=7.04 Hz, 2H) 7.22 (d, J=1.96 Hz, 1H) 7.73 (d,J=1.96 Hz, 1H) 8.41 (d, J=2.35 Hz, 1H) 8.63 (d, J=1.96 Hz, 1H) 9.29 (d,J=2.35 Hz, 1H) 9.92 (d, J=1.57 Hz, 1H). LCMS (m/z) (M+H)=515.1, Rt=0.72min.

Example 283:2-(1-cyanocyclopropyl)-N-(6′-methoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.85 (dt, J=12.52, 2.93 Hz, 4H) 2.69 (s,3H) 3.11-3.19 (m, 4H) 3.81-3.91 (m, 4H) 4.05 (s, 3H) 7.32 (d, J=1.96 Hz,1H) 7.78 (dd, J=5.09, 1.57 Hz, 1H) 7.89 (d, J=1.96 Hz, 1H) 8.16 (s, 1H)8.44 (d, J=2.35 Hz, 1H) 8.70 (d, J=5.09 Hz, 1H) 9.33 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=471.3, Rt=0.65 min.

Example 284:6-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.49 (t, J=6.94 Hz, 3H) 1.94 (s, 6H)2.31 (s, 3H) 3.18-3.25 (m, 4H) 3.85-3.93 (m, 4H) 4.51 (d, J=7.25 Hz, 2H)7.33 (s, 2H) 7.67 (s, 2H) 7.80 (s, 1H) 8.38 (d, J=1.89 Hz, 1H) 9.64 (s,1H). LCMS (m/z) (M+H)=487.2, Rt=0.88 min.

Example 285:(R)-N-(6′-ethoxy-2-methyl-5′-(3-methylmorpholino)-[3,3′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.01 (d, J=6.31 Hz, 3H) 1.42-1.51 (m,3H) 2.69 (s, 3H) 2.84-2.95 (m, 1H) 3.37-3.63 (m, 2H) 3.78-3.96 (m, 4H)4.40-4.61 (m, 2H) 7.39-7.45 (m, 1H) 7.90-7.97 (m, 1H) 8.36-8.43 (m, 1H)8.63-8.68 (m, 1H) 9.23-9.29 (m, 1H) 9.91-9.98 (m, 1H). LCMS (m/z)(M+H)=503.1, Rt=0.69 min.

Example 286:(S)-N-(6′-ethoxy-2-methyl-5′-(3-methylmorpholino)-[3,3′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 0.98 (d, J=6.65 Hz, 3H) 1.45 (t, J=7.04Hz, 3H) 2.66 (s, 3H) 2.88 (ddd, J=11.93, 6.06, 3.13 Hz, 1H) 3.34-3.39(m, 1H) 3.54 (dd, J=11.15, 5.28 Hz, 1H) 3.75-3.95 (m, 4H) 4.41-4.60 (m,2H) 7.40 (d, J=2.35 Hz, 1H) 7.91 (d, J=1.96 Hz, 1H) 8.36 (d, J=2.35 Hz,1H) 8.63 (d, J=1.96 Hz, 1H) 9.21 (d, J=2.35 Hz, 1H) 9.92 (d, J=1.96 Hz,1H). LCMS (m/z) (M+H)=503.1, Rt=0.69 min.

Example 287:6-(2-cyanopropan-2-yl)-N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 1.92 (s, 6H)2.70 (s, 3H) 3.11-3.19 (m, 4H) 3.81-3.90 (m, 4H) 4.50 (d, J=7.04 Hz, 2H)7.30 (d, J=2.35 Hz, 1H) 7.86 (d, J=1.96 Hz, 1H) 8.43 (dd, J=9.19, 2.15Hz, 2H) 9.32 (d, J=2.35 Hz, 1H) 9.66 (d, J=1.96 Hz, 1H). LCMS (m/z)(M+H)=488.1, Rt=0.64 min.

Example 288:N-(6′-chloro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(1-cyanocyclopropyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.78-1.91 (m, 4H) 2.63 (s, 3H) 3.15-3.22(m, 4H) 3.85-3.94 (m, 4H) 7.66 (d, J=1.96 Hz, 1H) 7.77 (dd, J=5.09, 1.57Hz, 1H) 8.15 (d, J=1.96 Hz, 2H) 8.39 (d, J=2.35 Hz, 1H) 8.70 (d, J=5.09Hz, 1H) 9.21 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=475.1, Rt=0.66 min.

Example 289:N-(6′-chloro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-cyanopropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.82 (s, 6H) 2.63 (s, 3H) 3.15-3.22 (m,4H) 3.84-3.93 (m, 4H) 7.66 (d, J=1.96 Hz, 1H) 7.87 (dd, J=4.89, 1.37 Hz,1H) 8.13 (s, 1H) 8.15 (d, J=1.96 Hz, 1H) 8.39 (d, J=2.35 Hz, 1H) 8.82(d, J=5.09 Hz, 1H) 9.21 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=477.1,Rt=0.66 min.

Example 290:N-(6′-chloro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.71 (s, 3H) 1.77 (s, 3H) 2.64 (s, 3H)3.14-3.21 (m, 4H) 3.81-3.93 (m, 4H) 7.67 (d, J=1.96 Hz, 1H) 7.83 (dd,J=5.09, 1.96 Hz, 1H) 8.13 (s, 1H) 8.15 (d, J=1.96 Hz, 1H) 8.43 (d,J=2.35 Hz, 1H) 8.75 (d, J=5.09 Hz, 1H) 9.26 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=470.1, Rt=0.69 min.

Example 291:N-(6′-chloro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.63 (s, 3H) 3.14-3.22 (m, 4H) 3.85-3.93(m, 4H) 7.66 (d, J=2.35 Hz, 1H) 8.14 (d, J=2.35 Hz, 1H) 8.17 (d, J=3.91Hz, 1H) 8.36 (s, 1H) 8.39 (d, J=2.35 Hz, 1H) 8.96 (d, J=4.70 Hz, 1H)9.21 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=478.1, Rt=0.70 min.

Example 292:N-(6′-chloro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.60 (s, 3H) 3.14-3.21 (m, 4H) 3.84-3.95(m, 4H) 7.65 (d, J=1.96 Hz, 1H) 8.13 (d, J=2.35 Hz, 1H) 8.34 (d, J=2.35Hz, 1H) 8.62 (d, J=1.96 Hz, 1H) 9.13 (d, J=2.35 Hz, 1H) 9.91 (d, J=1.96Hz, 1H). LCMS (m/z) (M+H)=479.1, Rt=0.65 min.

Example 293:N-(6′-chloro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-6-(2-cyanopropan-2-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.93 (s, 6H) 2.63 (s, 3H) 3.15-3.22 (m,4H) 3.83-3.94 (m, 4H) 7.66 (d, J=1.96 Hz, 1H) 8.15 (d, J=2.35 Hz, 1H)8.39 (d, J=2.35 Hz, 1H) 8.41 (d, J=1.96 Hz, 1H) 9.21 (d, J=2.35 Hz, 1H)9.66 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=478.3, Rt=0.62 min.

Example 294:2-(2-fluoropropan-2-yl)-N-(2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.71 (s, 3H) 1.77 (s, 3H) 2.59 (s, 3H)3.44-3.50 (m, 4H) 3.85-3.93 (m, 4H) 7.82 (dd, J=5.09, 1.57 Hz, 1H) 8.04(d, J=0.78 Hz, 1H) 8.12 (s, 1H) 8.28 (d, J=0.78 Hz, 1H) 8.48 (t, J=2.35Hz, 2H) 8.75 (d, J=5.09 Hz, 1H) 9.07 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=436.4, Rt=0.52 min.

Example 295:N-(2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.56 (s, 3H) 3.42-3.47 (m, 4H) 3.84-3.94(m, 4H) 8.01 (s, 1H) 8.16 (d, J=3.91 Hz, 1H) 8.26 (d, J=0.78 Hz, 1H)8.34 (s, 1H) 8.42 (d, J=2.35 Hz, 1H) 8.46 (d, J=2.74 Hz, 1H) 8.92-9.00(m, 2H). LCMS (m/z) (M+H)=444.3, Rt=0.52 min.

Example 296:6-(2-cyanopropan-2-yl)-N-(2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.92 (s, 6H) 2.55 (s, 3H) 3.42-3.48 (m,4H) 3.82-3.93 (m, 4H) 8.02 (s, 1H) 8.25 (d, J=1.17 Hz, 1H) 8.40 (t,J=1.96 Hz, 2H) 8.46 (d, J=2.74 Hz, 1H) 8.93 (d, J=2.35 Hz, 1H) 9.65 (d,J=1.96 Hz, 1H). LCMS (m/z) (M+H)=444.1, Rt=0.45 min.

Example 297:2-(2-cyanopropan-2-yl)-N-(2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.82 (s, 6H) 2.57 (s, 3H) 3.42-3.51 (m,4H) 3.83-3.92 (m, 4H) 7.85 (dd, J=4.89, 1.37 Hz, 1H) 8.02 (d, J=0.78 Hz,1H) 8.12 (s, 1H) 8.26 (d, J=1.17 Hz, 1H) 8.43 (d, J=2.35 Hz, 1H) 8.47(d, J=2.74 Hz, 1H) 8.81 (d, J=4.70 Hz, 1H) 8.99 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=443.4, Rt=0.50 min.

Example 298:N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.71 (s, 3H) 1.77 (s, 3H) 2.65 (s, 3H)3.16-3.24 (m, 4H) 3.82-3.91 (m, 4H) 7.57 (dd, J=9.78, 1.96 Hz, 1H)7.79-7.87 (m, 2H) 8.13 (s, 1H) 8.44 (d, J=1.96 Hz, 1H) 8.76 (d, J=5.09Hz, 1H) 9.29 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=454.1, Rt=0.69 min.

Example 299:2-(2-fluoropropan-2-yl)-N-(6′-(2-hydroxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.71 (s, 3H) 1.77 (s, 3H) 2.67-2.73 (m,3H) 3.16-3.22 (m, 4H) 3.85-3.91 (m, 4H) 3.93-3.99 (m, 2H) 4.50-4.57 (m,2H) 7.33 (d, J=1.96 Hz, 1H) 7.81-7.88 (m, 2H) 8.14 (s, 1H) 8.46 (d,J=1.96 Hz, 1H) 8.76 (d, J=5.09 Hz, 1H) 9.34 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=496.1, Rt=0.61 min.

Example 300:2-(2-cyanopropan-2-yl)-N-(6′-(2-hydroxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.76-1.86 (m, 6H) 2.66-2.71 (m, 3H)3.16-3.23 (m, 4H) 3.83-3.89 (m, 4H) 3.91-3.97 (m, 2H) 4.51-4.56 (m, 2H)7.32 (d, J=2.35 Hz, 1H) 7.84-7.88 (m, 2H) 8.11-8.15 (m, 1H) 8.42 (d,J=2.35 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 9.31 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=503.4, Rt=0.60 min.

Example 301:N-(6′-(2-hydroxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-4-(trifluoromethyl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.67-2.72 (m, 3H) 3.16-3.23 (m, 4H)3.84-3.90 (m, 4H) 3.92-3.98 (m, 2H) 4.49-4.57 (m, 2H) 7.34 (d, J=1.96Hz, 1H) 7.88 (d, J=1.96 Hz, 1H) 7.99 (d, J=4.30 Hz, 1H) 8.50 (s, 1H)8.67 (d, J=2.35 Hz, 1H) 9.02 (d, J=5.09 Hz, 1H) 9.43 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=504.3, Rt=0.67 min.

Example 302:6-(1-cyanocyclopropyl)-N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.63-1.74 (m, 2H) 1.90-1.95 (m, 2H) 2.01(d, J=3.13 Hz, 4H) 2.22 (s, 3H) 3.06 (br. s., 4H) 3.54 (ddd, J=11.35,8.41, 2.93 Hz, 2H) 3.68-3.76 (m, 4H) 3.78-3.86 (m, 2H) 5.31 (dt, J=7.92,4.06 Hz, 1H) 7.12 (d, J=1.96 Hz, 1H) 7.31 (d, J=8.61 Hz, 1H) 7.59 (d,J=1.96 Hz, 1H) 7.66 (dd, J=8.22, 2.35 Hz, 1H) 7.70 (d, J=1.96 Hz, 1H)8.00 (d, J=1.96 Hz, 1H) 9.53 (d, J=1.96 Hz, 1H) 10.70 (s, 1H). LCMS(m/z) (M+H)=541.2, Rt=0.85 min.

Example 303:(R)-6-(2-cyanopropan-2-yl)-N-(6′-ethoxy-2-methyl-5′-(3-methylmorpholino)-[3,3′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.01 (d, J=6.31 Hz, 3H) 1.48 (t, J=6.94Hz, 3H) 1.95 (s, 6H) 2.72 (s, 3H) 2.86-2.95 (m, 1H) 3.42-3.44 (m, 1H)3.53-3.62 (m, 1H) 3.91 (br. s., 4H) 4.42-4.61 (m, 2H) 7.45 (d, J=2.21Hz, 1H) 7.95 (d, J=1.89 Hz, 1H) 8.46 (dd, J=7.09, 2.36 Hz, 2H) 9.34 (d,J=2.21 Hz, 1H) 9.70 (d, J=1.89 Hz, 1H). LCMS (m/z) (M+H)=502.2, Rt=0.65min.

Example 304:N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-6-(2-fluoropropan-2-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 1.78-1.91 (m,6H) 2.27 (s, 3H) 3.11-3.23 (m, 4H) 3.81-3.93 (m, 4H) 4.47 (d, J=7.04 Hz,2H) 7.28 (d, J=1.96 Hz, 2H) 7.64 (s, 2H) 7.76 (d, J=1.96 Hz, 1H) 8.34(d, J=1.57 Hz, 1H) 9.56 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=480.2,Rt=0.92 min.

Example 305:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-6-(2-fluoropropan-2-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (t, J=7.04 Hz, 3H) 1.79-1.93 (m,6H) 2.70 (s, 3H) 3.08-3.21 (m, 4H) 3.80-3.94 (m, 4H) 4.50 (d, J=7.04 Hz,2H) 7.30 (d, J=1.96 Hz, 1H) 7.86 (d, J=1.96 Hz, 1H) 8.41 (d, J=1.96 Hz,1H) 8.45 (d, J=2.35 Hz, 1H) 9.33 (d, J=1.96 Hz, 1H) 9.61 (d, J=1.96 Hz,1H). LCMS (m/z) (M+H)=481.2, Rt=0.66 min.

Example 306: Synthesis of3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methyl-N-(2-(trifluoromethyl)pyridin-4-yl)benzamide

To a solution of 3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylbenzoicacid (1.0 equiv.) in DCM (0.1 M) at 0° C. was added1-chloro-N,N,2-trimethyl-1-propenylamine (1.2 equiv.) and the mixturewas allowed to stir at for 1 h. The mixture was subsequently added to asolution of 4-amino-2-(trifluoromethyl)pyridine (1.3 equiv.) and Et₃N (3equiv.) in DCM (0.1 M) and the reaction was allowed to warm to 25° C.and stirred for 1 h. The mixture was concentrated, taken up in DMSO,filtered, and purified via preparative reverse phase HPLC. Uponlyophilization of the pure fractions,3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methyl-N-(2-(trifluoromethyl)pyridin-4-yl)benzamidewas isolated as the TFA salt in 52% yield. ¹H NMR (400 MHz, <dmso>) δppm 1.35 (t, J=7.04 Hz, 3H) 2.27-2.35 (m, 3H) 3.06 (br. s., 4H) 3.72 (d,J=4.30 Hz, 4H) 4.39 (d, J=7.04 Hz, 2H) 7.18 (d, J=1.96 Hz, 1H) 7.50 (d,J=8.61 Hz, 1H) 7.78 (d, J=1.96 Hz, 1H) 7.87-7.96 (m, 2H) 8.06 (d, J=3.91Hz, 1H) 8.28 (d, J=1.57 Hz, 1H) 8.65 (d, J=5.48 Hz, 1H) 10.81 (s, 1H).LCMS (m/z) (M+H)=487.1, Rt=1.09 min.

Example 307: Synthesis ofN-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DMF (0.25 M) was added a 5.6M solution of dimethylaminein ethanol (5.0 equiv.). The mixture was stirred at 90° C. overnight.The cooled mixture was diluted with DMSO, filtered, and purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractionsN-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt, a light yellow solid, in 28% yield. ¹H NMR(400 MHz, <cd3od>) δ ppm 2.65 (s, 3H) 3.04-3.12 (m, 4H) 3.30 (s, 6H)3.87-3.96 (m, 4H) 7.61 (d, J=1.96 Hz, 1H) 7.74-7.83 (m, 1H) 7.90 (d,J=1.56 Hz, 1H) 7.97 (d, J=7.83 Hz, 1H) 8.28 (d, J=8.22 Hz, 1H) 8.34 (s,1H) 8.46 (d, J=2.35 Hz, 1H) 9.13 (d, J=1.96 Hz, 1H); LCMS (m/z)(M+H)=486.3, Rt=0.60 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 307 using the appropriatestarting materials.

Example 308:N-(6′-(dimethylamino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.42 (d, J=7.04 Hz, 6H) 2.65 (s, 3H)3.02-3.11 (m, 4H) 3.33 (s, 6H) 3.86-3.97 (m, 4H) 7.65 (d, J=1.96 Hz, 1H)7.88 (d, J=1.96 Hz, 1H) 7.97 (dd, J=5.48, 1.57 Hz, 1H) 8.08 (s, 1H) 8.47(d, J=1.96 Hz, 1H) 8.77 (d, J=5.48 Hz, 1H) 9.12 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=461.2, Rt=0.45 min.

Example 309: Synthesis ofN-(2-methyl-5′-(3-oxomorpholino)-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.1 M) was added benzyltriethylammonium chloride(6.1 equiv.) and potassium permanganate (6.0 equiv.). The mixture wasstirred at 45° C. for 2 hr. The cooled reaction mixture was diluted withwater and treated with sodium bisulfite (18 equiv.). The mixture wasstirred for 15 min at ambient temperature. Additional water was added,and the mixture was extracted with DCM. The organic layer was washedwith saturated aqueous sodium bicarbonate, dried over sodium sulfate,filtered, and concentrated. The crude material was purified bypreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(2-methyl-5′-(3-oxomorpholino)-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt, a white solid, in 27% yield. ¹H NMR (400MHz, <cd3od>) δ ppm 1.80-1.94 (m, 2H) 2.13 (ddd, J=9.59, 6.46, 3.13 Hz,2H) 2.69 (s, 3H) 3.69 (ddd, J=11.54, 7.83, 3.33 Hz, 2H) 3.79 (t, J=5.09Hz, 2H) 3.97 (ddd, J=11.25, 6.95, 3.72 Hz, 2H) 4.06-4.16 (m, 2H) 4.36(s, 2H) 5.48 (tt, J=7.58, 3.77 Hz, 1H) 7.76-7.84 (m, 1H) 7.92 (d, J=2.35Hz, 1H) 7.98 (d, J=7.83 Hz, 1H) 8.26-8.33 (m, 2H) 8.36 (s, 1H) 8.45 (d,J=2.35 Hz, 1H) 9.28 (d, J=2.35 Hz, 1H); LCMS (m/z) (M+H)=557.2, Rt=0.75min.

Example 310: Synthesis of(S)-N-(2-methyl-5′-morpholino-6′-((tetrahydrofuran-3-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of (S)-(+)-3-hydroxytetrahydrofuran (5 equiv.) in dioxane(0.1 M) at 25° C. was added NaH (5.2 equiv.), and the mixture wasstirred for 15 min.N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was then added, and the reaction was heated to 105° C. andstirred for 1 h. The reaction was cooled to room temperature, quenchedwith a few drops of water, and concentrated. The crude material waspurified by preparative reverse phase HPLC. Upon lyophilization of thepure fractions,(S)-N-(2-methyl-5′-morpholino-6′-((tetrahydrofuran-3-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt, a pale yellow solid, in 44% yield. ¹H NMR(400 MHz, <dmso>) δ ppm 2.05-2.13 (m, 1H) 2.22-2.29 (m, 1H) 2.52 (s, 3H)3.08 (br. s., 4H) 3.71-3.78 (m, 4H) 3.78-3.91 (m, 3H) 3.96 (dd, J=10.37,4.50 Hz, 1H) 5.61 (dd, J=5.87, 4.70 Hz, 1H) 7.28 (d, J=1.57 Hz, 1H)7.78-7.90 (m, 2H) 8.02 (d, J=7.83 Hz, 1H) 8.22 (s, 1H) 8.30 (d, J=7.83Hz, 1H) 8.34 (s, 1H) 8.99 (d, J=1.96 Hz, 1H) 10.85 (s, 1H). LCMS (m/z)(M+H)=529.2, Rt=0.77 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 310 using the appropriatestarting materials Differences in the workup and/or purificationprotocols are noted where applicable.

Example 311:(R)-N-(2-methyl-5′-morpholino-6′-((tetrahydrofuran-3-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.09 (d, J=6.65 Hz, 1H) 2.22-2.31 (m, 1H)2.53 (s, 3H) 3.08 (br. s., 4H) 3.67-3.77 (m, 4H) 3.78-3.91 (m, 3H) 3.96(dd, J=10.17, 4.70 Hz, 1H) 5.55-5.67 (m, 1H) 7.28 (d, J=1.56 Hz, 1H)7.84 (s, 2H) 8.03 (d, J=7.83 Hz, 1H) 8.23 (s, 1H) 8.30 (d, J=8.22 Hz,1H) 8.34 (s, 1H) 9.00 (s, 1H) 10.88 (s, 1H). LCMS (m/z) (M+H)=529.2,Rt=0.76 min.

Example 312:N-(6′-(2-methoxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.49 (s, 3H) 3.05-3.12 (m, 4H) 3.31 (s,3H) 3.67-3.77 (m, 6H) 4.42-4.49 (m, 2H) 7.25 (d, J=1.56 Hz, 1H)7.77-7.86 (m, 2H) 8.01 (d, J=7.83 Hz, 1H) 8.19 (s, 1H) 8.28 (d, J=7.83Hz, 1H) 8.32 (s, 1H) 8.97 (d, J=1.96 Hz, 1H) 10.83 (s, 1H). LCMS (m/z)(M+H)=517.2, Rt=0.72 min.

Example 313:2-isopropyl-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.39 (d, J=7.04 Hz, 6H) 1.84 (dtd,J=12.77, 8.29, 8.29, 3.91 Hz, 2H) 2.08-2.18 (m, 2H) 2.69 (s, 3H)3.15-3.19 (m, 4H) 3.21-3.27 (m, 1H) 3.67 (ddd, J=11.35, 8.22, 3.13 Hz,2H) 3.83-3.90 (m, 4H) 3.93-4.01 (m, 2H) 5.44 (tt, J=7.83, 3.91 Hz, 1H)7.31 (d, J=1.96 Hz, 1H) 7.85 (d, J=1.96 Hz, 1H) 7.89 (dd, J=5.28, 1.37Hz, 1H) 8.00 (s, 1H) 8.44 (d, J=2.35 Hz, 1H) 8.74 (d, J=5.48 Hz, 1H)9.31 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=518.3, Rt=0.57 min.

Example 314:N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.85 (td, J=8.51, 4.11 Hz, 2H) 2.08-2.19(m, 2H) 2.67 (s, 3H) 3.13-3.18 (m, 4H) 3.67 (ddd, J=11.64, 8.31, 3.13Hz, 2H) 3.82-3.90 (m, 4H) 3.93-4.01 (m, 2H) 5.44 (tt, J=7.83, 3.91 Hz,1H) 7.31 (d, J=1.96 Hz, 1H) 7.85 (d, J=1.96 Hz, 1H) 8.18 (d, J=4.30 Hz,1H) 8.36 (s, 1H) 8.41 (d, J=2.35 Hz, 1H) 8.97 (d, J=5.09 Hz, 1H) 9.28(d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=544.3, Rt=0.69 min.

Example 315:N-(2-methyl-5′-morpholino-6′-(oxetan-3-yloxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

The reaction mixture was quenched with water and extracted three timeswith ethyl acetate. The combined organics were dried over magnesiumsulfate, filtered, and concentrated. The crude residue was purified viaflash chromatography over silica gel eluting with heptane and 0-100%ethyl acetate gradient. Pure product fractions were concentrated,re-dissolved in acetonitrile/water, and lyophilized. IsolatedN-(2-methyl-5′-morpholino-6′-(oxetan-3-yloxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideas a white solid in 44% yield. ¹H NMR (400 MHz, <dmso>) δ ppm 2.43 (s,3H) 3.13 (br. s., 4H) 3.70-3.83 (m, 4H) 4.62 (dd, J=7.04, 5.48 Hz, 2H)4.93 (t, J=6.85 Hz, 2H) 5.63 (quin, J=5.67 Hz, 1H) 7.28 (d, J=1.96 Hz,1H) 7.74 (d, J=1.56 Hz, 1H) 7.81 (t, J=7.83 Hz, 1H) 8.00 (d, J=7.83 Hz,1H) 8.04 (d, J=2.35 Hz, 1H) 8.28 (d, J=7.83 Hz, 1H) 8.32 (s, 1H) 8.84(d, J=2.35 Hz, 1H) 10.65 (s, 1H). LCMS (m/z) (M+H)=515.1, Rt=0.72 min.

Examples 316 and 317:N-(6′-(((1r,4r)-4-hydroxycyclohexyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideandN-(6′-(((1s,4s)-4-hydroxycyclohexyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

After initial purification by preparative reverse phase HPLC, a secondpurification of the diastereomeric mixture was performed via chiral HPLC(SFC, methanol, OJ column). Isolated N-(6′-(((1r,4r)-4-hydroxycyclohexyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideandN-(6′-(((1s,4s)-4-hydroxycyclohexyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideas white solids. The stereochemical identity of the two peaks was notdetermined. Peak 1 (11% yield, Rt=1.91 min)¹H NMR (400 MHz, <cdcl3>) δppm 1.70-1.91 (m, 6H) 2.08-2.19 (m, 2H) 2.53 (s, 3H) 3.12-3.22 (m, 4H)3.83-3.93 (m, 5H) 5.32 (br. s., 1H) 7.04 (d, J=1.96 Hz, 1H) 7.61-7.71(m, 1H) 7.76 (d, J=1.96 Hz, 1H) 7.85 (d, J=7.83 Hz, 1H) 7.92 (br. s.,1H) 8.09 (d, J=7.83 Hz, 1H) 8.15 (s, 2H) 8.62 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=557.2, Rt=0.75. Peak 2 (4% yield, Rt=5.19 min)¹H NMR (400MHz, <cdcl3>) δ ppm 1.59-1.72 (m, 4H) 2.06 (d, J=6.26 Hz, 2H) 2.23-2.32(m, 2H) 2.53 (s, 3H) 3.14 (br. s., 4H) 3.80-3.93 (m, 5H) 5.15-5.25 (m,1H) 7.04 (s, 1H) 7.68 (t, J=7.63 Hz, 1H) 7.77 (s, 1H) 7.82-7.90 (m, 2H)8.09 (d, J=7.43 Hz, 1H) 8.12-8.19 (m, 2H) 8.61 (d, J=1.96 Hz, 1H). LCMS(m/z) (M+H)=557.2, Rt=0.75 min.

Examples 318 and 319rac-N-(6′-(((1,3-cis)-3-hydroxycyclopentyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideandrac-N-(6′-(((1,3-trans)-3-hydroxycyclopentyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

After initial purification by preparative reverse phase HPLC, a secondpurification of the diastereomeric mixture was performed via chiral HPLC(SFC, ethanol, OJ column). Isolatedrac-N-(6′-(((1,3-cis)-3-hydroxycyclopentyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(Peak 1, Rt=2.28 min) in 6% yield andrac-N-(6′-(((1,3-trans)-3-hydroxycyclopentyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(Peak 2, Rt=5.35 min) in 4% yield as white solids.rac-N-(6′-(((1,3-cis)-3-hydroxycyclopentyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide¹H NMR (400 MHz, <cdcl3>) δ ppm 1.90-2.08 (m, 4H) 2.09-2.28 (m, 2H) 2.53(s, 3H) 2.97-3.08 (m, 2H) 3.10-3.24 (m, 2H) 3.79-3.95 (m, 4H) 4.40 (br.s., 1H) 5.69 (br. s., 1H) 7.11 (d, J=1.57 Hz, 1H) 7.64-7.71 (m, 1H)7.81-7.89 (m, 3H) 8.09 (d, J=7.83 Hz, 1H) 8.14 (d, J=2.74 Hz, 2H) 8.62(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=543.1, Rt=0.72 min.rac-N-(6′-(((1,3-trans)-3-hydroxycyclopentyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide¹H NMR (400 MHz, <cdcl3>) δ ppm 1.67-1.80 (m, 1H) 1.87-1.99 (m, 1H)2.06-2.16 (m, 1H) 2.19 (t, J=4.89 Hz, 2H) 2.31-2.44 (m, 1H) 2.52 (s, 3H)3.12 (d, J=2.74 Hz, 4H) 3.88 (t, J=4.30 Hz, 4H) 4.58 (d, J=4.30 Hz, 1H)5.68 (br. s., 1H) 7.04 (s, 1H) 7.63-7.72 (m, 1H) 7.79 (s, 1H) 7.83-7.91(m, 2H) 8.09 (d, J=7.83 Hz, 1H) 8.14 (d, J=6.26 Hz, 2H) 8.61 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=543.1, Rt=0.73 min.

Example 320:N-(6′-((3-hydroxycyclohexyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

After initial purification by preparative reverse phase HPLC, a secondpurification of the diastereomeric mixture was performed via chiral HPLC(SFC, isopropanol, OD column). One of the four enantiomerically purepossible stereoisomers was isolated in pure form (Rt=10.29 min); theabsolute or relative configuration of this compound was not determined.IsolatedN-(6′-((3-hydroxycyclohexyl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideas a white solid in 31% yield. ¹H NMR (400 MHz, <cdcl3>) b ppm 1.47-1.56(m, 3H) 1.69-1.89 (m, 3H) 1.90-2.07 (m, 2H) 2.24 (d, J=12.91 Hz, 1H)2.52 (s, 3H) 3.07 (br. s., 2H) 3.14-3.22 (m, 2H) 3.89 (t, J=4.11 Hz, 5H)5.38 (dt, J=7.24, 3.81 Hz, 1H) 7.09 (d, J=1.96 Hz, 1H) 7.64-7.71 (m, 1H)7.79 (d, J=1.96 Hz, 1H) 7.83-7.91 (m, 2H) 8.06-8.17 (m, 3H) 8.62 (d,J=2.35 Hz, 1H). LCMS (m/z) (M+H)=557.1, Rt=0.76 min.

Example 321:N-(2-methyl-6′-((1-methylazetidin-3-yl)oxy)-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

After purification by preparative reverse phase HPLC, pure productfractions were stirred with saturated aqueous sodium carbonate for 15min. The mixture was extracted three times with ethyl acetate; thecombined organics were washed with brine, dried over magnesium sulfate,and concentrated. The residue was taken up in acetonitrile/water andlyophilized. IsolatedN-(2-methyl-6′-((1-methylazetidin-3-yl)oxy)-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideas a white solid in 23% yield. ¹H NMR (400 MHz, <cd3od>) δ ppm 2.48 (s,3H) 2.50-2.56 (m, 5H) 3.13-3.21 (m, 4H) 3.40-3.48 (m, 2H) 3.83-3.90 (m,4H) 3.98 (dd, J=8.80, 7.24 Hz, 2H) 5.34 (t, J=5.67 Hz, 1H) 7.28 (d,J=1.96 Hz, 1H) 7.70-7.81 (m, 2H) 7.92 (d, J=7.83 Hz, 1H) 8.11 (d, J=2.35Hz, 1H) 8.24 (d, J=7.83 Hz, 2H) 8.30 (s, 2H) 8.81 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=528.1, Rt=0.61 min.

Example 322N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

The crude residue was purified by preparative neutral reverse phase HPLC(acetonitrile/3.75 mM aqueous ammonium acetate eluent). Uponlyophilization of the pure fractions,N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the free base, a white solid, in 53% yield. ¹H NMR (400MHz, <cd3od>) δ ppm 2.32-2.42 (m, 2H) 2.48 (s, 3H) 2.88 (ddd, J=10.37,7.04, 2.93 Hz, 2H) 3.09-3.17 (m, 4H) 3.79-3.89 (m, 4H) 4.71 (s, 2H) 4.79(s, 2H) 5.16 (quin, J=6.95 Hz, 1H) 7.25 (d, J=1.96 Hz, 1H) 7.72-7.79 (m,2H) 7.92 (d, J=7.43 Hz, 1H) 8.10 (d, J=2.35 Hz, 1H) 8.24 (d, J=7.83 Hz,1H) 8.30 (s, 1H) 8.81 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=555.2,Rt=0.78 min.

Example 323 Synthesis of2-isopropyl-N-(6′-methoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

To a solution of NaOMe (5 equiv.) in dioxane (0.1 M) at 25° C. was addedN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-isopropylisonicotinamide(1.0 equiv.), and the reaction was heated to 105° C. and stirred for 1h. The reaction was cooled to room temperature, quenched with a fewdrops of water, and concentrated. The crude material was purified bypreparative reverse phase HPLC. Upon lyophilization of the purefractions,2-isopropyl-N-(6′-methoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamidewas isolated as the TFA salt, a pale yellow solid, in 52% yield. ¹H NMR(400 MHz, <cd3od>) δ ppm 1.40 (d, J=6.65 Hz, 6H) 2.69 (s, 3H) 3.10-3.18(m, 4H) 3.22-3.29 (m, 1H) 3.80-3.90 (m, 4H) 4.06 (s, 3H) 7.32 (d, J=1.96Hz, 1H) 7.89 (d, J=1.57 Hz, 1H) 7.91 (dd, J=5.48, 1.57 Hz, 1H) 8.02 (s,1H) 8.45 (d, J=1.96 Hz, 1H) 8.75 (d, J=5.48 Hz, 1H) 9.33 (d, J=2.35 Hz,1H). LCMS (m/z) (M+H)=448.3, Rt=0.52 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 323 using the appropriatestarting materials Differences in the workup and/or purificationprotocols are noted where applicable.

Example 324:N-(6′-methoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.69 (s, 3H) 3.05-3.18 (m, 4H) 3.79-3.90(m, 4H) 4.05 (s, 3H) 7.31 (d, J=1.96 Hz, 1H) 7.88 (d, J=1.96 Hz, 1H)8.18 (d, J=4.30 Hz, 1H) 8.36 (s, 1H) 8.44 (d, J=2.35 Hz, 1H) 8.97 (d,J=5.09 Hz, 1H) 9.33 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=474.2, Rt=0.66min.

Example 325: Synthesis ofN-(6′-(azetidin-3-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of 1-N-Boc-3-hydroxyazetidine (6 equiv.) in dioxane (0.1M) at 25° C. was added NaH (5.2 equiv.), and the mixture was stirred for15 min.N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was then added, and the reaction was heated to 105° C. andstirred for 4 h. The reaction was cooled to room temperature, pouredonto water, and extracted three times with ethyl acetate. The combinedorganics were dried over magnesium sulfate, filtered, and concentrated.The crude residue was taken up in DCM/TFA (5:1, 0.05 M), stirred at 25°C. overnight, and then concentrated. The crude material was purified bypreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(6′-(azetidin-3-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt, a pale yellow solid, in 61% yield. ¹H NMR(400 MHz, <cd3od>) δ ppm 2.56 (s, 3H) 3.35-3.46 (m, 4H) 3.66-3.74 (m,2H) 3.87 (dt, J=5.58, 3.47 Hz, 4H) 4.87-4.93 (m, 1H) 5.27 (dd, J=12.52,9.78 Hz, 1H) 5.75-5.88 (m, 1H) 7.73-7.80 (m, 1H) 7.86 (s, 1H) 7.94 (d,J=7.83 Hz, 1H) 8.22-8.27 (m, 2H) 8.30 (s, 1H) 8.45 (d, J=2.35 Hz, 1H)8.85 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=514.3, Rt=0.53 min.

Example 326:N-(6′-(2-cyanopropan-2-yl)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of isobutyronitrile (5 equiv.) in dioxane (0.1 M) at 25°C. was added KHMDS (0.5 M in toluene, 5.2 equiv.) and the mixture wasstirred for 15 min.N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was then added, and the reaction was stirred for 30 min.The reaction was cooled to room temperature, quenched with a few dropsof water, and concentrated. The crude material was purified bypreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(6′-(2-cyanopropan-2-yl)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt, a white solid, in 49% yield. ¹H NMR (400MHz, <cd3od>) δ ppm 1.86 (s, 6H) 2.65 (s, 3H) 2.92-3.12 (m, 4H) 3.92 (t,J=4.50 Hz, 4H) 7.75-7.82 (m, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.17 (d, J=1.96Hz, 1H) 8.28 (d, J=7.83 Hz, 1H) 8.35 (s, 1H) 8.44 (d, J=2.35 Hz, 1H)8.57 (d, J=1.96 Hz, 1H) 9.29 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=510.1,Rt=0.82 min.

Example 327:N-(2-methyl-6′-((methylsulfonyl)methyl)-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in THF (0.26 M) at 25° C. was added NaHMDS (1 M in THF, 5.1equiv.) followed by methyl sulfone (5 equiv.). The reaction was heatedto 80° C. and stirred for 2 h. The reaction was cooled to roomtemperature, poured onto brine and extracted three times with ethylacetate. The combined organics were dried over magnesium sulfate,filtered, and concentrated. The crude residue was purified bypreparative neutral reverse phase HPLC (acetonitrile/3.75 mM aqueousammonium acetate eluent). Upon lyophilization of the pure fractions,N-(2-methyl-6′-((methylsulfonyl)methyl)-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the free base in 60% yield. ¹H NMR (500 MHz, <cd3od>) δppm 2.54 (s, 3H) 3.02-3.08 (m, 4H) 3.24 (s, 3H) 3.88-3.93 (m, 4H)4.84-4.87 (m, 2H) 7.78 (t, J=7.72 Hz, 1H) 7.89 (d, J=1.89 Hz, 1H) 7.95(d, J=7.88 Hz, 1H) 8.22 (d, J=2.21 Hz, 1H) 8.27 (d, J=8.20 Hz, 1H) 8.33(s, 1H) 8.49 (d, J=1.89 Hz, 1H) 8.90 (d, J=2.21 Hz, 1H). LCMS (m/z)(M+H)=535.2, Rt=0.67 min.

Example 328: Synthesis ofN-methyl-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in THF/DMF (5:1; 0.05 M) was added sodium hydride (1.5equiv.) and methyl iodide (1.5 equiv.) and the reaction was heated to60° C. and stirred for 3 h. The reaction mixture was partitioned betweenwater and ethyl acetate, and the organic phase was dried with sodiumsulfate, filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-methyl-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 2% yield. LCMS (m/z) (M+H)=557.2,Rt=0.81 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 328 using the appropriatestarting materials.

Example 329:N-ethyl-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.07 (s, 3H) 1.54-1.71 (m, 2H) 1.92-2.05(m, 2H) 2.30 (s, 3H) 2.99 (br. s., 4H) 3.48-3.53 (m, 3H) 3.69 (br. s.,7H) 5.15-5.32 (m, 1H) 6.83-6.93 (m, 1H) 7.39-7.50 (m, 1H) 7.51-7.74 (m,4H) 8.07-8.21 (m, 1H). LCMS (m/z) (M+H)=571.2, Rt=0.84 min.

Example 330:N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-N-propyl-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.74-0.85 (m, 2H) 1.00-1.18 (m, 2H)1.38-1.55 (m, 1H) 1.59-1.72 (m, 2H) 1.87-2.03 (m, 2H) 2.32 (s, 3H) 2.99(br. s., 4H) 3.49 (br. s., 2H) 3.69 (d, J=3.91 Hz, 7H) 5.16-5.42 (m, 1H)6.82-7.04 (m, 1H) 7.40-7.74 (m, 6H) 8.05-8.38 (m, 1H). LCMS (m/z)(M+H)=585.3, Rt=0.9 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 117 using the appropriatestarting materials.

Example 331:N-(3-(1-ethyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.38 (t, J=7.04 Hz, 3H) 2.31 (s, 3H)3.11-3.21 (m, 4H) 3.82-3.91 (m, 4H) 4.11 (q, J=7.30 Hz, 2H) 6.96 (d,J=1.96 Hz, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.38 (d, J=1.96 Hz, 1H) 7.58 (d,J=8.22 Hz, 1H) 7.62 (s, 1H) 7.69-7.76 (m, 1H) 7.89 (d, J=7.83 Hz, 1H)8.20 (d, J=7.83 Hz, 1H) 8.25 (s, 1H), LCMS (m/z) (M+H)=486.2, Rt=0.95min.

Example 332:2-(2-cyanopropan-2-yl)-N-(1′-ethyl-2-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.39 (t, J=7.24 Hz, 3H) 1.82 (s, 6H)2.70 (s, 3H) 3.16 (br. s., 4H) 3.66-3.91 (m, 4H) 4.13 (q, J=7.30 Hz, 2H)6.94 (d, J=1.96 Hz, 1H) 7.54 (d, J=1.96 Hz, 1H) 7.86 (d, J=5.09 Hz, 1H)8.13 (s, 1H) 8.41 (d, J=1.96 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 9.22 (d,J=1.96 Hz, 1H), LCMS (m/z) (M+H)=487.3, Rt=0.56 min.

Example 333:N-(1′-(2-cyanoethyl)-2-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.55 (s, 3H) 3.05 (t, J=6.46 Hz, 2H)3.14 (br. s., 4H) 3.74 (t, J=4.41 Hz, 4H) 4.24 (t, J=6.46 Hz, 2H) 6.83(d, J=1.58 Hz, 1H) 7.60 (d, J=1.58 Hz, 1H) 7.84 (t, J=7.88 Hz, 1H) 8.03(d, J=7.88 Hz, 1H) 8.18 (br. s., 1H) 8.30 (d, J=7.88 Hz, 1H) 8.35 (s,1H) 8.93 (s, 1H) 10.83 (br. s., 1H), LCMS (m/z) (M+H)=512.3, Rt=0.66min.

Example 334:N-(3-(1-(2-cyanoethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.03 (t, J=19.17 Hz, 3H) 2.25 (s, 3H)3.00 (t, J=6.46 Hz, 2H) 3.10 (br. s., 4H) 3.60-3.69 (m, 4H) 4.20 (t,J=6.46 Hz, 2H) 6.71 (s, 1H) 7.28 (d, J=8.61 Hz, 1H) 7.43 (d, J=1.57 Hz,1H) 7.62 (d, J=1.96 Hz, 1H) 7.67 (d, J=8.22 Hz, 1H) 8.01 (d, J=4.70 Hz,1H) 8.16 (s, 1H) 8.86 (d, J=4.70 Hz, 1H) 10.61 (s, 1H), LCMS (m/z)(M+H)=508.2, Rt=0.78 min.

Example 335:N-(3-(1-(2-cyanoethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-2-(2-cyanopropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 2.26 (s, 3H) 3.00 (t, J=6.26Hz, 2H) 3.10 (br. s., 4H) 3.70 (d, J=4.30 Hz, 4H) 4.20 (t, J=6.46 Hz,2H) 6.71 (d, J=1.57 Hz, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.43 (d, J=1.96 Hz,1H) 7.61 (s, 1H) 7.65 (d, J=8.61 Hz, 1H) 7.84 (d, J=5.09 Hz, 1H) 7.99(s, 1H) 8.79 (d, J=5.09 Hz, 1H) 10.53 (s, 1H), LCMS (m/z) (M+H)=511.3,Rt=0.76 min.

Example 336:N-(3-(1-(2-cyanoethyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(difluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 3.00 (t, J=6.26 Hz, 2H) 3.11(br. s., 4H) 3.70 (d, J=4.30 Hz, 4H) 4.20 (t, J=6.46 Hz, 2H) 6.72 (d,J=1.96 Hz, 1H) 6.91-7.30 (m, 2H) 7.43 (d, J=1.96 Hz, 1H) 7.60-7.69 (m,3H) 7.77 (d, J=7.43 Hz, 1H) 8.06-8.18 (m, 2H) 10.37 (s, 1H), LCMS (m/z)(M+H)=493.3, Rt=0.80 min.

Example 337:N-(4-methyl-3-(1-((3-methyloxetan-3-yl)methyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.04 (s, 3H) 2.25 (s, 3H) 3.01-3.20 (m,4H) 3.43 (br. s., 2H) 3.74 (t, J=4.30 Hz, 4H) 4.34 (d, J=13.69 Hz, 1H)4.44-4.58 (m, 2H) 4.65 (d, J=10.56 Hz, 1H) 7.37 (d, J=8.22 Hz, 1H) 7.68(dd, J=8.22, 1.96 Hz, 1H) 7.75-7.86 (m, 2H) 7.97 (d, J=7.83 Hz, 1H) 8.07(s, 1H) 8.21-8.32 (m, 2H) 10.55 (s, 1H), LCMS (m/z) (M+H)=542.4, Rt=0.80min.

Example 338:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-((3-methyloxetan-3-yl)methyl)-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.95 (s, 3H) 1.72 (s, 6H) 2.40 (s, 3H)2.76-3.01 (m, 4H) 3.64 (br. s., 5H) 4.30 (d, J=13.69 Hz, 1H) 4.39-4.52(m, 2H) 4.61 (d, J=10.56 Hz, 1H) 7.24-7.49 (m, 3H) 7.63-7.78 (m, 2H)7.92 (s, 1H) 8.19 (s, 1H) 8.76 (d, J=4.70 Hz, 1H) 10.42 (s, 1H), LCMS(m/z) (M+H)=542.4, Rt=0.66 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 171 using the appropriatestarting materials.

Example 339:4-methoxy-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.32 (s, 3H) 3.13-3.25 (m, 4H) 3.66 (s,3H) 3.84-3.94 (m, 4H) 4.02 (s, 3H) 7.02 (d, J=1.96 Hz, 1H) 7.31 (dd,J=15.65, 8.22 Hz, 2H) 7.40 (d, J=1.96 Hz, 1H) 7.55 (dd, J=8.22, 1.96 Hz,1H) 7.61 (d, J=1.96 Hz, 1H) 8.17-8.27 (m, 2H). LCMS (m/z) (M+H)=502.2,Rt=0.87 min.

Example 340:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethoxy)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.32 (s, 3H) 3.15-3.22 (m, 4H) 3.66 (s,3H) 3.84-3.93 (m, 4H) 6.99 (d, J=1.96 Hz, 1H) 7.31 (d, J=8.22 Hz, 1H)7.39 (d, J=1.96 Hz, 1H) 7.53 (d, J=8.22 Hz, 1H) 7.58 (dd, J=8.02, 2.15Hz, 1H) 7.61-7.68 (m, 2H) 7.87 (s, 1H) 7.97 (d, J=7.83 Hz, 1H). LCMS(m/z) (M+H)=488.3, Rt=0.93 min.

Example 341:2-(1,1-difluoropropyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cdcl3>) δ ppm 1.03 (t, J=7.43 Hz, 3H) 2.29 (s, 3H)2.32-2.49 (m, 2H) 3.17 (d, J=3.91 Hz, 4H) 3.60 (s, 3H) 3.80-3.94 (m, 4H)6.64 (s, 1H) 6.99 (d, J=1.56 Hz, 1H) 7.29 (d, J=8.61 Hz, 1H) 7.49-7.62(m, 2H) 7.86 (d, J=4.30 Hz, 1H) 8.06 (s, 1H) 8.24 (s, 1H) 8.85 (d,J=5.09 Hz, 1H). LCMS (m/z) (M+H)=483.2, Rt=0.85 min.

Example 344:3-ethoxy-4-fluoro-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.46 (t, J=7.04 Hz, 3H) 2.31 (s, 3H)3.17-3.27 (m, 4H) 3.66 (s, 3H) 3.84-3.96 (m, 4H) 4.21 (q, J=7.04 Hz, 2H)7.06 (d, J=2.35 Hz, 1H) 7.23 (dd, J=10.76, 8.41 Hz, 1H) 7.29 (d, J=8.22Hz, 1H) 7.42 (d, J=2.35 Hz, 1H) 7.50-7.58 (m, 2H) 7.61 (d, J=1.96 Hz,1H) 7.67 (dd, J=8.22, 1.96 Hz, 1H). LCMS (m/z) (M+H)=466.1, Rt=0.87 min.

Example 345:3-isopropoxy-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.36 (d, J=5.87 Hz, 6H) 2.32 (s, 3H)3.15-3.26 (m, 4H) 3.66 (s, 3H) 3.84-3.96 (m, 4H) 4.70 (dt, J=12.13, 6.06Hz, 1H) 7.02 (d, J=2.35 Hz, 1H) 7.13 (dd, J=8.22, 1.57 Hz, 1H) 7.29 (d,J=8.22 Hz, 1H) 7.38-7.44 (m, 2H) 7.45-7.52 (m, 2H) 7.56 (dd, J=8.22,2.35 Hz, 1H) 7.61 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=462.2, Rt=0.89min.

Example 346:2-chloro-3-(1-cyanocyclopropyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45-1.53 (m, 2H) 1.77-1.85 (m, 2H) 2.32(s, 3H) 3.16-3.26 (m, 4H) 3.66 (s, 3H) 3.84-3.96 (m, 4H) 7.03 (d, J=2.35Hz, 1H) 7.30 (d, J=8.61 Hz, 1H) 7.41 (d, J=2.35 Hz, 1H) 7.45-7.52 (m,1H) 7.52-7.60 (m, 1H) 7.60-7.66 (m, 1H). LCMS (m/z) (M+H)=503.1, Rt=0.80min.

Example 347:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.30 (s, 3H) 2.99-3.20 (m, 4H) 3.64 (s,3H) 3.78-3.94 (m, 4H) 6.99 (d, J=1.96 Hz, 1H) 7.27 (d, J=8.22 Hz, 1H)7.38 (d, J=1.96 Hz, 1H) 7.47-7.63 (m, 3H) 7.92 (d, J=7.04 Hz, 1H), LCMS(m/z) (M+H)=404.1, Rt=0.75 min.

Example 348:2-isopropyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (d, J=7.04 Hz, 6H) 2.31 (s, 3H)3.03-3.19 (m, 4H) 3.32-3.44 (m, 1H) 3.63 (s, 3H) 3.76-3.96 (m, 4H) 6.93(d, J=1.96 Hz, 1H) 7.28-7.41 (m, 2H) 7.58-7.70 (m, 2H) 8.12 (dd, J=5.67,1.37 Hz, 1H) 8.23 (s, 1H) 8.79 (d, J=5.87 Hz, 1H), LCMS (m/z)(M+H)=447.1, Rt=0.60 min.

Example 349:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(1,3,4-oxadiazol-2-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.17 (br. s., 4H) 3.64 (s,3H) 3.80-3.93 (m, 4H) 6.99 (d, J=1.96 Hz, 1H) 7.30 (d, J=8.22 Hz, 1H)7.39 (d, J=1.96 Hz, 1H) 7.54-7.66 (m, 2H) 7.75 (t, J=7.83 Hz, 1H) 8.17(d, J=8.22 Hz, 1H) 8.29 (d, J=7.83 Hz, 1H) 8.64 (s, 1H) 9.07 (s, 1H),LCMS (m/z) (M+H)=472.3, Rt=0.69 min.

Example 350:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.67 (s, 6H) 2.31 (s, 3H) 3.05-3.19(m, 4H) 3.63 (s, 3H) 3.79-3.92 (m, 4H) 6.93 (d, J=1.57 Hz, 1H) 7.26-7.40(m, 2H) 7.53-7.73 (m, 2H) 8.10 (d, J=5.87 Hz, 1H) 8.40 (s, 1H) 8.76 (d,J=5.48 Hz, 1H), LCMS (m/z) (M+H)=463.3, Rt=0.55 min.

Example 351:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(2-(methylsulfonyl)propan-2-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.80 (s, 6H) 2.24 (s, 3H) 2.72 (s, 3H)3.09 (br. s., 4H) 3.48 (s, 3H) 3.66-3.77 (m, 4H) 6.69 (d, J=1.96 Hz, 1H)7.25 (d, J=8.22 Hz, 1H) 7.38 (d, J=1.96 Hz, 1H) 7.56 (t, J=7.83 Hz, 1H)7.60-7.68 (m, 2H) 7.81 (d, J=8.22 Hz, 1H) 7.96 (d, J=7.43 Hz, 1H) 8.10(s, 1H) 10.25 (s, 1H), LCMS (m/z) (M+H)=524, Rt=0.70 min.

Example 352:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(oxetan-3-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.24 (s, 3H) 3.09 (br. s., 4H) 3.48 (br.s., 3H) 3.69 (d, J=4.30 Hz, 4H) 4.33 (t, J=7.63 Hz, 1H) 4.67 (t, J=6.26Hz, 2H) 4.96 (dd, J=8.22, 5.87 Hz, 2H) 6.69 (d, J=1.96 Hz, 1H) 7.24 (d,J=8.22 Hz, 1H) 7.38 (d, J=1.96 Hz, 1H) 7.46-7.54 (m, 1H) 7.57-7.71 (m,3H) 7.83 (d, J=7.43 Hz, 1H) 7.96 (s, 1H) 10.21 (s, 1H), LCMS (m/z)(M+H)=460.2, Rt=0.70 min.

Example 353:2-ethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.28 (t, J=7.63 Hz, 3H) 2.25 (s, 3H) 2.90(q, J=7.70 Hz, 2H) 3.09 (br. s., 4H) 3.48 (s, 3H) 3.64-3.88 (m, 4H) 6.69(d, J=1.96 Hz, 1H) 7.27 (d, J=8.22 Hz, 1H) 7.39 (d, J=1.96 Hz, 1H)7.58-7.69 (m, 2H) 7.80 (d, J=4.70 Hz, 1H) 7.87 (s, 1H) 8.73 (d, J=5.09Hz, 1H) 10.51 (s, 1H), LCMS (m/z) (M+H)=433.1, Rt=0.59 min.

Example 354:2-cyclopropyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.08-1.23 (m, 2H) 1.31 (dd, J=8.02, 2.93Hz, 2H) 2.30 (s, 4H) 3.02-3.18 (m, 4H) 3.63 (s, 3H) 3.78-3.92 (m, 4H)6.91 (d, J=1.96 Hz, 1H) 7.24-7.42 (m, 2H) 7.53-7.69 (m, 2H) 7.81-8.04(m, 2H) 8.64 (d, J=5.48 Hz, 1H), LCMS (m/z) (M+H)=445.1, Rt=0.60 min.

Example 355:2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.71 (s, 3H) 1.76 (s, 3H) 2.31 (s, 3H)3.11-3.22 (m, 4H) 3.64 (s, 3H) 3.83-3.99 (m, 4H) 7.03 (d, J=1.96 Hz, 1H)7.30 (d, J=8.22 Hz, 1H) 7.41 (d, J=1.96 Hz, 1H) 7.58 (dd, J=8.22, 2.35Hz, 1H) 7.64 (d, J=1.96 Hz, 1H) 7.80 (dd, J=5.09, 1.57 Hz, 1H) 8.08 (s,1H) 8.71 (d, J=5.09 Hz, 1H), LCMS (m/z) (M+H)=465.0, Rt=0.79 min.

Example 356:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(oxetan-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.30 (s, 3H) 2.98-3.20 (m, 4H) 3.64 (s,3H) 3.79-3.95 (m, 4H) 4.45-4.65 (m, 1H) 4.96 (t, J=6.26 Hz, 2H) 5.11(dd, J=8.61, 5.87 Hz, 2H) 6.97 (d, J=2.35 Hz, 1H) 7.30 (d, J=8.22 Hz,1H) 7.37 (d, J=1.96 Hz, 1H) 7.53-7.67 (m, 2H) 7.86 (dd, J=5.28, 1.37 Hz,1H) 7.99 (s, 1H) 8.78 (d, J=5.48 Hz, 1H), LCMS (m/z) (M+H)=461.0,Rt=0.61 min.

Example 357:2-(1-cyanocyclopropyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.74-1.89 (m, 4H) 2.30 (s, 3H) 3.05-3.20(m, 4H) 3.64 (s, 3H) 3.80-3.93 (m, 4H) 6.93 (d, J=1.96 Hz, 1H) 7.26-7.43(m, 2H) 7.52-7.63 (m, 2H) 7.67-7.80 (m, 1H) 8.07 (s, 1H) 8.64 (d, J=5.09Hz, 1H), LCMS (m/z) (M+H)=470.0, Rt=0.77 min.

Example 358:2-(difluoromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.17-3.22 (m, 4H) 3.65 (s,3H) 3.85-3.91 (m, 4H) 6.67-6.98 (m, 1H) 7.02 (d, J=1.96 Hz, 1H) 7.31 (d,J=8.22 Hz, 1H) 7.40 (d, J=1.96 Hz, 1H) 7.59 (dd, J=8.41, 2.15 Hz, 1H)7.65 (d, J=1.96 Hz, 1H) 8.01 (d, J=5.09 Hz, 1H) 8.17 (s, 1H) 8.83 (d,J=5.09 Hz, 1H). LCMS (m/z) (M+H)=455.1, Rt=0.75 min.

Example 359:3-(cyanomethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.24 (s, 3H) 3.09 (br. s., 4H) 3.43-3.52(m, 3H) 3.62-3.75 (m, 4H) 3.86 (s, 1H) 4.09-4.18 (m, 3H) 6.69 (d, J=1.96Hz, 1H) 7.20-7.28 (m, 1H) 7.39 (d, J=1.96 Hz, 1H) 7.48-7.58 (m, 2H)7.59-7.71 (m, 2H) 7.86-7.92 (m, 2H) 10.27 (s, 1H). LCMS (m/z)(M+H)=443.3, Rt=0.71 min.

Example 360:6-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.84 (s, 6H) 2.26 (s, 3H) 3.09 (br. s.,4H) 3.48 (s, 3H) 3.66-3.72 (m, 5H) 6.68 (d, J=1.57 Hz, 1H) 7.30 (d,J=8.22 Hz, 1H) 7.39 (d, J=1.96 Hz, 1H) 7.60 (d, J=1.96 Hz, 1H) 7.64 (dd,J=8.22, 1.96 Hz, 1H) 8.28 (d, J=1.56 Hz, 1H) 9.63 (d, J=1.96 Hz, 1H)10.71 (s, 1H). LCMS (m/z) (M+H)=473.1, Rt=0.67 min.

Example 361:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-6-(trifluoromethyl) pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.08-3.22 (m, 4H) 3.64 (s,3H) 3.80-3.93 (m, 4H) 7.01 (d, J=1.96 Hz, 1H) 7.32 (d, J=8.22 Hz, 1H)7.40 (d, J=2.35 Hz, 1H) 7.55-7.70 (m, 2H) 8.57 (d, J=1.96 Hz, 1H) 9.86(d, J=1.57 Hz, 1H). LCMS (m/z) (M+H)=474.1, Rt=0.76 min.

Example 362:6-cyclopropyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.15-1.34 (m, 4H) 2.30 (s, 3H) 2.33-2.45(m, 1H) 3.11-3.19 (m, 4H) 3.64 (s, 3H) 3.82-3.89 (m, 4H) 6.95 (d, J=1.96Hz, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.36 (d, J=1.96 Hz, 1H) 7.55-7.65 (m,2H) 7.96 (d, J=1.96 Hz, 1H) 9.39 (d, J=1.96 Hz, 1H). LCMS (m/z)(M+H)=446.2, Rt=0.68 min.

Example 363:6-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.77-1.92 (m, 6H) 2.31 (s, 3H) 3.13-3.23(m, 4H) 3.64 (s, 3H) 3.81-3.95 (m, 4H) 7.02 (d, J=1.96 Hz, 1H) 7.31 (d,J=8.22 Hz, 1H) 7.40 (d, J=2.35 Hz, 1H) 7.60 (dd, J=8.22, 2.35 Hz, 1H)7.66 (d, J=1.96 Hz, 1H) 8.33 (d, J=1.57 Hz, 1H) 9.56 (d, J=1.96 Hz, 1H).LCMS (m/z) (M+H)=466.2, Rt=0.74 min.

Example 364:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-4-(trifluoromethyl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.33 (s, 3H) 3.16-3.26 (m, 4H) 3.67 (s,3H) 3.84-3.96 (m, 4H) 7.02 (d, J=2.35 Hz, 1H) 7.33 (d, J=8.22 Hz, 1H)7.42 (d, J=1.96 Hz, 1H) 7.67-7.78 (m, 2H) 7.94 (d, J=3.91 Hz, 1H) 8.45(s, 1H) 8.98 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=473.1, Rt=0.89 min.

Example 365:1-ethyl-3-methyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1H-pyrazole-4-carboxamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.38 (t, J=7.25 Hz, 3H) 2.23 (s, 3H)2.34 (s, 3H) 3.11 (br. s., 4H) 3.49 (s, 3H) 3.72 (t, J=4.41 Hz, 4H) 4.09(q, J=7.25 Hz, 2H) 6.70 (d, J=1.89 Hz, 1H) 7.20 (d, J=8.20 Hz, 1H) 7.39(d, J=2.21 Hz, 1H) 7.51-7.61 (m, 2H) 8.33 (s, 1H) 9.61 (s, 1H). LCMS(m/z) (M+H)=436.1, Rt=0.67 min.

Example 366:1,3-dimethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1H-pyrazole-4-carboxamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.22 (s, 3H) 2.33 (s, 3H) 3.10 (m, 4H)3.49 (s, 3H) 3.72 (t, J=4.41 Hz, 4H) 3.81 (s, 3H) 6.70 (d, J=2.21 Hz,1H) 7.14-7.26 (m, 1H) 7.39 (d, J=1.89 Hz, 1H) 7.56 (dd, J=4.41, 2.21 Hz,2H) 8.27 (s, 1H) 9.62 (s, 1H). LCMS (m/z) (M+H)=422.1, Rt=0.62 min.

Example 367:1-isopropyl-3-methyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1H-pyrazole-4-carboxamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.42 (d, J=6.62 Hz, 6H) 2.23 (s, 3H)2.35 (s, 3H) 3.10 (br. s., 4H) 3.49 (s, 3H) 3.72 (t, J=4.41 Hz, 4H) 4.43(spt, J=6.62 Hz, 1H) 6.70 (d, J=2.21 Hz, 1H) 7.20 (d, J=8.20 Hz, 1H)7.39 (d, J=2.21 Hz, 1H) 7.49-7.65 (m, 2H) 8.38 (s, 1H) 9.59 (s, 1H).LCMS (m/z) (M+H)=450.1, Rt=0.72 min.

Example 368:3-cyclopropyl-1-methyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1H-pyrazole-5-carboxamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.42 (d, J=6.62 Hz, 6H) 2.23 (s, 3H)2.35 (s, 3H) 3.10 (br. s., 4H) 3.49 (s, 3H) 3.72 (t, J=4.41 Hz, 4H) 4.43(spt, J=6.62 Hz, 1H) 6.70 (d, J=2.21 Hz, 1H) 7.20 (d, J=8.20 Hz, 1H)7.39 (d, J=2.21 Hz, 1H) 7.49-7.65 (m, 2H) 8.38 (s, 1H) 9.59 (s, 1H).LCMS (m/z) (M+H)=448.1, Rt=0.78 min.

Example 369:1-methyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.26 (s, 3H) 3.11 (br. s., 4H) 3.50 (s,3H) 3.72 (t, J=4.41 Hz, 4H) 4.16 (s, 3H) 6.70 (d, J=1.89 Hz, 1H) 7.28(d, J=8.20 Hz, 1H) 7.41 (d, J=1.89 Hz, 1H) 7.51 (s, 1H) 7.57-7.63 (m,2H) 10.38 (s, 1H). LCMS (m/z) (M+H)=476.1, Rt=0.86 min.

Example 371:5-isopropyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isoxazole-3-carboxamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.29 (d, J=6.94 Hz, 6H) 2.25 (s, 3H)3.10 (br. s., 4H) 3.13-3.22 (m, 1H) 3.49 (s, 3H) 3.68-3.74 (m, 4H)6.61-6.77 (m, 2H) 7.25 (d, J=8.20 Hz, 1H) 7.40 (d, J=2.21 Hz, 1H)7.58-7.74 (m, 2H) 10.59 (s, 1H). LCMS (m/z) (M+H)=437.1, Rt=0.87 min.

Example 372:5-cyclopropyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isoxazole-3-carboxamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 0.92-0.99 (m, 2H) 1.09-1.16 (m, 2H)2.19-2.24 (m, 1H) 2.25 (s, 3H) 3.10 (br. s., 4H) 3.49 (s, 3H) 3.71 (t,J=4.26 Hz, 4H) 6.61 (s, 1H) 6.70 (d, J=1.89 Hz, 1H) 7.25 (d, J=8.83 Hz,1H) 7.40 (d, J=1.89 Hz, 1H) 7.56-7.75 (m, 2H) 10.56 (s, 1H). LCMS (m/z)(M+H)=435.1, Rt=0.82 min.

Example 373:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-1-ethyl-3-methyl-1H-pyrazole-4-carboxamide

LCMS (m/z) (M+H)=437.1, Rt=0.48 min.

Example 374:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-1,3-dimethyl-1H-pyrazole-4-carboxamide

LCMS (m/z) (M+H)=423.1, Rt=0.44 min.

Example 375:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-1-isopropyl-3-methyl-1H-pyrazole-4-carboxamide

LCMS (m/z) (M+H)=451.1, Rt=0.52 min.

Example 376:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-1,3-dimethyl-1H-pyrazole-5-carboxamide

LCMS (m/z) (M+H)=423.1, Rt=0.47 min.

Example 377:3-cyclopropl-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-1-methyl-iH-pyrazole-5-carboxamide

LCMS (m/z) (M+H)=449.1, Rt=0.54 min.

Example 379:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-5-isopropylisoxazole-3-carboxamide

LCMS (m/z) (M+H)=438.1, Rt=0.59 min.

Example 380:5-cyclopropl-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)isoxazole-3-carboxamide

LCMS (m/z) (M+H)=436.1, Rt=0.55 min.

Example 381:1,3-dimethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1H-pyrazole-5-carboxamide

¹H NMR (500 MHz, DMSO-d₆) δ ppm 2.08-2.31 (m, 6H) 3.11 (br. s., 4H) 3.50(s, 3H) 3.72 (t, J=4.41 Hz, 4H) 3.99 (s, 3H) 6.69 (d, J=1.89 Hz, 1H)6.82 (s, 1H) 7.25 (d, J=8.51 Hz, 1H) 7.40 (d, J=1.89 Hz, 1H) 7.52-7.70(m, 3H) 10.09 (s, 1H). LCMS (m/z) (M+H)=422.1, Rt=0.69 min.

Example 382:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide

LCMS (m/z) (M+H)=477.1, Rt=0.60 min.

Example 383:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2,5-dimethyloxazole-4-carboxamide

LCMS (m/z) (M+H)=424.1, Rt=0.51 min.

Example 384:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2,5-dimethyloxazole-4-carboxamide

LCMS (m/z) (M+H)=424.1, Rt=0.51 min.

Example 385: racemictrans-1,3-dimethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1H-pyrazole-5-carboxamide

¹H NMR (400 MHz, CDCl₃) δ ppm 0.93 (dd, J=16.82, 6.65 Hz, 6H) 1.57-2.08(m, 7H) 2.50 (s, 3H) 2.81-2.95 (m, 1H) 3.11-3.29 (m, 4H) 3.42 (ddd,J=9.88, 7.14, 2.15 Hz, 1H) 3.60 (s, 3H) 3.71-4.01 (m, 7H) 6.60 (d,J=1.96 Hz, 1H) 7.00 (d, J=2.35 Hz, 1H) 7.57 (br. s., 1H) 8.23 (br. s.,1H) 8.38 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=455.1, Rt=0.52 min.

Example 386: racemiccis-1,3-dimethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-1H-pyrazole-5-carboxamide

¹H NMR (400 MHz, CDCl₃) δ ppm 0.94 (dd, J=12.52, 6.65 Hz, 6H) 1.42-2.01(m, 8H) 2.43-2.62 (m, 4H) 3.06 (dd, J=9.98, 6.06 Hz, 1H) 3.20 (d, J=4.30Hz, 4H) 3.40-3.53 (m, 1H) 3.60 (s, 3H) 3.80-3.99 (m, 4H) 4.03-4.24 (m,1H) 6.61 (d, J=1.57 Hz, 1H) 7.00 (d, J=1.57 Hz, 1H) 8.22 (br. s., 1H)8.40 (s, 1H). LCMS (m/z) (M+H)=455.1, Rt=0.52 min.

Example 387:(R)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2-(tetrahydrofuran-2-yl)acetamide

¹H NMR (400 MHz, CDCl₃) δ ppm 1.50-1.83 (m, 7H) 1.90-2.05 (m, 2H)2.08-2.22 (m, 1H) 2.49 (s, 2H) 2.55-2.63 (m, 1H) 2.63-2.71 (m, 1H)3.15-3.27 (m, 4H) 3.60 (s, 3H) 3.84-3.94 (m, 5H) 3.96-4.08 (m, 1H)4.15-4.32 (m, 1H) 6.61 (d, J=1.96 Hz, 1H) 6.99 (d, J=1.96 Hz, 1H) 8.12(d, J=1.57 Hz, 1H) 8.41 (d, J=2.35 Hz, 1H) 8.78 (br. s., 1H). LCMS (m/z)(M+H)=413.1, Rt=0.43 min.

Example 388:(S)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2-(tetrahydrofuran-2-yl)acetamide

¹H NMR (400 MHz, CDCl₃) δ ppm 1.50-1.83 (m, 7H) 1.90-2.05 (m, 2H)2.08-2.22 (m, 1H) 2.49 (s, 2H) 2.55-2.63 (m, 1H) 2.63-2.71 (m, 1H)3.15-3.27 (m, 4H) 3.60 (s, 3H) 3.84-3.94 (m, 5H) 3.96-4.08 (m, 1H)4.15-4.32 (m, 1H) 6.61 (d, J=1.96 Hz, 1H) 6.99 (d, J=1.96 Hz, 1H) 8.12(d, J=1.57 Hz, 1H) 8.41 (d, J=2.35 Hz, 1H) 8.78 (br. s., 1H). LCMS (m/z)(M+H)=413.1, Rt=0.43 min.

Example 389:3-(2-cyanopropan-2-yl)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.82 (s, 6H) 2.69 (s, 3H) 3.15-3.22 (m,4H) 3.67 (s, 3H) 3.83-3.93 (m, 4H) 6.98 (d, J=1.96 Hz, 1H) 7.53 (d,J=1.96 Hz, 1H) 7.65 (t, J=7.83 Hz, 1H) 7.85 (d, J=7.83 Hz, 1H) 7.99 (d,J=7.83 Hz, 1H) 8.18 (s, 1H) 8.39 (d, J=1.96 Hz, 1H) 9.19 (s, 1H). LCMS(m/z) (M+H)=472.1, Rt=0.60 min.

Example 390:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.72 (s, 3H) 3.14-3.22 (m, 4H) 3.67 (s,3H) 3.83-3.91 (m, 4H) 6.97 (d, J=2.30 Hz, 1H) 7.54 (d, J=2.25 Hz, 1H)8.19 (dd, J=5.01, 1.54 Hz, 1H) 8.37 (s, 1H) 8.43 (d, J=2.35 Hz, 1H) 8.99(d, J=5.14 Hz, 1H) 9.23 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=474.0,Rt=0.56 min.

Example 391:2-(1,1-difluoroethyl)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.07 (t, J=18.73 Hz, 3H) 2.69 (s, 3H)3.14-3.22 (m, 4H) 3.67 (s, 3H) 3.83-3.92 (m, 4H) 6.97 (d, J=2.25 Hz, 1H)7.53 (d, J=2.20 Hz, 1H) 8.03 (d, J=5.09 Hz, 1H) 8.26 (d, J=0.73 Hz, 1H)8.39 (d, J=2.35 Hz, 1H) 8.88 (d, J=5.09 Hz, 1H) 9.17 (d, J=2.30 Hz, 1H).LCMS (m/z) (M+H)=470.1, Rt=0.55 min.

Example 392:2-(difluoromethyl)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.71 (s, 3H) 3.16-3.22 (m, 4H) 3.67 (s,3H) 3.84-3.92 (m, 4H) 6.70-7.03 (m, 2H) 7.54 (d, J=2.30 Hz, 1H) 8.08 (d,J=5.14 Hz, 1H) 8.26 (s, 1H) 8.42 (d, J=2.40 Hz, 1H) 8.91 (d, J=4.99 Hz,1H) 9.22 (d, J=2.30 Hz, 1H). LCMS (m/z) (M+H)=456.0, Rt=0.50 min.

Example 393:3-(1,1-difluoroethyl)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.01 (t, J=18.39 Hz, 3H) 2.73 (s, 3H)3.12-3.25 (m, 4H) 3.67 (s, 3H) 3.81-3.95 (m, 4H) 6.98 (d, J=1.96 Hz, 1H)7.56 (d, J=1.96 Hz, 1H) 7.64-7.74 (m, 1H) 7.84 (d, J=7.83 Hz, 1H) 8.13(d, J=7.83 Hz, 1H) 8.22 (s, 1H) 8.48 (d, J=2.35 Hz, 1H) 9.32 (d, J=1.96Hz, 1H). LCMS (m/z) (M+H)=469.1, Rt=0.62 min.

Example 394:3-(difluoromethyl)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.73 (s, 3H) 3.15-3.23 (m, 4H) 3.67 (s,3H) 3.83-3.93 (m, 4H) 6.74-7.09 (m, 2H) 7.55 (d, J=2.30 Hz, 1H)7.67-7.76 (m, 1H) 7.85 (d, J=7.58 Hz, 1H) 8.17 (d, J=7.82 Hz, 1H) 8.23(s, 1H) 8.47 (d, J=2.35 Hz, 1H) 9.30 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=455.0, Rt=0.57 min.

Example 395:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-ethoxy-4-fluorobenzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.48 (t, J=7.04 Hz, 3H) 2.68 (s, 3H)3.13-3.23 (m, 4H) 3.67 (s, 3H) 3.82-3.93 (m, 4H) 4.23 (q, J=7.04 Hz, 2H)6.97 (d, J=1.96 Hz, 1H) 7.28 (dd, J=10.76, 8.41 Hz, 1H) 7.52 (d, J=2.35Hz, 1H) 7.62 (ddd, J=8.22, 4.11, 2.15 Hz, 1H) 7.74 (dd, J=8.02, 1.76 Hz,1H) 8.36 (d, J=2.35 Hz, 1H) 9.15 (s, 1H). LCMS (m/z) (M+H)=467.3,Rt=0.61 min.

Example 396:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-4-fluoro-3-isopropoxybenzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.40 (d, J=5.87 Hz, 6H) 2.70 (s, 3H)3.12-3.24 (m, 4H) 3.67 (s, 3H) 3.82-3.94 (m, 4H) 4.74 (dt, J=12.13, 6.06Hz, 1H) 6.97 (d, J=1.96 Hz, 1H) 7.29 (dd, J=10.56, 8.61 Hz, 1H) 7.54 (d,J=1.96 Hz, 1H) 7.64 (ddd, J=8.41, 4.11, 2.35 Hz, 1H) 7.76 (dd, J=7.83,1.96 Hz, 1H) 8.41 (d, J=1.96 Hz, 1H) 9.22 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=481.2, Rt=0.66 min.

Example 397:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-ethoxybenzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.44 (t, J=6.85 Hz, 3H) 2.70 (s, 3H)3.14-3.23 (m, 4H) 3.67 (s, 3H) 3.83-3.93 (m, 4H) 4.15 (q, J=6.78 Hz, 2H)6.97 (d, J=1.96 Hz, 1H) 7.21 (dd, J=8.02, 2.15 Hz, 1H) 7.47 (t, J=8.02Hz, 1H) 7.51-7.62 (m, 3H) 8.41 (d, J=1.96 Hz, 1H) 9.23 (d, J=1.96 Hz,1H). LCMS (m/z) (M+H)=449.3, Rt=0.59 min.

Example 398:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-isopropoxybenzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.37 (d, J=5.87 Hz, 6H) 2.70 (s, 3H)3.15-3.24 (m, 4H) 3.67 (s, 3H) 3.81-3.94 (m, 4H) 4.72 (quin, J=6.16 Hz,1H) 6.97 (d, J=1.96 Hz, 1H) 7.20 (dd, J=8.02, 2.15 Hz, 1H) 7.47 (t,J=8.02 Hz, 1H) 7.50-7.60 (m, 3H) 8.42 (d, J=1.96 Hz, 1H) 9.23 (d, J=1.96Hz, 1H). LCMS (m/z) (M+H)=463.3, Rt=0.63 min.

Example 399:2-(tert-butyl)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.47 (s, 9H) 2.73 (s, 3H) 3.15-3.24 (m,4H) 3.67 (s, 3H) 3.82-3.93 (m, 4H) 6.97 (d, J=1.96 Hz, 1H) 7.55 (d,J=2.35 Hz, 1H) 7.78-7.87 (m, 1H) 8.07 (s, 1H) 8.46 (d, J=1.96 Hz, 1H)8.76 (d, J=5.09 Hz, 1H) 9.27 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=462.3,Rt=0.47 min.

Example 400:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.42 (d, J=6.65 Hz, 6H) 2.72 (s, 3H)3.15-3.22 (m, 4H) 3.23-3.30 (m, 1H) 3.67 (s, 3H) 3.82-3.93 (m, 4H) 6.97(d, J=1.96 Hz, 1H) 7.54 (d, J=1.96 Hz, 1H) 7.91 (dd, J=5.28, 1.37 Hz,1H) 8.02 (s, 1H) 8.45 (d, J=2.35 Hz, 1H) 8.76 (d, J=5.48 Hz, 1H) 9.26(d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=448.3, Rt=0.44 min.

Example 401:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-((dimethylamino)methyl)-5-(trifluoromethyl) benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.70 (s, 3H) 2.94 (s, 6H) 3.15-3.23 (m,4H) 3.67 (s, 3H) 3.83-3.93 (m, 4H) 4.55 (s, 2H) 6.96 (d, J=2.35 Hz, 1H)7.53 (d, J=1.96 Hz, 1 H) 8.17 (s, 1H) 8.45 (d, J=1.96 Hz, 1H) 8.50 (d,J=6.65 Hz, 2H) 9.21 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=540.3, Rt=0.50min.

Example 402:N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(4-ethylpiperazin-1-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (t, J=7.24 Hz, 3H) 2.67 (s, 3H)3.11-3.20 (m, 4H) 3.21-3.29 (m, 2H) 3.67 (s, 3H) 3.73 (br. s., 1H)3.83-3.94 (m, 4H) 4.11 (br. s., 1H) 6.96 (d, J=2.35 Hz, 1H) 7.51 (d,J=1.96 Hz, 1H) 7.58 (s, 1H) 7.88 (d, J=8.61 Hz, 2H) 8.36 (d, J=1.96 Hz,1H) 9.12 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=585.2, Rt=0.55 min.

Example 403:2-chloro-3-(1-cyanocyclopropyl)-N-(1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45-1.53 (m, 2H) 1.78-1.88 (m, 2H) 2.70(s, 3H) 3.11-3.23 (m, 4H) 3.66 (s, 3H) 3.81-3.92 (m, 4H) 6.96 (d, J=1.96Hz, 1H) 7.48-7.58 (m, 2H) 7.65 (dd, J=7.83, 1.57 Hz, 1H) 7.70 (dd,J=7.63, 1.37 Hz, 1H) 8.28 (d, J=2.35 Hz, 1H) 9.19 (d, J=1.96 Hz, 1H).LCMS (m/z) (M+H)=504.2, Rt=0.59 min.

The following compounds were prepared using methods similar to thosedescribed in Method 7 and Example 171 using the appropriate startingmaterials.

Example 404:N-(2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.14-3.24 (m, 4H) 3.67 (s, 3H) 3.82-3.93(m, 4H) 7.10 (d, J=1.96 Hz, 1H) 7.59 (d, J=2.35 Hz, 1H) 8.17 (d, J=4.70Hz, 1H) 8.30-8.39 (m, 2H) 8.75 (d, J=2.74 Hz, 1H) 8.96 (d, J=4.70 Hz,1H). LCMS (m/z) (M+H)=494.0, Rt=0.74 min.

Example 405:N-(2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.06 (t, J=18.78 Hz, 3H) 3.12-3.26 (m,4H) 3.67 (s, 3H) 3.82-3.95 (m, 4H) 7.10 (d, J=2.35 Hz, 1H) 7.59 (d,J=1.96 Hz, 1H) 8.01 (d, J=5.09 Hz, 1H) 8.23 (s, 1H) 8.35 (d, J=2.35 Hz,1H) 8.75 (d, J=2.74 Hz, 1H) 8.85 (d, J=5.09 Hz, 1H). LCMS (m/z)(M+H)=490.1, Rt=0.72 min.

Example 406:N-(2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(difluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.14-3.24 (m, 4H) 3.67 (s, 3H) 3.85-3.94(m, 4H) 6.73-7.06 (m, 1H) 7.10 (d, J=1.96 Hz, 1H) 7.59 (d, J=1.96 Hz,1H) 7.65-7.74 (m, 1H) 7.82 (d, J=7.43 Hz, 1H) 8.14 (d, J=7.43 Hz, 1H)8.19 (s, 1H) 8.34 (d, J=2.35 Hz, 1H) 8.74 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=475.0, Rt=0.75 min.

Example 407:N-(2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.15-3.24 (m, 4H) 3.67 (s, 3H) 3.85-3.93(m, 4H) 7.11 (d, J=1.96 Hz, 1H) 7.59 (d, J=2.35 Hz, 1H) 7.73-7.83 (m,1H) 7.95 (d, J=7.83 Hz, 1H) 8.26 (d, J=7.83 Hz, 1H) 8.32 (s, 1H) 8.35(d, J=2.74 Hz, 1H) 8.75 (d, J=2.74 Hz, 1H). LCMS (m/z) (M+H)=493.0,Rt=0.84 min.

Example 408:N-(2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-4-methoxy-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.12-3.24 (m, 4H) 3.67 (s, 3H) 3.84-3.93(m, 4H) 4.03 (s, 3H) 7.10 (d, J=1.96 Hz, 1H) 7.37 (d, J=8.61 Hz, 1H)7.59 (d, J=1.96 Hz, 1H) 8.21-8.37 (m, 3H) 8.72 (d, J=2.74 Hz, 1H). LCMS(m/z) (M+H)=523.2, Rt=0.83 min.

Example 409:N-(4-chloro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.14-3.23 (m, 4H) 3.67 (s, 3H) 3.84-3.93(m, 4H) 7.10 (d, J=1.96 Hz, 1H) 7.48-7.56 (m, 2H) 7.68-7.80 (m, 2H) 7.86(d, J=2.74 Hz, 1H) 7.92 (d, J=7.83 Hz, 1H) 8.23 (d, J=7.83 Hz, 1H) 8.28(s, 1H). LCMS (m/z) (M+H)=492.2, Rt=0.90 min.

Example 410:N-(4-chloro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.17-3.25 (m, 4H) 3.68 (s, 3H) 3.86-3.93(m, 4H) 7.19 (s, 1H) 7.20-7.29 (m, 1H) 7.64-7.72 (m, 2H) 7.72-7.81 (m,1H) 7.85-7.96 (m, 2H) 8.24 (d, J=7.83 Hz, 1H) 8.30 (s, 1H). LCMS (m/z)(M+H)=476.3, Rt=0.86 min.

Example 411:N-(4-cyano-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.18-3.23 (m, 4H) 3.68 (s, 3H) 3.85-3.92(m, 4H) 7.22 (d, J=1.96 Hz, 1H) 7.68 (dd, J=8.22, 1.57 Hz, 1H) 7.77-7.83(m, 1H) 7.83-7.89 (m, 2H) 7.93 (d, J=1.57 Hz, 1H) 7.98 (d, J=7.83 Hz,1H) 8.26-8.33 (m, 2H) 8.36 (s, 1H). LCMS (m/z) (M+H)=483.3, Rt=0.86 min.

Example 412:N-(4-chloro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(difluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.12-3.24 (m, 4H) 3.67 (s, 3H) 3.85-3.93(m, 4H) 6.73-7.05 (m, 1H) 7.08 (d, J=2.35 Hz, 1H) 7.52 (dd, J=5.28, 3.33Hz, 2H) 7.63-7.75 (m, 2H) 7.80 (d, J=7.83 Hz, 1H) 7.85 (d, J=2.35 Hz,1H) 8.11 (d, J=7.83 Hz, 1H) 8.15 (s, 1H). LCMS (m/z) (M+H)=474.0,Rt=0.88 min.

Example 413:N-(4-chloro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.15-3.25 (m, 4H) 3.67 (s, 3H) 3.82-3.95(m, 4H) 7.10 (d, J=1.96 Hz, 1H) 7.48-7.59 (m, 2H) 7.74 (dd, J=8.80, 2.54Hz, 1H) 7.87 (d, J=2.35 Hz, 1H) 8.14 (d, J=4.70 Hz, 1H) 8.32 (s, 1H)8.94 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=493.1, Rt=0.87 min.

Example 414:N-(4-chloro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.05 (t, J=18.78 Hz, 3H) 3.16-3.25 (m,4H) 3.67 (s, 3H) 3.83-3.94 (m, 4H) 7.12 (d, J=2.35 Hz, 1H) 7.48-7.58 (m,2H) 7.74 (dd, J=8.80, 2.54 Hz, 1H) 7.87 (d, J=2.74 Hz, 1H) 7.98 (d,J=4.70 Hz, 1H) 8.20 (s, 1H) 8.83 (d, J=5.09 Hz, 1H). LCMS (m/z)(M+H)=489.2, Rt=0.81 min.

Example 415:N-(4-cyano-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.18-3.26 (m, 4H) 3.68 (s, 3H) 3.84-3.94(m, 4H) 7.24 (d, J=1.96 Hz, 1H) 7.70 (dd, J=8.22, 1.57 Hz, 1H) 7.82-7.91(m, 2H) 7.95 (d, J=1.57 Hz, 1H) 8.20 (d, J=4.30 Hz, 1H) 8.37 (s, 1H)8.99 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=484.2, Rt=0.72 min.

Example 416:N-(4-cyano-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.07 (t, J=18.78 Hz, 3H) 3.18-3.28 (m,4H) 3.68 (s, 3H) 3.83-3.96 (m, 4H) 7.27 (d, J=1.96 Hz, 1H) 7.69 (dd,J=8.22, 1.57 Hz, 1H) 7.87 (dd, J=5.09, 3.13 Hz, 2H) 7.94 (d, J=1.17 Hz,1H) 8.04 (d, J=4.70 Hz, 1H) 8.27 (s, 1H) 8.88 (d, J=4.70 Hz, 1H). LCMS(m/z) (M+H)=484.2, Rt=0.72 min.

Example 417:3-(difluoromethyl)-N-(4-fluoro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.18-3.27 (m, 4H) 3.68 (s, 3H) 3.86-3.95(m, 4H) 6.73-7.07 (m, 1H) 7.18-7.29 (m, 2H) 7.62-7.73 (m, 3H) 7.79 (d,J=7.83 Hz, 1H) 7.89 (dd, J=7.04, 2.74 Hz, 1H) 8.12 (d, J=7.83 Hz, 1H)8.16 (s, 1H). LCMS (m/z) (M+H)=458.2, Rt=0.79 min.

Example 418:N-(4-cyano-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.19-3.26 (m, 4H) 3.68 (s, 3H) 3.86-3.95(m, 4H) 7.17-7.32 (m, 2H) 7.63-7.74 (m, 2H) 7.92 (dd, J=6.85, 2.54 Hz,1H) 8.15 (d, J=4.70 Hz, 1H) 8.33 (s, 1H) 8.94 (d, J=5.09 Hz, 1H). LCMS(m/z) (M+H)=477.2, Rt=0.78 min.

Example 419:N-(4-cyano-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.06 (t, J=18.59 Hz, 3H) 3.19-3.27 (m,4H) 3.68 (s, 3H) 3.86-3.97 (m, 4H) 7.17-7.31 (m, 2H) 7.63-7.75 (m, 2H)7.91 (dd, J=7.04, 2.35 Hz, 1H) 7.99 (d, J=4.70 Hz, 1H) 8.21 (s, 1H) 8.84(d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=473.2, Rt=0.76 min.

Example 420:N-(4-cyano-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(difluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.18-3.24 (m, 4H) 3.68 (s, 3H) 3.85-3.91(m, 4H) 6.76-7.10 (m, 1H) 7.22 (d, J=2.35 Hz, 1H) 7.64-7.69 (m, 1H)7.69-7.77 (m, 1H) 7.80-7.89 (m, 3H) 7.93 (d, J=1.57 Hz, 1H) 8.19 (d,J=7.83 Hz, 1H) 8.23 (s, 1H). LCMS (m/z) (M+H)=465.3, Rt=0.78 min.

Example 421:N-(4-chloro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.44 (d, J=7.04 Hz, 6H) 3.12-3.21 (m,4H) 3.66 (s, 3H) 3.83-3.93 (m, 4H) 7.04 (d, J=1.96 Hz, 1H) 7.50 (d,J=1.96 Hz, 1H) 7.55 (d, J=8.61 Hz, 1H) 7.71-7.78 (m, 1H) 7.86 (d, J=2.35Hz, 1H) 8.00 (d, J=5.48 Hz, 1H) 8.11 (s, 1H) 8.77 (d, J=5.87 Hz, 1H).LCMS (m/z) (M+H)=467.1, Rt=0.67 min.

Example 422:N-(2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (d, J=7.04 Hz, 6H) 3.14-3.22 (m,4H) 3.67 (s, 3H) 3.84-3.92 (m, 4H) 7.07 (d, J=2.35 Hz, 1H) 7.57 (d,J=2.35 Hz, 1H) 8.05 (dd, J=5.48, 1.17 Hz, 1H) 8.16 (s, 1H) 8.34 (d,J=2.74 Hz, 1H) 8.76 (d, J=2.74 Hz, 1H) 8.80 (d, J=5.48 Hz, 1H). LCMS(m/z) (M+H)=468.1, Rt=0.59 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 171 using the appropriatestarting materials.

Example 423:2-chloro-1′-methyl-5′-morpholino-6′-oxo-N-(3-(trifluoromethyl)phenyl)-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.16-3.24 (m, 4H) 3.67 (s, 3H) 3.85-3.92(m, 4H) 7.14 (d, J=1.96 Hz, 1H) 7.48 (d, J=7.83 Hz, 1H) 7.55-7.65 (m,2H) 7.97 (d, J=7.83 Hz, 1H) 8.18 (s, 1H) 8.39 (d, J=2.35 Hz, 1H) 8.93(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=493.2, Rt=0.86 min.

Example 424: 2-chloro-N-(3-(2-hydroxypropan-2-yl)phenyl)-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.57 (s, 6H) 3.14-3.24 (m, 4H) 3.67 (s,3H) 3.84-3.92 (m, 4H) 7.13 (d, J=1.96 Hz, 1H) 7.31-7.39 (m, 2H)7.58-7.66 (m, 2H) 7.82 (s, 1H) 8.37 (d, J=2.35 Hz, 1H) 8.91 (d, J=1.96Hz, 1H). LCMS (m/z) (M+H)=483.2, Rt=0.67 min.

Example 425:4-chloro-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.16-3.25 (m, 4H) 3.67 (s, 3H) 3.84-3.94(m, 4H) 7.15 (d, J=2.35 Hz, 1H) 7.46 (d, J=7.83 Hz, 1H) 7.52-7.62 (m,2H) 7.69 (d, J=8.61 Hz, 1H) 7.91-7.99 (m, 2H) 8.01 (d, J=2.35 Hz, 1H)8.17 (s, 1H). LCMS (m/z) (M+H)=492.2, Rt=0.92 min.

Example 426:4-chloro-N-(3-(difluoromethyl)phenyl)-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 3.16-3.25 (m, 4H) 3.67 (s, 3H) 3.84-3.95(m, 4H) 6.60-6.97 (m, 1H) 7.13 (d, J=2.35 Hz, 1H) 7.35 (d, J=7.83 Hz,1H) 7.51 (t, J=7.83 Hz, 1H) 7.57 (d, J=1.96 Hz, 1H) 7.69 (d, J=8.22 Hz,1H) 7.85 (d, J=8.22 Hz, 1H) 7.94 (dd, J=8.22, 1.96 Hz, 1H) 7.97-8.07 (m,2H). LCMS (m/z) (M+H)=474.2, Rt=0.84 min.

Example 427:4-chloro-N-(3-(2-cyanopropan-2-yl)phenyl)-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.77 (s, 6H) 3.15-3.22 (m, 4H) 3.67 (s,3H) 3.83-3.93 (m, 4H) 7.10 (d, J=2.35 Hz, 1H) 7.35 (d, J=8.22 Hz, 1H)7.45 (t, J=8.02 Hz, 1H) 7.56 (d, J=2.35 Hz, 1H) 7.66-7.75 (m, 2H)7.91-7.98 (m, 2H) 8.01 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=491.3,Rt=0.85 min.

Example 428:4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.43 (s, 3H) 2.48 (s, 3H) 3.10-3.22 (m,4H) 3.67 (s, 3H) 3.82-3.94 (m, 4H) 6.95 (d, J=1.96 Hz, 1H) 7.40 (d,J=1.96 Hz, 1H) 7.50 (d, J=7.83 Hz, 1H) 7.79-7.99 (m, 4H) 8.16 (s, 1H)8.61 (s, 1H) 9.44 (s, 1H). LCMS (m/z) (M+H)=552.3, Rt=0.69 min.

Example 429:4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-phenylbenzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.39 (s, 3H) 3.09-3.24 (m, 4H) 3.65 (s,3H) 3.81-4.07 (m, 4H) 7.03 (d, J=1.96 Hz, 1H) 7.11-7.19 (m, 1H) 7.35 (t,J=7.83 Hz, 2H) 7.41-7.46 (m, 2H) 7.67 (d, J=7.83 Hz, 2H) 7.81 (s, 1H)7.84 (dd, J=7.83, 1.96 Hz, 1H), LCMS (m/z) (M+H)=404.1, Rt=0.77 min.

Example 430:N-(3-(difluoromethyl)phenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.40 (s, 3H) 3.07-3.23 (m, 4H) 3.65 (s,3H) 3.80-3.92 (m, 4H) 6.51-6.95 (m, 1H) 7.02 (d, J=1.96 Hz, 1H) 7.31 (d,J=7.83 Hz, 1H) 7.38-7.62 (m, 3H) 7.74-7.89 (m, 3H) 7.97 (s, 1H), LCMS(m/z) (M+H)=454.1, Rt=0.85 min.

Example 431:N-(3-(2-cyanopropan-2-yl)phenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.74 (s, 6H) 2.40 (s, 3H) 3.09-3.23 (m,4H) 3.65 (s, 3H) 3.82-3.94 (m, 4H) 7.03 (d, J=1.96 Hz, 1H) 7.31 (d,J=7.83 Hz, 1H) 7.38-7.51 (m, 3H) 7.68 (d, J=8.22 Hz, 1H) 7.80-7.89 (m,2H) 7.93 (s, 1H), LCMS (m/z) (M+H)=471.2, Rt=0.85 min.

Example 432:4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(pyridin-2-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.42 (s, 3H) 3.01-3.20 (m, 4H) 3.64 (s,3H) 3.80-3.91 (m, 4H) 6.94 (d, J=1.96 Hz, 1H) 7.39 (d, J=2.35 Hz, 1H)7.44-7.63 (m, 2H) 7.83-8.00 (m, 3H) 8.15-8.31 (m, 1H) 8.42 (d, J=5.48Hz, 1H), LCMS (m/z) (M+H)=405.1, Rt=0.56 min.

Example 433:4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(pyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.41 (s, 3H) 3.07-3.18 (m, 4H) 3.64 (s,3H) 3.81-3.92 (m, 4H) 6.92 (d, J=1.96 Hz, 1H) 7.38 (d, J=1.96 Hz, 1H)7.48 (d, J=7.83 Hz, 1H) 7.84-8.01 (m, 3H) 8.52 (d, J=5.09 Hz, 1H) 8.61(d, J=8.22 Hz, 1H) 9.42 (d, J=2.35 Hz, 1H), LCMS (m/z) (M+H)=405.1,Rt=0.51 min.

Example 434:4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.41 (s, 3H) 3.00-3.22 (m, 4H) 3.65 (s,3H) 3.82-3.98 (m, 4H) 7.01 (d, J=1.56 Hz, 1H) 7.35-7.54 (m, 3H)7.79-7.99 (m, 2H) 8.48-8.65 (m, 2H), LCMS (m/z) (M+H)=473.2, Rt=0.86min.

Example 435:N-(3-ethylphenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.25 (t, J=7.43 Hz, 3H) 2.39 (s, 3H)2.66 (q, J=7.56 Hz, 2H) 3.08-3.23 (m, 4H) 3.65 (s, 3H) 3.80-3.98 (m, 4H)6.85-7.09 (m, 2H) 7.26 (t, J=7.83 Hz, 1H) 7.35-7.58 (m, 4H) 7.75-7.98(m, 2H), LCMS (m/z) (M+H)=432.3, Rt=0.87 min.

Example 436:N-(3-isopropylphenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.26 (d, J=7.04 Hz, 7H) 2.39 (s, 3H)2.90 (dt, J=13.69, 6.85 Hz, 1H) 3.13-3.25 (m, 4H) 3.65 (s, 3H) 3.81-4.01(m, 4H) 7.03 (d, J=7.43 Hz, 1H) 7.09 (d, J=1.57 Hz, 1H) 7.26 (t, J=7.83Hz, 1H) 7.38-7.52 (m, 3H) 7.56 (s, 1H) 7.78-7.91 (m, 1H), LCMS (m/z)(M+H)=446.3, Rt=0.92 min.

Example 437:N-(3-(1,3,4-oxadiazol-2-yl)phenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.40 (s, 3H) 3.17 (br. s., 4H) 3.65 (s,3H) 3.78-3.99 (m, 4H) 6.99 (d, J=1.96 Hz, 1H) 7.41 (d, J=1.96 Hz, 1H)7.46 (d, J=7.83 Hz, 1H) 7.58 (t, J=8.02 Hz, 1H) 7.82-7.90 (m, 3H) 7.96(d, J=7.83 Hz, 1H) 8.52 (s, 1H) 9.03 (s, 1H), LCMS (m/z) (M+H)=472.2,Rt=0.69 min.

Example 438:4-methyl-N-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.41 (s, 3H) 2.66 (s, 3H) 3.25 (br. s.,4H) 3.66 (s, 3H) 3.83-3.99 (m, 4H) 7.12 (s, 1H) 7.49 (dt, J=16.34, 8.07Hz, 3H) 7.77-7.96 (m, 4H) 8.42 (s, 1H), LCMS (m/z) (M+H)=486.3, Rt=0.80min.

Example 439:N-(3-(2-hydroxypropan-2-yl)phenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.54 (s, 6H) 2.39 (s, 3H) 3.16 (br. s.,4H) 3.64 (s, 3H) 3.79-4.13 (m, 4H) 6.98 (d, J=1.57 Hz, 1H) 7.18-7.34 (m,2H) 7.35-7.50 (m, 2H) 7.58 (d, J=7.04 Hz, 1H) 7.75-7.94 (m, 1H), LCMS(m/z) (M+H)=462.3, Rt=0.70 min.

Example 440:N-(3-methoxyphenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.41 (s, 3H) 3.16-3.22 (m, 4H) 3.67 (s,3H) 3.83 (s, 3H) 3.85-3.91 (m, 4H) 6.74 (dt, J=7.14, 2.10 Hz, 1H) 7.01(d, J=1.96 Hz, 1H) 7.20-7.31 (m, 2H) 7.39-7.44 (m, 2H) 7.46 (d, J=7.83Hz, 1H) 7.82 (s, 1H) 7.86 (dd, J=8.02, 1.76 Hz, 1H). LCMS (m/z)(M+H)=434.3, Rt=0.80 min.

Example 441:4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)-N-(3-(trifluoromethoxy)phenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.42 (s, 3H) 3.17-3.23 (m, 4H) 3.67 (s,3H) 3.85-3.93 (m, 4H) 7.00-7.09 (m, 2H) 7.41-7.50 (m, 3H) 7.67 (d,J=9.39 Hz, 1H) 7.82-7.90 (m, 3H). LCMS (m/z) (M+H)=488.4, Rt=0.96 min.

Example 442:N-(5-methoxypyridin-3-yl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.43 (s, 3H) 3.13-3.19 (m, 4H) 3.66 (s,3H) 3.85-3.91 (m, 4H) 4.01 (s, 3H) 6.95 (d, J=1.96 Hz, 1H) 7.40 (d,J=1.96 Hz, 1H) 7.50 (d, J=7.83 Hz, 1H) 7.89 (s, 1H) 7.90-7.96 (m, 1H)8.21 (d, J=16.04 Hz, 2H) 8.88 (s, 1H). LCMS (m/z) (M+H)=435.3, Rt=0.57min.

Synthesis of1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylicacid

Step 1

To a 0.15M solution of methyl2-chloro-1′-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylate(1.00 equiv.) in DME was added trimethylboroxine (2.00 equiv.),PdCl2(dppf).CH2Cl2 adduct (0.10 equiv.), and 2M aqueous sodium carbonate(3.00 equiv.). The reaction mixture was irradiated at 130° C. for 15 minin the microwave. The cooled reaction mixture was diluted with 2:1DCM:MeOH and filtered. The filtrate was concentrated and purified byflash chromatography over silica gel (heptanes with 50-100% 10:1 ethylacetate:methanol gradient) to give methyl1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylate(17.0% yield) as a yellow film. LCMS (m/z) (M+H)=344.1, Rt=0.43 min.

Step 2

To a 0.10M solution of methyl1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylate(1.00 equiv.) in THF was added 2.0M aqueous lithium hydroxide (3.00equiv.). The mixture was stirred at ambient temperature for 1.5 hr. Thereaction mixture was acidified to pH 3 with aqueous HCl and concentratedto give crude1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxylicacid as a yellow solid (assumed 100% yield). LCMS (m/z) (M+H)=330.0,Rt=0.32 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 171 using the appropriatestarting materials.

Example 443:1′,2-dimethyl-5′-morpholino-6′-oxo-N-(3-(trifluoromethyl)phenyl)-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.74 (s, 3H) 3.13-3.26 (m, 4H) 3.67 (s,3H) 3.83-3.94 (m, 4H) 7.01 (d, J=1.96 Hz, 1H) 7.49 (d, J=7.83 Hz, 1H)7.54 (d, J=2.35 Hz, 1H) 7.60 (t, J=8.02 Hz, 1H) 7.98 (d, J=8.22 Hz, 1H)8.19 (s, 1H) 8.55 (d, J=1.96 Hz, 1H) 9.11 (d, J=1.96 Hz, 1H). LCMS (m/z)(M+H)=473.2, Rt=0.69 min.

Example 444:N-(3-(2-cyanopropan-2-yl)phenyl)-1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.76 (s, 6H) 2.77 (s, 3H) 3.12-3.25 (m,4H) 3.67 (s, 3H) 3.80-3.94 (m, 4H) 7.01 (d, J=2.35 Hz, 1H) 7.36 (d,J=8.22 Hz, 1H) 7.46 (t, J=7.83 Hz, 1H) 7.55 (d, J=1.96 Hz, 1H) 7.75 (d,J=8.22 Hz, 1H) 7.98 (s, 1H) 8.64 (d, J=1.96 Hz, 1H) 9.13 (d, J=1.57 Hz,1H). LCMS (m/z) (M+H)=472.3, Rt=0.63 min.

Example 445:N-(3-(difluoromethyl)phenyl)-1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.73 (s, 3H) 3.15-3.24 (m, 4H) 3.67 (s,3H) 3.83-3.94 (m, 4H) 6.63-6.97 (m, 1H) 7.01 (d, J=1.96 Hz, 1H) 7.37 (d,J=7.83 Hz, 1H) 7.48-7.60 (m, 2H) 7.87 (d, J=8.22 Hz, 1H) 8.02 (s, 1H)8.51 (d, J=1.96 Hz, 1H) 9.09 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=455.2,Rt=0.60 min.

Example 446:N-(3-(2-hydroxypropan-2-yl)phenyl)-1′,2-dimethyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridine]-5-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.56 (s, 6H) 2.77 (s, 3H) 3.11-3.25 (m,4H) 3.67 (s, 3H) 3.80-3.94 (m, 4H) 7.02 (d, J=1.96 Hz, 1H) 7.29-7.41 (m,2H) 7.56 (d, J=1.96 Hz, 1H) 7.64 (d, J=7.04 Hz, 1H) 7.83 (s, 1H) 8.67(d, J=1.57 Hz, 1H) 9.13 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=463.3,Rt=0.52 min.

Example 451:N-(4-methyl-3-(1-methyl-6-oxo-5-(3-oxomorpholino)-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

To a 0.1M solution ofN-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide(1.00 equiv.) in DCM was added benzyltriethylammonium chloride (4.10equiv.) and potassium permanganate (4.00 equiv.). The mixture wasstirred at 45° C. for 7 hr. The cooled reaction mixture was diluted withwater and treated with sodium bisulfite (12.0 equiv.). The mixture wasstirred for 15 min at ambient temperature. Additional water was added,and the mixture was extracted with DCM. The organic layer was washedwith saturated aqueous sodium bicarbonate, dried over sodium sulfate,filtered, and concentrated. The crude material was purified byreverse-phase HPLC and lyophilized to giveN-(4-methyl-3-(1-methyl-6-oxo-5-(3-oxomorpholino)-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamideas its TFA salt, a white solid, in 11.0% yield.

¹H NMR (400 MHz, <cd3od>) δ ppm 2.35 (s, 3H) 3.67-3.80 (m, 5H) 4.02-4.12(m, 2H) 4.31 (s, 2H) 7.33 (d, J=8.22 Hz, 1H) 7.58-7.68 (m, 2H) 7.71-7.78(m, 2H) 7.80 (d, J=2.35 Hz, 1H) 7.91 (d, J=7.83 Hz, 1H) 8.22 (d, J=7.83Hz, 1H) 8.28 (s, 1H); LCMS (m/z) (M+H)=486.1, Rt=0.86 min.

Example 452:2-(dimethylamino)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

Step 1

To a solution of5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.) in DMF (0.09M) was added 2-fluoroisonicotinic acid (1.2 equiv),EDC (1.2 equiv.) and HOAt (1.2 equiv.). The solution was stirred at roomtemperature overnight. Worked up by partitioning between water and ethylacetate, the organic phase was dried with sodium sulfate, filtered andconcentrated. The crude material was used for the next step withoutfurther purification. LCMS (m/z) (M+H)=423, Rt=0.74 min.

Step 2

To a solution of2-fluoro-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide(1.0 equiv.) in DMSO was added dimethyl amine (1.5 equiv., HCl salt) andDIEA (2.0 equiv.) and the reaction was heated to 140 C for 3 hours. Thesolution was then filtered through a HPLC filter and purified viareverse phase prep-HPLC. The pure fractions were lyophilized to yield2-(dimethylamino)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamideas the TFA salt. 1H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.13 (d,J=3.52 Hz, 4H) 3.34 (s, 6H) 3.63 (s, 3H) 3.78-3.91 (m, 4H) 6.89 (d,J=1.96 Hz, 1H) 7.19-7.39 (m, 3H) 7.53-7.74 (m, 3H) 8.04 (d, J=6.65 Hz,1H), LCMS (m/z) (M+H)=449.2, Rt=0.60 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 452 using the appropriatestarting materials.

Example 453:2-(ethyl(methyl)amino)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.31 (t, J=7.24 Hz, 3H) 2.31 (s, 3H)3.03-3.18 (m, 4H) 3.75 (q, J=7.04 Hz, 2H) 3.81-3.91 (m, 4H) 6.89 (d,J=1.96 Hz, 1H) 7.20-7.38 (m, 3H) 7.54-7.70 (m, 3H) 8.02 (d, J=6.26 Hz,1H), LCMS (m/z) (M+H)=462.2, Rt=0.61 min.

Example 454:2-(azetidin-1-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.30 (s, 3H) 2.61 (quin, J=7.73 Hz, 2H)3.03-3.16 (m, 4H) 3.63 (s, 3H) 3.79-4.05 (m, 4H) 4.39 (t, J=7.63 Hz, 4H)6.89 (d, J=2.35 Hz, 1H) 7.18-7.37 (m, 4H) 7.53-7.67 (m, 2H) 7.98 (d,J=6.65 Hz, 1H), LCMS (m/z) (M+H)=460.2, Rt=0.60 min.

Example 455:2-((2-methoxyethyl)(methyl)amino)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (500 MHz, METHANOL-d₄) δ ppm 2.34 (s, 3H) 3.16 (br. s., 4H) 3.37(s, 3H) 3.39 (s, 3H) 3.66 (s, 3H) 3.74 (t, J=4.89 Hz, 2H) 3.82-3.90 (m,4H) 3.94 (t, J=5.04 Hz, 2H) 6.93 (d, J=1.89 Hz, 1H) 7.29-7.39 (m, 3H)7.59-7.65 (m, 2H) 7.73 (s, 1H) 8.05 (d, J=6.31 Hz, 1H), LCMS (m/z)(M+H)=492.2, Rt=0.64 min.

Example 456:2-((2-hydroxyethyl)(methyl)amino)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (500 MHz, METHANOL-d₄) δ ppm 2.33 (s, 3H) 3.04-3.18 (m, 4H) 3.38(s, 3H) 3.66 (s, 3H) 3.84-3.97 (m, 8H) 6.94 (d, J=2.21 Hz, 1H) 7.29-7.35(m, 2H) 7.37 (d, J=2.21 Hz, 1H) 7.59-7.67 (m, 2H) 7.77 (s, 1H) 8.05 (d,J=6.62 Hz, 1H), LCMS (m/z) (M+H)=478.2, Rt=0.60 min.

Example 457:2-(methyl(2-(methylamino)ethyl)amino)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)isonicotinamide

¹H NMR (500 MHz, METHANOL-d₄) δ ppm 2.33 (s, 3H) 2.77 (s, 3H) 3.17 (br.s., 4H) 3.21 (s, 3H) 3.66 (s, 3H) 3.78-3.92 (m, 4H) 3.98 (t, J=5.67 Hz,2H) 6.97 (d, J=2.21 Hz, 1H) 7.20 (d, J=5.36 Hz, 1H) 7.26 (s, 1H) 7.32(d, J=8.20 Hz, 1H) 7.38 (d, J=1.89 Hz, 1H) 7.57-7.65 (m, 2H) 8.29 (d,J=5.36 Hz, 1H), LCMS (m/z) (M+H)=491.3, Rt=0.60 min.

Example 460:4-(1,2-dihydroxyethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of methyl 4-bromo-3-(trifluoromethyl)benzoate (1.0 equiv.)and 2,4,6-trivinyl-1,3,5,2,4,6-trioxatriborinane (2.0 equiv.) in DME and2M sodium carbonate (3:1, 0.18 M) was added PdCl₂(dppf)-DCM adduct (0.05equiv.) in a microwave vial equipped with a stir bar. The reaction washeated to 120° C. for 30 min in the microwave. The reaction was quenchedwith water and extracted with ethyl acetate. The aqueous phase wasacidified with conc. HCl, and extracted with ethyl acetate. The organicphase was dried with magnesium sulfate, filtered and concentrated togive 3-(trifluoromethyl)-4-vinylbenzoic acid as a white solid in 18%yield. LCMS (m/z) (M+H)=217.1, Rt=0.85 min.

Step 2

5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (1.0 equiv.),N-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.0 equiv.), and 3-(trifluoromethyl)-4-vinylbenzoic acid(1.0 equiv.) were dissolved in DMF (0.095 M) at RT. The reaction wasmonitored by LCMS. After about 3 hr, the reaction mixture was purifiedvia preparative reverse phase HPLC to giveN-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)-4-vinylbenzamidein64% yield. LCMS (m/z) (M+H)=498.2, Rt=0.99 min.

Step 3

N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)-4-vinylbenzamide(1.0 equiv.), 4-methylmorpholine 4-oxide (1.5 equiv.), and 2.5 wt %osmium(VIII) oxide in t-butanol (0.1 equiv.) were dissolved in 1:1 THFand water (0.03 M) at RT. The reaction was monitored by LCMS. Afterabout 4 hr, the reaction mixture was purified via preparative reversephase HPLC to give4-(1,2-dihydroxyethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamidein 39% yield. 1H NMR (400 MHz, <cdcl3>) δ ppm 2.29 (s, 3H) 2.61 (br. s.,2H) 3.20 (br. s., 6H) 3.52 (dd, J=11.15, 8.02 Hz, 1H) 3.62 (s, 3H) 3.73(dd, J=11.35, 2.35 Hz, 1H) 3.80-3.99 (m, 4H) 5.20 (d, J=7.04 Hz, 1H)6.71 (s, 1H) 7.07 (s, 1H) 7.24 (d, J=8.22 Hz, 1H) 7.41-7.51 (m, 3H) 7.60(d, J=8.22 Hz, 1H) 7.75 (s, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.22 (d, J=8.22Hz, 1H) 8.31 (s, 1H) 9.90 (br. s., 1H). LCMS (m/z) (M+H)=532.1, Rt=0.71min.

Example 461:4-(1,2-dihydroxyethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (1.0 equiv.),N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.0 equiv.), and4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.0 equiv.) weredissolved in DMF (0.114 M) at RT. The reaction was monitored by LCMS.After about 5 hr, the reaction mixture was purified via preparativereverse phase HPLC to give4-(chloromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamidein 46% yield. LCMS (m/z) (M+H)=520.2, Rt=0.97 min.

Step 2

4-(chloromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was dissolved in 7 M ammonia in methanol (0.046 M). Afterbeing heated at 50° C. until no further progress by LCMS, the reactionmixture was concentrated and purified via preparative reverse phase HPLCto give4-(aminomethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamidein 47% yield. LCMS (m/z) (M+H)=501.3, Rt=0.62 min.

Example 462:4-(hydroxymethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamideand Example 463:4-(2-aminoethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.0 equiv.) andpotassium cyanide (0.9 equiv.) in DMSO (0.177 M) were stirred at RT. Thereaction was monitored by LCMS until no further progression. The crudereaction mixture was used directly for next step.

Step 2

The crude mixture from previous step and5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1equiv.), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (1.0 equiv.), andN1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.0 equiv.) were mixed in DMF (0.233 M). After 3 hr, thereaction mixture was purified via preparative reverse phase HPLC to give4-(hydroxymethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamideand4-(cyanomethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamidein 2.8% yield and 8.5% yield respectively over two steps. For4-(hydroxymethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide,LCMS (m/z) (M+H)=502.1, Rt=0.79 min. For4-(cyanomethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide,LCMS (m/z) (M+H)=511.2, Rt=0.86 min.

Step 3

To a solution of4-(cyanomethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide(1 equiv.) in ethanol (0.02 M), nickel chloride (4 equiv.) and sodiumborohydride (20 equiv.) were added at RT. After 2 hr, the reactionmixture was quenched with diethyltriamine, partitioned between saturatedsodium bicarbonate solution and ethyl acetate. The organic phase wasdried over magnesium sulfate, filtered and concentrated. The residue waspurified via preparative reverse phase HPLC to give4-(2-aminoethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamidein47% yield. LCMS (m/z) (M+H)=515.1, Rt=0.66 min.

Synthesis of3-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-5-bromo-1-methylpyridin-2(1H)-one

To a solution of 3,5-dibromo-1-methylpyridin-2(1H)-one (1.0 equiv.) indioxane (0.190 M) in a microwave vial, were added6-oxa-3-azabicyclo[3.1.1]heptane TsOH (1.0 equiv.), xantphos (0.1equiv.), cesium carbonate (3.0 equiv.) and Pd2(dba)3 (0.05 equiv.). Thereaction vessel was degassed by a stream of argon for 15 min and thereaction vessel was sealed and stirred at 80° C. in a regular sand bathfor 16 hr. LCMS showed an estimated 45% conversion. The reactiontemperature was increased at 100° C. for 6 hr. The reaction mixture wascooled to room temperature and extracted with ethyl acetate. The organicphase was washed with brine, dried over sodium sulfate, filtered andconcentrated The solvent was removed under vacuum and the crude materialwas purified via flash chromatography over silica gel eluting with DCMand 0-10% MeOH gradient. Isolated3-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-5-bromo-1-methylpyridin-2(1H)-onein 39% yield. LCMS (m/z) (M+H)=286.9, Rt=0.64 min.

Example 464:N-(3-(5-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.06-1.29 (m, 1H) 2.04-2.11 (m, 1H) 2.22(s, 3H) 2.90-3.01 (m, 1H) 3.43 (s, 3H) 4.04 (d, J=12.13 Hz, 2H) 4.50 (d,J=5.87 Hz, 2H) 6.43-6.63 (m, 1H) 7.12-7.27 (m, 2H) 7.51-7.66 (m, 2H)7.72 (t, J=7.83 Hz, 1H) 7.90 (d, J=7.43 Hz, 1H) 8.13-8.30 (m, 2H) 10.38(s, 1H). LCMS (m/z) (M+H)=484.2, Rt=0.98 min.

Example 465:N-(3-(5-(6-oxa-3-azabicyclo[3.1.1]heptan-3-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-methylphenyl)-2-(2-cyanopropan-2-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.14-1.27 (m, 4H) 1.75 (s, 6H) 2.12 (d,J=8.22 Hz, 1H) 2.27 (s, 3H) 3.01 (q, J=6.65 Hz, 1H) 3.48 (s, 3H) 4.08(d, J=12.13 Hz, 2H) 4.54 (d, J=6.26 Hz, 2H) 6.55-6.61 (m, 1H) 7.20-7.31(m, 2H) 7.62-7.68 (m, 2H) 7.85 (d, J=5.09 Hz, 1H) 7.93-8.06 (m, 1H) 8.79(d, J=5.09 Hz, 1H) 10.42-10.61 (m, 1H) LCMS (m/z) (M+H)=484, Rt=0.79min.

Example 466:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamide

Step 1

Aza-HOBt (1.0 equiv.) was added to a solution of5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.), 4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.5 equiv.)and EDC.HCl (1.0 equiv.) in DMF (0.11 M) and the reaction mix wasstirred at RT for 5 hr. The crude was partitioned in H₂O/EtOAc. Theorganic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. Crude was purified silicagel column to give the desired4-(chloromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamidein 46% yield. LCMS (m/z) (M+H)=520, Rt=0.97 min.

Step 2

A mixture of4-(chloromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and MeNH₂ 2M in THF (70 equiv.) was stirred at RTovernight. LCMS showed desired product MH+=515 at LC=0.64 mins. Thesolvent was removed under vacuum and the residue was purified by HPLC togiveN-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamideas the TFA salt in 46% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.20 (s,3H) 2.66 (t, J=4.89 Hz, 3H) 3.04 (br. s., 4H) 3.43 (s, 4H) 3.65 (d,J=4.30 Hz, 4H) 4.33 (br. s., 2H) 6.62 (d, J=1.96 Hz, 1H) 7.22 (d, J=8.22Hz, 1H) 7.33 (d, J=1.96 Hz, 1H) 7.56 (d, J=1.96 Hz, 1H) 7.62 (d, J=8.61Hz, 1H) 7.82 (d, J=8.61 Hz, 1H) 8.19-8.39 (m, 2H) 8.95 (br. s., 2H)10.32-10.51 (m, 1H). LCMS (m/z) (M+H)=515, Rt=0.64 min.

Example 467:N-(4-(aminomethyl)-3-(trifluoromethyl)phenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamide

Step 1

HATU (1.1 equiv.) was added to a solution of4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzoicacid (1.0 and DIEA (2.0 equiv.) in DMF (Volume: 1 mL) at 0° C., and themixture was stirred for 30 min. Tert-butyl4-amino-2-(trifluoromethyl)benzylcarbamate (1.0) was added and thereaction mix was left stirring overnight at RT. Reaction mix was treatedwith water and extracted twice with EtOAc. The combined organics wereconcentrated to dryness. The crude was purified on silicagel columnusing 0 to 70% EtOAc in heptane to give tert-butyl4-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamido)-2-(trifluoromethyl)benzylcarbamate in 20% yield. LCMS (m/z)(M+H)=601, Rt=1.0 min.

Step 2

To a solution of tert-butyl4-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamido)-2-(trifluoromethyl)benzylcarbamate(1.0 equiv.) in DCM (0.01 M) was added TFA (15 equiv.) and the reactionmix was stirred at RT for 1 h. The solvent was removed under vacuum andthe residue was purified by HPLC to giveN-(4-(aminomethyl)-3-(trifluoromethyl)phenyl)-4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)benzamideas the TFA salt in 51% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.35 (s,3H) 3.10 (br. s., 4H) 3.70 (d, J=4.30 Hz, 4H) 4.14 (d, J=5.48 Hz, 2H)6.58-6.82 (m, 1H) 7.35-7.54 (m, 2H) 7.66 (d, J=8.61 Hz, 1H) 7.78-7.98(m, 2H) 8.18 (d, J=8.61 Hz, 1H) 8.25 (br. s., 4H) 10.53 (s, 1H). LCMS(m/z) (M+H)=501, Rt=0.63 min.

Example 468 and Example 469: Synthesis ofN-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-((methylamino) methyl)-5-(trifluoromethyl)benzamide AND3-(hydroxymethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide

To a 0.08 M solution of3-formyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide(1.00 equiv.), prepared using methods similar to those described for thepreparation of Example 171 using the appropriate starting materials) inethanol was added methylamine, 33 wt % in ethanol (5.00 equiv.). Themixture was stirred overnight at ambient temperature. The reactionmixture was degassed by bubbling argon through the solution for 5 min.Degussa type 10% palladium on carbon (23.86 mg, 0.022 mmol) was added.The reaction vessel was purged and flushed twice with hydrogen from aballoon. The reaction was stirred under a hydrogen atmosphere for 2.5 hrand then filtered. The filtrate was concentrated and purified by reversephase HPLC and lyophilized to giveN-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-((methylamino)methyl)-5-(trifluoromethyl)benzamide (17.4%yield) and3-(hydroxymethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide(8.5% yield) as their TFA salts.

N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3-((methylamino)methyl)-5-(trifluoromethyl)benzamide:¹H NMR (400 MHz, <cd3od>) ppm 2.33 (s, 3H) 2.81 (s, 3H) 3.10-3.21 (m,4H) 3.65 (s, 3H) 3.82-3.94 (m, 4H) 4.40 (s, 2H) 6.94 (d, J=1.96 Hz, 1H)7.32 (d, J=8.22 Hz, 1H) 7.36 (d, J=1.96 Hz, 1H) 7.57-7.66 (m, 2H) 8.08(s, 1H) 8.34 (s, 1H) 8.41 (s, 1H). LCMS (m/z) (M+H)=515.2, Rt=0.67 min.

3-(hydroxymethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide:¹H NMR (400 MHz, <cd3od>) ppm 2.33 (s, 3H) 3.16-3.24 (m, 4H) 3.66 (s,3H) 3.84-3.95 (m, 4H) 4.79 (s, 2H) 7.01 (d, J=1.96 Hz, 1H) 7.31 (d,J=8.22 Hz, 1H) 7.41 (d, J=1.96 Hz, 1H) 7.59 (dd, J=8.02, 2.15 Hz, 1H)7.64 (d, J=1.96 Hz, 1H) 7.91 (s, 1H) 8.16 (s, 1H) 8.19 (s, 1H). LCMS(m/z) (M+H)=502.1, Rt=0.79 min.

Example 470: Synthesis of3-(aminomethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide

Step 1

To a 0.15M solution of3-bromo-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide(1.00 equiv., prepared using methods similar to those described for thepreparation of Example 171 using the appropriate starting materials) inDMF was added zinc cyanide (4.00 equiv.) andtetrakis(triphenylphosphine)palladium (0.100 equiv.). The reactionmixture was irradiated at 130° C. for 15 min in the microwave. Thecooled reaction mixture was filtered. The filtrate was concentrated andpurified by flash chromatography over silica gel (95:5 ethylacetate:methanol) to give3-cyano-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide(99.0% yield) as a yellow solid. LCMS (m/z) (M+H)=497.2, Rt=0.89 min.

Step 2

To a degassed 0.05M solution of3-cyano-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide(1.00 equiv.) in methanol was added a methanol slurry of washedRaney-Ni. The mixture was hydrogenated under 60 psi of hydrogenovernight. The degassed reaction mixture was filtered. The filtrate wasconcentrated to dryness. The residue was purified by reverse phase HPLCand lyophilized to give3-(aminomethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamideas its TFA salt (8.8% yield), a white solid.

¹H NMR (400 MHz, <cd3od>) δ ppm 2.33 (s, 3H) 3.16 (d, J=4.70 Hz, 4H)3.66 (s, 3H) 3.83-3.92 (m, 4H) 4.34 (s, 2H) 6.93 (d, J=1.96 Hz, 1H) 7.32(d, J=8.22 Hz, 1H) 7.36 (d, J=1.96 Hz, 1H) 7.56-7.66 (m, 2H) 8.06 (s,1H) 8.33 (s, 1H) 8.38 (s, 1H). LCMS (m/z) (M+H)=501.1, Rt=0.69 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 171 using the appropriatestarting materials.

Example 471:2-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamideSynthesis of4-(5-amino-2-methylphenyl)-1-methyl-6-morpholinopyridin-2(1H)-one

To a 0.2M solution of 4-bromo-1-methyl-6-morpholinopyridin-2(1H)-one(1.00 equiv.) in DME was added4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.00equiv.), PdCl2(dppf).CH2Cl2 adduct (0.50 equiv.), and 2M aqueous sodiumcarbonate (8.00 equiv.). The reaction mixture was irradiated at 110° C.for 20 min in the microwave. The cooled reaction mixture was dilutedwith water and extracted with ethyl acetate. The combined organics weredried over magnesium sulfate, filtered, concentrated, and purified byflash chromatography over silica gel (heptanes with 50-100% ethylacetate gradient) to give4-(5-amino-2-methylphenyl)-1-methyl-6-morpholinopyridin-2(1H)-one (43.8%yield) as a brown oil. LCMS (m/z) (M+H)=300.1, Rt=0.44 min.

1H NMR (400 MHz, <dmso>) δ ppm 1.91-2.12 (m, 3H) 2.24 (s, 3H) 2.93 (br.s., 4H) 3.45 (s, 3H) 3.73 (br. s., 4H) 5.80 (s, 1H) 6.05 (s, 1H) 7.29(d, J=8.22 Hz, 1H) 7.65 (s, 1H) 7.72 (d, J=8.22 Hz, 1H) 8.01 (d, J=4.70Hz, 1H) 8.16 (s, 1H) 8.86 (d, J=5.09 Hz, 1H) 10.63 (s, 1H). LCMS (m/z)(M+H)=469.2, Rt=0.80 min.

Example 472:2-(tert-butyl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.29-1.38 (m, 9H) 2.16-2.27 (m, 3H) 2.93(br. s., 4H) 3.45 (s, 3H) 3.73 (t, J=4.11 Hz, 4H) 5.74-5.86 (m, 1H) 6.05(d, J=1.17 Hz, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.63 (d, J=1.57 Hz, 1H) 7.70(d, J=5.87 Hz, 2H) 7.87 (s, 1H) 8.71 (d, J=5.09 Hz, 1H) 10.47 (s, 1H).LCMS (m/z) (M+H)=461.2, Rt=0.67 min.

Example 473:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.23 (s, 3H) 2.94 (br. s., 4H) 3.45 (s,3H) 3.73 (br. s., 4H) 5.80 (s, 1H) 6.05 (s, 1H) 7.25 (d, J=8.61 Hz, 1H)7.45-7.54 (m, 2H) 7.54-7.61 (m, 1H) 7.66 (s, 1H) 7.72 (d, J=8.22 Hz, 1H)7.93 (d, J=7.83 Hz, 2H) 10.23 (s, 1H). LCMS (m/z) (M+H)=404.2, Rt=0.77min.

Example 474:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 2.94 (br. s., 4H) 3.27-3.36(m, 3H) 3.40-3.50 (m, 3H) 3.62-3.79 (m, 4H) 5.81 (s, 1H) 6.05 (s, 1H)7.30 (d, J=8.22 Hz, 1H) 7.66 (s, 1H) 7.72 (d, J=8.61 Hz, 1H) 8.20 (d,J=4.70 Hz, 1H) 8.51 (s, 1H) 8.98 (d, J=4.70 Hz, 1H) 10.57-10.91 (m, 1H).LCMS (m/z) (M+H)=483.1, Rt=0.68 min.

Example 475:2-(1,1-difluoropropyl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.94 (t, J=7.24 Hz, 3H) 2.26 (s, 3H)2.28-2.46 (m, 2H) 2.95 (br. s., 4H) 3.46 (s., 3H) 3.64-3.81 (m, 4H) 5.82(s, 1H) 6.07 (s, 1H) 7.31 (d, J=8.22 Hz, 1H) 7.67 (s, 1H) 7.73 (d,J=8.22 Hz, 1H) 8.02 (d, J=5.09 Hz, 1H) 8.16 (s, 1H) 8.89 (d, J=4.70 Hz,1H) 10.56-10.72 (m, 1H). LCMS (m/z) (M+H)=483.2, Rt=0.89 min.

Example 476:2-ethyl-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.21-1.32 (m, 3H) 2.24 (s, 3H) 2.82-3.00(m, 6H) 3.46 (s., 3H) 3.73 (d, J=3.91 Hz, 4H) 5.80 (d, J=1.17 Hz, 1H)6.05 (d, J=1.17 Hz, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.64 (d, J=1.96 Hz, 1H)7.70 (dd, J=8.22, 1.96 Hz, 1H) 7.78 (br. s., 1H) 7.85 (br. s., 1H)8.67-8.78 (m, 1H) 10.53 (br. s., 1H). LCMS (m/z) (M+H)=433.1, Rt=0.62min.

Example 477:2-cyclopropyl-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H (400 MHz, <cd3od>) δ ppm 1.29-1.41 (m, 2H) 1.53-1.68 (m, 2H) 2.32 (s,3H) 2.45-2.58 (m, 1H) 3.09 (br. s., 4H) 3.68 (s, 3H) 3.95-4.04 (m, 4H)6.20 (s, 1H) 6.36 (s, 1H) 7.43 (d, J=7.83 Hz, 1H) 7.48-7.57 (m, 2H) 7.96(s, 1H) 8.08-8.17 (m, 1H) 8.75 (d, J=6.26 Hz, 1H). LCMS (m/z)(M+H)=445.1, Rt=0.63 min.

Example 478:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-2-(oxetan-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.06 (s, 2H) 2.29 (s, 2H) 3.06 (br. s.,4H) 3.63 (s, 3H) 3.91 (br. s., 4H) 4.56 (m, 1H) 6.14 (s, 1H) 6.32 (s,1H) 7.39 (d, J=9.00 Hz, 1H) 7.56 (br. s., 2H) 7.76 (d, J=5.48 Hz, 1H)7.83 (s, 1H) 8.74 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=461.0, Rt=0.59min.

Example 479:2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.85-1.97 (m, 6H) 2.38 (s, 3H) 3.17 (br.s., 4H) 3.73 (s, 3H) 4.02 (br. s., 4H) 6.35 (s, 1H) 6.46 (s, 1H)7.48-7.54 (m, 1H) 7.58 (s, 1H) 7.58-7.64 (m, 1H) 8.05 (br. s., 1H) 8.25(s, 1H) 8.85 (d, J=5.48 Hz, 1H). LCMS (m/z) (M+H)=465.1, Rt=0.80 min.

Example 480:2-(1-cyanocyclopropyl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.70-1.78 (m, 2H) 1.83-1.92 (m, 2H) 2.24(s, 3H) 2.93 (br. s., 4H) 3.45 (s, 3H) 3.73 (br. s., 4H) 5.80 (d, J=1.57Hz, 1H) 6.05 (d, J=1.17 Hz, 1H) 7.29 (d, J=8.61 Hz, 1H) 7.63 (d, J=1.96Hz, 1H) 7.70 (dd, J=8.22, 1.96 Hz, 1H) 7.77 (dd, J=4.89, 0.98 Hz, 1H)7.90 (s, 1H) 8.69 (d, J=5.09 Hz, 1H) 10.56 (s, 1H). LCMS (m/z)(M+H)=470.1, Rt=0.77 min.

Example 481:1-ethyl-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.29 (t, J=7.04 Hz, 3H) 2.23 (s, 3H) 2.93(br. s., 4H) 3.45 (s, 3H) 3.73 (t, J=3.91 Hz, 4H) 4.06 (q, J=7.04 Hz,2H) 5.79 (d, J=1.17 Hz, 1H) 6.04 (d, J=1.17 Hz, 1H) 7.27 (d, J=8.22 Hz,1H) 7.54 (d, J=1.96 Hz, 1H) 7.64 (dd, J=8.22, 1.96 Hz, 1H) 8.45 (d,J=1.96 Hz, 1H) 8.79 (d, J=2.35 Hz, 1H) 10.14 (s, 1H). LCMS (m/z)(M+H)=517.2, Rt=0.79 min.

Example 482:2-isopropyl-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.28 (d, J=7.04 Hz, 6H) 2.24 (s, 3H) 2.93(br. s., 4H) 3.15 (spt, J=6.85 Hz, 1H) 3.45 (s, 3H) 3.73 (t, J=3.91 Hz,4H) 5.80 (d, J=1.17 Hz, 1H) 6.05 (s, 1H) 7.29 (d, J=8.61 Hz, 1H) 7.63(d, J=1.57 Hz, 1H) 7.67-7.75 (m, 2H) 7.80 (s, 1H) 8.71 (d, J=5.09 Hz,1H) 10.41-10.56 (m, 1H). LCMS (m/z) (M+H)=447.2, Rt=0.63 min.

Example 483:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.48 (s, 6H) 2.24 (s, 3H) 2.93 (br. s.,4H) 3.45 (s, 3H) 3.73 (t, J=3.91 Hz, 4H) 5.80 (d, J=1.57 Hz, 1H)6.00-6.10 (m, 1H) 7.20-7.37 (m, 1H) 7.64 (d, J=1.96 Hz, 1H) 7.68-7.79(m, 2H) 8.16 (s, 1H) 8.68 (d, J=5.48 Hz, 1H) 10.54 (s, 1H). LCMS (m/z)(M+H)=463.2, Rt=0.59 min.

Example 484:3-(difluoromethyl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.24 (s, 3H) 2.94 (br. s., 4H) 3.45 (s,3H) 3.71-3.78 (m, 4H) 5.80 (d, J=1.17 Hz, 1H) 6.05 (d, J=1.17 Hz, 1H)6.96-7.31 (m, 2H) 7.63-7.75 (m, 3H) 7.77 (d, J=7.43 Hz, 1H) 8.07-8.16(m, 2H) 10.35-10.42 (m, 1H). LCMS (m/z) (M+H)=454.2, Rt=0.82 min.

Example 485N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 2.93 (br. s., 4H) 3.45 (s,3H) 3.74 (d, J=3.91 Hz, 4H) 5.80 (s, 1H) 6.05 (s, 1H) 7.30 (d, J=8.22Hz, 1H) 7.65 (s, 1H) 7.71 (dd, J=8.22, 1.96 Hz, 1H) 8.17 (d, J=5.09 Hz,1H) 8.34 (s, 1H) 8.97 (d, J=4.69 Hz, 1H) 10.67 (s, 1H). LCMS (m/z)(M+H)=473.3, Rt=0.82 min.

Example 486:2-(difluoromethyl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 2.94 (br. s., 4H) 3.45 (s,3H) 3.73 (d, J=3.91 Hz, 4H) 5.70-5.88 (m, 1H) 6.05 (d, J=1.17 Hz, 1H)6.83-7.23 (m, 1H) 7.25-7.37 (m, 1H) 7.57-7.67 (m, 1H) 7.72 (dd, J=8.22,1.96 Hz, 1H) 8.04 (d, J=5.09 Hz, 1H) 8.16 (s, 1H) 8.89 (d, J=5.09 Hz,1H) 10.63 (s, 1H). LCMS (m/z) (M+H)=455.2, Rt=0.74 min.

Example 487:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 2.24 (s, 3H) 2.93 (br. s.,4H) 3.45 (s, 3H) 3.73 (br. s., 4H) 5.80 (s, 1H) 6.05 (s, 1H) 7.30 (d,J=8.22 Hz, 1H) 7.63 (s, 1H) 7.70 (dd, J=8.41, 1.76 Hz, 1H) 7.84 (d,J=4.70 Hz, 1H) 7.98 (s, 1H) 8.79 (d, J=4.70 Hz, 1H) 10.54 (s, 1H). LCMS(m/z) (M+H)=472.3, Rt=0.77 min.

Example 488:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-3-(methylsulfonyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.24 (s, 3H) 2.94 (br. s., 4H) 3.21-3.34(m, 3H) 3.39-3.48 (m, 3H) 3.8 (br. s., 4H) 5.74-5.88 (m, 1H) 5.98-6.12(m, 1H) 7.19-7.34 (m, 1H) 7.65 (d, J=1.56 Hz, 1H) 7.68-7.75 (m, 1H)7.76-7.87 (m, 1H) 8.08-8.17 (m, 1H) 8.22-8.32 (m, 1H) 8.39-8.53 (m, 1H)10.51 (s, 1H). LCMS (m/z) (M+H)=482.3, Rt=0.70 min.

Example 489:6-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.83 (s, 6H) 2.25 (s, 3H) 2.93 (br. s.,4H) 3.45 (s, 3H) 3.73 (d, J=4.30 Hz, 4H) 5.80 (d, J=1.57 Hz, 1H) 6.05(s, 1H) 7.32 (d, J=8.61 Hz, 1H) 7.62 (d, J=1.96 Hz, 1H) 7.69 (dd,J=8.22, 1.96 Hz, 1H) 8.28 (d, J=1.96 Hz, 1H) 9.62 (d, J=1.57 Hz, 1H)10.74 (s, 1H). LCMS (m/z) (M+H)=473.2, Rt=0.74 min.

Example 490:3-(4-ethylpiperazin-1-yl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.25 (t, J=7.24 Hz, 3H) 2.24 (s, 3H) 2.93(br. s., 4H) 3.06-3.15 (m, 4H) 3.18-3.24 (m, 2H) 3.45 (s, 3H) 3.59 (d,J=7.43 Hz, 2H) 3.73 (t, J=4.11 Hz, 4H) 4.10 (d, J=9.78 Hz, 2H) 5.80 (d,J=1.56 Hz, 1H) 6.04 (d, J=1.17 Hz, 1H) 7.19-7.35 (m, 1H) 7.50 (s, 1H)7.61 (d, J=1.96 Hz, 1H) 7.65-7.80 (m, 3H) 9.42 (br. s., 1H) 10.36 (s,1H). LCMS (m/z) (M+H)=584.3, Rt=0.77 min.

Example 491:3-fluoro-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-5-morpholinobenzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.23 (s, 3H) 2.93 (br. s., 4H) 3.17-3.24(m, 4H) 3.45 (s, 3H) 3.71-3.75 (m, 8H) 5.79 (d, J=1.56 Hz, 1H) 6.04 (d,J=1.57 Hz, 1H) 6.90-7.01 (m, 1H) 7.11 (d, J=8.61 Hz, 1H) 7.20-7.34 (m,2H) 7.61 (d, J=2.35 Hz, 1H) 7.69 (dd, J=8.22, 2.35 Hz, 1H) 10.17 (s,1H). LCMS (m/z) (M+H)=507.1, Rt=0.86 min.

Example 492:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-3-(oxetan-3-yl)benzamide

LCMS (m/z) (M+H)=460.2, Rt=0.78 min.

Example 493:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-3-(1,3,4-oxadiazol-2-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 2.94 (br. s., 4H) 3.45 (s,3H) 3.72-3.75 (m, 4H) 5.81 (d, J=1.57 Hz, 1H) 6.06 (d, J=1.57 Hz, 1H)7.17-7.36 (m, 1H) 7.58-7.87 (m, 3H) 8.16-8.28 (m, 2H) 8.59 (s, 1H) 9.40(s, 1H) 10.50 (s, 1H). LCMS (m/z) (M+H)=472.1, Rt=0.75 min.

Example 494:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-3-(2-(methylsulfonyl)propan-2-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.80 (s, 6H) 2.24 (s, 3H) 2.72 (s, 3H)2.93 (br. s., 4H) 3.45 (s, 3H) 3.73 (t, J=4.11 Hz, 4H) 5.80 (d, J=1.57Hz, 1H) 6.05 (d, J=1.57 Hz, 1H) 7.27 (d, J=8.61 Hz, 1H) 7.56 (t, J=7.83Hz, 1H) 7.63 (d, J=1.96 Hz, 1H) 7.70 (dd, J=8.22, 1.96 Hz, 1H) 7.81 (d,J=8.22 Hz, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.10 (s, 1H) 10.28 (s, 1H). LCMS(m/z) (M+H)=524.1, Rt=0.77 min.

Example 495:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-6-(trifluoromethyl) pyridazine-4-carboxamide

¹H NMR (500 MHz, <dmso>) δ ppm 2.27 (s, 3H), 2.94 (s, 4H), 3.46 (s, 3H),3.74 (d, J=4.7 Hz, 4H), 5.81 (d, J=1.7 Hz, 1H), 6.06 (d, J=1.7 Hz, 1H),7.34 (d, J=8.4 Hz, 1H), 7.65 (d, J=2.3 Hz, 1H), 7.72 (dd, J=8.3, 2.3 Hz,1H), 8.67 (d, J=2.0 Hz, 1H), 9.91 (d, J=2.0 Hz, 1H), 10.86 (s, 1H). LCMS(m/z) (M+H)=474.0, Rt=0.80 min.

Example 496:6-cyclopropyl-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.07-1.23 (m, 4H) 2.24 (s, 3H) 2.32-2.40(m, 1H) 2.93 (br. s., 4H) 3.45 (s, 3H) 3.73 (br. s., 4H) 5.79 (d, J=1.57Hz, 1H) 6.04 (d, J=1.57 Hz, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.62 (d, J=1.96Hz, 1H) 7.68 (dd, J=8.22, 2.35 Hz, 1H) 7.87 (d, J=1.96 Hz, 1H) 9.36 (d,J=1.96 Hz, 1H) 10.61 (s, 1H). LCMS (m/z) (M+H)=446.2, Rt=0.70 min.

Example 497:3-((dimethylamino)methyl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 2.77 (br. s., 6H) 2.93 (br.s., 4H) 3.45 (s, 3H) 3.70-3.76 (m, 4H) 4.43-4.49 (m, 2H) 5.80 (d, J=1.57Hz, 1H) 6.05 (d, J=1.57 Hz, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.62 (d, J=1.96Hz, 1H) 7.71 (dd, J=8.22, 1.96 Hz, 1H) 8.12 (s, 1H) 8.35 (s, 1H) 8.43(s, 1H) 10.53 (s, 1H). LCMS (m/z) (M+H)=529.3, Rt=0.68 min.

The compounds listed below were prepared using methods similar to thosedescribed in the preparation of Example 171 using the appropriatestarting materials.

Example 498:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideSynthesis of5-amino-1′,2-dimethyl-6′-morpholino-[3,4′-bipyridin]-2′(1′H)-one

Following the preparation of the precursor in Example 471, using theappropriate starting materials gave5-amino-1′,2-dimethyl-6′-morpholino-[3,4′-bipyridin]-2′(1′H)-one (60%yield) as a light brown residue. LCMS (m/z) (M+H)=301.1, Rt=0.35 min.

¹H NMR (400 MHz, <dmso>) δ ppm 2.44 (s, 3H) 2.95 (br. s., 4H) 3.45 (s,3H) 3.73 (t, J=4.11 Hz, 4H) 5.87 (d, J=1.56 Hz, 1H) 6.13 (d, J=1.56 Hz,1H) 7.79 (t, J=7.63 Hz, 1H) 7.98 (d, J=7.83 Hz, 1H) 8.03 (d, J=2.35 Hz,1H) 8.26 (d, J=7.83 Hz, 1H) 8.30 (s, 1H) 8.85 (d, J=2.35 Hz, 1H) 10.66(s, 1H). LCMS (m/z) (M+H)=473.0, Rt=0.67 min.

Example 499:2-(2-cyanopropan-2-yl)-N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.77 (s, 6H) 2.96 (br. s., 4H) 3.47 (s,3H) 3.75 (br. s., 4H) 5.91 (s, 1H) 6.17 (s, 1H) 7.89 (d, J=4.70 Hz, 1H)8.04 (s, 1H) 8.12 (d, J=1.57 Hz, 1H) 8.84 (d, J=5.09 Hz, 1H) 8.93 (d,J=1.57 Hz, 1H) 10.90 (s, 1H). LCMS (m/z) (M+H)=473.2, Rt=0.54 min.

Example 500:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.95 (br. s., 4H) 3.46 (s, 3H) 3.74 (t,J=4.11 Hz, 4H) 5.89 (d, J=1.17 Hz, 1H) 6.16 (d, J=1.17 Hz, 1H) 8.13 (d,J=2.35 Hz, 1H) 8.20 (d, J=4.70 Hz, 1H) 8.37 (s, 1H) 8.93 (d, J=2.35 Hz,1H) 9.01 (d, J=5.09 Hz, 1H) 11.01 (s, 1H). LCMS (m/z) (M+H)=474.1,Rt=0.57 min.

Example 501:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-2-(2-hydroxypropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.46 (s., 6H) 2.52 (s, 3H) 2.95 (br. s.,4H) 3.38-3.50 (m, 3H) 3.67-3.80 (m, 4H) 5.91 (s, 1H) 6.10-6.25 (m, 1H)7.66-7.83 (m, 1H) 8.14-8.25 (m, 2H) 8.65-8.77 (m, 1H) 9.00 (d, J=1.96Hz, 1H) 10.97 (s, 1H). LCMS (m/z) (M+H)=464.1, Rt=0.33 min.

Example 502:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-1-ethyl-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.31 (t, J=7.24 Hz, 3H) 2.96 (br. s., 4H)3.48 (s, 3H) 3.76 (t, J=4.11 Hz, 4H) 4.09 (quin, J=7.53 Hz, 2H) 5.91 (s,1H) 6.18 (s, 1H) 8.15 (d, J=1.96 Hz, 1H) 8.49 (d, J=1.57 Hz, 1H) 8.79(d, J=1.96 Hz, 1H) 8.85 (s, 1H) 10.56 (br. s., 1H). LCMS (m/z)(M+H)=518.1, Rt=0.58 min.

Example 503:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.45 (br. s., 3H) 2.90 (br. s., 4H)3.35-3.47 (m, 3H) 3.69 (t, J=4.11 Hz, 4H) 5.86 (d, J=1.17 Hz, 1H) 6.12(d, J=1.17 Hz, 1H) 7.44-7.54 (m, 2H) 7.54-7.63 (m, 1H) 7.93 (d, J=7.04Hz, 2H) 8.10-8.20 (m, 1H) 8.95 (d, J=1.96 Hz, 1H) 10.59 (s, 1H). LCMS(m/z) (M+H)=405.0, Rt=0.53 min.

Example 504:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.44 (br. s., 3H) 2.90 (br. s., 4H)3.23-3.33 (m, 3H) 3.41 (s, 3H) 3.69 (br. s., 4H) 5.85 (s, 1H) 6.11 (s,1H) 8.09 (s, 1H) 8.17 (d, J=5.09 Hz, 1H) 8.50 (s, 1H) 8.89 (s, 1H) 8.97(d, J=4.70 Hz, 1H) 11.06 (s, 1H). LCMS (m/z) (M+H)=484.0, Rt=0.46 min.

Example 505:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.29 (d, J=6.65 Hz, 6H) 2.52 (s, 3H) 2.95(br. s., 4H) 3.16 (spt, J=6.72 Hz, 1H) 3.46 (s, 3H) 3.74 (br. s., 4H)5.91 (s, 1H) 6.18 (s, 1H) 7.77 (d, J=5.09 Hz, 1H) 7.84 (s, 1H) 8.21 (s,1H) 8.75 (d, J=5.09 Hz, 1H) 9.00 (s, 1H) 10.95 (s, 1H). LCMS (m/z)(M+H)=448.1, Rt=0.45 min.

Example 506:3-(difluoromethyl)-N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.49 (br. s., 3H) 2.95 (br. s., 4H) 3.46(s, 3H) 3.72-3.76 (m, 4H) 5.90 (d, J=1.17 Hz, 1H) 6.11-6.21 (m, 1H)6.95-7.33 (m, 1H) 7.67-7.76 (m, 1H) 7.82 (d, J=7.83 Hz, 1H) 8.10-8.22(m, 3H) 8.97 (d, J=1.96 Hz, 1H) 10.45-10.96 (m, 1H). LCMS (m/z)(M+H)=455.2, Rt=0.57 min.

Example 507:2-(tert-butyl)-N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) ™ppm 1.36 (s, 9H) 2.50 (br. s., 3H) 2.95 (br.s., 4H) 3.46 (s, 3H) 3.74 (t, J=4.11 Hz, 4H) 5.90 (d, J=1.17 Hz, 1H)6.17 (d, J=1.17 Hz, 1H) 7.70 (dd, J=5.09, 1.17 Hz, 1H) 7.88 (s, 1H) 8.15(d, J=1.57 Hz, 1H) 8.68-8.80 (m, 1H) 8.96 (d, J=1.96 Hz, 1H) 10.82 (s,1H). LCMS (m/z) (M+H)=462.3, Rt=0.48 min.

Example 508:2-(difluoromethyl)-N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.48 (s, 3H) 2.95 (br. s., 4H) 3.46 (s,3H) 3.74 (br. s., 4H) 5.89 (d, J=1.17 Hz, 1H) 6.16 (d, J=1.56 Hz, 1H)6.90-7.27 (m, 1H) 8.06 (d, J=5.09 Hz, 1H) 8.12 (d, J=1.96 Hz, 1H) 8.19(s, 1H) 8.87-8.99 (m, 2H) 10.95 (s, 1H). LCMS (m/z) (M+H)=456.3, Rt=0.50min.

Example 509:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-3-(methylsulfonyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.48 (s, 3H) 2.91 (br. s., 4H) 3.24 (s,3H) 3.41 (s, 3H) 3.66-3.72 (m, 4H) 5.85 (d, J=1.57 Hz, 1H) 6.12 (d,J=1.57 Hz, 1H) 7.80 (t, J=7.83 Hz, 1H) 8.06-8.16 (m, 2H) 8.26 (d, J=7.83Hz, 1H) 8.46 (s, 1H) 8.91 (d, J=2.35 Hz, 1H) 10.81 (s, 1H). LCMS (m/z)(M+H)=483.3, Rt=0.47 min.

Example 510:2-(1,1-difluoroethyl)-N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

LCMS (m/z) (M+H)=470.4, Rt=0.55 min.

Example 511:2-cyclopropyl-N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.88-1.10 (m, 4H) 2.15-2.27 (m, 1H) 2.49(s, 3H) 2.95 (br. s., 4H) 3.46 (s, 3H) 3.71-3.76 (m, 4H) 5.89 (d, J=1.57Hz, 1H) 6.15 (d, J=1.56 Hz, 1H) 7.60 (dd, J=5.09, 1.17 Hz, 1H) 7.76 (s,1H) 8.12 (d, J=1.96 Hz, 1H) 8.60 (d, J=5.09 Hz, 1H) 8.93 (d, J=2.35 Hz,1H) 10.77 (s, 1H). LCMS (m/z) (M+H)=446.2, Rt=0.48 min.

Example 512:N-(1′,2-dimethyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-3-(2-(methylsulfonyl)propan-2-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.81 (s, 6H) 2.49 (s, 3H) 2.73 (s, 3H)2.89-3.00 (m, 4H) 3.46 (s, 3H) 3.73 (d, J=4.30 Hz, 4H) 5.90 (d, J=1.57Hz, 1H) 6.16 (d, J=1.17 Hz, 1H) 7.60 (s, 1H) 7.85 (d, J=8.61 Hz, 1H)8.01 (d, J=7.83 Hz, 1H) 8.08-8.18 (m, 2H) 8.94 (d, J=1.96 Hz, 1H) 10.60(s, 1H). LCMS (m/z) (M+H)=525.1, Rt=0.56 min.

The compounds listed below were prepared using methods similar to thosedescribed in the preparation of Example 171 using the appropriatestarting materials.

Synthesis of5-amino-2-chloro-1′-methyl-6′-morpholino-[3,4′-bipyridin]-2′(1′H)-one

Following the preparation in Example 471 using the appropriate startingmaterials gave crude5-amino-2-chloro-1′-methyl-6′-morpholino-[3,4′-bipyridin]-2′(1′H)-one(assumed 100% yield) which was used without further purification.

LCMS (m/z) (M+H)=321.0, Rt=0.49 min.

Example 513:N-(2-chloro-1′-methyl-6′-morpholino-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.04 (t, J=19.17 Hz, 3H) 2.95 (br. s.,4H) 3.46 (s, 3H) 3.71-3.76 (m, 4H) 5.95 (d, J=1.57 Hz, 1H) 6.22 (d,J=1.17 Hz, 1H) 8.03 (d, J=5.09 Hz, 1H) 8.20 (s, 1H) 8.26 (d, J=2.35 Hz,1H) 8.84 (d, J=2.35 Hz, 1H) 8.91 (d, J=5.09 Hz, 1H) 11.03 (s, 1H). LCMS(m/z) (M+H)=490.2, Rt=0.76 min.

Step 1 Synthesis of methyl4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)benzoate

To a 0.20M solution of 4-bromo-1-methyl-6-morpholinopyridin-2(1H)-one(1.00 equiv.) in DME was added methyl4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.10equiv.), PdCl2(dppf).CH2Cl2 adduct (0.50 equiv.), and 2M aqueous sodiumcarbonate (8.00 equiv.). The reaction mixture was irradiated at 110° C.for 15 min in the microwave. The cooled reaction mixture was dilutedwith water and extracted with ethyl acetate. The combined extracts weredried over magnesium sulfate, filtered, concentrated to give crudemethyl4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)benzoate(80.0% yield) as a brown oil. LCMS (m/z) (M+H)=343.2, Rt=0.72 min.

Step 2 Synthesis of4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)benzoicacid

To a 0.20M solution of methyl4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)benzoate(1.00 equiv.) in 1:1 THF:water was added lithium hydroxide (2.00equiv.). The mixture was stirred at ambient temperature for 20 hr. Thereaction mixture was acidified with aqueous HCl and extracted with ethylacetate. The combined extracts were dried over magnesium sulfate,filtered, and concentrated to give crude4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)benzoicacid as an off-white solid (63% yield). LCMS (m/z) (M+H)=329.1, Rt=0.56min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 171 using the appropriatestarting materials.

Example 514:N-(3-(difluoromethyl)phenyl)-4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.27-2.39 (m, 3H) 2.95 (br. s., 4H) 3.46(s, 3H) 3.63-3.85 (m, 4H) 5.87 (d, J=1.17 Hz, 1H) 6.15 (d, J=1.17 Hz,1H) 6.80-7.20 (m, 1H) 7.27 (d, J=7.83 Hz, 1H) 7.41-7.52 (m, 2H) 7.85 (s,1H) 7.90 (d, J=7.83 Hz, 2H) 8.04 (s, 1H) 10.38 (s, 1H). LCMS (m/z)(M+H)=454.2, Rt=0.83 min.

Example 515:N-(3-(2-cyanopropan-2-yl)phenyl)-4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.60-1.71 (m, 6H) 2.34 (s, 3H) 2.95 (br.s., 4H) 3.46 (s, 3H) 3.73 (t, J=3.91 Hz, 4H) 5.87 (d, J=1.17 Hz, 1H)6.15 (s, 1H) 7.22 (d, J=7.83 Hz, 1H) 7.39 (t, J=7.83 Hz, 1H) 7.45 (d,J=8.22 Hz, 1H) 7.80 (d, J=8.22 Hz, 1H) 7.85 (s, 1H) 7.87-7.98 (m, 2H)10.30 (s, 1H). LCMS (m/z) (M+H)=471.3, Rt=0.85 min.

Example 516:N-(3-(2-hydroxypropan-2-yl)phenyl)-4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.43 (s, 6H) 2.36 (s, 3H) 2.96 (br. s.,4H) 3.48 (s, 3H) 3.75 (d, J=3.91 Hz, 4H) 5.88 (d, J=1.56 Hz, 1H) 6.17(d, J=1.17 Hz, 1H) 7.14-7.22 (m, 1H) 7.23-7.30 (m, 1H) 7.45 (d, J=8.22Hz, 1H) 7.69 (d, J=8.22 Hz, 1H) 7.78-7.88 (m, 2H) 7.88-7.96 (m, 1H)10.16 (s, 1H). LCMS (m/z) (M+H)=462.3, Rt=0.74 min.

Example 517:4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.35 (s, 3H) 2.95 (br. s., 4H) 3.46 (s,3H) 3.73 (d, J=4.30 Hz, 4H) 5.86 (d, J=1.57 Hz, 1H) 6.15 (d, J=1.57 Hz,1H) 7.38-7.51 (m, 2H) 7.58 (t, J=8.02 Hz, 1H) 7.86 (d, J=1.17 Hz, 1H)7.91 (dd, J=7.83, 1.57 Hz, 1H) 8.04 (d, J=8.22 Hz, 1H) 8.21 (s, 1H)10.48 (s, 1H). LCMS (m/z) (M+H)=472.1, Rt=0.91 min.

Example 518:4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)-N-phenylbenzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.34 (s, 3H) 2.95 (br. s., 4H) 3.46 (s,3H) 3.73 (br. s., 4H) 5.86 (d, J=1.56 Hz, 1H) 6.15 (d, J=1.56 Hz, 1H)7.03-7.13 (m, 1H) 7.33 (t, J=8.02 Hz, 2H) 7.44 (d, J=7.83 Hz, 1H) 7.74(d, J=7.83 Hz, 2H) 7.83 (d, J=1.17 Hz, 1H) 7.88 (dd, J=7.83, 1.57 Hz,1H) 10.18 (s, 1H). LCMS (m/z) (M+H)=404.1, Rt=0.77 min.

Synthesis of4-(5-amino-2-methylphenyl)-1-ethyl-6-morpholinopyridin-2(1H)-one

Following the preparation of4-(5-amino-2-methylphenyl)-1-methyl-6-morpholinopyridin-2(1H)-one usingthe appropriate starting materials gave4-(5-amino-2-methylphenyl)-1-ethyl-6-morpholinopyridin-2(1H)-one (37.7%yield) as a white solid. LCMS (m/z) (M+H)=314.2, Rt=0.51 min.

The compounds listed below were prepared using methods similar to thosedescribed in the preparation of Example 171 using the appropriatestarting materials.

Example 519:2-(1,1-difluoroethyl)-N-(3-(1-ethyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.22 (t, J=6.85 Hz, 3H) 2.03 (t, J=19.17Hz, 3H) 2.25 (s, 3H) 2.91 (d, J=4.30 Hz, 4H) 3.72 (br. s., 4H) 4.08 (q,J=6.65 Hz, 2H) 5.95 (d, J=1.17 Hz, 1H) 6.09 (s, 1H) 7.30 (d, J=8.61 Hz,1H) 7.66 (d, J=1.96 Hz, 1H) 7.71 (d, J=8.22 Hz, 1H) 8.01 (d, J=5.09 Hz,1H) 8.16 (s, 1H) 8.81-8.89 (m, 1H) 10.57-10.66 (m, 1H). LCMS (m/z)(M+H)=483.0, Rt=0.88 min.

Example 520:2-(1,1-difluoropropyl)-N-(3-(1-ethyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.93 (t, J=7.63 Hz, 3H) 1.22 (t, J=6.85Hz, 3H) 2.25 (s, 3H) 2.30-2.41 (m, 2H) 2.91 (t, J=4.11 Hz, 4H) 3.72 (br.s., 4H) 4.08 (q, J=7.04 Hz, 2H) 5.95 (d, J=1.57 Hz, 1H) 6.10 (d, J=1.56Hz, 1H) 7.30 (d, J=8.61 Hz, 1H) 7.65 (d, J=1.96 Hz, 1H) 7.71 (dd,J=8.41, 2.15 Hz, 1H) 8.00 (d, J=4.30 Hz, 1H) 8.14 (s, 1H) 8.87 (d,J=5.09 Hz, 1H) 10.62 (s, 1H). LCMS (m/z) (M+H)=497.3, Rt=0.91 min.

Example 521:N-(3-(1-ethyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)-4-methylphenyl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.22 (t, J=6.85 Hz, 3H) 1.66 (s, 3H) 1.72(s, 3H) 2.25 (s, 3H) 2.91 (t, J=4.11 Hz, 4H) 3.72 (br. s., 4H) 4.08 (d,J=7.04 Hz, 2H) 5.95 (d, J=1.57 Hz, 1H) 6.10 (d, J=1.57 Hz, 1H) 7.29 (d,J=8.22 Hz, 1H) 7.65 (d, J=1.96 Hz, 1H) 7.71 (dd, J=8.22, 1.96 Hz, 1H)7.80 (dd, J=4.89, 1.37 Hz, 1H) 8.00 (s, 1H) 8.74 (d, J=5.09 Hz, 1H)10.54 (s, 1H). LCMS (m/z) (M+H)=479.2, Rt=0.85 min.

Example 522:N-(3-(1-ethyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)-4-methylphenyl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.19-1.28 (m, 9H) 2.25 (s, 3H) 2.85-2.95(m, 4H) 3.11 (dt, J=13.69, 6.85 Hz, 1H) 3.72 (br. s., 4H) 4.08 (d,J=6.65 Hz, 2H) 5.94 (d, J=1.57 Hz, 1H) 6.09 (d, J=1.57 Hz, 1H) 7.28 (d,J=8.22 Hz, 1H) 7.58-7.79 (m, 4H) 8.67 (d, J=5.09 Hz, 1H) 10.43 (s, 1H).LCMS (m/z) (M+H)=461.2, Rt=0.68 min.

The compounds listed below were prepared using methods similar to thosedescribed in the preparation of Example 162 using the appropriatestarting materials.

Synthesis of(R)-4-bromo-1-methyl-6-(3-methylmorpholino)pyridin-2(1H)-one

Following the preparation of4-bromo-1-methyl-6-morpholinopyridin-2(1H)-one using the appropriatestarting materials gave(R)-4-bromo-1-methyl-6-(3-methylmorpholino)pyridin-2(1H)-one (assumedquantitative yield) as a brown residue. LCMS (m/z) (M+H)=286.8/288.8,Rt=0.63 min.

Example 523:(R)-2-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-6-(3-methylmorpholino)-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.87 (d, J=5.87 Hz, 3H) 2.00 (t, J=19.17Hz, 3H) 2.21 (s, 3H) 2.56-2.64 (m, 1H) 3.08 (br. s., 1H) 3.21 (br. s.,1H) 3.26-3.35 (m, 1H) 3.44 (s, 3H) 3.58-3.72 (m, 2H) 3.77 (dd, J=10.96,2.74 Hz, 1H) 5.94 (br. s., 1H) 6.07 (s, 1H) 7.27 (d, J=8.22 Hz, 1H) 7.61(d, J=1.96 Hz, 1H) 7.66-7.75 (m, 1H) 7.98 (d, J=4.70 Hz, 1H) 8.13 (s,1H) 8.83 (d, J=5.09 Hz, 1H) 10.60 (s, 1H). LCMS (m/z) (M+H)=483.1,Rt=0.86 min.

Example 524:(R)-2-(1,1-difluoroethyl)-N-(1′,2-dimethyl-6′-(3-methylmorpholino)-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H (400 MHz, <dmso>) δ ppm 0.93 (d, J=6.26 Hz, 3H) 2.06 (t, J=19.17 Hz,3H) 2.67 (dt, J=11.35, 5.67 Hz, 1H) 3.16 (d, J=10.96 Hz, 1H) 3.23-3.32(m, 1H) 3.36 (d, J=5.87 Hz, 1H) 3.50 (s, 3H) 3.74 (br. s., 2H) 3.82 (dd,J=10.76, 2.54 Hz, 1H) 6.08 (br. s., 1H) 6.21 (s, 1H) 8.05 (d, J=4.30 Hz,1H) 8.11 (d, J=2.35 Hz, 1H) 8.21 (s, 1H) 8.91 (d, J=5.09 Hz, 1H) 8.94(d, J=2.35 Hz, 1H) 10.94 (s, 1H). LCMS (m/z) (M+H)=484.1, Rt=0.62 min.

Synthesis of(S)-4-bromo-1-methyl-6-(3-methylmorpholino)pyridin-2(1H)-one

Following the preparation of4-bromo-1-methyl-6-morpholinopyridin-2(1H)-one using the appropriatestarting materials gave(S)-4-bromo-1-methyl-6-(3-methylmorpholino)pyridin-2(1H)-one (assumedquantitative yield) as a brown residue. LCMS (m/z) (M+H)=286.8/288.8,Rt=0.63 min.

The compounds listed below were prepared using methods similar to thosedescribed in the preparation of Example 162 using the appropriatestarting materials.

Example 525:(S)-2-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-6-(3-methylmorpholino)-2-oxo-1,2-dihydropyridin-4-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.92 (d, J=5.87 Hz, 3H) 2.05 (t, J=19.17Hz, 3H) 2.26 (s, 3H) 2.61-2.70 (m, 1H) 3.13 (br. s., 1H) 3.26 (br. s.,1H) 3.36 (br. s., 1H) 3.49 (s, 3H) 3.74 (br. s., 2H) 3.82 (dd, J=10.96,2.74 Hz, 1H) 5.99 (br. s., 1H) 6.12 (s, 1H) 7.32 (d, J=8.22 Hz, 1H) 7.66(d, J=1.96 Hz, 1H) 7.75 (dd, J=8.22, 1.96 Hz, 1H) 8.03 (d, J=4.70 Hz,1H) 8.18 (s, 1H) 8.88 (d, J=5.09 Hz, 1H) 10.65 (s, 1H). LCMS (m/z)(M+H)=483.2, Rt=0.86 min.

Example 526:(S)-2-(1,1-difluoroethyl)-N-(1′,2-dimethyl-6′-(3-methylmorpholino)-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.93 (d, J=5.87 Hz, 3H) 2.06 (t, J=19.17Hz, 3H) 2.61-2.71 (m, 1H) 3.16 (d, J=10.96 Hz, 1H) 3.28 (br. s., 1H)3.33-3.41 (m, 1H) 3.50 (s, 3H) 3.74 (br. s., 2H) 3.82 (dd, J=11.15, 2.54Hz, 1H) 6.09 (br. s., 1H) 6.23 (s, 1H) 8.05 (d, J=4.30 Hz, 1H) 8.16 (d,J=1.96 Hz, 1H) 8.22 (s, 1H) 8.92 (d, J=4.70 Hz, 1H) 8.98 (d, J=2.35 Hz,1H) 10.99

Synthesis of6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-4-bromo-1-methylpyridin-2(1H)-one

Following the preparation of4-bromo-1-methyl-6-morpholinopyridin-2(1H)-one using the appropriatestarting materials gave(S)-4-bromo-1-methyl-6-(3-methylmorpholino)pyridin-2(1H)-one (36%yield). LCMS (m/z) (M+H)=299.0/301.0, Rt=0.59 min.

The compounds listed below were prepared using methods similar to thosedescribed in the preparation of Example 162 using the appropriatestarting materials.

Example 527:N-(3-(6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-4-methylphenyl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.90 (s, 4H) 2.03 (t, J=19.17 Hz, 3H)2.23 (s, 3H) 3.52 (s, 3H) 3.58 (d, J=10.17 Hz, 2H) 3.75-3.85 (m, 4H)5.64 (d, J=1.17 Hz, 1H) 5.93 (s, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.63 (d,J=1.96 Hz, 1H) 7.71 (dd, J=8.22, 1.96 Hz, 1H) 8.00 (d, J=4.70 Hz, 1H)8.15 (s, 1H) 8.86 (d, J=5.09 Hz, 1H) 10.61 (s, 1H). LCMS (m/z)(M+H)=495.3, Rt=0.86 min.

Synthesis of5-amino-6′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-chloro-1′-methyl-[3,4′-bipyridin]-2′(1′H)-one

Following the preparation in Example 527, using the appropriate startingmaterials gave5-amino-6′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-chloro-1′-methyl-[3,4′-bipyridin]-2′(1′H)-one(assumed 100% yield) as a light brown residue. LCMS (m/z) (M+H)=347.1,Rt=0.53 min.

The compounds listed below were prepared using methods similar to thosedescribed in the preparation of Example 171 using the appropriatestarting materials.

Example 528:N-(6′-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-chloro-1′-methyl-2‘-oxo-’,2′-dihydro-[3,4′-bipyridin]-5-yl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (500 MHz, <dmso>) δ ppm 1.90 (s, 3H), 2.03 (t, J=19.1 Hz, 3H),3.30-3.60 (m, 8H), 3.74-3.83 (m, 2H), 5.83 (s, 1H), 6.08 (s, 1H), 8.01(d, J=5.0 Hz, 1H), 8.17 (s, 1H), 8.21 (d, J=2.6 Hz, 1H), 8.82 (d, J=2.5Hz, 1H), 8.88 (d, J=5.0 Hz, 1H). LCMS (m/z) (M+H)=516.3, Rt=0.81 min.

The compounds listed below were prepared using methods similar to thosedescribed in the preparation of Example 171 using the appropriatestarting materials.

Synthesis of4-bromo-6-(2-(hydroxymethyl)morpholino)-1-methylpyridin-2(1H)-one

To a solution of 4-bromo-6-chloro-1-methylpyridin-2(1H)-one (1.0 equiv.)and morpholin-2-ylmethanol (1.5 equiv.) was added potassium carbonate(6.0 equiv.) and the mixture was heated to 115° C. for 18 h. Thereaction mixture was partitioned between EtOAc and water, and was thenextracted five times with EtOAc. The combined organics were dried oversodium sulfate and then purified by normal phase chromatography. Producteluted with 25% MeOH in DCM.4-bromo-6-(2-(hydroxymethyl)morpholino)-1-methylpyridin-2(1H)-one wasused in the next step without further purification. LCMS (m/z)(M+H)=273.0, Rt=0.23 min.

Example 529:(R)-2-(1,1-difluoroethyl)-N-(6′-(2-(hydroxymethyl)morpholino)-1′,2-dimethyl-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.96-2.11 (m, 3H) 2.44 (s, 3H) 2.53 (m,2H) 2.63-2.68 (m, 1H) 2.75 (d, J=2.35 Hz, 1H) 3.10 (d, J=11.74 Hz, 1H)3.16 (d, J=11.74 Hz, 1H) 3.45 (s, 3H) 3.56-3.74 (m, 2H) 3.88 (d, J=10.96Hz, 1H) 5.86 (d, J=1.57 Hz, 1H) 6.13 (d, J=1.17 Hz, 1H) 8.02 (d, J=2.35Hz, 2H) 8.19 (s, 1H) 8.79-8.93 (m, 2H) 10.83 (s, 1H). LCMS (m/z)(M+H)=500.2, Rt=0.52 min.

Example 530:(S)-2-(1,1-difluoroethyl)-N-(6′-(2-(hydroxymethyl)morpholino)-1′,2-dimethyl-2′-oxo-1′,2′-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.04 (t, J=19.17 Hz, 3H) 2.31 (d, J=1.96Hz, 1H) 2.44 (s, 3H) 2.53-2.59 (m, 1H) 2.62-2.66 (m, 1H) 2.69-2.81 (m,1H) 3.07-3.18 (m, 2H) 3.45 (s, 3H) 3.61 (d, J=7.83 Hz, 1H) 3.69 (d,J=1.96 Hz, 1H) 3.88 (d, J=10.96 Hz, 1H) 5.86 (d, J=1.57 Hz, 1H) 6.13 (d,J=1.57 Hz, 1H) 8.03 (d, J=2.35 Hz, 2H) 8.19 (s, 1H) 8.79-8.93 (m, 2H)10.84 (s, 1H). LCMS (m/z) (M+H)=500.2, Rt=0.52 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 118 using the appropriatestarting materials.

Example 531:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(6-morpholinopyrazin-2-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.41 (s, 3H) 3.60-3.71 (m,4H) 3.78-3.87 (m, 4H) 7.34 (d, J=8.22 Hz, 1H) 7.70 (dd, J=8.22, 2.35 Hz,1H) 7.78-7.90 (m, 2H) 8.01 (s, 1H) 8.07 (s, 1H) 8.18 (s, 1H) 8.76 (d,J=5.09 Hz, 1H). LCMS (m/z) (M+H)=443.2, Rt=0.94 min.

Example 532:2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.82 (s, 6H) 2.81 (s, 3H) 3.63-3.72 (m,4H) 3.78-3.90 (m, 4H) 7.87 (dd, J=5.09, 1.57 Hz, 1H) 8.09-8.20 (m, 2H)8.35 (s, 1H) 8.66 (d, J=2.35 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 9.31 (d,J=2.35 Hz, 1H). LCMS (m/z) (M+H)=444.1, Rt=0.61 min.

Example 533:2-(1,1-difluoroethyl)-N-(6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-yl)isonicotinamide

Step 1

To a solution of 4-(6-chloropyrazin-2-yl)morpholine (1.0 equiv.) in DME(0.2M) was added6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.1 equiv.) and PdCl2(dppf).CH2Cl2 adduct (0.1 equiv.), followed by 2Msodium carbonate solution (3.0 equiv.). The reaction was heated to 120°C. in a microwave vial for 10 min. Partitioned between water and ethylacetate, the aqueous phase was extracted with ethyl acetate three times,the organics were combined, dried with sodium sulfate, filtered andconcentrated. The crude material was purified via silica gel columnchromatography eluting with 0-100% ethyl acetate in heptanes, then 10%methanol in ethyl acetate. The pure fractions were concentrated to yield6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-amine in 74% yield. LCMS(m/z) (M+H)=272.0, Rt=0.41 min.

Step 2

To a solution of 6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-amine inDMF (0.1M) was added EDC (1.2 equiv.), HOAt (1.2 equiv.) and2-(1,1-difluoroethyl)isonicotinic acid (1.2 equiv.) and the reaction wasstirred at rt for 3 hours. Upon completion, filtered through a HPLCfilter and purified via reverse phase prep-HPLC. The pure fractions werelyophilized to yield2-(1,1-difluoroethyl)-N-(6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-yl)isonicotinamideas the TFA salt in 39% yield. ¹H NMR (400 MHz, <cd3od>) δ ppm 2.05 (t,J=18.78 Hz, 3H) 2.84 (s, 3H) 3.64-3.74 (m, 4H) 3.79-3.91 (m, 4H) 8.03(d, J=4.70 Hz, 1H) 8.17 (s, 1H) 8.26 (s, 1H) 8.37 (s, 1H) 8.73 (d,J=2.35 Hz, 1H) 8.87 (d, J=5.09 Hz, 1H) 9.39 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=441.2, Rt=0.63 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 533 using the appropriatestarting materials.

Example 534:2-(2-fluoropropan-2-yl)-N-(6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.66-1.82 (m, 6H) 2.84 (s, 3H) 3.61-3.73(m, 4H) 3.78-3.87 (m, 4H) 7.84 (dd, J=4.89, 1.76 Hz, 1H) 8.11-8.21 (m,2H) 8.36 (s, 1H) 8.73 (d, J=2.35 Hz, 1H) 8.76 (d, J=5.09 Hz, 1H) 9.38(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=437.2, Rt=0.63 min.

Example 535:2-(difluoromethyl)-N-(6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.85 (s, 3H) 3.61-3.73 (m, 4H) 3.78-3.89(m, 4H) 6.64-7.08 (m, 1H) 8.08 (d, J=5.09 Hz, 1H) 8.17 (s, 1H) 8.26 (s,1H) 8.37 (s, 1H) 8.74 (d, J=2.35 Hz, 1H) 8.89 (d, J=4.70 Hz, 1H) 9.39(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=427.1, Rt=0.58 min.

Example 536:N-(6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.69 (s, 3H) 3.59-3.72 (m, 4H) 3.78-3.89(m, 4H) 8.10 (s, 1H) 8.16 (d, J=5.09 Hz, 1H) 8.29 (s, 1H) 8.35 (s, 1H)8.47 (d, J=2.35 Hz, 1H) 8.95 (d, J=5.09 Hz, 1H) 9.06 (s, 1H). LCMS (m/z)(M+H)=445.1, Rt=0.65 min.

Example 537:2-(1,1-difluoropropyl)-N-(6-methyl-5-(6-morpholinopyrazin-2-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.01 (t, J=7.43 Hz, 3H) 2.39 (td,J=16.63, 7.43 Hz, 2H) 2.81 (s, 3H) 3.59-3.73 (m, 4H) 3.78-3.89 (m, 4H)8.03 (d, J=3.91 Hz, 1H) 8.15 (s, 1H) 8.35 (s, 2H) 8.68 (d, J=2.35 Hz,1H) 8.87 (d, J=5.09 Hz, 1H) 9.31 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=455.2, Rt=0.68 min.

Example 538:N-(3-(5-ethoxy-6-morpholinopyrazin-2-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

Step 1 Synthesis of 6-chloro-3-ethoxypyrazin-2-amine

To a 0.5M solution of 3-bromo-6-chloropyrazin-2-amine (1.00 equiv.) inethanol was added sodium ethoxide, 21 wt % in ethanol (3.00 equiv.). Themixture was stirred at 85° C. for 1.5 hr. The cooled reaction mixturewas diluted with DCM and washed with saturated aqueous sodiumbicarbonate. The organic phase was dried over sodium sulfate, filtered,and concentrated to give 6-chloro-3-ethoxypyrazin-2-amine as a peachsolid in 82.0% yield. LCMS (m/z) (M+H)=174.0, Rt=0.65 min.

Step 2 Synthesis of 4-(6-chloro-3-ethoxypyrazin-2-yl)morpholine

6-Chloro-3-ethoxypyrazin-2-amine (1.00 equiv.) was added to a 0.6Msolution of NaH, 60% dispersion (3.00 equiv.) in DMF at ambienttemperature. The mixture was stirred for 20 min at ambient temperature.Bis(2-bromoethyl) ether (1.50 equiv.) was added. The mixture was heatedto 80° C. and stirred for 1 hr. The cooled reaction mixture was pouredinto water and stirred for 1 hr. The mixture was filtered. The filtercake was rinsed with water and air-dried to give4-(6-chloro-3-ethoxypyrazin-2-yl)morpholine as a yellow solid in 43.4%yield. LCMS (m/z) (M+H)=244.0, Rt=0.93 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 118 using the appropriatestarting materials.

¹H NMR (400 MHz, <cd3od>) δ ppm 1.46 (t, J=7.04 Hz, 3H) 2.39 (s, 3H)3.54-3.66 (m, 4H) 3.79-3.87 (m, 4H) 4.48 (q, J=7.04 Hz, 2H) 7.30 (d,J=8.61 Hz, 1H) 7.65 (dd, J=8.22, 2.35 Hz, 1H) 7.70-7.77 (m, 2H) 7.78 (d,J=1.96 Hz, 1H) 7.90 (d, J=7.83 Hz, 1H) 8.22 (d, J=7.83 Hz, 1H) 8.27 (s,1H); LCMS (m/z) (M+H)=487.1, Rt=1.13 min.

Example 539:N-(5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.48 (t, J=7.04 Hz, 3H) 2.83 (s, 3H)3.61-3.70 (m, 4H) 3.81-3.87 (m, 4H) 4.54 (q, J=7.04 Hz, 2H) 7.80 (t,J=8.02 Hz, 1H) 7.92 (s, 1H) 7.98 (d, J=8.22 Hz, 1H) 8.30 (d, J=8.22 Hz,1H) 8.36 (s, 1H) 8.66 (d, J=1.96 Hz, 1H) 9.29 (d, J=2.35 Hz, 1H); LCMS(m/z) (M+H)=488.1, Rt=0.85 min.

Step 1 Synthesis of 4-(3-bromo-6-chloropyrazin-2-yl)morpholine

6-Chloro-3-ethoxypyrazin-2-amine (1.00 equiv.) was added to a 0.6Msolution of NaH, 60% dispersion (3.00 equiv.) in DMF at ambienttemperature. The mixture was stirred for 20 min at ambient temperature.Bis(2-bromoethyl) ether (1.50 equiv.) was added. The mixture was heatedto 60° C. and stirred for 45 min. The cooled reaction mixture was pouredinto water and extracted with ethyl acetate. The combined organic layerswere dried over sodium sulfate, filtered and concentrated to give crude4-(3-bromo-6-chloropyrazin-2-yl)morpholine as a tan oil in 100% yield.LCMS (m/z) (M+H)=277.8/279.8, Rt=0.82 min.

Step 2 Synthesis of 4-(6-chloro-3-methoxypyrazin-2-yl)morpholine

To a 0.3M solution of 4-(3-bromo-6-chloropyrazin-2-yl)morpholine (1.00equiv.) in methanol was added sodium methoxide (3.00 equiv.). Themixture was stirred at 60° C. for 1 hr. The cooled reaction mixture wasconcentrated to about half of its original volume and poured into 4volumes of water. The resulting precipitate was collected by vacuumfiltration and air-dried to give4-(6-chloro-3-methoxypyrazin-2-yl)morpholine as a yellow solid in 76.0%yield. LCMS (m/z) (M+H)=230.0, Rt=0.80 min Step 3: Synthesis of5-(5-methoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-amine

To a 0.15M solution of 4-(6-chloro-3-methoxypyrazin-2-yl)morpholine(1.00 equiv.) in DME was added6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.00 equiv.), PdCl2(dppf).CH2Cl2 adduct (0.10 equiv.), and 2M aqueoussodium carbonate (3.00 equiv.). The reaction mixture was irradiated at130° C. for 15 min in the microwave. The cooled reaction mixture wasdiluted with 2:1 DCM:MeOH and filtered. The filtrate was concentratedand purified by flash chromatography over silica gel (ethyl acetate with5% methanol) to give5-(5-methoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-amine (44.7%yield) as a tan solid. LCMS (m/z) (M+H)=302.0, Rt=0.51 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 539 using the appropriatestarting materials.

Example 540:2-(2-cyanopropan-2-yl)-N-(5-(5-methoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.84 (s, 6H) 2.86 (s, 3H) 3.60-3.70 (m,4H) 3.78-3.89 (m, 4H) 4.08 (s, 3H) 7.90 (dd, J=5.09, 1.57 Hz, 1H) 7.95(s, 1H) 8.16 (s, 1H) 8.70 (d, J=2.35 Hz, 1H) 8.84 (d, J=4.70 Hz, 1H)9.33 (d, J=2.35 Hz, 1H); LCMS (m/z) (M+H)=474.2, Rt=0.69 min.

Example 541:2-(1-cyanocyclopropyl)-N-(5-(5-methoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.79-1.93 (m, 4H) 2.85 (s, 3H) 3.60-3.68(m, 4H) 3.78-3.89 (m, 4H) 4.08 (s, 3H) 7.79 (dd, J=4.89, 1.37 Hz, 1H)7.95 (s, 1H) 8.18 (s, 1H) 8.68 (d, J=2.35 Hz, 1H) 8.72 (d, J=4.70 Hz,1H) 9.30 (d, J=2.35 Hz, 1H); LCMS (m/z) (M+H)=472.2, Rt=0.69 min.

Example 542:2-(1,1-difluoroethyl)-N-(5-(5-methoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.07 (t, J=18.78 Hz, 3H) 2.81 (s, 3H)3.61-3.69 (m, 4H) 3.80-3.89 (m, 4H) 4.08 (s, 3H) 7.92 (s, 1H) 8.04 (d,J=3.52 Hz, 1H) 8.27 (s, 1H) 8.63 (d, J=1.96 Hz, 1H) 8.88 (d, J=5.09 Hz,1H) 9.23 (d, J=1.96 Hz, 1H); LCMS (m/z) (M+H)=471.2, Rt=0.71 min.

Example 543:3-((dimethylamino)methyl)-N-(5-(5-methoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.71 (s, 3H) 2.95 (s, 6H) 3.60-3.67 (m,4H) 3.80-3.89 (m, 4H) 4.07 (s, 3H) 4.54 (s, 2H) 7.87 (s, 1H) 8.16 (s,1H) 8.43 (s, 1H) 8.46 (s, 1H) 8.53 (s, 1H) 9.02 (s, 1H); LCMS (m/z)(M+H)=495.1, Rt=0.84 min.

Example 544:2-(2-fluoropropan-2-yl)-N-(5-(5-methoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.69-1.82 (m, 6H) 2.86 (s, 3H) 3.61-3.69(m, 4H) 3.81-3.88 (m, 4H) 4.09 (s, 3H) 7.86 (dd, J=5.09, 1.57 Hz, 1H)7.95 (s, 1H) 8.16 (s, 1H) 8.72 (d, J=2.35 Hz, 1H) 8.78 (d, J=5.09 Hz,1H) 9.35 (d, J=2.35 Hz, 1H); LCMS (m/z) (M+H)=467.2, Rt=0.71 min.

Synthesis of5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-amine

Following the preparation in Example 539 using the appropriate startingmaterials gave5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-amine (68.3%yield) as a tan solid. LCMS (m/z) (M+H)=316.1, Rt=0.59 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 539 using the appropriatestarting materials.

Example 540:2-(2-cyanopropan-2-yl)-N-(5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.48 (t, J=7.04 Hz, 3H) 1.84 (s, 6H)2.83 (s, 3H) 3.61-3.72 (m, 4H) 3.80-3.91 (m, 4H) 4.54 (q, J=7.04 Hz, 2H)7.86-7.93 (m, 2H) 8.15 (s, 1H) 8.64 (d, J=2.35 Hz, 1H) 8.84 (d, J=5.09Hz, 1H) 9.26 (d, J=2.35 Hz, 1H); LCMS (m/z) (M+H)=488.2, Rt=0.74 min.

Example 541:N-(5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.48 (t, J=7.04 Hz, 3H) 2.83 (s, 3H)3.60-3.72 (m, 4H) 3.78-3.91 (m, 4H) 4.54 (q, J=7.04 Hz, 2H) 7.91 (s, 1H)8.20 (d, J=3.91 Hz, 1H) 8.38 (s, 1H) 8.66 (d, J=2.35 Hz, 1H) 8.98 (d,J=5.09 Hz, 1H) 9.27 (d, J=2.35 Hz, 1H); LCMS (m/z) (M+H)=489.1, Rt=0.78min.

Example 542:2-(1,1-difluoroethyl)-N-(5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.48 (t, J=7.04 Hz, 3H) 2.07 (t, J=18.78Hz, 3H) 2.84 (s, 3H) 3.58-3.72 (m, 4H) 3.78-3.91 (m, 4H) 4.54 (q, J=7.04Hz, 2H) 7.92 (s, 1H) 8.04 (d, J=4.30 Hz, 1H) 8.27 (s, 1H) 8.68 (d,J=1.96 Hz, 1H) 8.88 (d, J=5.09 Hz, 1H) 9.29 (d, J=2.35 Hz, 1H); LCMS(m/z) (M+H)=485.1, Rt=0.76 min.

Example 543:N-(5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.48 (t, J=7.04 Hz, 3H) 1.76 (m, J=1.00Hz, 6H) 2.85 (s, 3H) 3.58-3.73 (m, 4H) 3.79-3.91 (m, 4H) 4.54 (q, J=7.04Hz, 2H) 7.85 (dd, J=5.09, 1.57 Hz, 1H) 7.93 (s, 1H) 8.16 (s, 1H) 8.72(d, J=2.35 Hz, 1H) 8.77 (d, J=5.09 Hz, 1H) 9.33 (d, J=2.35 Hz, 1H); LCMS(m/z) (M+H)=481.1, Rt=0.77 min.

Example 544:N-(5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)-4-(trifluoromethyl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.49 (t, J=7.04 Hz, 3H) 2.85 (s, 3H)3.60-3.73 (m, 4H) 3.77-3.92 (m, 4H) 4.54 (q, J=7.04 Hz, 2H) 7.94 (s, 1H)8.01 (d, J=4.30 Hz, 1H) 8.51 (s, 1H) 8.89 (d, J=2.35 Hz, 1H) 9.04 (d,J=4.70 Hz, 1H) 9.39 (d, J=2.35 Hz, 1H); LCMS (m/z) (M+H)=489.2, Rt=0.83min.

Example 545:3-((dimethylamino)methyl)-N-(5-(5-ethoxy-6-morpholinopyrazin-2-yl)-6-methylpyridin-3-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.48 (t, J=7.04 Hz, 3H) 2.77 (s, 3H)2.95 (s, 6H) 3.60-3.70 (m, 4H) 3.79-3.91 (m, 4H) 4.48-4.60 (m, 4H) 7.88(s, 1H) 8.17 (s, 1H) 8.46 (s, 1H) 8.54 (s, 1H) 8.57 (d, J=2.35 Hz, 1H)9.15 (d, J=1.96 Hz, 1H); LCMS (m/z) (M+H)=545.3, Rt=0.67 min.

Synthesis of 3-(5-methoxy-6-morpholinopyrazin-2-yl)-4-methylaniline

Following the preparation in Example 539 using the appropriate startingmaterials gave 3-(5-methoxy-6-morpholinopyrazin-2-yl)-4-methylaniline(88.0% yield) as a tan solid. LCMS (m/z) (M+H)=301.0, Rt=0.57 min.

Example 546:N-(3-(5-methoxy-6-morpholinopyrazin-2-yl)-4-methylphenyl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) ™ 1H NMR (400 MHz, <cd3od>) δ ppm 2.39 (s, 3H)3.30 (s, 3H) 3.51-3.67 (m, 4H) 3.77-3.90 (m, 4H) 4.03 (s, 3H) 7.30 (d,J=8.22 Hz, 1H) 7.68 (dd, J=8.22, 2.35 Hz, 1H) 7.74 (s, 1H) 7.80 (d,J=2.35 Hz, 1H) 8.16 (dd, J=4.89, 1.37 Hz, 1H) 8.56 (s, 1H) 8.93 (d,J=5.09 Hz, 1H); LCMS (m/z) (M+H)=484.0, Rt=0.85 min.

Example 547:N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

Step 1

To a flask containing 3,4,6-trichloropyridazine (1.0 equiv.) in EtOH(1.3 M) was added morpholine (2.3 equiv.) and the reaction mix wasstirred at RT for 60 min. A precipitate appeared which was removed byfiltration. The solid recovered was suspended in water and stirred forfew minutes to remove salts. After filtration the solid was dried undervacuum giving 4-(3,6-dichloropyridazin-4-yl)morpholine in 86% yieldwhich was used as is in the next step. LCMS (m/z) (M+H)=234/236, Rt=0.57min.

Step 2

Sodium methoxide (2.0 equiv.) was added portion wise to a flaskcontaining 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0 equiv.) in MeOH(0.43 M) and the reaction mix was stirred overnight at RT. The solventwas removed under vacuum and the crude was partitioned in brine/EtOAc.The organic phase was isolated and the aqueous layer was extracted oncemore with EtOAc. The combined organics were concentrated to dryness andthe residue was dissolved in DCM, and adsorbed in silica gel. The solidwas loaded into a cartridge and purified on a silica gel column using 0to 60% EtOAc in heptane. The desired4-(6-chloro-3-methoxypyridazin-4-yl)morpholine was obtained in 71%yield.

LCMS (m/z) (M+H)=230, Rt=0.44 min.

Step 3

To a solution of 4-(6-chloro-3-methoxypyridazin-4-yl)morpholine (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.) in DME (0.12 M) was added Na₂CO₃ (3.0 equiv.) and the system wasflushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.05 equiv.) was addedto the reaction mix and the system was flushed once again with nitrogen.The reaction mix was heated in a bath at 110° C., overnight. The crudewas partitioned in H₂O/EtOAc. The organic layer was isolated, dried overNa₂SO₄, filtered and concentrated. Crude was purified using a reversephase system of 0 to 40% acetonitrile in water. The fractions containingthe product were concentrated until a small volume of solvent was leftand extracted three times with EtOAc. The combined organics were driedover Na₂SO₄, filtered and concentrated to give3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylaniline in 78% yield.

LCMS (m/z) (M+H)=301, Rt=0.38 min.

Step 4

DIEA (3.0 equiv.) was added to a solution of3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylaniline (1.0 equiv.),2-(trifluoromethyl)isonicotinic acid (1.0 equiv.) and HATU (1.0 equiv.)in DMF (0.07 M), and the mixture was left stirring at RT overnight. Thereaction mix was treated with water and extracted three times withEtOAc. The combined organics were concentrated to dryness and the crudepurified by HPLC givingN-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamideas the TFA salt in 33% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.27 (s,3H) 3.74 (br. s., 8H) 4.07 (s, 3H) 7.28 (br. s., 1H) 7.44 (d, J=8.61 Hz,1H) 7.80 (dd, J=8.22, 1.96 Hz, 1H) 7.92 (s, 1H) 8.18 (d, J=5.09 Hz, 1H)8.35 (s, 1H) 8.99 (d, J=5.09 Hz, 1H) 10.84 (s, 1H). LCMS (m/z)(M+H)=474, Rt=0.70 min.

Example 548:2-(1,1-difluoroethyl)-N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) ppm 1.95-2.11 (m, 3H) 2.26 (s, 3H) 3.74 (br.s., 8H) 4.07 (s, 3H) 7.29 (br. s., 1H) 7.43 (d, J=8.22 Hz, 1H) 7.81 (dd,J=8.61, 1.96 Hz, 1H) 7.93 (s, 1H) 8.01 (d, J=4.70 Hz, 1H) 8.16 (s, 1H)8.88 (d, J=5.09 Hz, 1H) 10.79 (s, 1H). LCMS (m/z) (M+H)=470, Rt=0.69min.

Example 549:2-(1,1-difluoropropyl)-N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ 0.93 (t, J=7.43 Hz, 4H) 1.21 (s, 2H) 2.27 (s,4H) 2.79 (d, J=10.96 Hz, 1H) 3.73 (br. s., 5H) 4.07 (s, 4H) 7.41 (d,J=8.61 Hz, 1H) 7.79 (d, J=10.17 Hz, 1H) 7.89 (br. s., 1H) 8.01 (d,J=5.09 Hz, 1H) 8.15 (s, 1H) 8.89 (d, J=5.09 Hz, 1H) 10.75 (br. s., 1H).LCMS (m/z) (M+H)=484, Rt=0.74 min.

Example 550:2-cyclopropyl-N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.87-1.11 (m, 4H) 2.15-2.24 (m, 1H) 2.26(s, 3H) 3.74 (d, J=4.70 Hz, 8H) 4.00-4.11 (m, 4H) 7.34 (s, 1H) 7.43 (d,J=8.61 Hz, 1H) 7.55 (dd, J=5.09, 1.57 Hz, 1H) 7.72 (s, 1H) 7.79 (dd,J=8.41, 2.15 Hz, 1H) 7.96 (d, J=1.56 Hz, 1H) 8.58 (d, J=5.09 Hz, 1H)10.62 (s, 1H). LCMS (m/z) (M+H)=446, Rt=0.52 min.

Example 551:N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 2.27 (s, 3H) 3.73 (br. s., 7H) 4.07 (s,3H) 7.28 (br. s., 1H) 7.46 (d, J=8.22 Hz, 1H) 7.79 (dd, J=8.22, 1.96 Hz,1H) 7.91 (s, 1H) 8.66 (d, J=1.96 Hz, 1H) 9.91 (d, J=1.96 Hz, 1H) 11.00(s, 1H). LCMS (m/z) (M+H)=475, Rt=0.76 min.

Example 552:2-(2-fluoropropan-2-yl)-N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.66 (s, 3H) 1.72 (s, 3H) 2.26 (s, 3H)3.70-3.90 (m, 8H) 4.01-4.12 (m, 3H) 7.33 (br. s., 1H) 7.43 (d, J=8.22Hz, 1H) 7.76-7.85 (m, 2H) 7.94 (s, 1H) 8.00 (s, 1H) 8.76 (d, J=5.09 Hz,1H) 10.73 (s, 1H). LCMS (m/z) (M+H)=466, Rt=0.68 min.

Example 553:N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.26 (s, 3H) 3.28 (s, 3H) 3.74 (br. s.,7H) 4.07 (s, 3H) 7.30 (br. s., 1H) 7.42 (d, J=8.61 Hz, 1H) 7.78-7.86 (m,2H) 7.93 (s, 1H) 8.15 (d, J=7.83 Hz, 1H) 8.27 (d, J=7.83 Hz, 1H) 8.46(s, 1H) 10.68 (s, 1H). LCMS (m/z) (M+H)=483, Rt=0.60 min.

Example 554:N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 2.27 (s, 3H) 3.73 (br. s., 7H) 4.07 (s,3H) 7.28 (br. s., 1H) 7.46 (d, J=8.22 Hz, 1H) 7.79 (dd, J=8.22, 1.96 Hz,1H) 7.91 (s, 1H) 8.66 (d, J=1.96 Hz, 1H) 9.91 (d, J=1.96 Hz, 1H) 11.00(s, 1H). LCMS (m/z) (M+H)=475, Rt=0.76 min.

Example 555:2-(2-fluoropropan-2-yl)-N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.66 (s, 3H) 1.72 (s, 3H) 2.26 (s, 3H)3.70-3.90 (m, 8H) 4.01-4.12 (m, 3H) 7.33 (br. s., 1H) 7.43 (d, J=8.22Hz, 1H) 7.76-7.85 (m, 2H) 7.94 (s, 1H) 8.00 (s, 1H) 8.76 (d, J=5.09 Hz,1H) 10.73 (s, 1H). LCMS (m/z) (M+H)=466, Rt=0.68 min.

Example 556:2-(2-hydroxypropan-2-yl)-N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.42-1.52 (m, 7H) 2.26 (s, 3H) 4.03-4.12(m, 4H) 7.36 (s, 1H) 7.44 (d, J=8.61 Hz, 1H) 7.69 (dd, J=5.09, 1.57 Hz,1H) 7.81 (dd, J=8.41, 2.15 Hz, 1H) 7.96 (d, J=1.96 Hz, 1H) 8.12 (s, 1H)8.68 (d, J=5.09 Hz, 1H) 10.71 (s, 1H). LCMS (m/z) (M+H)=464, Rt=0.50min.

Example 557:6-(2-cyanopropan-2-yl)-N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.84 (s, 12H) 2.27 (s, 8H) 2.31 (br. s.,1H) 3.73 (br. s., 15H) 4.04-4.10 (m, 8H) 7.26 (br. s., 1H) 7.45 (d,J=8.22 Hz, 1H) 7.78 (dd, J=8.61, 1.96 Hz, 1H) 7.88 (br. s., 1H) 8.28 (d,J=1.96 Hz, 1H) 9.63 (d, J=1.96 Hz, 1H) 10.90 (br. s., 1H). LCMS (m/z)(M+H)=474, Rt=0.61 min.

Example 558:2-(2-cyanopropan-2-yl)-N-(3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 2.18-2.32 (m, 3H) 3.62-3.88(m, 7H) 3.99-4.15 (m, 3H) 7.30 (br. s., 1H) 7.43 (d, J=8.61 Hz, 1H) 7.79(dd, J=8.22, 1.96 Hz, 1H) 7.84 (dd, J=4.89, 1.37 Hz, 1H) 7.90 (s, 1H)7.98 (s, 1H) 8.81 (d, J=5.09 Hz, 1H) 10.72 (s, 1H). LCMS (m/z)(M+H)=473, Rt=0.66 min.

Example 559:N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamide

Step 1

To a flask containing 3,4,6-trichloropyridazine (1.0 equiv.) in EtOH(1.3 M) was added morpholine (2.3 equiv.) and the reaction mix wasstirred at RT for 60 min. A precipitate appeared which was removed byfiltration. The solid recovered was suspended in water and stirred forfew minutes to remove salts. After filtration the solid was dried undervacuum giving 4-(3,6-dichloropyridazin-4-yl)morpholine in 86% yieldwhich was used as is in the next step. LCMS (m/z) (M+H)=234/236, Rt=0.57min.

Step 2

To a flask containing 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0equiv.) in EtOH (0.23 M) was added sodium ethoxide 21% in ethanol (1.4equiv.) and the reaction mix was stirred o.n. at RT. The solvent wasremoved under vacuum and the crude was partitioned in brine/EtOAc. Theorganic phase was concentrated to dryness and the residue was dissolvedin DCM, and adsorbed in silica gel. The solid was loaded into acartridge and purified on a silica gel column. using 0 to 40% EtOAc inheptane. The desired 4-(6-chloro-3-ethoxypyridazin-4-yl)morpholine wasobtained in 48% yield. LCMS (m/z) (M+H)=246, Rt=0.36 min.

Step 3

To a solution of 4-(6-chloro-3-ethoxypyridazin-4-yl)morpholine (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.) in DME (0.11 M) was added Na₂CO₃ (2M, 3.0 equiv.) and the systemwas flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.05 equiv.) wasadded to the reaction mix and the system was flushed once again withnitrogen. The reaction flask was heated in a bath at 110° C. overnight.The reaction mix was partitioned in H₂O/EtOAc. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. Crude waspurified using a reverse phase system of 0 to 40% acetonitrile in water.The fractions containing the product were concentrated until a smallvolume of solvent was left and extracted three times with EtOAc. Thecombined organics were dried over Na₂SO₄, filtered and concentrated togive 3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylaniline in 62%yield. LCMS (m/z) (M+H)=315, Rt=0.44 min.

Step 4

DIEA (3.0 equiv.) was added to a solution of3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylaniline (1.0 equiv.),3-(methylsulfonyl)benzoic acid (1.0 equiv.) and HATU (1.0 equiv.) in DMF(0.07 M), and the mixture was left stirring at RT overnight. Thereaction mix was treated with water and extracted three times withEtOAc. The combined organics were concentrated to dryness and the crudepurified by HPLC givingN-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamideas the TFA salt in 53% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.43 (d,J=3.52 Hz, 3H) 2.26 (br. s., 4H) 3.63-3.91 (m, 8H) 4.36-4.57 (m, 2H)7.33 (br. s., 1H) 7.43 (d, J=6.26 Hz, 1H) 7.75-7.87 (m, 2H) 7.94 (br.s., 1H) 8.14 (d, J=6.65 Hz, 1H) 8.27 (d, J=6.65 Hz, 1H) 8.46 (br. s.,1H) 10.69 (br. s., 1H). LCMS (m/z) (M+H)=497, Rt=0.66 min.

Example 560:2-(1,1-difluoropropyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.82-0.99 (m, 3H) 1.34-1.51 (m, 3H) 2.26(s, 3H) 2.29-2.43 (m, 2H) 3.71-3.77 (m, 4H) 3.81 (br. s., 3H) 4.48 (q,J=7.04 Hz, 2H) 7.32 (br. s., 1H) 7.44 (d, J=8.22 Hz, 1H) 7.81 (dd,J=8.22, 1.96 Hz, 1H) 7.93 (s, 1H) 8.01 (d, J=4.30 Hz, 1H) 8.14 (s, 1H)8.89 (d, J=5.09 Hz, 1H) 10.80 (s, 1H). LCMS (m/z) (M+H)=498, Rt=0.78min.

Example 561: Synthesis of3-(difluoromethyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)benzamide

5-(6-Ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine (1.0equiv.), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.1 equiv.), and4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.1 equiv.) weredissolved in DMF (0.106 M) at RT. Hunig's base (2.2 equiv.) wassubsequently added to mixture. The reaction was monitored by LCMS. Afterabout 1 hr, the reaction mixture was purified via preparative reversephase HPLC to give3-(difluoromethyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)benzamidein47% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.43 (s, 1H) 2.26 (s, 1H) 3.74(br. s., 2H) 4.48 (d, J=7.04 Hz, 1H) 6.94-7.33 (m, 2H) 7.40 (d, J=8.61Hz, 1H) 7.62-7.74 (m, 1H) 7.79 (d, J=8.22 Hz, 2H) 7.94 (br. s., 1H)8.07-8.20 (m, 2H) 10.55 (br. s., 1H). LCMS (m/z) (M+H)=469.2, Rt=0.78min.

Example 562: Synthesis of2-(difluoromethyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.43 (t, J=7.04 Hz, 1H) 2.26 (s, 1H) 3.74(br. s., 3H) 4.48 (q, J=7.04 Hz, 1H) 6.94 (s, 1H) 7.07 (s, 2H) 7.21 (s,1H) 7.29 (br. s., 1H) 7.43 (d, J=8.22 Hz, 1H) 7.80 (dd, J=8.41, 2.15 Hz,1H) 7.93 (s, 1H) 8.04 (d, J=5.09 Hz, 1H) 8.16 (s, 1H) 8.90 (d, J=5.09Hz, 1H) 10.80 (s, 1H). LCMS (m/z) (M+H)=470.2, Rt=0.70 min.

Example 563: Synthesis of2-cyclopropyl-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.92-1.08 (m, 1H) 1.43 (t, J=7.04 Hz, 1H)2.15-2.28 (m, 1H) 3.74 (br. s., 1H) 4.48 (q, J=6.78 Hz, 1H) 7.41 (d,J=8.22 Hz, 1H) 7.55 (dd, J=5.09, 1.57 Hz, 1H) 7.66-7.83 (m, 2H) 7.93(br. s., 1H) 8.57 (d, J=5.09 Hz, 1H) 10.58 (br. s., 1H). LCMS (m/z)(M+H)=460.2, Rt=0.60 min.

Example 564: Synthesis ofN-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-2-(2-fluoropropan-2-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.43 (t, J=7.04 Hz, 1H) 1.59-1.76 (m, 2H)2.26 (s, 1H) 3.68-3.89 (m, 3H) 4.48 (q, J=7.04 Hz, 1H) 7.29-7.37 (m, 1H)7.43 (d, J=8.61 Hz, 1H) 7.76-7.84 (m, 2H) 7.94 (s, 1H) 8.00 (s, 1H)8.63-8.88 (m, 1H) 10.58-10.79 (m, 1H). LCMS (m/z) (M+H)=480.2, Rt=0.75min.

Example 565: Synthesis of2-(1,1-difluoroethyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.43 (t, J=7.04 Hz, 1H) 2.04 (t, J=19.17Hz, 1H) 2.26 (s, 1H) 3.74 (d, J=2.35 Hz, 2H) 4.48 (d, J=7.04 Hz, 1H)7.19-7.35 (m, 1H) 7.42 (d, J=8.22 Hz, 2H) 7.80 (dd, J=8.22, 1.96 Hz, 2H)7.91 (br. s., 2H) 8.01 (d, J=4.70 Hz, 2H) 8.17 (s, 2H) 8.80-9.01 (m, 2H)10.65-10.87 (m, 2H). LCMS (m/z) (M+H)=484.2, Rt=0.76 min.

Example 566: Synthesis ofN-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.38 (t, J=7.04 Hz, 4H) 2.22 (s, 4H) 3.69(br. s., 10H) 4.43 (q, J=6.91 Hz, 3H) 7.23 (br. s., 1H) 7.39 (d, J=8.22Hz, 1H) 7.75 (dd, J=8.22, 1.96 Hz, 1H) 7.87 (br. s., 1H) 8.13 (d, J=4.30Hz, 1H) 8.30 (s, 1H) 8.94 (d, J=5.09 Hz, 1H) 10.78 (s, 1H). LCMS (m/z)(M+H)=480.2, Rt=0.75 min.

Example 567: Synthesis of6-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.42 (s, 1H) 1.84 (s, 2H) 2.27 (s, 1H)3.73 (br. s., 1H) 4.49 (d, J=7.04 Hz, 1H) 7.43 (d, J=8.22 Hz, 1H)7.68-7.95 (m, 2H) 8.28 (d, J=1.96 Hz, 1H) 9.63 (d, J=1.57 Hz, 1H)10.78-10.95 (m, 1H). LCMS (m/z) (M+H)=488.2, Rt=0.68 min.

Example 568: Synthesis of2-(1-cyanocyclopropyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.43 (t, J=7.04 Hz, 1H) 1.69-1.79 (m, 1H)1.83-1.93 (m, 1H) 2.26 (s, 1H) 3.74 (d, J=2.35 Hz, 2H) 4.48 (q, J=7.04Hz, 1H) 7.41 (d, J=8.22 Hz, 1H) 7.69-8.02 (m, 5H) 8.70 (d, J=5.09 Hz,1H) 10.71 (br. s., 1H). LCMS (m/z) (M+H)=485.2, Rt=0.74 min.

Example 569: Synthesis ofN-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-2-(2-hydroxypropan-2-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.37-1.55 (m, 12H) 2.26 (s, 4H) 3.71-3.78(m, 9H) 3.86 (br. s., 7H) 4.47 (d, J=7.04 Hz, 3H) 7.36 (s, 1H) 7.44 (d,J=8.22 Hz, 1H) 7.68 (dd, J=5.09, 1.57 Hz, 1H) 7.81 (dd, J=8.41, 2.15 Hz,1H) 7.96 (d, J=1.96 Hz, 1H) 8.12 (s, 1H) 8.68 (d, J=5.09 Hz, 1H)10.55-10.85 (m, 1H). LCMS (m/z) (M+H)=478.1, Rt=0.56 min.

Example 570: Synthesis ofN-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.43 (t, J=7.04 Hz, 5H) 2.27 (s, 5H) 3.74(br. s., 10H) 4.38-4.63 (m, 3H) 7.25 (br. s., 1H) 7.45 (d, J=8.22 Hz,1H) 7.78 (dd, J=8.41, 2.15 Hz, 1H) 7.86-7.94 (m, 1H) 8.55-8.78 (m, 2H)9.90 (d, J=1.57 Hz, 2H) 10.99 (s, 2H). LCMS (m/z) (M+H)=489.1, Rt=0.71min.

Example 571: Synthesis of(S)-N-(5-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

A mixture of 3,4,6-trichloropyridazine (1.0 equiv.),(S)-3-methylmorpholine (1.0 equiv.), and Hunig's base (1.1 equiv.) inNMP (2.73 M) was stirred at RT for 2 days. Water was added to thereaction mixture. The solid that precipitated was collected byfiltration and dried in air to give(S)-4-(3,6-dichloropyridazin-4-yl)-3-methylmorpholine as white solid in62% yield. LC/MS (m/z)=247.9 (MH⁺), R_(t)=0.63 min.

Step 2

A mixture of (S)-4-(3,6-dichloropyridazin-4-yl)-3-methylmorpholine (1.0equiv.) and 21 wt % sodium ethoxide in ethanol (2.0 equiv.) in 1.5:1ethanol and water was stirred overnight at RT. The resulting mixture waspartitioned between EtOAc and water. The organic phase was washed withbrine and then dried over magnesium sulfate. After concentration, thecrude material was purified via preparative reverse phase HPLC. Uponlyophilization of the pure fractions,(S)-4-(6-chloro-3-ethoxypyridazin-4-yl)-3-methylmorpholine was isolatedas the TFA salt in 55% yield. LC/MS (m/z)=258.0 (MH⁺), R_(t)=0.59 min.

Step 3

A mixture of (S)-4-(6-chloro-3-ethoxypyridazin-4-yl)-3-methylmorpholine(1.0 equiv.),N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.), Na₂CO₃ (2 M, 3 equiv.) and PdCl₂(dppf) (0.05 equiv.) inDME (0.203 M) were heated at 120° C. for 15 min in the microwave. Theresulting mixture was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,(S)-N-(5-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 32% yield. 1H NMR (400 MHz, <dmso>) δppm 1.31 (d, J=6.65 Hz, 5H) 1.43 (t, J=6.85 Hz, 5H) 3.69 (d, J=1.57 Hz,4H) 3.91 (d, J=9.78 Hz, 2H) 4.36-4.64 (m, 3H) 7.34 (br. s., 1H) 7.81 (t,J=7.83 Hz, 1H) 8.01 (d, J=7.83 Hz, 1H) 8.24-8.39 (m, 3H) 8.95 (d, J=2.35Hz, 1H) 10.84 (s, 1H). LCMS (m/z) (M+H)=502.2, Rt=0.78 min.

Example 572: Synthesis of(S)-2-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-4-methylphenyl)isonicotinamide

A mixture of (S)-4-(6-chloro-3-ethoxypyridazin-4-yl)-3-methylmorpholine(1.0 equiv.),2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv.), Na2CO3 (2 M, 3 equiv.) and PdCl₂(dppf) (0.05 equiv.) inDME (0.058 M) were heated at 120° C. for 15 min in the microwave. Theresulting mixture was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,(S)-2-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-4-methylphenyl)isonicotinamidewas isolated as the TFA salt in 11% yield. 1H NMR (400 MHz, <dmso>) δppm 1.32 (br. s., 2H) 1.43 (t, J=6.85 Hz, 3H) 1.75 (s, 6H) 2.05 (s, 2H)2.26 (s, 3H) 3.50-3.63 (m, 2H) 3.68 (s, 2H) 3.89 (br. s., 1H) 4.41-4.54(m, 2H) 7.43 (d, J=8.61 Hz, 1H) 7.76-7.93 (m, 3H) 7.98 (s, 1H) 8.81 (d,J=5.09 Hz, 1H) 10.71 (br. s., 1H). LCMS (m/z) (M+H)=501.2, Rt=0.78 min.

Example 573:2-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added to a solution of4-(6-chloro-3-ethoxypyridazin-4-yl)morpholine (1.0 equiv.),2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv.) and Na₂CO₃ 2M solution (3.0 equiv.) in DME (0.04 M) and thesystem was flushed with nitrogen. The vial was sealed and placed in themicrowave for 20 minutes at 120° C. The solvent was removed under vacuumand the residue was partitioned in EtOAC/H2O. The organic layer wasisolated and the aqueous layer was back extracted twice with EtOAc. Thecombined organics were dried over Na₂SO₄, filtered and concentrated. Thecrude was purified by HPLC to give2-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamidein 25% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.32-1.49 (m, 3H) 1.68-1.80(m, 7H) 2.27 (s, 3H) 3.65-3.78 (m, 5H) 4.52 (q, J=7.04 Hz, 2H) 6.94 (br.s., 1H) 7.32 (d, J=8.22 Hz, 1H) 7.69-7.79 (m, 2H) 7.85 (dd, J=5.09, 1.17Hz, 1H) 8.00 (s, 1H) 8.79 (d, J=5.09 Hz, 1H) 10.57 (s, 1H). LCMS (m/z)(M+H)=487, Rt=0.73 min.

Example 574: Synthesis ofN-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamide

Step 1

3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylaniline (1.0 equiv.),N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.1 equiv.), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (1.1equiv.) and 4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.1 equiv.)were dissolved in DMF (0.181 M) at RT. The reaction was monitored byLCMS. After about 1 hr, the reaction mixture was purified viapreparative reverse phase HPLC to give4-(chloromethyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamidein 68% yield.

LCMS (m/z) (M+H)=535.1, Rt=1.02 min.

Step 2

4-(chloromethyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was dissolved in 2M ammonia in methanol (0.028 M). Afterstirring at RT overnight, the reaction mixture was concentrated andpurified via preparative reverse phase HPLC to giveN-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamidein 58% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.42 (t, J=7.04 Hz, 6H)2.26 (s, 6H) 2.36 (d, J=6.26 Hz, 2H) 2.71 (br. s., 6H) 3.74 (br. s., 7H)4.38 (br. s., 4H) 4.44-4.59 (m, 4H) 7.16 (br. s., 1H) 7.39 (d, J=8.22Hz, 1H) 7.79 (dd, J=8.22, 1.96 Hz, 2H) 7.83-7.94 (m, 1H) 8.35 (br. s.,1H) 8.94-9.22 (m, 3H) 10.50-10.74 (m, 1H). LCMS (m/z) (M+H)=530.1,Rt=0.62 min.

Example 575:N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-4-((ethylamino)methyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) ppm 1.11 (t, J=7.43 Hz, 2H) 1.25 (t, J=7.24 Hz,10H) 1.43 (t, J=7.04 Hz, 8H) 2.26 (s, 8H) 2.36 (d, J=6.26 Hz, 1H)2.74-2.90 (m, 1H) 3.13 (dd, J=11.93, 6.46 Hz, 1H) 3.74 (br. s., 2H) 4.38(br. s., 1H) 4.49 (d, J=7.04 Hz, 1H) 7.12-7.29 (m, 2H) 7.40 (d, J=8.22Hz, 3H) 7.80 (dd, J=8.22, 1.96 Hz, 3H) 7.85-7.98 (m, 6H) 8.35 (d, J=3.91Hz, 6H) 8.86-9.12 (m, 5H) 10.66 (br. s., 2H). LCMS (m/z) (M+H)=544.1,Rt=0.64 min.

Example 576:4-((dimethylamino)methyl)-N-(3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.38 (t, J=6.85 Hz, 1H) 2.22 (s, 1H)2.46-2.55 (m, 1H) 2.77 (br. s., 1H) 3.69 (br. s., 1H) 4.35-4.60 (m, 1H)7.34 (d, J=8.22 Hz, 1H) 7.74 (dd, J=8.41, 1.76 Hz, 1H) 7.78-7.88 (m, 2H)7.95 (d, J=8.61 Hz, 2H) 8.33 (br. s., 4H) 10.48-10.74 (m, 2H). LCMS(m/z) (M+H)=544.1, Rt=0.63 min.

Example 577:N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)-6-(trifluoromethyl) pyridazine-4-carboxamide

Step 1

To a flask containing 3,4,6-trichloropyridazine (1.0 equiv.) in EtOH(1.3 M) was added morpholine (2.3 equiv.) and the reaction mix wasstirred at RT for 60 min. A precipitate appeared which was removed byfiltration. The solid recovered was suspended in water and stirred forfew minutes to remove salts. After filtration the solid was dried undervacuum giving 4-(3,6-dichloropyridazin-4-yl)morpholine in 86% yieldwhich was used as is in the next step. LCMS (m/z) (M+H)=234/236, Rt=0.57min.

Step 2

NaH (2.0 equiv.) was added to a solution of tetrahydro-2H-pyran-4-ol(1.7 equiv.) and 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0 equiv.)in THF (0.3 M) at 0° C. and the reaction mix was left stirring overnightat RT. The reaction mix was quench with water and extracted three timeswith EtOAc. The combined organics were washed with brine and dried overNa₂SO4. The crude was dissolved in DCM, and adsorbed in silica gel. Thesolid was loaded into a cartridge and purified on a silica gel columnusing 0 to 40% EtOAc in heptane. The desired4-(6-chloro-3-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-4-yl)morpholinewas obtained in 75% yield. LCMS (m/z) (M+H)=300, Rt=0.54 min.

Step 3

To a solution of4-(6-chloro-3-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-4-yl)morpholine(1.0 equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.) in DME (0.11 M) was added Na₂CO₃ (2M, 3.0 equiv.) and the systemwas flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.05 equiv.) wasadded to the reaction mix and the system was flushed once again withnitrogen. The reaction mix was heated in a bath for 4 hr at 120° C. Thecrude was partitioned in H₂O/EtOAc. The organic layer was isolated,dried over Na₂SO₄, filtered and concentrated. Crude was purified silicagel column using DCM to 5% MeOH in DCM to give4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)anilinein 77% yield. LCMS (m/z) (M+H)=371, Rt=0.43 min.

Step 4

DIEA (3.0 equiv.) was added to a solution of4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)aniline(1.0 equiv.), 6-(trifluoromethyl)pyridazine-4-carboxylic acid (1.0equiv.) and HATU (1.0 equiv.) in DMF (0.05 M), and the mixture was leftstirring at RT overnight. The reaction mix was treated with water andextracted three times with EtOAc. The combined organics were dried overNa₂SO₄, filtered and concentrated. The crude was purified by HPLC givingN-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)-6-(trifluoromethyl)pyridazine-4-carboxamideas the TFA salt in 55% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.71-1.91(m, 2H) 2.00-2.17 (m, 2H) 2.21-2.33 (m, 3H) 3.67-3.90 (m, 10H) 5.25-5.44(m, 1H) 7.29 (br. s., 1H) 7.46 (d, J=8.61 Hz, 1H) 7.77 (dd, J=8.22, 1.96Hz, 1H) 7.92 (s, 1H) 8.66 (d, J=1.96 Hz, 1H) 9.90 (d, J=1.56 Hz, 1H)11.01 (s, 1H). LCMS (m/z) (M+H)=545, Rt=0.69 min.

Example 578:2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.61-1.74 (m, 6H) 1.76-1.90 (m, 2H)2.02-2.17 (m, 2H) 2.21-2.31 (m, 3H) 7.34 (br. s., 1H) 7.43 (d, J=8.22Hz, 1H) 7.75-7.84 (m, 2H) 7.95 (s, 1H) 8.00 (s, 1H) 8.76 (d, J=5.09 Hz,1H) 10.73 (s, 1H). LCMS (m/z) (M+H)=536, Rt=0.70 min.

Example 579:2-(1,1-difluoroethyl)-N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.68-1.83 (m, 3H) 1.94 (s, 1H) 1.97-2.11(m, 4H) 2.22 (s, 3H) 5.19-5.38 (m, 1H) 7.28 (br. s., 1H) 7.39 (d, J=8.22Hz, 1H) 7.74 (dd, J=8.22, 1.96 Hz, 1H) 7.90 (s, 1H) 7.96 (d, J=4.70 Hz,1H) 8.11 (s, 1H) 8.83 (d, J=5.09 Hz, 1H) 10.75 (s, 1H). LCMS (m/z)(M+H)=540, Rt=0.71 min.

Example 580:N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)-4-(trifluoromethyl)picolinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.77 (d, J=8.61 Hz, 3H) 2.03 (br. s., 3H)2.23 (s, 4H) 3.53 (t, J=8.22 Hz, 3H) 5.31 (br. s., 1H) 7.26 (br. s., 1H)7.37 (d, J=8.22 Hz, 1H) 7.91 (d, J=7.83 Hz, 1H) 8.04 (br. s., 2H) 8.27(s, 1H) 8.98 (d, J=4.70 Hz, 1H) 10.91 (br. s., 1H). LCMS (m/z)(M+H)=544, Rt=0.80 min.

Example 581:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.41-1.50 (m, 7H) 1.75-1.91 (m, 2H)2.02-2.14 (m, 2H) 2.26 (s, 3H) 3.58 (ddd, J=11.35, 7.83, 3.13 Hz, 2H)5.33 (dt, J=7.43, 3.72 Hz, 1H) 7.37 (s, 1H) 7.43 (d, J=8.22 Hz, 1H) 7.68(dd, J=5.09, 1.57 Hz, 1H) 7.79 (dd, J=8.22, 1.96 Hz, 1H) 7.97 (d, J=1.57Hz, 1H) 8.12 (s, 1H) 8.68 (d, J=5.09 Hz, 1H) 10.70 (s, 1H). LCMS (m/z)(M+H)=534, Rt=0.55 min.

Example 582:N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.74-1.89 (m, 2H) 2.10 (dt, J=6.65, 3.33Hz, 2H) 2.27 (s, 3H) 3.34 (s, 4H) 3.72-3.88 (m, 10H) 5.35 (br. s., 1H)7.31 (br. s., 1H) 7.44 (d, J=8.22 Hz, 1H) 7.80 (dd, J=8.41, 2.15 Hz, 1H)7.94 (s, 1H) 8.20 (dd, J=4.89, 1.37 Hz, 1H) 8.51 (s, 1H) 9.00 (d, J=4.70Hz, 1H) 10.93 (s, 1H). LCMS (m/z) (M+H)=554, Rt=0.61 min.

Example 583:6-(2-cyanopropan-2-yl)-N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.67-1.92 (m, 9H) 1.97-2.15 (m, 2H)2.18-2.35 (m, 4H) 3.65-3.90 (m, 7H) 5.38 (br. s., 1H) 7.43 (d, J=8.22Hz, 1H) 7.76 (dd, J=8.22, 1.96 Hz, 1H) 7.88 (br. s., 1H) 8.28 (d, J=1.96Hz, 1H) 9.63 (d, J=1.96 Hz, 1H) 10.88 (br. s., 1H). LCMS (m/z)(M+H)=544, Rt=0.65 min.

Example 584:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.21 (s, 1H) 1.66-1.83 (m, 9H) 1.97 (s,2H) 2.04-2.15 (m, 2H) 2.27 (s, 3H) 3.52-3.62 (m, 2H) 3.67-3.77 (m, 4H)3.79-3.87 (m, 2H) 4.01 (q, J=7.04 Hz, 1H) 5.41-5.58 (m, 1H) 6.95 (br.s., 1H) 7.32 (d, J=8.61 Hz, 1H) 7.69-7.79 (m, 2H) 7.85 (d, J=5.09 Hz,1H) 7.99 (s, 1H) 8.79 (d, J=5.09 Hz, 1H) 10.56 (s, 1H). LCMS (m/z)(M+H)=543, Rt=0.71 min.

Example 585:N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

Step 1

To a solution of 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0 equiv.)and ethane-1,2-diol (3.0 equiv.) in THF (0.14M) was added sodium hydride(60% oil dispersion, 3.0 equiv.) under nitrogen and the reaction washeated to 60° C. for 4 hours. Upon completion, cooled to roomtemperature and quenched by the addition of water. Extracted with ethylacetate three times, the organics were combined, dried with Na₂SO₄,filtered and concentrated. The crude material was triturated in DCM andthe precipitate was filtered. Isolated2-((6-chloro-4-morpholinopyridazin-3-yl)oxy)ethanol as the desiredproduct in 51% yield as a white solid. LCMS (m/z) (M+H)=260.0, Rt=0.39min.

Step 2

To a solution 2-((6-chloro-4-morpholinopyridazin-3-yl)oxy)ethanol (1.0equiv.) in DME (0.2 M) was added4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.2equiv.) and PdCl₂(dppf).CH₂Cl₂ adduct (0.10 equiv.), and 2M Na₂CO₃ (3.00equiv.). The reaction was heated in the microwave at 120° C. for 20 min.Partitioned between water and ethyl acetate, the aqueous phase wasextracted 3 times with ethyl acetate, the organics were combined, driedwith sodium sulfate, filtered and concentrated. The crude material waspurified via silica gel chromatography eluting with 0-100% ethyl acetatein heptanes followed by 10% methanol in EtOAc. The pure fractions wereconcentrated under vacuum to yield2-((6-(5-amino-2-methylphenyl)-4-morpholinopyridazin-3-yl)oxy)ethanol in39% yield. LCMS (m/z) (M+H)=331.0, Rt=0.35 min.

Step 3

To a solution of2-((6-(5-amino-2-methylphenyl)-4-morpholinopyridazin-3-yl)oxy)ethanol(1.0 equiv.) in DMF (0.06 M) was added 2-(trifluoromethyl)isonicotinicacid (1.0 equiv.) and EDC (1.0 equiv.) and HOAt (1.0 equiv.). Thesolution was stirred at room temperature overnight. Filtered through aHPLC filter and purified via reverse phase prep-HPLC. The pure fractionswere lyophilized for several days to yieldN-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamidein 21% yield. 1H NMR (400 MHz, <cd3od>) δ ppm 2.35 (s, 3H) 3.81-3.90 (m,4H) 3.94-4.08 (m, 6H) 4.51-4.63 (m, 2H) 7.31 (s, 1H) 7.48 (d, J=8.61 Hz,1H) 7.72 (dd, J=8.41, 2.15 Hz, 1H) 8.05 (d, J=2.35 Hz, 1H) 8.12 (d,J=3.91 Hz, 1H) 8.29 (s, 1H) 8.92 (d, J=5.09 Hz, 1H). LCMS (m/z)(M+H)=504.1, Rt=0.64 min.

Example 586:N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)-4-(trifluoromethyl)picolinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.35 (s, 3H) 3.78-3.90 (m, 4H) 3.95-4.08(m, 6H) 4.49-4.61 (m, 2H) 7.32 (s, 1H) 7.48 (d, J=8.61 Hz, 1H) 7.87 (dd,J=8.22, 2.35 Hz, 1H) 7.94 (d, J=4.30 Hz, 1H) 8.09 (d, J=2.35 Hz, 1H)8.43 (s, 1H) 8.97 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=504.2, Rt=0.70min.

Example 587:2-(1,1-difluoroethyl)-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.03 (t, J=18.78 Hz, 3H) 2.35 (s, 3H)3.77-3.90 (m, 4H) 3.94-4.06 (m, 6H) 4.48-4.62 (m, 2H) 7.30 (s, 1H) 7.47(d, J=8.61 Hz, 1H) 7.71 (dd, J=8.22, 1.96 Hz, 1H) 7.96 (d, J=4.70 Hz,1H) 8.04 (d, J=2.35 Hz, 1H) 8.17 (s, 1H) 8.82 (d, J=5.09 Hz, 1H). LCMS(m/z) (M+H)=500.1, Rt=0.63 min.

Example 588:2-(2-fluoropropan-2-yl)-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.62-1.83 (m, 6H) 2.35 (s, 3H) 3.80-3.90(m, 4H) 3.95-4.07 (m, 6H) 4.49-4.65 (m, 2H) 7.31 (s, 1H) 7.47 (d, J=8.22Hz, 1H) 7.62-7.79 (m, 2H) 7.97-8.10 (m, 2H) 8.71 (d, J=5.09 Hz, 1H).LCMS (m/z) (M+H)=496.2, Rt=0.62 min.

Example 589:2-(1,1-difluoropropyl)-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.00 (t, J=7.43 Hz, 3H) 2.25-2.50 (m,5H) 3.82-3.91 (m, 4H) 3.95-4.05 (m, 5H) 4.52-4.65 (m, 2H) 7.30 (s, 1H)7.47 (d, J=8.22 Hz, 1H) 7.72 (dd, J=8.61, 2.35 Hz, 1H) 7.96 (d, J=3.91Hz, 1H) 8.04 (d, J=1.96 Hz, 1H) 8.15 (s, 1H) 8.83 (d, J=5.09 Hz, 1H).LCMS (m/z) (M+H)=514.2, Rt=0.67 min.

Example 590:N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.25 (s, 3H) 3.71-3.82 (m, 4H) 3.84-3.96(m, 6H) 4.42-4.53 (m, 2H) 7.22 (s, 1H) 7.37 (d, J=8.22 Hz, 1H) 7.57-7.71(m, 2H) 7.82 (d, J=7.83 Hz, 1H) 7.93 (d, J=1.96 Hz, 1H) 8.11 (d, J=8.22Hz, 1H) 8.16 (s, 1H). LCMS (m/z) (M+H)=503.1, Rt=0.72 min.

Example 591:2-(2-cyanopropan-2-yl)-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

To a solution of 2-((6-chloro-4-morpholinopyridazin-3-yl)oxy)ethanol(1.0 equiv.) in DME (0.06 M) was added2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.2 equiv.), followed by PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) and 2MNa₂CO₃ (3.0 equiv.). The reaction was heated to 120° C. for 10 min themicrowave. The layers were separated; the organic phase was concentratedto dryness and purified via reverse phase HPLC. The pure fractions werelyophilized for several days to yield2-(2-cyanopropan-2-yl)-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamideas the TFA salt in 29% yield.

1H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.35 (s, 3H) 3.76-3.90 (m,4H) 3.93-4.08 (m, 6H) 4.51-4.65 (m, 2H) 7.31 (s, 1H) 7.47 (d, J=8.61 Hz,1H) 7.71 (dd, J=8.22, 2.35 Hz, 1H) 7.81 (dd, J=5.09, 1.57 Hz, 1H)8.00-8.13 (m, 2H) 8.77 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=503.1,Rt=0.61 min.

Example 592:2-(1,1-difluoroethyl)-N-(3-(6-isopropoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

Synthetic conditions similar to Example 585.

Step 1

4-(6-chloro-3-isopropoxypyridazin-4-yl)morpholine. LCMS (m/z)(M+H)=258.2, 259.7, Rt=0.59 min.

Step 2

3-(6-isopropoxy-5-morpholinopyridazin-3-yl)-4-methylaniline. LCMS (m/z)(M+H)=329.3, Rt=0.50 min.

Step 3

2-(1,1-difluoroethyl)-N-(3-(6-isopropoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide.¹H NMR (400 MHz, <dmso>) δ ppm 1.42 (d, J=6.26 Hz, 6H) 2.03 (t, J=19.17Hz, 3H) 2.27 (s, 3H) 3.74 (br. s., 8H) 5.23-5.40 (m, 1H) 7.28 (br. s.,1H) 7.42 (d, J=8.61 Hz, 1H) 7.79 (dd, J=8.41, 2.15 Hz, 1H) 7.93 (s, 1H)8.01 (d, J=4.70 Hz, 1H) 8.16 (s, 1H) 8.88 (d, J=5.09 Hz, 1H) 10.79 (s,1H). LCMS (m/z) (M+H)=498.2, Rt=0.76 min.

Example 593:2-(difluoromethyl)-N-(3-(6-isopropoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.42 (d, J=5.87 Hz, 6H) 2.27 (s, 3H) 3.74(br. s., 8H) 5.26-5.38 (m, 1H) 6.87-7.23 (m, 1H) 7.29 (br. s., 1H) 7.43(d, J=8.22 Hz, 1H) 7.79 (dd, J=8.41, 2.15 Hz, 1H) 7.94 (s, 1H) 8.04 (d,J=5.09 Hz, 1H) 8.16 (s, 1H) 8.90 (d, J=5.09 Hz, 1H) 10.80 (s, 1H). LCMS(m/z) (M+H)=484.2, Rt=0.72 min.

Example 594:N-(3-(6-isopropoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)-4-(trifluoromethyl)picolinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 2.27 (s, 3H)3.69-3.92 (m, 8H) 5.22-5.39 (m, 1H) 7.32 (s, 1H) 7.43 (d, J=8.22 Hz, 1H)7.96 (dd, J=8.41, 2.15 Hz, 1H) 8.06-8.14 (m, 2H) 8.32 (s, 1H) 9.03 (d,J=5.09 Hz, 1H) 10.98 (s, 1H). LCMS (m/z) (M+H)=502.1, Rt=0.83 min.

Example 595:2-(2-fluoropropan-2-yl)-N-(3-(6-isopropoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.42 (d, J=5.87 Hz, 6H) 1.66 (s, 3H) 1.71(s, 3H) 2.27 (s, 3H) 3.74 (d, J=4.70 Hz, 4H) 3.82 (br. s., 4H) 5.30 (dt,J=12.23, 6.21 Hz, 1H) 7.33 (s, 1H) 7.43 (d, J=8.22 Hz, 1H) 7.75-7.84 (m,2H) 7.96 (d, J=1.57 Hz, 1H) 8.00 (s, 1H) 8.75 (d, J=5.09 Hz, 1H) 10.74(s, 1H). LCMS (m/z) (M+H)=494.1, Rt=0.77 min.

Example 596:2-(2-cyanopropan-2-yl)-N-(3-(6-isopropoxy-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

It was prepared following similar procedure as LXH202. 1H NMR (400 MHz,<dmso>) b ppm 1.42 (d, J=6.26 Hz, 6H) 1.70-1.82 (m, 6H) 2.27 (s, 3H)3.74 (br. s., 8H) 5.25-5.39 (m, 1H) 7.29 (br. s., 1H) 7.43 (d, J=8.22Hz, 1H) 7.78 (dd, J=8.22, 1.96 Hz, 1H) 7.84 (dd, J=5.09, 1.17 Hz, 1H)7.91 (s, 1H) 7.98 (s, 1H) 8.81 (d, J=5.09 Hz, 1H) 10.71 (s, 1H). LCMS(m/z) (M+H)=501.2, Rt=0.75 min.

Example 597:2-(1,1-difluoroethyl)-N-(3-(6-(2-methoxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

Synthetic conditions similar to Example 585.

Step 1

4-(6-chloro-3-(2-methoxyethoxy)pyridazin-4-yl)morpholine. LCMS (m/z)(M+H)=329.3, Rt=0.50 min.

Step 2

3-(6-(2-methoxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylaniline. LCMS(m/z) (M+H)=345.2, Rt=0.40 min.

Step 3

2-(1,1-difluoroethyl)-N-(3-(6-(2-methoxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide.¹H NMR (400 MHz, <dmso>) ppm 1.94-2.13 (m, 3H) 2.26 (s, 3H) 3.32 (s, 3H)3.68-3.82 (m, 10H) 4.49-4.57 (m, 2H) 7.27 (br. s., 1H) 7.42 (d, J=8.61Hz, 1H) 7.80 (dd, J=8.41, 2.15 Hz, 1H) 7.89-7.94 (m, 1H) 8.01 (d, J=4.70Hz, 1H) 8.16 (s, 1H) 8.88 (d, J=4.70 Hz, 1H) 10.78 (s, 1H). LCMS (m/z)(M+H)=514.2, Rt=0.68 min.

Example 598:2-(difluoromethyl)-N-(3-(6-(2-methoxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.26 (s, 3H) 3.32 (s, 4H) 3.70-3.80 (m,10H) 4.53 (br. s., 2H) 6.89-7.32 (m, 2H) 7.42 (d, J=8.61 Hz, 1H) 7.79(dd, J=8.61, 1.96 Hz, 1H) 7.91 (br. s., 1H) 8.04 (d, J=5.09 Hz, 1H) 8.16(s, 1H) 8.90 (d, J=4.70 Hz, 1H) 10.78 (br. s., 1H). LCMS (m/z)(M+H)=500.2, Rt=0.64 min.

Example 599:N-(3-(6-(2-methoxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)-4-(trifluoromethyl)picolinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.27 (s, 3H) 3.33 (s, 3H) 3.67-3.82 (m,10H) 4.49-4.58 (m, 2H) 7.28 (br. s., 1H) 7.41 (d, J=8.22 Hz, 1H) 7.96(dd, J=8.22, 1.96 Hz, 1H) 8.03-8.14 (m, 2H) 8.32 (s, 1H) 9.03 (d, J=4.70Hz, 1H) 10.95 (s, 1H). LCMS (m/z) (M+H)=518.1, Rt=0.76 min.

Example 600:2-(2-fluoropropan-2-yl)-N-(3-(6-(2-methoxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.66 (s, 3H) 1.71 (s, 3H) 2.26 (s, 3H)3.32 (s, 3H) 3.70-3.82 (m, 10H) 4.52 (dd, J=5.09, 3.52 Hz, 2H) 7.31 (br.s., 1H) 7.42 (d, J=8.22 Hz, 1H) 7.75-7.84 (m, 2H) 7.93 (d, J=1.57 Hz,1H) 8.00 (s, 1H) 8.75 (d, J=5.09 Hz, 1H) 10.72 (s, 1H). LCMS (m/z)(M+H)=510.1, Rt=0.68 min.

Example 601:2-(2-cyanopropan-2-yl)-N-(3-(6-(2-methoxyethoxy)-5-morpholinopyridazin-3-yl)-4-methylphenyl)isonicotinamide

It was prepared following similar procedure as LXH202. 1H NMR (400 MHz,<dmso>) δ ppm 1.75 (s, 6H) 2.26 (s, 3H) 3.32 (s, 3H) 3.68-3.84 (m, 10H)4.53 (dd, J=5.28, 3.33 Hz, 2H) 7.29 (br. s., 1H) 7.43 (d, J=8.22 Hz, 1H)7.79 (dd, J=8.22, 1.96 Hz, 1H) 7.84 (dd, J=5.09, 1.17 Hz, 1H) 7.89 (s,1H) 7.98 (s, 1H) 8.81 (d, J=5.09 Hz, 1H) 10.71 (s, 1H). LCMS (m/z)(M+H)=517.3, Rt=0.67 min.

Example 602:N-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing 3,4,6-trichloropyridazine (1.0 equiv.) in EtOH(1.3 M) was added morpholine (2.3 equiv.) and the reaction mix wasstirred at RT for 60 min. A precipitate appeared which was removed byfiltration. The solid recovered was suspended in water and stirred forfew minutes to remove salts. After filtration the solid was dried undervacuum giving 4-(3,6-dichloropyridazin-4-yl)morpholine in 86% yieldwhich was used as is in the next step. LCMS (m/z) (M+H)=234/236, Rt=0.57min.

Step 2

To a flask containing 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0equiv.) in DMF (0.14 M) was added sodium thiomethoxide (1.5 equiv.) andthe reaction mix was stirred at RT overnight. The solvent was removedunder vacuum and the crude was suspended in large volume of water. Thesolids that were removed by filtration were dissolved in DCM. The smallaqueous layer was removed and the organic layer was dried over MgSO₄,filtered and concentrated. The crude4-(6-chloro-3-(methylthio)pyridazin-4-yl)morpholine was used as is inthe next step. Yield was assumed to be quantitative.

Step 3

A solution of Oxone (2.2 equiv.) in water (0.043M) was added to asolution of 4-(6-chloro-3-(methylthio)pyridazin-4-yl)morpholine (1.0equiv.) in THF (0.043 M) at 0° C. and the reaction mix was left to reachRT overnight. The reaction mix was poured into water and extracted threetimes with EtOAc. The combined organics were dried over Na₂SO₄, filteredand concentrated. The residue was dissolved in DCM, and adsorbed insilica gel. The solid was loaded into a cartridge and purified on asilica gel column using 0 to 60% EtOAc in heptane. The desired4-(6-chloro-3-(methylsulfonyl)pyridazin-4-yl)morpholine was obtained in63% yield. LCMS (m/z) (M+H)=278, Rt=0.48 min.

Step 4

To a solution of 4-(6-chloro-3-(methylsulfonyl)pyridazin-4-yl)morpholine(1.0 equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.) in DME (0.11 M) was added Na₂CO₃ (2M, 3.0 equiv.) and the systemwas flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) wasadded to the reaction mix and the system was flushed once again withnitrogen. The reaction vial was heated in a microwave reactor at 120° C.for 20 minutes. The reaction mix was partitioned in H₂O/EtOAc. Theorganic layer was isolated, dried over Na2SO4, filtered andconcentrated. Crude was purified by HPLC to giveN-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)-3-(trifluoromethyl)benzamidein 24% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.22-2.37 (m, 3H) 3.68-3.79(m, 7H) 7.34-7.40 (m, 1H) 7.41 (s, 1H) 7.73-7.83 (m, 2H) 7.90 (d, J=2.35Hz, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.25 (d, J=7.83 Hz, 1H) 8.29 (s, 1H)10.43-10.66 (m, 1H). LCMS (m/z) (M+H)=521, Rt=0.89 min.

Example 603:2-(1,1-difluoroethyl)-N-(5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

Step 1

To a flask containing 3,4,6-trichloropyridazine (1.0 equiv.) in EtOH(1.3 M) was added morpholine (2.3 equiv.) and the reaction mix wasstirred at RT for 60 min. A precipitate appeared which was removed byfiltration. The solid recovered was suspended in water and stirred forfew minutes to remove salts. After filtration the solid was dried undervacuum giving 4-(3,6-dichloropyridazin-4-yl)morpholine in 86% yieldwhich was used as is in the next step. LCMS (m/z) (M+H)=234/236, Rt=0.57min.

Step 2

Sodium methoxide (2.0 equiv.) was added portion wise to a flaskcontaining 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0 equiv.) in MeOH(0.43 M) and the reaction mix was stirred overnight at RT. The solventwas removed under vacuum and the crude was partitioned in brine/EtOAc.The organic phase was isolated and the aqueous layer was extracted oncemore with EtOAc. The combined organics were concentrated to dryness andthe residue was dissolved in DCM, and adsorbed in silica gel. The solidwas loaded into a cartridge and purified on a silica gel column. using 0to 60% EtOAc in heptane. The desired4-(6-chloro-3-methoxypyridazin-4-yl)morpholine was obtained in 71%yield. LCMS (m/z) (M+H)=230, Rt=0.44 min.

Step 3

To a solution of 4-(6-chloro-3-methoxypyridazin-4-yl)morpholine (1.0equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv.) in DME (0.08 M) was added Na₂CO₃ (2M, 3.0 equiv.) and thesystem was flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.)was added to the reaction mix and the system was flushed once again withnitrogen. The reaction vial was capped and heated in a bath for 4 hr at120° C. The crude was partitioned in H₂O/EtOAc. The organic layer wasisolated, dried over Na2SO4, filtered and concentrated. Crude waspurified silica gel column using DCM to 5% MeOH in DCM to give5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine in 54%yield. LCMS (m/z) (M+H)=317, Rt=0.38 min.

Step 4

DIEA (3.0 equiv.) was added to a solution of5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine (1.0equiv.), 2-(1,1-difluoroethyl)isonicotinic acid (1.0 equiv.) and HATU(1.0 equiv.) in DMF (0.07 M), and the mixture was left stirring at RTovernight. The reaction mix was treated with water and the precipitatewas filtered. The solid was purified by HPLC giving2-(1,1-difluoroethyl)-N-(5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamideas the TFA salt in 30% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.04 (t,J=19.17 Hz, 3H) 3.74 (s, 8H) 4.08 (s, 3H) 7.38 (s, 1H) 8.04 (d, J=4.70Hz, 1H) 8.20 (s, 1H) 8.35 (d, J=1.96 Hz, 1H) 8.83-9.01 (m, 2H)10.91-11.13 (m, 1H). LCMS (m/z) (M+H)=471, Rt=0.59 min.

Example 604:3-(difluoromethyl)-N-(5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 4.07 (s, 12H) 6.97-7.31 (m, 1H) 7.01 (s,1H) 7.15 (s, 2H) 7.29 (s, 1H) 7.35 (s, 1H) 7.67-7.75 (m, 1H) 7.82 (d,J=7.83 Hz, 1H) 8.09-8.21 (m, 2H) 8.37 (d, J=2.35 Hz, 1H) 8.95 (d, J=2.35Hz, 1H) 10.80 (s, 1H). LCMS (m/z) (M+H)=456, Rt=0.61 min.

Example 605:N-(5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 3.69 (br. s., 7H) 4.03 (s, 3H) 7.31 (br.s., 1H) 8.16 (d, J=4.70 Hz, 1H) 8.29 (d, J=1.96 Hz, 1H) 8.33 (s, 1H)8.89 (d, J=2.35 Hz, 1H) 8.97 (d, J=4.70 Hz, 1H) 11.01 (s, 1H). LCMS(m/z) (M+H)=475, Rt=0.61 min.

Example 606:2-cyclopropyl-N-(5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.87-1.05 (m, 5H) 2.11-2.27 (m, 1H)3.66-3.86 (m, 8H) 3.98-4.14 (m, 3H) 7.39 (s, 1H) 7.58 (dd, J=5.09, 1.17Hz, 1H) 7.75 (s, 1H) 8.36 (d, J=2.35 Hz, 1H) 8.59 (d, J=5.09 Hz, 1H)8.93 (d, J=2.35 Hz, 1H) 10.88 (s, 1H). LCMS (m/z) (M+H)=447, Rt=0.45min.

Example 607:2-(1,1-difluoropropyl)-N-(5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.93 (t, J=7.43 Hz, 2H) 2.26-2.43 (m, 2H)3.74 (s, 7H) 3.65-3.82 (m, 1H) 3.87-4.36 (m, 8H) 7.38 (s, 1H) 8.03 (d,J=4.30 Hz, 1H) 8.18 (s, 1H) 8.35 (d, J=2.35 Hz, 1H) 8.83-9.02 (m, 1H)11.03 (s, 1H). LCMS (m/z) (M+H)=485, Rt=0.65 min.

Example 608:2-(2-fluoropropan-2-yl)-N-(5-(6-methoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.56-1.83 (m, 6H) 3.62-3.78 (m, 4H)3.99-4.15 (m, 3H) 6.97-7.11 (m, 1H) 7.83 (dd, J=5.09, 1.57 Hz, 1H) 8.05(s, 1H) 8.19 (d, J=2.35 Hz, 1H) 8.76 (d, J=5.09 Hz, 1H) 8.88 (d, J=2.35Hz, 1H) 10.78 (s, 1H). LCMS (m/z) (M+H)=543, Rt=0.71 min.

Example 609:N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing 3,4,6-trichloropyridazine (1.0 equiv.) in EtOH(1.3 M) was added morpholine (2.3 equiv.) and the reaction mix wasstirred at RT for 60 min. A precipitate appeared which was removed byfiltration. The solid recovered was suspended in water and stirred forfew minutes to remove salts. After filtration the solid was dried undervacuum giving 4-(3,6-dichloropyridazin-4-yl)morpholine in 86% yieldwhich was used as is in the next step. LCMS (m/z) (M+H)=234/236, Rt=0.57min.

Step 2

To a flask containing 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0equiv.) in EtOH (0.23 M) was added sodium ethoxide 21% in ethanol (1.4equiv.) and the reaction mix was stirred overnight at RT. The solventwas removed under vacuum and the crude was partitioned in brine/EtOAc.The organic phase was concentrated to dryness and the residue wasdissolved in DCM, and adsorbed in silica gel. The solid was loaded intoa cartridge and purified on a silica gel column using 0 to 40% EtOAc inheptane. The desired 4-(6-chloro-3-ethoxypyridazin-4-yl)morpholine wasobtained in 48% yield. LCMS (m/z) (M+H)=246, Rt=0.36 min.

Step 3

PdCl₂(dppf).CH₂Cl₂ adduct (0.1) was added to a solution of4-(6-chloro-3-ethoxypyridazin-4-yl)morpholine (1.0 equiv.),N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and Na₂CO₃ 2M solution (3.0 equiv.) in DME (0.07 M) and thesystem was flushed with nitrogen. The vial was sealed and placed in themicrowave reactor for 20 minutes at 120° C. The solvent was removedunder vacuum and the residue was partitioned in EtOAC/H₂O. The organiclayer was isolated and the aqueous layer was back extracted twice withEtOAc. The combined organics were dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC givingN-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamideas the TFA salt in 33% yield. 1H NMR (400 MHz, <dmso>) b ppm 1.43 (t,J=7.04 Hz, 3H) 3.74 (br. s., 8H) 4.50 (q, J=7.04 Hz, 2H) 7.36 (s, 1H)7.81 (t, J=7.83 Hz, 1H) 8.01 (d, J=7.83 Hz, 1H) 8.28 (d, J=7.83 Hz, 1H)8.32 (s, 1H) 8.36 (d, J=2.35 Hz, 1H) 8.80-9.07 (m, 1H) 10.71-10.95 (m,1H). LCMS (m/z) (M+H)=488, Rt=0.75 min.

Example 610:N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

Step 1

To a flask containing 3,4,6-trichloropyridazine (1.0 equiv.) in EtOH(1.3 M) was added morpholine (2.3 equiv.) and the reaction mix wasstirred at RT for 60 min. A precipitate appeared which was removed byfiltration. The solid recovered was suspended in water and stirred forfew minutes to remove salts. After filtration the solid was dried undervacuum giving 4-(3,6-dichloropyridazin-4-yl)morpholine in 86% yieldwhich was used as is in the next step. LCMS (m/z) (M+H)=234/236, Rt=0.57min.

Step 2

To a flask containing 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0equiv.) in EtOH (0.23 M) was added sodium ethoxide 21% in ethanol (1.4equiv.) and the reaction mix was stirred overnight at RT. The solventwas removed under vacuum and the crude was partitioned in brine/EtOAc.The organic phase was concentrated to dryness and the residue wasdissolved in DCM, and adsorbed in silica gel. The solid was loaded intoa cartridge and purified on a silica gel column using 0 to 40% EtOAc inheptane. The desired 4-(6-chloro-3-ethoxypyridazin-4-yl)morpholine wasobtained in 48% yield. LCMS (m/z) (M+H)=246, Rt=0.36 min.

Step 3

To a solution of 4-(6-chloro-3-ethoxypyridazin-4-yl)morpholine (1.0equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv.) in DME (0.08 M) was added Na₂CO₃ (2M, 3.0 equiv.) and thesystem was flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.)was added to the reaction mix and the system was flushed once again withnitrogen. The reaction vial was capped and heated in a bath for 4 hr at120° C. The crude was partitioned in H₂O/EtOAc. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. Crude waspurified silica gel column using DCM to 5% MeOH in DCM to give5-(6-ethoxy-5-morpholino-1,6-dihydropyridazin-3-yl)-6-methylpyridin-3-aminein 54% yield. LCMS (m/z) (M+H)=317, Rt=0.38 min.

Step 4

DIEA (3.0 equiv.) was added to a solution of5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine (1.0equiv.), 2-(2-fluoropropan-2-yl)isonicotinic acid (1.0 equiv.) and HATU(1.0 equiv.) in DMF (0.07 M), and the mixture was left stirring at RTovernight. The reaction mix was treated with water and the precipitatewas filtered. The solid was purified by HPLC givingN-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-2-(2-fluoropropan-2-yl)isonicotinamideas the TFA salt in 50% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.36-1.52(m, 3H) 1.60-1.82 (m, 7H) 4.50 (q, J=6.91 Hz, 2H) 7.39 (s, 1H) 7.83 (dd,J=5.09, 1.57 Hz, 1H) 8.04 (s, 1H) 8.36 (d, J=2.35 Hz, 1H) 8.78 (d,J=5.09 Hz, 1H) 8.96 (d, J=2.35 Hz, 1H) 10.97 (s, 1H). LCMS (m/z)(M+H)=481, Rt=0.65 min.

Example 611:N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-4-(trifluoromethyl)picolinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.28-1.54 (m, 3H) 3.76 (br. s., 9H) 4.50(q, J=7.04 Hz, 2H) 7.27-7.49 (m, 1H) 8.13 (d, J=4.30 Hz, 1H) 8.34 (s,1H) 8.50 (d, J=1.96 Hz, 1H) 8.95-9.20 (m, 2H) 11.29 (s, 1H). LCMS (m/z)(M+H)=489, Rt=0.75 min.

Example 612:2-cyclopropyl-N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.88-1.11 (m, 5H) 1.29-1.53 (m, 4H)2.05-2.08 (m, 1H) 2.15-2.28 (m, 1H) 2.71 (s, 1H) 2.87 (s, 1H) 3.64-3.81(m, 9H) 4.37-4.63 (m, 2H) 7.33 (br. s., 1H) 7.58 (dd, J=5.09, 1.57 Hz,1H) 7.75 (s, 1H) 7.93 (s, 1H) 8.34 (d, J=1.96 Hz, 1H) 8.60 (d, J=5.09Hz, 1H) 8.82-9.03 (m, 1H) 10.73-10.91 (m, 1H). LCMS (m/z) (M+H)=461,Rt=0.57 min.

Example 613:2-(2-cyanopropan-2-yl)-N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.43 (t, J=6.85 Hz, 3H) 1.71-1.84 (m, 7H)4.50 (q, J=6.91 Hz, 2H) 7.35 (s, 1H) 7.88 (dd, J=5.09, 1.17 Hz, 1H) 8.02(s, 1H) 8.32 (d, J=1.96 Hz, 1H) 8.77-8.88 (m, 1H) 8.93 (d, J=2.35 Hz,1H) 10.95 (s, 1H). LCMS (m/z) (M+H)=488, Rt=0.68 min.

Example 614:N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.43 (t, J=6.85 Hz, 3H) 4.50 (q, J=7.04Hz, 2H) 7.36 (s, 1H) 8.32 (d, J=2.35 Hz, 1H) 8.69 (d, J=1.96 Hz, 1H)8.92 (d, J=2.35 Hz, 1H) 9.93 (d, J=1.96 Hz, 1H) 11.24 (s, 1H). LCMS(m/z) (M+H)=490, Rt=0.61 min.

Example 615:N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.38 (t, J=6.85 Hz, 3H) 2.01 (s, 2H) 3.30(s, 3H) 4.45 (q, J=7.04 Hz, 2H) 7.30 (br. s., 1H) 8.18 (dd, J=4.70, 1.56Hz, 1H) 8.29 (d, J=2.35 Hz, 1H) 8.50 (s, 1H) 8.90 (d, J=2.35 Hz, 1H)8.98 (d, J=4.70 Hz, 1H) 10.96-11.22 (m, 1H). LCMS (m/z) (M+H)=499,Rt=0.53 min.

Example 616:N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.43 (t, J=7.04 Hz, 4H) 3.43-3.83 (m,16H) 4.51 (q, J=7.04 Hz, 3H) 7.28 (br. s., 1H) 8.20 (d, J=5.09 Hz, 1H)8.30 (s, 1H) 8.38 (s, 1H) 8.92 (d, J=2.35 Hz, 1H) 9.01 (d, J=5.09 Hz,1H) 11.02 (s, 1H). LCMS (m/z) (M+H)=489, Rt=0.66 min.

Example 617:2-(1,1-difluoropropyl)-N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.85-0.98 (m, 3H) 1.43 (t, J=7.04 Hz, 3H)2.25-2.41 (m, 2H) 3.75 (s, 7H) 4.50 (q, J=7.04 Hz, 2H) 7.37 (s, 1H) 8.03(d, J=4.70 Hz, 1H) 8.18 (s, 1H) 8.34 (d, J=2.35 Hz, 1H) 8.87-9.00 (m,2H) 11.02 (s, 1H). LCMS (m/z) (M+H)=499, Rt=0.69 min.

Example 618:N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-3-(methylsulfonyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.36-1.50 (m, 3H) 2.52 (s, 1H) 3.19-3.34(m, 4H) 4.37-4.59 (m, 2H) 7.39 (s, 1H) 7.85 (t, J=7.83 Hz, 1H) 8.18 (d,J=7.83 Hz, 1H) 8.30 (d, J=7.83 Hz, 1H) 8.37 (d, J=2.35 Hz, 1H) 8.50 (s,1H) 8.96 (d, J=2.35 Hz, 1H) 10.93 (s, 1H). LCMS (m/z) (M+H)=498, Rt=0.56min.

Example 619:3-(difluoromethyl)-N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.36 (t, J=7.04 Hz, 3H) 2.01 (s, 1H) 3.68(br. s., 4H) 4.49 (q, J=6.91 Hz, 2H) 6.92-7.26 (m, 2H) 7.54-7.83 (m, 2H)8.01-8.21 (m, 3H) 8.83 (d, J=1.96 Hz, 1H) 10.43-10.68 (m, 1H). LCMS(m/z) (M+H)=460, Rt=0.68 min.

Example 620:2-(1,1-difluoroethyl)-N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.41 (t, J=7.04 Hz, 3H) 1.96-2.12 (m, 4H)3.65-3.79 (m, 4H) 4.54 (q, J=7.04 Hz, 2H) 6.89-7.17 (m, 1H) 8.04 (d,J=4.30 Hz, 1H) 8.15-8.25 (m, 2H) 8.75-8.99 (m, 2H) 10.72-10.94 (m, 1H).LCMS (m/z) (M+H)=485, Rt=0.65 min.

Example 621:N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-2-isopropylisonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.17-1.32 (m, 9H) 1.35-1.46 (m, 3H) 2.05(s, 1H) 3.01-3.18 (m, 1H) 3.66-3.77 (m, 4H) 4.54 (q, J=7.04 Hz, 2H) 7.04(s, 1H) 7.68 (dd, J=5.09, 1.57 Hz, 1H) 7.75 (s, 1H) 8.18 (d, J=2.35 Hz,1H) 8.65-8.74 (m, 1H) 8.88 (d, J=2.35 Hz, 1H) 10.65 (s, 1H). LCMS (m/z)(M+H)=463, Rt=0.51 min.

Example 622: Synthesis of(R)-N-(5-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

A mixture of 3,4,6-trichloropyridazine (1.0 equiv.),(R)-3-methylmorpholine (1.0 equiv.), and Hunig's base (1.1 equiv.) inNMP (2.73 M) was stirred at RT for 2 days. Water was added to thereaction mixture. The resulting precipitate was collected by filtrationand dried in air to give(R)-4-(3,6-dichloropyridazin-4-yl)-3-methylmorpholine as white solid in66% yield. LC/MS (m/z)=247.9 (MH⁺), Rt=0.63 min.

Step 2

A mixture of (R)-4-(3,6-dichloropyridazin-4-yl)-3-methylmorpholine (1.0equiv.) and 21 wt % sodium ethoxide in ethanol (2.0 equiv.) in 1.5:1ethanol and water was stirred overnight at RT. The resulting mixture waspartitioned between EtOAc and water. The organic phase was washed withbrine and then dried over magnesium sulfate. After concentration, thecrude material was purified via preparative reverse phase HPLC. Uponlyophilization of the pure fractions,(R)-4-(6-chloro-3-ethoxypyridazin-4-yl)-3-methylmorpholine was isolatedas the TFA salt in 41% yield. LC/MS (m/z)=258.0 (MH⁺), Rt=0.59 min.

Step 3

A mixture of (R)-4-(6-chloro-3-ethoxypyridazin-4-yl)-3-methylmorpholine(1.0 equiv.),N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.), Na₂CO₃ (2 M, 3 equiv.) and PdCl₂(dppf) (0.05 equiv.) inDME (0.203 M) were heated at 120° C. for 15 min in the microwave. Theresulting mixture was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,(R)-N-(5-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 20% yield. 1H NMR (400 MHz, <dmso>) δppm 1.30 (d, J=6.26 Hz, 2H) 1.43 (t, J=7.04 Hz, 2H) 2.05 (s, 2H)3.52-3.62 (m, 3H) 3.69 (s, 2H) 3.91 (d, J=9.78 Hz, 1H) 4.49 (dd, J=7.04,1.96 Hz, 4H) 7.33 (br. s., 1H) 7.76-7.86 (m, 1H) 8.00 (d, J=7.83 Hz, 1H)8.23-8.38 (m, 3H) 8.95 (d, J=2.35 Hz, 1H) 10.84 (s, 1H). LCMS (m/z)(M+H)=502.2, Rt=0.84 min.

Example 623: Synthesis of(R)-2-(2-cyanopropan-2-yl)-N-(5-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

A mixture of (R)-4-(6-chloro-3-ethoxypyridazin-4-yl)-3-methylmorpholine(1.0 equiv.),2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)isonicotinamide(1.0 equiv.), Na₂CO₃ (2 M, 3 equiv.) and PdCl₂(dppf) (0.05 equiv.) inDME (0.203 M) were heated at 120° C. for 30 min in the microwave. Theresulting mixture was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,(R)-2-(2-cyanopropan-2-yl)-N-(5-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamidewas isolated as the TFA salt in 20% yield. 1H NMR (400 MHz, <dmso>) dppm 1.30 (d, J=5.87 Hz, 2H) 1.43 (t, J=7.04 Hz, 2H) 1.75 (s, 5H) 2.05(s, 2H) 3.54-3.63 (m, 4H) 3.69 (s, 2H) 3.91 (d, J=9.78 Hz, 1H) 4.49 (dd,J=7.04, 1.96 Hz, 4H) 7.25-7.40 (m, 1H) 7.88 (dd, J=5.09, 1.17 Hz, 1H)8.02 (s, 1H) 8.31 (d, J=1.96 Hz, 1H) 8.72-9.04 (m, 2H) 10.86-11.02 (m,1H) LCMS (m/z) (M+H)=502.4, Rt=0.66 min.

Example 624: Synthesis of(R)-2-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-4-methylphenyl)isonicotinamide

A mixture of (R)-4-(6-chloro-3-ethoxypyridazin-4-yl)-3-methylmorpholine(1.0 equiv.),2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv.), Na₂CO₃ (2 M, 3 equiv.) and PdCl₂(dppf) (0.05 equiv.) inDME (0.058 M) were heated at 120° C. for 15 min in the microwave. Theresulting mixture was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,(R)-2-(2-cyanopropan-2-yl)-N-(3-(6-ethoxy-5-(3-methylmorpholino)pyridazin-3-yl)-4-methylphenyl)isonicotinamidewas isolated as the TFA salt in 13% yield. 1H NMR (400 MHz, <dmso>) δppm 1.31 (br. s., 3H) 1.43 (t, J=6.85 Hz, 4H) 1.75 (s, 8H) 2.05 (s, 2H)2.26 (s, 3H) 3.50-3.63 (m, 3H) 3.68 (s, 2H) 3.83-4.02 (m, 1H) 4.38-4.56(m, 2H) 7.42 (d, J=8.22 Hz, 1H) 7.76-7.92 (m, 3H) 7.99 (s, 1H) 8.81 (d,J=4.70 Hz, 1H) 10.55-10.83 (m, 1H). LCMS (m/z) (M+H)=501.2, Rt=0.76 min.

Example 625: Synthesis ofN-(5-(5-(2-(1H-imidazol-2-yl)morpholino)-6-ethoxypyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

A mixture of 3,4,6-trichloropyridazine (1.0 equiv.),2-(1H-imidazol-2-yl)morpholine (1.0 equiv.), and Hunig's base (3.0equiv.) in NMP (0.182 M) was stirred at RT for 1 hr. A few drops ofwater were added to result in a solution, which was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions, 4-(3,6-dichloropyridazin-4-yl)-2-(1H-imidazol-2-yl)morpholinewas isolated as the TFA salt in 50% yield. LC/MS (m/z)=299.9 (MH⁺),Rt=0.37 min.

Step 2

A mixture of4-(6-chloro-3-ethoxypyridazin-4-yl)-2-(1H-imidazol-2-yl)morpholine (1.0equiv.),N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.), Na₂CO₃ (2 M, 3 equiv.) and PdCl₂(dppf) (0.05 equiv.) inDME (0.203 M) were heated at 120° C. for 30 min in the microwave. Theresulting mixture was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,N-(5-(5-(2-(1H-imidazol-2-yl)morpholino)-6-ethoxypyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 9.3% yield. 1H NMR (400 MHz, <dmso>) δppm 1.16 (t, J=7.24 Hz, 16H) 1.43 (t, J=7.04 Hz, 3H) 1.97 (s, 9H) 2.76(s, 1H) 3.12-3.48 (m, 4H) 4.01 (q, J=7.04 Hz, 10H) 4.56 (dd, J=7.04,3.52 Hz, 2H) 5.13 (dd, J=9.98, 2.54 Hz, 1H) 7.28 (s, 1H) 7.68 (s, 2H)7.75-7.87 (m, 1H) 8.00 (d, J=7.83 Hz, 1H) 8.22-8.34 (m, 3H) 8.90 (d,J=2.35 Hz, 1H) 10.80 (s, 1H). LCMS (m/z) (M+H)=554.2, Rt=0.61 min.

Example 626: Synthesis ofN-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamide

Step 1

5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine (1.0equiv.), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.0 equiv.), and4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.0 equiv.) weredissolved in DMF (0.106 M) at RT. The reaction was monitored by LCMS.After about 1 hr, the reaction mixture was purified via preparativereverse phase HPLC to give4-(chloromethyl)-N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamidein 62% yield. LCMS (m/z) (M+H)=536.1, Rt=0.80 min.

Step 2

4-(chloromethyl)-N-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was dissolved in 2M ammonia in methanol (0.08 M). Afterstirring at RT overnight, the reaction mixture was concentrated andpurified via preparative reverse phase HPLC to giveN-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamidein 24% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.34-1.50 (m, 7H) 2.29 (s,7H) 3.62-3.78 (m, 9H) 3.86 (s, 4H) 4.46-4.62 (m, 5H) 7.04 (s, 2H)7.87-8.01 (m, 2H) 8.16-8.33 (m, 6H) 8.85-8.92 (m, 2H) 10.44-10.97 (m,1H). LCMS (m/z) (M+H)=531.2, Rt=0.54 min.

Example 627: Synthesis ofN-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-4-(hydroxymethyl)-3-(trifluoromethyl)benzamide

5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine (1.0equiv.), N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.0 equiv.), and 4-formyl-3-(trifluoromethyl)benzoic acid(1.0 equiv.) were dissolved in DMF (0.02 M) at RT. The reaction wasmonitored by LCMS. After about 1 hr, the reaction mixture was purifiedvia preparative reverse phase HPLC to giveN-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-4-formyl-3-(trifluoromethyl)benzamide.LCMS (m/z) (M+H)=516.2, Rt=0.72 min. The product was subsequentlydissolved in MeOH and treated with excess sodium borohydride at RT. Thereaction mixture was purified via preparative reverse phase HPLC whenbubbling ceased to giveN-(5-(6-ethoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-4-(hydroxymethyl)-3-(trifluoromethyl)benzamidein 13% yield over two steps. 1H NMR (400 MHz, <dmso>) δ ppm 1.43 (s, 3H)2.05 (s, 8H) 3.74 (br. s., 9H) 4.44-4.59 (m, 2H) 4.69-4.81 (m, 2H) 7.34(s, 1H) 7.97 (d, J=8.22 Hz, 1H) 8.23-8.40 (m, 3H) 8.95 (d, J=2.35 Hz,1H) 10.63-10.94 (m, 1H). LCMS (m/z) (M+H)=518.1, Rt=0.65 min.

Example 628:2-(1,1-difluoroethyl)-N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl) isonicotinamide

Step 1

To a flask containing 3,4,6-trichloropyridazine (1.0 equiv.) in EtOH(1.3 M) was added morpholine (2.3 equiv.) and the reaction mix wasstirred at RT for 60 min. A precipitate appeared which was removed byfiltration. The solid recovered was suspended in water and stirred forfew minutes to remove salts. After filtration the solid was dried undervacuum giving 4-(3,6-dichloropyridazin-4-yl)morpholine in 86% yieldwhich was used as is in the next step. LCMS (m/z) (M+H)=234/236, Rt=0.57min.

Step 2

NaH (2.0 equiv.) was added to a solution of tetrahydro-2H-pyran-4-ol(1.7 equiv.) and 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0 equiv.)in THF (0.3 M) at 0° C. and the reaction mix was left stirring overnightat RT. The reaction mix was quench with water and extracted three timeswith EtOAc. The combined organics were washed with brine and dried overNa₂SO₄. The crude was dissolved in DCM, and adsorbed in silica gel. Thesolid was loaded into a cartridge and purified on a silica gel columnusing 0 to 40% EtOAc in heptane. The desired4-(6-chloro-3-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-4-yl)morpholinewas obtained in 75% yield. LCMS (m/z) (M+H)=300, Rt=0.54 min.

Step 3

To a solution of4-(6-chloro-3-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-4-yl)morpholine(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv.) in DME (0.11 M) was added Na₂CO₃ (2M, 3.0 equiv.) and thesystem was flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.05equiv.) was added to the reaction mix and the system was flushed onceagain with nitrogen. The reaction mix was heated in a bath for 4 hr at120° C. The crude was partitioned in H₂O/EtOAc. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. Crude waspurified silica gel column using DCM to 5% MeOH in DCM to give6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-aminein 40% yield. LCMS (m/z) (M+H)=372, Rt=0.37 min.

Step 4

DIEA (3.0 equiv.) was added to a solution of6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-amine(1.0 equiv.), 2-(1,1-difluoroethyl)isonicotinic acid (1.0 equiv.) andHATU (1.0 equiv.) in DMF (0.05 M), and the mixture was left stirring atRT overnight. The reaction mix was treated with water and extractedthree times with EtOAc. The combined organics were dried over Na₂SO₄,filtered and concentrated. The crude was purified by HPLC2-(1,1-difluoroethyl)-N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)isonicotinamideas the TFA salt in 39% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.70-1.86(m, 2H) 2.04 (t, J=19.17 Hz, 5H) 5.40 (br. s., 1H) 7.32 (br. s., 1H)8.04 (d, J=4.70 Hz, 1H) 8.20 (s, 1H) 8.33 (d, J=1.96 Hz, 1H) 8.79-8.97(m, 2H) 10.90-11.07 (m, 1H). LCMS (m/z) (M+H)=541, Rt=0.63 min.

Example 629:N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)-4-(trifluoromethyl)picolinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.75 (dtd, J=12.57, 8.29, 8.29, 3.72 Hz,2H) 1.98-2.12 (m, 2H) 3.68-3.82 (m, 8H) 5.37 (dt, J=7.53, 3.86 Hz, 1H)7.25 (s, 1H) 8.07 (d, J=4.70 Hz, 1H) 8.30 (s, 1H) 8.41 (d, J=1.96 Hz,1H) 8.92-9.12 (m, 2H) 11.06-11.31 (m, 1H). LCMS (m/z) (M+H)=545, Rt=0.69min.

Example 630:2-(2-fluoropropan-2-yl)-N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.70-1.89 (m, 9H) 1.97-2.18 (m, 2H) 5.41(br. s., 1H) 7.17-7.41 (m, 1H) 8.17-8.38 (m, 2H) 8.90 (d, J=2.35 Hz, 1H)9.65 (d, J=1.96 Hz, 1H) 11.11 (s, 1H). LCMS (m/z) (M+H)=537, Rt=0.63min.

Example 631:N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.71-1.88 (m, 2H) 2.01-2.18 (m, 2H) 3.60(ddd, J=11.44, 8.12, 3.13 Hz, 3H) 3.55-3.64 (m, 1H) 5.41 (dt, J=7.53,3.86 Hz, 1H) 7.39 (s, 1H) 8.35 (d, J=1.96 Hz, 1H) 8.71 (d, J=1.57 Hz,1H) 8.93 (d, J=2.35 Hz, 1H) 9.94 (d, J=1.57 Hz, 1H) 11.14-11.39 (m, 1H).LCMS (m/z) (M+H)=546, Rt=0.60 min.

Example 632:N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.67-1.83 (m, 2H) 1.98-2.12 (m, 2H) 3.30(s, 3H) 5.29-5.42 (m, 1H) 7.29 (br. s., 1H) 8.18 (dd, J=4.89, 1.37 Hz,1H) 8.29 (d, J=1.96 Hz, 1H) 8.50 (s, 1H) 8.89 (d, J=2.35 Hz, 1H) 8.98(d, J=4.70 Hz, 1H) 11.09 (s, 1H). LCMS (m/z) (M+H)=555, Rt=0.52 min.

Example 633:2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)isonicotinamide

LCMS (m/z) (M+H)=544, Rt=0.62 min.

Example 634:2-(2-hydroxypropan-2-yl)-N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.47 (s, 6H) 1.67-1.91 (m, 2H) 2.01-2.18(m, 2H) 3.47-3.67 (m, 2H) 4.39 (br. s., 1H) 5.23-5.45 (m, 1H) 7.41 (s,1H) 7.73 (dd, J=4.89, 1.37 Hz, 1H) 8.17 (s, 1H) 8.39 (d, J=2.35 Hz, 1H)8.71 (d, J=5.09 Hz, 1H) 8.95 (d, J=2.35 Hz, 1H) 10.96 (s, 1H). LCMS(m/z) (M+H)=535, Rt=0.48 min.

Example 635:6-(2-cyanopropan-2-yl)-N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)pyridazine-4-carboxamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.74-1.89 (m, 10H) 2.06-2.17 (m, 2H)3.60 (ddd, J=11.35, 8.22, 3.13 Hz, 7H) 3.73-3.80 (m, 5H) 3.80-3.89 (m,2H) 5.45 (br. s., 1H) 7.26 (br. s., 1H) 8.28 (s, 1H) 8.33 (d, J=1.96 Hz,1H) 8.91 (d, J=2.35 Hz, 1H) 9.67 (d, J=1.96 Hz, 1H) 11.00-11.20 (m, 1H).LCMS (m/z) (M+H)=555, Rt=0.49 min.

Example 636: Synthesis ofN-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

A mixture of4-(6-chloro-3-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-4-yl)morpholine(1.0 equiv.),N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.), Na₂CO₃ (2 M, 3 equiv.) and PdCl₂(dppf) (0.05 equiv.) inTHF (0.214 M) were heated at 130° C. for 30 min in the microwave. Theresulting mixture was partitioned between EtOAc and water. The organicphase was washed with brine and then dried over magnesium sulfate. Afterconcentration, the crude material was purified via preparative reversephase HPLC. Upon lyophilization of the pure fractions,N-(6-methyl-5-(5-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 12% yield. 1H NMR (400 MHz, <dmso>) δppm 1.70-1.90 (m, 2H) 2.00-2.20 (m, 2H) 3.33-4.18 (m, 60H) 5.29-5.46 (m,1H) 7.37 (s, 1H) 7.76-7.87 (m, 1H) 8.01 (d, J=7.83 Hz, 1H) 8.23-8.42 (m,3H) 8.94 (d, J=2.35 Hz, 1H) 10.87 (s, 1H). LCMS (m/z) (M+H)=544.2,Rt=0.76 min.

Example 637:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-3-(2-(methylsulfonyl)propan-2-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.80 (s, 6H) 2.28 (s, 3H) 2.68-2.77 (m,3H) 3.44-3.47 (m, 4H) 3.63-3.75 (m, 7H) 6.59 (s, 1H) 7.27 (d, J=8.61 Hz,1H) 7.56 (t, J=7.83 Hz, 1H) 7.67-7.77 (m, 2H) 7.82 (d, J=8.22 Hz, 1H)7.98 (d, J=7.83 Hz, 1H) 8.07-8.17 (m, 1H) 10.30 (s, 1H). LCMS (m/z)(M+H)=525.3, Rt=0.78 min.

Example 638:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.47 (s, 6H) 2.25-2.34 (m, 3H) 3.43-3.48(m, 4H) 3.67 (s, 3H) 3.70 (d, J=3.91 Hz, 4H) 6.59 (s, 1H) 7.28 (d,J=9.00 Hz, 1H) 7.65-7.81 (m, 3H) 8.15 (s, 1H) 8.67 (d, J=5.09 Hz, 1H)10.54 (s, 1H). LCMS (m/z) (M+H)=464.2, Rt=0.66 min.

Example 639:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-3-(1,3,4-oxadiazol-2-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.26-2.31 (m, 3H) 3.41-3.52 (m, 4H)3.63-3.76 (m, 7H) 6.60 (s, 1H) 7.28 (d, J=9.00 Hz, 1H) 7.69-7.83 (m, 3H)8.21 (t, J=6.85 Hz, 2H) 8.60 (s, 1H) 9.41 (s, 1H) 10.52 (s, 1H). LCMS(m/z) (M+H)=473.3, Rt=0.77 min.

Example 640:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 2.29 (s, 3H) 3.40-3.52 (m,4H) 3.62-3.76 (m, 7H) 6.59 (s, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.67-7.77 (m,2H) 7.81-7.91 (m, 1H) 8.00 (s, 1H) 8.79 (d, J=5.09 Hz, 1H) 10.56 (s,1H). LCMS (m/z) (M+H)=473.2, Rt=0.81 min.

Example 641:1-ethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.29 (t, J=7.04 Hz, 3H) 2.28 (s, 3H)3.43-3.47 (m, 4H) 3.65-3.72 (m, 7H) 4.06 (q, J=7.30 Hz, 2H) 6.58 (s, 1H)7.27 (d, J=8.61 Hz, 1H) 7.63 (d, J=2.35 Hz, 1H) 7.69 (dd, J=8.22, 2.35Hz, 1H) 8.46 (d, J=1.96 Hz, 1H) 8.80 (d, J=2.35 Hz, 1H) 10.16 (s, 1H).LCMS (m/z) (M+H)=518.1, Rt=0.87 min.

Example 642:2-ethyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.27 (t, J=7.63 Hz, 3H) 2.29 (s, 3H) 2.86(d, J=7.83 Hz, 2H) 3.44-3.47 (m, 4H) 3.67 (s, 3H) 3.68-3.71 (m, 6H)6.55-6.63 (m, 1H) 7.23-7.35 (m, 1H) 7.68-7.76 (m, 3H) 7.80 (s, 1H) 8.69(d, J=5.09 Hz, 1H) 10.49 (s, 1H). LCMS (m/z) (M+H)=434.2, Rt=0.61 min.

Example 643:2-(1,1-difluoropropyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.93 (t, J=7.43 Hz, 3H) 2.24-2.42 (m, 5H)3.43-3.51 (m, 4H) 3.62-3.77 (m, 7H) 6.59 (s, 1H) 7.30 (d, J=8.22 Hz, 1H)7.67-7.83 (m, 2H) 8.01 (d, J=4.30 Hz, 1H) 8.15 (s, 1H) 8.87 (d, J=5.09Hz, 1H) 10.64 (s, 1H). LCMS (m/z) (M+H)=484.1, Rt=0.93 min.

Example 644:6-cyclopropyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.10-1.18 (m, 4H) 2.29 (s, 3H) 2.32-2.39(m, 1H) 3.46 (d, J=4.70 Hz, 4H) 3.67 (s, 7H) 6.58 (s, 1H) 7.19-7.37 (m,1H) 7.63-7.79 (m, 2H) 7.88 (d, J=1.96 Hz, 1H) 9.37 (d, J=1.96 Hz, 1H)10.57-10.67 (m, 1H). LCMS (m/z) (M+H)=447.2, Rt=0.71 min.

Example 645:2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.76 (s, 6H) 2.54 (s, 3H) 3.39-3.53 (m,4H) 3.65-3.75 (m, 7H) 6.71 (s, 1H) 7.81-7.92 (m, 1H) 8.04 (s, 1H) 8.22(d, J=2.35 Hz, 1H) 8.83 (d, J=5.09 Hz, 1H) 8.94 (d, J=1.96 Hz, 1H) 10.90(s, 1H). LCMS (m/z) (M+H)=474.2, Rt=0.67 min.

Example 646:6-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.76-1.88 (s, 6H) 2.30 (s, 3H) 3.41-3.48(m, 4H) 3.67 (s, 3H) 3.68-3.73 (m, 5H) 6.59 (s, 1H) 7.32 (d, J=8.61 Hz,1H) 7.66-7.78 (m, 2H) 8.29 (d, J=1.57 Hz, 1H) 9.63 (d, J=1.57 Hz, 1H)10.76 (s, 1H). LCMS (m/z) (M+H)=474.1, Rt=0.81 min.

Example 647:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.30 (s, 3H) 3.46 (d, J=3.13 Hz, 4H) 3.67(s, 3H) 3.69 (d, J=3.52 Hz, 4H) 6.56-6.61 (m, 1H) 7.27-7.35 (m, 1H)7.56-7.66 (m, 2H) 7.70-7.78 (m, 1H) 8.68 (d, J=1.56 Hz, 1H) 9.91 (d,J=1.57 Hz, 1H) 10.88 (s, 1H). LCMS (m/z) (M+H)=475.0, Rt=0.80 min.

Example 648:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-2-(oxetan-3-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.28 (s, 3H) 3.43-3.49 (m, 4H) 3.67 (s,3H) 3.68-3.73 (m, 4H) 4.49 (q, J=7.73 Hz, 1H) 4.82 (t, J=6.26 Hz, 2H)4.92 (dd, J=8.41, 5.67 Hz, 2H) 6.58 (s, 1H) 7.28 (d, J=9.00 Hz, 1H)7.65-7.77 (m, 3H) 7.80 (s, 1H) 8.78 (d, J=5.09 Hz, 1H) 10.49 (s, 1H).LCMS (m/z) (M+H)=462.1, Rt=0.66 min.

Example 649:3-(4-ethylpiperazin-1-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.25 (t, J=7.43 Hz, 3H) 2.29 (s, 3H) 3.11(d, J=8.22 Hz, 4H) 3.20 (d, J=6.26 Hz, 2H) 3.42-3.48 (m, 4H) 3.60 (d,J=5.87 Hz, 2H) 3.67 (s, 3H) 3.68-3.74 (m, 4H) 4.10 (d, J=8.61 Hz, 2H)6.58 (s, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.50 (s, 1H) 7.70 (d, J=1.96 Hz,1H) 7.74 (m, 3H) 10.39 (s, 1H). LCMS (m/z) (M+H)=585.2, Rt=0.75 min.

Example 650:2-(difluoromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.29 (s, 3H) 2.31 (m, 1H) 3.42-3.49 (m,4H) 3.67 (s, 3H) 3.68-3.74 (m, 4H) 6.59 (s, 1H) 7.30 (d, J=8.22 Hz, 1H)7.76 (m, 2H) 8.05 (d, J=5.09 Hz, 1H) 8.17 (s, 1H) 8.89 (d, J=5.09 Hz,1H) 10.65 (s, 1H). LCMS (m/z) (M+H)=456.0, Rt=0.74 min.

Example 651:N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.56 (s, 3H) 3.40-3.54 (m, 4H) 3.62-3.77(m, 7H) 6.72 (s, 1H) 7.75-7.87 (m, 1H) 8.00 (d, J=7.83 Hz, 1H) 8.25-8.31(m, 2H) 8.33 (s, 1H) 8.99 (d, J=2.35 Hz, 1H) 10.84 (s, 1H). LCMS (m/z)(M+H)=474.3, Rt=0.71 min.

Example 652:3-(cyanomethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.28 (s, 3H) 3.43-3.49 (m, 4H) 3.67 (s,3H) 3.68-3.75 (m, 4H) 4.13 (s, 2H) 6.58 (s, 1H) 7.26 (d, J=9.00 Hz, 1H)7.52-7.58 (m, 2H) 7.70-7.78 (m, 2H) 7.85-7.95 (m, 2H) 10.32 (s, 1H).LCMS (m/z) (M+H)=444.3, Rt=0.76 min.

Example 653:4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.34 (s, 3H) 3.43 (br. s., 4H) 3.64 (m7H) 6.62 (s, 1H) 7.32-7.46 (m, 2H) 7.48-7.59 (m, 1H) 7.89 (d, J=8.22 Hz,1H) 7.92 (s, 1H) 8.00 (d, J=7.83 Hz, 1H) 8.18 (s, 1H) 10.46 (s, 1H).LCMS (m/z) (M+H)=473.2, Rt=0.99 min.

Example 654:2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.66 (s, 3H) 1.72 (s, 3H) 2.29 (s, 3H)3.39-3.49 (m, 4H) 3.67 (s, 3H) 3.68-3.72 (m, 4H) 6.59 (s, 1H) 7.29 (d,J=7.83 Hz, 1H) 7.68-7.78 (m, 2H) 7.81 (dd, J=5.09, 1.57 Hz, 1H) 8.01 (s,1H) 8.74 (d, J=4.70 Hz, 1H) 10.57 (s, 1H). LCMS (m/z) (M+H)=466.1,Rt=0.86 min.

Example 655:3-(difluoromethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.23-2.33 (m, 3H) 3.37-3.52 (m, 4H)3.61-3.77 (m, 7H) 6.59 (s, 1H) 6.95-7.32 (m, 2H) 7.60-7.71 (m, 1H)7.71-7.80 (m, 2H) 8.07-8.18 (m, 2H) 10.41 (s, 1H). LCMS (m/z)(M+H)=455.0, Rt=0.86 min.

Example 656:2-cyclopropyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 0.91-1.07 (m, 4H) 2.20 (m, 1H) 2.28 (s,3H) 3.36-3.51 (m, 4H) 3.68-3.73 (m, 7H) 6.58 (s, 1H) 7.25-7.30 (m, 1H)7.47-7.55 (m, 1H) 7.59 (dd, J=5.09, 1.57 Hz, 1H) 7.68-7.79 (m, 2H) 8.57(d, J=5.09 Hz, 1H) 10.46 (s, 1H). LCMS (m/z) (M+H)=466.0, Rt=0.67 min.

Example 657:2-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.03 (t, J=19.17 Hz, 3H) 2.29 (s, 3H)3.40-3.48 (m, 4H) 3.67 (s, 3H) 3.68-3.72 (m, 4H) 6.59 (s, 1H) 7.29 (d,J=8.22 Hz, 1H) 7.70-7.78 (m, 2H) 8.02 (d, J=4.70 Hz, 1H) 8.18 (s, 1H)8.86 (d, J=4.70 Hz, 1H) 10.65 (s, 1H). LCMS (m/z) (M+H)=470.1, Rt=0.87min.

Example 658:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.29 (s, 3H) 3.43-3.52 (m, 4H) 3.67 (s,3H) 3.68-3.76 (m, 4H) 6.59 (s, 1H) 7.31 (d, J=8.22 Hz, 1H) 7.69-7.79 (m,2H) 8.18 (d, J=4.30 Hz, 1H) 8.36 (s, 1H) 8.98 (d, J=5.09 Hz, 1H) 10.69(s, 1H). LCMS (m/z) (M+H)=474.2, Rt=0.93 min.

Example 659:2-(1-cyanocyclopropyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.69-1.77 (m, 2H) 1.84-1.90 (m, 2H) 2.29(s, 3H) 3.38-3.50 (m, 4H) 3.67 (s, 3H) 3.68-3.72 (m, 4H) 6.59 (s, 1H)7.29 (d, J=9.00 Hz, 1H) 7.67-7.76 (m, 2H) 7.78 (dd, J=5.09, 1.17 Hz, 1H)7.92 (s, 1H) 8.69 (d, J=5.09 Hz, 1H) 10.58 (s, 1H). LCMS (m/z)(M+H)=471.1, Rt=0.84 min.

Example 660:2-isopropyl-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <D2O>) δ ppm 1.24-1.38 (m, 6H) 2.16 (s, 3H) 3.23-3.32(m, 4H) 3.33 (m, 1H) 3.65 (s, 3H) 3.72-3.80 (m, 4H) 6.67 (s, 1H) 7.29(d, J=8.22 Hz, 1H) 7.39-7.49 (m, 2H) 8.07 (dd, J=6.06, 1.37 Hz, 1H) 8.19(s, 1H) 8.66 (d, J=6.26 Hz, 1H). LCMS (m/z) (M+H)=448.1, Rt=0.65 min.

Example 661:3-((dimethylamino)methyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.29 (s, 3H) 2.77 (d, J=3.13 Hz, 6H)3.43-3.47 (m, 4H) 3.64-3.76 (m, 7H) 4.46 (d, J=3.91 Hz, 2H) 6.59 (s, 1H)7.30 (d, J=8.22 Hz, 1H) 7.70 (d, J=1.96 Hz, 1H) 7.75 (dd, J=8.22, 1.96Hz, 1H) 8.12 (s, 1H) 8.36 (s, 1H) 8.45 (s, 1H) 10.54 (s, 1H). LCMS (m/z)(M+H)=530.3, Rt=0.69 min.

(S)-6-chloro-2-methyl-4-(3-methylmorpholino)pyridazin-3(2H)-one

A mixture of 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (1.0 equiv.),(S)-3-methylmorpholine (1 eq) and potassium carbonate (6 eq) in NMP(0.15 M) was heated in an oil bath at 115° C. for 18 h. The reactionmixture was partitioned between EtOAc and water. The organics werewashed with brine and dried over sodium sulfate. After concentration,the resulting(S)-6-chloro-2-methyl-4-(3-methylmorpholino)pyridazin-3(2H)-one was usedin the next step without further purification. LCMS (m/z) (M+H)=244.0,Rt=0.63 min.

Example 662:(S)-2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-5-(3-methylmorpholino)-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.09 (d, J=6.65 Hz, 3H) 1.66 (s, 3H)1.69-1.76 (m, 3H) 2.28 (s, 3H) 3.22 (d, J=3.13 Hz, 1H) 3.44-3.72 (m, 9H)6.51 (s, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.67-7.78 (m, 2H) 7.81 (dd, J=4.89,1.37 Hz, 1H) 8.01 (s, 1H) 8.73 (d, J=5.09 Hz, 1H) 10.56 (s, 1H). LCMS(m/z) (M+H)=480.2, Rt=0.86 min.

Example 663:(S)-2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-(3-methylmorpholino)-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.09 (d, J=6.65 Hz, 3H) 1.75 (s, 6H) 2.28(s, 3H) 3.17-3.28 (m, 1H) 3.47-3.63 (m, 4H) 3.66 (m, 3H) 3.68-3.72 (m,1H) 3.85 (d, J=10.56 Hz, 2H) 6.51 (s, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.70(d, J=1.96 Hz, 1H) 7.74 (dd, J=8.22, 1.96 Hz, 1H) 7.85 (dd, J=5.09, 1.17Hz, 1H) 8.00 (s, 1H) 8.79 (d, J=5.09 Hz, 1H) 10.55 (s, 1H). LCMS (m/z)(M+H)=487.2, Rt=0.85 min.

Example 664:(S)-2-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-5-(3-methylmorpholino)-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.22 (d, J=6.65 Hz, 3H) 2.16 (t, J=19.17Hz, 3H) 2.37-2.44 (m, 3H) 3.30-3.40 (m, 1H) 3.64-3.86 (m, 8H) 3.98 (d,J=12.13 Hz, 1H) 6.64 (s, 1H) 7.36-7.48 (m, 1H) 7.79-7.94 (m, 2H) 8.15(d, J=4.70 Hz, 1H) 8.30 (s, 1H) 8.99 (d, J=5.09 Hz, 1H) 10.77 (s, 1H).LCMS (m/z) (M+H)=484.2, Rt=0.87 min.

6-chloro-4-(2,2-dimethylmorpholino)-2-methylpyridazin-3(2H)-one

6-Chloro-4-(2,2-dimethylmorpholino)-2-methylpyridazin-3(2H)-one wassynthesized using the same method as(S)-6-chloro-2-methyl-4-(3-methylmorpholino)pyridazin-3(2H)-one. LCMS(m/z) (M+H)=258.0, Rt=0.69 min.

Example 665:N-(3-(5-(2,2-dimethylmorpholino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-methylphenyl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.18 (s, 6H) 1.66 (s, 3H) 1.69-1.76 (m,3H) 2.28 (s, 3H) 3.33-3.41 (m, 4H) 3.66 (s, 3H) 3.70-3.76 (m, 2H) 6.57(s, 1H) 7.24-7.32 (m, 1H) 7.71 (d, J=1.96 Hz, 1H) 7.73 (s, 1H) 7.81 (dd,J=4.89, 1.37 Hz, 1H) 8.01 (s, 1H) 8.74 (d, J=5.09 Hz, 1H) 10.56 (s, 1H).LCMS (m/z) (M+H)=494.3, Rt=0.90 min.

Example 666:2-(2-cyanopropan-2-yl)-N-(3-(5-(2,2-dimethylmorpholino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.18 (s, 6H) 1.75 (s, 6H) 2.28 (s, 3H)3.38-3.40 (m, 4H) 3.66 (s, 3H) 3.69-3.76 (m, 2H) 6.57 (s, 1H) 7.26-7.33(m, 1H) 7.69 (d, J=1.96 Hz, 1H) 7.73 (dd, J=8.22, 1.96 Hz, 1H) 7.85 (dd,J=5.09, 1.17 Hz, 1H) 7.99 (s, 1H) 8.79 (d, J=4.70 Hz, 1H) 10.55 (s, 1H).LCMS (m/z) (M+H)=501.2, Rt=0.89 min.

Example 667:2-(1,1-difluoroethyl)-N-(3-(5-(2,2-dimethylmorpholino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.18 (s, 6H) 2.03 (s, 3H) 2.28 (s, 3H)3.37-3.40 (m, 4H) 3.66 (s, 3H) 3.69-3.76 (m, 2H) 6.57 (s, 1H) 7.29 (d,J=8.22 Hz, 1H) 7.72 (d, J=1.96 Hz, 1H) 7.75 (dd, J=8.22, 1.96 Hz, 1H)8.02 (d, J=4.70 Hz, 1H) 8.17 (s, 1H) 8.86 (d, J=4.70 Hz, 1H) 10.64 (s,1H). LCMS (m/z) (M+H)=498.3, Rt=0.89 min.

4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-chloro-2-methylpyridazin-3(2H)-one

4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-chloro-2-methylpyridazin-3(2H)-onewas synthesized using the same method as(S)-6-chloro-2-methyl-4-(3-methylmorpholino)pyridazin-3(2H)-one. LCMS(m/z) (M+H)=255.0, Rt=0.63 min.

Example 668:N-(3-(5-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-methylphenyl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.66 (s, 3H) 1.71 (s, 3H) 1.85-1.97 (m,4H) 2.29 (s, 3H) 3.48-3.51 (m, 4H) 3.60-3.63 (m, 2H) 3.65 (s, 3H) 6.57(s, 1H) 7.27 (d, J=8.61 Hz, 1H) 7.70-7.77 (m, 2H) 7.80 (dd, J=5.09, 1.17Hz, 1H) 8.01 (s, 1H) 8.73 (d, J=5.09 Hz, 1H) 10.55 (s, 1H). LCMS (m/z)(M+H)=492.1, Rt=0.87 min.

Example 669:N-(3-(5-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-methylphenyl)-2-(2-cyanopropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 1.85-1.98 (m, 4H) 2.26-2.31(m, 3H) 3.48-3.54 (m, 4H) 3.58-3.63 (m, 2H) 3.65 (s, 3H) 6.57 (s, 1H)7.28 (d, J=8.61 Hz, 1 H) 7.69 (d, J=1.96 Hz, 1H) 7.74 (dd, J=8.22, 1.96Hz, 1H) 7.85 (dd, J=5.09, 1.17 Hz, 1H) 7.99 (s, 1H) 8.78 (d, J=5.09 Hz,1H) 10.54 (s, 1H). LCMS (m/z) (M+H)=499.1, Rt=0.86 min.

Example 670:N-(3-(5-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-methylphenyl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.95-2.10 (m, 4H) 2.10-2.23 (m, 3H) 2.43(s, 3H) 3.58 (d, J=10.96 Hz, 4H) 3.70-3.84 (m, 5H) 6.70 (s, 1H) 7.42 (d,J=8.22 Hz, 1H) 7.79-7.94 (m, 2H) 8.15 (d, J=4.70 Hz, 1H) 8.31 (s, 1H)9.00 (d, J=5.09 Hz, 1H) 10.77 (s, 1H). LCMS (m/z) (M+H)=496.2, Rt=0.88min.

6-chloro-4-(3,3-dimethylmorpholino)-2-methylpyridazin-3(2H)-one

6-chloro-4-(3,3-dimethylmorpholino)-2-methylpyridazin-3(2H)-one wassynthesized using the same method as(S)-6-chloro-2-methyl-4-(3-methylmorpholino)pyridazin-3(2H)-one. LCMS(m/z) (M+H)=258.0, Rt=0.67 min.

Example 671:2-(2-cyanopropan-2-yl)-N-(3-(5-(3,3-dimethylmorpholino)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.39 (s, 6H) 1.88 (s, 6H) 2.44 (s, 3H)3.49 (br. s., 4H) 3.80 (s, 3H) 3.84 (t, J=4.50 Hz, 2H) 6.92 (s, 1H) 7.44(d, J=9.00 Hz, 1H) 7.82-7.90 (m, 2H) 7.98 (dd, J=5.09, 1.17 Hz, 1H) 8.12(s, 1H) 8.92 (d, J=5.09 Hz, 1H) 10.71 (s, 1H). LCMS (m/z) (M+H)=501.2,Rt=0.88 min.

Synthesis of(R)-6-chloro-2-methyl-4-(3-methylmorpholino)pyridazin-3(2H)-one

To a solution of 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (1.0equiv.) in DMF (0.2 M) was added Huenig's Base (1.0 equiv.) and(R)-3-methylmorpholine (1.0 equiv.) at room temperature. The reactionwas heated to 130° C. for 5 hours. Cooled to room temperature,partitioned between water and ethyl acetate, the organic phase was driedwith sodium sulfate, filtered and concentrated. The crude material wasused for the next step without further purification. LCMS (m/z)(M+H)=244.0, Rt=0.63 min.

Example 672:(R)-2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-(3-methylmorpholino)-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.21 (d, J=7.04 Hz, 3H) 1.81 (s, 6H)2.35 (s, 3H) 3.34-3.55 (m, 2H) 3.63-3.76 (m, 2H) 3.79 (s, 3H) 3.87 (dd,J=11.35, 2.74 Hz, 1H) 3.94 (d, J=10.56 Hz, 1H) 6.62 (s, 1H) 7.31 (d,J=8.22 Hz, 1H) 7.66 (dd, J=8.22, 2.35 Hz, 1H) 7.76 (d, J=2.35 Hz, 1H)7.81 (dd, J=4.89, 1.37 Hz, 1H) 8.06 (s, 1H) 8.76 (d, J=5.09 Hz, 1H).LCMS (m/z) (M+H)=487.2, Rt=0.85 min.

Example 673:(R)-2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-5-(3-methylmorpholino)-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.21 (d, J=7.04 Hz, 3H) 1.65-1.79 (m,6H) 2.35 (s, 3H) 3.36-3.50 (m, 1H) 3.64-3.76 (m, 2H) 3.79 (s, 3H) 3.87(dd, J=11.54, 2.93 Hz, 1H) 3.94 (d, J=13.69 Hz, 1H) 6.62 (s, 1H) 7.31(d, J=8.22 Hz, 1H) 7.66 (dd, J=8.22, 2.35 Hz, 1H) 7.73-7.85 (m, 2H) 8.06(s, 1H) 8.70 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=480.2, Rt=0.86 min.

Example 674:(R)-2-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-5-(3-methylmorpholino)-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.21 (d, J=6.65 Hz, 3H) 2.03 (t, J=18.59Hz, 3H) 2.35 (s, 3H) 3.40 (dd, J=11.74, 3.52 Hz, 1H) 3.47 (br. s., 1H)3.62-3.76 (m, 2H) 3.79 (s, 3H) 3.87 (dd, J=11.35, 3.13 Hz, 1H) 3.94 (d,J=10.96 Hz, 1H) 6.62 (s, 1H) 7.31 (d, J=8.22 Hz, 1H) 7.67 (dd, J=8.22,1.96 Hz, 1H) 7.77 (d, J=2.35 Hz, 1H) 7.96 (d, J=4.30 Hz, 1H) 8.17 (s,1H) 8.80 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=484.2, Rt=0.88 min.

Synthesis of6-(5-amino-2-methylphenyl)-2-methyl-4-(tetrahydro-2H-pyran-4-yl)pyridazin-3(2H)-one

Step 1

To a solution of 4-bromo-6-chloro-2-methylpyridazin-3(2H)-one (1.0equiv.) in DME (0.2 M) was added2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1.0 equiv.) and PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.), followed by 2MNa₂CO₃ (3.0 equiv.). The reaction was heated to 80° C. for 30 min atwhich time LC/MS indicated completion. The solution was partitionedbetween water and ethyl acetate, the organic phase was dried with sodiumsulfate, filtered and concentrated to give6-chloro-4-(3,6-dihydro-2H-pyran-4-yl)-2-methylpyridazin-3(2H)-one. Thecrude material was used for the next step without further purification.LCMS (m/z) (M+H)=227.0, Rt=0.61 min.

Step 2

To a solution of6-chloro-4-(3,6-dihydro-2H-pyran-4-yl)-2-methylpyridazin-3(2H)-one (1.0equiv.) in DME (0.15 M) was added4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.) and PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.), followed by 2MNa₂CO₃ (3.0 equiv.). The solution was heated to 100° C. for 3 hours.Cooled to room temperature, partitioned between water and ethyl acetate,the organic phase was washed with water, dried with sodium sulfate,filtered and concentrated under vacuo. The crude material was purifiedvia silica gel column chromatography eluting with 0-100% ethyl acetatein heptanes. The pure fractions were concentrated under vacuo to yield6-(5-amino-2-methylphenyl)-4-(3,6-dihydro-2H-pyran-4-yl)-2-methylpyridazin-3(2H)-oneas the desired product in 56% yield. LCMS (m/z) (M+H)=298.0, Rt=0.49min.

Step 3

To a degassed solution of6-(5-amino-2-methylphenyl)-4-(3,6-dihydro-2H-pyran-4-yl)-2-methylpyridazin-3(2H)-one(1.0 equiv.) in ethanol (0.06 M) was added Pd/C (0.1 equiv.) and thereaction was stirred under a hydrogen balloon. After 2 hours, thereaction was filtered and concentrated to dryness under vacuo. Obtained6-(5-amino-2-methylphenyl)-2-methyl-4-(tetrahydro-2H-pyran-4-yl)pyridazin-3(2H)-oneas the desired product in 78% yield. LCMS (m/z) (M+H)=300.1, Rt=0.46min.

Example 675:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-6-oxo-5-(tetrahydro-2H-pyran-4-yl)-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.64-1.76 (m, 2H) 1.81 (s, 6H) 1.83-1.91(m, 2H) 2.37 (s, 3H) 3.10-3.22 (m, 1H) 3.59 (td, J=11.74, 1.96 Hz, 2H)3.85 (s, 3H) 4.05 (dd, J=11.15, 3.72 Hz, 2H) 7.33 (d, J=8.22 Hz, 1H)7.42 (s, 1H) 7.69 (dd, J=8.41, 2.15 Hz, 1H) 7.76-7.83 (m, 2H) 8.07 (s,1H) 8.76 (d, J=4.70 Hz, 1H). LCMS (m/z) (M+H)=472.2, Rt=0.84 min.

Example 676:2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-6-oxo-5-(tetrahydro-2H-pyran-4-yl)-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.61-1.80 (m, 8H) 1.87 (d, J=11.74 Hz,2H) 2.37 (s, 3H) 3.08-3.23 (m, 1H) 3.53-3.65 (m, 2H) 3.85 (s, 3H) 4.05(dd, J=11.35, 3.91 Hz, 2H) 7.33 (d, J=8.61 Hz, 1H) 7.42 (s, 1H) 7.70(dd, J=8.41, 2.15 Hz, 1H) 7.77-7.86 (m, 2H) 8.10 (s, 1H) 8.71 (d, J=5.09Hz, 1H). LCMS (m/z) (M+H)=465.2, Rt=0.85 min.

Synthesis of6-(5-amino-2-methylpyridin-3-yl)-2-methyl-4-morpholinopyridazin-3(2H)-one

To a solution of 6-chloro-2-methyl-4-morpholinopyridazin-3(2H)-one (1.0equiv.) in DME (0.26 M) was added6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv.), PdCl₂(dppf).CH₂Cl₂ adduct (0.5 equiv.) and 2M Na₂CO₃ (7.0equiv.). The solution was heated to 120° C. for 2 hours, at which pointLC/MS indicated the reaction was complete. Diluted with ethyl acetateand water, the aqueous layer was separated and extracted with ethylacetate two more times. The organic layers were combined, dried overmagnesium sulfate, and concentrated invactuo to yield a brown oil. Theresidue was further purified via flash column chromatography elutingwith 100% heptanes to 50% ethyl acetate and heptanes to 80% ethylacetate and heptanes. The pure fractions were concentrated to yield6-(5-amino-2-methylpyridin-3-yl)-2-methyl-4-morpholinopyridazin-3(2H)-oneas a brown residue in 99% yield. LCMS (m/z) (M+H)=302.0, Rt=0.38 min.

Example 677:2-(2-fluoropropan-2-yl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.53-1.89 (m, 6H) 2.73 (s, 3H) 3.41-3.61(m, 4H) 3.71-3.93 (m, 7H) 6.77 (s, 1H) 7.82 (dd, J=5.09, 1.57 Hz, 1H)8.12 (s, 1H) 8.55 (d, J=2.35 Hz, 1H) 8.74 (d, J=5.09 Hz, 1H) 9.19 (d,J=2.35 Hz, 1H). LCMS (m/z) (M+H)=467.2, Rt=0.61 min.

Example 678:2-(1,1-difluoroethyl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.94 (t, J=18.59 Hz, 3H) 2.48 (s, 3H)3.36-3.46 (m, 4H) 3.67-3.82 (m, 7H) 6.64 (s, 1H) 7.90 (d, J=4.30 Hz, 1H)8.12 (s, 1H) 8.19 (d, J=2.35 Hz, 1H) 8.68-8.78 (m, 1H). LCMS (m/z)(M+H)=471.2, Rt=0.61 min.

Example 679:2-(1,1-difluoropropyl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.01 (t, J=7.43 Hz, 3H) 2.22-2.53 (m,2H) 2.73 (s, 3H) 3.44-3.61 (m, 4H) 3.76-3.98 (m, 7H) 6.76 (s, 1H) 8.01(d, J=3.91 Hz, 1H) 8.22 (s, 1H) 8.53 (d, J=2.35 Hz, 1H) 8.86 (d, J=5.09Hz, 1H) 9.17 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=485.2, Rt=0.64 min.

Example 680:2-(difluoromethyl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.73 (s, 3H) 3.42-3.62 (m, 4H) 3.74-3.92(m, 7H) 6.65-7.05 (m, 2H) 8.06 (d, J=5.09 Hz, 1H) 8.23 (s, 1H) 8.53 (d,J=2.35 Hz, 1H) 8.88 (d, J=5.09 Hz, 1H) 9.18 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=457.1, Rt=0.56 min.

Example 681:3-(difluoromethyl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.74 (s, 3H) 3.46-3.61 (m, 4H) 3.76-3.88(m, 7H) 6.66-7.11 (m, 2H) 7.58-7.76 (m, 1H) 7.82 (d, J=7.83 Hz, 1H)8.08-8.27 (m, 2H) 8.56 (d, J=2.35 Hz, 1H) 9.21 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=456.2, Rt=0.64 min.

Example 682:2-cyclopropyl-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.02-1.37 (m, 4H) 2.08-2.38 (m, 1H) 2.74(s, 3H) 3.49-3.61 (m, 4H) 3.75-3.95 (m, 7H) 6.77 (s, 1H) 7.71-7.94 (m,2H) 8.47-8.73 (m, 2H) 9.20 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=447.2,Rt=0.48 min.

Example 683:2-(1-cyanocyclopropyl)-N-(6-methyl-5-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)pyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.71-1.98 (m, 4H) 2.57 (s, 3H) 3.43-3.62(m, 4H) 3.74-3.96 (m, 8H) 6.73 (s, 1H) 7.74 (d, J=5.09 Hz, 1H) 8.10 (s,1H) 8.27 (d, J=2.35 Hz, 1H) 8.66 (d, J=5.09 Hz, 1H) 8.83 (d, J=2.35 Hz,1H). LCMS (m/z) (M+H)=472.2, Rt=0.60 min.

Synthesis of 4-(5-amino-2-methylpyridin-3-yl)-2-morpholinobenzonitrile

Step 1

A 0.5M solution of 4-bromo-2-fluorobenzonitrile (1.00 equiv.) inacetonitrile was treated with morpholine (1.10 equiv.), and DIEA (2.00equiv.). The mixture was stirred at 90° C. for 4 hr. The cooled reactionmixture was diluted with four volumes of water. The precipitate wascollected by vacuum filtration and air-dried to give4-bromo-2-morpholinobenzonitrile as a peach solid in 82% yield. LCMS(m/z) (M+H)=266.9/268.9, Rt=0.90 min.

Step 2

To a 0.15M solution of 4-bromo-2-morpholinobenzonitrile (1.00 equiv.) inDME was added6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.40 equiv.), PdCl2(dppf).CH2Cl2 adduct (0.10 equiv.), and 2M aqueoussodium carbonate (3.00 equiv.). The reaction mixture was irradiated at120° C. for 10 min in the microwave. The cooled reaction mixture wasdiluted with 2:1 DCM:MeOH and filtered. The filtrate was concentratedand purified by flash chromatography over silica gel (ethyl acetate with0-15% methanol gradient) to give4-(5-amino-2-methylpyridin-3-yl)-2-morpholinobenzonitrile in 87.0% yieldas a tan solid. LCMS (m/z) (M+H)=295.1, Rt=0.52 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 171 using the appropriatestarting materials.

Example 684:N-(5-(4-cyano-3-morpholinophenyl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.62 (s, 3H) 3.30 (d, J=4.60 Hz, 4H)3.88-3.94 (m, 4H) 7.19-7.27 (m, 2H) 7.76-7.86 (m, 2H) 7.97 (d, J=7.87Hz, 1H) 8.29 (d, J=7.82 Hz, 1H) 8.35 (s, 1H) 8.40 (d, J=2.40 Hz, 1H)9.23 (d, J=2.40 Hz, 1H). LCMS (m/z) (M+H)=467.1, Rt=0.77 min.

Example 685:N-(5-(4-cyano-3-morpholinophenyl)-6-methylpyridin-3-yl)-3-((dimethylamino)methyl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.57 (s, 3H) 2.95 (s, 6H) 3.26-3.31 (m,4H) 3.84-3.97 (m, 4H) 4.54 (s, 2H) 7.16-7.25 (m, 2H) 7.81 (d, J=7.83 Hz,1H) 8.16 (s, 1H) 8.31 (d, J=2.35 Hz, 1H) 8.45 (s, 1H) 8.51 (s, 1H) 9.08(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=524.2, Rt=0.63 min.

Example 686:N-(5-(4-cyano-3-morpholinophenyl)-6-methylpyridin-3-yl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.42 (d, J=6.65 Hz, 6H) 2.63 (s, 3H)3.23-3.31 (m, 5H) 3.86-3.96 (m, 4H) 7.22 (d, J=8.22 Hz, 1H) 7.25 (s, 1H)7.83 (d, J=7.83 Hz, 1H) 7.92 (dd, J=5.28, 1.37 Hz, 1H) 8.03 (s, 1H) 8.40(d, J=2.35 Hz, 1H) 8.76 (d, J=5.09 Hz, 1H) 9.23 (d, J=1.96 Hz, 1H). LCMS(m/z) (M+H)=442.2, Rt=0.59 min.

Example 687:N-(6-methyl-5-(4-(methylsulfonyl)-3-morpholinophenyl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

A solution of (4-bromo-2-nitrophenyl)(methyl)sulfane (1.0 equiv.) andmCPBA (3.0 equiv.) in DCM (0.13 M) was stirred at RT overnight. Thereaction mix was partitioned between 1N NaOH solution and EtOAc. Theorganic layer was isolated, washed twice with 1N NaOH solution, driedover MgSO₄, filtered and concentrated. The crude4-bromo-1-(methylsulfonyl)-2-nitrobenzene will be used as is in the nextstep.

Step 2

Morpholine (3.0 equiv.) was added to a solution of4-bromo-1-(methylsulfonyl)-2-nitrobenzene (1.0 equiv.) in DME (Volume:15 mL) and the reaction mix was stirred at RT overnight. The crude waspartitioned in H₂O/EtOAc. The organic layer was isolated, dried overNa₂SO₄, filtered and concentrated and purified on silicagel column usingheptane to 100% EtOAc in heptane giving4-(5-bromo-2-(methylsulfonyl)phenyl)morpholine in 8.7% yield. LCMS (m/z)(M+H)=321, Rt=0.75 min.

Step 3

PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added to a solution of4-(5-bromo-2-(methylsulfonyl)phenyl)morpholine (1.0 equiv.),N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and 2M Na₂CO₃ solution (3.0 equiv.) in DME (0.08) and thesystem was flushed with nitrogen. The vial was sealed and the mixturewas irradiated at 120° C. for 20 min in the microwave. The solvent wasremoved under vacuum and the residue was partitioned in EtOAC/H₂O. Theorganic layer was isolated and the aqueous layer was back extractedtwice with EtOAc. The combined organics were dried over Na₂SO₄, filteredand concentrated. The residue was taken in DMSO and purified by HPLC togiveN-(6-methyl-5-(4-(methylsulfonyl)-3-morpholinophenyl)pyridin-3-yl)-3-(trifluoromethyl)benzamideas the TFA salt in 22% yield. LCMS (m/z) (M+H)=520, Rt=0.76 min.

Example 691:N-(3-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1-methyl-6-oxo-1,6-dihydropyridin-2-yl)-4-methylphenyl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.92 (br. s., 4H) 2.03 (s, 3H) 2.12 (s,3H) 2.99 (s, 3H) 3.42 (d, J=10.96 Hz, 2H) 3.59-3.63 (m, 2H) 4.23 (br.s., 2H) 5.62 (d, J=2.35 Hz, 1 H) 6.00 (d, J=1.96 Hz, 1H) 7.36 (d, J=8.22Hz, 1H) 7.68 (d, J=1.56 Hz, 1H) 7.79 (dd, J=8.22, 1.96 Hz, 1H) 8.01 (d,J=5.09 Hz, 1H) 8.16 (s, 1H) 8.87 (d, J=4.70 Hz, 1H) 10.70 (s, 1H). LCMS(m/z) (M+H)=495.3, Rt=0.79 min.

Synthesis of4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-chloro-1-methylpyridin-2(1H)-one

A solution of 4-bromo-6-chloro-1-methylpyridin-2(1H)-one (1.0 equiv.),3-oxa-8-azabicyclo[3.2.1]octane (1.3 equiv.) and DIEA (2.5 equiv.) inDMF (2.8 M) was heated to 110° C. for 18 h. The reaction mixture waspartitioned between EtOAc and water, washed with brine and dried overNa₂SO₄. After concentration the crude product was purified by normalphase chromatography to give4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-chloro-1-methylpyridin-2(1H)-onein 14% yield. LCMS (m/z) (M+H)=255.1, Rt=0.52 min.

Example 694: -Synthesis ofN-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

Step 1

To a solution of 4-(6-chloro-2-(methylsulfonyl)pyrimidin-4-yl)morpholine(1.0 equiv.) in THF (0.14 M) was added 2M ethylamine solution in THF(2.0 equiv.) at room temperature. The reaction was stirred at ambienttemperature for 16 h. The reaction was partitioned between water andethyl acetate and the separated organic phase was dried with sodiumsulfate, filtered and concentrated under vacuo to yield4-chloro-N-ethyl-6-morpholinopyrimidin-2-amine in quantitative yield.LCMS (m/z) (M+H)=243/245, Rt=0.5 min.

Step 2

To a solution of 4-chloro-N-ethyl-6-morpholinopyrimidin-2-amine (1.0equiv.) in DME (0.6 M) was added4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.equiv.), PdCl2(dppf)-DCM adduct (0.1 equiv.) and 2M aqueous sodiumcarbonate (3.00 equiv.), and the reaction was heated to 120° C. for 20min in the microwave.

LC/MS showed incomplete reaction, allowed to heat in the oil bath at100° C. for 3 hours. At this time, the reaction was complete. Cooled toroom temperature, partitioned between water and ethyl acetate, theorganic phase was dried with sodium sulfate, filtered and concentrated.The crude material was purified via silica gel column chromatographyeluting with 0-100% ethyl acetate in heptanes. The pure fractions wereconcentrated under vacuo to yield4-(5-amino-2-methylphenyl)-N-ethyl-6-morpholinopyrimidin-2-amine as thedesired product in 84% yield. LCMS (m/z) (M+H)=314.2, Rt=0.48 min.

Step 3

To a solution of 2-(trifluoromethyl)isonicotinic acid (1. equiv.) in DMF(0.04 M) was added EDC (1 eq) and HOBT (1 eq) followed by4-(5-amino-2-methylphenyl)-N-ethyl-6-morpholinopyrimidin-2-amine (1.0equiv.) and the reaction mixture was stirred at ambient temperature for16 h. The reaction mixture was partitioned between water and ethylacetate, and the separated organic layer was dried with sodium sulfate,filtered and concentrated. The concentrated crude was dissolved in DMSO,filtered through a HPLC filter and purified via auto-preparative reversephase HPLC. The pure fractions were lyophilized to yieldN-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide.

1H NMR (400 MHz, <demos>) δ ppm 1.16 (s, 3H) 2.30 (s, 3H) 3.69 (br. s.,8H) 6.50-6.62 (m, 1H) 7.36-7.46 (m, 1H) 7.62-7.72 (m, 1H) 7.74-7.82 (m,1H) 7.84-7.93 (m, 1H) 8.11-8.22 (m, 1H) 8.32-8.43 (m, 1H) 8.90-9.04 (m,1H) 10.82-10.90 (m, 1H) LCMS (m/z) (M+H)=487.3, Rt=0.7 min.

Example 695:N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.16 (s, 3H) 2.29 (s, 3H) 3.35-3.46 (m,4H) 3.57-3.79 (m, 5H) 3.86-4.01 (m, 1H) 6.51-6.65 (m, 1H) 7.29-7.40 (m,1H) 7.48-7.64 (m, 3H) 7.73-7.82 (m, 1H) 7.90-8.00 (m, 3H) 10.32-10.44(m, 1H) LCMS (m/z) (M+H)=418.2, Rt=0.72 min.

Example 696:2-(tert-butyl)-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.12-1.20 (m, 3H) 1.35 (s, 9H) 2.23-2.33(m, 3H) 3.27-3.45 (m, 2H) 3.72-3.80 (m, 5H) 3.81-4.06 (m, 3H) 6.49-6.65(m, 1H) 7.35-7.45 (m, 1H) 7.60-7.69 (m, 1H) 7.76-7.91 (m, 3H) 8.65-8.78(m, 1H) 10.57-10.66 (m, 1H), LCMS (m/z) (M+H)=475.4, Rt=0.64 min.

Example 697:2-(1,1-difluoroethyl)-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.16 (s, 3H) 2.04 (s, 3H) 2.30 (s, 3H)3.63-4.04 (m, 8H) 6.47-6.62 (m, 1H) 7.34-7.48 (m, 1H) 7.54-7.65 (m, 1H)7.72-7.84 (m, 1H) 7.86-7.91 (m, 1H) 7.98-8.05 (m, 1H) 8.13-8.24 (m, 1H)8.82-8.92 (m, 1H) 10.73-10.85 (m, 1H), LCMS (m/z) (M+H)=483.3, Rt=0.75min.

Example 698:3-(difluoromethyl)-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.03-1.23 (m, 3H) 2.29 (s, 3H) 3.64-3.97(m, 7H) 6.96-7.02 (m, 1H) 7.10-7.17 (m, 1H) 7.23-7.30 (m, 1H) 7.34-7.43(m, 1H) 7.64-7.73 (m, 1H) 7.75-7.81 (m, 2H) 7.87-7.96 (m, 1H) 8.06-8.21(m, 2H) 10.48-10.63 (m, 1H), LCMS (m/z) (M+H)=468.3, Rt=0.77 min.

Example 699:N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(1,3,4-oxadiazol-2-yl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.16 (t, J=7.04 Hz, 3H) 2.30 (s, 3H)3.41-3.48 (m, 1H) 3.49-3.57 (m, 1H) 3.59-3.78 (m, 5H) 3.80-4.03 (m, 1H)6.53-6.64 (m, 1H) 7.33-7.44 (m, 1H) 7.73-7.85 (m, 2H) 7.89-7.99 (m, 1H)8.15-8.27 (m, 2H) 8.56-8.64 (m, 1H) 9.36-9.47 (m, 1H) 10.58-10.71 (m,1H), LCMS (m/z) (M+H)=486.3, Rt=0.69 min.

Example 700:N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-isopropylisonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.10-1.19 (m, 3H) 1.27 (d, J=7.04 Hz, 6H)2.29 (s, 3H) 3.04-3.17 (m, 1H) 3.67-3.78 (m, 7H) 3.85-3.97 (m, 2H)6.54-6.61 (m, 1H) 7.33-7.47 (m, 1H) 7.62-7.80 (m, 3H) 7.86-7.95 (m, 1H)8.65-8.72 (m, 1H) 10.55-10.64 (m, 1H), LCMS (m/z) (M+H)=461.4, Rt=0.58min.

Example 701:3-(1,1-difluoroethyl)-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.03-1.29 (m, 3H) 1.97 (s, 3H) 2.24 (s,3H) 3.55-3.72 (m, 6H) 3.79-3.94 (m, 1H) 6.48-6.57 (m, 1H) 7.28-7.41 (m,1H) 7.57-7.67 (m, 1H) 7.69-7.78 (m, 2H) 7.80-7.91 (m, 1H) 7.97-8.13 (m,2H) 10.46-10.51 (m, 1H), LCMS (m/z) (M+H)=482.4, Rt=0.82 min.

Example 702:N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) v ppm 1.15 (s, 3H) 2.30 (s, 4H) 3.62-3.75 (m,5H) 3.85-3.99 (m, 1H) 6.50-6.61 (m, 1H) 7.37-7.47 (m, 1H) 7.74-7.93 (m,2H) 8.11-8.25 (m, 1H) 8.46-8.56 (m, 1H) 8.92-9.05 (m, 1H) 10.88-10.97(m, 1H), LCMS (m/z) (M+H)=497.3, Rt=0.6 min.

Example 703:1-ethyl-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.04-1.21 (m, 3H) 1.29 (s, 3H) 2.28 (s,3H) 3.39-3.44 (m, 2H) 3.61-3.80 (m, 5H) 3.85-3.98 (m, 1H) 4.02-4.15 (m,2H) 6.50-6.65 (m, 1H) 7.35-7.47 (m, 1H) 7.67-7.84 (m, 2H) 8.41-8.50 (m,1H) 8.74-8.87 (m, 1H) 10.21-10.35 (m, 1H), LCMS (m/z) (M+H)=531.3,Rt=0.74 min.

Example 704:N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.00-1.17 (m, 3H) 2.23-2.35 (m, 4H)3.27-3.27 (m, 5H) 3.47-3.56 (m, 4H) 3.59-3.69 (m, 4H) 6.00-6.10 (m, 1H)7.17-7.27 (m, 1H) 7.66-7.74 (m, 2H) 7.77-7.85 (m, 1H) 8.07-8.16 (m, 1H)8.24-8.32 (m, 1H) 8.43-8.52 (m, 1H) 10.42-10.51 (m, 1H), LCMS (m/z)(M+H)=474.3, Rt=0.89 min.

Example 705:N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(2-hydroxypropan-2-yl)isonicotinamide

1H NMR (500 MHz, DMSO-d6) δ ppm 1.19 (t, J=7.09 Hz, 3H) 1.49 (s, 6H)2.32 (s, 4H) 3.43 (br. s., 3H) 3.73-3.79 (m, 5H) 3.95 (br. s., 3H) 6.62(s, 1H) 6.64-6.65 (m, 1H) 7.43 (d, J=8.51 Hz, 1H) 7.71 (dd, J=5.04, 1.26Hz, 1H) 7.78-7.86 (m, 1H) 7.93 (s, 1H) 8.15 (s, 1H) 8.71 (d, J=5.04 Hz,1H) 10.72 (s, 1H), LCMS (m/z) (M+H)=477.3, Rt=0.55 min.

Example 706: 2-(1,1-difluoropropyl)-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.93 (t, J=7.43 Hz, 3H) 1.16 (t, J=7.04Hz, 3H) 2.26-2.43 (m, 5H) 3.69 (br. s., 9H) 3.83-4.07 (m, 1H) 6.46-6.65(m, 1H) 7.32-7.46 (m, 1H) 7.71-7.85 (m, 1H) 7.85-7.93 (m, 1H) 7.97-8.06(m, 1H) 8.15 (s, 1H) 8.79-8.96 (m, 1H) 10.71-10.83 (m, 1H), LCMS (m/z)(M+H)=497.3, Rt=0.85 min.

Example 707:N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(oxetan-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.08-1.23 (m, 3H) 2.24-2.35 (m, 3H)3.64-3.78 (m, 7H) 3.86-3.98 (m, 1H) 4.43-4.55 (m, 1H) 4.77-4.84 (m, 1H)4.89-4.94 (m, 1H) 6.52-6.61 (m, 1H) 7.34-7.48 (m, 1H) 7.65-7.81 (m, 3H)7.86-7.94 (m, 1H) 8.76-8.86 (m, 1H) 10.59-10.67 (m, 1H), LCMS (m/z)(M+H)=475.2, Rt=0.61 min.

Example 708:2-(1-cyanocyclopropyl)-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.08-1.21 (m, 3H) 1.68-1.80 (m, 2H)1.84-1.95 (m, 2H) 2.30 (s, 3H) 3.62-3.79 (m, 5H) 3.92 (br. s., 1H)6.51-6.61 (m, 1H) 7.32-7.47 (m, 1H) 7.72-7.80 (m, 2H) 7.86-7.96 (m, 2H)8.66-8.77 (m, 1H) 10.71-10.77 (m, 1H), LCMS (m/z) (M+H)=484.2, Rt=0.76min.

Example 709:6-(2-cyanopropan-2-yl)-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.08-1.22 (m, 3H) 1.84 (s, 6H) 2.27-2.34(m, 3H) 3.41-3.52 (m, 2H) 3.60-3.79 (m, 6H) 3.83-4.00 (m, 1H) 6.51-6.62(m, 1H) 7.36-7.48 (m, 1H) 7.72-7.87 (m, 2H) 8.25-8.32 (m, 1H) 9.55-9.68(m, 1H) 10.86-10.95 (m, 1H), LCMS (m/z) (M+H)=487.3, Rt=0.7 min.

Example 710:3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl) benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.05-1.22 (m, 3H) 2.40 (s, 3H) 3.39-3.44(m, 4H) 3.64-3.94 (m, 6H) 6.54-6.69 (m, 1H) 7.40-7.49 (m, 1H) 7.54-7.69(m, 2H) 7.96-8.12 (m, 3H) 8.19-8.25 (m, 1H) 10.51-10.59 (m, 1H), LCMS(m/z) (M+H)=486.3, Rt=0.85 min.

Example 711:(R)-2-(2-cyanopropan-2-yl)-N-(3-(2-(ethylamino)-6-(3-methylmorpholino)pyrimidin-4-yl)-4-methylphenyl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.16 (s, 3H) 1.23-1.32 (m, 3H) 1.75 (s,6H) 2.30 (s, 3H) 3.46-3.55 (m, 8H) 6.48-6.58 (m, 1H) 7.37-7.44 (m, 1H)7.73-7.90 (m, 3H) 7.95-8.02 (m, 1H) 8.74-8.86 (m, 1H) 10.69-10.77 (m,1H), LCMS (m/z) (M+H)=500.3, Rt=0.78 min.

Example 712: (R)-N-(3-(2-(ethylamino)-6-(3-methylmorpholino)pyrimidin-4-yl)-4-methylphenyl)-2-(2-hydroxypropan-2-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.16 (s, 6H) 1.46 (s, 6H) 2.29 (s, 3H)3.54-3.78 (m, 2H) 3.83-4.04 (m, 1H) 6.51-6.60 (m, 1H) 7.31-7.47 (m, 1H)7.59-7.70 (m, 1H) 7.75-7.83 (m, 1H) 7.86-7.94 (m, 1H) 8.06-8.16 (m, 1H)8.60-8.73 (m, 1H) 10.61-10.73 (m, 1H), LCMS (m/z) (M+H)=491.3, Rt=0.62min.

Example 713: (S)-N-(3-(2-(ethylamino)-6-(3-methylmorpholino)pyrimidin-4-yl)-4-methylphenyl)-2-(2-hydroxypropan-2-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.10-1.20 (m, 3H) 1.23-1.31 (m, 3H)2.21-2.36 (m, 3H) 3.55-4.40 (m, 8H) 6.47-6.62 (m, 1H) 7.35-7.44 (m, 1H)7.63-7.71 (m, 1H) 7.75-7.81 (m, 1H) 7.86-7.94 (m, 1H) 8.06-8.16 (m, 1H)8.62-8.72 (m, 1H) 10.60-10.74 (m, 1H), LCMS (m/z) (M+H)=491.3, Rt=0.62min.

Example 714:(S)-2-(2-cyanopropan-2-yl)-N-(3-(2-(ethylamino)-6-(3-methylmorpholino)pyrimidin-4-yl)-4-methylphenyl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.10-1.19 (m, 3H) 1.21-1.32 (m, 3H) 1.75(s, 6H) 2.23-2.34 (m, 3H) 3.45-3.49 (m, 7H) 6.46-6.61 (m, 1H) 7.36-7.48(m, 1H) 7.75-7.91 (m, 3H) 7.95-8.03 (m, 1H) 8.75-8.86 (m, 1H)10.69-10.75 (m, 1H), LCMS (m/z) (M+H)=500.3, Rt=0.79 min.

Example 716:N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

To a solution of 4-chloro-N-ethyl-6-morpholinopyrimidin-2-amine (1.0equiv.) in DME was addedN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(Intermediate B, 1.3 equiv.), followed by PdCl2(dppf).CH2Cl2 adduct(0.10 equiv.), and 2M aqueous sodium carbonate (3.00 equiv.). Thereaction was heated in the microwave for 10 min at 120° C. LC/MS showedcompletion of the reaction. The organic phase was concentrated todryness, dissolved in DMSO, filtered through a HPLC filter and purifiedvia auto-preparative reverse phase HPLC. The pure fractions werelyophilized to yieldN-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide in 43% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.06-1.24 (m, 3H)3.29-3.47 (m, 2H) 3.64-3.76 (m, 11H) 6.62-6.75 (m, 1H) 7.63-7.86 (m, 1H)7.96-8.04 (m, 1H) 8.23-8.40 (m, 3H) 8.85-8.98 (m, 1H) 10.78-10.91 (m,1H), LCMS (m/z) (M+H)=487.1, Rt=0.73 min.

Example 717:2-(2-cyanopropan-2-yl)-N-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.01-1.24 (m, 3H) 1.75 (s, 5H) 2.29 (s,3H) 3.27-3.45 (m, 2H) 3.64-4.07 (m, 9H) 6.45-6.58 (m, 1H) 7.28-7.47 (m,1H) 7.70-7.93 (m, 3H) 7.93-8.11 (m, 1H) 8.74-8.84 (m, 1H) 10.65-10.81(m, 1H), LCMS (m/z) (M+H)=486.3, Rt=0.7 min.

Example 718:2-(2-cyanopropan-2-yl)-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.01-1.16 (m, 3H) 1.75 (s, 7H) 2.51 (br.s., 3H) 3.50-3.69 (m, 9H) 6.08-6.20 (m, 1H) 7.82-7.91 (m, 1H) 7.98-8.05(m, 1H) 8.07-8.18 (m, 1H) 8.74-8.88 (m, 2H) 10.64-10.79 (m, 1H), LCMS(m/z) (M+H)=487.2, Rt=0.65 min.

Example 719: -Synthesis ofN-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

Step 1

To a solution of 4-chloro-N-ethyl-6-morpholinopyrimidin-2-amine (1.0equiv.) in DME (0.1 M) was added6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.1 equiv.), PdCl2(dppf)-DCM adduct (0.05 equiv.) and 2M aqueous sodiumcarbonate (3.00 equiv.), and the reaction mixture was purged withnitrogen and was heated to 100° C. for 2 h. Cooled to room temperature,partitioned between water and ethyl acetate and the organic phase wasdried with sodium sulfate, filtered and concentrated to yield4-(5-amino-2-methylpyridin-3-yl)-N-ethyl-6-morpholinopyrimidin-2-amineas the desired product in 79% yield. LCMS (m/z) (M+H)=315.1, Rt=0.4 min.

Step 2

To a solution of 2-(trifluoromethyl)isonicotinic acid (1. equiv.) in DMF(0.04 M) was added EDC (1 eq) and HOAT (1 eq) followed by4-(5-amino-2-methylpyridin-3-yl)-N-ethyl-6-morpholinopyrimidin-2-amine(1.0 equiv.) and the reaction mixture was stirred at ambient temperaturefor 16 h. The reaction mixture was partitioned between water and ethylacetate, and the separated organic layer was dried sodium sulfate,filtered and concentrated. The concentrated crude was dissolved in DMSO,filtered through a HPLC filter and purified via auto-preparative reversephase HPLC. The pure fractions were lyophilized to yieldN-(3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide.

1H NMR (400 MHz, <demos>) δ ppm 1.18 (t, J=7.24 Hz, 1H) 2.50 (br. s.,12H) 3.29-3.55 (m, 1H) 3.71 (br. s., 10H) 3.78 (br. s., 13H) 6.68(br.s., 1H) 8.22 (d, J=4.70 Hz, 1H) 8.30 (br. s., 1H) 8.39 (s, 1H) 8.93(d, J=1.96 Hz, 1H) 9.04 (d, J=5.09 Hz, 1H) 11.07 (s, 1H) LCMS (m/z)(M+H)=488.8, Rt=0.62 min.

Example 720:1-ethyl-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

1H NMR (400 MHz, DMSO-d6) δ ppm 0.92-1.43 (m, 13H) 3.28-3.51 (m, 3H)4.07 (s, 5H) 6.54-6.73 (m, 1H) 8.02-8.29 (m, 2H) 8.47 (d, J=1.96 Hz, 1H)8.68-8.94 (m, 3H) 10.46-10.63 (m, 1H), LCMS (m/z) (M+H)=532.3, Rt=0.61min.

Example 721:2-(difluoromethyl)-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.18 (t, J=7.04 Hz, 5H) 3.71 (br. s., 8H)6.42-6.46 (m, 1H) 6.65-7.28 (m, 3H) 8.06-8.07 (m, 1H) 8.08 (d, J=4.70Hz, 1H) 8.21 (s, 1H) 8.31 (s, 1H) 8.93-8.97 (m, 3H) 11.04 (s, 1H), LCMS(m/z) (M+H)=470.4, Rt=0.46 min.

Example 722:3-(difluoromethyl)-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.18 (t, J=7.04 Hz, 1H) 3.20 (s, 1H) 3.42(br. s., 1H) 3.71 (br. s., 3H) 3.88 (br. s., 13H) 4.14 (br. s., 19H)6.69 (s, 3H) 7.03 (s, 1H) 7.17 (s, 2H) 7.31 (s, 1H) 7.71-7.76 (m, 5H)7.84 (d, J=7.83 Hz, 4H) 8.14-8.21 (m, 8H) 8.33 (d, J=1.57 Hz, 3H) 8.94(d, J=2.35 Hz, 3H) 10.80 (s, 3H), LCMS (m/z) (M+H)=469.3, Rt=0.62 min.

Example 723:N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-2-(2-hydroxypropan-2-yl)isonicotinamide

1H NMR (400 MHz, DMSO-d6) δ ppm 1.18 (t, J=7.04 Hz, 1H) 1.49 (s, 2H)2.54 (s, 1H) 3.42 (br. s., 2H) 6.69 (s, 1H) 7.73 (dd, J=4.89, 1.37 Hz,1H) 7.72-7.74 (m, 2H) 7.72-7.74 (m, 2H) 8.18 (s, 1H) 8.31 (d, J=1.96 Hz,1H) 8.72 (d, J=5.09 Hz, 1H) 8.94 (d, J=2.35 Hz, 1H) 10.92 (s, 1H), LCMS(m/z) (M+H)=478.8, Rt=0.47 min.

Example 724:2-(tert-butyl)-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.18 (t, J=7.04 Hz, 1H) 1.38 (s, 3H) 3.21(d, J=7.04 Hz, 1H) 3.35 (s, 1H) 3.52 (br. s., 1H) 3.59-3.64 (m, 1H) 3.71(br. s., 2H) 6.69 (s, 4H) 7.69-7.73 (m, 5H) 7.69-7.74 (m, 5H) 7.89 (s,6H) 8.29 (d, J=1.96 Hz, 5H) 8.75 (d, J=4.70 Hz, 6H) 8.94 (d, J=2.35 Hz,5H) 10.87 (s, 5H), LCMS (m/z) (M+H)=476.4, Rt=0.55 min.

Example 725: 2-(1,1-difluoroethyl)-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.18 (t, J=7.04 Hz, 1H) 2.06 (t, J=19.17Hz, 1H) 2.34-2.69 (m, 3H) 2.48-2.50 (m, 11H) 2.53-2.54 (m, 1H) 3.42 (br.s., 3H) 6.68 (s, 2H) 8.05 (d, J=4.70 Hz, 2H) 8.18-8.35 (m, 4H) 8.89-8.97(m, 4H) 11.04 (s, 2H), LCMS (m/z) (M+H)=488.8, Rt=0.62 min.

Example 726:3-(2-cyanopropan-2-yl)-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.18 (t, J=7.24 Hz, 1H) 1.76 (s, 12H)3.42 (br. s., 1H) 6.68 (br. s., 1H) 7.60-7.68 (m, 1H) 7.80 (d, J=7.83Hz, 1H) 7.98 (d, J=7.83 Hz, 1H) 8.08 (s, 1H) 8.31 (s, 1H) 8.94 (d,J=2.35 Hz, 1H) 10.71 (s, 2H), LCMS (m/z) (M+H)=486.5, Rt=0.65 min.

Example 727:6-cyclopropyl-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.02-1.19 (m, 7H) 2.27-2.37 (m, 1H)3.32-3.39 (m, 1H) 3.67-3.74 (m, 6H) 6.52-6.66 (m, 1H) 7.80-7.94 (m, 1H)8.15-8.26 (m, 1H) 8.79-8.88 (m, 1H) 9.30-9.41 (m, 1H) 10.92-11.01 (m,1H), LCMS (m/z) (M+H)=461.2, Rt=0.56 min.

Example 728:2-(1-cyanocyclopropyl)-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.03-1.14 (m, 3H) 1.51-1.59 (m, 3H)1.70-1.78 (m, 2H) 1.80-1.94 (m, 2H) 3.51-3.57 (m, 3H) 3.60-3.70 (m, 3H)6.07-6.22 (m, 1H) 7.76-7.85 (m, 1H) 7.92-7.96 (m, 1H) 8.07-8.14 (m, 1H)8.63-8.72 (m, 1H) 8.79-8.85 (m, 1H), LCMS (m/z) (M+H)=485.3, Rt=0.65min.

Example 729:N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-2-(oxetan-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.02-1.21 (m, 3H) 3.34-3.44 (m, 2H)3.79-3.94 (m, 8H) 4.41-4.60 (m, 1H) 4.76-4.88 (m, 2H) 4.88-4.94 (m, 1H)6.57-6.71 (m, 1H) 7.68-7.88 (m, 2H) 8.21-8.35 (m, 1H) 8.76-8.99 (m, 2H)10.76-10.92 (m, 1H), LCMS (m/z) (M+H)=476.2, Rt=0.51 min.

Example 730:6-(2-cyanopropan-2-yl)-N-(5-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.10-1.21 (m, 3H) 1.85 (s, 6H) 3.39-3.40(m, 9H) 3.69 (br. s., 4H) 8.20-8.43 (m, 2H) 8.84-8.93 (m, 1H) 9.60-9.70(m, 1H) 11.04-11.16 (m, 1H), LCMS (m/z) (M+H)=488.2, Rt=0.59 min.

Example 731: -Synthesis of3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methyl-N-phenylbenzamide

Step 1

To a solution of 4-chloro-N-ethyl-6-morpholinopyrimidin-2-amine (1.0equiv.) in DME (0.6 M) was added methyl4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (1.equiv.), PdCl2(dppf)-DCM adduct (0.1 equiv.) and 2M aqueous sodiumcarbonate (3.00 equiv.), and the reaction was heated in the oil bath at100° C. for 4 hours. At this time, the reaction was complete. Cooled toroom temperature, partitioned between water and ethyl acetate and theorganic phase was dried with sodium sulfate, filtered and concentrated.The crude material was purified via silica gel column chromatographyeluting with 0-100% ethyl acetate in heptanes. The pure fractions wereconcentrated under vacuo to yield methyl3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylbenzoate as thedesired product in 75% yield. LCMS (m/z) (M+H)=357.1, Rt=0.65 min.

Step 2

To a solution of methyl3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylbenzoate (1.equiv.) in THF (0.15 M) was added 2M lithium hydroxide solution and themixture was stirred at RT for 16 h. 40% of starting material stillremained when checked by LC/MS. The reaction mixture was heated 70° C.for 3 h. The reaction mixture was acidified with 1N HCl to pH=2 and wasextracted with ethyl acetate. The separated organic layer was dried withsodium sulfate and concentrated to give3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylbenzoic acid in65% yield. LCMS (m/z) (M+H)=343.4, Rt=0.56 min.

Step 3

To a solution of3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylbenzoic acid (1.equiv.) in DMF (0.01 M) was added EDC (1 eq) and HOBT (1 eq) followed byaniline (1.0 equiv.) and the reaction mixture was stirred at ambienttemperature for 16 h. The reaction mixture was partitioned between waterand ethyl acetate, and the separated organic layer was dried sodiumsulfate, filtered and concentrated. The concentrated crude was dissolvedin DMSO, filtered through a HPLC filter and purified viaauto-preparative reverse phase HPLC. The pure fractions were lyophilizedto yield3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methyl-N-phenylbenzamide.

1H NMR (400 MHz, <dmso>) δ ppm 0.94-1.35 (m, 3H) 2.38-2.41 (m, 3H)3.31-3.47 (m, 3H) 3.62-3.81 (m, 10H) 6.54-6.68 (m, 1H) 6.96-7.18 (m, 1H)7.27-7.43 (m, 2H) 7.49-7.59 (m, 1H) 7.69-7.82 (m, 2H) 7.98-8.16 (m, 2H)10.20-10.31 (m, 1H) LCMS (m/z) (M+H)=418.3, Rt=0.7 min.

Example 732: N-(3-(2-cyanopropan-2-yl)phenyl)-3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylbenzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.02-1.22 (m, 3H) 1.68 (s, 6H) 2.34-2.42(m, 3H) 3.52-3.59 (m, 3H) 3.67-3.78 (m, 5H) 3.84-4.02 (m, 1H) 6.59-6.69(m, 1H) 7.18-7.30 (m, 1H) 7.33-7.46 (m, 1H) 7.52-7.62 (m, 1H) 7.79-7.87(m, 1H) 7.91-7.98 (m, 1H) 8.00-8.15 (m, 2H) 10.33-10.44 (m, 1H), LCMS(m/z) (M+H)=485.4, Rt=0.78 min.

Example 733: N-(3-(difluoromethyl)phenyl)-3-(2-(ethylamino)-6-morpholinopyrimidin-4-yl)-4-methylbenzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.16 (s, 3H) 2.40 (s, 3H) 3.38-3.44 (m,2H) 3.69 (br. s., 6H) 3.85-4.02 (m, 2H) 6.56-6.70 (m, 1H) 6.86-6.93 (m,1H) 7.00-7.06 (m, 1H) 7.12-7.22 (m, 1H) 7.26-7.36 (m, 1H) 7.42-7.63 (m,2H) 7.83-7.97 (m, 1H) 8.01-8.11 (m, 3H) 10.41-10.50 (m, 1H), LCMS (m/z)(M+H)=468.3, Rt=0.76 min.

Synthesis of 2-((4-chloro-6-morpholinopyrimidin-2-yl) amino) ethanol

To a solution of 4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl)morpholine (1.0 equiv.) in 1:1 THF: DMF (0.17M) was added ethanolamine(2.0 equiv.) and DIEA (2 eq) at room temperature. The reaction wasstirred at ambient temperature for 16 h. The reaction was partitionedbetween water and ethyl acetate and the separated organic phase wasdried with sodium sulfate, filtered and concentrated under vacuo toyield 2-((4-chloro-6-morpholinopyrimidin-2-yl)amino)ethanol in 87%yield. LCMS (m/z) (M+H)=259.1/261, Rt=0.39 min.

Example 734: 2-(2-cyanopropan-2-yl)-N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.73 (s, 6H) 2.38 (s, 3H) 3.40 (br. s.,2H) 3.46-3.54 (m, 2H) 3.56-3.65 (m, 4H) 3.67-3.78 (m, 4H) 6.61-6.69 (m,1H) 7.22-7.35 (m, 1H) 7.42-7.49 (m, 2H) 7.57-7.67 (m, 1H) 7.67-7.75 (m,1H) 7.87-7.95 (m, 1H) 8.73-8.83 (m, 1H), LCMS (m/z) (M+H)=502.4, Rt=0.64min.

Example 735: N-(5-(2-((2-hydroxyethyl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.45-2.46 (m, 3H) 3.37-3.47 (m, 2H)3.49-3.54 (m, 2H) 3.58-3.69 (m, 8H) 6.58-6.67 (m, 1H) 7.69-7.83 (m, 1H)7.91-8.00 (m, 1H) 8.17-8.33 (m, 3H) 8.83-8.93 (m, 1H) 10.71-10.85 (m,1H), LCMS (m/z) (M+H)=503.3, Rt=0.65 min.

Example 736: 2-(2-cyanopropan-2-yl)-N-(5-(2-((2-hydroxyethyl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.76 (s, 6H) 3.56 (d, J=5.09 Hz, 8H)6.63-6.74 (m, 1H) 7.79-7.92 (m, 1H) 7.97-8.08 (m, 1H) 8.22-8.41 (m, 1H)8.83-8.99 (m, 2H) 10.88-11.01 (m, 1H), LCMS (m/z) (M+H)=503.3, Rt=0.55min.

Example 737: 6-(2-cyanopropan-2-yl)-N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)pyridazine-4-carboxamide

LCMS (m/z) (M+H)=503.2, Rt=0.61 min.

Synthesis of (S)-1-((4-chloro-6-morpholinopyrimidin-2-yl) amino)propan-2-ol

To a solution of 4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl)morpholine (1.0 equiv.) in DMF (0.18 M) was added (S)-1-aminopropan-2-ol(2.0 equiv.) and DIEA (2 eq) at room temperature. The reaction wasstirred at ambient temperature for 16 h. The reaction was partitionedbetween water and ethyl acetate and the separated organic phase wasdried with sodium sulfate, filtered and concentrated under vacuo toyield of (S)-1-((4-chloro-6-morpholinopyrimidin-2-yl)amino)propan-2-ol Iin quantitative yield. LCMS (m/z) (M+H)=273/274.9, Rt=0.44 min.

Example 738: (S)-2-(2-cyanopropan-2-yl)-N-(5-(2-((2-hydroxypropyl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.00-1.11 (m, 3H) 1.71 (s, 7H) 2.45-2.49(m, 3H) 3.15-3.25 (m, 1H) 3.30-3.43 (m, 1H) 3.60-3.68 (m, 5H) 3.74-3.84(m, 4H) 6.58-6.67 (m, 1H) 7.53-7.63 (m, 1H) 7.79-7.87 (m, 1H) 7.93-8.00(m, 1H) 8.19-8.28 (m, 1H) 8.74-8.81 (m, 1H) 8.84-8.89 (m, 1H)10.88-10.99 (m, 1H), LCMS (m/z) (M+H)=517.3, Rt=0.58 min.

Example 739: (S)-2-(2-cyanopropan-2-yl)-N-(3-(2-((2-hydroxypropyl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.99-1.11 (m, 3H) 1.70 (s, 6H) 2.22-2.31(m, 3H) 3.13-3.25 (m, 1H) 3.57-3.93 (m, 10H) 6.49-6.57 (m, 1H) 7.32-7.42(m, 2H) 7.69-7.88 (m, 3H) 7.93-7.99 (m, 1H) 8.73-8.80 (m, 1H)10.67-10.73 (m, 1H), LCMS (m/z) (M+H)=516.2, Rt=0.68 min.

Example 740: (S)-N-(5-(2-((2-hydroxypropyl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.04-1.15 (m, 3H) 2.50-2.52 (m, 3H)3.19-3.30 (m, 1H) 3.69 (br. s., 6H) 3.75-3.93 (m, 4H) 6.65-6.71 (m, 1H)7.43-7.59 (m, 1H) 7.75-7.86 (m, 1H) 7.95-8.06 (m, 1H) 8.21-8.38 (m, 3H)8.89-8.95 (m, 1H) 10.79-10.89 (m, 1H), LCMS (m/z) (M+H)=517.2, Rt=0.67min.

Synthesis of (R)-1-((4-chloro-6-morpholinopyrimidin-2-yl) amino)propan-2-ol

To a solution of 4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl)morpholine (1.0 equiv.) in DMF (0.18 M) was added (R)-1-aminopropan-2-ol(2.0 equiv.) and DIEA (2 eq) at room temperature. The reaction wasstirred at ambient temperature for 16 h. The reaction mixture waspartitioned between water and ethyl acetate and the separated organicphase was dried with sodium sulfate, filtered and concentrated undervacuo to yield of(R)-1-((4-chloro-6-morpholinopyrimidin-2-yl)amino)propan-2-ol I inquantitative yield.

LCMS (m/z) (M+H)=273/274.9, Rt=0.43 min.

Example 741: (R)-2-(2-cyanopropan-2-yl)-N-(3-(2-((2-hydroxypropyl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.03-1.11 (m, 3H) 1.75 (s, 6H) 2.26-2.35(m, 3H) 3.17-3.30 (m, 1H) 3.35-3.47 (m, 1H) 3.68-3.82 (m, 9H) 6.55-6.65(m, 1H) 7.37-7.48 (m, 2H) 7.73-7.93 (m, 3H) 7.96-8.03 (m, 1H) 8.75-8.86(m, 1H) 10.70-10.78 (m, 1H), LCMS (m/z) (M+H)=516.2, Rt=0.68 min.

Example 742: (R)-2-(2-cyanopropan-2-yl)-N-(5-(2-((2-hydroxypropyl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.00-1.11 (m, 3H) 1.71 (s, 6H) 2.46-2.47(m, 3H) 3.13-3.25 (m, 1H) 3.73-3.89 (m, 9H) 6.56-6.69 (m, 1H) 7.76-7.89(m, 1H) 7.94-8.02 (m, 1H) 8.19-8.30 (m, 1H) 8.76-8.90 (m, 2H)10.82-10.94 (m, 1H), LCMS (m/z) (M+H)=517.2, Rt=0.57 min.

Example 743: (R)-N-(5-(2-((2-hydroxypropyl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.02-1.17 (m, 3H) 2.50-2.51 (m, 3H)3.18-3.31 (m, 1H) 3.65-3.86 (m, 9H) 6.64-6.73 (m, 1H) 7.76-7.86 (m, 1H)7.97-8.04 (m, 1H) 8.23-8.36 (m, 3H) 8.87-8.95 (m, 1H) 10.80-10.88 (m,1H), LCMS (m/z) (M+H)=517.2, Rt=0.66 min.

Synthesis of (S)-2-((4-chloro-6-morpholinopyrimidin-2-yl) amino)propan-1-ol

To a solution of 4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl)morpholine (1.0 equiv.) in DMF (0.18 M) was added (S)-2-aminopropan-1-ol(2.0 equiv.) and DIEA (2 eq) at room temperature. The reaction wasstirred at ambient temperature for 16 h. As starting material remainedwhen checked by LCMS more (S)-2-aminopropan-1-ol (4.0 equiv.) and DIEA(4 eq) was added and the stirred the mixture for 5 h. The reactionmixture was partitioned between water and ethyl acetate and theseparated organic phase was dried with sodium sulfate, filtered andconcentrated under vacuo. The concentrated crude was purified via silicagel chromatography and eluted with 0 to 100% ethyl acetate in heptanesto yield to yield(S)-2-((4-chloro-6-morpholinopyrimidin-2-yl)amino)propan-1-ol in 88%yield. LCMS (m/z) (M+H)=273/274.8, Rt=0.48 min.

Example 744: (S)-2-(2-cyanopropan-2-yl)-N-(5-(2-((1-hydroxypropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.09-1.29 (m, 3H) 1.76 (s, 6H) 2.51 (s,3H) 3.70 (br. s., 12H) 6.64-6.74 (m, 1H) 7.84-7.92 (m, 1H) 8.02 (s, 1H)8.26-8.36 (m, 1H) 8.79-8.93 (m, 2H) 10.89-11.00 (m, 1H), LCMS (m/z)(M+H)=517.2, Rt=0.6 min.

Example 745: (S)-N-(5-(2-((1-hydroxypropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.04-1.18 (m, 3H) 2.45-2.48 (m, 3H)3.28-3.53 (m, 10H) 3.99-4.05 (m, 1H) 6.56-6.68 (m, 1H) 7.32-7.44 (m, 1H)7.68-7.84 (m, 1H) 7.93-8.01 (m, 1H) 8.18-8.35 (m, 3H) 8.81-8.91 (m, 1H)10.74-10.83 (m, 1H), LCMS (m/z) (M+H)=517.2, Rt=0.7 min.

Example 746: (S)-2-(2-cyanopropan-2-yl)-N-(3-(2-((1-hydroxypropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.08-1.26 (m, 3H) 1.75 (s, 6H) 2.32 (s,3H) 3.61-3.82 (m, 6H) 3.82-4.22 (m, 3H) 6.47-6.68 (m, 1H) 7.26-7.49 (m,1H) 7.70-8.10 (m, 4H) 8.76-8.86 (m, 1H) 10.68-10.77 (m, 1H), LCMS (m/z)(M+H)=516.3, Rt=0.72 min.

Synthesis of (R)-2-((4-chloro-6-morpholinopyrimidin-2-yl) amino)propan-1-ol

To a solution of 4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl)morpholine (1.0 equiv.) in DMF (0.18 M) was added (R)-2-aminopropan-1-ol(2.0 equiv.) and DIEA (2 eq) and the reaction was stirred at ambienttemperature for 16 h. As the reaction was incomplete by LCMS to it wasadded (R)-2-aminopropan-1-ol (4.0 equiv.) and DIEA (4 eq) and thestirred the mixture for 5 h. The reaction mixture was partitionedbetween water and ethyl acetate and the separated organic phase wasdried with sodium sulfate, filtered and concentrated under vacuo. Theconcentrated crude was purified via silica gel chromatography and elutedwith 0 to 100% ethyl acetate in heptanes to yield to yield(R)-2-((4-chloro-6-morpholinopyrimidin-2-yl)amino)propan-1-ol in 92%yield. LCMS (m/z) (M+H)=273/274.8, Rt=0.48 min.

Example 747: (R)-2-(2-cyanopropan-2-yl)-N-(5-(2-((1-hydroxypropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.11-1.27 (m, 3H) 1.76 (s, 6H) 2.51-2.52(m, 2H) 3.70 (br. s., 8H) 6.60-6.75 (m, 1H) 7.81-7.92 (m, 1H) 7.97-8.07(m, 1H) 8.22-8.35 (m, 1H) 8.78-8.95 (m, 2H) 10.88-10.99 (m, 1H)), LCMS(m/z) (M+H)=517.3, Rt=0.64 min.

Example 748: (R)-N-(5-(2-((1-hydroxypropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.09-1.28 (m, 3H) 2.50-2.55 (m, 3H)3.42-3.48 (m, 2H) 3.69 (d, J=4.30 Hz, 8H) 4.01-4.16 (m, 1H) 6.62-6.75(m, 1H) 7.41-7.58 (m, 1H) 7.77-7.87 (m, 1H) 7.92-8.05 (m, 1H) 8.23-8.37(m, 3H) 8.86-8.98 (m, 1H) 10.78-10.89 (m, 1H), LCMS (m/z) (M+H)=517.2,Rt=0.7 min.

Example 749: (R)-2-(2-cyanopropan-2-yl)-N-(3-(2-((1-hydroxypropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.09-1.24 (m, 3H) 1.75 (s, 6H) 2.32 (s,3H) 3.44-3.51 (m, 3H) 3.61-3.78 (m, 5H) 3.82-4.24 (m, 2H) 6.53-6.65 (m,1H) 7.35-7.45 (m, 1H) 7.64-7.93 (m, 3H) 7.97-8.05 (m, 1H) 8.72-8.87 (m,1H) 10.67-10.76 (m, 1H), LCMS (m/z) (M+H)=516.3, Rt=0.7 min.

Synthesis of 2-((4-chloro-6-morpholinopyrimidin-2-yl)amino)-2-methylpropan-1-ol

To a solution of 4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl)morpholine (1.0 equiv.) in DMF (0.18 M) was added2-amino-2-methylpropan-1-ol (2.0 equiv.) and DIEA (2 eq) at roomtemperature. The reaction was stirred at ambient temperature for 16 h.The reaction mixture was partitioned between water and ethyl acetate andthe separated organic phase was dried with sodium sulfate, filtered andconcentrated under vacuo. The concentrated crude was purified via silicagel chromatography and eluted with 0 to 100% ethyl acetate in heptanesto yield to yield(R)-2-((4-chloro-6-morpholinopyrimidin-2-yl)amino)propan-1-ol. LCMS(m/z) (M+H)=287.1, Rt=0.5 min.

Example 750:2-(2-cyanopropan-2-yl)-N-(5-(2-((1-hydroxy-2-methylpropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl) isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.36 (s, 5H) 1.76 (s, 6H) 2.53 (s, 3H)3.43-3.52 (m, 2H) 3.66-3.79 (m, 9H) 6.65-6.75 (m, 1H) 7.12-7.23 (m, 1H)7.83-7.91 (m, 1H) 7.98-8.04 (m, 1H) 8.29-8.37 (m, 1H) 8.80-8.94 (m, 2H)10.93-11.01 (m, 1H), LCMS (m/z) (M+H)=531.2, Rt=0.62 min.

Example 751:2-(2-cyanopropan-2-yl)-N-(3-(2-((1-hydroxy-2-methylpropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl) isonicotinamide

LCMS (m/z) (M+H)=530.4, Rt=0.74 min.

Example 752:N-(5-(2-((1-hydroxy-2-methylpropan-2-yl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.37 (s, 6H) 2.53 (s, 3H) 3.66-3.95 (m,8H) 6.64-6.76 (m, 1H) 7.02-7.15 (m, 1H) 7.75-7.88 (m, 1H) 7.95-8.06 (m,1H) 8.22-8.44 (m, 3H) 8.84-8.94 (m, 1H) 10.73-10.89 (m, 1H), LCMS (m/z)(M+H)=531.3, Rt=0.7 min.

Example 753: 2-(2-cyanopropan-2-yl)-N-(5-(2-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)amino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl) isonicotinamide

Synthesis of(4-((4-chloro-6-morpholinopyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)methanol

To a solution of 4-(6-chloro-2-(methylsulfonyl)pyrimidin-4-yl)morpholine(1.0 equiv.) in DMF (0.18 M) was added 2-amino-2-methylpropan-1-ol (2.0equiv.) and DIEA (2 eq) and the reaction mixture was heated to 100° C.for 48 h. The reaction mixture was partitioned between water and ethylacetate and the separated organic phase was dried with sodium sulfate,filtered and concentrated under vacuo. The concentrated crude waspurified via silica gel chromatography and eluted with 0 to 100% ethylacetate in heptanes to yield(4-((4-chloro-6-morpholinopyrimidin-2-yl)amino)tetrahydro-2H-pyran-4-yl)methanol.LCMS (m/z) (M+H)=329, Rt=0.47 min.

1H NMR (400 MHz, <dmso>) δ ppm 1.57-1.68 (m, 2H) 1.71 (s, 6H) 1.96-2.13(m, 2H) 2.47-2.56 (m, 3H) 3.67-3.86 (m, 8H) 6.63-6.72 (m, 1H) 6.99-7.11(m, 1H) 7.78-7.87 (m, 1H) 7.94-8.02 (m, 1H) 8.25-8.37 (m, 1H) 8.75-8.89(m, 2H) 10.86-10.95 (m, 1H), LCMS (m/z) (M+H)=573.4.3, Rt=0.58 min.

Example 754: 2-(2-cyanopropan-2-yl)-N-(3-(2-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl) isonicotinamide

LCMS (m/z) (M+H)=572.3, Rt=0.68 min.

Synthesis of4-(5-amino-2-methylphenyl)-N,N-dimethyl-6-morpholinopyrimidin-2-amine

Step 1

To a solution of 4-(6-chloro-2-(methylsulfonyl)pyrimidin-4-yl)morpholine(1.0 equiv.) in 1,4-dioxane (0.18 M) was added dimethylamine solution inethanol (2.0 equiv.) at room temperature. The reaction was stirred for30 min, at which point two products were observed with the desired oneas the major product. The reaction was concentrated to dryness undervacuo and the crude was purified via silica gel column chromatographyeluting with 0-100% ethyl acetate in heptanes to yield4-chloro-N,N-dimethyl-6-morpholinopyrimidin-2-amine as a white solid in57% yield. LCMS (m/z) (M+H)=243.2, Rt=0.60 min.

Step 2

To a solution of 4-chloro-N,N-dimethyl-6-morpholinopyrimidin-2-amine(1.0 equiv.) in DME (0.14 M) was added4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.3equiv.), PdCl2(dppf)-DCM adduct (0.1 equiv.) and 2M aqueous sodiumcarbonate (3.00 equiv.), and the reaction was heated to 120° C. for 35min in the microwave. LC/MS showed incomplete reaction, allowed to heatin the oil bath at 100° C. for 3 hours. At this time, the reaction wascomplete. Cooled to room temperature, partitioned between water andethyl acetate, the organic phase was dried with sodium sulfate, filteredand concentrated. The crude material was purified via silica gel columnchromatography eluting with 0-100% ethyl acetate in heptanes. The purefractions were concentrated under vacuo to yield4-(5-amino-2-methylphenyl)-N,N-dimethyl-6-morpholinopyrimidin-2-amine asthe desired product in 76% yield. LCMS (m/z) (M+H)=314, Rt=0.41 min.

Example 755:2-(2-cyanopropan-2-yl)-N-(3-(2-(dimethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.37 (s, 3H) 3.25 (s, 6H)3.78 (br. s., 5H) 4.03 (br. s., 1H) 6.52 (s, 1H) 7.42 (d, J=8.61 Hz, 1H)7.65 (dd, J=8.22, 1.96 Hz, 1H) 7.81 (dd, J=5.09, 1.17 Hz, 1H) 7.95 (d,J=1.96 Hz, 1H) 8.07 (s, 1H) 8.77 (d, J=5.09 Hz, 1H), LCMS (m/z)(M+H)=486.2, Rt=0.73 min.

Example 756:2-(1,1-difluoroethyl)-N-(3-(2-(dimethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.03 (t, J=18.59 Hz, 3H) 2.37 (s, 3H)3.25 (s, 6H) 3.78 (br. s., 5H) 6.52 (s, 1H) 7.42 (d, J=8.22 Hz, 1H) 7.66(dd, J=8.22, 2.35 Hz, 1H) 7.96 (d, J=2.35 Hz, 2H) 8.17 (s, 1H) 8.82 (d,J=5.09 Hz, 1H), LCMS (m/z) (M+H)=483.2, Rt=0.76 min.

Example 757:N-(3-(2-(dimethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.11 (t, J=7.24 Hz, 1H) 1.22 (d, J=7.04Hz, 6H) 2.23 (s, 3H) 2.84-3.25 (m, 7H) 3.63 (br. s., 3H) 7.31 (br. s.,1H) 7.55-8.04 (m, 3H) 8.63 (d, J=5.09 Hz, 1H), LCMS (m/z) (M+H)=461.1,Rt=0.54 min.

Example 758:N-(3-(2-(dimethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.37 (s, 3H) 3.25 (s, 6H) 3.78 (br. s.,5H) 6.52 (s, 1H) 7.42 (d, J=8.22 Hz, 1H) 7.67 (dd, J=8.41, 2.15 Hz, 1H)7.96 (d, J=1.96 Hz, 1H) 8.12 (d, J=4.70 Hz, 1H) 8.29 (s, 1H) 8.92 (d,J=5.09 Hz, 1H), LCMS (m/z) (M+H)=487.1, Rt=0.76 min.

Example 759:N-(3-(2-(dimethylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.37 (s, 3H) 3.25 (s, 7H) 3.78 (br. s.,7H) 6.52 (s, 1H) 7.42 (d, J=8.61 Hz, 1H) 7.68 (dd, J=8.22, 2.35 Hz, 1H)7.96 (d, J=1.96 Hz, 1H) 8.10-8.22 (m, 1H) 8.54 (s, 1H) 8.94 (d, J=5.09Hz, 1H), LCMS (m/z) (M+H)=497.1, Rt=0.63 min.

Example 760:N-(5-(2-(dimethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

To a solution of 4-chloro-N,N-dimethyl-6-morpholinopyrimidin-2-amine(1.0 equiv.) in DME was addedN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(Intermediate B, 1.3 equiv.), followed by PdCl2(dppf).CH2Cl2 adduct(0.10 equiv.), and 2M aqueous sodium carbonate (3.00 equiv.). Thereaction was heated in the microwave for 10 min at 120° C. LC/MS showedcompletion of the reaction. The organic phase was concentrated todryness, dissolved in DMSO, filtered through a HPLC filter and purifiedvia auto-preparative reverse phase HPLC. The pure fractions werelyophilized to yieldN-(5-(2-(dimethylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamideas a fluffy solid in 19% yield. 1H NMR (400 MHz, <cd3od>) δ ppm 2.57 (s,3H) 3.26 (s, 6H) 3.80 (d, J=4.70 Hz, 4H) 6.61 (s, 1H) 7.70-7.80 (m, 1H)7.94 (d, J=7.83 Hz, 1H) 8.24 (d, J=7.43 Hz, 1H) 8.30 (s, 1H) 8.46 (d,J=2.35 Hz, 1H) 8.84 (d, J=2.35 Hz, 1H), LCMS (m/z) (M+H)=487.2, Rt=0.66min.

Synthesis of 4-(6-chloro-2-ethoxypyrimidin-4-yl) morpholine

To a solution of 4-(6-chloro-2-(methylsulfonyl)pyrimidin-4-yl)morpholine(1.0 equiv.) was added 21% sodium ethoxide in ethanol (2 equiv.) and themixture was stirred at ambient temperature for 16 h. The reaction waspartitioned between water and ethyl acetate the separated organic phasewas dried with sodium sulfate, filtered and concentrated under vacuo.The concentrated crude was purified via silica gel chromatography andeluted with 0 to 100% ethyl acetate in heptanes to4-(6-chloro-2-ethoxypyrimidin-4-yl) morpholine in 87% yield. LCMS (m/z)(M+H)=244/245.9, Rt=0.71 min.

Example 761: 2-(1,1-difluoroethyl)-N-(3-(2-ethoxy-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.27 (t, J=7.04 Hz, 3H) 1.99 (t, J=19.17Hz, 3H) 2.26 (s, 3H) 3.63 (br. s., 8H) 4.33 (d, J=4.30 Hz, 2H) 6.54-6.68(m, 1H) 7.22-7.30 (m, 1H) 7.64-7.82 (m, 2H) 7.88-8.02 (m, 1H) 8.08-8.19(m, 1H) 8.75-8.88 (m, 1H) 10.55-10.73 (m, 1H), LCMS (m/z) (M+H)=484.2,Rt=0.74 min.

Example 762:N-(3-(2-ethoxy-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.27 (t, J=7.04 Hz, 3H) 2.26 (s, 3H) 3.63(br. s., 8H) 4.32 (d, J=4.30 Hz, 2H) 6.55-6.74 (m, 1H) 7.19-7.40 (m, 1H)7.66-7.83 (m, 2H) 8.03-8.20 (m, 1H) 8.25-8.38 (m, 1H) 8.88-9.01 (m, 1H)10.58-10.81 (m, 1H), LCMS (m/z) (M+H)=488.2, Rt=0.76 min.

Example 763:N-(3-(2-ethoxy-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-isopropylisonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.27 (t, J=7.04 Hz, 3H) 1.99 (t, J=19.17Hz, 3H) 2.26 (s, 3H) 3.63 (br. s., 8H) 4.33 (d, J=4.30 Hz, 2H) 6.54-6.68(m, 1H) 7.22-7.30 (m, 1H) 7.64-7.82 (m, 2H) 7.88-8.02 (m, 1H) 8.08-8.19(m, 1H) 8.75-8.88 (m, 1H) 10.55-10.73 (m, 1H), LCMS (m/z) (M+H)=484.2,Rt=0.74 min.

Example 764:2-(2-cyanopropan-2-yl)-N-(3-(2-ethoxy-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.33 (s, 3H) 1.75 (s, 6H) 2.31 (s, 3H)3.69 (d, J=2.74 Hz, 9H) 4.36-4.50 (m, 2H) 6.63-6.78 (m, 1H) 7.27-7.39(m, 1H) 7.70-7.88 (m, 3H) 7.95-8.05 (m, 1H) 8.76-8.81 (m, 1H)10.59-10.71 (m, 1H), LCMS (m/z) (M+H)=487.2, Rt=0.74 min.

Synthesis of 1-(4-chloro-6-morpholinopyrimidin-2-yl)azetidin-3-ol

To a solution of 4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl)morpholine (1.0 equiv.) in THF (0.01 M) was added azetidine-3-ol (2.0equiv.) and DIEA (2 eq) at room temperature. The reaction was stirred atambient temperature for 16 h. The reaction mixture showed 50% startingmaterial being present by LC/MS. To the mixture was added 5 ml of DMFand another portion of azetidine-3-ol (2.0 equiv.) and DIEA (2 eq) andthe mixture was stirred at ambient temperature for 4 h. The reaction waspartitioned between water and ethyl acetate the separated organic phasewas dried with sodium sulfate, filtered and concentrated under vacuo toyield 1-(4-chloro-6-morpholinopyrimidin-2-yl)azetidin-3-ol inquantitative yield. LCMS (m/z) (M+H)=271/273, Rt=0.43 min.

Example 765:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.22 (s, 3H) 3.62 (br. s., 6H) 3.78-3.96(m, 3H) 4.25-4.39 (m, 1H) 4.48-4.59 (m, 1H) 6.44-6.69 (m, 1H) 7.28-7.42(m, 1H) 7.65-7.83 (m, 3H) 7.88-7.98 (m, 1H) 8.16-8.34 (m, 2H)10.45-10.61 (m, 1H) 12.20-12.34 (m, 1H), LCMS (m/z) (M+H)=514.2, Rt=0.79min.

Example 766:3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl) benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.27-2.37 (m, 3H) 3.54-3.70 (m, 6H)3.75-3.95 (m, 3H) 4.23-4.40 (m, 1H) 4.44-4.58 (m, 1H) 7.34-7.43 (m, 1H)7.47-7.62 (m, 2H) 7.86-8.08 (m, 3H) 8.14-8.21 (m, 1H) 10.44-10.53 (m,1H), LCMS (m/z) (M+H)=514.2, Rt=0.81 min.

Example 767:2-(2-cyanopropan-2-yl)-N-(5-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)isonicotinamide

LCMS (m/z) (M+H)=515.4, Rt=0.56 min.

Example 768:N-(5-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.27-2.37 (m, 3H) 3.54-3.70 (m, 6H)3.75-3.95 (m, 3H) 4.23-4.40 (m, 1H) 4.44-4.58 (m, 1H) 7.34-7.43 (m, 1H)7.47-7.62 (m, 2H) 7.86-8.08 (m, 3H) 8.14-8.21 (m, 1H) 10.44-10.53 (m,1H), LCMS (m/z) (M+H)=515.3, Rt=0.65 min.

Example 769:N-(5-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.73 (s, 6H) 2.38 (s, 3H) 3.41-3.67 (m,4H) 3.71-4.09 (m, 3H) 4.13-4.35 (m, 1H) 4.42-4.59 (m, 1H) 6.53-6.69 (m,1H) 7.34-7.52 (m, 2H) 7.64-7.73 (m, 1H) 7.84-7.90 (m, 1H) 8.73-8.85 (m,1H), LCMS (m/z) (M+H)=514.3, Rt=0.65 min.

Example 770:3-(difluoromethyl)-N-(5-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 3.60-3.74 (m, 4H) 3.84-3.99 (m, 2H)4.27-4.43 (m, 2H) 4.49-4.69 (m, 1H) 7.12-7.17 (m, 1H) 7.63-7.79 (m, 1H)7.77-7.90 (m, 1H) 8.09-8.20 (m, 2H) 8.24-8.33 (m, 1H) 8.88-8.95 (m, 1H)10.70-10.83 (m, 1H), LCMS (m/z) (M+H)=497.3, Rt=0.57 min.

Example 771:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-isopropylisonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.22 (d, J=7.04 Hz, 6H) 2.22 (s, 3H)2.97-3.14 (m, 1H) 3.56-3.73 (m, 5H) 3.78-3.91 (m, 3H) 4.22-4.40 (m, 2H)4.45-4.58 (m, 1H) 6.46-6.60 (m, 1H) 7.29-7.39 (m, 1H) 7.60-7.63 (m, 1H)7.66-7.69 (m, 1H) 7.70-7.86 (m, 2H) 8.59-8.67 (m, 1H) 10.49-10.58 (m,1H), LCMS (m/z) (M+H)=489.2, Rt=0.61 min.

Example 772: 2-(1,1-difluoroethyl)-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) ™δ ppm 2.04 (s, 3H) 2.27 (s, 3H) 3.65-3.70 (m,6H) 3.82-3.96 (m, 4H) 4.30-4.43 (m, 2H) 4.50-4.68 (m, 1H) 6.50-6.60 (m,1H) 7.33-7.47 (m, 1H) 7.77-7.92 (m, 2H) 7.96-8.08 (m, 1H) 8.14-8.22 (m,1H) 8.79-8.94 (m, 1H) 10.70-10.84 (m, 1H), LCMS (m/z) (M+H)=511.2,Rt=0.65 min.

Example 773:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.28 (s, 3H) 3.56-3.77 (m, 6H) 3.80-3.98(m, 3H) 4.31-4.43 (m, 2H) 4.49-4.68 (m, 1H) 6.52-6.69 (m, 1H) 7.33-7.47(m, 1H) 7.76-7.91 (m, 2H) 8.12-8.22 (m, 1H) 8.32-8.40 (m, 1H) 8.93-9.07(m, 1H) 10.72-10.92 (m, 1H), LCMS (m/z) (M+H)=515.3, Rt=0.67 min.

Example 774:N-(5-(2-(4-ethylpiperazin-1-yl)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.24 (t, J=7.24 Hz, 1H) 2.38-2.67 (m, 6H)3.19 (d, J=11.74 Hz, 1H) 3.54 (d, J=11.35 Hz, 1H) 3.63-3.70 (m, 4H) 3.77(br. s., 6H) 4.74 (d, J=14.09 Hz, 1H) 6.42 (s, 1H) 7.80-7.85 (m, 2H)8.01 (d, J=7.43 Hz, 2H) 8.27 (d, J=2.35 Hz, 1H) 8.28 (br. s., 1H) 8.31(s, 1H) 8.33 (s, 2H) 8.91 (d, J=2.35 Hz, 1H) 10.79 (s, 1H), LCMS (m/z)(M+H)=556.3, Rt=0.63 min.

Example 775: N-(6-methyl-5-(6-morpholino-2-(piperazin-1-yl)pyrimidin-4-yl) pyridin-3-yl)-3-(trifluoromethyl) benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.55 (s, 1H) 3.17 (br. s., 1H) 3.29 (s,1H) 3.66 (br. s., 5H) 3.92 (br. s., 4H) 6.40 (s, 1H) 7.79-7.85 (m, 1H)8.01 (d, J=7.83 Hz, 1H) 8.23 (d, J=2.35 Hz, 1H) 8.28 (s, 1H) 8.30 (s,1H) 8.33 (s, 2H) 8.88 (d, J=2.35 Hz, 1H) 10.74 (s, 1H), LCMS (m/z)(M+H)=528.2, Rt=0.61 min.

Synthesis of tert-butyl 3-((4-chloro-6-morpholinopyrimidin-2-yl) oxy)azetidine-1-carboxylate

To N-BOC-3-azetidinol (1.2 eq) in DMF (0.36M) in a flame dried flask wasadded 60% sodium hydride (1.2 eq) followed by4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl) morpholine (1.0 equiv.)and the reaction was stirred at ambient temperature for 16 h. Thereaction was partitioned between water and ethyl acetate the separatedorganic phase was dried with sodium sulfate, filtered and concentratedunder vacuo. The concentrated crude was purified via silica gelchromatography and eluted with 0 to 100% ethyl acetate in heptanes toyield tert-butyl3-((4-chloro-6-morpholinopyrimidin-2-yl)oxy)azetidine-1-carboxylate in84% yield. LCMS (m/z) (M+H)=371.2, Rt=0.85 min.

Example 776:N-(5-(2-(azetidin-3-yloxy)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

To a solution of tert-butyl3-((4-chloro-6-morpholinopyrimidin-2-yl)oxy)azetidine-1-carboxylate (1.0equiv.) in DME was addedN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(Intermediate B, 1.0 equiv.), followed by PdCl2(dppf).CH2Cl2 adduct(0.10 equiv.), and 2M aqueous sodium carbonate (3.00 equiv.). Thereaction mixture was heated in the microwave for 20 min at 120° C. LC/MSshowed completion of the reaction. The reaction was partitioned betweenwater and ethyl acetate and the separated organic phase was dried withsodium sulfate, filtered and concentrated under vacuo. It was purifiedvia silica gel chromatography and eluted with 0 to 100% ethyl acetate inheptanes to yield tert-butyl3-((4-(2-methyl-5-(3-(trifluoromethyl)benzamido)pyridin-3-yl)-6-morpholinopyrimidin-2-yl)oxy)azetidine-1-carboxylatein 60% yield. To it was added 30% TFA in DCM and stirred for 1 h. Theconcentrated crude was dissolved in DMSO, filtered through a HPLC filterand purified via auto-preparative reverse phase HPLC. The pure fractionswere lyophilized to giveN-(5-(2-(azetidin-3-yloxy)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide.

1H NMR (400 MHz, <demos>) ppm 3.29-3.51 (m, 2H) 3.60-3.78 (m, 4H)3.82-4.10 (m, 5H) 4.14-4.27 (m, 1H) 4.32-4.43 (m, 1H) 4.58-4.66 (m, 1H)4.78 (d, J=10.17 Hz, 1H) 5.31-5.51 (m, 1H) 7.15-7.25 (m, 1H) 7.74-7.89(m, 1H) 7.98-8.07 (m, 1H) 8.24-8.34 (m, 4H) 8.43-8.53 (m, 1H) 8.83-8.90(m, 1H) 10.92-11.01 (m, 1H), LCMS (m/z) (M+H)=515.4, Rt=0.57 min.

Example 777:N-(3-(2-(azetidin-3-yloxy)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(2-cyanopropan-2-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 2.27-2.36 (m, 3H) 3.66-3.69(m, 8H) 4.01-4.14 (m, 2H) 4.29-4.40 (m, 2H) 5.25-5.38 (m, 1H) 6.60-6.69(m, 1H) 7.25-7.33 (m, 1H) 7.62-7.73 (m, 1H) 7.79-7.88 (m, 2H) 7.95-8.01(m, 1H) 8.75-8.84 (m, 1H) 10.56-10.61 (m, 1H), LCMS (m/z) (M+H)=515.4,Rt=0.58 min.

Example 778:N-(3-(2-(azetidin-3-yloxy)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-isopropylisonicotinamide

LCMS (m/z) (M+H)=489.3, Rt=0.49 min.

Example 779:N-(3-(2-(azetidin-3-yloxy)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(1,1-difluoroethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.96-2.10 (m, 3H) 2.32 (s, 3H) 3.64 (d,J=5.48 Hz, 6H) 3.98-4.12 (m, 2H) 4.27-4.43 (m, 3H) 5.27-5.40 (m, 1H)6.59-6.70 (m, 1H) 7.22-7.37 (m, 1H) 7.64-7.75 (m, 1H) 7.79-7.92 (m, 1H)7.95-8.07 (m, 1H) 8.12-8.20 (m, 1H) 8.66-8.77 (m, 1H) 8.83-8.90 (m, 1H)8.93-9.07 (m, 1H) 10.61-10.75 (m, 1H), LCMS (m/z) (M+H)=511.3, Rt=0.61min.

Example 780:N-(3-(2-(azetidin-3-yloxy)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.32 (s, 3H) 3.95-4.25 (m, 8H) 4.26-4.44(m, 3H) 5.25-5.41 (m, 1H) 6.59-6.70 (m, 1H) 7.26-7.36 (m, 1H) 7.64-7.74(m, 1H) 7.80-7.91 (m, 1H) 8.14-8.23 (m, 1H) 8.31-8.38 (m, 1H) 8.57-8.78(m, 1H) 8.92-9.06 (m, 2H) 10.67-10.78 (m, 1H), LCMS (m/z) (M+H)=515.2,Rt=0.62 min.

Synthesis(S)-3-(4-chloro-6-morpholinopyrimidin-2-yl)-4-methyloxazolidin-2-one

To a solution of (S)-4-methyloxazolidin-2-one (2 equiv.) in THF (0.27M)was added sodium hydride (2.1 equiv.) portion wise. The reaction mixturewas stirred at RT for 10 min. To the reaction mixture was added4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl) morpholine (1 equiv.) andwas stirred at RT 4 h. The reaction was partitioned between water andethyl acetate the separated organic phase was dried with sodium sulfate,filtered and concentrated under vacuo to give(S)-3-(4-chloro-6-morpholinopyrimidin-2-yl)-4-methyloxazolidin-2-one.LCMS (m/z) (M+H)=299.2, Rt=0.59 min.

Example 781:(S)-N-(6-methyl-5-(2-(4-methyl-2-oxooxazolidin-3-yl)-6-morpholinopyrimidin-4-yl)pyridin-3-yl)-3-(trifluoromethyl) benzamide

1H NMR (400 MHz, DMSO-d6) δ ppm 1.39 (d, J=5.87 Hz, 4H) 2.51-2.67 (m,5H) 3.86-4.07 (m, 3H) 4.55-4.79 (m, 2H) 6.82 (s, 1H) 7.53-7.64 (m, 1H)7.68-8.40 (m, 5H) 8.91-9.06 (m, 1H) 10.75-10.91 (m, 1H), LCMS (m/z)(M+H)=543.3, Rt=0.69 min.

Example 782:(S)-2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-(4-methyl-2-oxooxazolidin-3-yl)-6-morpholinopyrimidin-4-yl)phenyl) isonicotinamide

1H NMR (400 MHz, DMSO-d6) δ ppm 0.99-1.51 (m, 3H) 1.75 (s, 6H) 4.28-4.84(m, 2H) 6.25-6.95 (m, 1H) 7.16-8.12 (m, 7H) 8.64-8.89 (m, 1H)10.51-10.65 (m, 1H), LCMS (m/z) (M+H)=542.2, Rt=0.7 min.

Example 783:(S)-N-(4-methyl-3-(2-(4-methyl-2-oxooxazolidin-3-yl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl) benzamide

1H NMR (400 MHz, DMSO-d6) δ ppm 1.33 (d, J=6.26 Hz, 3H) 3.63 (br. s.,8H) 7.18-8.30 (m, 7H) 10.34-10.57 (m, 1H), LCMS (m/z) (M+H)=542.1,Rt=0.86 min.

Example 784:(S)-2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(2-(4-methyl-2-oxooxazolidin-3-yl)-6-morpholinopyrimidin-4-yl)pyridin-3-yl) isonicotinamide

1H NMR (400 MHz, DMSO-d6) δ ppm 1.37 (d, J=5.87 Hz, 4H) 1.54-1.86 (m,9H) 4.26-4.81 (m, 4H) 6.55-6.85 (m, 2H) 7.51 (br. s., 21H) 8.65-9.00 (m,2H) 10.72-11.01 (m, 1H), LCMS (m/z) (M+H)=543.3, Rt=0.6 min.

Example 785:(S)-2-(difluoromethyl)-N-(4-methyl-3-(2-(4-methyl-2-oxooxazolidin-3-yl)-6-morpholinopyrimidin-4-yl)phenyl)isonicotinamide

LCMS (m/z) (M+H)=525.2, Rt=0.71 min.

Synthesis of tert-butyl3-((4-chloro-6-morpholinopyrimidin-2-yl)amino)azetidine-1-carboxylate

To a solution of 4-(6-chloro-2-(methylsulfonyl) pyrimidin-4-yl)morpholine (1.0 equiv.) in DMF (0.36M) was added tert-butyl3-aminoazetidine-1-carboxylate (2.0 equiv.) and DIEA (2 eq) at roomtemperature. The reaction was stirred at ambient temperature for 16 h.The reaction was partitioned between water and ethyl acetate and theseparated organic phase was dried with sodium sulfate, filtered andconcentrated under vacuo. The concentrated crude was purified via silicagel chromatography and eluted with 0 to 100% ethyl acetate in heptanesto yield tert-butyl3-((4-chloro-6-morpholinopyrimidin-2-yl)amino)azetidine-1-carboxylate in76% yield. LCMS (m/z) (M+H)=371.2, Rt=0.85 min.

Example 786:N-(3-(2-(azetidin-3-ylamino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(2-cyanopropan-2-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) ppm 1.75 (s, 6H) 2.25-2.34 (m, 3H) 3.61-3.73(m, 6H) 3.90-4.04 (m, 1H) 4.12-4.23 (m, 1H) 4.73-4.94 (m, 1H) 7.67-7.73(m, 1H) 7.80-7.87 (m, 2H) 7.94-8.05 (m, 1H) 8.52-8.64 (m, 1H) 8.74-8.84(m, 1H), LCMS (m/z) (M+H)=513.3, Rt=0.64 min.

Example 787:N-(5-(2-(azetidin-3-ylamino)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

LCMS (m/z) (M+H)=514.3, Rt=0.63 min.

Synthesis of 2-(4-chloro-6-morpholinopyrimidin-2-yl) propan-2-ol

Step 1

To a solution of sodium cyanide (1.2 equiv.) in 1:1 DMSO: water (0.12M)and triethylenediamine (0.5 equiv.) was added4-(6-chloro-2-(methylsulfonyl)pyrimidin-4-yl)morpholine (1 equiv.) andthe mixture was stirred at RT for 16 h. As starting material remained byLC/MS to it was added sodium cyanide (4 eq) and as the reaction mixtureremained a suspension to it was added water 1:1 water: DMSO until thereaction mixture went in to a solution. It was then let stir at RT over16 h. The reaction was partitioned between water and ethyl acetate theseparated organic phase was dried with sodium sulfate, filtered andconcentrated under vacuo. The concentrated crude was purified via silicagel chromatography and eluted with 0 to 100% ethyl acetate in heptanesto yield 4-chloro-6-morpholinopyrimidine-2-carbonitrile in 20% yield.LCMS (m/z) (M+H)=243.1, Rt=0.39 min.

Step 2

To a solution of 4-chloro-6-morpholinopyrimidine-2-carbonitrile (1.0equiv.) in THF (0.024M) at −78° C. was added 3M methyl magnesium bromidein THF and the reaction mixture was stirred at that temperature for 20min. The reaction was then brought to ambient temperature and quenchedwith saturated ammonium chloride and then partitioned between water andethyl acetate. The separated organic phase was dried with sodiumsulfate, filtered and concentrated under vacuo to give1-(4-chloro-6-morpholinopyrimidin-2-yl)ethanone 87% yield. LCMS (m/z)(M+H)=242.1/244, Rt=0.59 min.

Step 3

To a solution of 1-(4-chloro-6-morpholinopyrimidin-2-yl) ethanone (1equiv.) at −78° C. in THF (0.33M) was added 3M methyl magnesium bromide(5 equiv.). The reaction mixture was stirred at −78° C. for 20 mins. Thereaction was then brought to ambient temperature and quenched withsaturated ammonium chloride and then partitioned between water and ethylacetate. The concentrated crude was purified by silica gelchromatography and eluted with 0 to 100% ethyl acetate in heptanes toyield 2-(4-chloro-6-morpholinopyrimidin-2-yl)propan-2-ol in 22% yield.

Example 788:N-(5-(2-(2-hydroxypropan-2-yl)-6-morpholinopyrimidin-4-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 1.44 (s, 6H) 3.56-3.87 (m, 7H) 7.00 (br.s., 1H) 7.70-7.82 (m, 1H) 7.91-8.02 (m, 1H) 8.17-8.35 (m, 3H) 8.82-8.88(m, 1H) 10.68-10.76 (m, 1H), LCMS (m/z) (M+H)=502.3, Rt=0.69 min.

Example 789:2-(2-cyanopropan-2-yl)-N-(3-(2-(2-hydroxypropan-2-yl)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

LCMS (m/z) (M+H)=501.1, Rt=0.68 min.

Example 790: Synthesis of2-(2-fluoropropan-2-yl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)isonicotinamide

Step 1

To 5,7-dichloropyrazolo(1,5-a)pyrimidine (1.0 eq) in Ethanol (Volume: 15mL) was added morpholine (1.0 eq) and the mixture was heated to 120° C.for 20 mins in the microwave. 50% conversion to the product was observedby LCMS. To the reaction mixture was added morpholine (1 eq) and it wasreheated in the microwave for 10 mins at 120° C. The crude reactionmixture was partitioned between ethyl acetate and water. The separatedorganic layer was dried with sodium sulfate and concentrated. Theconcentrated crude was purified via silica gel column chromatographyeluting with 0-100% ethyl acetate in heptanes. The pure fractions wereconcentrated under vacuo to4-(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)morpholine as the desiredproduct in 90% yield.

LCMS (m/z) (M+H)=239/240.8, Rt=0.63 min.

1H NMR (400 MHz, <dmso>) δ ppm 3.72-3.87 (m, 8H) 6.35-6.44 (m, 1H)6.48-6.57 (m, 1H) 8.09-8.22 (m, 1H), LCMS (m/z) (M+H)=239/240.8, Rt=0.63min.

Step 2

To a solution of 4-(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)morpholine(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.2 equiv.) in DME (0.3 M) was added sodium carbonate (2.0 equiv, 2 Maqueous solution) and the mixture was degassed for 10 mins before addingPdCl₂(dppf)-DCM adduct (0.05 equiv.) and the mixture was heated in anoil bath for 3 hours at 120° C. Methanol was added and the mixture andpartitioned between ethyl acetate and water. The organic layer was driedwith sodium sulfate, filtered, concentrated and purified by silica gelchromatography (ISCO, 0-20% methanol in DCM). The pure fractions wereconcentrated to give6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-amine in78% yield. LCMS (m/z) (M+H)=311.1, Rt=0.42 min.

Step 3

To a solution of 2-(2-fluoropropan-2-yl)isonicotinic acid (1.0 equiv.)in DMF (0.18 M) was addedN1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.0 equiv.), 1H-benzo[d][1,2,3]triazol-1-ol hydrate (1.0equiv.) and6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-amine(1.0 equiv.) and the mixture was stirred at rt overnight. The solutionwas partitioned between ethyl acetate and water. The organic phase waswashed 3× with water and brine solution, dried over sodium sulfate,filtered and concentrated. The crude material was purified via silicagel chromatography (ISCO, 0-100% ethyl acetate in heptanes, then 0-20%methanol in DCM) and again via reverse phase prep-HPLC (acetonitrile,TFA/water). The pure fractions were neutralized with solid sodiumbicarbonate and extracted with ethyl acetate. The organic phase wasdried with sodium sulfate, filtered and concentrated to give2-(2-fluoropropan-2-yl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)isonicotinamideas a white solid in 46% yield. ¹H NMR (400 MHz, <dmso>) δ ppm 1.60-1.76(m, 6H) 2.58-2.65 (m, 3H) 3.82 (s, 8H) 6.55-6.69 (m, 2H) 7.79-7.89 (m,1H) 8.02-8.10 (m, 1H) 8.17-8.24 (m, 1H) 8.33-8.42 (m, 1H) 8.70-8.85 (m,1H) 8.94-9.05 (m, 1H) 10.88-10.97 (m, 1H), LCMS (m/z) (M+H)=476.2,Rt=0.64 min.

Example 791: 2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.76 (s, 6H) 2.60-2.71 (m, 3H) 3.72-3.93(m, 8H) 6.58-6.71 (m, 2H) 7.85-7.95 (m, 1H) 8.03-8.08 (m, 1H) 8.18-8.25(m, 1H) 8.42-8.48 (m, 1H) 8.78-8.87 (m, 1H) 9.00-9.13 (m, 1H)10.97-11.08 (m, 1H), LCMS (m/z) (M+H)=483.2, Rt=0.64 min.

Example 792:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)isonicotinamide

LCMS (m/z) (M+H)=482.2, Rt=0.7 min.

Example 793:N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.58-2.70 (m, 3H) 3.79-3.84 (m, 8H)6.56-6.68 (m, 2H) 7.76-7.85 (m, 1H) 7.93-8.06 (m, 1H) 8.13-8.23 (m, 1H)8.26-8.37 (m, 2H) 8.39-8.46 (m, 1H) 8.98-9.09 (m, 1H) 10.80-10.91 (m,1H), LCMS (m/z) (M+H)=483.4, Rt=0.74 min.

Example 794:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)isonicotinamide

LCMS (m/z) (M+H)=473.2, Rt=0.54 min.

Example 795:6-(2-cyanopropan-2-yl)-N-(4-methyl-3-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.84 (s, 6H) 2.35-2.42 (m, 3H) 3.74-3.89(m, 8H) 6.44-6.52 (m, 1H) 6.57-6.66 (m, 1H) 7.30-7.42 (m, 1H) 7.75-7.91(m, 2H) 8.16-8.23 (m, 1H) 8.26-8.34 (m, 1H) 9.55-9.69 (m, 1H)10.77-10.83 (m, 1H), LCMS (m/z) (M+H)=483.2, Rt=0.65 min.

Example 796:2-(1-cyanocyclopropyl)-N-(4-methyl-3-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.73-1.78 (m, 2H) 1.84-1.88 (m, 2H)2.34-2.40 (m, 3H) 3.74-3.92 (m, 8H) 6.42-6.50 (m, 1H) 6.55-6.64 (m, 1H)7.27-7.40 (m, 1H) 7.73-7.82 (m, 2H) 7.84-7.97 (m, 2H) 8.12-8.22 (m, 1H)8.62-8.75 (m, 1H) 10.58-10.66 (m, 1H)), LCMS (m/z) (M+H)=480.1, Rt=0.7min.

Example 797:2-(2-hydroxypropan-2-yl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.49 (s, 6H) 2.59-2.73 (m, 3H) 3.66-3.91(m, 9H) 6.53-6.69 (m, 2H) 7.71-7.81 (m, 1H) 8.16-8.27 (m, 2H) 8.44-8.57(m, 1H) 8.68-8.79 (m, 1H) 9.04-9.14 (m, 1H) 10.99-11.08 (m, 1H), LCMS(m/z) (M+H)=474.1, Rt=0.5 min.

Example 798:N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.52-2.62 (m, 3H) 3.69-3.83 (m, 7H)6.43-6.63 (m, 2H) 8.12-8.22 (m, 2H) 8.28-8.41 (m, 2H) 8.88-9.01 (m, 2H)10.90-11.01 (m, 1H), LCMS (m/z) (M+H)=484.2, Rt=0.66 min.

Example 799:2-(1,1-difluoroethyl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.91-2.12 (m, 3H) 2.55-2.65 (m, 4H) 3.82(s, 8H) 6.57-6.59 (m, 1H) 6.62-6.64 (m, 1H) 8.00-8.10 (m, 1H) 8.17-8.27(m, 2H) 8.29-8.38 (m, 1H) 8.84-9.01 (m, 2H) 10.88-10.97 (m, 1H), LCMS(m/z) (M+H)=480.2, Rt=0.65 min.

Example 800:2-(1,1-difluoropropyl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.85-1.02 (m, 3H) 2.54-2.62 (m, 4H) 3.82(s, 8H) 6.55-6.59 (m, 1H) 6.61-6.66 (m, 1H) 7.98-8.10 (m, 1H) 8.15-8.26(m, 2H) 8.29-8.37 (m, 1H) 8.85-9.02 (m, 2H) 10.86-10.98 (m, 1H)), LCMS(m/z) (M+H)=494.1, Rt=0.69 min.

Example 801:N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 2.56 (s, 3H) 3.77 (s, 8H) 6.48-6.64 (m,2H) 8.08-8.20 (m, 1H) 8.22-8.34 (m, 1H) 8.63-8.75 (m, 1H) 8.82-8.95 (m,1H) 9.83-9.97 (m, 1H) 11.00-11.19 (m, 1H), LCMS (m/z) (M+H)=485.1,Rt=0.61 min.

Example 802:2-(1-cyanocyclopropyl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.71-1.80 (m, 2H) 1.83-1.94 (m, 2H)2.57-2.62 (m, 3H) 3.82 (s, 8H) 6.53-6.68 (m, 2H) 7.79-7.84 (m, 1H)7.94-7.99 (m, 1H) 8.17-8.25 (m, 1H) 8.32-8.38 (m, 1H) 8.68-8.77 (m, 1H)8.92-9.01 (m, 1H) 10.85-10.94 (m, 1H), LCMS (m/z) (M+H)=481.1, Rt=0.61min.

Example 803:2-(difluoromethyl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.53-2.62 (m, 3H) 3.69-3.86 (m, 8H)6.52-6.65 (m, 2H) 7.00-7.08 (m, 1H) 8.00-8.07 (m, 1H) 8.14-8.20 (m, 2H)8.30-8.39 (m, 1H) 8.83-8.90 (m, 1H) 8.95-9.03 (m, 1H) 10.93-11.01 (m,1H), LCMS (m/z) (M+H)=466.1, Rt=0.6 min.

Example 804:3-(difluoromethyl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)benzamide

1H NMR (400 MHz, <dmso>) δ ppm 2.56-2.63 (m, 4H) 3.82 (s, 8H) 6.53-6.67(m, 2H) 7.64-7.73 (m, 1H) 7.77-7.84 (m, 1H) 8.11-8.25 (m, 3H) 8.33-8.47(m, 1H) 8.94-9.04 (m, 1H) 10.69-10.77 (m, 1H) LCMS (m/z) (M+H)=465.1,Rt=0.67 min.

Example 805:2-(difluoromethyl)-N-(4-methyl-3-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.30-2.34 (m, 2H) 3.26-3.30 (m, 4H)3.70-3.86 (m, 8H) 6.37-6.46 (m, 1H) 6.50-6.60 (m, 1H) 7.25-7.34 (m, 1H)7.70-7.89 (m, 2H) 8.06-8.21 (m, 2H) 8.42-8.52 (m, 1H) 8.87-8.99 (m, 1H)10.74-10.83 (m, 1H), LCMS (m/z) (M+H)=465.3, Rt=0.68 min.

Example 806:N-(4-methyl-3-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.37 (s, 3H) 3.81 (s, 9H) 6.42-6.51 (m,1H) 6.55-6.63 (m, 1H) 6.87-6.96 (m, 1H) 7.00-7.09 (m, 1H) 7.15-7.23 (m,1H) 7.29-7.36 (m, 1H) 7.77-7.84 (m, 1H) 7.87-7.95 (m, 1H) 8.03-8.09 (m,1H) 8.14-8.22 (m, 2H) 8.85-8.93 (m, 1H) 10.64-10.73 (m, 1H), LCMS (m/z)(M+H)=493.2, Rt=0.59 min.

Example 807:N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.61 (s, 3H) 3.27-3.41 (m, 3H) 3.78-3.89(m, 8H) 6.51-6.70 (m, 2H) 8.14-8.25 (m, 2H) 8.34-8.38 (m, 1H) 8.56-8.61(m, 1H) 8.94-9.07 (m, 2H) 11.06-11.11 (m, 1H), LCMS (m/z) (M+H)=494.1,Rt=0.53 min.

Example 808:6-(2-cyanopropan-2-yl)-N-(6-methyl-5-(7-morpholinopyrazolo[1,5-al]pyrimidin-5-yl)pyridin-3-yl)pyridazine-4-carboxamide

1H NMR (400 MHz, <dmso>) δ ppm 1.84 (s, 6H) 2.58-2.63 (m, 3H) 3.82 (s,8H) 6.52-6.70 (m, 2H) 8.15-8.24 (m, 1H) 8.31-8.37 (m, 2H) 8.92-8.97 (m,1H) 9.62-9.71 (m, 1H) 11.02-11.09 (m, 1H), LCMS (m/z) (M+H)=484.2,Rt=0.58 min.

Example 810:N-(6-methyl-5-(7-morpholinopyrazolo[1,5-a]pyrimidin-5-yl)pyridin-3-yl)-4-(trifluoromethyl)picolinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.56-2.61 (m, 3H) 3.82 (s, 8H) 6.51-6.70(m, 2H) 8.07-8.13 (m, 1H) 8.18-8.24 (m, 1H) 8.32-8.40 (m, 1H) 8.50-8.56(m, 1H) 8.99-9.15 (m, 2H) 11.15-11.22 (m, 1H), LCMS (m/z) (M+H)=484.1,Rt=0.7 min.

Example 811:(R)-N-(4-methyl-3-(4-(3-methylmorpholino)-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

A solution of 2-bromo-N-methyl-5-nitro-4-pyridinamine (1.0 equiv.) inconc. HCl (0.29 M) in a 500 ml RB was heated to 90° C. Tin(II) chloridedihydrate (5 equiv.) was added portion wise and the resulting mixturewas stirred at 90° C. for 90 min. and allowed to cool to RT. The acidicsolution was cooled to RT and concentrated until about of liquid wasleft. The mixture was poured in an ice bath and made basic (pH-10) bycautious addition of 50% aqueous NaOH while stirring. The suspension wasextracted with EtOAc and the combined organic extracts were dried overNa₂SO₄. The solvent was evaporated to give6-bromo-2-chloropyridine-3,4-diamine in 89% yield as a low melting brownsolid. Product was used without further purification. LCMS (m/z)(M+H)=222/224/226, Rt=0.44 min.

Step 2

Acetic anhydride (9.0 equiv.) was added to a solution of6-bromo-2-chloropyridine-3,4-diamine (1.0 equiv.) in triethylorthoformate (6.0 equiv.), and the resulting mixture was heated at 60°C. for about 2 min and slowly increased to 90° C. and maintained at thistemperature for 6 hr, then allowed to cool to room temperature. Thereaction mixture was concentrated to dryness, then dissolved in aqueousNaOH (10 M, 14.0 equiv.) and stirred at 55° C. for 30 minutes. Aftercooling, the mixture was acidified using glacial acetic acid until pH 6.The suspension was stirred in an ice bath for 1 hr, then filtered offand washed with small amounts of water The precipitate was dissolved ina 1:2 THF: ether solution. The solution was dried over sodium sulfate,filtered and concentrated, giving6-bromo-4-chloro-1H-imidazo[4,5-c]pyridine (4.7 g, 20.22 mmol, 100%yield) as a brown solid. LCMS (m/z) (M+H)=231.9/233.9/235.9, Rt=0.48min.

Step 3

6-bromo-4-chloro-1H-imidazo[4,5-c]pyridine (1.0 equiv.),(R)-3-methylmorpholine (5.0 equiv.), TEA (2.0 equiv.) in NMP (1.4 M)were mixed in a 20 mL vessel, sealed and heated at 140° C. for 72 hours.The reaction vessel was left to reach RT and the mixture was partitionedbetween EtOAc and water. The aqueous layer was extracted three timeswith EtOAc. The combined organics were washed with brine dried oversodium sulfate, filtered and concentrated. The residue was purified viaflash chromatography over silica gel eluting with heptane and 0-70%EtOAc gradient.(R)-4-(6-bromo-1H-imidazo[4,5-c]pyridin-4-yl)-3-methylmorpholine wasisolated as a light yellow solid in 58% yield. LCMS (m/z) (M+H)=297/299,Rt=0.65 min.

Step 4

To a solution of(R)-4-(6-bromo-1H-imidazo[4,5-c]pyridin-4-yl)-3-methylmorpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DME (0.1 M) was added Na₂CO₃ (3.0 equiv.) and the systemwas flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂ adduct (0.1equiv.) was added and the system was flushed once again. The vial wascapped and place in a microwave reactor for 20 minutes at 120° C. Thereaction mix was partitioned in EtOAc/H₂O. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crude waspurified by HPLC.(R)-N-(4-methyl-3-(4-(3-methylmorpholino)-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-3-(trifluoromethyl)benzamidewas obtained in 12% yield. 1H NMR (400 MHz, <dmso>) b ppm 1.17 (br. s.,1H) 2.26 (br. s., 3H) 2.60 (d, J=1.57 Hz, 1H) 3.51 (br. s., 1H) 3.68(br. s., 2H) 3.90 (d, J=9.39 Hz, 1H) 5.37 (br. s., 1H) 6.88 (br. s., 1H)7.21 (br. s., 1H) 7.57-7.83 (m, 2H) 7.91 (d, J=7.83 Hz, 1H) 8.14-8.29(m, 2H) 10.28-10.47 (m, 1H). LCMS (m/z) (M+H)=496 at Rt=0.77 mins.

Example 812:N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

Sulfuric acid (3:1 ratio to nitric acid) was cooled to 0° C. and2,6-dichloropyridin-4-amine (1.0 equiv.) was added portion wise so thatthe rate of addition did not increase the internal temperature above 10°C. The mixture was cooled to −5° C. and 90% nitric acid fuming (0.746 Mfinal concentration) was added over a period of 30 minutes ensuring thatthe internal temperature remained at 0° C. The reaction was continuedfor 2 hr at 0° C. The reaction mixture was poured on ice water andstirred at 0° C. for 30 minutes, then filtered. The filter cake wassuspended in water and stirred for 15 minutes, then filtered, and driedby azeotroping with toluene. N-(2,6-dichloropyridin-4-yl)nitramide wasobtained in 94% yield and used as is in the next step. LCMS (m/z)(M+H)=207.9/209.9, Rt=0.70 min.

Step 2

N-(2,6-dichloropyridin-4-yl)nitramide (1.0 equiv.) was added portionwise to a flask containing sulfuric acid (1 M) making sure that thetemperature did not rise above 40° C. The reaction was then heated at100° C. for 1 h. The resulting mixture was red clear. The reactionmixture was poured on ice water and the pH was adjusted to 9.5 byaddition of 10N sodium hydroxide solution and then stirred for 10minutes at RT. The precipitate was collected by filtration, suspended inwater, stirred for 15 minutes and filtered. The water was removed byazeotroping with toluene. The desired2,6-dichloro-3-nitropyridin-4-amine was isolated in 90% yield and usedas is in the next step. LCMS (m/z) (M+H)=207.9/209.9, Rt=0.68 min.

Step 3

Raney Nickel (1.0 equiv.) was washed with water (3 times) and methanol(3 times) and was then transferred as slurry into a flask containing2,6-dichloro-3-nitropyridin-4-amine (1.0 equiv.) in MeOH (0.155 M) undernitrogen. The reaction mix was then hydrogenated overnight underatmospheric pressure. The system was purged with nitrogen and thereaction mixture was filtered over a celite pad. The filtrate wasconcentrated to give 2,6-dichloropyridine-3,4-diamine as a brown solidin 96% yield which was used as is in next step. LCMS (m/z) (M+H)=179.8,Rt=0.31 min.

Step 4

2,6-dichloropyridine-3,4-diamine (1.0 equiv.) in triethyl orthoformate(6.0 equiv.) and acetic anhydride (9.0 equiv.) in a round bottom flaskwas fitted a condenser and the mixture was warmed to 60° C. and then thetemperature was increased to 90° C. and the mixture was stirred at thattemperature for 5 hr. LCMS showed acetylated product LCMS (m/z)(M+H)=229.8/231.7 Rt=0.64 mins. The reaction mixture was concentratedand then dissolved in 10% NaOH (1.0 equiv.) and warmed at 60° C. for 30mins when complete conversion to the desired product was observed. Thereaction mix was cooled to room temperature, treated with acetic aciduntil pH=6 and the mixture cooled to 0° C. for 20 mins. The brown solidthat formed was filtered and then azeotroped with toluene to give4,6-dichloro-1H-imidazo[4,5-c]pyridine in quantitative yield. Productwas used as is in the next step. LCMS (m/z) (M+H)=187.9/189.8 Rt=0.45min.

Step 5

4,6-dichloro-1H-imidazo[4,5-c]pyridine (1.0 equiv.) and morpholine (2.0equiv.) in ethanol (0.7 M) were stirred at 120° C. in a sealed tubeovernight. Some starting material was still present, therefore 2equivalents of morpholine were added and the reaction left for 6 hruntil reaction completion. The cooled reaction mixture was concentratedto dryness. Crude 4-(6-chloro-1H-imidazo[4,5-c]pyridin-4-yl)morpholinewas used as is in the next step. LCMS (m/z) (M+H)=239.2 Rt=0.51 min.

Step 6

To a solution of 4-(6-chloro-1H-imidazo[4,5-c]pyridin-4-yl)morpholine(1.0 equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv) in DME (0.1 M) was added 2M Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thevial was capped and place in a microwave reactor for 20 minutes at 120°C. The reaction mix was partitioned in EtOAc/H₂O. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crude waspurified by HPLC givingN-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 16% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.29 (s,3H) 4.15 (br. s., 3H) 7.08 (br. s., 1H) 7.33 (br. s., 1H) 7.68-7.82 (m,2H) 7.86 (br. s., 1H) 7.96 (d, J=7.83 Hz, 1H) 8.16-8.38 (m, 2H) 10.52(br. s., 1H). LCMS (m/z) (M+H)=482 at Rt=0.76 mins.

Example 813:N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-3-(methylsulfonyl)benzamide

Step 1

To a solution of 4-(6-chloro-1H-imidazo[4,5-c]pyridin-4-yl)morpholine(1.0 equiv's),4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.2equiv's), in DME (12 mL) and 2M aqueous Na₂CO₃ (6.00 mL) was addedPdCl₂(dppf).CH2Cl2 adduct (0.05 equiv's). The resulting mixture was thendegassed by bubbling Ar through for 15 mins. The stirred mixture wasthen heated to 95° C. After 6 h, additional PdCl₂(dppf).CH₂Cl₂ adduct(0.1 equiv's) was added and continued refluxing for 22 h. The mixturewas then allowed to cool to RT, then filtered through Celite rinsingwell with EtOAc. The solvent was evaporated under reduced pressure, andthe residue then partitioned between EtOAc and 1M NaOH. The organicswere separated, then washed with 1M NaOH (×2), sat. brine (×4) thendried, (Na2SO4), filtered and evaporated under reduced. The residue waspurified by silica gel chromatography eluting with 0-12% MeOH/CH2Cl2increasing to 17% MeOH/CH2Cl2 to give4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)aniline in 40%yield as a tan solid. LCMS (m/z) (M+H)=310.1, Rt=0.37 min.

Step 2

To a solution of6-methyl-5-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)pyridin-3-amine(1.0 equiv's), 3-(methylsulfonyl)benzoic acid (1.0 equiv's) and1-hydroxy-7-azabenzotriazole (HOAT) (1.3 equiv's) in DMA (0.7 mL) wasadded Et3N (1.3 equiv's). After 5 mins, EDC.HCl (1.3 equiv's) was added.After 5 d the homogeneous reaction mixture was diluted with DMSO andwater then filtering through 0.45 micron filter and the solutionpurified by reverse phase prep HPLC. The pure fractions were collectedand lyophallised to giveN-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-3-(methylsulfonyl)benzamidein 26% yield as the TFA salt. 1H NMR (500 MHz, <dmso>) b ppm 2.30 (br.s., 5H) 3.30 (s, 5H) 3.80 (br. s., 6H) 4.17 (br. s., 3H) 7.35 (br. s.,1H) 7.67-7.97 (m, 3H) 8.15 (d, J=7.57 Hz, 1H) 8.30 (d, J=7.88 Hz, 1H)8.49 (s, 1H). LCMS (m/z) (M+H)=492.0 at Rt=0.58 mins.

Example 814:1-ethyl-3-methyl-N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-1H-pyrazole-4-carboxamide

This compound was prepared following the same procedures described forExample 813. 1H NMR (500 MHz, <dmso>) δ ppm 1.39 (t, J=7.25 Hz, 3H) 2.26(s, 3H) 2.35 (s, 3H) 3.80 (br. s., 4H) 4.10 (q, J=7.25 Hz, 2H) 4.18 (br.s., 4H) 7.10 (br. s., 1H) 7.28 (br. s., 1H) 7.66 (d, J=7.57 Hz, 1H) 7.83(br. s., 1H) 8.36 (s, 1H) 9.75 (br. s., 1H). LCMS (m/z) (M+H)=446.2,Rt=0.57 mins.

Example 815:1,3-dimethyl-N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-1H-pyrazole-4-carboxamide

This compound was prepared following the same procedures described forExample 813. LCMS (m/z) (M+H)=432.2, Rt=0.53 mins.

Example 816:1-isopropyl-3-methyl-N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-1H-pyrazole-4-carboxamide

This compound was prepared following the same procedures described forExample 813. LCMS (m/z) (M+H)=460.2, Rt=0.61 mins.

Example 817:1,3-dimethyl-N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-1H-pyrazole-5-carboxamide

This compound was prepared following the same procedures described forExample 813. LCMS (m/z) (M+H)=432.2, Rt=0.57 mins.

Example 818:3-cyclopropyl-1-methyl-N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-1H-pyrazole-5-carboxamide

This compound was prepared following the same procedures described forExample 813. LCMS (m/z) (M+H)=458.2, Rt=0.64 mins.

Example 820:5-cyclopropyl-N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)isoxazole-3-carboxamide

This compound was prepared following the same procedures described forExample 813. LCMS (m/z) (M+H)=445.1, Rt=0.68 mins.

Example 821:N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-2-(methylsulfonyl)isonicotinamide

This compound was prepared following the same procedures described forExample 813. LCMS (m/z) (M+H)=493.1, Rt=0.55 mins.

Example 822:N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)-3-(1,3,4-oxadiazol-2-yl)benzamide

This compound was prepared following the same procedures described forExample 813. LCMS (m/z) (M+H)=482.1, Rt=0.60 mins.

Example 823:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(4-morpholino-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)isonicotinamide

This compound was prepared following the same procedures described forExample 813. LCMS (m/z) (M+H)=473.3, Rt=0.51 mins.

Example 824:N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyrazin-6-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To 3,5-dibromopyrazin-2-amine (1.0 equiv.) in DMF (0.4 M) was addedchloroacetaldehyde 50% in water (10.0 equiv.) and the mixture was heatedto 100° C. for 16 hr. The reaction mixture was concentrated to a slurryand the crude 6,8-dibromoimidazo[1,2-a]pyrazine was used as such in thenext step. Yield is assumed to be quantitative. LCMS (m/z)(M+H)=275.9/277.9/279.9 at Rt=0.51 mins.

Step 2

6,8-Dibromoimidazo[1,2-a]pyrazine (1.0 equiv.) and morpholine (10.0equiv.) were stirred in a sealed tube at 60° C. for 4 hr. The crude wastransferred to a round bottom flask and concentrated to dryness. Thereaction mixture was purified via flash chromatography over silica geleluting with heptane and 0-80% EtOAc gradient.4-(6-Bromoimidazo[1,2-a]pyrazin-8-yl)morpholine was isolated in 67%yield. LCMS (m/z) (M+H)=285 at Rt=0.69 mins.

Step 3

To a solution of 4-(6-bromoimidazo[1,2-a]pyrazin-8-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thevial was capped and place in a microwave reactor for 20 minutes at 120°C. The reaction mix was partitioned in EtOAc/H₂O. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crude waspurified by HPLC givingN-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyrazin-6-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 32% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.35 (s,3H) 4.14-4.26 (m, 4H) 7.27 (d, J=8.22 Hz, 1H) 7.60 (d, J=0.78 Hz, 1H)7.70 (dd, J=8.41, 2.15 Hz, 1H) 7.78 (t, J=7.83 Hz, 1H) 7.87 (d, J=2.35Hz, 1H) 7.92-8.02 (m, 2H) 8.10 (s, 1H) 8.21-8.33 (m, 2H) 10.40-10.54 (m,1H). LCMS (m/z) (M+H)=482 at Rt=0.88 mins.

Example 825:(R)-N-(4-methyl-3-(8-(3-methylmorpholino)imidazo[1,2-a]pyrazin-6-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To 3,5-dichloropyrazin-2-amine (1.0 equiv.) in DMF (1.0 M) was addedchloroacetaldehyde 50% in water (10.0 equiv.) and the mixture was heatedto 100° C. for 16 hr. The reaction mixture was concentrated to a slurryand the crude 6,8-dibromoimidazo[1,2-a]pyrazine was used as such in thenext step. Yield is assumed to be quantitative. LCMS (m/z)(M+H)=188/190/192 at Rt=0.46 mins.

Step 2

6,8-Dichloroimidazo[1,2-a]pyrazine (1.0 equiv.) and(R)-3-methylmorpholine (3.0 equiv.) were stirred in a sealed tube at 50°C. for 3 hr. Some product was observed, additional 2 equiv of(R)-3-methylmorpholine were added, the temperature increased to 65° C.and the reaction was left overnight. The crude was transferred to around bottom flask and concentrated to dryness. The reaction mixture waspurified via flash chromatography over silica gel eluting with heptaneand 0-30% EtOAc gradient.(R)-4-(6-chloroimidazo[1,2-a]pyrazin-8-yl)-3-methylmorpholine wasisolated in 97% yield. LCMS (m/z) (M+H)=253/255 at Rt=0.77 mins.

Step 3

To a solution of(R)-4-(6-chloroimidazo[1,2-a]pyrazin-8-yl)-3-methylmorpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 15 minutes at 120° C. Some starting material was still present.Additional 0.3 equiv. ofN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamideand 0.1 equiv of the palladium catalyst were added and the system wasflushed with nitrogen. The vial was capped and placed in the microwavereactor for 15 minutes at 120° C. The reaction mix was partitioned inEtOAc/H₂O. The organic layer was isolated, dried over Na₂SO₄, filteredand concentrated. The crude was purified by HPLC giving(R)-N-(4-methyl-3-(8-(3-methylmorpholino)imidazo[1,2-a]pyrazin-6-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 8% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.12-1.33(m, 3H) 2.30 (s, 3H) 3.21-3.38 (m, 1H) 3.50 (td, J=11.74, 2.35 Hz, 2H)4.97 (br. s., 1H) 5.51 (br. s., 1H) 7.18-7.33 (m, 1H) 7.54 (s, 1H) 7.65(dd, J=8.22, 1.96 Hz, 1H) 7.73 (t, J=7.83 Hz, 1H) 7.81 (d, J=2.35 Hz,1H) 7.87-7.96 (m, 2H) 8.02 (s, 1H) 8.12-8.31 (m, 2H) 10.41 (s, 1H). LCMS(m/z) (M+H)=496 at Rt=0.88 mins.

Example 826:N-(4-methyl-3-(5-morpholino-2-oxo-2,3-dihydrobenzo[d]oxazol-7-yl)phenyl)-3-(trifluoromethyl)benzamideand Example 827:N-(4-methyl-3-(7-morpholino-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)-3-(trifluoromethyl) benzamide

Step 1

3,5-dibromo-2-hydroxybenzoic acid (1.0 equiv.), triethylamine (1.0equiv.) and diphenyl phosphoryl azide (1.0 equiv.) were suspended intoluene (1.7 M) and the reaction mix was heated at 110° C. for 20 hr.The reaction mix was cooled to RT, quenched with brine and extractedwith EtOAc. The isolated organic was washed twice with saturatedsolution of sodium bicarbonate, dried over MgSO4, filtered andconcentrated. The crude material was purified via flash chromatographyover silica gel eluting with heptane and 0-40% EtOAc gradient. Isolated5,7-dibromobenzo[d]oxazol-2(3H)-one in 63% yield as a white solid. LCMS(m/z) (M+H)=490./492.9/494.9, Rt=0.80 min.

Step 2

To a solution of 5,7-dibromobenzo[d]oxazol-2(3H)-one (1.0 equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DME (0.68 M) was added Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.)was added to the reaction mix and the system was flushed with nitrogenonce again. The vial was capped and microwaved for 20 minutes at 120° C.The crude was partitioned in H2O/EtOAc and the organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crudematerial was purified via flash chromatography over silica gel elutingwith heptane and 0-50% EtOAc gradient. The reaction gave an almost 1:1ratio of the two possible products(N-(3-(5-bromo-2-oxo-2,3-dihydrobenzo[d]oxazol-7-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamideandN-(3-(7-bromo-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide)which were taken together into the next step. LCMS (m/z) (M+H)=493.1 atRt=1.07 and 1.08.

Step 3

A mixture ofN-(3-(5-bromo-2-oxo-2,3-dihydrobenzo[d]oxazol-7-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamideandN-(3-(7-bromo-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.), morpholine (4.0 equiv.), RuPhos precatalyst (0.1 equiv.),2-dicyclohexylphosphino-2″,6″-diisopropoxybiphenyl (0.1 equiv.) weredissolved in THF (0.055) and the system was purged with nitrogen. HMDS(7.0 equiv.) was added to the mix and the reaction vessel was sealed andheated at 70° C. overnight. The reaction mixture was cooled to roomtemperature, diluted with a saturated solution of NH4Cl and extractedthree times with EtOAc. The combined organics were dried over MgSO4,filtered and concentrated. The crude material was purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(4-methyl-3-(5-morpholino-2-oxo-2,3-dihydrobenzo[d]oxazol-7-yl)phenyl)-3-(trifluoromethyl)benzamideandN-(4-methyl-3-(7-morpholino-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)-3-(trifluoromethyl)benzamidewere isolated as the TFA salt in 9 and 8% yield respectively. LCMS (m/z)(M+H)=498 at Rt=0.84 and LCMS (m/z) (M+H)=498 at Rt=0.93. Structureassignment is tentative; no HNMR data available at this time.

Example 828:N-(4-methyl-3-(5-morpholinoimidazo[1,2-c]pyrimidin-7-yl)phenyl)-3-(trifluoromethyl)benzamid

Step 1

To 6-chloro-2-(methylthio)pyrimidin-4-amine (1.0 equiv.) in EtOH (0.7M)) was added chloroacetaldehyde 50% in water (10.0 equiv.) and themixture was refluxed for 3 h. LCMS showed product (m/z) (M+H)=200 atRt=0.41 mins and small amounts of starting material. Reaction was leftfor additional 40 minutes. The reaction mixture was cooled to RT andconcentrated. The residue was dissolved in DCM, washed with saturatedsolution of sodium bicarbonate, brine, dried over sodium sulfate,filtered and concentrated. The crude material was purified via flashchromatography over silica gel eluting with DCM and 0-4% MeOH gradient.The desired 7-chloro-5-(methylthio)imidazo[1,2-c]pyrimidine was isolatedin quantitative yield. LCMS (m/z) (M+H)=201.9 at Rt=0.40 mins.

Step 2

7-chloro-5-(methylthio)imidazo[1,2-c]pyrimidine (1.0 equiv.) in MeOH(1.13M) and 2N potassium hydroxide solution (3.5 equiv.) was refluxedfor 2 h. The reaction mixture was concentrated and the residue wasdissolved in DCM and small amounts of MeOH, loaded onto celite,concentrated and transferred to a cartridge. The crude material waspurified via flash chromatography over silica gel eluting with DCM and0-13% MeOH gradient. Isolated 7-chloroimidazo[1,2-c]pyrimidin-5-ol in75%. LCMS (m/z) (M+H)=170 at Rt=0.23 mins.

Step 3

To a flask containing 7-chloroimidazo[1,2-c]pyrimidin-5-ol (1.0 equiv.)was added POCl₃ (13.0 equiv.) and the reaction mix was refluxedovernight. The reaction mixture was concentrated, loaded on celite andpurified via flash chromatography over silica gel eluting with DCM and0-10% MeOH gradient. Isolated 5,7-dichloroimidazo[1,2-c]pyrimidine in56% yield. LCMS (m/z) (M+H)=188/190 at Rt=0.49 mins.

Step 4

To a flask containing 5,7-dichloroimidazo[1,2-c]pyrimidine (1.0 equiv.)in a 3:1 mixture of DCM and MeOH (0.7 M) at 0° C. was added morpholine(4.0 equiv.) and the reaction mix was brought to RT. After 3 h there waslittle starting material left. Reaction mix was stirred for 1 h more toensure completion. The reaction mixture was concentrated and purifiedvia flash chromatography over silica gel eluting with DCM and 0-5% MeOHgradient. Isolated 4-(7-chloroimidazo[1,2-c]pyrimidin-5-yl)morpholine in27% yield. LCMS (m/z) (M+H)=238.9 at Rt=0.41 mins.

Step 5

To a solution of 4-(7-chloroimidazo[1,2-c]pyrimidin-5-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 15 minutes at 120° C. Some starting material was still present.Additional 0.1 equiv. of the palladium catalyst were added and thesystem was flushed with nitrogen. The vial was capped and placed in themicrowave reactor for 15 minutes at 120° C. The reaction mix waspartitioned in EtOAc/H₂O. The organic layer was isolated, dried overNa₂SO₄, filtered and concentrated. The crude was purified by HPLC givingN-(4-methyl-3-(5-morpholinoimidazo[1,2-c]pyrimidin-7-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 20% yield. 1H NMR (400 MHz, <dmso>) b ppm 2.41 (s,3H) 2.52 (s, 1H) 3.54 (br. s., 4H) 3.82 (d, J=4.30 Hz, 4H) 7.33 (s, 1H)7.49 (s, 1H) 7.71-7.83 (m, 2H) 7.97 (d, J=7.83 Hz, 1H) 8.03-8.10 (m, 2H)8.17 (s, 1H) 8.23-8.35 (m, 2H) 10.56 (s, 1H). LCMS (m/z) (M+H)=482 atRt=0.78 mins.

Example 829:N-(4-methyl-3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

2,4-Dichlorothieno[3,2-d]pyrimidine (1.0 equiv.) and morpholine (2.2equiv.) were stirred in a sealed tube at RT for 2 hr. The reactionmixture was concentrated and the residue was purified via flashchromatography over silica gel eluting with heptane and 0-100% EtOAcgradient. The desired 4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholinewas isolated in 90% yield. LCMS (m/z) (M+H)=256 at Rt=0.68 mins.

Step 2

To a solution of 4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 120° C. Some starting material was still present. Thevial was placed in the microwave reactor for additional 20 minutes at120° C. The reaction mix was partitioned in EtOAc/H₂O. The organic layerwas isolated, dried over Na₂SO₄, filtered and concentrated. The crudewas purified by HPLC givingN-(4-methyl-3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 14% yield. 1H NMR (400 MHz, <dmso>) ppm 3.67-3.71 (m,1H) 3.75 (t, J=4.70 Hz, 4H) 3.82-3.88 (m, 1H) 3.97 (d, J=4.30 Hz, 4H)7.29 (d, J=8.61 Hz, 1H) 7.47 (d, J=5.48 Hz, 1H) 7.68-7.82 (m, 2H) 7.91(d, J=7.83 Hz, 1H) 8.12 (d, J=1.96 Hz, 1H) 8.19-8.29 (m, 2H) 8.33 (d,J=5.09 Hz, 1H) 10.51 (s, 1H). LCMS (m/z) (M+H)=499 at Rt=0.83 mins.

Example 830:N-(4-methyl-3-(4-morpholino-5H-pyrrolo[3,2-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine (1.0 equiv.)in THF (0.53 M) was added morpholine (1.2 equiv.) followed by DIEA (2.0equiv.) and the reaction mixture was stirred at RT for overnight. Thereaction mixture was concentrated and the crude was partitioned inEtOAc/NaHCO₃. The organic layer was isolated, washed with brine, driedover Na₂SO₄, filtered and concentrated. The desired4-(2-chloro-5H-pyrrolo[3,2-d]pyrimidin-4-yl)morpholine was used as is inthe next step. LCMS (m/z) (M+H)=239 at Rt=0.56 mins.

Step 2

To a solution of 4-(2-chloro-5H-pyrrolo[3,2-d]pyrimidin-4-yl)morpholine(1.0 equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 120° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC givingN-(4-methyl-3-(4-morpholino-5H-pyrrolo[3,2-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 20% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.38 (s,3H) 3.80 (t, J=4.50 Hz, 4H) 4.04 (br. s., 4H) 6.60 (br. s., 1H) 7.42 (d,J=7.83 Hz, 1H) 7.74-7.87 (m, 2H) 7.87-8.01 (m, 2H) 8.11 (d, J=1.96 Hz,1H) 8.21-8.32 (m, 2H) 10.64 (br. s., 1H). LCMS (m/z) (M+H)=482 atRt=0.81 mins.

Example 831:N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To 6-chloropyridazin-3-amine (1.0 equiv.) and NaHCO₃(1.84 equiv.) inMeOH (2.3 M) at 0° C. was added bromine (1.1 equiv.) drop wise and themixture was left stirring for 3 hr at RT. The reaction mixture wasquenched by addition of water and concentrated until the solidprecipitated. The mixture was then cooled in an ice water bath, filteredand dried to afford the desired 4-bromo-6-chloropyridazin-3-amine as abrown solid in 86% yield. LCMS (m/z) (M+H)=207.9/209.9/211.9 at Rt=0.50mins.

Step 2

To 4-bromo-6-chloropyridazin-3-amine (1.0 equiv.) in EtOH (0.48 M) wasadded chloroacetaldehyde 50% in water (10.0 equiv.) and the mixture washeated to 100° C. for 16 h. The reaction mixture was concentrated to abrown slurry and the desired 8-bromo-6-chloroimidazo[1,2-b]pyridazinewas used as such in the next step. Yield was assumed to be quantitative.LCMS (m/z) (M+H)=231.9/233.9/235.9 at Rt=0.55 mins.

Step 3

To a flask containing 8-bromo-6-chloroimidazo[1,2-b]pyridazine (1.0equiv.) in EtOH (0.650 M) was added morpholine (10.0 equiv.) and thereaction mix was stirred at RT for 3 hr when the reaction was complete.The solvent was removed under vacuum and the crude4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)morpholine was used as is in thenext step. Yield was assumed to be quantitative. LCMS (m/z) (M+H)=239.1at Rt=0.68 mins.

Step 4

To a solution of 4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 15 minutes at 120° C. Some unreacted starting material was stillpresent, additional 0.3 equivalents ofN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamidewere added and the vial was placed in the microwave reactor for 15minutes at 130° C. The reaction mix was partitioned in EtOAc/H₂O. Theorganic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC givingN-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 20% yield. 1H NMR (400 MHz, <dmso>) δ ppm 0.96-1.10(m, 5H) 2.25-2.35 (m, 3H) 3.42 (q, J=7.04 Hz, 4H) 3.71-3.80 (m, 5H)6.31-6.41 (m, 1H) 7.26-7.37 (m, 1H) 7.55-7.65 (m, 1H) 7.71-7.86 (m, 3H)7.90-8.00 (m, 1H) 8.06-8.13 (m, 1H) 8.20-8.34 (m, 2H) 10.44-10.55 (m,1H). LCMS (m/z) (M+H)=482 at Rt=0.89 mins.

Example 832: Synthesis ofN-(5-(8-(2-(1H-imidazol-2-yl)morpholino)imidazo[1,2-b]pyridazin-6-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

A solution of 8-bromo-6-chloroimidazo[1,2-b]pyridazine (1.0 equiv.),2-(1H-imidazol-2-yl)morpholine bis-hydrochloride salt (1.0 equiv.) andtriethylamine (3.0 equiv.) in NMP (0.143 M) was heated at 60° C. for 1hr. The mixture was purified via preparative reverse phase HPLC. Uponlyophilization of the pure fractions,4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)-2-(1H-imidazol-2-yl)morpholinewas isolated as the TFA salt in 14% yield. LCMS (m/z) (M+H)=304.9,Rt=0.50 min.

Step 2

A mixture of4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)-2-(1H-imidazol-2-yl)morpholine(1.0 equiv.),N-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.), sodium carbonate (2 M, 3 equiv.) and PdCl₂(dppf) (0.5equiv.) in DME (0.08 M) were heated to 120° C. for 30 min in themicrowave. After cooling to RT, the organic phase purified viapreparative reverse phase HPLC. Upon lyophilization of the purefractions,N-(5-(8-(2-(1H-imidazol-2-yl)morpholino)imidazo[1,2-b]pyridazin-6-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamidewas isolated as the TFA salt in 3.1% yield. LCMS (m/z) (M+H)=549.2,Rt=0.67 min. 1H NMR (400 MHz, <cd3od>) δ ppm 3.12-3.21 (m, 4H), 3.64 (s,3H), 3.80-3.90 (m, 4H), 6.96 (d, J=1.96 Hz, 2H), 7.41 (d, J=1.96 Hz,2H), 7.52-7.62 (m, 1H), 7.84-7.92 (m, 1H), 7.97 (br. s., 2H), 8.05-8.12(m, 1H), 8.14-8.20 (m, 1H).

Example 833:N-(4-methyl-3-(4-morpholinopyrido[2,3-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing 2,4-dichloropyrido[2,3-d]pyrimidine (1.0 equiv.)in THF (0.42 M) was added morpholine (1.2 equiv.) and DIEA (2.0 equiv.)and the reaction mix was stirred at RT for 1 hr. The solvent was removedunder vacuum and the residue was partitioned in EtOAC/NaHCO₃. Theorganic layer was isolated, washed with brine, dried over Na₂SO₄,filtered and concentrated. The crude4-(2-chloropyrido[2,3-d]pyrimidin-4-yl)morpholine was used as is in thenext step. Yield was assumed to be quantitative. LCMS (m/z) (M+H)=251 atRt=0.58 mins.

Step 2

To a solution of 4-(2-chloropyrido[2,3-d]pyrimidin-4-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 120° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC givingN-(4-methyl-3-(4-morpholinopyrido[2,3-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 40% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.40-2.47(m, 9H) 2.47 (s, 1H) 3.68-3.83 (m, 1H) 3.76 (t, J=4.50 Hz, 1H) 4.04 (br.s., 1H) 7.34 (d, J=8.22 Hz, 1H) 7.62 (dd, J=8.22, 4.30 Hz, 1H) 7.70-7.77(m, 1H) 7.80 (dd, J=8.22, 1.96 Hz, 1H) 7.92 (d, J=7.43 Hz, 1H) 8.12-8.32(m, 1H) 8.61 (d, J=8.22 Hz, 1H) 8.93-9.05 (m, 1H) 10.58 (s, 1H). LCMS(m/z) (M+H)=494 at Rt=0.78 mins.

Example 834:N-(4-methyl-3-(4-morpholino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing tert-butyl2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate (1.0equiv.) in THF (0.55 M) was added morpholine (1.2 equiv.) and DIEA (2.0equiv.) and the reaction mix was stirred at RT for 2 h. LCMS showed onemajor product. The reaction mixture was concentrated and the mixtureused as is in the next step. LCMS (m/z) (M+H)=355 at Rt=0.82 mins.

Step 2

To a solution of the crude tert-butyl2-chloro-4-morpholino-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate(1.0 equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DME (0.14 M) was added 2M Na₂CO₃ solution (3.0 equiv.)and the system was flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.1equiv.) was added to the reaction mix and the system was flushed onceagain with nitrogen. The reaction vial was capped and microwaved for 20minutes at 120° C. The crude was partitioned in H2O/EtOAc. The organiclayer was isolated, dried over Na₂SO₄, filtered and concentrated. Crudewas purified on a silica gel column using heptane to 50% EtOAc inheptane. Isolated tert-butyl2-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-morpholino-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylatein 27% yield. LCMS (m/z) [M+H]+=598 at Rt=0.89 min.

Step 3

To a solution of tert-butyl2-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-morpholino-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate(1.0 equiv.) in DCM (0.04 M) was added TFA (15 equiv.) and the reactionmix was stirred at RT for 1 h. The solvent was removed under vacuum andthe residue was taken in DMSO and purified on the prep. IsolatedN-(4-methyl-3-(4-morpholino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 68% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.75-3.01(m, 2H) 3.22 (s, 1H) 3.73 (d, J=4.30 Hz, 4H) 4.08-4.37 (m, 2H) 5.74 (s,1H) 7.28 (d, J=8.22 Hz, 1H) 7.67-7.83 (m, 2H) 7.96 (d, J=7.83 Hz, 1H)8.11-8.40 (m, 3H) 9.17 (br. s., 2H) 10.34-10.65 (m, 1H). LCMS (m/z)(M+H)=498 at Rt=0.57 mins.

Example 835:N-(4-methyl-3-(4-morpholino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

This compound was prepared following the same procedure reported forcompound Example 834. 1H NMR (400 MHz, <dmso>) δ ppm 3.02 (t, J=6.26 Hz,2H) 3.35 (d, J=4.30 Hz, 5H) 3.67 (d, J=4.30 Hz, 5H) 4.07-4.26 (m, 2H)7.08-7.37 (m, 1H) 7.61-7.79 (m, 2H) 7.91 (d, J=7.83 Hz, 1H) 8.06-8.33(m, 3H) 8.80-9.08 (m, 2H) 10.47 (s, 1H). LCMS (m/z) (M+H)=498 at Rt=0.68mins.

Example 836:N-(4-methyl-3-(4-morpholino-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

This compound was prepared following the same procedure reported forcompound Example 834. 1H NMR (400 MHz, <dmso>) δ ppm 2.37-2.61 (m, 11H)3.68 (br. s., 5H) 4.39 (br. s., 1H) 4.75 (br. s., 1H) 7.28 (d, J=8.22Hz, 1H) 7.69-7.82 (m, 1H) 7.96 (d, J=7.83 Hz, 1H) 8.12-8.36 (m, 1H) 9.59(br. s., 1H) 10.51 (s, 1H). LCMS (m/z) (M+H)=484 at Rt=0.72 mins.

Example 837:N-(4-methyl-3-(1-methyl-7-morpholino-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing5,7-dichloro-1-methyl-3a,7a-dihydro-1H-pyrazolo[4,3-d]pyrimidine (1.0equiv.) in EtOH (0.25 M) was added morpholine (10.0 equiv.) and thereaction mix was stirred at RT for 45 min. The solvent was removed undervacuum and the crude4-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)morpholine wasused as is in the next step. Yield was assumed to be quantitative. LCMS(m/z) (M+H)=254 at Rt=0.56 mins.

Step 2

To a solution of4-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 120° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC givingN-(4-methyl-3-(1-methyl-7-morpholino-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)-3-(trifluoromethyl)benzamidesthe TFA salt in 20% yield. 1H NMR (400 MHz, <dmso>) δ ppm 3.72-3.88 (m,5H) 4.09-4.25 (m, 3H) 7.14-7.41 (m, 1H) 7.70-7.84 (m, 2H) 7.89-8.03 (m,1H) 8.15-8.38 (m, 4H) 10.51 (s, 1H). LCMS (m/z) (M+H)=497 at Rt=0.82mins.

Example 838:N-(4-methyl-3-(4-morpholinofuro[3,2-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing 2,4-dichlorofuro[3,2-d]pyrimidine (1.0 equiv.) inEtOH (0.79 M) was added morpholine (10.0 equiv.) and the reaction mixwas stirred at RT for 2 hr. The solvent was removed under vacuum and thecrude 2-chloro-4-morpholinofuro[3,2-d]pyrimidine was used as is in thenext step. Yield was assumed to be quantitative. LCMS (m/z)(M+H)=240/242 at Rt=0.59 mins.

Step 2

To a solution of 2-chloro-4-morpholinofuro[3,2-d]pyrimidine (1.0 equiv.)andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 120° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC givingN-(4-methyl-3-(4-morpholinofuro[3,2-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 40% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.45 (s,3H) 3.76 (t, J=4.50 Hz, 4H) 3.98 (d, J=4.30 Hz, 4H) 7.07 (d, J=1.96 Hz,1H) 7.28 (d, J=8.22 Hz, 1H) 7.66-7.85 (m, 2H) 7.95 (d, J=7.43 Hz, 1H)8.12 (d, J=1.96 Hz, 1H) 8.21-8.39 (m, 3H) 10.50 (s, 1H). LCMS (m/z)(M+H)=483 at Rt=0.81 mins.

Example 839:N-(4-methyl-3-(7-morpholinothiazolo[5,4-d]pyrimidin-5-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing 5,7-dichlorothiazolo[5,4-d]pyrimidine (1.0 equiv.)in EtOH (0.73 M) was added morpholine (10.0 equiv.) and the reaction mixwas stirred at RT for 2 hr. The solvent was removed under vacuum and thecrude 4-(5-chlorothiazolo[5,4-d]pyrimidin-7-yl)morpholine was used as isin the next step. Yield was assumed to be quantitative. LCMS (m/z)(M+H)=257/259 at Rt=0.70 mins.

Step 2

To a solution of 4-(5-chlorothiazolo[5,4-d]pyrimidin-7-yl)morpholine(1.0 equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv) in DME (0.1 M) was added 2M Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thevial was capped and place in a microwave reactor for 20 minutes at 125°C. The reaction mix was partitioned in EtOAc/H₂O. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crude waspurified by HPLC givingN-(4-methyl-3-(7-morpholinothiazolo[5,4-d]pyrimidin-5-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 40% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.73 (s,1H) 2.52 (s, 1H) 3.76 (t, J=4.50 Hz, 4H) 4.33 (br. s., 3H) 7.29 (d,J=8.22 Hz, 1H) 7.77 (t, J=7.83 Hz, 1H) 7.84 (dd, J=8.22, 1.96 Hz, 1H)7.95 (d, J=7.83 Hz, 1H) 8.20 (d, J=1.96 Hz, 1H) 8.24-8.35 (m, 2H) 9.26(s, 1H) 10.52 (s, 1H). LCMS (m/z) (M+H)=500 at Rt=1.02 mins.

Example 840:N-(4-methyl-3-(1-methyl-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing 4,6-dichloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidine(1.0 equiv.) in EtOH (0.70 M) was added morpholine (10.0 equiv.) and thereaction mix was stirred at RT for 2 hr. The solvent was removed undervacuum and the crude4-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine wasused as is in the next step. Yield was assumed to be quantitative. LCMS(m/z) (M+H)=254/256 at Rt=0.60 mins.

Step 2

To a solution of4-(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 15 minutes at 125° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC givingN-(4-methyl-3-(1-methyl-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamideas the TFA salt in 40% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.73 (s,1H) 3.72-3.78 (m, 8H) 7.27 (d, J=8.22 Hz, 2H) 7.70-7.85 (m, 3H) 7.95 (d,J=7.83 Hz, 1H) 8.16 (d, J=1.96 Hz, 1H) 8.23-8.36 (m, 5H) 10.50 (s, 2H).LCMS (m/z) (M+H)=497 at Rt=0.93 mins.

Example 841: 2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(8morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)isonicotinamide

Step 1

A round bottom flask containing a solution of4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)morpholine (1.0 equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv) and 2M Na₂CO₃ (3.0 equiv.) in DME (1.3M) was flushed withnitrogen for 5 minutes. PdCl₂(dppf).CH₂₂ adduct (0.07 equiv.) was addedto the solution and the system was flushed again for 10 more minutes.The reaction mix was refluxed at 120° C. overnight under an inertatmosphere. The reaction mix was cooled to RT, diluted with water andextracted with EtOAc. The combined organics were dried over MgSO4,filtered and concentrated. The crude was purified on a neutral reversephase column using 40% acetonitrile/water giving4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)aniline in 60%yield. 1H NM_(R)(400 MHz, dmso) in ppm 2.01-2.19 (m, 3H) 3.65-3.80 (m,4H) 3.89-4.04 (m, 4H) 4.96 (s, 2H) 6.24 (s, 1H) 6.55 (dd, J=8.22, 2.35Hz, 1 H) 6.61 (d, J=2.35 Hz, 1H) 6.93 (d, J=7.83 Hz, 1H) 7.54 (d, J=0.78Hz, 1H) 8.03 (d, J=0.78 Hz, 1H). LCMS (m/z) (M+H)=310 at Rt=0.42 mins.

Step 2

To a round bottom flask containing a solution of4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)aniline (1.0equiv.) and 2-(2-hydroxypropan-2-yl)isonicotinic acid (1.1 equiv) in DMF(3.9 M) was added HATU (1.1 equiv.) and DIEA (3.0 equiv.) and thereaction mix was left stirring overnight at RT. The reaction mix wasdiluted with water and was extracted three times with EtOAc/H₂O. Thecombined organics were dried over MgSO4, filtered and concentrated.purified on a neutral reverse phase column using 40% acetonitrile/watergiving2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)isonicotinamidein 64% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.39-1.54 (m, 6H) 2.30 (s,3H) 3.30 (s, 6H) 3.69-3.84 (m, 4H) 3.93-4.10 (m, 4H) 5.34 (s, 1H) 6.34(s, 1H) 7.32 (d, J=8.61 Hz, 1H) 7.58 (d, J=1.17 Hz, 1H) 7.69 (dd,J=5.09, 1.57 Hz, 1H) 7.75-7.86 (m, 2H) 8.08 (d, J=0.78 Hz, 1H) 8.12 (s,1H) 8.66 (d, J=4.70 Hz, 1H) 10.40-10.66 (m, 1H). LCMS (m/z) (M+H)=473 atRt=0.58 mins.

Example 842:2-isopropyl-N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)isonicotinamide

This compound was prepared following the same procedure reported forExample 841. 1H NMR (400 MHz, <dmso>) δ ppm 1.28 (d, J=6.65 Hz, 6H) 2.30(s, 3H) 3.15 (spt, J=6.91 Hz, 1H) 3.70-3.80 (m, 5H) 6.36 (s, 1H) 7.33(d, J=8.22 Hz, 1H) 7.60 (s, 1H) 7.71-7.86 (m, 4H) 7.99-8.17 (m, 1H)8.55-8.86 (m, 1H) 10.53 (s, 1H). LCMS (m/z) (M+H)=457.3 at Rt=0.59 mins.

Example 843:2-(1,1-difluoroethyl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)isonicotinamide

This compound was prepared following the same procedure reported forExample 841. 1H NMR (400 MHz, <dmso>) δ ppm 2.03 (t, J=19.17 Hz, 3H)2.31 (s, 3H) 3.76 (d, J=4.30 Hz, 5H) 3.99 (d, J=4.70 Hz, 8H) 6.36 (s,1H) 7.34 (d, J=8.22 Hz, 1H) 7.60 (s, 1H) 7.75-7.85 (m, 2H) 8.02 (d,J=4.70 Hz, 1H) 8.10 (s, 1H) 8.18 (s, 1H) 8.73-9.01 (m, 1H) 10.55-10.80(m, 1H). LCMS (m/z) (M+H)=479.3 at Rt=0.74 mins.

Example 844:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)isonicotinamide

This compound was prepared following the same procedure reported forcompound Example 841. 1H NMR (400 MHz, <dmso>) δ ppm 1.67-1.75 (m, 6H)2.26 (s, 4H) 3.66-3.76 (m, 4H) 3.95 (d, J=4.30 Hz, 4H) 6.30 (s, 1H) 7.29(d, J=8.61 Hz, 1H) 7.54 (s, 1H) 7.70-7.76 (m, 2H) 7.80 (d, J=4.70 Hz,1H) 7.95 (s, 1H) 8.04 (s, 1H) 8.74 (d, J=5.09 Hz, 1H) 10.53 (s, 1H).LCMS (m/z) (M+H)=482 at Rt=0.74 mins.

Example 845:2-(tert-butyl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)isonicotinamide

This compound was prepared following the same procedure reported forExample 841. 1H NMR (400 MHz, <dmso>) ppm 1.31 (s, 9H) 2.25 (s, 3H)3.58-3.77 (m, 5H) 6.32 (s, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.57 (s, 1H) 7.65(d, J=3.91 Hz, 1H) 7.70-7.78 (m, 2H) 7.83 (s, 1H) 8.05 (s, 1H) 8.66 (d,J=5.09 Hz, 1H) 10.46 (s, 1H). LCMS (m/z) (M+H)=471 at Rt=0.63 mins.

Example 846:3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)benzamide

This compound was prepared following the same procedure reported forExample 841. 1H NMR (400 MHz, <dmso>) ppm 1.69-1.78 (m, 6H) 2.30 (s, 3H)3.71-3.81 (m, 4H) 3.94-4.01 (m, 5H) 6.38 (s, 1H) 7.31 (d, J=7.83 Hz, 1H)7.54-7.63 (m, 2H) 7.73 (d, J=8.22 Hz, 1H) 7.76-7.83 (m, 2H) 7.93 (d,J=7.83 Hz, 1H) 8.04 (s, 1H) 8.11 (s, 1H) 10.34 (s, 1H). LCMS (m/z)(M+H)=481 at Rt=0.78 mins.

Example 847:3-(difluoromethyl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)benzamide

This compound was prepared following the same procedure reported forExample 841. 1H NMR (400 MHz, <dmso>) ppm 2.30 (s, 3H) 3.95-4.04 (m, 5H)6.38 (s, 1H) 6.99 (s, 1H) 6.96-7.28 (m, 1H) 7.13 (s, 1H) 7.27 (s, 1H)7.31 (d, J=8.61 Hz, 1H) 7.61 (s, 1H) 7.64-7.71 (m, 1H) 7.74-7.86 (m, 3H)8.01-8.23 (m, 3H) 10.35-10.55 (m, 1H).

LCMS (m/z) (M+H)=464 at Rt=0.77 mins.

Example 848:N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

NaH (3.0 equiv.) was added to a solution of6-bromoimidazo[1,2-a]pyridin-8-amine (1.0 equiv.) in DMF (2.4 M) at 0°C. The mix was left to reach RT and stirred for 15 min.1-Bromo-2-(2-bromoethoxy)ethane (1.5 equiv) was added to it and thereaction mixture was warmed to 80° C. overnight. The reaction mix wascooled in an ice bath and quenched by dropwise addition of water. Asolid precipitated which was filtered and the aqueous layer was backextracted twice with EtOAc. The combined organics were dried over MgSO4,filtered and concentrated. The precipitate and the extraction productwere combined to give the desired4-(6-bromoimidazo[1,2-a]pyridin-8-yl)morpholine in 56% yield which wasused as is in the next step. LCMS (m/z) (M+H)=284 at Rt=0.38 mins.

Step 2

To a solution of 4-(6-bromoimidazo[1,2-a]pyridin-8-yl)morpholine (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv) in DME (0.07 M) was added 2M Na₂CO₃ (3.0 equiv.) and the systemwas flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂ adduct (0.1equiv.) was added to the solution and the system was flushed once again.The vial was capped and place in a microwave reactor for 20 minutes at120° C. Some boronate ester was still present therefore additional 0.5equiv. of 4-(6-bromoimidazo[1,2-a]pyridin-8-yl)morpholine were added andthe vial was placed in the microwave reactor for additional 20 min at120° C. The reaction mix was partitioned in EtOAc/H₂O. The organic layerwas isolated, dried over Na₂SO₄, filtered and concentrated. The crudewas purified on a silica gel column using heptane to 100% EtOAc inheptane. 4-Methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)aniline wasobtained in 61% yield. LCMS (m/z) (M+H)=309 at Rt=0.37 mins.

Step 3

HATU (1.1 equiv.) was added to a solution of4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)aniline (1.0 equiv.),3-(difluoromethyl)benzoic acid (1.0 equiv) and DIEA (2.0 equiv.) in DMF(0.1 M) and the reaction mix was left stirring overnight at RT. Thereaction was treated with water and the precipitate was removed byfiltration. The solid was dissolved in DCM and purified on a silica gelcolumn using heptane to 85% EtOAc in heptane.3-(difluoromethyl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)benzamidewas obtained in 76% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.26 (s, 3H)2.67 (s, 1H) 3.54 (d, J=4.30 Hz, 4H) 3.75-3.84 (m, 4H) 6.38 (s, 1H)6.98-7.27 (m, 1H) 7.30 (d, J=9.00 Hz, 1H) 7.50 (s, 1H) 7.64-7.80 (m, 4H)7.89 (s, 1H) 8.06-8.23 (m, 3H) 10.26-10.51 (m, 1H). LCMS (m/z)(M+H)=463.2 at Rt=0.76 mins.

Example 849:N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

This compound was prepared following the same procedure described forExample 848. The crude was purified by HPLC and the product isolated asthe TFA salt in 71% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.22 (s, 3H)3.20 (br. s., 4H) 3.74-3.84 (m, 4H) 6.97-7.15 (m, 1H) 7.33 (d, J=8.22Hz, 1H) 7.66 (dd, J=8.22, 1.96 Hz, 1H) 7.77 (d, J=1.96 Hz, 1H) 8.00 (br.s., 1H) 8.06-8.22 (m, 2H) 8.30 (s, 1H) 8.45 (br. s., 1H) 8.93 (d, J=5.09Hz, 1H) 10.70 (s, 1H). LCMS (m/z) (M+H)=482.2 at Rt=0.74 mins.

Example 850:2-(difluoromethyl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)isonicotinamide

This compound was prepared following the same procedure described forExample 848. 1H NMR (400 MHz, <dmso>) δ ppm 2.26 (s, 3H) 3.54 (d, J=4.30Hz, 4H) 3.71-3.85 (m, 4H) 6.37 (s, 1H) 6.88-7.23 (m, 1H) 7.32 (d, J=9.00Hz, 1H) 7.50 (s, 1H) 7.69-7.75 (m, 2H) 7.90 (s, 1H) 8.04 (d, J=4.70 Hz,1H) 8.16 (d, J=2.35 Hz, 2H) 8.89 (d, J=4.70 Hz, 1H) 10.64 (s, 1H). LCMS(m/z) (M+H)=464.4 at Rt=0.68 mins.

Example 851:N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)-2-(methylsulfonyl)isonicotinamide

This compound was prepared following the same procedure described forExample 848. The crude was purified by HPLC and the product isolated asthe TFA salt in 37% yield.

1H NMR (400 MHz, <dmso>) δ ppm 2.27 (s, 3H) 3.24 (br. s., 4H) 3.30-3.37(m, 4H) 3.79-3.90 (m, 4H) 7.04-7.23 (m, 1H) 7.39 (d, J=8.22 Hz, 1H) 7.72(dd, J=8.22, 1.96 Hz, 1H) 7.83 (d, J=1.56 Hz, 1H) 8.08 (br. s., 1H)8.17-8.29 (m, 2H) 8.51 (s, 2H) 8.99 (d, J=4.70 Hz, 1H) 10.84 (s, 1H).LCMS (m/z) (M+H)=492.2 at Rt=0.61 mins.

Example 852:N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

This compound was prepared following the same procedure described forExample 848. The crude was purified by HPLC and the product isolated asthe TFA salt in 36% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.27 (s, 6H)3.26 (br. s., 8H) 3.78-3.90 (m, 7H) 7.08 (d, J=7.83 Hz, 1H) 7.41 (d,J=8.22 Hz, 1H) 7.70 (dd, J=8.22, 2.35 Hz, 1H) 7.81 (d, J=1.57 Hz, 1H)8.05 (br. s., 1H) 8.23 (br. s., 1H) 8.49 (br. s., 1H) 8.66 (d, J=1.57Hz, 1H) 9.90 (d, J=1.56 Hz, 1H) 10.92 (s, 1H). LCMS (m/z) (M+H)=483.2 atRt=0.69 mins.

Example 853:N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamide

Step 1

1-Hydroxy-7-azabenzotriazole (1.0 equiv.) was added to a solution of4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)aniline (1.0 equiv.),4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.0 equiv) and EDC.HCl(1.0 equiv.) in DMF (0.1 M) and the reaction mix was left stirringovernight at RT. The reaction was treated with water and the precipitatewas removed by filtration. The solid was dried and used as is in thenext step.

Step 2

Methylamine 2M in THF (70 equiv.) was added to a solution4-(bromomethyl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and the vial was sealed and heated to 70° C. overnight. Thereaction mix was concentrated to dryness and the crude was purified byHPLC to give the desiredN-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamideas the TFA salt in 53% yield. 1H NMR (400 MHz, <dmso>) b ppm 2.26 (s,3H) 2.71 (br. s., 3H) 3.30 (br. s., 4H) 3.79-3.87 (m, 4H) 4.38 (br. s.,2H) 7.36 (d, J=8.61 Hz, 1H) 7.72 (dd, J=8.22, 1.96 Hz, 1H) 7.79 (s, 1H)7.88 (d, J=8.61 Hz, 1H) 7.96 (br. s., 1H) 8.17 (br. s., 1H) 8.29-8.38(m, 2H) 8.43 (br. s., 1H) 9.08 (br. s., 2H) 10.59 (s, 1H) LCMS (m/z)(M+H)=524 at Rt=0.59 mins.

Example 854:3-(difluoromethyl)-N-(4-methyl-3-(4-morpholino-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)benzamide

Step 1

To a flask containing 2,4-dichloro-6,7-dihydrothieno[3,2-d]pyrimidine(1.0 equiv.) in EtOH (0.48 M) was added morpholine (10.0 equiv.) and thereaction mix was stirred at RT for 30 min. The solvent was removed undervacuum and the crude4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)morpholine was usedas is in the next step. Yield was assumed to be quantitative. LCMS (m/z)(M+H)=254/258 at Rt=0.68 mins.

Step 2

A round bottom flask containing a solution of4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)morpholine (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv) and 2M Na₂CO₃ (3.0 equiv.) in DME (1.3M) was flushed withnitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂ adduct (0.07 equiv.) wasadded to the solution and the system was flushed again for 10 moreminutes. The reaction mix was refluxed at 120° C. overnight under aninert atmosphere. The reaction mix was cooled to RT, diluted with waterand extracted with EtOAc. The combined organics were dried over MgSO4,filtered and concentrated. The crude was purified on a silica gel columnusing heptane to 100% EtOAc in heptane giving4-methyl-3-(4-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)anilinein 41% yield. LCMS (m/z) (M+H)=329 at Rt=0.44 mins.

Step 3

HATU (1.1 equiv.) was added to a solution of4-methyl-3-(4-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)aniline(1.0 equiv.), 3-(difluoromethyl)benzoic acid (1.0 equiv.) and DIEA (2.0)in DMF (0.17 M), and the mixture was left stirring at RT overnight. Thereaction flask was cooled in an ice bath and water was added dropwise toit. A precipitate formed that was removed by filtration and anadditional amount of product was obtained by extracting the filtratewith EtOAc and concentrating it to dryness. The solid and extractionwere purified on a silica gel column using heptane to 60% HeptaneEtOAc.). LCMS (m/z) (M+H)=483 at Rt=0.81 mins.

Step 4

mCPBA (2.2 equiv.) was added portionwise to a solution of3-(difluoromethyl)-N-(4-methyl-3-(4-morpholino-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)benzamide(1.0 equiv.) in DCM (0.03 M) at 0° C. and the reaction mix was leftstirring overnight at RT. The reaction mix was diluted with DCM andwashed three times with 0.5 M aqueous Na₂CO₃. It was dried over Na₂SO₄,filtered and concentrated to give the crude product as a white solid.Crude was purified on silica gel column using heptane to 80% EtOAc inheptane giving3-(difluoromethyl)-N-(4-methyl-3-(4-morpholino-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)benzamidein 45% yield. 1H NMR (400 MHz, <dmso>) δ ppm 3.32 (t, J=7.24 Hz, 2H)3.56-3.74 (m, 6H) 3.82-3.98 (m, 4H) 6.93-7.23 (m, 1H) 7.24 (d, J=8.22Hz, 1H) 7.58-7.67 (m, 1H) 7.73 (d, J=7.43 Hz, 1H) 7.79 (dd, J=8.22, 1.96Hz, 1H) 8.04-8.14 (m, 2H) 8.17 (d, J=1.96 Hz, 1H) 10.29-10.53 (m, 1H).LCMS (m/z) (M+H)=515 at Rt=0.89 mins.

Example 855:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-morpholino-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)isonicotinamide

This compound was prepared following the same procedure described forExample 855. 1H NMR (400 MHz, <dmso>) δ ppm 1.60-1.91 (m, 6H) 3.36 (t,J=7.24 Hz, 2H) 3.57-3.81 (m, 6H) 3.87-4.06 (m, 4H) 7.22-7.42 (m, 1H)7.80-7.90 (m, 2H) 8.01 (s, 1H) 8.09-8.30 (m, 1H) 8.68-8.90 (m, 1H)10.51-10.73 (m, 1H). LCMS (m/z) (M+H)=533 at Rt=0.81 mins.

Example 856:2-(difluoromethyl)-N-(4-methyl-3-(4-morpholino-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)isonicotinamide

This compound was prepared following the same procedure described forExample 855. 1H NMR (400 MHz, <dmso>) δ ppm 3.60-3.73 (m, 7H) 3.91 (t,J=4.50 Hz, 4H) 6.84-7.17 (m, 1H) 7.27 (d, J=8.61 Hz, 1H) 7.80 (dd,J=8.41, 2.15 Hz, 1H) 8.01 (d, J=5.09 Hz, 1H) 8.13 (s, 1H) 8.17 (d,J=1.96 Hz, 1H) 8.84 (d, J=5.09 Hz, 1H) 10.56-10.77 (m, 1H). LCMS (m/z)(M+H)=516 at Rt=0.78 mins.

Example 857:N-(4-methyl-3-(4-morpholino-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thevial was capped and place in a microwave reactor for 15 minutes at 120°C. Some starting boronic ester was present therefore, additional 0.5quiv. of 4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)morpholinewere added and the vial microwaved for 30 minutes at 100° C. Thereaction mix was partitioned in EtOAc/H₂O. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crude waspurified on a silica gel column using heptane to 35% EtOAc in heptanegivingN-(4-methyl-3-(5-morpholinoimidazo[1,2-c]pyrimidin-7-yl)phenyl)-3-(trifluoromethyl)benzamidein 39% yield. LCMS (m/z) (M+H)=501 at Rt=0.82 mins.

Step 2

mCPBA (2.2 equiv.) was added portionwise to a solution ofN-(4-methyl-3-(5-morpholinoimidazo[1,2-c]pyrimidin-7-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.02 M) at 0° C. and the reaction mix was leftstirring overnight at RT. The reaction mix was diluted with DCM andwashed three times with 0.5 M aqueous Na₂CO₃. It was dried over Na₂SO₄,filtered and concentrated to give the crude product as a white solid.Crude was purified on silica gel column using heptane to 50% EtOAc inheptane givingN-(4-methyl-3-(4-morpholino-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)phenyl)-3-(trifluoromethyl)benzamidein 85% yield. 1H NMR (500 MHz, DMSO-d6) δ ppm 3.32 (s, 2H) 3.39 (t,J=7.25 Hz, 2H) 3.69-3.79 (m, 6H) 3.99 (t, J=4.57 Hz, 4H) 7.33 (d, J=8.20Hz, 1H) 7.80 (t, J=7.72 Hz, 1H) 7.88 (dd, J=8.35, 2.05 Hz, 1H) 7.98 (d,J=7.57 Hz, 1H) 8.24 (d, J=1.89 Hz, 1H) 8.29 (d, J=7.88 Hz, 1H) 8.33 (s,1H) 10.45-10.77 (m, 1H). LCMS (m/z) (M+H)=533 at Rt=0.90 mins.

Example 858: (R)-2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-(3methylmorpholino)-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)isonicotinamide

Step 2

To a solution of(R)-4-(6-bromo-1H-imidazo[4,5-c]pyridin-4-yl)-3-methylmorpholine (1.0equiv.) and2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv) in DME (0.1 M) was added 2M Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thevial was capped and place in a microwave reactor for 20 minutes at 120°C. The reaction mix was partitioned in EtOAc/H₂O. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crude waspurified by HPLC.(R)-2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-(3-methylmorpholino)-1H-imidazo[4,5-c]pyridin-6-yl)phenyl)isonicotinamidewas obtained in 24% yield. 1H NMR (400 MHz, <dmso>) b ppm 1.11-1.48 (m,3H) 1.75 (s, 6H) 2.29 (br. s., 3H) 2.65 (d, J=1.57 Hz, 1H) 3.74 (br. s.,2H) 3.96 (d, J=8.61 Hz, 1H) 5.41 (br. s., 1H) 7.32 (br. s., 1H) 7.72(br. s., 1H) 7.79-7.89 (m, 2H) 7.95-8.04 (m, 1H) 8.80 (d, J=5.09 Hz, 1H)10.44-10.69 (m, 1H). LCMS (m/z) (M+H)=496 at Rt=0.67 mins.

Example 859:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)isonicotinamide

To a solution 4-(6-chloroimidazo[1,2-a]pyrazin-8-yl)morpholine (1.0equiv.) and2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv) in DME (0.1 M) was added 2M Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thevial was capped and place in a microwave reactor for 20 minutes at 120°C. The reaction mix was extracted three times with EtOAc. The combinedorganic layers were dried over Na₂SO₄, filtered and concentrated. Thecrude was purified by HPLC giving2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)phenyl)isonicotinamideas the TFA salt in 27% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.68 (s,6H) 2.40 (s, 3H) 2.52 (s, 1H) 2.99 (br. s., 4H) 7.20 (br. s., 1H)7.31-7.40 (m, 2H) 7.42-7.48 (m, 1H) 7.68 (d, J=4.30 Hz, 1H) 7.86 (s, 1H)8.07 (br. s., 1H) 8.27 (s, 1H) 8.63 (s, 1H) 8.72 (d, J=4.70 Hz, 1H)10.36 (s, 1H). LCMS (m/z) (M+H)=481 at Rt=0.67 mins.

Example 860:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyrazin-6-yl)phenyl)isonicotinamide

To a solution 4-(6-chloroimidazo[1,2-a]pyrazin-8-yl)morpholine (1.0equiv.) and2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv) in DME (0.1 M) was added 2M Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thevial was capped and place in a microwave reactor for 20 minutes at 120°C. The reaction mix was partitioned in EtOAc/H₂O. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crude waspurified by HPLC giving2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-a]pyrazin-6-yl)phenyl)isonicotinamideas the TFA salt in 23% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.69-1.83(m, 6H) 2.36 (s, 3H) 3.74 (t, J=4.50 Hz, 4H) 4.20 (br. s., 4H) 7.29 (d,J=8.61 Hz, 1H) 7.60 (s, 1H) 7.68 (dd, J=8.22, 1.96 Hz, 1H) 7.85 (d,J=2.35 Hz, 2H) 7.94-8.04 (m, 2H) 8.10 (s, 1H) 8.79 (d, J=4.70 Hz, 1H)10.55 (s, 1H) 1H LCMS (m/z) (M+H)=482 at Rt=0.74 mins.

Example 861:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-7-morpholino-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)isonicotinamide

To a solution4-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)morpholine (1.0equiv.) and2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 15 minutes at 125° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC giving2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-7-morpholino-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)isonicotinamideas the TFA salt in 22% yield. 1H NMR (400 MHz, <dmso>) b ppm 1.70-1.79(m, 6H) 3.59 (br. s., 5H) 4.19 (s, 3H) 7.31 (d, J=8.22 Hz, 1H) 7.79 (dd,J=8.22, 1.96 Hz, 1H) 7.87 (d, J=4.30 Hz, 1H) 8.01 (s, 1H) 8.21 (d,J=1.96 Hz, 1H) 8.26 (s, 1H) 8.79 (d, J=5.09 Hz, 1H) 10.60 (s, 1H). LCMS(m/z) (M+H)=497 at Rt=0.71 mins.

Example 862:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenyl)isonicotinamide

To a solution 4-(2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine (1.0equiv.) and2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 120° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC giving2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenyl)isonicotinamideas the TFA salt in 19% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.75 (s,6H) 3.76-3.85 (m, 5H) 3.96-4.07 (m, 4H) 7.34 (d, J=8.61 Hz, 1H) 7.51 (d,J=5.48 Hz, 1H) 7.78-7.89 (m, 2H) 8.01 (s, 1H) 8.14 (d, J=1.96 Hz, 1H)8.36 (d, J=5.09 Hz, 1H) 8.80 (d, J=5.09 Hz, 1H) 10.64 (s, 1H). LCMS(m/z) (M+H)=499 at Rt=0.72 mins.

Example 863:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-morpholino-5H-pyrrolo[3,2-d]pyrimidin-2-yl)phenyl)isonicotinamide

To a solution 4-(2-bromo-5H-pyrrolo[3,2-d]pyrimidin-4-yl)morpholine (1.0equiv.) and2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)isonicotinamide(1.0 equiv) in DME (0.1 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 125° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC giving2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-morpholino-5H-pyrrolo[3,2-d]pyrimidin-2-yl)phenyl)isonicotinamideas the TFA salt in 45% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.75 (s,6H) 2.34-2.43 (m, 3H) 3.81 (d, J=4.30 Hz, 4H) 4.04 (br. s., 4H) 6.61(br. s., 1H) 7.44 (d, J=8.22 Hz, 1H) 7.78-7.88 (m, 2H) 7.89-7.97 (m, 1H)8.00 (s, 1H) 8.08 (d, J=1.57 Hz, 1H) 8.81 (d, J=5.09 Hz, 1H) 10.74 (s,1H). LCMS (m/z) (M+H)=482 at Rt=0.70 mins.

Example 864: tert-butyl2-(5-(2-(2-cyanopropan-2-yl)isonicotinamido)-2-methylphenyl)-4-morpholino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate

Step 2

To a solution of tert-butyl2-chloro-4-morpholino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate(1.0 equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DME (0.14 M) was added 2M Na₂CO₃ solution (3.0 equiv.)and the system was flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.1equiv.) was added to the reaction mix and the system was flushed onceagain with nitrogen. The reaction vial was capped and microwaved for 20minutes at 120° C. The crude was partitioned in H₂O/EtOAc. The organiclayer was isolated, dried over Na₂SO₄, filtered and concentrated. Crudewas purified on a silica gel column using heptane to 50% EtOAc inheptane. Isolated tert-butyl2-(5-(2-(2-cyanopropan-2-yl)isonicotinamido)-2-methylphenyl)-4-morpholino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylatein 35% yield. LCMS (m/z) [M+H]+=598 at Rt=1.03 min.

Step 3

To a solution of tert-butyl2-(5-(2-(2-cyanopropan-2-yl)isonicotinamido)-2-methylphenyl)-4-morpholino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate(1.0 equiv.) in DCM (0.04 M) was added TFA (15 equiv.) and the reactionmix was stirred at RT for 1 h. The solvent was removed under vacuum andthe residue was taken in DMSO and purified on the prep. Isolated2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-morpholino-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)phenyl)isonicotinamideas the TFA salt in 75% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.75 (s,6H) 2.37 (s, 3H) 3.03 (t, J=6.26 Hz, 2H) 3.40-3.53 (m, 7H) 3.71 (d,J=4.30 Hz, 5H) 4.24 (br. s., 3H) 7.39 (dd, J=8.22, 1.56 Hz, 1H)7.81-7.91 (m, 1H) 7.99 (s, 1H) 8.27 (s, 1H) 8.48 (d, J=8.22 Hz, 1H) 8.88(d, J=5.09 Hz, 1H) 9.08 (br. s., 2H) 13.31 (s, 1H). LCMS (m/z) (M+H)=498at Rt=0.57 mins.

Example 865:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-morpholino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)isonicotinamide

This compound was prepared following the same synthetic procedurereported for Example 864. 1H NMR (400 MHz, <dmso>) δ ppm 1.63-1.85 (m,6H) 2.37 (s, 3H) 2.79-2.91 (m, 2H) 3.50 (d, J=4.30 Hz, 5H) 3.70 (d,J=4.30 Hz, 4H) 4.24 (br. s., 2H) 5.74 (s, 1H) 7.38 (d, J=8.61 Hz, 1H)7.89 (d, J=4.30 Hz, 1H) 7.98 (s, 1H) 8.27 (s, 1H) 8.47 (d, J=8.22 Hz,1H) 8.86 (d, J=5.09 Hz, 1H) 9.16 (br. s., 2H) 13.07 (s, 1H). LCMS (m/z)(M+H)=498 at Rt=0.77 mins.

Example 866:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(4-morpholino-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)phenyl)isonicotinamide

This compound was prepared following a similar synthetic procedure asreported for Example 864. H NMR (400 MHz, <dmso>) δ ppm 1.63-1.76 (m,6H) 2.47 (s, 1H) 4.02 (br. s., 1H) 4.34 (br. s., 2H) 4.70 (br. s., 2H)7.25 (d, J=8.22 Hz, 1H) 7.70 (dd, J=8.22, 1.96 Hz, 1H) 7.81 (d, J=4.30Hz, 1H) 7.88-8.01 (m, 1H) 8.13 (d, J=1.96 Hz, 1H) 8.74 (d, J=5.09 Hz,1H) 9.43-9.66 (m, 2H) 10.55 (s, 1H). LCMS (m/z) (M+H)=484 at Rt=0.64mins.

Example 867:N-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 4

To a solution of 4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)morpholine (1.0equiv.) andN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(0.9 equiv) in DME (0.1 M) was added 2M Na₂CO₃ (3.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thereaction mix was partitioned in EtOAc/H₂O. The organic layer wasisolated, dried over Na₂SO₄, filtered and concentrated. The crude waspurified by HPLC givingN-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamideas the TFA salt in 6% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.13-2.66(m, 230H) 3.68-3.76 (m, 4H) 3.99 (d, J=4.70 Hz, 4H) 5.69 (s, 4H) 6.40(s, 1H) 7.56 (s, 1H) 7.75 (t, J=7.83 Hz, 1H) 7.94 (d, J=7.83 Hz, 1H)8.07 (s, 1H) 8.20 (d, J=2.35 Hz, 1H) 8.23 (d, J=7.83 Hz, 1H) 8.28 (s,1H) 8.90 (d, J=2.35 Hz, 1 H) 10.68 (s, 1H). LCMS (m/z) (M+H)=483 atRt=0.69 mins.

Example 868:N-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-(trifluoromethyl)picolinamide

Step 1

A round bottom flask containing a solution of4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)morpholine (1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv) and 2M Na₂CO₃ (3.0 equiv.) in DME (0.1 M) was flushed withnitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂ adduct (0.07 equiv.) wasadded to the solution and the system was flushed again for 10 moreminutes. The reaction mix was heated at 120° C. for 4 hr. under an inertatmosphere. The reaction mix was cooled to RT, diluted with water andextracted three times with EtOAc. The combined organics were dried overMgSO₄, filtered and concentrated. The crude was purified on a silica gelcolumn using DCM to 5% MeOH in DCM giving6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-amine in35% yield. LCMS (m/z) (M+H)=311 at Rt=0.38 mins.

Step 2

To a round bottom flask containing a solution of6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-amine(1.0 equiv.) and 4-(trifluoromethyl)picolinic acid (1.0 equiv) in DMF(0.1 M) was added HATU (1.0 equiv.) and DIEA (3.0 equiv.) and thereaction mix was left stirring overnight at RT. The reaction mix wasdiluted with water and was extracted three times with EtOAc/H₂O. Thecombined organics were dried over MgSO4, filtered and concentrated. Thecrude was purified by HPLC givingN-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-(trifluoromethyl)picolinamideas the TFA salt in 21% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.54 (s,4H) 3.74-3.81 (m, 5H) 4.04 (d, J=4.30 Hz, 4H) 6.46 (s, 1H) 7.61 (d,J=0.78 Hz, 1H) 8.08-8.16 (m, 2H) 8.36 (s, 1H) 8.45 (d, J=1.96 Hz, 1H)8.98-9.15 (m, 2H) 11.20 (s, 1H). LCMS (m/z) (M+H)=484 at Rt=0.71 mins.

Example 869:2-isopropyl-N-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)isonicotinamide

This compound was prepared following the same procedures described forExample 868. LCMS (m/z) (M+H)=458.1 at Rt=0.52 mins.

Example 870:2-(2-hydroxypropan-2-yl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)isonicotinamide

This compound was prepared following the same procedures described forExample 868. 1H NMR (400 MHz, <dmso>) δ ppm 1.43-1.52 (m, 7H) 2.52-2.57(m, 4H) 3.74-3.80 (m, 6H) 4.04 (d, J=4.30 Hz, 4H) 6.47 (s, 1H) 7.62 (s,1H) 7.74 (d, J=5.09 Hz, 1H) 8.13 (s, 1H) 8.18 (s, 1H) 8.30 (s, 1H) 8.70(d, J=5.09 Hz, 1H) 8.98 (d, J=1.96 Hz, 1H) 10.87 (s, 1H). LCMS (m/z)(M+H)=474.2 at Rt=0.49 mins.

Example 871:2-(1,1-difluoroethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)isonicotinamide

This compound was prepared following the same procedures described forExample 868. The final compound was purified on silica gel prep plateobtaining2-(1,1-difluoroethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)isonicotinamideas the free base. 1H NMR (400 MHz, <dmso>) δ ppm 1.90-2.08 (m, 3H)3.63-3.79 (m, 4H) 3.99 (d, J=4.30 Hz, 4H) 6.40 (s, 1H) 7.56 (s, 1H) 7.99(d, J=5.09 Hz, 1H) 8.07 (s, 1H) 8.16 (s, 1H) 8.20 (d, J=1.96 Hz, 1H)8.72-8.98 (m, 2H) 10.74-10.94 (m, 1H). LCMS (m/z) (M+H)=480.1 at Rt=0.64mins.

Example 872:3-(difluoromethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)benzamide

This compound was prepared following the same procedures described forExample 868. 1H NMR (400 MHz, <dmso>) δ ppm 3.72-3.82 (m, 4H) 4.04 (d,J=4.30 Hz, 4H) 6.46 (s, 1H) 6.97-7.32 (m, 1H) 7.61 (s, 1H) 7.67-7.74 (m,1H) 7.81 (d, J=7.83 Hz, 1H) 8.09-8.21 (m, 3H) 8.28 (d, J=1.96 Hz, 1H)8.97 (d, J=2.35 Hz, 1H) 10.70 (s, 1H). LCMS (m/z) (M+H)=465.1 at Rt=0.67mins.

Example 873:4-(1,2-dihydroxyethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

This compound was prepared following the same procedures described forExample 868. LCMS (m/z) (M+H)=543.1 at Rt=0.57 mins.

Example 874:3-(difluoromethyl)-N-(4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)phenyl)benzamide

Step 1

A mixture of 8-bromo-6-chloroimidazo[1,2-b]pyridazine (1.0 equiv.),R,S-2-carboxymorpholine hydrochloride (1.0 equiv.) and DIEA (3.0 equiv.)in DMF (0.57 M) was stirred at RT overnight. LCMS showed conversion tothe desired product. The reaction mix was concentrated to dryness togive 4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)morpholine-2-carboxylicacid as a brown syrup which was used as is in the next step. LCMS (m/z)(M+H)=282 at Rt=0.53 mins.

Step 2

1-hydroxy-7-azabenzotriazole (1.0 equiv.) was added to a solution of4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)morpholine-2-carboxylic acid(1.0 equiv.), EDC.HCl (1.0 equiv.) methyl amine (2M THF, 1.2 equiv.) andDIEA (30. Equiv.) in DMF (0.14 M), and the mixture was left stirring atRT during the weekend. The reaction mix was treated with water andextracted three times with EtOAc. The combined organics were dried overNa₂SO₄, filtered and concentrated and the crude was purified on theHPLC. The desired4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)-N-methylmorpholine-2-carboxamidewas isolated as the TFA salt in 60% yield. LCMS (m/z) (M+H)=296 atRt=0.56 mins.

Step 3

To a solution of4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)-N-methylmorpholine-2-carboxamide(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv) in DME (0.04 M) was added 2M Na₂CO₃ (5.0 equiv.) and thesystem was flushed with nitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂adduct (0.1 equiv.) was added and the system was flushed once again. Thevial was capped and place in a microwave reactor for 20 minutes at 120°C. The reaction mix was concentrated to dryness and the crude waspurified by HPLC giving4-(6-(5-amino-2-methylpyridin-3-yl)imidazo[1,2-b]pyridazin-8-yl)-N-methylmorpholine-2-carboxamideas the TFA salt in 32% yield. LCMS (m/z) (M+H)=368 at Rt=0.48 mins.

Step 4

1-Hydroxy-7-azabenzotriazole was added to a solution of4-(6-(5-amino-2-methylpyridin-3-yl)imidazo[1,2-b]pyridazin-8-yl)-N-methylmorpholine-2-carboxamide(1.0 equiv.) and 3-(trifluoromethyl)benzoic acid (1.1 equiv) and EDC.HCl(1.0 equiv.) in DMF (0.03 M) and the reaction mix was left stirringovernight at RT. The reaction was not complete, additional 0.3 equiv. ofEDC.HCl and HOAt were added and the reaction was left stirring foradditional 24 hr. The reaction mix was concentrated to dryness and thecrude was purified by HPLC.N-methyl-4-(6-(2-methyl-5-(3-(trifluoromethyl)benzamido)pyridin-3-yl)imidazo[1,2-b]pyridazin-8-yl)morpholine-2-carboxamidewas obtained as the TFA salt in 39% yield. 1H NMR (400 MHz, <dmso>) bppm 2.61 (d, J=4.70 Hz, 3H) 3.15 (dd, J=12.91, 10.56 Hz, 1H) 3.71-3.84(m, 1H) 4.04 (d, J=11.35 Hz, 1H) 4.13 (dd, J=10.37, 2.54 Hz, 1H) 4.71(d, J=12.13 Hz, 1H) 5.19 (br. s., 1H) 6.49 (s, 1H) 7.64 (s, 1H) 7.80 (t,J=7.83 Hz, 1H) 7.89 (d, J=4.70 Hz, 1H) 7.99 (d, J=7.83 Hz, 1H) 8.14 (s,1H) 8.24-8.37 (m, 3H) 8.98 (d, J=1.96 Hz, 1H) 10.78 (s, 1H). LCMS (m/z)(M+H)=540 at Rt=0.72 mins.

Example 875:N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamide

Step 1

1-Hydroxy-7-azabenzotriazole (1.0 equiv.) was added to a solution of6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-amine(1.0 equiv.), 4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.0equiv) and EDC.HCl (1.0 equiv.) in DMF (0.11 M) and the reaction mix wasleft stirring at RT for 2 hr. The reaction was treated with water andthe precipitate was removed by filtration. The crude was p[urified onsilica gel column using DCM to 10% MeOH in DCM.4-(Bromomethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamidewas isolated in 59% yield. LCMS (m/z) (M+H)=531 at Rt=0.78 mins.

Step 2

Methylamine 2M in THF (60 equiv.) was added to a solution4-(Bromomethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and the vial was sealed and heated to 70° C. overnight. Thereaction mix was concentrated to dryness and the crude was purified byHPLC to give the desiredN-(6-methyl-5-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)pyridin-3-yl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamideas the TFA salt in 63% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.52-2.57(m, 4H) 2.71 (t, J=4.70 Hz, 3H) 3.72-3.80 (m, 5H) 4.39 (br. s., 2H) 6.46(s, 1H) 7.62 (d, J=0.78 Hz, 1H) 7.90 (d, J=8.22 Hz, 1H) 8.12 (d, J=1.17Hz, 1H) 8.27 (d, J=2.35 Hz, 1H) 8.35-8.43 (m, 2H) 8.97 (d, J=2.35 Hz,1H) 9.07 (br. s., 2H) 10.83 (s, 1H). LCMS (m/z) (M+H)=526 at Rt=0.52mins.

Example 876:N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-4-(trifluoromethyl)picolinamide

Step 1

A round bottom flask containing a solution of4-(6-bromoimidazo[1,2-a]pyridin-8-yl)morpholine (1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv) and 2M Na₂CO₃ (3.0 equiv.) in DME (0.1 M) was flushed withnitrogen for 5 minutes. PdCl₂(dppf).CH₂Cl₂ adduct (0.07 equiv.) wasadded to the solution and the system was flushed again for 10 moreminutes. The reaction mix was heated at 120° C. for 4 hr. under an inertatmosphere. The reaction mix was cooled to RT, diluted with water andextracted three times with EtOAc. The combined organics were dried overMgSO₄, filtered and concentrated. The crude was purified on a silica gelcolumn using DCM to 5% MeOH in DCM giving6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-amine in27% yield. LCMS (m/z) (M+H)=310 at Rt=0.29 mins.

Step 2

To a round bottom flask containing a solution of6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-amine (1.0equiv.) and 4-(trifluoromethyl)picolinic acid (1.0 equiv) in DMF (0.07M) was added HATU (1.1 equiv.) and DIEA (2.0 equiv.) and the reactionmix was left stirring overnight at RT. The reaction mix was diluted withwater and was extracted three times with EtOAc/H₂O. The combinedorganics were dried over MgSO4, filtered and concentrated. The crude waspurified by HPLC givingN-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-4-(trifluoromethyl)picolinamideas the TFA salt in 38% yield. 1H NMR (400 MHz, <dmso>) b ppm 3.76-3.89(m, 21H) 7.97 (br. s., 1H) 8.12 (d, J=4.30 Hz, 1H) 8.19 (br. s., 1H)8.31-8.40 (m, 3H) 8.53 (br. s., 1H) 8.95-9.14 (m, 2H) 11.19 (s, 1H).LCMS (m/z) (M+H)=483 at Rt=0.6 mins.

Example 877:4-cyano-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

This compound was prepared following the same procedures described forExample 876. LCMS (m/z) (M+H)=507.1 at Rt=0.59 mins.

Example 878:2-(2-hydroxypropan-2-yl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)isonicotinamide

This compound was prepared following the same procedures described forExample 876. 1H NMR (400 MHz, <dmso>) δ ppm 1.47 (s, 6H) 3.28 (br. s.,5H) 3.83 (br. s., 4H) 7.71 (d, J=3.91 Hz, 1H) 8.05 (br. s., 1H) 8.16 (s,1H) 8.20-8.28 (m, 2H) 8.57 (br. s., 1H) 8.70 (d, J=5.09 Hz, 1H) 8.89 (d,J=1.96 Hz, 1H) 10.84 (s, 1H). LCMS (m/z) (M+H)=473.3 at Rt=0.39 mins.

Example 879:2-(1,1-difluoroethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)isonicotinamide

This compound was prepared following the same procedures described forExample 876. 1H NMR (400 MHz, <dmso>) δ ppm 2.06 (t, J=19.17 Hz, 3H)3.27 (br. s., 5H) 7.25 (br. s., 1H) 8.01-8.15 (m, 2H) 8.22 (s, 1H) 8.28(s, 2H) 8.62 (s, 1H) 8.89-8.95 (m, 2H) 10.95-11.08 (m, 1H). LCMS (m/z)(M+H)=479.3 at Rt=0.52 mins.

Example 880:3-(difluoromethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzamide

This compound was prepared following the same procedures described forExample 876. 1H NMR (400 MHz, <dmso>) δ ppm 3.67-3.92 (m, 7H) 6.92-7.36(m, 2H) 7.66-7.74 (m, 2H) 7.81 (d, J=7.83 Hz, 2H) 8.11-8.20 (m, 5H) 8.23(s, 2H) 8.50 (br. s., 1H) 8.88 (d, J=1.96 Hz, 1H) 10.70 (s, 1H). LCMS(m/z) (M+H)=464.2 at Rt=0.53 mins.

Example 881:2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)isonicotinamide

This compound was prepared following the same procedures described forExample 876. 1H NMR (400 MHz, <dmso>) δ ppm 1.61-1.83 (m, 7H) 3.25 (br.s., 4H) 7.24 (br. s., 1 H) 7.88 (d, J=3.91 Hz, 1H) 8.02 (s, 1H) 8.11(br. s., 1H) 8.20-8.30 (m, 2H) 8.60 (s, 1H) 8.83 (d, J=4.70 Hz, 1H) 8.88(d, J=1.96 Hz, 1H) 10.92 (s, 1H). LCMS (m/z) (M+H)=482.4 at Rt=0.52mins.

Example 882:2-isopropyl-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)isonicotinamide

This compound was prepared following the same procedures described forExample 876. 1H NMR (400 MHz, <dmso>) δ ppm 1.25-1.34 (m, 7H) 2.52 (s,7H) 3.05-3.18 (m, 1H) 3.20-3.35 (m, 4H) 7.07-7.26 (m, 1H) 7.70 (dd,J=5.09, 1.17 Hz, 1H) 7.76 (s, 1H) 8.06 (br. s., 1H) 8.24 (d, J=1.96 Hz,2H) 8.57 (s, 1H) 8.71 (d, J=5.09 Hz, 1H) 8.88 (d, J=1.96 Hz, 1H)10.64-10.91 (m, 1H). LCMS (m/z) (M+H)=457.2 at Rt=0.42 mins.

Example 883:N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

This compound was prepared following the same procedures described forExample 876. 1H NMR (400 MHz, <dmso>) δ ppm 3.25 (br. s., 4H) 3.83 (d,J=4.70 Hz, 3H) 3.84 (br. s., 1H) 7.23 (br. s., 1H) 7.75-7.86 (m, 1H)8.00 (d, J=7.83 Hz, 1H) 8.10 (br. s., 1H) 8.23-8.35 (m, 4H) 8.51-8.68(m, 1H) 8.91 (d, J=2.35 Hz, 1H) 10.83 (s, 1H). LCMS (m/z) (M+H)=482.3 atRt=0.60 mins.

Example 884:N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <dmso>) ppm 3.25 (br. s., 4H) 3.83 (d, J=4.70 Hz, 3H)3.84 (br. s., 1H) 7.23 (br. s., 1H) 7.75-7.86 (m, 1H) 8.00 (d, J=7.83Hz, 1H) 8.10 (br. s., 1H) 8.23-8.35 (m, 4H) 8.51-8.68 (m, 1H) 8.91 (d,J=2.35 Hz, 1H) 10.83 (s, 1H). LCMS (m/z) (M+H)=482.3 at Rt=0.60 mins.

Example 885:N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamide

Step 1

1-Hydroxy-7-azabenzotriazole (1.0 equiv.) was added to a solution of4-methyl-3-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)aniline (1.0 equiv.),4-(bromomethyl)-3-(trifluoromethyl)benzoic acid (1.0 equiv) and EDC.HCl(1.0 equiv.) in DMF (0.1 M) and the reaction mix was left stirring at RTfor 1 hr. The reaction was treated with water and the precipitate wasremoved by filtration. The solid4-(bromomethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamidewas dried and used as is in the next step. LCMS (m/z) (M+H)=530 atRt=0.65 mins.

Step 2

Methylamine 2M in THF (60 equiv.) was added to a solution4-(bromomethyl)-N-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and the vial was sealed and heated to 70° C. overnight. Thereaction mix was concentrated to dryness and the crude was purified byHPLC to give the desiredN-(6-methyl-5-(8-morpholinoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-4-((methylamino)methyl)-3-(trifluoromethyl)benzamideas the TFA salt in 33% yield. LCMS (m/z) (M+H)=526 at Rt=0.56 mins.

Example 886:N-(6-methyl-5-(4-morpholino-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

To a flask containing 2,4-dichloro-5,7-dihydrothieno[3,4-d]pyrimidine(1.0 equiv.) in EtOH (2.4 M) was added morpholine (10.0 equiv.) and thereaction mix was stirred at RT for 30 min. The solvent was removed undervacuum and the crude4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)morpholine was usedas is in the next step. Yield was assumed to be quantitative. LCMS (m/z)(M+H)=254/258 at Rt=0.68 mins.

Step 2

To a solution of4-(2-chloro-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)morpholine (1.0equiv.) andN-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide(1.0 equiv) in DME (0.12 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 120° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by on a silica gel column usingheptane to 90% EtOAc in heptane givingN-(6-methyl-5-(4-morpholino-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamidein 51% yield. LCMS (m/z) (M+H)=502 at Rt=0.81 mins.

Step 3

A solution of oxone (2.3 equiv.) in 3 ml of water was added portionwiseto a solution ofN-(6-methyl-5-(4-morpholino-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in THF (0.013 M) at 0° C. and the reaction mix was leftstirring for 4 hr at the same temperature. The reaction mix was dilutedwith DCM and washed three times with 0.5 M aqueous Na₂CO₃. It was driedover Na₂SO₄, filtered and concentrated. The crude was purified by HPLCgivingN-(6-methyl-5-(4-morpholino-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamideas the TFA salt in 38% yield. 1H NMR (400 MHz, <dmso>) b ppm 2.52 (s,1H) 2.69-2.81 (m, 3H) 3.68 (d, J=4.30 Hz, 10H) 4.56 (s, 2H) 4.74 (s, 2H)7.81 (t, J=7.83 Hz, 1H) 8.00 (d, J=7.83 Hz, 1H) 8.21-8.42 (m, 2H) 8.72(d, J=1.96 Hz, 1H) 9.04 (d, J=1.96 Hz, 1H) 10.84 (s, 1H). LCMS (m/z)(M+H)=515 at Rt=0.89 mins.

Example 887:2-methyl-3-(4-morpholino-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-5-(3-(trifluoromethyl)benzamido)pyridine1-oxide

mCPBA (2.2 equiv was added portionwise to a solution ofN-(6-methyl-5-(4-morpholino-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.024 M) at 0° C. and the reaction mix was leftstirring overnight at RT. The reaction mix was diluted with DCM andwashed three times with 0.5 M aqueous Na₂CO₃. It was dried over Na₂SO₄,filtered and concentrated. The crude was purified by HPLC giving2-methyl-3-(4-morpholino-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)-5-(3-(trifluoromethyl)benzamido)pyridine1-oxide as the TFA salt in 19% yield. 1H NMR (400 MHz, <dmso>) δ ppm2.54 (s, 2H) 3.53-3.79 (m, 6H) 3.81-4.27 (m, 6H) 4.56 (s, 2H) 4.75 (s,1H) 7.75-7.85 (m, 1H) 7.96-8.05 (m, 1H) 8.20-8.37 (m, 1H) 8.98-9.11 (m,1H) 10.79 (s, 1H). LCMS (m/z) (M+H)=550 at Rt=0.76 mins.

Example 888:4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

Step 2

To a solution of 4-(6-chloroimidazo[1,2-b]pyridazin-8-yl)morpholine (1.0equiv.)4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(3-(trifluoromethyl)phenyl)benzamide(0.9 equiv) in DME (0.11 M) was added 2M sodium carbonate (3.0 equiv.)and the system was flushed with nitrogen for 5 minutes.PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.) was added and the system wasflushed once again. The vial was capped and place in a microwave reactorfor 20 minutes at 120° C. The reaction mix was partitioned in EtOAc/H₂O.The organic layer was isolated, dried over Na₂SO₄, filtered andconcentrated. The crude was purified by HPLC giving4-methyl-3-(8-morpholinoimidazo[1,2-b]pyridazin-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamidein 40% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.35 (s, 3H) 3.66-3.76 (m,4H) 3.99 (br. s., 4H) 6.36 (s, 1H) 7.39 (d, J=7.83 Hz, 1H) 7.46 (d,J=7.83 Hz, 1H) 7.50-7.57 (m, 2H) 7.89-7.96 (m, 1H) 7.97-8.03 (m, 2H)8.05 (s, 1H) 8.18 (s, 1H) 10.46 (s, 1H). LCMS (m/z) (M+H)=482 at Rt=0.88mins.

Example 889:4-methyl-3-(4-morpholino-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)-N-(3-(trifluoromethyl)phenyl)benzamide

Step 1

To a flask containing 2,4-dichloropyrido[2,3-d]pyrimidine (1 equiv.) inTHF (0.46) was added morpholine (1.2 equiv.) and the reaction mix wasstirred at RT for 1 h. The reaction mixture was concentrated to drynessand the crude tert-butyl2-chloro-4-morpholino-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate wasused as is in the next step. Yield is assumed to be quantitative. LCMS(m/z) [M+H]+=341 at Rt=0.91 min.

Step 2

To a solution of tert-butyl2-chloro-4-morpholino-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(3-(trifluoromethyl)phenyl)benzamide(0.9 equiv.) in DME (0.44 M) was added 2M Na₂CO₃ solution (3.0 equiv.)and the system was flushed with nitrogen. PdCl₂(dppf).CH₂Cl₂ adduct (0.1equiv.) was added to the reaction mix and the system was flushed onceagain with nitrogen. The reaction vial was capped and microwaved for 20minutes at 120° C. The crude was partitioned in H2O/EtOAc. The organiclayer was isolated, dried over Na₂SO₄, filtered and concentrated. Thecrude was purified on a silica gel column using heptane to 50% EtOAc inheptane. Isolated tert-butyl2-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-4-morpholino-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylatein 28% yield. LCMS (m/z) [M+H]+=584 at Rt=0.95 min.

Step 3

To a solution of tert-butyl2-(2-methyl-5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-4-morpholino-5H-pyrrolo[3,4-d]pyrimidine-6(7H)-carboxylate(1.0 equiv.) in DCM (0.07 M) was added TFA (10 equiv.) and the reactionmix was stirred at RT overnight. The solvent was removed under vacuumand the residue was taken in DMSO and purified on the prep. Isolated4-methyl-3-(4-morpholino-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)-N-(3-(trifluoromethyl)phenyl)benzamideas the TFA salt in 24% yield. 1H NMR (400 MHz, <dmso>) δ ppm 2.56 (s,3H) 3.69 (br. s., 10H) 4.43 (br. s., 2H) 4.76 (br. s., 2H) 7.46 (dd,J=14.09, 7.83 Hz, 2H) 7.59 (t, J=8.02 Hz, 1H) 7.98 (dd, J=7.83, 1.57 Hz,1H) 8.04 (d, J=8.22 Hz, 1H) 8.24 (s, 1H) 8.34 (d, J=1.17 Hz, 1H) 9.67(br. s., 2H) 10.42-10.65 (m, 1H). LCMS (m/z) (M+H)=484 at Rt=0.76 mins.

Example 899:6-(1-cyanocyclopropyl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.83-1.92 (m, 2H) 1.94-2.03 (m, 2H) 2.20(s, 3H) 2.88 (br. s., 4H) 3.40 (s, 3H) 3.69 (d, J=3.91 Hz, 4H) 5.75 (d,J=1.57 Hz, 1H) 6.00 (d, J=1.17 Hz, 1H) 7.26 (d, J=8.22 Hz, 1H) 7.56 (d,J=1.96 Hz, 1H) 7.63 (dd, J=8.22, 1.96 Hz, 1H) 7.96 (d, J=1.56 Hz, 1H)9.49 (d, J=1.57 Hz, 1H) 10.67 (s, 1H). LCMS (m/z) (M+H)=471.1, Rt=0.71min.

Example 900:4-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)picolinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.67-1.78 (m, 6H) 2.25 (s, 3H) 2.94 (br.s., 4H) 3.45 (s, 3H) 3.70-3.76 (m, 4H) 5.82 (d, J=1.57 Hz, 1H) 6.02-6.13(m, 1H) 7.27 (d, J=8.61 Hz, 1H) 7.75-7.89 (m, 3H) 8.24 (d, J=1.57 Hz,1H) 8.77 (d, J=5.48 Hz, 1H) 10.69 (s, 1H). LCMS (m/z) (M+H)=472.2,Rt=0.84 min.

Example 901:N-(4-methyl-3-(1-methyl-6-morpholino-2-oxo-1,2-dihydropyridin-4-yl)phenyl)-5-(trifluoromethyl)nicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.24 (s, 3H) 2.93 (br. s., 4H) 3.45 (s,3H) 3.70-3.75 (m, 4H) 5.80 (d, J=1.57 Hz, 1H) 6.05 (d, J=1.57 Hz, 1H)7.29 (d, J=8.22 Hz, 1H) 7.63 (d, J=1.96 Hz, 1H) 7.70 (dd, J=8.22, 2.35Hz, 1H) 8.66 (s, 1H) 9.16 (d, J=0.78 Hz, 1H) 9.35 (d, J=1.57 Hz, 1H)10.61 (s, 1H). LCMS (m/z) (M+H)=473.1, Rt=0.80 min.

Example 902:6-(1-cyanocyclopropyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl) pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.87-1.97 (m, 2H) 1.97-2.06 (m, 2H) 2.25(s, 3H) 3.08 (br. s., 4H) 3.48 (s, 3H) 3.65-3.77 (m, 4H) 6.68 (d, J=1.96Hz, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.38 (d, J=1.96 Hz, 1H) 7.59 (d, J=1.96Hz, 1H) 7.63 (dd, J=8.22, 2.35 Hz, 1H) 8.01 (d, J=1.96 Hz, 1H) 9.54 (d,J=1.96 Hz, 1H) 10.68 (s, 1H). LCMS (m/z) (M+H)=471.1, Rt=0.67 min.

Example 903:4-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)picolinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.74 (s, 6H) 2.25 (s, 3H) 3.10 (br. s.,4H) 3.48 (s, 3H) 3.67-3.73 (m, 4H) 6.71 (d, J=1.96 Hz, 1H) 7.25 (d,J=8.22 Hz, 1H) 7.40 (d, J=2.35 Hz, 1H) 7.73-7.86 (m, 3H) 8.24 (d, J=1.57Hz, 1H) 8.77 (d, J=5.09 Hz, 1H) 10.63 (s, 1H). LCMS (m/z) (M+H)=472.1,Rt=0.82 min.

Example 904:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)nicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.25 (s, 3H) 3.09 (br. s., 4H) 3.48 (s,3H) 3.66-3.73 (m, 4H) 6.69 (d, J=1.96 Hz, 1H) 7.27 (d, J=8.22 Hz, 1H)7.39 (d, J=2.35 Hz, 1H) 7.61 (d, J=1.96 Hz, 1H) 7.66 (dd, J=8.22, 1.96Hz, 1H) 8.66 (s, 1H) 9.16 (s, 1H) 9.35 (d, J=1.57 Hz, 1H) 10.57 (s, 1H).LCMS (m/z) (M+H)=473.0, Rt=0.77 min.

Example 905:4-(1,1-difluoroethyl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)picolinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.03 (t, J=19.17 Hz, 3H) 2.26 (s, 3H)3.10 (br. s., 4H) 3.48 (s, 3H) 3.63-3.76 (m, 4H) 6.72 (d, J=1.96 Hz, 1H)7.26 (d, J=8.22 Hz, 1H) 7.40 (d, J=1.96 Hz, 1H) 7.77 (d, J=1.96 Hz, 1H)7.81 (dd, J=8.22, 1.96 Hz, 1H) 7.83-7.87 (m, 1H) 8.22 (s, 1H) 8.88 (d,J=5.09 Hz, 1H) 10.67 (s, 1H). LCMS (m/z) (M+H)=469.1, Rt=0.85 min.

Example 906:4-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)picolinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.45 (s, 6H) 2.25 (s, 3H) 3.10 (br. s.,4H) 3.48 (s, 3H) 3.66-3.74 (m, 4H) 6.72 (d, J=1.96 Hz, 1H) 7.24 (d,J=8.61 Hz, 1H) 7.40 (d, J=1.96 Hz, 1H) 7.70 (dd, J=5.09, 1.57 Hz, 1H)7.76 (d, J=1.96 Hz, 1H) 7.80 (dd, J=8.41, 2.15 Hz, 1H) 8.23 (d, J=1.17Hz, 1H) 8.63 (d, J=5.09 Hz, 1H) 10.55 (s, 1H). LCMS (m/z) (M+H)=463.1,Rt=0.71 min.

Example 907:4-(2-fluoropropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)picolinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.66 (s, 3H) 1.72 (s, 3H) 2.26 (s, 3H)3.10 (br. s., 4H) 3.48 (s, 3H) 3.67-3.74 (m, 4H) 6.72 (d, J=1.96 Hz, 1H)7.25 (d, J=8.22 Hz, 1H) 7.40 (d, J=1.96 Hz, 1H) 7.68 (dd, J=5.09, 1.96Hz, 1H) 7.76 (d, J=1.96 Hz, 1H) 7.80 (dd, J=8.22, 1.96 Hz, 1H) 8.13 (d,J=1.17 Hz, 1H) 8.72 (d, J=5.09 Hz, 1H) 10.60 (s, 1H). LCMS (m/z)(M+H)=465.1, Rt=0.87 min.

Example 908:3-(2-aminopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamide

Step 1

To a solution of5-(5-amino-2-methylphenyl)-1-methyl-3-morpholinopyridin-2(1H)-one (1.0equiv.) and3-(2-((tert-butoxycarbonyl)amino)propan-2-yl)-5-(trifluoromethyl)benzoicacid (1.0 equiv.) in DMF (0.1 M) was added EDC (2.2 equiv.) and HOAt(2.2 equiv.) and the reaction was stirred at rt until completion.Purified via reverse phase HPLC and lyophilize to give tert-butyl(2-(3-((4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)carbamoyl)-5-(trifluoromethyl)phenyl)propan-2-yl)carbamatethat was used for the next step. LCMS (m/z) (M+H)=629.3, Rt=1.00 min.

Step 2

A solution of tert-butyl(2-(3-((4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)carbamoyl)-5-(trifluoromethyl)phenyl) propan-2-yl)carbamate (1.0equiv.) was dissolved in DCM and TFA (4:1) and the reaction was stirredat rt for 4 hours. Concentrated to dryness and dissolved in acetonitrileand water and lyophilized to give3-(2-aminopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-5-(trifluoromethyl)benzamidein 57% yield. ¹H NMR (400 MHz, <dmso>) δ ppm 1.70 (s, 6H) 2.26 (s, 3H)3.02-3.13 (m, 4H) 3.48 (s, 3H) 3.65-3.75 (m, 4H) 6.68 (d, J=2.35 Hz, 1H)7.28 (d, J=8.61 Hz, 1H) 7.38 (d, J=2.35 Hz, 1H) 7.59 (d, J=2.35 Hz, 1H)7.68 (dd, J=8.22, 2.35 Hz, 1H) 8.08 (s, 1H) 8.34 (s, 2H) 10.49 (s, 1H).LCMS (m/z) (M+H)=529.1, Rt=0.68 min.

Example 909:N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)-5-(trifluoromethyl)nicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.29 (s, 3H) 3.42-3.47 (m, 4H) 3.65-3.72(m, 7H) 6.58 (s, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.67-7.80 (m, 2H) 8.68 (s,1H) 9.16 (d, J=0.78 Hz, 1H) 9.36 (d, J=1.57 Hz, 1H) 10.62 (s, 1H). LCMS(m/z) (M+H)=474.2, Rt=0.85 min.

Example 910:4-(2-cyanopropan-2-yl)-N-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)picolinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.74 (s, 6H) 2.30 (s, 3H) 3.41-3.50 (m,4H) 3.67 (s, 3H) 3.68-3.72 (m, 4H) 6.60 (s, 1H) 7.24-7.31 (m, 1H) 7.82(dd, J=5.09, 1.96 Hz, 1H) 7.86 (dd, J=8.22, 2.35 Hz, 1H) 7.92 (d, J=1.96Hz, 1H) 8.25 (d, J=1.57 Hz, 1H) 8.77 (d, J=5.09 Hz, 1H) 10.68 (s, 1H).LCMS (m/z) (M+H)=473.3, Rt=0.92 min.

Synthesis of5-(6-isopropoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine

Step 1

To a solution of 4-(3,6-dichloropyridazin-4-yl)morpholine (1.0 equiv.)and propan-2-01 (1.8 equiv.) in THF (0.3M) was added sodium hydride (2.0equiv.) and the reaction was stirred at room temperature untilcompletion. The mixture was quenched with water and extracted with ethylacetate twice. The combined organics were washed with brine and driedover sodium sulfate. The crude material was purified via silica gelchromatography (ISCO, 10% methanol/DCM) to give4-(6-chloro-3-isopropoxypyridazin-4-yl)morpholine in 72% yield as awhite solid. LCMS (m/z) (M+H)=258.2/259.7, Rt=0.59 min.

Step 2

To a solution of 4-(6-chloro-3-isopropoxypyridazin-4-yl)morpholine (1.1equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv.) in DME (0.1 M) was added PdCl₂(dppf)-DCM adduct (0.5equiv.) and sodium carbonate (8.0 equiv, 2M aqueous solution) and themixture was heated to 110° C. for 15 min in the microwave. The reactionwas concentrated to dryness and then partitioned between ethyl acetateand water. The organic layer was washed with brine and dried over sodiumsulfate. The crude material was purified via silica gel chromatography(ISCO, 10% methanol/DCM) to give5-(6-isopropoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine in88% yield. LCMS (m/z) (M+H)=330.0, Rt=0.46 min.

Example 911:2-(2-fluoropropan-2-yl)-N-(5-(6-isopropoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.42 (s, 3H) 1.43 (s, 3H) 1.66 (s, 3H)1.72 (s, 3H) 3.74 (s, 7H) 5.28-5.43 (m, 1H) 7.37 (s, 1H) 7.83 (dd,J=4.89, 1.37 Hz, 1H) 8.04 (s, 1H) 8.36 (d, J=2.35 Hz, 1H) 8.78 (d,J=5.09 Hz, 1H) 8.94 (d, J=2.35 Hz, 1H) 10.95 (s, 1H). LCMS (m/z)(M+H)=495.3, Rt=0.70 min.

Example 912:2-(1,1-difluoroethyl)-N-(5-(6-isopropoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.42 (d, J=6.26 Hz, 6H) 1.98-2.11 (m, 3H)3.73 (br. s., 7H) 5.36 (spt, J=6.13 Hz, 1H) 7.34 (s, 1H) 8.03 (d, J=4.70Hz, 1H) 8.19 (s, 1H) 8.35 (d, J=2.35 Hz, 1H) 8.90 (d, J=5.09 Hz, 1H)8.93 (d, J=2.35 Hz, 1H) 11.02 (s, 1H). LCMS (m/z) (M+H)=499.3, Rt=0.69min.

Example 913:2-(difluoromethyl)-N-(5-(6-isopropoxy-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.42 (d, J=6.26 Hz, 6H) 3.74 (s, 7H)5.27-5.42 (m, 1H) 6.86-7.25 (m, 1H) 7.36 (s, 1H) 8.07 (d, J=4.69 Hz, 1H)8.19 (s, 1H) 8.36 (d, J=2.35 Hz, 1H) 8.87-8.98 (m, 2H) 11.04 (s, 1H).LCMS (m/z) (M+H)=485.3, Rt=0.66 min.

Synthesis of5-(6-(2,2-difluoroethoxy)-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-amine

Step 1

NaH (3.0 equiv.) was added slowly in portions to a solution of2,2-difluoroethanol (3.0 equiv.) and4-(3,6-dichloropyridazin-4-yl)morpholine (1.0 equiv.) in THF (0.15 M)under nitrogen. The solution was stirred at room temperature for 2hours. Quenched by the addition of water and extracted 3 times withethyl acetate. The organics were combined dried with sodium sulfate,filtered and concentrated. The crude material was purified via silicagel column chromatography eluting with ethyl acetate and hepanes(product elutes at about 50/50 ethyl acetate/heptanes). The purefractions were concentrated to give4-(6-chloro-3-(2,2-difluoroethoxy)pyridazin-4-yl)morpholine as a whitesolid in 65% yield. LCMS (m/z) (M+H)=279.9, Rt=0.59 min.

Step 2

To a solution of4-(6-chloro-3-(2,2-difluoroethoxy)pyridazin-4-yl)morpholine (1.0 equiv.)in DME and 2M Na₂CO₃ (3:1, 0.18 M) was added6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.2 equiv.) and PdCl₂(dppf).CH₂Cl₂ adduct (0.1 equiv.). The reactionwas heated to reflux for 3 hours, then cooled to room temperature.Partitioned between water and ethyl acetate, the organic phase was driedwith sodium sulfate, filtered and concentrated. Purification via silicagel column chromatography eluting with 0-100 ethyl acetate in heptanesfollowed by 10% methanol in ethyl acetate give5-(6-(2,2-difluoroethoxy)-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-aminein 60% yield. LCMS (m/z) (M+H)=352, Rt=0.39 min.

Example 914:N-(5-(6-(2,2-difluoroethoxy)-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-2-(1,1-difluoropropyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.01 (t, J=7.43 Hz, 3H) 2.20-2.47 (m,2H) 2.56 (s, 3H) 3.89 (d, J=5.09 Hz, 8H) 4.77 (td, J=14.28, 3.13 Hz, 2H)6.17-6.56 (m, 1H) 7.39 (s, 1H) 7.99 (d, J=3.91 Hz, 1H) 8.20 (s, 1H) 8.56(d, J=2.74 Hz, 1H) 8.85 (d, J=5.09 Hz, 1H) 8.93 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=535.2, Rt=0.72 min.

Example 915:N-(5-(6-(2,2-difluoroethoxy)-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-2-(1,1-difluoroethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.94 (t, J=18.78 Hz, 3H) 2.43 (s, 3H)3.31-3.44 (m, 4H) 3.69-3.86 (m, 4H) 4.63-4.73 (m, 2H) 6.07-6.47 (m, 1H)7.01 (s, 1H) 7.90 (d, J=4.70 Hz, 1H) 8.12 (s, 1H) 8.19 (d, J=2.35 Hz,1H) 8.73 (d, J=4.70 Hz, 1H) 8.80 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=521.1, Rt=0.64 min.

Example 916:N-(5-(6-(2,2-difluoroethoxy)-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-4-(trifluoromethyl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.57 (s, 3H) 3.89 (d, J=4.30 Hz, 7H)4.77 (td, J=14.28, 3.13 Hz, 2H) 6.13-6.59 (m, 1H) 7.40 (s, 1H) 7.97 (d,J=3.91 Hz, 1H) 8.45 (s, 1H) 8.63 (d, J=2.35 Hz, 1H) 9.00 (d, J=5.09 Hz,1H) 9.11 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=525.1, Rt=0.73 min.

Example 917:N-(5-(6-(2,2-difluoroethoxy)-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-5-(trifluoromethyl)nicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.43 (s, 3H) 3.34-3.42 (m, 4H) 3.70-3.79(m, 4H) 4.62-4.74 (m, 2H) 6.03-6.47 (m, 1H) 7.02 (s, 1H) 8.19 (d, J=2.35Hz, 1H) 8.60 (s, 1H) 8.80 (d, J=2.35 Hz, 1H) 9.00 (s, 1H) 9.28 (d,J=1.57 Hz, 1H). LCMS (m/z) (M+H)=525.1, Rt=0.67 min.

Example 918:N-(5-(6-(2,2-difluoroethoxy)-5-morpholinopyridazin-3-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.56 (s, 3H) 3.88 (s, 8H) 4.77 (td,J=14.28, 3.52 Hz, 2H) 6.16-6.69 (m, 1H) 7.38 (s, 1H) 7.72-7.81 (m, 1H)7.94 (d, J=7.83 Hz, 1H) 8.17-8.35 (m, 2H) 8.55 (d, J=2.35 Hz, 1H) 8.93(d, J=2.74 Hz, 1H). LCMS (m/z) (M+H)=524.1, Rt=0.72 min.

Synthesis of6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-amine

To a solution of 4-(6-chloro-3-(methylsulfonyl)pyridazin-4-yl)morpholine(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv.) in DME (0.05 M) was added sodium carbonate (3.0 equiv., 2M)and purged with nitrogen. PdCl₂(dppf)-DCM adduct (0.06 equiv.) was addedto the reaction and the system was flushed once again with nitrogen. Thereaction was heated to 120° C. for 20 min in the microwave. The crudewas partitioned between water and ethyl acetate, the organic layer wasisolated, dried over sodium sulfate, filtered and concentrated. Thecrude material was purified via reverse phase chromatography (Gracesystem, 0-30% acetonitrile in water). Upon partial concentration, theprecipitate was filtered off and dried under high vacuo to give6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-aminein 54% yield. LCMS (m/z) (M+H)=350.2, Rt=0.40 min.

Synthesis of4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)aniline

To a solution of 4-(6-chloro-3-(methylsulfonyl)pyridazin-4-yl)morpholine(1.0 equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0equiv.) in DME (0.04 M) was added sodium carbonate (3.0 equiv., 2M) andpurged with nitrogen. PdCl₂(dppf)-DCM adduct (0.06 equiv.) was added tothe reaction and the system was flushed once again with nitrogen. Thereaction was heated to 120° C. for 20 min in the microwave. The crudewas partitioned between water and ethyl acetate, the organic layer wasisolated, dried over sodium sulfate, filtered and concentrated. Thecrude material was purified via silica gel chromatography (5% methanolin DCM) to give4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)aniline in 60%yield. LCMS (m/z) (M+H)=349.2, Rt=0.43 min.

Example 919:N-(6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide

To a solution of6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-amine(1.0 equiv.) in DMF was added DIEA (3.0 equiv.),3-(trifluoromethyl)benzoic acid (1.0 equiv.) and HATU (1.0 equiv.) andthe reaction was stirred at rt overnight. Partitioned between water andethyl acetate, the organic layer was isolated and the aqueous layer wasback-extracted with ethyl acetate. The combined organics were dried oversodium sulfate, filtered and concentrated. The crude material wasdissolved in DMSO and purified via reverse phase HPLC. The purefractions were lyophilized to giveN-(6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide in 35% yield. LCMS (m/z)(M+H)=522.1, Rt=0.68 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 919 above using the appropriatestarting materials.

Example 920:2-(1,1-difluoroethyl)-N-(6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.97-2.12 (m, 3H) 2.52-2.56 (m, 4H)3.47-3.56 (m, 8H) 3.70-3.78 (m, 4H) 4.09 (br. s., 1H) 7.54 (s, 1H) 8.05(d, J=4.70 Hz, 1H) 8.21 (s, 1H) 8.35 (d, J=2.35 Hz, 1H) 8.90 (d, J=5.09Hz, 1H) 8.96 (d, J=2.35 Hz, 1H) 10.90-11.02 (m, 1H). LCMS (m/z)(M+H)=519.2, Rt=0.59 min.

Example 921:N-(6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.52-2.56 (m, 3H) 3.47-3.57 (m, 7H)3.71-3.79 (m, 4H) 7.54 (s, 1H) 8.21 (d, J=4.69 Hz, 1H) 8.35 (d, J=2.35Hz, 1H) 8.39 (s, 1H) 8.95 (d, J=2.35 Hz, 1H) 9.01 (d, J=4.70 Hz, 1H)11.02 (s, 1H). LCMS (m/z) (M+H)=523.1, Rt=0.61 min.

Example 923:N-(6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-yl)-4-(trifluoromethyl)picolinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.53 (s, 5H) 3.72-3.78 (m, 7H) 7.54 (s,2H) 8.12 (d, J=4.69 Hz, 2H) 8.35 (s, 1H) 8.49 (d, J=2.35 Hz, 1H) 9.05(d, J=4.70 Hz, 1H) 9.11 (d, J=2.35 Hz, 1H) 11.10-11.28 (m, 1H). LCMS(m/z) (M+H)=523.1, Rt=0.65 min.

Example 924:2-(2-cyanopropan-2-yl)-N-(6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.76 (s, 6H) 2.52-2.56 (m, 4H) 3.47-3.56(m, 7H) 3.70-3.78 (m, 4H) 7.54 (s, 1H) 7.89 (dd, J=4.89, 1.37 Hz, 1H)8.03 (s, 1H) 8.33 (d, J=1.96 Hz, 1H) 8.83 (d, J=5.09 Hz, 1H) 8.95 (d,J=2.35 Hz, 1H) 10.90 (s, 1H). LCMS (m/z) (M+H)=522.2, Rt=0.59 min.

Example 925:2-(1,1-difluoropropyl)-N-(6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.93 (t, J=7.63 Hz, 3H) 2.26-2.42 (m, 2H)2.53 (s, 3H) 3.47-3.57 (m, 7H) 3.67-3.81 (m, 4H) 7.54 (s, 1H) 8.04 (d,J=3.91 Hz, 1H) 8.19 (s, 1H) 8.35 (d, J=2.35 Hz, 1H) 8.91 (d, J=4.70 Hz,1H) 8.96 (d, J=2.35 Hz, 1H) 10.97 (s, 1H). LCMS (m/z) (M+H)=533.1,Rt=0.64 min.

Example 926:2-(1,1-difluoropropyl)-N-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.93 (t, J=7.43 Hz, 3H) 2.31 (s, 3H)2.33-2.42 (m, 2H) 3.52 (s, 4H) 3.69-3.78 (m, 4H) 7.35-7.44 (m, 2H) 7.81(dd, J=8.41, 2.15 Hz, 1H) 7.90 (d, J=2.35 Hz, 1H) 8.02 (d, J=4.30 Hz,1H) 8.16 (s, 1H) 8.88 (d, J=5.09 Hz, 1H) 10.61-10.77 (m, 1H). LCMS (m/z)(M+H)=532.1, Rt=0.78 min.

Example 927:2-(2-fluoropropan-2-yl)-N-(6-methyl-5-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)pyridin-3-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.67 (s, 3H) 1.72 (s, 3H) 3.74 (d, J=4.70Hz, 4H) 7.53 (s, 1H) 7.84 (d, J=5.09 Hz, 1H) 8.05 (s, 1H) 8.33 (d,J=2.35 Hz, 1H) 8.77 (d, J=4.70 Hz, 1H) 8.94 (d, J=2.74 Hz, 1H) 10.87 (s,1H). LCMS (m/z) (M+H)=515.2, Rt=0.59 min.

Example 928:2-(2-fluoropropan-2-yl)-N-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.57-1.77 (m, 7H) 2.31 (s, 3H) 7.29-7.46(m, 2H) 7.77-7.84 (m, 2H) 7.90 (d, J=1.96 Hz, 1H) 7.94-8.07 (m, 1H) 8.75(d, J=5.09 Hz, 1H) 10.64 (s, 1H). LCMS (m/z) (M+H)=514.1, Rt=0.72 min.

Example 929:2-(1,1-difluoroethyl)-N-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.95-2.11 (m, 3H) 2.28-2.34 (m, 3H)3.43-3.57 (m, 7H) 3.69-3.78 (m, 4H) 7.34-7.45 (m, 2H) 7.81 (dd, J=8.22,1.96 Hz, 1H) 7.91 (d, J=2.35 Hz, 1H) 7.99-8.05 (m, 1H) 8.18 (s, 1H)8.77-8.95 (m, 1H) 10.72 (s, 1H). LCMS (m/z) (M+H)=518.1, Rt=0.74 min.

Example 930:N-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.27-2.36 (m, 3H) 3.43-3.56 (m, 8H)7.27-7.51 (m, 2H) 7.80 (dd, J=8.22, 2.35 Hz, 1H) 7.90 (d, J=1.96 Hz, 1H)8.10-8.27 (m, 1H) 8.29-8.45 (m, 1H) 8.89-9.06 (m, 1H) 10.77 (s, 1H).LCMS (m/z) (M+H)=522.1, Rt=0.76 min.

Example 931:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.66-1.83 (m, 8H) 2.32 (s, 4H) 3.49 (d,J=4.70 Hz, 5H) 3.72-3.78 (m, 6H) 7.36-7.45 (m, 2H) 7.79 (dd, J=8.22,1.96 Hz, 1H) 7.83-7.91 (m, 2H) 7.94-8.06 (m, 1H) 8.70-8.87 (m, 1H)10.57-10.71 (m, 1H). LCMS (m/z) (M+H)=521.1, Rt=0.72 min.

Example 932:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.48 (s, 6H) 2.27-2.34 (m, 3H) 3.42-3.57(m, 7H) 3.69-3.80 (m, 4H) 7.34-7.44 (m, 2H) 7.73 (dd, J=4.89, 1.37 Hz,1H) 7.80 (dd, J=8.22, 2.35 Hz, 1H) 7.90 (d, J=1.96 Hz, 1H) 8.16 (s, 1H)8.68 (d, J=5.09 Hz, 1H) 10.62 (s, 1H). LCMS (m/z) (M+H)=512.1, Rt=0.55min.

Example 933:N-(4-methyl-3-(6-(methylsulfonyl)-5-morpholinopyridazin-3-yl)phenyl)-4-(trifluoromethyl)picolinamide

1H NMR (400 MHz, <dmso>) δ ppm 2.25-2.37 (m, 3H) 3.37-3.62 (m, 7H)3.66-3.84 (m, 4H) 7.29-7.47 (m, 2H) 7.96 (dd, J=8.41, 2.15 Hz, 1H) 8.05(d, J=2.35 Hz, 1H) 8.09 (d, J=3.91 Hz, 1H) 8.33 (s, 1H) 9.02 (d, J=4.70Hz, 1H) 10.80-10.91 (m, 1H). LCMS (m/z) (M+H)=522.1, Rt=0.83 min.

Example 934:N-(5-(6-methoxy-5-morpholinopyridin-3-yl)-6-methylpyridazin-3-yl)-3-(trifluoromethyl)benzamide

Step 1

To a degassed mixture of4-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)morpholine(1.0 equiv.) and 4,6-dichloro-3-methylpyridazine (1.0 equiv.) in 4:11,4-dioxane:water (0.2 M) was added cesium carbonate (3.0 equiv.),Pd(OAc)₂ (0.1 equiv.) and tri-t-butylphosphine (1.0 M in toluene, 0.2equiv.). The reaction mixture was stirred at 75° C. for 5 hr. LC-MSshows a mixture of isomeric products. The cooled reaction mixture wasdiluted with water and extracted with ethyl acetate (2×). The combinedextracts were dried over sodium sulfate, filtered, concentrated, andpurified by flash chromatography over silica gel (ISCO, ethyl acetatewith 0-5% methanol gradient) to give4-(5-(6-chloro-3-methylpyridazin-4-yl)-2-methoxypyridin-3-yl)morpholinein 68% yield as a light brown, crystalline solid. The minor isomer isalso present (20%). LCMS (m/z) (M+H)=321.0, Rt=0.66 min.

Step 2

To a solution of4-(5-(6-chloro-3-methylpyridazin-4-yl)-2-methoxypyridin-3-yl)morpholineand4-(5-(5-chloro-6-methylpyridazin-3-yl)-2-methoxypyridin-3-yl)morpholine(1.0 equiv.) in 1,4-dioxane (0.2 M) was added ammonium hydroxide (32equiv.) and the mixture was stirred at 140° C. overnight. Upon overnightstirring, an additional 32 equiv. of ammonium hydroxide was added andthe mixture was stirred at 175° C. for 3 days. The reaction wasconcentrated to dryness to give5-(6-methoxy-5-morpholinopyridin-3-yl)-6-methylpyridazin-3-amine and6-(6-methoxy-5-morpholinopyridin-3-yl)-3-methylpyridazin-4-amine as amixture of isomers (1:1 ratio). LCMS (m/z) (M+H)=301.9, Rt=0.45 and 0.47min.

Step 3

To a solution of5-(6-methoxy-5-morpholinopyridin-3-yl)-6-methylpyridazin-3-amine and6-(6-methoxy-5-morpholinopyridin-3-yl)-3-methylpyridazin-4-amine (1.0equiv, mixture of isomers) in DCM (0.1 M) was added DIEA (5.0 equiv.)and 3-(trifluoromethyl)benzoyl chloride (2.2 equiv.). The mixture wasstirred at ambient temperature. LC-MS at 4 hr showed partial conversionto product. An additional 3.00 equiv of DIEA and 1.3 equiv of acylchloride were added. The reaction was stirred for 7 days at ambienttemperature. The reaction mixture was quenched with saturated aqueoussodium bicarbonate and extracted with DCM (2×). The combined extractswere dried over sodium sulfate, filtered, and concentrated. The crudeproduct was purified by reverse phase HPLC and lyophilized to giveN-(5-(6-methoxy-5-morpholinopyridin-3-yl)-6-methylpyridazin-3-yl)-3-(trifluoromethyl)benzamidein 28% yield as its TFA salt, a yellow solid. ¹H NMR (400 MHz, <cd3od>)δ ppm 2.76 (s, 3H) 3.15-3.23 (m, 4H) 3.83-3.93 (m, 4H) 4.08 (s, 3H) 7.39(d, J=2.35 Hz, 1H) 7.76-7.85 (m, 1H) 7.95-8.02 (m, 2H) 8.31 (d, J=8.22Hz, 1H) 8.37 (s, 1H) 8.70 (s, 1H). LCMS (m/z) (M+H)=474.1, Rt=0.85 min.

Example 935:N-(6′-(2,2-difluoroethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-5-(trifluoromethyl)nicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 3.08 (d, J=3.91 Hz, 4H) 3.69-3.75 (m, 4H)4.64 (td, J=15.16, 3.33 Hz, 2H) 6.21-6.64 (m, 1H) 7.32 (d, J=1.96 Hz,1H) 7.83 (d, J=1.96 Hz, 1H) 8.17 (d, J=1.96 Hz, 1H) 8.70 (s, 1H)8.91-9.01 (m, 1H) 9.21 (s, 1H) 9.39 (d, J=1.57 Hz, 1H) 11.00 (s, 1H).LCMS (m/z) (M+H)=524.3, Rt=0.74 min.

Example 936:6-(1-cyanocyclopropyl)-N-(6′-(2,2-difluoroethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.87-1.96 (m, 2H) 2.00-2.08 (m, 2H) 3.07(br. s., 4H) 3.70-3.75 (m, 4H) 4.64 (d, J=3.52 Hz, 2H) 6.26-6.63 (m, 1H)7.29 (d, J=1.96 Hz, 1H) 7.81 (d, J=1.96 Hz, 1H) 8.06 (dd, J=4.50, 2.15Hz, 2H) 8.87 (d, J=2.35 Hz, 1H) 9.56 (d, J=1.96 Hz, 1H) 11.03 (s, 1H).LCMS (m/z) (M+H)=522.1, Rt=0.68 min.

Example 937:N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(methylsulfonyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.86 (dtd, J=12.67, 8.34, 8.34, 3.91 Hz,2H) 2.08-2.22 (m, 2H) 2.71 (s, 3H) 3.15-3.26 (m, 7H) 3.69 (ddd, J=11.64,8.31, 3.13 Hz, 2H) 3.82-3.93 (m, 4H) 3.94-4.06 (m, 2H) 5.46 (tt, J=7.92,3.81 Hz, 1H) 7.34 (d, J=2.35 Hz, 1H) 7.82-7.92 (m, 2H) 8.25 (d, J=8.22Hz, 1H) 8.36 (d, J=7.83 Hz, 1H) 8.48 (d, J=2.35 Hz, 1H) 8.61 (s, 1H)9.36 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=553.1, Rt=0.61 min.

Example 938:2-(1,1-difluoroethyl)-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.86 (dtd, J=12.67, 8.34, 8.34, 3.91 Hz,2H) 2.07 (t, J=18.78 Hz, 3H) 2.12-2.22 (m, 2H) 2.71 (s, 3H) 3.16-3.23(m, 4H) 3.69 (ddd, J=11.64, 8.31, 3.13 Hz, 2H) 3.83-3.93 (m, 4H)3.94-4.07 (m, 2H) 5.46 (tt, J=7.83, 3.91 Hz, 1H) 7.33 (d, J=2.35 Hz, 1H)7.87 (d, J=1.96 Hz, 1H) 8.04 (d, J=4.30 Hz, 1H) 8.27 (s, 1H) 8.46 (d,J=2.35 Hz, 1H) 8.88 (d, J=5.09 Hz, 1H) 9.34 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=540.1, Rt=0.69 min.

Example 939:2-(2-hydroxypropan-2-yl)-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.64 (s, 6H) 1.76-1.91 (m, 2H) 2.06-2.20(m, 2H) 2.70 (s, 3H) 3.10-3.23 (m, 4H) 3.66 (ddd, J=11.64, 8.31, 3.13Hz, 2H) 3.80-3.91 (m, 4H) 3.91-4.04 (m, 2H) 5.44 (tt, J=7.83, 3.91 Hz,1H) 7.32 (d, J=1.96 Hz, 1H) 7.85 (d, J=2.35 Hz, 1H) 8.03 (dd, J=5.48,1.57 Hz, 1H) 8.39 (s, 1H) 8.51 (d, J=2.35 Hz, 1H) 8.78 (d, J=5.48 Hz,1H) 9.36 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=534.2, Rt=0.53 min.

Example 940:2-(1-cyanocyclopropyl)-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.77-1.94 (m, 6H) 2.07-2.23 (m, 2H) 2.67(s, 3H) 3.15-3.23 (m, 4H) 3.69 (ddd, J=11.64, 8.31, 3.13 Hz, 2H)3.83-3.93 (m, 4H) 3.94-4.05 (m, 2H) 5.46 (dt, J=8.12, 3.96 Hz, 1H) 7.33(d, J=1.96 Hz, 1H) 7.78 (dd, J=5.09, 1.57 Hz, 1H) 7.86 (d, J=2.35 Hz,1H) 8.17 (s, 1H) 8.39 (d, J=2.35 Hz, 1H) 8.71 (d, J=5.09 Hz, 1H) 9.24(d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=531.2, Rt=0.68 min.

Example 941:2-cyclopropyl-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.07-1.18 (m, 2H) 1.22 (dt, J=8.02, 3.03Hz, 2H) 1.86 (dtd, J=12.77, 8.29, 8.29, 3.91 Hz, 2H) 2.08-2.21 (m, 2H)2.23-2.36 (m, 1H) 2.71 (s, 3H) 3.15-3.24 (m, 4H) 3.68 (ddd, J=11.54,8.22, 3.33 Hz, 2H) 3.82-3.93 (m, 4H) 3.94-4.06 (m, 2H) 5.46 (tt, J=7.83,3.91 Hz, 1H) 7.33 (d, J=1.96 Hz, 1H) 7.81 (dd, J=5.48, 1.57 Hz, 1H) 7.87(d, J=2.35 Hz, 2H) 8.46 (d, J=2.35 Hz, 1H) 8.65 (d, J=5.48 Hz, 1H) 9.34(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=516.2, Rt=0.56 min.

Example 942:N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-4-(trifluoromethyl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.87 (dtd, J=12.67, 8.34, 8.34, 3.91 Hz,2H) 2.10-2.22 (m, 2H) 2.71 (s, 3H) 3.16-3.24 (m, 4H) 3.69 (ddd, J=11.64,8.31, 3.13 Hz, 2H) 3.84-3.94 (m, 4H) 3.94-4.06 (m, 2H) 5.47 (dt, J=8.12,3.96 Hz, 1H) 7.35 (d, J=1.96 Hz, 1H) 7.89 (d, J=1.96 Hz, 1H) 8.01 (d,J=3.91 Hz, 1H) 8.51 (s, 1H) 8.69 (d, J=2.35 Hz, 1H) 9.03 (d, J=5.09 Hz,1H) 9.44 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=544.2, Rt=0.75 min.

Example 943:4-(2-cyanopropan-2-yl)-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.76-1.93 (m, 8H) 2.09-2.22 (m, 2H) 2.71(s, 3H) 3.16-3.25 (m, 4H) 3.69 (ddd, J=11.64, 8.31, 3.13 Hz, 2H)3.83-3.94 (m, 4H) 3.94-4.05 (m, 2H) 5.47 (dt, J=7.83, 3.91 Hz, 1H) 7.35(d, J=1.96 Hz, 1H) 7.85 (dd, J=5.09, 1.96 Hz, 1H) 7.89 (d, J=2.35 Hz,1H) 8.44 (d, J=1.57 Hz, 1H) 8.69 (d, J=2.35 Hz, 1H) 8.82 (d, J=5.09 Hz,1H) 9.45 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=543.3, Rt=0.70 min.

Example 944:6-(1-cyanocyclopropyl)-N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.87 (dtd, J=12.77, 8.29, 8.29, 3.91 Hz,2H) 1.99-2.11 (m, 4H) 2.11-2.21 (m, 2H) 2.64-2.69 (m, 3H) 3.16-3.22 (m,4H) 3.69 (ddd, J=11.44, 8.31, 3.33 Hz, 2H) 3.83-3.93 (m, 4H) 3.94-4.05(m, 2H) 5.46 (dt, J=7.83, 3.91 Hz, 1H) 7.32 (d, J=1.96 Hz, 1H) 7.85 (d,J=1.96 Hz, 1H) 8.36 (d, J=1.96 Hz, 2H) 9.20 (d, J=2.35 Hz, 1H) 9.59 (d,J=1.96 Hz, 1H). LCMS (m/z) (M+H)=542.2, Rt=0.61 min.

Synthesis of 3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylaniline

Step 1

Sodium hydride (3.0 equiv.) was added to 2-propanol (0.4M) at rt and themixture was stirred for 20 min at 90° C. The reaction was cooled to rtand 4-(5-bromo-2-fluoropyridin-3-yl)morpholine (1.0 equiv.) was added.The mixture was stirred at 90° C. for 1.5 hours. The cooled reaction waspoured into water and extracted with ethyl acetate (2×). The combinedextracts were dried over sodium sulfate, filtered and concentrated. Thecrude material was purified via silica gel chromatography (DCM with0-10% methanol) to give 4-(5-bromo-2-isopropoxypyridin-3-yl)morpholineas a yellow green oil. LCMS (m/z) (M+H)=301/303.1, Rt=0.99 min.

Step 2

To a degassed mixture of 4-(5-bromo-2-isopropoxypyridin-3-yl)morpholine(1.0 equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.2equiv.) and 2M aqueous sodium carbonate (3.0 equiv.) in DME (0.18 M) wasadded PdCl₂(dppf)-DCM adduct (0.1 equiv.) and the reaction mixture washeated in the microwave at 120° C. for 15 min. The cooled reactionmixture was diluted with water and extracted with ethyl acetate. Thecombined organics were dried over sodium sulfate, filtered andconcentrated. The crude product was purified via silica gel flashchromatography (10-70% ethyl acetate/heptanes) to give3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylaniline as a yellowoil in 37% yield. LCMS (m/z) (M+H)=328.0, Rt=0.65 min.

Synthesis of6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

To a solution of 4-(5-bromo-2-isopropoxypyridin-3-yl)morpholine (1.0equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.2 equiv.) in DME (0.18 M) was added PdCl₂(dppf)-DCM adduct (0.1equiv.) and 2M aqueous sodium carbonate (3.0 equiv.) and the mixture washeated to 125° C. for 20 min the microwave followed by 130° C. for 15min. The cooled reaction mixture was diluted with water and extractedwith ethyl acetate. The combined organics were dried over sodiumsulfate, filtered and concentrated. The crude product was purified viasilica gel chromatography (ethyl acetate/5-15% methanol) to give6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine as apurple oil in 54% yield. LCMS (m/z) (M+H)=329.2, Rt=0.60 min.

Example 945:2-(1,1-difluoroethyl)-N-(3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 2.05 (t, J=18.78Hz, 3H) 2.29 (s, 3H) 3.15-3.24 (m, 4H) 3.83-3.95 (m, 4H) 5.42 (dt,J=12.23, 6.21 Hz, 1H) 7.29 (d, J=2.35 Hz, 1H) 7.33 (d, J=9.39 Hz, 1H)7.61-7.67 (m, 2H) 7.79 (d, J=2.35 Hz, 1H) 7.95-8.00 (m, 1H) 8.19 (s, 1H)8.81 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=497.1, Rt=1.06 min.

Example 946:2-(2-fluoropropan-2-yl)-N-(3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 1.69-1.81 (m,6H) 2.29 (s, 3H) 3.17-3.26 (m, 4H) 3.84-3.94 (m, 4H) 5.42 (quin, J=6.16Hz, 1H) 7.29-7.36 (m, 2H) 7.60-7.66 (m, 2H) 7.80 (d, J=2.35 Hz, 1H) 7.83(dd, J=5.28, 1.76 Hz, 1H) 8.08-8.12 (m, 1H) 8.69-8.75 (m, 1H). LCMS(m/z) (M+H)=493.1, Rt=1.05 min.

Example 947:2-(2-hydroxypropan-2-yl)-N-(3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.42 (d, J=6.26 Hz, 6H) 1.70 (s, 6H)2.30 (s, 3H) 3.09-3.21 (m, 4H) 3.81-3.93 (m, 4H) 5.41 (quin, J=6.16 Hz,1H) 7.22 (d, J=1.96 Hz, 1H) 7.35 (d, J=8.22 Hz, 1H) 7.63 (d, J=2.35 Hz,1H) 7.68 (dd, J=8.22, 2.35 Hz, 1H) 7.75 (d, J=1.96 Hz, 1H) 8.18 (dd,J=5.67, 1.76 Hz, 1H) 8.46 (dd, J=1.57, 0.78 Hz, 1H) 8.77-8.81 (m, 1H).LCMS (m/z) (M+H)=491.1, Rt=0.81 min.

Example 948:4-(2-cyanopropan-2-yl)-N-(3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.44 (d, J=6.26 Hz, 6H) 1.81 (s, 6H)2.29 (s, 3H) 3.21 (dd, J=5.48, 3.91 Hz, 4H) 3.83-3.94 (m, 4H) 5.43(quin, J=6.16 Hz, 1H) 7.29-7.37 (m, 2H) 7.68-7.74 (m, 2H) 7.76-7.82 (m,2H) 8.37 (dd, J=1.96, 0.78 Hz, 1H) 8.73-8.78 (m, 1H). LCMS (m/z)(M+H)=500.1, Rt=1.11 min.

Example 949:4-(2-hydroxypropan-2-yl)-N-(3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.44 (d, J=6.26 Hz, 6H) 1.58 (s, 6H)2.29 (s, 3H) 3.22 (dd, J=5.48, 3.91 Hz, 4H) 3.86-3.95 (m, 4H) 5.43(quin, J=6.16 Hz, 1H) 7.31-7.36 (m, 2H) 7.67-7.74 (m, 2H) 7.76 (dd,J=5.28, 1.76 Hz, 1H) 7.81 (d, J=2.35 Hz, 1H) 8.38 (dd, J=1.96, 0.78 Hz,1H) 8.64-8.68 (m, 1H). LCMS (m/z) (M+H)=491.1, Rt=1.00 min.

Example 950:N-(3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 2.30 (s, 3H)3.16-3.24 (m, 4H) 3.83-3.94 (m, 4H) 5.43 (quin, J=6.16 Hz, 1H) 7.27 (d,J=1.96 Hz, 1H) 7.34 (d, J=7.83 Hz, 1H) 7.62-7.69 (m, 2H) 7.78 (d, J=1.96Hz, 1H) 8.17 (dd, J=5.09, 1.57 Hz, 1H) 8.54-8.58 (m, 1H) 8.95 (dd,J=4.69, 0.78 Hz, 1H). LCMS (m/z) (M+H)=511.1, Rt=0.93 min.

Example 951:N-(3-(6-isopropoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 2.29 (s, 3H)3.19 (dd, J=5.48, 3.91 Hz, 4H) 3.83-3.94 (m, 4H) 5.42 (dt, J=12.23, 6.21Hz, 1H) 7.28 (d, J=1.96 Hz, 1H) 7.30-7.36 (m, 1H) 7.60-7.67 (m, 2H) 7.78(d, J=1.96 Hz, 1H) 8.64-8.70 (m, 1H) 9.08 (d, J=1.17 Hz, 1H) 9.36 (d,J=1.96 Hz, 1H). LCMS (m/z) (M+H)=501.1, Rt=1.06 min.

Example 952:2-(1,1-difluoroethyl)-N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 2.06 (t, J=18.78Hz, 3H) 2.72 (s, 3H) 3.12-3.21 (m, 4H) 3.82-3.92 (m, 4H) 5.47 (quin,J=6.16 Hz, 1H) 7.31 (d, J=1.96 Hz, 1H) 7.88 (d, J=2.35 Hz, 1H) 8.02-8.07(m, 1H) 8.26-8.29 (m, 1H) 8.48 (d, J=2.35 Hz, 1H) 8.88 (dd, J=5.09, 0.78Hz, 1H) 9.37 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=498.1, Rt=0.79 min.

Example 953:2-(2-fluoropropan-2-yl)-N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 1.66-1.83 (m,6H) 2.73 (s, 3H) 3.10-3.22 (m, 4H) 3.82-3.93 (m, 4H) 5.47 (quin, J=6.16Hz, 1H) 7.31 (d, J=2.35 Hz, 1H) 7.85 (dd, J=5.09, 1.56 Hz, 1H) 7.88 (d,J=2.35 Hz, 1H) 8.14-8.18 (m, 1H) 8.50 (d, J=2.35 Hz, 1H) 8.75-8.80 (m,1H) 9.39 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=494.1, Rt=0.79 min.

Example 954:2-(2-cyanopropan-2-yl)-N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=5.87 Hz, 6H) 1.84 (s, 6H)2.72 (s, 3H) 3.12-3.21 (m, 4H) 3.83-3.93 (m, 4H) 5.47 (quin, J=6.16 Hz,1H) 7.31 (d, J=2.35 Hz, 1H) 7.86-7.92 (m, 2H) 8.14-8.18 (m, 1H) 8.47 (d,J=2.35 Hz, 1H) 8.84 (dd, J=5.09, 0.78 Hz, 1H) 9.38 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=501.1, Rt=0.77 min.

Example 955:2-(2-hydroxypropan-2-yl)-N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 1.64 (s, 6H)2.71 (s, 3H) 3.13-3.20 (m, 4H) 3.84-3.92 (m, 4H) 5.47 (dt, J=12.23, 6.21Hz, 1H) 7.30 (d, J=2.35 Hz, 1H) 7.87 (d, J=2.35 Hz, 1H) 7.91-7.95 (m,1H) 8.34 (dd, J=1.76, 0.98 Hz, 1H) 8.48 (d, J=2.35 Hz, 1H) 8.77 (dd,J=5.28, 0.98 Hz, 1H) 9.36 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=492.1,Rt=0.62 min.

Example 956:4-(1,1-difluoroethyl)-N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=5.87 Hz, 6H) 2.02 (t, J=18.58Hz, 3H) 2.72 (s, 3H) 3.14-3.22 (m, 4H) 3.81-3.93 (m, 4H) 5.48 (dt,J=12.23, 6.21 Hz, 1H) 7.32 (d, J=2.35 Hz, 1H) 7.81-7.86 (m, 1H) 7.89 (d,J=2.35 Hz, 1H) 8.38-8.41 (m, 1H) 8.70 (d, J=2.35 Hz, 1H) 8.88-8.92 (m,1H) 9.46 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=498.1, Rt=0.85 min.

Example 957:4-(2-fluoropropan-2-yl)-N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 1.67-1.81 (m,6H) 2.72 (s, 3H) 3.15-3.23 (m, 4H) 3.83-3.93 (m, 4H) 5.48 (dt, J=12.23,6.21 Hz, 1H) 7.32 (d, J=2.35 Hz, 1H) 7.71 (dd, J=5.28, 1.76 Hz, 1H) 7.89(d, J=2.35 Hz, 1H) 8.28-8.32 (m, 1H) 8.70 (d, J=2.35 Hz, 1H) 8.76 (d,J=5.09 Hz, 1H) 9.46 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=494.1, Rt=0.87min.

Example 958:4-(2-cyanopropan-2-yl)-N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=5.87 Hz, 6H) 1.83 (s, 6H)2.72 (s, 3H) 3.15-3.23 (m, 4H) 3.80-3.92 (m, 4H) 5.42-5.54 (m, 1H) 7.32(d, J=2.35 Hz, 1H) 7.85 (dd, J=5.09, 1.96 Hz, 1H) 7.89 (d, J=1.96 Hz,1H) 8.44 (dd, J=1.96, 0.78 Hz, 1H) 8.70 (d, J=2.35 Hz, 1H) 8.79-8.84 (m,1H) 9.47 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=501.1, Rt=0.82 min.

Example 959:4-(2-hydroxypropan-2-yl)-N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.44 (d, J=6.26 Hz, 6H) 1.59 (s, 6H)2.71 (s, 3H) 3.15-3.21 (m, 4H) 3.83-3.92 (m, 4H) 5.48 (dt, J=12.23, 6.21Hz, 1H) 7.32 (d, J=2.35 Hz, 1H) 7.77 (dd, J=5.09, 1.96 Hz, 1H) 7.89 (d,J=2.35 Hz, 1H) 8.41 (dd, J=1.96, 0.78 Hz, 1H) 8.67 (d, J=2.35 Hz, 1H)8.70 (dd, J=5.09, 0.78 Hz, 1H) 9.45 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=492.1, Rt=0.74 min.

Example 960:N-(6′-isopropoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-5-(trifluoromethyl)nicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.26 Hz, 6H) 2.71 (s, 3H)3.14-3.21 (m, 4H) 3.83-3.93 (m, 4H) 5.47 (quin, J=6.26 Hz, 1H) 7.31 (d,J=2.35 Hz, 1H) 7.87 (d, J=2.35 Hz, 1H) 8.44 (d, J=2.35 Hz, 1H) 8.73-8.77(m, 1H) 9.14-9.18 (m, 1H) 9.33 (d, J=2.35 Hz, 1H) 9.43 (d, J=1.96 Hz,1H). LCMS (m/z) (M+H)=502.1, Rt=0.79 min.

Example 961:3-(6-ethoxy-5-morpholinopyridin-3-yl)-N-(5-fluoro-2-(trifluoromethyl)pyridin-4-yl)-4-methylbenzamide

Step 1

To a solution of 3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylbenzoicacid (1.0 equiv.) in DCM (0.06 M) was added1-chloro-N,N,2-trimethylprop-1-en-1-amine (2.0 equiv.) and the mixturewas stirred at 0° C. for 1 hour. Upon concentration under vacuo, thecrude residue was used for the next step without further purification.

Step 2

5-fluoro-2-(trifluoromethyl)pyridin-4-amine (1.0 equiv.) was dissolvedin 2-methyltetrahydrofurn (0.17 M) and NaHMDS (2.0 equiv.) was added andstirred for 1 h at rt. The crude solution from the above reaction wasadded to this mixture and stirred for 1 h at rt. The reaction wasquenched by the addition of water, then partitioned between with ethylacetate and the organic phase was concentrated to dryness. The residuewas purified via silica gel chromatography followed by reverse phaseHPLC to give3-(6-ethoxy-5-morpholinopyridin-3-yl)-N-(5-fluoro-2-(trifluoromethyl)pyridin-4-yl)-4-methylbenzamidein 10% yield. ¹H NMR (500 MHz, METHANOL-d₄) ppm 1.48 (t, J=6.94 Hz, 3H)2.40 (s, 3H) 3.14-3.23 (m, 4H) 3.84-3.93 (m, 4H) 4.51 (d, J=6.94 Hz, 2H)7.32 (d, J=1.89 Hz, 1H) 7.53 (s, 1H) 7.82 (d, J=2.21 Hz, 1H) 7.86 (d,J=2.21 Hz, 1H) 7.89-7.95 (m, 1H) 8.64 (d, J=2.21 Hz, 1H) 8.79 (d, J=5.99Hz, 1H). LCMS (m/z) (M+H)=505.0, Rt=1.07 min.

Synthesis of6′-(2,2-difluoroethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

To a degassed solution of4-(5-bromo-2-(2,2-difluoroethoxy)pyridin-3-yl)morpholine (1.0 equiv.) inDME and 2M Na₂CO₃ (3:1, 0.1 M) was added6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.1 equiv.) and PdCl₂(dppf)-DCM adduct (0.1 equiv.). The reaction washeated to 100° C. for 2 hours in an oil bath. LCMS indicated completion.Cooled to rt, partitioned between water and ethyl acetate, the organicphase was dried with sodium sulfate, filtered and concentrated. Thecrude material was purified via silica gel column chromatography (ISCO,eluting with 0-100% ethyl acetate in heptanes, followed by 10% methanolin ethyl acetate). The pure fractions were combined and concentratedunder vacuo to give6′-(2,2-difluoroethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-aminein 79% yield. LCMS (m/z) (M+H)=351, Rt=0.55 min.

Example 962:6-(2-cyanopropan-2-yl)-N-(6′-(2,2-difluoroethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.92 (s, 6H) 2.63 (s, 3H) 3.12-3.19 (m,4H) 3.79-4.03 (m, 4H) 4.66 (td, J=14.18, 3.72 Hz, 2H) 6.04-6.57 (m, 1H)7.34 (d, J=1.96 Hz, 1H) 7.85 (d, J=1.96 Hz, 1H) 8.28-8.48 (m, 2H) 9.16(d, J=2.35 Hz, 1H) 9.66 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=524.1,Rt=0.66 min.

Synthesis of6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

Step 1

To a solution of 2-oxaspiro[3.3]heptan-6-ol (1.5 equiv.) in dioxane(0.13 M) at rt was added sodium hydride (1.5 equiv.) and the mixture wasstirred for 15 min. 4-(5-bromo-2-fluoropyridin-3-yl)morpholine (1.0equiv.) was then added, and the reaction was heated to 105° C. andstirred for 1.5 hours. Added another 1.5 equiv. of2-oxaspiro[3.3]heptan-6-ol and sodium hydride and heated for 3 morehours. The mixture was carefully poured into water and extracted threetimes with ethyl acetate. The combined organics were washed with water,brine, dried over magnesium sulfate, filtered and concentrated. Thecrude residue was purified via Grace flash column chromatography oversilica gel, eluting with heptanes and 0-50% ethyl acetate. The purefractions were concentrated to give4-(2-(2-oxaspiro[3.3]heptan-6-yloxy)-5-bromopyridin-3-yl)morpholine as apale yellow oil in 72% yield. LCMS (m/z) (M+H)=355.1/357.1, Rt=0.86 min.

Step 2

A solution of4-(2-(2-oxaspiro[3.3]heptan-6-yloxy)-5-bromopyridin-3-yl)morpholine (1.0equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.2 equiv.) in DME (0.1 M) and sodium carbonate (2M aqueous, 3.0equiv.) was purged with argon for 5 min. PdCl₂(dppf)-DCM adduct (0.05equiv.) was then added, and the mixture was purged with argon again,then heated to 100° C. for 1 hour. The mixture was poured onto water andextracted three times with ethyl acetate. The combined organics werewashed with brine, dried over magnesium sulfate, filtered andconcentrated. The crude residue was purified via Grace flash columnchromatography over silica gel eluting with DCM and 0-15% methanol.Product fractions were concentrated to give6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amineas a light brown foam in 86% yield. LCMS (m/z) (M+H)=383.1, Rt=0.52 min.

Example 963:N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) (ppm 1.74 (d, J=1.00 Hz, 6H) 2.32-2.42 (m, 2H)2.50 (s, 3H) 2.81-2.92 (m, 2H) 3.09-3.18 (m, 4H) 3.83-3.90 (m, 4H) 4.71(s, 2H) 4.79 (s, 2H) 5.17 (t, J=7.04 Hz, 1H) 7.25 (d, J=2.35 Hz, 1H)7.76 (d, J=2.35 Hz, 1H) 7.80 (dd, J=5.09, 1.57 Hz, 1H) 8.10 (s, 1H) 8.13(d, J=2.35 Hz, 1H) 8.72 (d, J=5.09 Hz, 1H) 8.86 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=548.3, Rt=0.72 min.

Example 964:N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-hydroxypropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.59 (s, 6H) 2.30-2.43 (m, 2H) 2.50 (s,3H) 2.82-2.93 (m, 2H) 3.10-3.18 (m, 4H) 3.79-3.91 (m, 4H) 4.71 (s, 2H)4.79 (s, 2H) 5.17 (quin, J=6.95 Hz, 1H) 7.25 (d, J=1.96 Hz, 1H) 7.74(dd, J=5.28, 1.76 Hz, 1H) 7.76 (d, J=1.96 Hz, 1H) 8.13 (d, J=2.35 Hz,1H) 8.19 (s, 1H) 8.69 (d, J=4.69 Hz, 1H) 8.87 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=546.3, Rt=0.57 min.

Example 965:N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(difluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.28-2.41 (m, 2H) 2.49 (s, 3H) 2.81-2.94(m, 2H) 3.07-3.16 (m, 4H) 3.75-3.92 (m, 4H) 4.71 (s, 2H) 4.79 (s, 2H)5.17 (t, J=6.85 Hz, 1H) 6.83 (t, J=1.00 Hz, 1H) 7.25 (d, J=1.96 Hz, 1H)7.76 (d, J=2.35 Hz, 1H) 8.04 (d, J=4.70 Hz, 1H) 8.12 (d, J=2.35 Hz, 1H)8.22 (s, 1H) 8.80-8.90 (m, 2H). LCMS (m/z) (M+H)=538.3, Rt=0.67 min.

Example 966:N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-cyclopropylisonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.02-1.14 (m, 4H) 2.16-2.26 (m, 1H)2.33-2.41 (m, 2H) 2.49 (s, 3H) 2.88 (ddd, J=10.47, 7.14, 3.13 Hz, 2H)3.09-3.16 (m, 4H) 3.81-3.90 (m, 4H) 4.71 (s, 2H) 4.79 (s, 2H) 5.16 (t,J=6.85 Hz, 1H) 7.24 (d, J=1.96 Hz, 1H) 7.61 (dd, J=5.09, 1.57 Hz, 1H)7.71 (s, 1H) 7.75 (d, J=1.96 Hz, 1H) 8.11 (d, J=2.35 Hz, 1H) 8.55 (d,J=5.09 Hz, 1H) 8.84 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=528.3, Rt=0.59min.

Example 967:N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-cyanopropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.82 (s, 6H) 2.32-2.41 (m, 2H) 2.50 (s,3H) 2.81-2.93 (m, 2H) 3.04-3.16 (m, 4H) 3.79-3.90 (m, 4H) 4.71 (s, 2H)4.79 (s, 2H) 5.17 (quin, J=6.95 Hz, 1H) 7.25 (d, J=1.96 Hz, 1H) 7.76 (d,J=1.96 Hz, 1H) 7.85 (dd, J=4.89, 1.37 Hz, 1H) 8.10 (s, 1H) 8.13 (d,J=2.35 Hz, 1H) 8.79 (d, J=5.09 Hz, 1H) 8.86 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=555.3, Rt=0.70 min.

Example 968:N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-4-(2-fluoropropan-2-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.72 (d, J=1.00 Hz, 6H) 2.34-2.42 (m,2H) 2.49 (s, 3H) 2.78-2.93 (m, 2H) 3.10-3.19 (m, 4H) 3.79-3.90 (m, 4H)4.72 (s, 2H) 4.80 (s, 2H) 5.17 (t, J=6.85 Hz, 1H) 7.26 (d, J=1.96 Hz,1H) 7.65 (dd, J=4.89, 1.76 Hz, 1H) 7.77 (d, J=1.96 Hz, 1H) 8.21 (d,J=2.35 Hz, 1H) 8.24 (d, J=1.17 Hz, 1H) 8.72 (d, J=5.09 Hz, 1H) 8.95 (d,J=2.35 Hz, 1H). LCMS (m/z) (M+H)=548.3, Rt=0.78 min.

Example 969:N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-4-(2-hydroxypropan-2-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.57 (s, 6H) 2.32-2.43 (m, 2H) 2.50 (s,3H) 2.75-2.95 (m, 2H) 3.06-3.18 (m, 4H) 3.76-3.93 (m, 4H) 4.72 (s, 2H)4.80 (s, 2H) 5.17 (t, J=6.85 Hz, 1H) 7.26 (d, J=1.96 Hz, 1H) 7.72 (dd,J=5.28, 1.76 Hz, 1H) 7.77 (d, J=1.96 Hz, 1H) 8.22 (d, J=2.35 Hz, 1H)8.35 (d, J=1.17 Hz, 1H) 8.66 (d, J=5.09 Hz, 1H) 8.96 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=546.3, Rt=0.66 min.

Example 970:N-(6′-(2-oxaspiro[3.3]heptan-6-yloxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-4-(2-cyanopropan-2-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.34-2.42 (m, 2H) 2.50 (s,3H) 2.80-2.93 (m, 2H) 3.10-3.17 (m, 4H) 3.75-3.92 (m, 4H) 4.72 (s, 2H)4.80 (s, 2H) 5.17 (quin, J=6.95 Hz, 1H) 7.26 (d, J=2.35 Hz, 1H) 7.77 (d,J=2.35 Hz, 1H) 7.80 (dd, J=5.09, 1.96 Hz, 1H) 8.23 (d, J=2.35 Hz, 1H)8.38 (d, J=1.57 Hz, 1H) 8.77 (d, J=5.09 Hz, 1H) 8.97 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=555.3, Rt=0.74 min.

Example 971:4-(2-fluoropropan-2-yl)-N-(6′-(2-hydroxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.68-1.78 (m, 6H) 2.71 (s, 3H) 3.13-3.23(m, 4H) 3.80-3.90 (m, 4H) 3.93-3.98 (m, 2H) 4.51-4.56 (m, 2H) 7.33-7.37(m, 1H) 7.70 (dd, J=5.09, 1.57 Hz, 1H) 7.86-7.91 (m, 1H) 8.29 (d, J=1.17Hz, 1H) 8.72 (d, J=2.35 Hz, 1 H) 8.75 (d, J=5.09 Hz, 1H) 9.48 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=496.1, Rt=0.55 min.

Example 972:N-(6′-(2-hydroxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-4-(2-hydroxypropan-2-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.58 (s, 6H) 2.71 (s, 3H) 3.12-3.24 (m,4H) 3.81-3.91 (m, 4H) 3.93-3.98 (m, 2H) 4.52-4.57 (m, 2H) 7.33-7.37 (m,1H) 7.76 (dd, J=5.09, 1.57 Hz, 1H) 7.87-7.91 (m, 1H) 8.40 (d, J=1.17 Hz,1H) 8.69 (d, J=5.09 Hz, 1H) 8.72 (d, J=1.96 Hz, 1H) 9.49 (d, J=2.35 Hz,1H). LCMS (m/z) (M+H)=494.1, Rt=0.53 min.

Example 973:4-(2-cyanopropan-2-yl)-N-(6′-(2-hydroxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.71 (s, 3H) 3.13-3.23 (m,4H) 3.79-3.91 (m, 4H) 3.93-3.99 (m, 2H) 4.49-4.58 (m, 2H) 7.31-7.37 (m,1H) 7.84 (dd, J=5.48, 1.96 Hz, 1H) 7.87-7.91 (m, 1H) 8.43 (d, J=1.57 Hz,1H) 8.72 (d, J=2.35 Hz, 1H) 8.80 (d, J=5.09 Hz, 1H) 9.48 (d, J=2.35 Hz,1H). LCMS (m/z) (M+H)=503.1, Rt=0.61 min.

Example 974:4-(1,1-difluoroethyl)-N-(6′-(2-hydroxyethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)picolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.01 (t, J=18.78 Hz, 3H) 2.65 (s, 3H)3.16-3.24 (m, 4H) 3.84-3.91 (m, 4H) 3.93-4.01 (m, 2H) 4.47-4.57 (m, 2H)7.33 (d, J=1.96 Hz, 1H) 7.82 (d, J=5.09 Hz, 1H) 7.86 (d, J=1.96 Hz, 1H)8.37 (s, 1H) 8.57 (d, J=1.96 Hz, 1H) 8.88 (d, J=5.09 Hz, 1H) 9.33 (d,J=2.35 Hz, 1H). LCMS (m/z) (M+H)=500.1, Rt=0.66 min.

Example 975:N-(3-(6-ethoxy-5-morpholinopyridin-3-yl)-4-methylphenyl)-3-(S-methylsulfonimidoyl)benzamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 1.45 (t, J=7.09 Hz, 3H) 2.28 (s,3H) 3.14 (br. s., 4H) 3.67 (s, 3H) 3.81-3.91 (m, 4H) 4.46 (q, J=7.15 Hz,2H) 7.23 (d, J=1.89 Hz, 1H) 7.32 (d, J=8.51 Hz, 1H) 7.60 (d, J=2.21 Hz,1H) 7.64 (dd, J=8.20, 2.21 Hz, 1H) 7.73 (d, J=2.21 Hz, 1H) 7.91 (t,J=7.88 Hz, 1H) 8.30-8.35 (m, 1H) 8.41 (d, J=7.88 Hz, 1H) 8.67 (t, J=1.73Hz, 1H). LCMS (m/z) (M+H)=495.1, Rt=0.74 min.

Example 976:N-(6′-ethoxy-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(S-methylsulfonimidoyl)benzamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 1.46 (t, J=7.09 Hz, 3H) 2.70 (s,3H) 3.16 (dd, J=5.36, 3.78 Hz, 4H) 3.49 (s, 3H) 3.84-3.89 (m, 4H) 4.50(q, J=7.04 Hz, 2H) 7.32 (d, J=2.21 Hz, 1H) 7.87 (d, J=2.21 Hz, 1H) 7.91(t, J=7.88 Hz, 1H) 8.34 (ddd, J=7.88, 1.89, 0.95 Hz, 1H) 8.42 (dt,J=7.80, 1.30 Hz, 1H) 8.47 (d, J=2.21 Hz, 1H) 8.71 (t, J=1.89 Hz, 1H)9.37 (d, J=2.21 Hz, 1H). LCMS (m/z) (M+H)=496.1, Rt=0.55 min

Example 977:N-(2-methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(2,2,2-trifluoro-1-hydroxyethyl)benzamide

LCMS (m/z) (M+H)=573.1, Rt=0.70 min.

Synthesis of6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine

To a solution of 4-(5-bromo-2-(difluoromethoxy)pyridin-3-yl)morpholine(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.2 equiv.) in DME (0.4 M) was added sodium carbonate (2M, 1.0 equiv.)and PdCl₂(dppf)-DCM adduct (0.1 equiv.) and the mixture was heated inthe microwave at 120° C. for 20 min. The reaction was partitionedbetween ethyl acetate and water, the organic layer was dried with sodiumsulfate, filtered and concentrated. The residue was purified via silicagel chromatography (ISCO, 0-15% methanol in DCM) to give6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-amine in92% yield. LCMS (m/z) (M+H)=337.0, Rt=0.54 min.

Example 978:N-(6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 3.05-3.13 (m, 4H) 3.74-3.75 (m, 3H)7.43-7.50 (m, 1H) 7.76-7.81 (m, 1H) 7.85-7.98 (m, 1H) 8.08-8.11 (m, 1H)8.18-8.24 (m, 1H) 8.36-8.41 (m, 1H) 8.86-8.92 (m, 1H) 8.99-9.05 (m, 1H)10.96-10.99 (m, 1H). LCMS (m/z) (M+H)=510.1, Rt=0.74 min.

Example 979:N-(6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(2-hydroxypropan-2-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.48 (s, 6H) 3.00-3.16 (m, 4H) 3.69-3.82(m, 4H) 4.17-4.27 (m, 1H) 7.48-7.63 (m, 1H) 7.70-7.81 (m, 1H) 7.87-7.99(m, 1H) 8.12-8.26 (m, 2H) 8.67-8.78 (m, 1H) 8.94-9.02 (m, 1H)10.87-10.97 (m, 1H). LCMS (m/z) (M+H)=500.2, Rt=0.57 min.

Example 980:2-(1,1-difluoroethyl)-N-(6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

LCMS (m/z) (M+H)=506.1 Rt=0.72 min.

Example 981:4-(2-cyanopropan-2-yl)-N-(6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)picolinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 3.04-3.16 (m, 4H) 3.66-3.87(m, 4H) 7.45-7.55 (m, 1H) 7.75-7.79 (m, 1H) 7.82-7.98 (m, 2H) 8.23-8.30(m, 2H) 8.75-8.83 (m, 1H) 9.04-9.12 (m, 1H) 11.01-11.13 (m, 1H). LCMS(m/z) (M+H)=509.2, Rt=0.74 min.

Example 982:N-(6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(difluoromethyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 0.85-1.02 (m, 3H) 2.26-2.38 (m, 1H)3.04-3.11 (m, 3H) 3.67-3.81 (m, 4H) 7.46-7.54 (m, 1H) 7.75-7.83 (m, 1H)7.88-7.92 (m, 1H) 8.00-8.08 (m, 1H) 8.13-8.24 (m, 2H) 8.86-8.99 (m, 2H)10.93-11.02 (m, 1H). LCMS (m/z) (M+H)=492.2, Rt=0.68 min.

Example 983:N-(6′-(difluoromethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-2-(1,1-difluoropropyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 3.04-3.16 (m, 4H) 3.70-3.72 (m, 4H)7.05-7.12 (m, 1H) 7.44-7.53 (m, 1H) 7.72-7.79 (m, 1H) 7.86-7.91 (m, 1H)8.02-8.13 (m, 2H) 8.17-8.25 (m, 1H) 8.88-8.97 (m, 2H) 10.89-10.99 (m,1H). LCMS (m/z) (M+H)=520.2, Rt=0.77 min.

Example 984:(R)-N-(6′-(2-hydroxypropoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of sodium hydride (4.2 equiv.) in DMA was addedR-1,2-propanediol (4.0 equiv.) and the mixture was stirred for 15 min atrt.N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was added, and the reaction was heated to 100° C. andstirred for 16 hours. The cooled mixture was quenched with water andextracted with ethyl acetate (3×). The combined organics were washedwith water, brine, dried over sodium sulfate, filtered and concentrated.The residue was purified via reverse phase prep-HPLC and the purefractions were free based and lyophilized to give(R)-N-(6′-(2-hydroxypropoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideas the major project in 10% yield. LCMS (m/z) (M+H)=517.1, Rt=0.69 min.

Example 985:(S)-N-(6′-((1-hydroxypropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of(S)-N-(6′-((1-methoxypropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.04 M) at −78° C. was added 1M boron tribromide inDCM (1.2 equiv.) and the mixture was warmed to rt. The reaction wasquenched with one drop of methanol and partitioned between DCM andwater. The organic phase was dried with sodium sulfate, filtered andconcentrated. The residue was purified via reverse phase HPLC to give(S)-N-(6′-((1-hydroxypropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 17% yield. LCMS (m/z) (M+H)=517.1, Rt=0.69 min.

Example 986:N-(6′-((2-hydroxyethyl)(methyl)amino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DMF (0.25 M) was added 2-(methylamino)ethanol (3.0equiv.) and the mixture was stirred at 90° C. for 3 days. The cooledreaction mixture was diluted with DMSO, filtered and purified viareverse phase HPLC. The pure fractions were lyophilized to giveN-(6′-((2-hydroxyethyl)(methyl)amino)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 12% yield. ¹H NMR (400 MHz, <cd3od>) δ ppm 2.63 (s, 3H) 3.05-3.13 (m,4H) 3.35 (s, 3H) 3.84-3.89 (m, 2H) 3.90-3.95 (m, 4H) 3.96-4.03 (m, 2H)7.70 (d, J=1.96 Hz, 1H) 7.79 (t, J=7.83 Hz, 1H) 7.92-8.00 (m, 2H) 8.28(d, J=7.83 Hz, 1H) 8.34 (s, 1H) 8.44 (d, J=2.35 Hz, 1H) 9.07 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=516.1, Rt=0.59 min.

Synthesis of 5-bromo-N-methyl-3-morpholinopicolinamide

Step 1

A solution of 5-bromo-3-fluoropicolinonitrile (1.0 equiv.), morpholine(1.1 equiv.) and DIEA (2.0 equiv.) in CAN (0.5 M) was heated to 90° C.overnight. The cooled reaction was diluted with water and filtered. Theprecipitate was dried to give 5-bromo-3-morpholinopicolinonitrile as ayellow crystalline solid in 87% yield. LCMS (m/z) (M+H)=267.9/269.9,Rt=0.79 min.

Step 2

A solution of 5-bromo-3-morpholinopicolinonitrile (1.0 equiv.) inethanol (1.0 M) was treated with 6M aqueous sodium hydroxide (10.0equiv.) and stirred at 85° C. for 4 hours. The volatiles were removedunder vacuo and the mixture was acidified to pH=4 with 2M HCl.Acetonitrile was added to this mixture and lyophilized to give5-bromo-3-morpholinopicolinic acid as a yellow solid in 50% yield. LCMS(m/z) (M+H)=286.9/288.9, Rt=0.41 min.

Step 3

To a solution of 5-bromo-3-morpholinopicolinic acid (1.0 equiv.), EDC(1.1 equiv.) and HOAt (1.1 equiv.) and methylamine hydrochloride (1.2equiv.) in DMF (0.3M) was added DIEA (2.2 equiv.) and the mixture wasstirred overnight at rt. The solution was diluted with water andextracted with ethyl acetate. The combined extracts were washed withsat. sodium bicarbonate, dried over sodium sulfate, filtered andconcentrated to give 5-bromo-N-methyl-3-morpholinopicolinamide in 58%yield as a colorless residue. LCMS (m/z) (M+H)=299.9/301.9, Rt=0.47 min.

Note: the next several examples were made via a last-step Suzukicoupling.

Example 987:5-(5-(2-(1,1-difluoroethyl)isonicotinamido)-2-methylphenyl)-N-methyl-3-morpholinopicolinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.05 (t, J=18.78 Hz, 3H) 2.32 (s, 3H)3.03 (s, 3H) 3.91-4.01 (m, 4H) 7.41 (d, J=8.22 Hz, 1H) 7.69 (dd, J=8.22,1.96 Hz, 1H) 7.78 (d, J=2.35 Hz, 1H) 7.93 (s, 1H) 7.98 (d, J=4.70 Hz,1H) 8.20 (s, 1H) 8.43 (s, 1H) 8.83 (d, J=5.09 Hz, 1H). LCMS (m/z)(M+H)=496.2, Rt=0.69 min.

Example 988:N-(2-methyl-5′-morpholino-6′-oxo-1′,6′-dihydro-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

LCMS (m/z) (M+H)=469.1, Rt=0.65 min.

Example 989:(S)-N-(3-(6-(2-hydroxypropoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.10-1.21 (m, 3H) 2.17-2.27 (m, 4H)3.03-3.11 (m, 4H) 3.67-3.79 (m, 4H) 7.07-7.13 (m, 1H) 7.26-7.34 (m, 1H)7.57-7.77 (m, 4H) 8.16-8.25 (m, 1H) 8.47-8.53 (m, 1H) 8.93-9.01 (m, 1H)10.71-10.77 (m, 1H).

LCMS (m/z) (M+H)=527.1, Rt=0.71 min.

Example 990:(S)-2-(2-fluoropropan-2-yl)-N-(6′-(2-hydroxypropoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)isonicotinamide

1H NMR (500 MHz, DMSO-d6) δ ppm 1.14-1.25 (m, 3H) 1.65-1.77 (m, 6H) 2.45(s, 3H) 3.04-3.16 (m, 4H) 3.69-3.80 (m, 4H) 3.98-4.08 (m, 1H) 4.11-4.17(m, 1H) 4.20-4.28 (m, 2H) 4.76-4.91 (m, 2H) 7.15-7.28 (m, 2H) 7.73-7.80(m, 2H) 7.83-7.89 (m, 2H) 8.00-8.12 (m, 4H) 8.74-8.79 (m, 1H) 8.85-8.93(m, 1H) 10.72-10.80 (m, 1H). LCMS (m/z) (M+H)=510.2, Rt=0.62 min.

Example 991:(R)-N-(3-(2-((2-hydroxypropyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

A solution ofN-(3-(2-chloro-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide(1.0 equiv.), (R)-1-aminopropan-2-ol (2.0 equiv.), Pd-BrettPhos (0.1equiv.) and cesium carbonate (1.5 equiv.) in t-BuOH (0.5M) was purgedwith Argon and heated to 90° C. overnight. The reaction was cooled tort, diluted with aqueous sodium bicarbonate, extracted with ethylacetate, dried over magnesium sulfate, filtered and concentrated. Theresidue was diluted with DMSO and purified via reverse phase HPLC togive(R)-N-(3-(2-((2-hydroxypropyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamidein 37% yield. LCMS (m/z) (M+H)=516.1, Rt=0.77 min.

Example 992:N-(6′-((1,4-dioxan-2-yl)methoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

Sodium hydride (3.1 equiv.) was added to dioxane (0.15 M) at rt.(1,4-dioxan-2-yl)methanol (3.0 equiv.) was added and the mixture wasstirred for 30 min.N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was added and the reaction was stirred at 105° C. for 3hours. The cooled reaction mixture was poured into water and extractedwith ethyl acetate. The combined organics were washed with brine, driedover sodium sulfate, filtered and concentrated. The mixture was purifiedvia flash chromatography (0-10% methanol/DCM) to giveN-(6′-((1,4-dioxan-2-yl)methoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 49% yield. ¹H NMR (400 MHz, Methanol-d4) δ 8.80 (d, J=2.5 Hz, 1H),8.21 (dt, J=1.8, 1.1 Hz, 1H), 8.15 (ddd, J=8.0, 1.4, 0.7 Hz, 1H), 8.06(d, J=2.5 Hz, 1H), 7.82 (ddt, J=7.8, 1.8, 1.0 Hz, 1H), 7.71-7.61 (m,2H), 7.16 (d, J=2.1 Hz, 1H), 4.31 (d, J=4.9 Hz, 2H), 3.91 (dtd, J=9.9,4.9, 2.6 Hz, 1H), 3.86-3.59 (m, 9H), 3.58-3.44 (m, 2H), 3.15-2.98 (m,4H), 2.42 (s, 3H). LCMS (m/z) (M+H)=559.2, Rt=0.77 min.

Example 993:N-(6′-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

Step 1

To a stirred solution of bis(2-bromoethyl) ether (2.0 equiv.) in DMF at0° C. was slowly added sodium hydride (4.0 equiv.) and the mixture wasallowed to warm to rt over 15 min followed by the addition of5-bromo-2-methylpyridin-3-amine (1.0 equiv.) The mixture was heated to90° C. and stirred for 48 hours. Upon cooling to rt, the mixture waspoured onto ice water and extracted with ethyl acetate. The organiclayer was dried over magnesium sulfate, filtered and concentrated. Theresidue was purified via silica gel chromatography to give4-(5-bromo-2-methylpyridin-3-yl)morpholine in 63% yield. LCMS (m/z)(M+H)=258.9, Rt=0.43 min.

Step 2

A solution of 4-(5-bromo-2-methylpyridin-3-yl)morpholine (1.0 equiv.) inTHF under argon was cooled to −78° C. and treated with LDA (2.0 equiv.).The deep red solution was stirred for 1 hour at −78° C. at which timedihydro-2H-pyran-4(3H)-one (2.2 equiv.) was added dropwise. The mixturewas stirred for 1 hour at −78° C., then warmed to rt and quenched withammonium chloride (aq.), extracted with ethyl acetate (3×), dried,filtered and concentrated to give a crude oil. The residue was purifiedvia silica gel chromatography (0-100% ethyl acetate/heptanes) to give4-((5-bromo-3-morpholinopyridin-2-yl)methyl)tetrahydro-2H-pyran-4-ol in94% yield. LCMS (m/z) (M+H)=357.0/359.0, Rt=0.53 min.

Step 3

To a solution ofN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide (1.5 equiv.) and4-((5-bromo-3-morpholinopyridin-2-yl)methyl)tetrahydro-2H-pyran-4-ol(1.0 equiv.) in DME (0.1 M) was added PdCl₂(dppf)-DCM adduct (0.1equiv.) and sodium carbonate (3.0 equiv., 2M aqueous sin) and thereaction was purged with nitrogen. The mixture was heated in themicrowave at 120° C. for 30 mins, then quenched with sat. sodiumbicarbonate, extracted with ethyl acetate (3×), dried over magnesiumsulfate, filtered and concentrated. The residue was dissolved in DMSOand purified via reverse phase HPLC to giveN-(6′-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 24% yield. ¹H NMR (400 MHz, Methanol-d4) δ ppm 9.13 (d, J=2.4 Hz,1H), 8.51 (dd, J=9.7, 2.2 Hz, 2H), 8.32 (dq, J=1.8, 0.9 Hz, 1H),8.30-8.23 (m, 1H), 8.12 (d, J=1.9 Hz, 1H), 7.95 (ddt, J=7.8, 1.8, 1.0Hz, 1H), 7.78 (ddt, J=7.9, 7.2, 0.8 Hz, 1H), 3.93-3.86 (m, 4H),3.86-3.71 (m, 4H), 3.26 (s, 2H), 3.11-3.04 (m, 4H), 2.63 (s, 3H), 1.81(ddd, J=14.4, 10.1, 4.8 Hz, 2H), 1.56 (d, J=13.8 Hz, 2H). LCMS (m/z)(M+H)=557.2, Rt=0.64 min.

Example 994:N-(6′-((dihydro-2H-pyran-4(3H)-ylidene)methyl)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(6′-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.1 M) at −78° C. under argon was added DAST (1.3equiv.) and the solution was stirred at −78° C. for 2 hours. Quenched bythe addition of sat. sodium bicarbonate, extracted with DCM (3×), theorganic layer was dried over magnesium sulfate, filtered andconcentrated. The residue was purified via reverse phase prep-HPLC andthe pure fractions were lyophilized to giveN-(6′-((dihydro-2H-pyran-4(3H)-ylidene)methyl)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 42% yield. ¹H NMR (400 MHz, Methanol-d4) δ 9.12 (t, J=1.9 Hz, 1H),8.48-8.42 (m, 2H), 8.32 (dd, J=1.7, 0.9 Hz, 1H), 8.30-8.23 (m, 1H),8.02-7.91 (m, 2H), 7.82-7.73 (m, 1H), 5.47 (t, J=1.5 Hz, 1H), 4.12 (q,J=2.4 Hz, 2H), 3.91-3.84 (m, 5H), 3.84-3.75 (m, 4H), 3.09-3.02 (m, 4H),2.62 (s, 3H), 2.14 (s, 2H). LCMS (m/z) (M+H)=539.2, Rt=0.69 min.

Synthesis of2-((5-(5-amino-2-methylphenyl)-3-morpholinopyridin-2-yl)oxy)ethanol

Step 1

To a solution of ethylene glycol (5.0 equiv.) in dioxane and DMF (4:1,0.08 M) was added sodium hydride (5.0 equiv.) and the mixture wasstirred for 15 min at rt. 4-(5-bromo-2-fluoropyridin-3-yl)morpholine(1.0 equiv.) was then added, and the reaction was heated to 90° C. andstirred overnight. The mixture was carefully poured onto water andextracted three times with ethyl acetate. The combined organics werewashed with water, brine, dried over magnesium sulfate, filtered andconcentrated. The crude residue was purified via silica gelchromatography (0-100% ethyl acetate/heptanes) to give2-((5-bromo-3-morpholinopyridin-2-yl)oxy)ethanol as a yellow oil in 54%yield. LCMS (m/z) (M+H)=302.9/304.9, Rt=0.63 min.

Step 2

A solution of 2-((5-bromo-3-morpholinopyridin-2-yl)oxy)ethanol (1.0equiv.), 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline(1.9 equiv.), PdCl₂(dppf)-DCM (0.1 equiv.), and sodium carbonate (4.0equiv, 2M aqueous sin) was heated at 80° C. overnight. The cooledreaction was partitioned between water and ethyl acetate, the organicphase was dried with sodium sulfate, filtered and concentrated. Thecrude material was purified via silica gel chromatography (ISCO, elutingwith 0-10% methanol in DCM) and the pure fractions were concentrated togive 2-((5-(5-amino-2-methylphenyl)-3-morpholinopyridin-2-yl)oxy)ethanolas a brown foam in 56% yield. LCMS (m/z) (M+H)=330.0, Rt=0.46 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 919 above using the appropriatestarting materials.

Example 997:2-(2-fluoropropan-2-yl)-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

LCMS (m/z) (M+H)=495.2, Rt=0.80 min.

Example 998:2-(2-cyanopropan-2-yl)-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

LCMS (m/z) (M+H)=502.2, Rt=0.79 min.

Example 999:2-cyclopropyl-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

LCMS (m/z) (M+H)=475.2, Rt=0.63 min.

Example 1000:2-(1,1-difluoroethyl)-N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)isonicotinamide

LCMS (m/z) (M+H)=499.2, Rt=0.82 min.

Example 1001:N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)-5-(trifluoromethyl)nicotinamide

LCMS (m/z) (M+H)=503.2, Rt=0.83 min.

Example 1002:N-(3-(6-(2-hydroxyethoxy)-5-morpholinopyridin-3-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

LCMS (m/z) (M+H)=503.2, Rt=0.84 min.

Example 1003: (R)-methyl(2-((2′-methyl-5-morpholino-5′-(3-(trifluoromethyl)benzamido)-[3,3′-bipyridin]-6-yl)oxy)propyl)carbamate

Step 1

Sodium hydride (3.1 equiv.) was added to dioxane (0.09 M) at rt.(R)-1-aminopropan-2-ol (3.0 equiv.) was added, and the mixture wasstirred for 30 min.N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was added and the reaction was stirred at rt for 18 hours.Upon overnight stirring at rt, the reaction was heated to 60° C. for 5hours. The cooled reaction mixture was poured into water and extractedwith ethyl acetate (3×). The combined organics were washed with brine,dried over sodium sulfate, filtered and concentrated. The mixture waspurified by silica gel chromatography (0-10% methanol:DCM) and the purefractions were concentrated to give(R)-N-(6′-((1-aminopropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 20% yield. LCMS (m/z) (M+H)=516.1, Rt=0.64 min.

Step 2

(R)-N-(6′-((1-aminopropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.03 M) followed by methyl chloroformate (1.2equiv.) and the reaction was stirred at rt for 2 hours. Quenched by theaddition of sat. sodium bicarbonate, extracted with DCM (3×), dried overmagnesium sulfate, filtered and concentrated. The residue wasredissolved in DMSO and purified via reverse phase prep-HPLC to give(R)-methyl(2-((2′-methyl-5-morpholino-5′-(3-(trifluoromethyl)benzamido)-[3,3′-bipyridin]-6-yl)oxy)propyl)carbamatein 32% yield. ¹H NMR (400 MHz, Methanol-d4) δ 9.36 (d, J=2.4 Hz, 1H),8.46 (d, J=2.4 Hz, 1H), 8.34 (dt, J=1.7, 1.0 Hz, 1H), 8.32-8.24 (m, 1H),8.00-7.92 (m, 1H), 7.87 (d, J=2.2 Hz, 1H), 7.83-7.74 (m, 1H), 7.31 (d,J=2.2 Hz, 1H), 5.44 (td, J=6.6, 4.5 Hz, 1H), 3.86 (t, J=4.7 Hz, 4H),3.62 (s, 3H), 3.53-3.36 (m, 2H), 3.21-3.07 (m, 4H), 2.70 (s, 3H), 1.37(d, J=6.3 Hz, 3H). LCMS (m/z) (M+H)=574.2, Rt=0.77 min.

Synthesis of6′-chloro-3′-fluoro-2-methyl-2′-morpholino-[3,4′-bipyridin]-5-amine

Step 1

4-(4-bromo-6-chloropyridin-2-yl)morpholine (1.0 equiv.) was dissolved inacetonitrile (0.1 M). Selectfluor (1.1 equiv.) was added at rt andstirred for 18 hours. The reaction was diluted with ethyl acetate andwashed with water, brine, dried over sodium sulfate, filtered andconcentrated. The residue was purified by silica gel chromatography(ISCO, 0-10% ethyl acetate/heptanes) to give4-(4-bromo-6-chloro-3-fluoropyridin-2-yl)morpholine in 42% yield and4-(4-bromo-6-chloro-5-fluoropyridin-2-yl)morpholine in 14% yield. LCMS(m/z) (M+H)=294.7, Rt=0.95 and 0.99 min.

Step 2

To a solution of 4-(4-bromo-6-chloro-3-fluoropyridin-2-yl)morpholine(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.7 equiv.) in DME (0.04 M) and sodium carbonate (2M, 3.0 equiv.) wasadded Pd(PPh₃)₄(0.03 equiv.) and the reaction was heated at 100° C. for2 hours. The mixture was poured onto ice water and extracted with ethylacetate. The combined organics were washed with brine, dried overmagnesium sulfate, filtered and concentrated. The mixture was purifiedvia silica gel chromatography (10% methanol:ethyl acetate:heptanes) togive 6′-chloro-3′-fluoro-2-methyl-2′-morpholino-[3,4′-bipyridin]-5-amineas a yellow solid in 39% yield. ¹H NMR (400 MHz, <cdcl3>) δ ppm 2.32 (s,3H) 3.52-3.59 (m, 4H) 3.66 (br. s., 2H) 3.80-3.85 (m, 4H) 6.63 (d,J=3.91 Hz, 1H) 6.79-6.84 (m, 1H) 8.08 (d, J=2.74 Hz, 1H)

Synthesis of2′-chloro-3′-fluoro-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-amine

To a solution of 4-(4-bromo-6-chloro-5-fluoropyridin-2-yl)morpholine(1.0 equiv.) and6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.4 equiv.) in DME (0.02 M)) and Na₂CO₃ (2 M aq.) (3.0 equiv.) wasadded Pd(PPh₃)₄ and heated (thermally) at 100° C. for 2 h. LCMS showscomplete consumption of starting material with fairly clean conversionto desired product. The mixture was poured onto ice-water and extractedwith EtOAc (3×). The combined organics were washed with brine, dried(MgSO₄) and concentrated. The mixture was adsorbed onto Celite andpurified by ISCO flash column chromatography (silica gel, 10% methanolin EtOAc:heptane). Product fractions eluted around 40% EtOAc and wereconcentrated to give2′-chloro-3′-fluoro-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-amine in77% yield as a pale yellow solid. LCMS (m/z) (M+H)=322.9, Rt=0.62 min.

Synthesis of2-((4-(5-amino-2-methylphenyl)-3-fluoro-6-morpholinopyridin-2-yl)amino)ethanol

Step 1

To a solution of 4-(4-bromo-6-chloro-5-fluoropyridin-2-yl)morpholine(1.0 equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.2equiv.) in DME (0.1 M) and Na₂CO₃ (2 M aq.) (3.0 equiv.) was addedPd(PPh₃)₄ and heated (thermally) at 100° C. for 2 h. LCMS shows completeconsumption of starting material with fairly clean conversion to desiredproduct. The mixture was poured onto ice-water and extracted with EtOAc(3×). The combined organics were washed with brine, dried (MgSO₄) andconcentrated. The mixture was adsorbed onto Celite and purified by ISCOflash column chromatography (silica gel, 10% methanol in EtOAc:heptane).Product fractions eluted around 40% EtOAc and were concentrated to give3-(2-chloro-3-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline in 87%yield. LCMS (m/z) (M+H)=322, Rt=0.62 min.

Step 2

In a microwave vial was added3-(2-chloro-3-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline (1.0equiv.), 2-aminoethanol (50 equiv.), DIPEA (2.0 equiv.) in NMP (0.2).The vial was sealed with a crimp top. The reaction was then heated to250° C. for 30 min heated by microwave. LC-MS showed completion of thereaction. The reaction mixture was diluted with ethyl acetate, washedwith water, brine then dried over sodium sulfate. Concentrated to yieldcrude. Purified by 10% methanol in ethyl acetate to yield2-((4-(5-amino-2-methylphenyl)-3-fluoro-6-morpholinopyridin-2-yl)amino)ethanolin 43% yield. LCMS (m/z) (M+H)=347.0, Rt=0.50 min.

Example 1004:N-(3′-fluoro-6′-((2-hydroxyethyl)amino)-2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

6-(trifluoromethyl)pyridazine-4-carboxylic acid (1.2 equiv.),2-((5-amino-5′-fluoro-2-methyl-6′-morpholino-[3,4′-bipyridin]-2′-yl)amino)ethanol(1.0 equiv.) and DIPEA (1.5 equiv.) were added into DCM (0.09 M).2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (1.3equiv.) was added and the mixture was stirred at rt over the weekend.The reaction mixture was purified directly via silica gel chromatographyfollowed by neutral reverse phase prep-HPLC and the pure fractions werelyophilized to giveN-(3′-fluoro-6′-((2-hydroxyethyl)amino)-2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamidein 8% yield. ¹H NMR (400 MHz, <cdcl3>) δ ppm 2.48 (s, 3H) 3.39-3.54 (m,7H) 3.73-3.88 (m, 7H) 4.61-4.71 (m, 1H) 5.76 (d, J=2.74 Hz, 1H) 8.08 (d,J=1.96 Hz, 1H) 8.29 (d, J=1.96 Hz, 1H) 8.70 (d, J=2.35 Hz, 1H) 9.83 (s,1H). LCMS (m/z) (M+H)=522.1, Rt=0.62 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 1004 above using theappropriate starting materials.

Example 1006:N-(3-(3-fluoro-2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.26 (s, 3H) 3.36-3.43 (m, 4H) 3.70(m,, 3H) 3.80-3.86 (m, 4H) 3.86-3.92 (m, 2H) 5.03 (br. s., 1H) 5.72 (br.s., 1H) 7.33 (d, J=8.20 Hz, 1H) 7.52 (br. s., 1H) 7.61 (d, J=8.20 Hz,1H) 7.94 (d, J=2.84 Hz, 1H) 8.03 (br. s., 1H) 8.13 (s, 1H) 8.94 (d,J=4.73 Hz, 1H). LCMS (m/z) (M+H)=520.1, Rt=0.86 min.

Example 1007:N-(3-(3-fluoro-2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cdcl3>) δ ppm 2.23 (br. s., 3H) 3.35 (br. s., 4H) 3.66(br. s., 2H) 3.76-3.88 (m, 8H) 5.01 (br. s., 1H) 5.66 (br. s., 1H) 7.30(d, J=7.83 Hz, 1H) 7.45 (br. s., 1H) 7.62 (d, J=7.43 Hz, 1H) 8.28 (br.s., 1H) 8.64 (br. s., 1H) 9.78 (br. s., 1H). LCMS (m/z) (M+H)=521.1,Rt=0.81 min.

Example 1008:N-(3-(3-fluoro-6-((2-hydroxyethyl)amino)-2-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.19-2.31 (m, 3H) 2.97-3.29 (m, 1H)3.36-3.55 (m, 6H) 3.76-3.92 (m, 6H) 4.64 (br. s., 1H) 7.29-7.39 (m, 2H)7.51 (br. s., 1H) 7.58 (d, J=8.20 Hz, 1H) 7.94 (d, J=3.47 Hz, 1H) 8.13(br. s., 2H) 8.93 (d, J=4.41 Hz, 1H). LCMS (m/z) (M+H)=519.9, Rt=0.83min.

Example 1009:2-(difluoromethyl)-N-(3-(3-fluoro-6-((2-hydroxyethyl)amino)-2-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.24 (s, 3H) 3.18 (br. s., 1H)3.38-3.53 (m, 6H) 3.76-3.87 (m, 6H) 4.64 (br. s., 1H) 5.79 (d, J=2.84Hz, 1H) 6.55-6.89 (m, 1H) 7.31 (s, 1H) 7.52 (s, 1H) 7.58 (d, J=8.20 Hz,1H) 7.87 (d, J=4.41 Hz, 1H) 8.04 (s, 1H) 8.17 (s, 1H) 8.84 (d, J=5.04Hz, 1H). LCMS (m/z) (M+H)=502.1, Rt=0.76 min.

Example 1010:N-(3-(3-fluoro-6-((2-hydroxyethyl)amino)-2-morpholinopyridin-4-yl)-4-methylphenyl)-2-(2-hydroxypropan-2-yl)isonicotinamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 1.61 (s, 6H) 2.24 (s, 3H) 3.13-3.31(m, 1H) 3.39-3.56 (m, 6H) 3.83 (d, J=2.84 Hz, 6H) 4.48-4.78 (m, 2H) 5.78(br. s., 1H) 7.29-7.31 (m, 1H) 7.51 (s, 1H) 7.55-7.65 (m, 2H) 7.87 (s,1H) 8.16 (s, 1H) 8.68 (d, J=5.04 Hz, 1H). LCMS (m/z) (M+H)=510.2,Rt=0.62 min.

Example 1011:2-(1-cyanocyclopropyl)-N-(3-(3-fluoro-6-((2-hydroxyethyl)amino)-2-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 1.79-1.96 (m, 4H) 2.25 (d, J=2.84Hz, 3H) 3.04 (br. s., 1H) 3.41-3.56 (m, 6H) 3.80-3.92 (m, 6H) 4.62 (br.s., 1H) 5.84 (d, J=3.15 Hz, 1H) 7.32 (d, J=3.15 Hz, 1H) 7.54 (br. s.,1H) 7.58-7.71 (m, 2H) 7.94 (br. s., 1H) 8.04 (br. s., 1H) 8.60-8.71 (m,1H). LCMS (m/z) (M+H)=517.1, Rt=0.79 min.

Example 1012:6-(2-cyanopropan-2-yl)-N-(3-(3-fluoro-6-((2-hydroxyethyl)amino)-2-morpholinopyridin-4-yl)-4-methylphenyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 1.96 (s, 6H) 2.26 (s, 3H) 2.99-3.07(m, 1H) 3.46-3.52 (m, 6H) 3.82-3.87 (m, 6H) 4.58-4.68 (m, 1H) 5.77-5.85(m, 1H) 7.33 (d, J=8.20 Hz, 1H) 7.53 (s, 1H) 7.59-7.66 (m, 1H) 8.17 (s,1H) 8.20-8.27 (m, 1H) 9.62 (s, 1H). LCMS (m/z) (M+H)=520.1, Rt=0.74 min.

Example 1013:N-(3-(3-fluoro-6-((2-hydroxyethyl)amino)-2-morpholinopyridin-4-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (400 MHz, <cdcl3>) δ ppm 2.23 (s, 3H) 3.43-3.50 (m, 7H) 3.76-3.88(m, 7H) 5.76 (d, J=2.35 Hz, 1H) 7.30 (d, J=8.61 Hz, 1H) 7.47 (s, 1H)7.60 (d, J=7.43 Hz, 1H) 8.26 (s, 1H) 8.40 (s, 1H) 9.78 (s, 1H). LCMS(m/z) (M+H)=521.1, Rt=0.84 min.

Example 1014:N-(3-(3,5-difluoro-2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.20-2.32 (m, 3H) 3.04 (br. s., 1H)3.33-3.46 (m, 4H) 3.60-3.73 (m, 2H) 3.81-3.93 (m, 6H) 4.84 (br. s., 1H)7.34-7.42 (m, 1H) 7.57 (br. s., 1H) 7.63 (d, J=7.88 Hz, 1H) 7.94 (d,J=3.47 Hz, 1H) 8.04 (br. s., 1H) 8.12 (br. s., 1H) 8.94 (d, J=4.41 Hz,1H). LCMS (m/z) (M+H)=538.1, Rt=0.94 min.

Example 1015:N-(3-(3,5-difluoro-2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.17-2.30 (m, 3H) 3.19 (br. s., 1H)3.37 (d, J=3.78 Hz, 4H) 3.55-3.73 (m, 2H) 3.80-3.90 (m, 6H) 4.84 (br.s., 1H) 7.32-7.41 (m, 1H) 7.47-7.56 (m, 1H) 7.60-7.71 (m, 1H) 8.23-8.34(m, 1H) 8.55-8.66 (m, 1H) 9.75-9.84 (m, 1H). LCMS (m/z) (M+H)=539.1,Rt=0.90 min.

Example 1016:2-(difluoromethyl)-N-(3-(3-fluoro-2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (500 MHz, CHLOROFORM-d) δ ppm 2.26 (s, 3H) 3.35-3.44 (m, 4H) 3.70(br. s., 2H) 3.80-3.86 (m, 4H) 3.87-3.93 (m, 2H) 4.96-5.11 (m, 1H) 5.73(br. s., 1H) 6.60-6.89 (m, 1H) 7.32-7.36 (m, 1H) 7.54 (br. s., 1H) 7.62(d, J=8.20 Hz, 1H) 7.88 (d, J=4.10 Hz, 1H) 7.95 (br. s., 1H) 8.04 (s,1H) 8.87 (d, J=5.04 Hz, 1H). LCMS (m/z) (M+H)=502.1, Rt=0.79 min.

Synthesis of 3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylbenzoicacid

Step 1

To a degassed solution of 4-(6-chloro-3-methoxypyridazin-4-yl)morpholine(1.0 equiv.), methyl4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (2.0equiv.) and X-Phos (0.1 equiv.) in THF (0.3 M) was added K₃PO₄ (0.5 M,2.0 equiv.). The reaction was heated at 40° C. overnight thenpartitioned between ethyl acetate and water. The aqueous phase wasextracted with ethyl acetate (2×), the combined organics were dried overmagnesium sulfate, filtered and concentrated. The crude was purified viasilica gel chromatography (ISCO, 0-80% ethyl acetate/heptanes) and thepure fractions were concentrated to give methyl3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylbenzoate as a yellowoil in 55% yield. LCMS (m/z) (M+H)=344, Rt=0.58 min.

Step 2

To a solution of methyl3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylbenzoate (1.0 equiv.)in THF (0.13 M) was added lithium hydroxide (2.5 equiv., 1M aqueoussolution) and the reaction was stirred at rt overnight. The solution wasneutralized with 1M HCl and the volatiles were removed under reducedpressure. The product was extracted with ethyl acetate, dried overmagnesium sulfate, filtered and concentrated to give3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylbenzoic acid in 70%yield. LCMS (m/z) (M+H)=330.0, Rt=0.48 min.

Example 1017:3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methyl-N-(2-(trifluoromethyl)pyridin-4-yl)benzamide

To a stirred solution of3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylbenzoic acid (1.0equiv.) in DCM (0.06 M) at 0° C. was added1-chloro-N,N,2-trimethylprop-1-en-1-amine (1.2 equiv.) and the mixturewas allowed to stir at 0° C. for 1 hour. This solution was added toanother solution containing 2-(trifluoromethyl)pyridin-4-amine (1.3equiv.) and TEA (3.0 equiv.) in DCM and the reaction was allowed to warmto rt and stirred for 1 hour. The mixture was concentrated to dryness,dissolved in DMSO and purified via reverse phase prep-HPLC. The purefractions were lyophilized to give3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methyl-N-(2-(trifluoromethyl)pyridin-4-yl)benzamidein 23% yield. ¹H NMR (400 MHz, <cd3od>) δ ppm 2.45 (s, 3H) 3.83-3.90 (m,4H) 3.97 (br. s., 4H) 4.18 (s, 3H) 7.32 (s, 1H) 7.65 (d, J=8.22 Hz, 1H)8.02 (dd, J=5.48, 1.96 Hz, 1H) 8.10 (d, J=1.57 Hz, 1H) 8.16 (dd, J=7.83,1.96 Hz, 1H) 8.30 (d, J=1.56 Hz, 1H) 8.61 (d, J=5.87 Hz, 1H). LCMS (m/z)(M+H)=474.0, Rt=0.71 min.

The compounds listed below were prepared using methods similar to thosedescribed for the preparation of Example 1017 above using theappropriate starting materials.

Example 1019:N-(2-(1,1-difluoroethyl)pyridin-4-yl)-3-(6-methoxy-5-morpholinopyridazin-3-yl)-4-methylbenzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.99 (t, J=18.59 Hz, 3H) 2.45 (s, 3H)3.84-3.89 (m, 4H) 3.98 (br. s., 4H) 4.18 (s, 3H) 7.32 (s, 1H) 7.65 (d,J=8.22 Hz, 1H) 7.94 (dd, J=5.87, 1.96 Hz, 1H) 8.10 (d, J=1.96 Hz, 1H)8.14 (d, J=1.96 Hz, 1H) 8.14-8.17 (m, 1H) 8.53 (d, J=5.48 Hz, 1H). LCMS(m/z) (M+H)=470.1, Rt=0.66 min.

Example 1020:N-(2-(1,1-difluoroethyl)pyridin-4-yl)-3-(6-ethoxy-5-morpholinopyridazin-3-yl)-4-methylbenzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.51-1.57 (m, 3H) 1.99 (t, J=18.78 Hz,3H) 2.45 (s, 3H) 3.84-3.91 (m, 4H) 3.99 (br. s., 4H) 4.59 (q, J=7.04 Hz,2H) 7.32 (s, 1H) 7.65 (d, J=8.22 Hz, 1H) 7.94 (dd, J=5.87, 1.96 Hz, 1H)8.09 (d, J=1.56 Hz, 1H) 8.13-8.17 (m, 2H) 8.53 (d, J=5.87 Hz, 1H). LCMS(m/z) (M+H)=484.3, Rt=0.71 min.

Example 1021:(R)-N-(6′-((1-hydroxypropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of sodium hydride (4.2 equiv.) in DMAC at 90° C. was addedR-1-methoxy-2-propanol (4.0 equiv.) and the mixture was stirred for 15min.N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was added and the reaction was heated at 90° C. for 5hours. The mixture was cooled and quenched with water and extracted withethyl acetate. The combined organics were washed with water, brine,dried over sodium sulfate, filtered and concentrated. The crude residuewas purified via silica gel chromatography eluting with 0-100% ethylacetate in heptanes to give(R)-N-(6′-((1-methoxypropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideas the desired product. LCMS (m/z) (M+H)=531.2 Rt=0.78 min.

Step 2

To a solution of(R)-N-(6′-((1-methoxypropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.06 M) at 90° C. was added boron tribromide in DCM(1M, 1.0 equiv.) and the mixture was stirred at 90° C. for 16 hours.Upon cooling to rt, the reaction was quenched with methanol andconcentrated to dryness. The crude residue was purified via reversephase prep-HPLC and the pure fractions were lyophilized to give(R)-N-(6′-((1-hydroxypropan-2-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide.LCMS (m/z) (M+H)=517.3 Rt=0.71 min.

Example 1022:(S)-N-(6′-(2-hydroxypropoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

Step 1

To a solution of sodium hydride (4.2 equiv.) in dioxane (0.02 M) at 100°C. was added (S)-2-methoxypropan-1-ol (4.0 equiv.) and the mixture wasstirred for 15 min.N-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) was added and the reaction was heated at 100° C. for 4hours. The mixture was cooled and quenched with water and extracted withethyl acetate. The combined organics were washed with water, brine,dried over sodium sulfate, filtered and concentrated. The crude residuewas purified via silica gel chromatography eluting with 0-100% ethylacetate in heptanes to(S)-N-(6′-(2-methoxypropoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideas the desired product in 44% yield. LCMS (m/z) (M+H)=531.2 Rt=0.77 min.

Step 2

To a solution of(S)-N-(6′-(2-methoxypropoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) in DCM (0.05 M) was added boron tribromide in DCM (1M, 1.2equiv.) and the mixture was stirred at rt for 30 mins. The reaction wasquenched with methanol and concentrated to dryness. The crude residuewas purified via reverse phase prep-HPLC and the pure fractions werelyophilized to give(S)-N-(6′-(2-hydroxypropoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 9% yield. 1H NMR (400 MHz, <dmso>) δ ppm 1.07-1.18 (m, 3H) 2.45-2.46(m, 3H) 2.99-3.10 (m, 4H) 3.63-3.71 (m, 5H) 4.03-4.26 (m, 5H) 7.13-7.24(m, 1H) 7.72-7.82 (m, 2H) 7.92-8.01 (m, 1H) 8.10-8.17 (m, 1H) 8.21-8.32(m, 2H) 8.90-8.98 (m, 1H) 10.76-10.83 (m, 1H). LCMS (m/z) (M+H)=517.2,Rt=0.69 min.

Synthesis of(R)-1-((6-(5-amino-2-methylphenyl)-2-morpholinopyrimidin-4-yl)amino)propan-2-ol

Step 1

To a solution of 2,4,6-trichloropyrimidine (1.0 equiv.) in dioxane (0.36M) at 0° C. was added DIEA (1.1 equiv.) and (R)-1-aminopropan-2-ol (1.1equiv.) dropwise. The reaction was stirred at rt for 2 hours at whichpoint, two isomeric products were observed by TLC. The dioxane wasevaporated in vacuo and the residue was partitioned between water andDCM. The organic layer was separated and the aqueous layer was furtherextracted with DCM. The combined organics were dried over sodiumsulfate, filtered and concentrated in vacuo. The crude was purified viasilica gel chromatography (ISCO, 0-60% ethyl acetate in heptanes) togive (R)-1-((4,6-dichloropyrimidin-2-yl)amino)propan-2-ol and(R)-1-((4,6-dichloropyrimidin-2-yl)amino)propan-2-ol as white solids in41% and 42% yields respectively. 1H NMR (400 MHz, <dmso>) δ ppm 1.05 (d,J=6.26 Hz, 3H) 3.08-3.27 (m, 2H) 3.76 (spt, J=6.00 Hz, 1H) 4.71 (d,J=5.09 Hz, 1H) 6.86 (s, 1H) 8.05 (t, J=5.67 Hz, 1H) and ¹H NMR (400 MHz,<dmso>) δ ppm 1.07 (d, J=6.26 Hz, 3H) 3.05-3.30 (m, 2H) 3.75 (dq,J=11.44, 5.71 Hz, 1H) 4.84 (d, J=4.70 Hz, 1H) 6.60 (s, 1H) 8.22 (d,J=5.48 Hz, 1H).

Step 2

To a solution of (R)-1-((2,6-dichloropyrimidin-4-yl)amino)propan-2-ol(1.0 equiv.) in dioxane (0.2 M) was added DIEA (1.5 equiv.) andmorpholine (1.8 equiv.) and the reaction was heated to 70° C. for 5hours. The precipitate was filtered and the dioxane was evaporated invacuo. The crude solid was taken up in DCM and washed with water. Thecombined organics were dried over sodium sulfate, filtered andconcentrated to give(R)-1-((6-chloro-2-morpholinopyrimidin-4-yl)amino)propan-2-ol in 93%yield. 1H NMR (400 MHz, <cdcl3>) δ ppm 1.24 (d, J=6.26 Hz, 3H) 3.26 (dt,J=13.21, 6.50 Hz, 1H) 3.44-3.57 (m, 1H) 3.69-3.79 (m, 9H) 4.01 (br. s.,1H) 5.04 (br. s., 1H) 5.75 (s, 1H). LCMS (m/z) (M+H)=273, 275; Rt=0.52min.

Step 3

To a degassed solution of(R)-1-((6-chloro-2-morpholinopyrimidin-4-yl)amino)propan-2-ol (1.0equiv.) and4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.3equiv.) in DME and 2M sodium carbonate (3:1, 0.2 M) was addedPdCl₂(dppf)-DCM adduct (0.1 equiv.) and the reaction was heated to 70°C. for 4 hours. The cooled reaction was diluted with ethyl acetate andwashed with water and brine. The organics were dried over magnesiumsulfate, filtered and concentrated. The residue was purified via silicagel chromatography (ISCO, 0-100% ethyl acetate in heptanes, then 0-10%methanol in DCM) to give(R)-1-((6-(5-amino-2-methylphenyl)-2-morpholinopyrimidin-4-yl)amino)propan-2-olas a light brown foam in 56% yield. LCMS (m/z) (M+H)=344, Rt=0.41 min.

Example 1023:(R)-N-(3-(6-((2-hydroxypropyl)amino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.24 (d, J=6.26 Hz, 3H) 2.37 (s, 3H)3.46-3.62 (m, 2H) 3.81 (s, 8H) 3.98-4.04 (m, 1H) 6.17 (s, 1H) 7.43 (d,J=8.61 Hz, 1H) 7.67 (dd, J=8.22, 2.35 Hz, 1H) 7.97 (d, J=1.96 Hz, 1H)8.12 (d, J=4.70 Hz, 1H) 8.30 (s, 1H) 8.92 (d, J=5.09 Hz, 1H). LCMS (m/z)(M+H)=517.3, Rt=0.68 min.

Example 1024:(R)-2-(1,1-difluoroethyl)-N-(3-(6-((2-hydroxypropyl)amino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.24 (d, J=6.26 Hz, 3H) 2.04 (t, J=18.78Hz, 3H) 2.37 (s, 3H) 3.45-3.63 (m, 2H) 3.76-3.86 (m, 8H) 3.97-4.06 (m,1H) 6.17 (s, 1H) 7.42 (d, J=8.61 Hz, 1H) 7.67 (dd, J=8.41, 2.15 Hz, 1H)7.96 (d, J=2.35 Hz, 2H) 8.18 (s, 1H) 8.82 (d, J=5.09 Hz, 1H). LCMS (m/z)(M+H)=513.1, Rt=0.69 min.

Example 1025:(R)-2-(2-fluoropropan-2-yl)-N-(3-(6-((2-hydroxypropyl)amino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.24 (d, J=6.26 Hz, 3H) 1.68-1.80 (m,6H) 2.37 (s, 3H) 3.45-3.63 (m, 2H) 3.76-3.85 (m, 8H) 3.96-4.06 (m, 1H)6.18 (s, 1H) 7.42 (d, J=8.22 Hz, 1H) 7.66 (dd, J=8.22, 1.96 Hz, 1H) 7.77(dd, J=5.09, 1.57 Hz, 1H) 7.96 (d, J=2.35 Hz, 1H) 8.06 (s, 1H) 8.71 (d,J=5.09 Hz, 1H). LCMS (m/z) (M+H)=509.1, Rt=0.67 min.

Example 1026:(R)-2-(2-cyanopropan-2-yl)-N-(3-(6-((2-hydroxypropyl)amino)-2-morpholinopyrimidin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.24 (d, J=6.26 Hz, 3H) 1.81 (s, 6H)2.37 (s, 3H) 3.45-3.62 (m, 2H) 3.76-3.85 (m, 10H) 3.97-4.06 (m, 1H) 6.18(s, 1H) 7.42 (d, J=8.22 Hz, 1H) 7.66 (dd, J=8.22, 1.96 Hz, 1H) 7.81 (dd,J=4.89, 1.37 Hz, 1H) 7.96 (d, J=1.96 Hz, 1H) 8.07 (s, 1H) 8.78 (d,J=4.70 Hz, 1H). LCMS (m/z) (M+H)=516.4, Rt=0.67 min.

Synthesis of 5-ethoxy-2′-methyl-6-morpholino-[2,3′-bipyridin]-5′-amine

A solution of 2,6-dichloro-3-ethoxypyridine (1.0 equiv.) and morpholine(1.0 equiv.) in NMP (0.6 M) was heated at 150° C. in the microwave for30 min. At this point, LC/MS indicated incompletion of the reaction,heated for 1 hour at 150° C. The cooled reaction mixture was purifiedvia silica gel chromatography and the pure fractions were used for thenext reaction. To a solution of4-(6-bromo-3-ethoxypyridin-2-yl)morpholine (1.0 equiv.) in DME (0.4 M)was added sodium carbonate (3.0 equiv, 2M aqueous solution),6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine(1.0 equiv.), PdCl₂(dppf)-DCM (0.05 equiv.) and the reaction was heatedat 130° C. in the microwave for 30 min. The cooled reaction mixture waspartitioned between brine and ethyl acetate. The organic phase was driedwith MgSO₄, filtered and concentrated. The crude material was purifiedvia reverse phase prep-HPLC to give5-ethoxy-2′-methyl-6-morpholino-[2,3′-bipyridin]-5′-amine in 14% yield.LCMS (m/z) (M+H)=315.1, Rt=0.58 min.

Example 1027:N-(5-ethoxy-2′-methyl-6-morpholino-[2,3′-bipyridin]-5′-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.37 (t, J=7.04 Hz, 2H) 1.64-1.80 (m, 4H)2.60 (s, 2H) 3.30-3.43 (m, 2H) 3.54-3.78 (m, 5H) 4.11 (d, J=7.04 Hz, 1H)7.15 (d, J=7.83 Hz, 1H) 7.38 (d, J=8.22 Hz, 1H) 7.84 (dd, J=4.89, 1.37Hz, 1H) 8.05 (s, 1H) 8.35 (br. s., 1H) 8.78 (d, J=5.09 Hz, 1H) 8.87-8.96(m, 1H) 10.88 (br. s., 1H). LCMS (m/z) (M+H)=480.1, Rt=0.73 min.

Example 1028:2-(1,1-difluoroethyl)-N-(5-ethoxy-2′-methyl-6-morpholino-[2,3′-bipyridin]-5′-yl)isonicotinamide

1H NMR (400 MHz, <dmso>) δ ppm 1.37 (t, J=6.85 Hz, 1H) 2.05 (t, J=18.98Hz, 1H) 2.62 (s, 1H) 3.29-3.46 (m, 2H) 3.66-3.82 (m, 2H) 4.03-4.22 (m,1H) 7.16 (d, J=7.83 Hz, 1H) 7.39 (d, J=8.22 Hz, 1H) 8.05 (d, J=4.69 Hz,1H) 8.20 (s, 1H) 8.38 (br. s., 1H) 8.84-9.02 (m, 1H) 11.00 (s, 1H). LCMS(m/z) (M+H)=484.1, Rt=0.73 min.

Example 1029:N-(6′-(((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideand Example 1030:N-(6′-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.),4-(5-bromo-2-(((3R,4S)-3-fluorotetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)morpholine(1.0 equiv.) and sodium carbonate (2M aqueous solution, 3.0 equiv.) inDME (0.15 M) was added PdCl₂(dppf)-DCM (0.05 equiv.) and the reactionwas stirred at rt overnight. The mixture was purified via reverse phaseprep-HPLC and the pure fractions were lyophilized to give racemicproduct. The two enantiomers were separated via chiral HPLC(heptanes/ethanol:85/15, AD-H column, HPLC:1 mL/min) to give peak 1(6.889 min, 12 min run) and peak 2 (9.523 min, 12 min run). LCMS (m/z)(M+H)=561.2, Rt=0.78 min.

Example 1031:N-(6′-((4-deuterio-3-fluorotetrahydro-2H-pyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideand Example 1032:N-(2-methyl-5′-morpholino-6′-(trideuteriomethoxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution of dihydro-2H-pyran-4(3H)-one (1.0 equiv.) in CD3OD (0.1M) was added NaBD4 at rt. The mixture was stirred at rt until no morebubbling. Quenched with saturated ammonium chloride and extracted twicewith DCM. The organic phase was dried over sodium sulfate, filtered andconcentrated. The crude was used directly for the next step. To asolution ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(0.4 equiv.) and 4-deuterio-3-fluorotetrahydro-2H-pyran-4-ol (1.0equiv., containing CD3ONa from previous reaction) in THF (0.6 M) wasadded sodium hydride (3.0 equiv.) and the mixture was heated to 90° C.for 2 hours. The solution was quenched with water and purified viareverse phase prep-HPLC to giveN-(6′-((4-deuterio-3-fluorotetrahydro-2H-pyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamideandN-(2-methyl-5′-morpholino-6′-(trideuteriomethoxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide.LCMS (m/z) (M+H)=562.0, Rt=0.79 min and LCMS (m/z) (M+H)=476.1 Rt=0.76min respectively.

Example 1033:N-(6′-(2-(2-hydroxyethoxy)ethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and 2,2′-oxydiethanol (4.0 equiv.) in THF (0.1 M) was addedsodium hydride (4.0 equiv.) and the reaction was heated to 90° C. fortwo hours. The cooled reaction mixture was quenched with sat. ammoniumchloride, the organic phase was concentrated to dryness and purified viareverse phase prep-HPLC to giveN-(6′-(2-(2-hydroxyethoxy)ethoxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 27% yield. LCMS (m/z) (M+H)=547.1, Rt=0.69 min.

Example 1034:N-(6′-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and 4-hydroxytetrahydro-2H-thiopyran 1,1-dioxide

(4.0 equiv.) in THF (0.1 M) was added sodium hydride (4.0 equiv.) andthe reaction was heated to 90° C. for two hours. The cooled reactionmixture was quenched with sat. ammonium chloride, the organic phase wasconcentrated to dryness and purified via reverse phase prep-HPLC to giveN-(6′-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein 65% yield.

LCMS (m/z) (M+H)=591.1, Rt=0.72 min.

Example 1035:N-(2-methyl-5′-morpholino-6′-morpholino-6′-((4-deuteriotetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

To a solution ofN-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide(1.0 equiv.) and 4-deuteriotetrahydro-2H-pyran-4-ol (1.0 equiv.) in THF(0.7 M) was added sodium hydride (3.0 equiv.) and the reaction washeated to 90° C. for two hours. The cooled reaction mixture was quenchedwith water, the organic phase was concentrated to dryness and purifiedvia reverse phase prep-HPLC to giveN-(2-methyl-5′-morpholino-6′-((4-deuteriotetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamidein65% yield. LCMS (m/z) (M+H)=544.1, Rt=0.79 min.

Example 1036:3-(difluoromethyl)-N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)benzamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.34 (s, 3H) 3.54 (q, J=5.04 Hz, 6H)3.85 (dt, J=10.48, 5.00 Hz, 6H) 6.25 (d, J=14.82 Hz, 2H) 6.90 (t,J=56.40 Hz, 1H) 7.35 (d, J=8.20 Hz, 1H) 7.56-7.61 (m, 1H) 7.66-7.70 (m,1H) 7.77-7.81 (m, 2H) 8.10 (d, J=7.88 Hz, 1H) 8.15 (s, 1H). LCMS (m/z)(M+H)=483.1, Rt=0.72 min.

Example 1037:2-(1,1-difluoroethyl)-N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.06 (t, J=18.76 Hz, 3H) 2.35 (s, 3H)3.51-3.58 (m, 6H) 3.85 (dt, J=9.54, 4.85 Hz, 6H) 6.26 (d, J=14.82 Hz,2H) 7.37 (d, J=8.20 Hz, 1H) 7.62 (dd, J=8.20, 2.21 Hz, 1H) 7.81 (d,J=1.89 Hz, 1H) 7.98 (d, J=5.04 Hz, 1H) 8.20 (s, 1H) 8.84 (d, J=5.04 Hz,1H). LCMS (m/z) (M+H)=498.1, Rt=0.72 min.

Example 1038:3-(difluoromethyl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)benzamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.63 (s, 3H) 3.51-3.59 (m, 6H) 3.79-3.87(m, 6H) 6.17-6.24 (m, 1H) 6.92 (t, J=54.90 Hz, 1H) 7.69-7.75 (m, 1H)7.84 (d, J=7.88 Hz, 1H) 8.16 (d, J=7.88 Hz, 1H) 8.21 (s, 1H) 8.41 (d,J=2.21 Hz, 1H) 9.09 (s, 1H). LCMS (m/z) (M+H)=484.2, Rt=0.54 min.

Example 1039:2-(difluoromethyl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.61 (s, 3H) 3.52-3.59 (m, 6H) 3.80-3.88(m, 6H) 6.17-6.27 (m, 1H) 6.87 (t, J=54.90 Hz, 1H) 8.07 (d, J=5.04 Hz,1H) 8.24 (s, 1H) 8.37 (d, J=2.21 Hz, 1H) 8.89 (d, J=5.04 Hz, 1H) 9.00(br. s., 1H). LCMS (m/z) (M+H)=485.1, Rt=0.48 min.

Example 1040:N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.63 (s, 3H) 3.52-3.59 (m, 6H) 3.80-3.88(m, 6H) 6.20-6.28 (m, 1H) 8.41 (d, J=2.52 Hz, 1H) 8.73 (s, 1H) 9.06 (s,1H) 9.15 (s, 2H) 9.41 (d, J=1.89 Hz, 1H). LCMS (m/z) (M+H)=503.2,Rt=0.52 min.

Example 1041:2-(1,1-difluoroethyl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.07 (t, J=18.76 Hz, 3H) 2.64 (s, 3H)3.52-3.59 (m, 6H) 3.80-3.88 (m, 6H) 6.20-6.28 (m, 1H) 8.03 (d, J=5.04Hz, 1H) 8.25 (s, 1H) 8.43 (d, J=2.52 Hz, 1H) 8.88 (d, J=4.73 Hz, 1H)9.09 (d, J=1.58 Hz, 1H). LCMS (m/z) (M+H)=499.2, Rt=0.52 min.

Example 1042:2-(2-cyanopropan-2-yl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

LCMS (m/z) (M+H)=502.2, Rt=0.51 min.

Example 1043:N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(methylsulfonyl)isonicotinamide

LCMS (m/z) (M+H)=513.1, Rt=0.42 min.

Example 1044:1-ethyl-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.44 (t, J=7.09 Hz, 3H) 2.62 (s, 3H)3.51-3.58 (m, 6H) 3.80-3.87 (m, 6H) 4.19 (q, J=7.04 Hz, 2H) 8.35 (d,J=2.52 Hz, 1H) 8.53 (d, J=1.89 Hz, 1H) 8.80 (d, J=2.52 Hz, 1H) 9.02 (s,1H). LCMS (m/z) (M+H)=547.2, Rt=0.52 min.

Example 1045:3-(4-ethylpiperazin-1-yl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-5-(trifluoromethyl)benzamide

LCMS (m/z) (M+H)=614.2, Rt=0.51 min Exam pie 1046:N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(2-hydroxypropan-2-yl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.66 (s, 6H) 2.64 (s, 3H) 3.52-3.60 (m,6H) 3.80-3.88 (m, 6H) 7.97 (dd, J=5.36, 1.58 Hz, 1H) 8.36 (d, J=0.95 Hz,1H) 8.43 (d, J=2.21 Hz, 1H) 8.78 (d, J=5.36 Hz, 1H) 9.09 (d, J=2.21 Hz,1H). LCMS (m/z) (M+H)=493.2, Rt=0.39 min.

Example 1047:N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.35 (s, 3H) 3.49-3.58 (m, 6H) 3.85 (dt,J=9.69, 4.77 Hz, 6H) 6.22-6.28 (m, 2H) 7.39 (d, J=8.51 Hz, 1H) 7.65 (dd,J=8.35, 2.05 Hz, 1H) 7.83 (d, J=2.21 Hz, 1H) 8.60 (d, J=1.89 Hz, 1H)9.89 (d, J=1.58 Hz, 1H). LCMS (m/z) (M+H)=503.1, Rt=0.67 min.

Example 1048:6-cyclopropyl-N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.23-1.32 (m, 4H) 2.35 (s, 3H) 2.37-2.44(m, 1H) 3.46-3.61 (m, 6H) 3.85 (dt, J=9.30, 4.81 Hz, 6H) 6.24-6.29 (m,1H) 7.38 (d, J=8.51 Hz, 1H) 7.63 (dd, J=8.20, 2.21 Hz, 1H) 7.80 (d,J=2.21 Hz, 1H) 7.97 (d, J=1.89 Hz, 1H) 9.40 (d, J=1.89 Hz, 1H). LCMS(m/z) (M+H)=475.2, Rt=0.61 min.

Example 1049:6-(2-cyanopropan-2-yl)-N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) d ppm 1.90-1.95 (m, 6H) 2.36 (s, 3H) 3.48-3.61(m, 6H) 3.86 (dt, J=9.46, 4.73 Hz, 6H) 6.23-6.31 (m, 1H) 7.39 (d, J=8.51Hz, 1H) 7.64 (dd, J=8.20, 2.21 Hz, 1H) 7.82 (d, J=2.21 Hz, 1H) 8.38 (d,J=1.89 Hz, 1H) 9.63 (d, J=1.89 Hz, 1H).

LCMS (m/z) (M+H)=502.2, Rt=0.63 min.

Example 1050:2-(1-cyanocyclopropyl)-N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) ppm 1.81-1.90 (m, 4H) 2.35 (s, 3H) 3.46-3.61(m, 7H) 3.85 (dt, J=9.54, 4.85 Hz, 7H) 6.24-6.30 (m, 1H) 7.37 (d, J=8.20Hz, 1H) 7.61 (dd, J=8.20, 2.21 Hz, 1H) 7.71-7.75 (m, 1H) 7.81 (d, J=1.89Hz, 1H) 8.10 (s, 1H) 8.68 (d, J=5.04 Hz, 1H). LCMS (m/z) (M+H)=499.2,Rt=0.69 min.

Example 1051:N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) ppm 2.60 (s, 3H) 3.52-3.59 (m, 6H) 3.84 (dt,J=12.45, 4.97 Hz, 6H) 6.19-6.28 (m, 1H) 8.35 (d, J=2.21 Hz, 1H) 8.64 (d,J=1.89 Hz, 1H) 8.96 (s, 1H) 9.92 (d, J=1.89 Hz, 1H). LCMS (m/z)(M+H)=504.2, Rt=0.49 min.

Example 1052:6-cyclopropyl-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.22-1.33 (m, 4H) 2.38-2.45 (m, 1H) 2.63(s, 3H) 3.51-3.60 (m, 6H) 3.84 (dt, J=12.06, 4.85 Hz, 6H) 6.21-6.28 (m,1H) 7.99 (d, J=2.21 Hz, 1H) 8.39 (d, J=2.21 Hz, 1H) 9.02 (d, J=2.21 Hz,1H) 9.43 (d, J=1.89 Hz, 1H). LCMS (m/z) (M+H)=476.1, Rt=0.44 min.

Example 1053:2-(difluoromethyl)-N-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (500 MHz, METHANOL-d) δ ppm 2.30 (s, 5H) 3.43-3.55 (m, 10H)3.69-3.85 (m, 10H) 5.85-5.99 (m, 1H) 6.65-7.03 (m, 1H) 7.30 (d, J=8.20Hz, 1H) 7.57-7.68 (m, 2H) 8.03 (d, J=4.41 Hz, 1H) 8.19 (s, 1H) 8.85 (d,J=5.04 Hz, 1H). LC/MS (m/z): 484.3 (MH+), Rt=0.66 min.

Example 1054:N-(4-methyl-3-(2-morpholino-6-((tetrahydrofuran-3-yl)amino)pyridin-4-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.88-2.02 (m, 1H) 2.33 (s, 4H) 2.35-2.42(m, 1H) 3.45-3.57 (m, 4H) 3.73-3.90 (m, 6H) 3.91-4.04 (m, 2H) 4.37 (br.s., 1H) 6.05-6.35 (m, 1H) 7.34 (d, J=8.22 Hz, 1H) 7.61 (dd, J=8.22, 2.35Hz, 1H) 7.76 (br. s., 1H) 8.12 (d, J=4.30 Hz, 1H) 8.29 (s, 1H) 8.92 (d,J=5.09 Hz, 1H). LC/MS (m/z): 528.2 (MH+), Rt=0.78 min.

Example 1055:N-(4-methyl-3-(2-morpholino-6-(((tetrahydrofuran-3-yl)methyl)amino)pyridin-4-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.53-1.70 (m, 1H) 2.04 (dtd, J=12.77,7.90, 7.90, 5.48 Hz, 1H) 2.23 (s, 3H) 2.46-2.59 (m, 1H) 3.25 (d, J=7.43Hz, 3H) 3.35-3.46 (m, 4H) 3.52 (dd, J=8.80, 5.28 Hz, 1H) 3.66 (q, J=7.83Hz, 1H) 3.70-3.77 (m, 5H) 3.77-3.87 (m, 1H) 6.02-6.17 (m, 1H) 7.25 (d,J=8.22 Hz, 1H) 7.50 (dd, J=8.22, 2.35 Hz, 1H) 7.67 (s, 1H) 8.02 (d,J=3.91 Hz, 1H) 8.19 (s, 1H) 8.82 (d, J=5.09 Hz, 1H). LC/MS (m/z): 542.2(MH+), Rt=0.79 min.

Example 1056:2-(2-fluoropropan-2-yl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.71 (s, 3H) 1.77 (s, 4H) 2.62 (s, 3H)3.43-3.62 (m, 7H) 3.82 (dt, J=10.08, 4.94 Hz, 7H) 6.13-6.30 (m, 1H) 7.81(dd, J=5.09, 1.57 Hz, 1H) 8.11 (s, 1H) 8.41 (d, J=2.35 Hz, 1H) 8.74 (d,J=5.09 Hz, 1H) 9.07 (d, J=1.96 Hz, 1H). LC/MS (m/z): 495.2 (MH+),Rt=0.52 min.

Example 1057:2-cyclopropyl-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.06-1.34 (m, 4H) 2.23-2.35 (m, 1H) 2.61(s, 3H) 3.42-3.60 (m, 6H) 3.81 (dt, J=9.78, 4.89 Hz, 6H) 6.14-6.29 (m,1H) 7.71-7.91 (m, 2H) 8.39 (d, J=2.35 Hz, 1H) 8.64 (d, J=5.48 Hz, 1H)9.05 (d, J=2.35 Hz, 1H). LC/MS (m/z): 475.2 (MH+), Rt=0.40 min.

Example 1058:2-(1,1-difluoropropyl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.01 (t, J=7.63 Hz, 3H) 2.39 (td,J=16.63, 7.43 Hz, 2H) 2.60 (s, 3H) 3.44-3.63 (m, 7H) 3.82 (dt, J=10.37,4.99 Hz, 7H) 6.10-6.29 (m, 1H) 8.00 (d, J=5.09 Hz, 1H) 8.21 (s, 1H) 8.37(d, J=2.35 Hz, 1H) 8.86 (d, J=5.09 Hz, 1H) 9.01 (s, 1H). LC/MS (m/z):513.2 (MH+), Rt=0.57 min.

Example 1059:2-(2-cyanopropan-2-yl)-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.32 (s, 3H) 3.40-3.53 (m,5H) 3.80-3.89 (m, 4H) 4.05 (dd, J=9.39, 4.30 Hz, 2H) 4.42-4.51 (m, 2H)4.70-4.79 (m, 1H) 5.94-6.24 (m, 1H) 7.34 (d, J=8.61 Hz, 1H) 7.59 (dd,J=8.22, 1.96 Hz, 1H) 7.75 (s, 1H) 7.81 (d, J=4.70 Hz, 1H) 8.06 (s, 1H)8.77 (d, J=5.09 Hz, 1H). LC/MS (m/z): 513.2 (MH+), Rt=0.70 min.

Example 1060:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.38-3.54 (m, 4H) 3.69-3.89(m, 4H) 3.98 (dd, J=9.39, 4.30 Hz, 2H) 4.31-4.49 (m, 2H) 4.66-4.78 (m,1H) 5.85-6.20 (m, 1H) 7.33 (d, J=8.61 Hz, 1H) 7.61 (dd, J=8.22, 1.96 Hz,1H) 7.72 (s, 1H) 8.11 (d, J=5.09 Hz, 1H) 8.29 (s, 1H) 8.91 (d, J=5.09Hz, 1H). LC/MS (m/z): 514.1 (MH+), Rt=0.74 min.

Example 1061:1-ethyl-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.42 (t, J=7.04 Hz, 3H) 2.30 (s, 3H)3.37-3.52 (m, 4H) 3.75-3.88 (m, 4H) 3.99 (dd, J=9.00, 4.30 Hz, 2H) 4.16(q, J=7.17 Hz, 2H) 4.34-4.49 (m, 2H) 4.68-4.78 (m, 1H) 5.86-6.21 (m, 1H)7.30 (d, J=8.22 Hz, 1H) 7.53 (dd, J=8.22, 1.96 Hz, 1H) 7.65 (s, 1H) 8.47(s, 1H) 8.70 (d, J=2.35 Hz, 1H). LC/MS (m/z): 558.2 (MH+), Rt=0.72 min.

Example 1062:N-(3-(2-((2-hydroxy-2-methylpropyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.33 (s, 6H) 2.32 (s, 3H) 3.37 (s, 2H)3.46-3.58 (m, 4H) 3.76-3.89 (m, 4H) 6.22 (d, J=6.26 Hz, 1H) 7.33 (d,J=8.22 Hz, 1H) 7.57 (dd, J=8.22, 1.96 Hz, 1H) 7.68-7.80 (m, 2H) 7.90 (d,J=7.83 Hz, 1H) 8.20 (d, J=7.83 Hz, 1H) 8.25 (s, 1H). LC/MS (m/z): 529.2(MH+), Rt=0.87 min.

Example 1063:N-(4-methyl-3-(2-morpholino-6-((3,3,3-trifluoro-2-hydroxypropyl)amino)pyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.45-3.62 (m, 5H) 3.71-3.90(m, 5H) 4.28 (td, J=7.14, 3.33 Hz, 1H) 6.09-6.25 (m, 1H) 7.32 (d, J=8.22Hz, 1H) 7.57 (dd, J=8.22, 2.35 Hz, 1H) 7.66-7.79 (m, 2H) 7.90 (d, J=7.83Hz, 1H) 8.20 (d, J=7.83 Hz, 1H) 8.25 (s, 1H). LC/MS (m/z): 569.1 (MH+),Rt=0.91 min.

Example 1064:(R)-N-(3-(2-(4-hydroxy-2-oxopyrrolidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.28 (s, 3H) 2.52 (d, J=17.22 Hz, 1H)3.01 (dd, J=17.41, 6.06 Hz, 1H) 3.49-3.63 (m, 4H) 3.74-3.89 (m, 4H)4.07-4.17 (m, 1H) 4.18-4.29 (m, 1H) 4.52 (t, J=5.28 Hz, 1H) 6.56 (s, 1H)7.31 (d, J=7.83 Hz, 1H) 7.56 (br. s., 1H) 7.59-7.68 (m, 2H) 7.68-7.77(m, 1H) 7.89 (d, J=7.83 Hz, 1H) 8.20 (d, J=8.22 Hz, 1H) 8.26 (s, 1H).LC/MS (m/z): 541.2 (MH+), Rt=0.91 min.

Example 1065:(R)-N-(3-(2-(3-hydroxy-2-oxopyrrolidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.86-2.06 (m, 1H) 2.28 (s, 3H) 2.46-2.61(m, 1H) 3.49-3.64 (m, 4H) 3.70-3.93 (m, 5H) 4.21 (t, J=9.39 Hz, 1H) 4.49(t, J=8.80 Hz, 1H) 6.57 (s, 1H) 7.31 (d, J=9.00 Hz, 1H) 7.59 (s, 1H)7.61-7.67 (m, 2H) 7.68-7.76 (m, 1H) 7.89 (d, J=7.83 Hz, 1H) 8.20 (d,J=7.83 Hz, 1H) 8.26 (s, 1H). LC/MS (m/z): 541.2 (MH+), Rt=0.94 min.

Example 1066:N-(3-(2-(2-hydroxypropanamido)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.44 (d, J=6.65 Hz, 3H) 2.30 (s, 3H)3.50-3.62 (m, 4H) 3.74-3.87 (m, 4H) 4.30 (q, J=7.04 Hz, 1H) 6.63 (s, 1H)7.32 (d, J=8.61 Hz, 1H) 7.37 (s, 1H) 7.59-7.69 (m, 2H) 7.69-7.78 (m, 1H)7.89 (d, J=7.43 Hz, 1H) 8.20 (d, J=7.83 Hz, 1H) 8.26 (s, 1H). LC/MS(m/z): 529.2 (MH+), Rt=0.91 min.

Example 1067:2-(difluoromethyl)-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.26 (s, 3H) 3.40-3.52 (m, 4H) 3.67-3.85(m, 6H) 4.09-4.28 (m, 2H) 4.66 (t, J=5.48 Hz, 1H) 5.73 (s, 1H) 6.00 (s,1H) 6.59-7.02 (m, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.51-7.67 (m, 2H) 8.00 (d,J=4.70 Hz, 1H) 8.17 (s, 1H) 8.82 (d, J=5.09 Hz, 1H). LC/MS (m/z): 496.1(MH+), R_(t)=0.68 min.

Example 1068:2-cyclopropyl-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) vppm 0.98-1.15 (m, 4H) 2.12-2.23 (m, 1H) 2.26(s, 3H) 3.12 (d, J=6.65 Hz, 1H) 3.42-3.53 (m, 5H) 3.67-3.85 (m, 6H)4.12-4.28 (m, 2H) 4.58 (s, 2H) 4.66 (t, J=5.28 Hz, 1H) 5.73 (s, 1H) 6.00(s, 1H) 7.27 (d, J=8.22 Hz, 1H) 7.51-7.73 (m, 4H) 8.52 (d, J=5.09 Hz,1H). LC/MS (m/z): 486.1 (MH+), Rt=0.57 min.

Example 1069:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-isopropylisonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.40 (d, J=7.04 Hz, 6H) 2.31 (s, 3H)3.16-3.27 (m, 1H) 3.39-3.51 (m, 4H) 3.73-3.88 (m, 4H) 3.97 (dd, J=9.39,4.30 Hz, 2H) 4.41 (t, J=7.83 Hz, 2H) 4.63-4.78 (m, 1H) 5.86-6.19 (m, 1H)7.33 (d, J=8.22 Hz, 1H) 7.42-7.51 (m, 1H) 7.61 (dd, J=8.22, 1.96 Hz, 1H)7.71 (s, 1H) 7.86 (d, J=4.70 Hz, 1H) 7.97 (s, 1H) 8.02 (d, J=7.04 Hz,1H) 8.69 (d, J=5.09 Hz, 1H). LC/MS (m/z): 488.2 (MH+), Rt=0.57 min.

Example 1070:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.29 (s, 3H) 2.59-2.76 (m, 1H) 3.08-3.21(m, 3H) 3.42-3.51 (m, 6H) 3.69-3.93 (m, 6H) 4.29 (t, J=7.83 Hz, 2H)4.64-4.73 (m, 1H) 5.81 (s, 1H) 6.06 (s, 1H) 7.31 (d, J=9.00 Hz, 1H)7.42-7.50 (m, 1H) 7.65 (d, J=6.26 Hz, 2H) 8.02 (d, J=7.04 Hz, 1H) 8.58(d, J=1.96 Hz, 1H) 9.87 (d, J=1.96 Hz, 1H). LC/MS (m/z): 515.1 (MH+),Rt=0.70 min.

Example 1071:2-(1-cyanocyclopropyl)-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.82 (d, J=12.52 Hz, 4H) 2.26 (s, 3H)3.12 (d, J=9.00 Hz, 5H) 3.43-3.53 (m, 8H) 3.69-3.85 (m, 6H) 4.20 (t,J=7.63 Hz, 2H) 5.73 (s, 1H) 6.00 (s, 1H) 7.27 (d, J=8.61 Hz, 1H) 7.55(s, 1H) 7.61 (d, J=8.22 Hz, 1H) 7.71 (d, J=5.09 Hz, 1H) 8.06 (s, 1H)8.64 (d, J=5.09 Hz, 1H). LC/MS (m/z): 511.1 (MH+), Rt=0.71 min.

Example 1072:2-(difluoromethyl)-N-(3-(2-(3-hydroxy-3-methylazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.54 (s, 3H) 2.27 (s, 3H) 3.41-3.51 (m,4H) 3.68-3.81 (m, 4H) 3.81-3.96 (m, 4H) 5.74 (s, 1H) 6.01 (s, 1H)6.59-7.01 (m, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.53-7.69 (m, 2H) 8.00 (d,J=4.70 Hz, 1H) 8.17 (s, 1H) 8.82 (d, J=5.09 Hz, 1H). LC/MS (m/z): 510.1(MH+), Rt=0.70 min.

Example 1073:N-(3-(2-(3-hydroxy-3-methylazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.54 (s, 3H) 2.16 (s, 4H) 2.27 (s, 3H)3.40-3.52 (m, 6H) 3.70-3.81 (m, 4H) 3.81-3.92 (m, 4H) 4.58 (s, 2H) 5.73(s, 1H) 6.00 (s, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.56-7.73 (m, 1H) 8.58 (d,J=1.96 Hz, 1H) 9.87 (d, J=1.57 Hz, 1H). LC/MS (m/z): 529.1 (MH+),Rt=0.72 min.

Example 1074:N-(3-(2-(3-hydroxy-3-methylazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.54 (s, 3H) 2.27 (s, 3H) 3.19 (s, 3H)3.41-3.53 (m, 4H) 3.71-3.81 (m, 4H) 3.81-3.97 (m, 4H) 5.75 (s, 1H) 6.01(s, 1H) 7.27 (d, J=8.61 Hz, 1H) 7.52-7.65 (m, 2H) 7.79 (t, J=7.83 Hz,1H) 8.16 (d, J=8.22 Hz, 1H) 8.26 (d, J=7.83 Hz, 1H) 8.50 (s, 1H). LC/MS(m/z): 537.1 (MH+), Rt=0.66 min.

Example 1075:5-(difluoromethyl)-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.26 (s, 3H) 3.41-3.52 (m, 4H) 3.70-3.84(m, 6H) 4.15-4.26 (m, 2H) 4.58 (s, 1H) 4.62-4.70 (m, 1H) 5.71 (s, 1H)5.99 (s, 1H) 7.19-7.65 (m, 1H) 7.25 (s, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.38(s, 1H) 7.49-7.55 (m, 1H) 7.59 (dd, J=8.22, 1.96 Hz, 1H) 9.58 (s, 2H).LC/MS (m/z): 497.1 (MH+), Rt=0.61 min.

Example 1076:6-cyclopropyl-N-(3-(2-(3-hydroxy-3-methylazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)pyridazine-4-carboxamide

1H NMR (500 MHz, cd3od) δ ppm 1.10-1.37 (m, 4H) 1.56 (s, 3H) 2.30 (s,3H) 2.33-2.42 (m, 1H) 3.38-3.51 (m, 4H) 3.74-3.86 (m, 4H) 3.96-4.13 (m,4H) 5.94 (s, 1H) 6.14 (s, 1H) 7.32 (d, J=8.51 Hz, 1H) 7.60 (dd, J=8.20,2.21 Hz, 1H) 7.70 (s, 1H) 7.91 (d, J=1.89 Hz, 1H) 9.37 (d, J=1.58 Hz,1H). LC/MS (m/z): 501.3 (MH+), Rt=0.64 min.

Example 1077:3-(difluoromethyl)-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.41-3.51 (m, 4H) 3.79-3.87(m, 4H) 4.03 (dd, J=9.59, 4.11 Hz, 2H) 4.43-4.49 (m, 2H) 4.71-4.78 (m,1H) 6.00-6.20 (m, 1H) 6.87 (t, J=56.00 Hz, 1H) 7.32 (d, J=8.22 Hz, 1H)7.57 (dd, J=8.22, 2.35 Hz, 1H) 7.65 (t, J=7.83 Hz, 1H) 7.73 (s, 1H) 7.77(d, J=7.83 Hz, 1H) 8.08 (d, J=7.83 Hz, 1H) 8.12 (s, 1H). LCMS (m/z)(M+H)=495.1, Rt=0.75 min.

Example 1078:2-(1,1-difluoroethyl)-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.03 (t, J=18.78 Hz, 3H) 2.31 (s, 3H)3.41-3.49 (m, 4H) 3.79-3.85 (m, 4H) 4.03 (dd, J=9.59, 4.11 Hz, 2H)4.42-4.50 (m, 2H) 4.71-4.78 (m, 1H) 6.00-6.20 (m, 1H) 7.33 (d, J=8.22Hz, 1H) 7.59 (dd, J=8.41, 2.15 Hz, 1H) 7.75 (s, 1H) 7.95 (d, J=4.70 Hz,1H) 8.17 (s, 1H) 8.80 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=510.2,Rt=0.72 min.

Example 1079:3-(difluoromethyl)-N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.68 (s, 3H) 3.48-3.53 (m, 4H) 3.76-3.82(m, 4H) 3.85 (dd, J=9.19, 4.50 Hz, 2H) 4.25-4.34 (m, 2H) 4.66-4.74 (m,1H) 6.90 (t, J=56.00 Hz, 1H) 7.67-7.74 (m, 1H) 7.83 (d, J=7.83 Hz, 1H)8.16 (d, J=7.43 Hz, 1H) 8.21 (s, 1H) 8.47 (d, J=2.35 Hz, 1H) 9.36 (d,J=2.35 Hz, 1H). LCMS (m/z) (M+H)=496.1, Rt=0.61 min.

Example 1080:2-(1,1-difluoroethyl)-N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.05 (t, J=18.78 Hz, 3H) 2.67 (s, 3H)3.48-3.53 (m, 4H) 3.75-3.82 (m, 4H) 3.85 (dd, J=9.00, 4.30 Hz, 2H)4.27-4.33 (m, 2H) 4.67-4.75 (m, 1H) 8.02 (d, J=4.69 Hz, 1H) 8.25 (s, 1H)8.44 (d, J=2.35 Hz, 1H) 8.86 (d, J=5.09 Hz, 1H) 9.31 (d, J=2.35 Hz, 1H).LCMS (m/z) (M+H)=511.1, Rt=0.57 min.

Example 1081:N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-isopropylisonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.41 (d, J=7.04 Hz, 7H) 2.66 (s, 3H)3.48-3.53 (m, 4H) 3.76-3.82 (m, 4H) 3.85 (dd, J=9.00, 4.70 Hz, 2H)4.26-4.33 (m, 2H) 4.67-4.74 (m, 1H) 7.93 (dd, J=5.48, 1.57 Hz, 1H) 8.04(s, 1H) 8.41 (d, J=2.35 Hz, 1H) 8.76 (d, J=5.48 Hz, 1H) 9.27 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=489.1, Rt=0.46 min.

Example 1082:N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(2-hydroxypropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.63 (s, 6H) 2.67 (s, 3H) 3.47-3.53 (m,4H) 3.76-3.82 (m, 4H) 3.85 (dd, J=9.00, 4.70 Hz, 2H) 4.27-4.33 (m, 2H)4.67-4.74 (m, 1H) 7.94 (dd, J=5.48, 1.57 Hz, 1H) 8.34 (s, 1H) 8.43 (d,J=2.35 Hz, 1H) 8.76 (d, J=5.48 Hz, 1H) 9.29 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=505.2, Rt=0.43 min.

Example 1083:2-(2-cyanopropan-2-yl)-N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.82 (s, 6H) 2.68 (s, 3H) 3.47-3.53 (m,4H) 3.75-3.82 (m, 4H) 3.85 (dd, J=9.19, 4.50 Hz, 2H) 4.27-4.33 (m, 2H)4.67-4.75 (m, 1H) 7.87 (dd, J=4.89, 1.37 Hz, 1H) 8.13 (s, 1H) 8.44 (d,J=1.96 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 9.31 (d, J=1.96 Hz, 1H). LCMS(m/z) (M+H)=514.2, Rt=0.66 min.

Example 1084:N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-3-(methylsulfonyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.67 (s, 3H) 3.20 (s, 3H) 3.47-3.54 (m,4H) 3.76-3.81 (m, 4H) 3.83 (dd, J=9.00, 4.30 Hz, 2H) 4.24-4.31 (m, 2H)4.67-4.74 (m, 1H) 7.85 (t, J=8.02 Hz, 1H) 8.23 (d, J=7.83 Hz, 1H) 8.34(d, J=7.83 Hz, 1H) 8.43 (d, J=2.35 Hz, 1H) 8.59 (s, 1H) 9.32 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=524.2, Rt=0.52 min.

Example 1085:3-((dimethylamino)methyl)-N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.64 (s, 3H) 2.93 (s, 6H) 3.47-3.53 (m,4H) 3.76-3.80 (m, 4H) 3.83 (dd, J=9.00, 4.30 Hz, 2H) 4.24-4.31 (m, 2H)4.53 (s, 2H) 4.66-4.74 (m, 1H) 8.16 (s, 1H) 8.38 (d, J=2.35 Hz, 1H) 8.46(s, 1H) 8.50 (s, 1H) 9.22 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=571.2,Rt=0.50 min.

Example 1086:1-ethyl-N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.42 (t, J=7.24 Hz, 3H) 2.66 (s, 3H)3.47-3.53 (m, 4H) 3.75-3.80 (m, 4H) 3.83 (dd, J=9.00, 4.70 Hz, 2H) 4.18(q, J=7.04 Hz, 2H) 4.25-4.31 (m, 2H) 4.67-4.73 (m, 1H) 8.36 (d, J=2.35Hz, 1H) 8.52 (d, J=1.96 Hz, 1H) 8.79 (d, J=2.35 Hz, 1H) 9.25 (d, J=1.96Hz, 1H). LCMS (m/z) (M+H)=559.2, Rt=0.54 min.

Example 1087:3-(4-ethylpiperazin-1-yl)-N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-5-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.41 (t, J=7.24 Hz, 3H) 2.65 (s, 3H)3.15-3.27 (m, 2H) 3.47-3.54 (m, 4H) 3.64-3.86 (m, 8H) 4.09 (br. s., 2H)4.24-4.31 (m, 2H) 4.66-4.74 (m, 1H) 7.56 (s, 1H) 7.87 (d, J=10.56 Hz,2H) 8.40 (d, J=2.35 Hz, 1H) 9.26 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=626.2, Rt=0.61 min.

Example 1088:N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.66 (s, 3H) 3.47-3.53 (m, 4H) 3.76-3.81(m, 4H) 3.85 (dd, J=9.19, 4.50 Hz, 2H) 4.26-4.32 (m, 2H) 4.67-4.74 (m,1H) 8.17 (d, J=4.30 Hz, 1H) 8.36 (s, 1H) 8.40 (d, J=2.35 Hz, 1H) 8.97(d, J=5.09 Hz, 1H) 9.26 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=515.2,Rt=0.57 min.

Example 1089:2-(tert-butyl)-N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.45 (s, 9H) 2.66 (s, 3H) 3.48-3.53 (m,4H) 3.76-3.81 (m, 4H) 3.84 (dd, J=9.00, 4.70 Hz, 2H) 4.25-4.32 (m, 2H)4.67-4.74 (m, 1H) 7.81 (dd, J=5.09, 1.57 Hz, 1H) 8.06 (s, 1H) 8.41 (d,J=2.35 Hz, 1H) 8.74 (d, J=5.09 Hz, 1H) 9.28 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=503.3, Rt=0.50 min.

Example 1090:N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.66 (s, 3H) 3.47-3.53 (m, 4H) 3.76-3.81(m, 4H) 3.84 (dd, J=9.00, 4.30 Hz, 2H) 4.26-4.32 (m, 2H) 4.67-4.74 (m,1H) 8.20 (dd, J=4.89, 1.37 Hz, 1H) 8.40 (d, J=2.35 Hz, 1H) 8.61 (s, 1H)8.99 (d, J=4.69 Hz, 1H) 9.25 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=525.2,Rt=0.45 min.

Example 1091:N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-3-(2-(methylsulfonyl)propan-2-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.92 (s, 6H) 2.66 (s, 3H) 2.72 (s, 3H)3.47-3.55 (m, 4H) 3.76-3.81 (m, 4H) 3.81-3.84 (m, 2H) 4.23-4.30 (m, 2H)4.66-4.73 (m, 1H) 5.82 (s, 1H) 6.09 (s, 1H) 7.63 (t, J=7.83 Hz, 1H) 7.97(d, J=8.22 Hz, 1H) 8.03 (d, J=7.83 Hz, 1H) 8.28 (s, 1H) 8.41 (d, J=1.96Hz, 1H) 9.32 (d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=566.2, Rt=0.52 min.

Example 1092:N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-3-(1,3,4-oxadiazol-2-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.66 (s, 3H) 3.49-3.54 (m, 4H) 3.76-3.85(m, 6H) 4.24-4.31 (m, 2H) 4.69 (d, J=6.26 Hz, 1H) 5.83 (s, 1H) 6.10 (s,1H) 7.80 (t, J=7.83 Hz, 1H) 8.25 (d, J=7.83 Hz, 1H) 8.35 (d, J=7.83 Hz,1H) 8.42 (d, J=2.35 Hz, 1H) 8.73 (s, 1H) 9.10 (s, 1H) 9.31 (s, 1H). LCMS(m/z) (M+H)=514.2, Rt=0.50 min.

Example 1093:5-cyclopropyl-N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isoxazole-3-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 0.97-1.04 (m, 2H) 1.14-1.21 (m, 2H)2.17-2.26 (m, 1H) 2.63 (s, 3H) 3.46-3.53 (m, 4H) 3.74-3.85 (m, 6H)4.24-4.30 (m, 2H) 4.67-4.72 (m, 1H) 5.81 (s, 1H) 6.07 (s, 1H) 6.53 (s,1H) 8.39 (d, J=2.35 Hz, 1H) 9.19 (d, J=1.96 Hz, 1H). LCMS (m/z)(M+H)=477.2 Rt=0.57 min.

Example 1094:N-(2′-(3-hydroxyazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.63 (s, 3H) 3.47-3.54 (m, 4H) 3.75-3.84(m, 6H) 4.23-4.30 (m, 2H) 4.66-4.72 (m, 1H) 5.81 (s, 1H) 6.08 (s, 1H)7.78 (t, J=7.83 Hz, 1H) 7.96 (d, J=7.43 Hz, 1H) 8.27 (d, J=7.83 Hz, 1H)8.31-8.36 (m, 2H) 9.22 (s, 1H). LCMS (m/z) (M+H)=514.2, Rt=0.64 min

Example 1095:5-cyclopropyl-N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isoxazole-3-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 0.96-1.03 (m, 2H) 1.12-1.19 (m, 2H)2.15-2.23 (m, 1H) 2.29 (s, 3H) 3.41-3.48 (m, 4H) 3.78-3.85 (m, 4H) 3.99(dd, J=9.39, 4.30 Hz, 2H) 4.42 (t, J=8.02 Hz, 2H) 4.69-4.77 (m, 1H) 5.96(s, 1H) 6.14 (s, 1H) 6.46 (s, 1H) 7.30 (d, J=8.22 Hz, 1H) 7.59 (dd,J=8.22, 1.96 Hz, 1H) 7.66 (s, 1H). LCMS (m/z) (M+H)=476.2, Rt=0.73 min.

Example 1096:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(methylsulfonyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.32 (s, 3H) 3.19 (s, 3H) 3.41-3.50 (m,4H) 3.79-3.86 (m, 4H) 4.03 (dd, J=9.39, 4.30 Hz, 2H) 4.41-4.50 (m, 2H)4.71-4.79 (m, 1H) 5.99-6.20 (m, 1H) 7.33 (d, J=8.22 Hz, 1H) 7.59 (dd,J=8.22, 2.35 Hz, 1H) 7.74 (s, 1H) 7.80 (t, J=7.83 Hz, 1H) 8.17 (d,J=7.83 Hz, 1H) 8.26 (d, J=7.83 Hz, 1H) 8.51 (s, 1H). LCMS (m/z)(M+H)=523.2, Rt=0.62 min.

Example 1097:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.42-3.49 (m, 4H) 3.79-3.86(m, 4H) 4.01 (dd, J=9.39, 3.91 Hz, 2H) 4.40-4.47 (m, 2H) 4.70-4.78 (m,1H) 5.97-6.19 (m, 1H) 7.34 (d, J=8.61 Hz, 1H) 7.62 (dd, J=8.22, 1.96 Hz,1H) 7.74 (s, 1H) 8.15 (dd, J=4.89, 1.37 Hz, 1H) 8.54 (s, 1H) 8.94 (d,J=5.09 Hz, 1H). LCMS (m/z) (M+H)=524.2, Rt=0.59 min.

Example 1098:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(2-hydroxypropan-2-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.64 (s, 6H) 2.32 (s, 3H) 3.41-3.50 (m,4H) 3.79-3.86 (m, 4H) 4.02 (dd, J=9.39, 4.30 Hz, 2H) 4.41-4.49 (m, 2H)4.70-4.78 (m, 1H) 5.99-6.18 (m, 1H) 7.34 (d, J=8.22 Hz, 1H) 7.61 (dd,J=8.22, 1.96 Hz, 1H) 7.74 (s, 1H) 7.94 (d, J=4.30 Hz, 1H) 8.30 (s, 1H)8.73 (d, J=5.48 Hz, 1H). LCMS (m/z) (M+H)=504.2, Rt=0.53 min.

Example 1099:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2-(methylsulfonyl)propan-2-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.91 (s, 6H) 2.31 (s, 3H) 2.69 (s, 3H)3.42-3.49 (m, 4H) 3.80-3.86 (m, 4H) 4.03 (dd, J=9.59, 4.11 Hz, 2H)4.42-4.49 (m, 2H) 4.71-4.78 (m, 1H) 6.00-6.20 (m, 1H) 7.32 (d, J=8.22Hz, 1H) 7.54-7.61 (m, 2H) 7.72 (s, 1H) 7.94 (dd, J=13.30, 8.22 Hz, 2H)8.20 (s, 1H). LCMS (m/z) (M+H)=565.3, Rt=0.66 min.

Example 1100:N-(3-(2-(3-hydroxyazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(1,3,4-oxadiazol-2-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.31 (s, 3H) 3.42-3.49 (m, 4H) 3.79-3.86(m, 4H) 4.01 (dd, J=9.19, 4.11 Hz, 2H) 4.40-4.48 (m, 2H) 4.70-4.78 (m,1H) 5.98-6.19 (m, 1H) 7.33 (d, J=8.22 Hz, 1H) 7.60 (dd, J=8.22, 1.96 Hz,1H) 7.71-7.79 (m, 2H) 8.17 (d, J=8.22 Hz, 1H) 8.29 (d, J=7.83 Hz, 1H)8.65 (s, 1H) 9.08 (s, 1H). LCMS (m/z) (M+H)=513.2, Rt=0.64 min.

Example 1101:6-cyclopropyl-N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.22-1.33 (m, 4H) 1.57 (s, 3H) 2.38-2.45(m, 1H) 2.68 (s, 3H) 3.50-3.55 (m, 4H) 3.78-3.84 (m, 4H) 3.91-4.01 (m,4H) 5.85-6.14 (m, 1H) 8.00 (d, J=2.21 Hz, 1H) 8.40 (d, J=2.21 Hz, 1H)9.26 (d, J=2.21 Hz, 1H) 9.44 (d, J=2.21 Hz, 1H). LCMS (m/z) (M+H)=502.2,Rt=0.51 min.

Example 1102:2-cyclopropyl-N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.13-1.26 (m, 4H) 1.57 (s, 3H) 2.26-2.33(m, 1H) 2.68 (s, 3H) 3.50-3.55 (m, 4H) 3.77-3.83 (m, 4H) 3.91-4.00 (m,4H) 5.85-6.13 (m, 1H) 7.79 (dd, J=5.36, 1.58 Hz, 1H) 7.85 (s, 1H) 8.42(d, J=2.52 Hz, 1H) 8.65 (d, J=5.36 Hz, 1H) 9.30 (d, J=2.21 Hz, 1H). LCMS(m/z) (M+H)=501.2, Rt=0.46 min.

Example 1103:2-(difluoromethyl)-N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.55 (s, 3H) 2.67 (s, 3H) 3.47-3.55 (m,4H) 3.75-3.83 (m, 4H) 3.89-3.99 (m, 4H) 6.85 (t, J=55.60 Hz, 1H) 8.06(d, J=5.09 Hz, 1H) 8.24 (s, 1H) 8.43 (d, J=2.35 Hz, 1H) 8.89 (d, J=5.09Hz, 1H) 9.29 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=511.2, Rt=0.54 min.

Example 1104:N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.57 (s, 3H) 2.68 (s, 3H) 3.50-3.55 (m,4H) 3.78-3.83 (m, 4H) 3.91-4.00 (m, 4H) 5.85-6.13 (m, 1H) 8.20 (d,J=5.67 Hz, 1H) 8.36-8.39 (m, 1H) 8.41 (d, J=2.21 Hz, 1H) 8.99 (d, J=5.04Hz, 1H) 9.27 (d, J=1.89 Hz, 1H). LCMS (m/z) (M+H)=529.2, Rt=0.60 min.

Example 1105:2-(1,1-difluoroethyl)-N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.57 (s, 3H) 2.02-2.12 (m, 3H) 2.70 (s,3H) 3.51-3.55 (m, 4H) 3.79-3.83 (m, 4H) 3.92-4.00 (m, 4H) 5.87-6.14 (m,1H) 8.04 (d, J=5.36 Hz, 1H) 8.27 (s, 1H) 8.46 (d, J=2.21 Hz, 1H) 8.89(d, J=5.04 Hz, 1H) 9.33 (d, J=2.21 Hz, 1H). LCMS (m/z) (M+H)=525.2,Rt=0.59 min.

Example 1106:2-(2-fluoropropan-2-yl)-N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.58 (s, 3H) 1.74 (s, 3H) 1.78 (s, 3H)2.70 (s, 3H) 3.50-3.55 (m, 4H) 3.78-3.83 (m, 4H) 3.92-4.01 (m, 4H)7.83-7.88 (m, 1H) 8.16 (s, 1H) 8.49 (d, J=2.52 Hz, 1H) 8.78 (dd, J=5.04,0.63 Hz, 1H) 9.36 (d, J=2.52 Hz, 1H). LCMS (m/z) (M+H)=521.2, Rt=0.60min.

Example 1107:N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-6-(trifluoromethyl)pyridazine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.58 (s, 3H) 2.67 (s, 3H) 3.50-3.55 (m,4H) 3.79-3.83 (m, 4H) 3.93-4.02 (m, 4H) 8.39 (d, J=2.21 Hz, 1H) 8.65 (d,J=1.89 Hz, 1H) 9.23 (d, J=2.21 Hz, 1H) 9.93 (d, J=1.89 Hz, 1H). LCMS(m/z) (M+H)=530.2, Rt=0.56 min.

Example 1108:2-(2-cyanopropan-2-yl)-N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.57 (s, 3H) 1.84 (s, 6H) 2.70 (s, 3H)3.50-3.55 (m, 4H) 3.78-3.83 (m, 4H) 3.93-4.02 (m, 4H) 7.90 (dd, J=4.89,1.42 Hz, 1H) 8.16 (d, J=0.63 Hz, 1H) 8.47 (d, J=2.21 Hz, 1H) 8.85 (d,J=5.04 Hz, 1H) 9.35 (d, J=2.21 Hz, 1H). LCMS (m/z) (M+H)=528.2, Rt=0.58min.

Example 1109:2-(1-cyanocyclopropyl)-N-(2′-(3-hydroxy-3-methylazetidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.57 (s, 3H) 1.79-1.91 (m, 4H) 2.70 (s,3H) 3.50-3.55 (m, 4H) 3.78-3.83 (m, 4H) 3.92-4.01 (m, 4H) 7.79 (dd,J=4.89, 1.10 Hz, 1H) 8.18 (s, 1H) 8.45 (d, J=2.52 Hz, 1H) 8.73 (d,J=5.04 Hz, 1H) 9.34 (d, J=2.21 Hz, 1H). LCMS (m/z) (M+H)=526.2, Rt=0.58min.

Example 1110:2-(2-cyanopropan-2-yl)-N-(3-(2-(3-hydroxy-3-methylazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.59 (s, 3H) 1.84 (s, 6H) 2.34 (s, 3H)3.45-3.50 (m, 4H) 3.82-3.87 (m, 4H) 4.08-4.17 (m, 4H) 7.36 (d, J=8.51Hz, 1H) 7.61 (dd, J=8.51, 2.21 Hz, 1H) 7.77 (d, J=1.89 Hz, 1H) 7.83 (dd,J=5.04, 1.58 Hz, 1H) 8.09 (s, 1H) 8.79 (d, J=5.04 Hz, 1H). LCMS (m/z)(M+H)=527.2, Rt=0.72 min.

Example 1111:2-(1-cyanocyclopropyl)-N-(3-(2-(3-hydroxy-3-methylazetidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.59 (s, 3H) 1.81-1.90 (m, 4H) 2.34 (s,3H) 3.45-3.50 (m, 4H) 3.83-3.87 (m, 4H) 4.09-4.19 (m, 4H) 7.36 (d,J=8.51 Hz, 1H) 7.61 (dd, J=8.20, 1.89 Hz, 1H) 7.73 (d, J=5.04 Hz, 1H)7.77 (s, 1H) 8.10 (s, 1H) 8.67 (d, J=5.04 Hz, 1H). LCMS (m/z)(M+H)=525.2, Rt=0.72 min.

Example 1112:N-(3-(2,6-dimorpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.28 (s, 3H) 3.42-3.58 (m, 8H) 3.72-3.87(m, 8H) 7.30 (d, J=8.22 Hz, 1H) 7.55-7.69 (m, 2H) 8.11 (d, J=4.30 Hz,1H) 8.29 (s, 1H) 8.90 (d, J=5.09 Hz, 1H). LC/MS (m/z): 528.1 (MH+),Rt=0.93 min.

Example 1113:2-(2-cyanopropan-2-yl)-N-(3-(2,6-dimorpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.81 (s, 6H) 2.29 (s, 3H) 3.39-3.55 (m,8H) 3.72-3.87 (m, 8H) 7.31 (d, J=8.22 Hz, 1H) 7.60 (dd, J=8.22, 1.96 Hz,1H) 7.67 (d, J=1.96 Hz, 1H) 7.81 (dd, J=4.89, 0.98 Hz, 1H) 8.06 (s, 1H)8.76 (d, J=5.09 Hz, 1H). LC/MS (m/z): 527.2 (MH+), Rt=0.88 min.

Example 1114:N-(3-(2,6-dimorpholinopyridin-4-yl)-4-methylphenyl)-1-ethyl-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.41 (t, J=7.04 Hz, 3H) 2.27 (s, 3H)3.41-3.59 (m, 8H) 3.74-3.90 (m, 8H) 4.15 (q, J=7.30 Hz, 2H) 7.27 (d,J=8.22 Hz, 1H) 7.46-7.64 (m, 2H) 8.47 (d, J=1.57 Hz, 1H) 8.69 (d, J=2.35Hz, 1H). LC/MS (m/z): 572.2 (MH+), Rt=0.89 min.

Example 1115:2-(difluoromethyl)-N-(3-(2,6-dimorpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.28 (s, 3H) 3.39-3.57 (m, 9H) 3.69-3.90(m, 8H) 6.13 (s, 1H) 6.60-7.01 (m, 1H) 7.29 (d, J=9.00 Hz, 1H) 7.62 (d,J=5.87 Hz, 2H) 8.00 (d, J=4.70 Hz, 1H) 8.17 (s, 1H) 8.83 (d, J=4.70 Hz,1H). LC/MS (m/z): 510.1 (MH+), Rt=0.85 min.

Example 1116:3-(difluoromethyl)-N-(3-(2,6-dimorpholinopyridin-4-yl)-4-methylphenyl)benzamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.28 (s, 3H) 3.41-3.60 (m, 9H) 3.69-3.89(m, 9H) 6.64-7.07 (m, 1H) 7.29 (d, J=8.22 Hz, 1H) 7.57 (dd, J=8.22, 1.96Hz, 1H) 7.60-7.70 (m, 2H) 7.76 (d, J=7.43 Hz, 1H) 7.98-8.16 (m, 1H).LC/MS (m/z): 509.2 (MH+), Rt=0.92 min.

Example 1117:N-(3-(2,6-dimorpholinopyridin-4-yl)-4-methylphenyl)-2-isopropylisonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.34 (d, J=7.04 Hz, 6H) 2.18 (s, 3H)3.30-3.49 (m, 8H) 3.60-3.78 (m, 8H) 7.20 (d, J=8.22 Hz, 1H) 7.43-7.61(m, 2H) 7.95 (d, J=5.09 Hz, 1H) 8.07 (s, 1H) 8.67 (d, J=5.87 Hz, 1H).LC/MS (m/z): 502.2 (MH+), Rt=0.72 min.

Example 1118:N-(3-(2,6-dimorpholinopyridin-4-yl)-4-methylphenyl)-2-(methylsulfonyl)isonicotinamide

1H NMR (400 MHz, <dmso>) ppm 2.21 (s, 3H) 3.33 (br. s., 5H) 3.40 (br.s., 17H) 3.54-3.78 (m, 8H) 6.03 (s, 1H) 7.28 (d, J=8.22 Hz, 1H) 7.60 (d,J=1.96 Hz, 1H) 7.66-7.76 (m, 1H) 8.07-8.27 (m, 1H) 8.51 (s, 1H) 8.98 (d,J=4.69 Hz, 1H) 10.74 (s, 1H). LC/MS (m/z): 538.2 (MH+), Rt=0.77 min.

Example 1119:2-isopropyl-N-(2-methyl-2′,6′-dimorpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.42 (d, J=7.04 Hz, 6H) 2.69 (s, 3H)3.49-3.55 (m, 8H) 3.75-3.82 (m, 8H) 7.97 (dd, J=5.48, 1.57 Hz, 1H) 8.08(s, 1H) 8.45 (d, J=1.96 Hz, 1H) 8.77 (d, J=5.48 Hz, 1H) 9.36 (d, J=2.35Hz, 1H). LC/MS (m/z): 503.2 (MH+), Rt=0.60 min.

Example 1120:N-(2-methyl-2′,6′-dimorpholino-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 2.68 (s, 3H) 3.49-3.56 (m, 8H) 3.75-3.82(m, 8H) 6.13 (s, 1H) 8.18 (d, J=4.30 Hz, 1H) 8.36 (s, 1H) 8.4 (d, J=2.35Hz, 1H) 8.97 (d, J=5.09 Hz, 1H) 9.33 (d, J=2.35 Hz, 1H). LC/MS (m/z):529.2 (MH+), Rt=0.75 min.

Example 1121:3-(difluoromethyl)-N-(2-methyl-2′,6′-dimorpholino-[3,4′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.68 (s, 3H) 3.49-3.56 (m, 8H) 3.75-3.82(m, 8H) 6.14 (s, 1H) 6.90 (t, J=56.30 Hz, 1H) 7.67-7.73 (m, 1H) 7.83 (d,J=7.83 Hz, 1H) 8.16 (d, J=7.83 Hz, 1H) 8.22 (s, 1H) 8.45 (d, J=2.35 Hz,1H) 9.39 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=510.2, Rt=0.76 min.

Example 1122:2-(difluoromethyl)-N-(2-methyl-2′,6′-dimorpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.69 (s, 3H) 3.49-3.55 (m, 8H) 3.76-3.81(m, 8H) 6.14 (s, 1H) 6.85 (t, J=54.80 Hz, 1H) 8.07 (d, J=5.09 Hz, 1H)8.25 (s, 1H) 8.44 (d, J=2.35 Hz, 1H) 8.89 (d, J=5.09 Hz, 1H) 9.37 (d,J=2.35 Hz, 1H). LCMS (m/z) (M+H)=511.1, Rt=0.69 min.

Example 1123:2-(2-cyanopropan-2-yl)-N-(2-methyl-2′,6′-dimorpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.82 (s, 6H) 2.68 (s, 3H) 3.49-3.56 (m,8H) 3.74-3.82 (m, 8H) 6.14 (s, 1H) 7.87 (dd, J=4.89, 1.37 Hz, 1H) 8.14(s, 1H) 8.43 (d, J=2.35 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 9.36 (d, J=2.35Hz, 1H). LCMS (m/z) (M+H)=528.1, Rt=0.72 min.

Example 1124:N-(2-methyl-2′,6′-dimorpholino-[3,4′-bipyridin]-5-yl)-2-(methylsulfonyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.68 (s, 3H) 3.48-3.55 (m, 8H) 3.75-3.82(m, 8H) 6.13 (s, 1H) 8.21 (dd, J=4.70, 1.57 Hz, 1H) 8.43 (d, J=1.96 Hz,1H) 8.62 (s, 1H) 8.99 (d, J=4.70 Hz, 1H) 9.33 (d, J=2.35 Hz, 1H). LCMS(m/z) (M+H)=539.0, Rt=0.62 min.

Example 1125:1-ethyl-N-(2-methyl-2′,6′-dimorpholino-[3,4′-bipyridin]-5-yl)-6-oxo-5-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.42 (t, J=7.24 Hz, 3H) 2.67 (s, 3H)3.51 (t, J=4.89 Hz, 8H) 3.74-3.83 (m, 8H) 4.18 (q, J=7.30 Hz, 2H) 6.13(s, 1H) 8.37 (d, J=2.35 Hz, 1H) 8.52 (d, J=1.96 Hz, 1H) 8.80 (d, J=2.35Hz, 1H) 9.30 (d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=573.1, Rt=0.73 min.

Example 1126:N-(4-methyl-3-(2-(1-methyl-1H-pyrazol-4-yl)-6-morpholinopyridin-4-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.33 (s, 3H) 3.67 (t, J=4.70 Hz, 4H)3.82-3.89 (m, 4H) 3.96 (s, 3H) 6.81 (s, 1H) 7.09 (s, 1H) 7.36 (d, J=8.22Hz, 1H) 7.65 (dd, J=8.41, 2.15 Hz, 1H) 7.76 (d, J=1.96 Hz, 1H) 8.04 (s,1H) 8.12 (d, J=4.30 Hz, 1H) 8.23 (s, 1H) 8.30 (s, 1H) 8.91 (d, J=5.09Hz, 1H). LCMS (m/z) (M+H)=523.1, Rt=0.84 min.

Example 1127:N-(3-(2-(3,5-dimethyl-1H-pyrazol-4-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.38 (s, 3H) 2.45 (s, 6H) 3.64-3.70 (m,4H) 3.83-3.89 (m, 4H) 6.92 (s, 1H) 6.99 (s, 1H) 7.38 (d, J=8.22 Hz, 1H)7.64 (dd, J=8.22, 2.35 Hz, 1H) 7.83 (d, J=1.96 Hz, 1H) 8.12 (d, J=4.70Hz, 1H) 8.30 (s, 1H) 8.92 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=537.2,Rt=0.74 min.

Example 1128:N-(4-methyl-3-(2-morpholino-6-(piperazin-1-yl)pyridin-4-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.27 (s, 3H) 3.47-3.53 (m, 6H) 3.79 (q,J=4.83 Hz, 10H) 6.18 (d, J=13.69 Hz, 2H) 7.30 (d, J=8.22 Hz, 1H) 7.55(dd, J=8.22, 1.96 Hz, 1H) 7.67 (d, J=2.35 Hz, 1H) 8.11 (d, J=5.09 Hz,1H) 8.29 (s, 1H) 8.91 (d, J=5.09 Hz, 1H). LCMS (m/z) (M+H)=527.2,Rt=0.78 min.

Example 1129:N-(2-methyl-2′-morpholino-6′-(piperazin-1-yl)-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.56 (s, 3H) 3.50-3.56 (m, 6H) 3.81 (dt,J=14.97, 5.04 Hz, 10H) 6.23 (d, J=10.17 Hz, 2H) 7.74-7.80 (m, 1H) 7.95(d, J=7.83 Hz, 1H) 8.25 (d, J=7.83 Hz, 1H) 8.31 (d, J=2.35 Hz, 2H) 8.98(d, J=2.35 Hz, 1H). LCMS (m/z) (M+H)=527.3, Rt=0.64 min.

Example 1130:N-(3-(2-(3-hydroxypyrrolidin-1-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.13 (br. s., 1H) 2.17-2.25 (m, 1H) 2.35(s, 3H) 3.44-3.58 (m, 5H) 3.66-3.76 (m, 3H) 3.86 (t, J=4.73 Hz, 4H) 4.60(br. s., 1H) 6.15 (s, 1H) 7.36 (d, J=8.51 Hz, 1H) 7.64 (dt, J=8.20, 2.52Hz, 1H) 7.76 (br. s., 1H) 8.14 (d, J=4.73 Hz, 1H) 8.32 (s, 1H) 8.94 (d,J=5.04 Hz, 1H). LCMS (m/z) (M+H)=528.2, Rt=0.75 min.

Example 1131:N-(2′-(3-hydroxypyrrolidin-1-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (500 MHz, <cd3od>) δ ppm 2.13 (d, J=3.78 Hz, 1H) 2.17-2.26 (m,1H) 2.35 (s, 3H) 3.43-3.57 (m, 5H) 3.66-3.76 (m, 3H) 3.86 (t, J=4.73 Hz,4H) 4.59 (d, J=1.89 Hz, 1H) 6.15 (br. s., 1H) 7.36 (d, J=8.20 Hz, 1H)7.65 (dd, J=8.35, 2.36 Hz, 1H) 7.76 (br. s., 1H) 8.14 (d, J=4.73 Hz, 1H)8.32 (s, 1H) 8.94 (d, J=4.73 Hz, 1H). LCMS (m/z) (M+H)=528.2, Rt=0.75min.

Example 1132:N-(3-(2-(1,4-dioxan-2-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)piperidine-4-carboxamide

¹H NMR (500 MHz, <cd3od>) δ ppm 1.90-2.04 (m, 2H) 2.23 (s, 3H) 2.38 (d,J=12.93 Hz, 1H) 2.76-2.86 (m, 1H) 3.49-3.57 (m, 5H) 3.62-3.71 (m, 2H)3.75-3.83 (m, 5H) 3.84-3.97 (m, 2H) 4.14 (dd, J=11.51, 2.68 Hz, 1H) 4.30(ddd, J=9.62, 6.46, 3.15 Hz, 1H) 4.61 (dd, J=9.93, 2.68 Hz, 1H) 6.66 (s,1H) 6.81 (s, 1H) 7.26 (d, J=8.20 Hz, 1H) 7.45 (dd, J=8.20, 2.21 Hz, 1H)7.47 (d, J=2.21 Hz, 1H) 9.95 (s, 1H). LCMS (m/z) (M+H)=535.3, Rt=0.61min.

Example 1133:N-(3-(2-ethoxy-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

LC/MS (m/z): 487.1 (MH+), Rt=1.09 min.

Synthesis of 4-(4-bromopyridin-2-yl)morpholin-3-one

To a suspension of 3-morpholinone (1.50 equiv.) in toluene was addedpotassium tert-butoxide, 1.0M in THF (1.40 equiv.). The mixture wasstirred for 10 min. 4-bromo-2-fluoropyridine (1.00 equiv.) was added.The mixture was stirred at 110° C. for 5 hr. The cooled reaction mixturewas diluted with ethyl acetate and washed with saturated aqueous sodiumbicarbonate. The separated organic phase was dried over sodium sulfate,filtered, and concentrated to give4-(4-bromopyridin-2-yl)morpholin-3-one. LCMS (m/z) (M+H)=256.9/258.8,Rt=0.59 min.

Example 1134:N-(4-methyl-3-(2-(3-oxomorpholino)pyridin-4-yl)phenyl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) (ppm 2.33 (s, 3H) 4.10 (s, 4H) 4.35 (s, 2H)7.32-7.40 (m, 2H) 7.66-7.78 (m, 3H) 7.90 (d, J=7.83 Hz, 1H) 7.95 (s, 1H)8.22 (d, J=7.83 Hz, 1H) 8.27 (s, 1H) 8.53 (d, J=5.09 Hz, 1H) LCMS (m/z)(M+H)=456.1, Rt=0.97 min.

Example 1135:N-(2-methyl-2′-(3-oxomorpholino)-[3,4′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide

¹H NMR (400 MHz, <cd3od>) δ ppm 2.70 (s, 3H) 4.06-4.20 (m, 4H) 4.36 (s,2H) 7.40 (dd, J=5.09, 1.57 Hz, 1H) 7.74-7.84 (m, 1H) 7.97 (d, J=7.83 Hz,1H) 8.18 (s, 1H) 8.29 (d, J=8.22 Hz, 1H) 8.36 (s, 1H) 8.50 (d, J=1.96Hz, 1H) 8.66 (d, J=5.09 Hz, 1H) 9.36 (d, J=2.35 Hz, 1H). LCMS (m/z)(M+H)=457.1, Rt=0.72 min.

Example 1136:2-isopropyl-N-(2-methyl-2′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <cd3od>) δ ppm 1.43 (d, J=6.65 Hz, 6H) 2.60 (s, 3H)3.24-3.31 (m, 1H) 3.66-3.76 (m, 4H) 3.83-3.93 (m, 4H) 7.06 (d, J=6.26Hz, 1H) 7.36 (s, 1H) 7.96 (dd, J=5.67, 1.37 Hz, 1H) 8.08 (s, 1H) 8.14(d, J=6.26 Hz, 1H) 8.43 (d, J=2.35 Hz, 1H) 8.77 (d, J=5.48 Hz, 1H) 9.01(d, J=1.96 Hz, 1H). LCMS (m/z) (M+H)=418.2, Rt=0.41 min.

Example 1137:2-(1,1-difluoroethyl)-N-(4-methyl-3-(2-morpholinopyridin-4-yl)phenyl)isonicotinamide

LC/MS (m/z): 439.1 (MH+), Rt=0.68 min.

Example 1138:(R)-2-(2-fluoropropan-2-yl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-(3-methylmorpholino)-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.35 (d, J=6.65 Hz, 3H) 1.60-1.85 (m,7H) 2.63 (s, 3H) 3.36-3.72 (m, 6H) 3.72-3.87 (m, 5H) 4.03 (d, J=10.96Hz, 1H) 4.17 (d, J=6.65 Hz, 1H) 6.07-6.32 (m, 1H) 7.81 (dd, J=5.09, 1.57Hz, 1H) 8.11 (s, 1H) 8.42 (d, J=2.35 Hz, 1H) 8.74 (d, J=5.09 Hz, 1H)9.07 (d, J=1.96 Hz, 1H). LC/MS (m/z): 509.4 (MH+), Rt=0.57 min.

Example 1139:(R)-2-(1,1-difluoroethyl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-(3-methylmorpholino)-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.34 (d, J=6.65 Hz, 3H) 2.05 (t, J=18.59Hz, 3H) 2.60 (s, 3H) 3.36-3.55 (m, 3H) 3.57-3.72 (m, 2H) 3.73-3.89 (m,4H) 4.02 (d, J=11.35 Hz, 1H) 4.18 (d, J=5.87 Hz, 1H) 6.05-6.33 (m, 1H)8.00 (d, J=4.70 Hz, 1H) 8.22 (s, 1H) 8.37 (d, J=2.35 Hz, 1H) 8.85 (d,J=5.09 Hz, 1H) 9.00 (s, 1H). LC/MS (m/z): 513.4 (MH+), Rt=0.56 min.

Example 1140:(R)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-(3-methylmorpholino)-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.34 (d, J=6.65 Hz, 3H) 2.59 (s, 3H)3.36-3.55 (m, 3H) 3.58-3.71 (m, 2H) 3.74-3.89 (m, 4H) 3.92-4.08 (m, 1H)4.17 (d, J=6.26 Hz, 1H) 6.04-6.29 (m, 1H) 8.15 (d, J=4.30 Hz, 1H)8.28-8.41 (m, 1H) 8.87-9.06 (m, 1H). LC/MS (m/z): 517.3 (MH+), Rt=0.58min.

Example 1141:(R)-2-(difluoromethyl)-N-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-(3-methylmorpholino)-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.35 (d, J=6.65 Hz, 3H) 2.61 (s, 3H)3.36-3.71 (m, 6H) 3.71-3.87 (m, 5H) 3.93-4.09 (m, 1H) 4.17 (d, J=6.65Hz, 1H) 6.08-6.32 (m, 1H) 6.66-7.09 (m, 1H) 8.05 (d, J=5.09 Hz, 1H)8.16-8.28 (m, 1H) 8.32-8.48 (m, 1H) 8.84-8.94 (m, 1H) 9.04 (d, J=1.96Hz, 1H). LC/MS (m/z): 499.4 (MH+), Rt=0.51 min.

Example 1142:N-(2′-ethoxy-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.38 (t, J=7.04 Hz, 4H) 1.62-1.86 (m,6H) 2.68 (s, 3H) 3.45-3.63 (m, 4H) 3.70-3.87 (m, 4H) 4.37 (q, J=7.04 Hz,2H) 6.14 (s, 1H) 6.31 (s, 1H) 7.83 (dd, J=5.09, 1.57 Hz, 1H) 8.13 (s,1H) 8.45 (d, J=2.35 Hz, 1H) 8.76 (d, J=5.09 Hz, 1H) 9.38 (d, J=2.35 Hz,1H). LC/MS (m/z): 480.2 (MH+), Rt=0.82 min.

Example 1143:2-(1,1-difluoroethyl)-N-(2′-ethoxy-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.24-1.46 (m, 5H) 2.05 (t, J=18.78 Hz,3H) 2.66 (s, 3H) 3.46-3.62 (m, 4H) 3.71-3.88 (m, 4H) 4.37 (q, J=7.04 Hz,2H) 6.14 (s, 1H) 6.30 (s, 1H) 8.02 (d, J=4.30 Hz, 1H) 8.25 (s, 1H) 8.40(d, J=2.35 Hz, 1H) 8.86 (d, J=5.09 Hz, 1H) 9.31 (d, J=2.35 Hz, 1H).LC/MS (m/z): 484.2 (MH+), Rt=0.82 min.

Example 1144:N-(3-(2-(1,4-dioxan-2-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(2-fluoropropan-2-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.62-1.83 (m, 6H) 2.29 (s, 3H) 3.46-4.02(m, 14H) 4.13 (dd, J=11.54, 2.54 Hz, 1H) 4.74 (dd, J=9.78, 2.35 Hz, 1H)6.95 (d, J=4.30 Hz, 2H) 7.34 (d, J=8.22 Hz, 1H) 7.63 (dd, J=8.22, 2.35Hz, 1H) 7.71 (d, J=1.96 Hz, 1H) 7.78 (dd, J=5.09, 1.57 Hz, 1H) 8.07 (s,1H) 8.70 (d, J=5.09 Hz, 1H). LC/MS (m/z): 521.2 (MH+), Rt=0.85 min.

Example 1145:N-(3-(2-(1,4-dioxan-2-yl)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(1,1-difluoroethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.32 (d, J=6.65 Hz, 3H) 2.03 (t, J=18.59Hz, 3H) 2.30 (s, 3H) 3.46-4.02 (m, 14H) 4.14 (dd, J=11.54, 2.54 Hz, 1H)4.76 (dd, J=9.78, 2.74 Hz, 1H) 6.98 (d, J=1.96 Hz, 2H) 7.35 (d, J=8.22Hz, 1H) 7.64 (dd, J=8.22, 2.35 Hz, 1H) 7.74 (d, J=1.96 Hz, 1H) 7.96 (d,J=4.30 Hz, 1H) 8.18 (s, 1H) 8.81 (d, J=5.09 Hz, 1H). LC/MS (m/z): 525.2(MH+), Rt=0.85 min.

Example 1146:2-(difluoromethyl)-N-(2′-ethoxy-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.38 (t, J=7.04 Hz, 3H) 2.68 (s, 3H)3.47-3.63 (m, 4H) 3.71-3.85 (m, 4H) 4.37 (q, J=7.04 Hz, 2H) 6.14 (s, 1H)6.31 (s, 1H) 6.61-7.04 (m, 1H) 8.07 (d, J=5.09 Hz, 1H) 8.25 (s, 1H) 8.44(d, J=2.35 Hz, 1H) 8.89 (d, J=5.09 Hz, 1H) 9.36 (d, J=2.35 Hz, 1H).LC/MS (m/z): 470.2 (MH+), Rt=0.78 min.

Example 1147:2-(2-cyanopropan-2-yl)-N-(2′-ethoxy-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.38 (t, J=7.04 Hz, 3H) 1.82 (s, 6H)2.67 (s, 3H) 3.46-3.62 (m, 4H) 3.70-3.87 (m, 4H) 4.37 (q, J=7.17 Hz, 2H)6.15 (s, 1H) 6.31 (s, 1H) 7.87 (dd, J=5.09, 1.17 Hz, 1H) 8.13 (s, 1H)8.42 (d, J=2.35 Hz, 1H) 8.82 (d, J=4.70 Hz, 1H) 9.36 (d, J=2.35 Hz, 1H).LC/MS (m/z): 487.2 (MH+), Rt=0.81 min.

Example 1148:N-(2′-ethoxy-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(2-hydroxypropan-2-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.38 (t, J=7.04 Hz, 3H) 1.64 (s, 6H)2.67 (s, 3H) 3.45-3.62 (m, 4H) 3.68-3.88 (m, 4H) 4.37 (q, J=7.04 Hz, 2H)6.14 (s, 1H) 6.31 (s, 1H) 7.95 (dd, J=5.28, 1.76 Hz, 1H) 8.34 (d, J=0.78Hz, 1H) 8.44 (d, J=2.35 Hz, 1H) 8.77 (d, J=5.48 Hz, 1H) 9.35 (d, J=2.35Hz, 1H). LC/MS (m/z): 478.3 (MH+), Rt=0.64 min.

Example 1149:2-cyclopropyl-N-(2′-ethoxy-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.06-1.27 (m, 4H) 1.38 (t, J=7.04 Hz,3H) 2.20-2.33 (m, 1H) 2.66 (s, 3H) 3.42-3.64 (m, 4H) 3.67-3.94 (m, 4H)4.37 (q, J=7.04 Hz, 2H) 6.14 (s, 1H) 6.30 (s, 1H) 7.78 (dd, J=5.48, 1.57Hz, 1H) 7.84 (s, 1H) 8.40 (d, J=1.96 Hz, 1H) 8.64 (d, J=5.09 Hz, 1H)9.33 (d, J=2.35 Hz, 1H). LC/MS (m/z): 460.3 (MH+), Rt=0.67 min.

Example 1150:2-(2-hydroxypropan-2-yl)-N-(4-methyl-3-(2-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-4-yl)phenyl)isonicotinamide

1H NMR (400 MHz, Methanol-d4) δ 8.76 (dd, J=5.8, 0.8 Hz, 1H), 8.41 (dd,J=1.7, 0.8 Hz, 1H), 8.13 (dd, J=5.8, 1.7 Hz, 1H), 7.69-7.57 (m, 2H),7.34-7.27 (m, 1H), 6.22 (d, J=0.9 Hz, 1H), 6.06 (d, J=0.9 Hz, 1H),5.26-5.15 (m, 1H), 3.96 (dt, J=11.7, 4.5 Hz, 2H), 3.83-3.75 (m, 4H),3.62 (ddd, J=11.8, 8.9, 3.0 Hz, 2H), 3.52-3.44 (m, 4H), 2.27 (s, 3H),2.13-2.03 (m, 2H), 1.78 (ddd, J=13.0, 8.6, 4.0 Hz, 2H), 1.67 (s, 6H).LC/MS (m/z): 533.2 (MH+), Rt=0.81 min.

Example 1151:2-(difluoromethyl)-N-(4-methyl-3-(2-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-4-yl)phenyl)isonicotinamide

1H NMR (400 MHz, Methanol-d4) δ 8.83 (dd, J=5.1, 0.7 Hz, 1H), 8.17 (d,J=1.7 Hz, 1H), 8.00 (ddd, J=4.4, 1.7, 0.9 Hz, 1H), 7.63 (dd, J=4.5, 2.1Hz, 2H), 7.34-7.26 (m, 1H), 6.82 (t, J=55.1 Hz, 1H), 6.32-6.26 (m, 1H),6.13 (d, J=1.0 Hz, 1H), 5.24-5.14 (m, 1H), 4.02-3.92 (m, 2H), 3.84-3.76(m, 4H), 3.62 (ddd, J=11.8, 8.9, 3.0 Hz, 2H), 3.51 (dd, J=5.7, 4.1 Hz,4H), 2.27 (s, 3H), 2.14-2.05 (m, 2H), 1.78 (dtd, J=12.8, 8.7, 4.0 Hz,2H). LC/MS (m/z): 525.2 (MH+), Rt=0.97 min.

Example 1152:2-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-4-yl)phenyl)isonicotinamide

1H NMR (400 MHz, Methanol-d4) δ 8.76 (dd, J=5.0, 0.9 Hz, 1H), 8.06 (dd,J=1.6, 0.9 Hz, 1H), 7.81 (dd, J=5.1, 1.6 Hz, 1H), 7.62 (d, J=8.2 Hz,2H), 7.30 (dd, J=8.0, 1.0 Hz, 1H), 6.29 (d, J=1.3 Hz, 1H), 6.13 (d,J=1.0 Hz, 1H), 5.25-5.13 (m, 1H), 4.02-3.92 (m, 2H), 3.84-3.76 (m, 4H),3.62 (ddd, J=11.8, 8.9, 3.0 Hz, 2H), 3.54-3.47 (m, 4H), 2.27 (s, 3H),2.09 (ddd, J=11.7, 6.1, 3.0 Hz, 2H), 1.81 (s, 8H). LC/MS (m/z): 542.2(MH+), Rt=0.99 min.

Example 1153:6-(2-cyanopropan-2-yl)-N-(4-methyl-3-(2-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-4-yl) phenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, Methanol-d4) b 9.61 (d, J=2.0 Hz, 1H), 8.35 (d, J=2.0Hz, 1H), 7.65 (dd, J=8.3, 2.3 Hz, 1H), 7.60 (d, J=2.4 Hz, 1H), 7.34-7.27(m, 1H), 6.23 (d, J=0.9 Hz, 1H), 6.07 (d, J=0.9 Hz, 1H), 5.25-5.16 (m,2H), 4.01-3.91 (m, 2H), 3.83-3.75 (m, 4H), 3.62 (ddd, J=11.8, 8.9, 3.1Hz, 2H), 3.52-3.45 (m, 5H), 2.27 (s, 3H), 2.12-2.04 (m, 2H), 1.91 (s,5H), 1.77 (dt, J=8.6, 4.2 Hz, 2H). LC/MS (m/z): 543.2 (MH+), Rt=0.93min.

Example 1154:6-cyclopropyl-N-(4-methyl-3-(2-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-4-yl)phenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, Methanol-d4) b 9.43 (d, J=2.0 Hz, 1H), 8.05 (d, J=2.0Hz, 1H), 7.67-7.57 (m, 2H), 7.30 (d, J=8.2 Hz, 1H), 6.25 (d, J=1.2 Hz,1H), 6.09 (d, J=1.0 Hz, 1H), 5.19 (dddt, J=7.8, 4.9, 3.9, 0.5 Hz, 1H),4.01-3.91 (m, 2H), 3.83-3.75 (m, 4H), 3.61 (ddd, J=11.8, 8.9, 3.0 Hz,2H), 3.49 (dd, J=5.4, 4.4 Hz, 4H), 2.45-2.36 (m, 1H), 2.26 (s, 3H),2.13-2.04 (m, 2H), 1.77 (dt, J=8.6, 4.1 Hz, 2H), 1.37-1.23 (m, 4H).LC/MS (m/z): 516.2 (MH+), Rt=0.91 min.

Example 1155:N-(4-methyl-3-(2-morpholino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-4-yl)phenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, Methanol-d4) b 9.86 (d, J=2.0 Hz, 1H), 8.57 (d, J=2.0Hz, 1H), 7.69-7.61 (m, 2H), 7.34-7.27 (m, 1H), 6.27 (d, J=1.3 Hz, 1H),6.11 (d, J=1.0 Hz, 1H), 5.24-5.14 (m, 1H), 3.96 (dt, J=11.6, 4.5 Hz,2H), 3.83-3.76 (m, 4H), 3.61 (ddd, J=11.8, 8.9, 3.0 Hz, 2H), 3.53-3.46(m, 4H), 2.27 (s, 3H), 2.08 (ddt, J=11.7, 5.7, 2.8 Hz, 2H), 1.77 (dtd,J=12.8, 8.7, 4.0 Hz, 2H). LC/MS (m/z): 544.2 (MH+), Rt=0.99 min.

Example 1156:N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

Step 1

2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine(1.0 equiv.), 3-bromo-4-methylaniline (1.04 equiv.) and Pd-Xphos precat(0.005 equiv.) were stirred in a solution of THF (0.5 M) under nitrogen.Potassium phosphate (2.0 equiv, 0.5 M solution) was added and themixture was heated to 35° C. overnight. Upon overnight stirring, another0.005 equiv. of catalyst was added and the mixture was warmed to 60° C.for 18 hours. The mixture was carefully poured onto water and extractedwith ethyl acetate (3×). The combined organics were washed with water,brine, dried over magnesium sulfate, filtered and concentrated. Thecrude residue was purified via silica gel chromatography (ISCO, 0-100%ethyl acetate in heptanes) to give3-(2,6-difluoropyridin-4-yl)-4-methylaniline in 64% yield. LCMS (m/z)(M+H)=220.9, Rt=0.54 min.

Step 2

To a solution of 3-(2,6-difluoropyridin-4-yl)-4-methylaniline (1.0equiv.) in DMSO (1 M) was added morpholine (3.0 equiv.) and potassiumcarbonate (2.0 equiv.) to give a yellow suspension. The mixture washeated to 40° C. for 3 hours and upon cooling to rt, diluted with waterand sodium bicarbonate, extracted with ethyl acetate (3×), dried,filtered and concentrated to give3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline in quantitativeyield. LCMS (m/z) (M+H)=288.0, Rt=0.60 min.

Step 3

To a solution of 3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline(1.0 equiv.) in dioxane (0.2 M) was added2-((tetrahydro-2H-pyran-2-yl)oxy)ethanol (2.0 equiv.) to give an orangesolution. Sodium hydride (60% dispersion, 2.0 equiv.) was addedcarefully and the reaction was stirred at rt for 30 min, then warmed to60° C. for 2 hours. At this point, about 75% conversion to product, sothe mixture was heated to 70° C. for another one hour. The reaction wascooled to rt, quenched with aqueous sodium bicarbonate, extracted withethyl acetate (3×), dried over magnesium sulfate, filtered andconcentrated. The crude material was purified via silica gelchromatography (ISCO, 0-5% methanol in DCM then 0-100% ethyl acetate inheptanes to give4-methyl-3-(2-morpholino-6-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)pyridin-4-yl)anilinein 72% yield. LCMS (m/z) (M+H)=414.1, Rt=0.73 min.

Step 4

A solution of4-methyl-3-(2-morpholino-6-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)pyridin-4-yl)aniline(1.0 equiv.), 2-(trifluoromethyl)isonicotinic acid (1.7 equiv.),N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diaminehydrochloride (1.7 equiv.), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-olhydrate (1.7 equiv.) and Huenig's base (2.0 equiv.) in DMF (0.1 M) wasstirred at rt overnight. HCl (5.0 equiv., 2.0 M aqueous solution) wasadded and the reaction was stirred for 90 min, at which point LC/MSindicated about 90% conversion to product. Additional 2.5 equiv. of HClwas added and stirred for 30 min at rt. The solution was diluted withwater and solid sodium bicarbonate was carefully added until pH=5 wasreached. The solution was extracted with ethyl acetate (3×), dried overmagnesium sulfate, filtered and concentrated. The crude material waspurified via silica gel chromatography (ISCO, 0-100% ethyl acetate inheptanes to giveN-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamidein 81% yield. ¹H NMR (400 MHz, Methanol-d4) b 8.93-8.86 (m, 1H),8.31-8.26 (m, 1H), 8.14-8.07 (m, 1H), 7.68-7.56 (m, 2H), 7.33-7.25 (m,1H), 6.32-6.24 (m, 1H), 6.13 (dd, J=28.4, 0.9 Hz, 1H), 4.76-4.59 (m,2H), 4.41-4.33 (m, 1H), 3.91-3.84 (m, 1H), 3.79 (ddd, J=6.7, 4.0, 1.8Hz, 4H), 3.51 (q, J=4.8 Hz, 4H), 2.26 (d, J=4.9 Hz, 3H). LC/MS (m/z):503.2 (MH+), Rt=0.88 min.

Example 1157:2-cyclopropyl-N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, Methanol-d4) (8.64 (dd, J=5.8, 0.8 Hz, 1H), 7.94-7.85(m, 2H), 7.63 (dd, J=8.2, 2.4 Hz, 1H), 7.57 (d, J=2.3 Hz, 1H), 7.29 (dd,J=8.3, 0.7 Hz, 1H), 6.22 (d, J=0.9 Hz, 1H), 6.10 (d, J=0.9 Hz, 1H),4.40-4.33 (m, 2H), 3.90-3.83 (m, 2H), 3.83-3.75 (m, 5H), 3.54-3.46 (m,5H), 2.38-2.26 (m, 1H), 2.26 (s, 3H), 1.38-1.17 (m, 5H). LC/MS (m/z):475.2 (MH+), Rt=0.69 min.

Example 1158:2-(2-fluoropropan-2-yl)-N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, Methanol-d4) δ 8.71 (dd, J=5.2, 0.9 Hz, 1H), 8.10 (dt,J=2.0, 1.0 Hz, 1H), 7.82 (ddd, J=5.2, 2.7, 1.7 Hz, 1H), 7.67-7.55 (m,2H), 7.33-7.25 (m, 1H), 6.34-6.25 (m, 1H), 6.14 (dd, J=32.5, 0.9 Hz,1H), 4.76-4.59 (m, 2H), 4.41-4.34 (m, 1H), 3.92-3.84 (m, 1H), 3.79 (ddd,J=5.1, 4.2, 2.3 Hz, 4H), 3.56-3.47 (m, 4H), 2.26 (d, J=5.7 Hz, 3H), 1.74(dd, J=22.0, 0.6 Hz, 6H). LC/MS (m/z): 495.2 (MH+), Rt=0.84 min.

Example 1159:2-(1,1-difluoroethyl)-N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, Methanol-d4) δ 8.79 (dt, J=5.1, 0.8 Hz, 1H), 8.17 (dd,J=1.6, 0.9 Hz, 1H), 7.95 (ddd, J=5.1, 1.5, 0.8 Hz, 1H), 7.67-7.55 (m,2H), 7.33-7.25 (m, 1H), 6.32-6.24 (m, 1H), 6.13 (dd, J=26.2, 0.9 Hz,1H), 4.76-4.59 (m, 2H), 4.41-4.33 (m, 2H), 3.91-3.84 (m, 2H), 3.83-3.75(m, 5H), 3.51 (dt, J=6.2, 3.9 Hz, 5H), 2.26 (d, J=4.6 Hz, 3H), 2.03 (t,J=18.7 Hz, 3H). LC/MS (m/z): 499.2 (MH+), Rt=0.85 min.

Example 1160:2-(difluoromethyl)-N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, Methanol-d4) δ 8.82 (dt, J=5.2, 0.8 Hz, 1H), 8.16 (d,J=1.6 Hz, 1H), 8.00 (ddt, J=5.2, 1.8, 0.9 Hz, 1H), 7.67-7.55 (m, 2H),7.33-7.25 (m, 1H), 6.81 (t, J=55.1 Hz, 1H), 6.32-6.24 (m, 1H), 6.13 (dd,J=26.0, 0.9 Hz, 1H), 4.76-4.59 (m, 2H), 4.41-4.33 (m, 1H), 3.91-3.84 (m,1H), 3.79 (ddd, J=6.5, 3.7, 1.6 Hz, 4H), 3.52 (dd, J=5.5, 4.0 Hz, 4H),2.26 (d, J=4.5 Hz, 3H). LC/MS (m/z): 485.2 (MH+), Rt=0.81 min.

Example 1161:2-(2-cyanopropan-2-yl)-N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)isonicotinamide

1H NMR (400 MHz, Methanol-d4) δ 8.75 (dd, J=5.1, 1.0 Hz, 1H), 8.05 (dt,J=1.5, 0.8 Hz, 1H), 7.80 (dd, J=5.1, 1.6 Hz, 1H), 7.67-7.54 (m, 2H),7.33-7.25 (m, 1H), 6.35-6.25 (m, 1H), 6.14 (dd, J=33.3, 0.9 Hz, 1H),4.76-4.59 (m, 2H), 4.41-4.34 (m, 1H), 3.92-3.84 (m, 1H), 3.84-3.75 (m,4H), 3.56-3.47 (m, 4H), 2.26 (d, J=5.9 Hz, 3H), 1.80 (s, 6H). LC/MS(m/z): 502.2 (MH+), Rt=0.83 min.

Example 1162:6-cyclopropyl-N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)pyridazine-4-carboxamide

1H NMR (400 MHz, Methanol-d4) b 9.41 (d, J=2.1 Hz, 1H), 8.00 (d, J=2.0Hz, 1H), 7.67-7.54 (m, 2H), 7.33-7.26 (m, 1H), 6.25 (d, J=1.1 Hz, 1H),6.13 (d, J=0.9 Hz, 1H), 4.76-4.61 (m, 1H), 4.41-4.33 (m, 2H), 3.91-3.83(m, 2H), 3.83-3.76 (m, 5H), 3.55-3.47 (m, 5H), 2.39 (tt, J=8.2, 4.9 Hz,1H), 2.26 (d, J=3.0 Hz, 3H), 1.35-1.21 (m, 5H). LC/MS (m/z): 476.2(MH+), Rt=0.75 min.

Example 1163:N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-4-(trifluoromethyl)picolinamide

1H NMR (400 MHz, Methanol-d4) δ 8.95 (dt, J=5.1, 0.7 Hz, 1H), 8.42 (dt,J=1.6, 0.7 Hz, 1H), 7.91 (ddd, J=5.1, 1.8, 0.8 Hz, 1H), 7.71 (dd, J=6.2,2.4 Hz, 2H), 7.30 (dd, J=8.9, 0.8 Hz, 1H), 6.27 (d, J=1.0 Hz, 1H), 6.15(d, J=0.9 Hz, 1H), 4.41-4.33 (m, 2H), 3.91-3.84 (m, 2H), 3.83-3.76 (m,4H), 3.56-3.48 (m, 5H), 2.26 (d, J=0.6 Hz, 3H). LC/MS (m/z): 503.2(MH+), Rt=0.96 min.

Example 1164:N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-6-(trifluoromethyl)pyridazine-4-carboxamide

1H NMR (400 MHz, Methanol-d4) δ 9.86 (d, J=2.0 Hz, 1H), 8.57 (d, J=2.0Hz, 1H), 7.70-7.57 (m, 2H), 7.34-7.27 (m, 1H), 6.27 (dd, J=6.5, 1.0 Hz,1H), 6.12 (dd, J=24.2, 0.9 Hz, 1H), 4.76-4.60 (m, 2H), 4.41-4.33 (m,2H), 3.91-3.84 (m, 2H), 3.79 (ddd, J=6.2, 3.6, 1.2 Hz, 5H), 3.55-3.48(m, 4H), 2.26 (d, J=3.8 Hz, 3H). LC/MS (m/z): 504.2 (MH+), Rt=0.83 min.

Example 1165:N-(2′-(1,4-dioxan-2-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) ppm 2.64 (s, 3H) 3.47-3.54 (m, 1H) 3.55-3.61(m, 4H) 3.63-3.71 (m, 1H) 3.75-3.83 (m, 5H) 3.85-3.97 (m, 2H) 4.18 (dd,J=11.35, 2.74 Hz, 1H) 4.62 (dd, J=9.98, 2.54 Hz, 1H) 6.77 (s, 1H) 6.92(s, 1H) 8.18 (d, J=3.91 Hz, 1H) 8.36 (s, 1H) 8.40 (d, J=2.35 Hz, 1H)8.97 (d, J=5.09 Hz, 1H) 9.28 (d, J=2.35 Hz, 1H). LC/MS (m/z): 530.1(MH+), Rt=0.72 min.

Example 1166:N-(2′-(1,4-dioxan-2-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(1,1-difluoroethyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) ppm 2.05 (t, J=18.78 Hz, 3H) 2.64 (s, 3H)3.46-3.54 (m, 1H) 3.55-3.61 (m, 4H) 3.63-3.71 (m, 1H) 3.75-3.83 (m, 5H)3.85-3.96 (m, 2H) 4.18 (dd, J=11.74, 2.74 Hz, 1H) 4.62 (dd, J=9.78, 2.74Hz, 1H) 6.77 (s, 1H) 6.92 (s, 1H) 8.02 (d, J=4.70 Hz, 1H) 8.25 (s, 1H)8.40 (d, J=2.35 Hz, 1H) 8.86 (d, J=5.09 Hz, 1H) 9.29 (d, J=2.35 Hz, 1H).LC/MS (m/z): 526.2 (MH+), Rt=0.70 min.

Example 1167:N-(2′-(1,4-dioxan-2-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(2-fluoropropan-2-yl)isonicotinamide

1H NMR (400 MHz, <cd3od>) ppm 1.67-1.80 (m, 6H) 2.66 (s, 3H) 3.50 (dd,J=11.54, 9.98 Hz, 1H) 3.55-3.61 (m, 4H) 3.63-3.70 (m, 1H) 3.75-3.83 (m,5H) 3.85-3.98 (m, 2H) 4.18 (dd, J=11.35, 2.74 Hz, 1H) 4.63 (dd, J=9.78,2.74 Hz, 1H) 6.78 (s, 1H) 6.93 (s, 1H) 7.83 (dd, J=5.09, 1.96 Hz, 1H)8.14 (s, 1H) 8.45 (d, J=2.35 Hz, 1H) 8.76 (d, J=5.09 Hz, 1H) 9.35 (d,J=2.35 Hz, 1H). LC/MS (m/z): 522.2 (MH+), Rt=0.71 min.

Example 1168:N-(2′-(1,4-dioxan-2-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-(1,1-difluoropropyl)isonicotinamide

1H NMR (400 MHz, <cd3od>) δ ppm 1.01 (t, J=7.63 Hz, 3H) 2.31-2.47 (m,2H) 2.65 (s, 3H) 3.50 (dd, J=11.35, 10.17 Hz, 1H) 3.55-3.61 (m, 4H)3.62-3.71 (m, 1H) 3.75-3.84 (m, 5H) 3.85-3.97 (m, 2H) 4.18 (dd, J=11.74,2.74 Hz, 1H) 4.62 (dd, J=9.78, 2.74 Hz, 1H) 6.77 (s, 1H) 6.92 (s, 1H)8.02 (d, J=5.09 Hz, 1H) 8.23 (s, 1H) 8.42 (d, J=2.35 Hz, 1H) 8.88 (d,J=5.09 Hz, 1H) 9.31 (d, J=2.35 Hz, 1H). LC/MS (m/z): 540.2 (MH+),Rt=0.76 min.

Example 1169:N-(2′-(1,4-dioxan-2-yl)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)-2-cyclopropylisonicotinamide

1H NMR (400 MHz, <cd3od>) d ppm 1.10-1.24 (m, 4H) 2.23-2.31 (m, 1H) 2.63(s, 3H) 3.50 (dd, J=11.35, 10.17 Hz, 1H) 3.54-3.61 (m, 4H) 3.62-3.71 (m,1H) 3.76-3.84 (m, 5H) 3.84-3.96 (m, 2H) 4.18 (dd, J=11.35, 2.74 Hz, 1H)4.62 (dd, J=10.17, 2.74 Hz, 1H) 6.77 (s, 1H) 6.91 (s, 1H) 7.76 (dd,J=5.09, 1.57 Hz, 1H) 7.82 (s, 1H) 8.38 (d, J=2.35 Hz, 1H) 8.63 (d,J=5.09 Hz, 1H) 9.27 (d, J=2.35 Hz, 1H). LC/MS (m/z): 502.2 (MH+),Rt=0.58 min.

5-amino-2′-morpholino-[3,4′-bipyridin]-2(1H)-one

Step 1

A mixture of4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine(1.0 equiv.), 5-bromo-6-methoxypyridin-3-amine (1.0 equiv.), sodiumcarbonate (2 M, 8 equiv.) and PdCl₂(dppf) (0.5 equiv.) in DME (0.1 M)were heated to 110° C. for 15 min in the microwave. After removing theDME soluble portion and concentrating, the resulting solid waspartitioned between EtOAc and water. The organic phase was washed withbrine and then dried over sodium sulfate. After concentration, the crudematerial was purified via normal phase chromatography.2-methoxy-2′-morpholino-[3,4′-bipyridin]-5-amine was isolated in 64%yield. LCMS (m/z) (M+H)=287.1, Rt=0.46 min.

Step 2

2-methoxy-2′-morpholino-[3,4′-bipyridin]-5-amine (1.0 equiv.) wasdissolved in a solution of 4 M HCl in dioxane (2.0 equiv.) and heated to110° C. for 1.5 h in the microwave. The dioxane soluble portion wasconcentrated and semi-crude5-amino-2′-morpholino-[3,4′-bipyridin]-2(1H)-one was used in the nextstep without further purification. LCMS (m/z) (M+H)=273.0, Rt=0.23 min.

6-methyl-2′-morpholino-4-oxo-4H-[1,4′-bipyridine]-3-carboxylic acid

Step 1

2-fluoropyridin-4-amine (1.0 equiv.) and morpholine (1.4 equiv.) in THF(6 M) were heated to 110° C. for 17 h in an oil bath. The reactionmixture was concentrated and semi-crude 2-morpholinopyridin-4-amine wasused in the next step without further purification. LCMS (m/z)(M+H)=180.2, Rt=0.26 min.

Step 2

To a suspension of 2-morpholinopyridin-4-amine (1.0 equiv.) and(E)-3-((dimethylamino)methylene)-6-methyl-2H-pyran-2,4(3H)-dione (1.0equiv.) in isopropanol (0.1 M) under an Ar atmosphere was addedpotassium 2-methylpropan-2-olate. The reaction mixture was heated toreflux for 17 h in an oil bath. The resulting thick orange mixture wasconcentrated and partitioned between EtOAc and water. The aqueous phasewas acidified with 6 N HCl and then extracted twice with EtOAc. Theresulting organic phase was dried over sodium sulfate and concentratedto give 6-methyl-2′-morpholino-4-oxo-4H-[1,4′-bipyridine]-3-carboxylicacid in 58% yield. LCMS (m/z) (M+H)=316.0, Rt=0.38 min.

Example 1170:2-(2-cyanopropan-2-yl)-N-(2-methoxy-2′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 3.53 (t, J=4.30 Hz, 4H)3.67-3.76 (m, 4H) 3.90 (s, 3H) 6.98 (d, J=5.48 Hz, 1H) 7.15 (br. s., 1H)7.88 (dd, J=4.89, 1.37 Hz, 1H) 8.02 (s, 1H) 8.11-8.23 (m, 2H) 8.58 (d,J=2.35 Hz, 1H) 8.82 (d, J=5.09 Hz, 1H) 10.73 (s, 1H). LCMS (m/z)(M+H)=459.3, Rt=0.69 min.

Example 1171:2-(1,1-difluoroethyl)-N-(2′-morpholino-2-oxo-1,2-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.94-2.12 (m, 3H) 3.54 (d, J=4.70 Hz, 4H)3.68-3.79 (m, 4H) 7.19 (d, J=5.48 Hz, 1H) 7.56 (br. s., 1H) 8.00 (d,J=4.70 Hz, 1H) 8.04-8.15 (m, 3H) 8.17 (s, 1H) 8.88 (d, J=5.09 Hz, 1H)10.54 (s, 1H). LCMS (m/z) (M+H)=442.2, Rt=0.60 min.

Example 1172:N-(2′-morpholino-2-oxo-1,2-dihydro-[3,4′-bipyridin]-5-yl)-2-(trifluoromethyl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 3.53 (d, J=4.30 Hz, 4H) 3.68-3.77 (m, 4H)7.17 (d, J=4.70 Hz, 1H) 7.52 (br. s., 1H) 8.00-8.14 (m, 3H) 8.17 (d,J=4.70 Hz, 1H) 8.34 (s, 1H) 9.00 (d, J=5.09 Hz, 1H) 10.59 (s, 1H). LCMS(m/z) (M+H)=446.2, Rt=0.61 min.

Example 1173:2-(2-cyanopropan-2-yl)-N-(2′-morpholino-2-oxo-1,2-dihydro-[3,4′-bipyridin]-5-yl)isonicotinamide

¹H NMR (400 MHz, <dmso>) δ ppm 1.75 (s, 6H) 3.60 (m, 4H) 3.69-3.79 (m,4H) 7.05-7.21 (m, 1H) 7.50 (br. s., 1H) 7.84 (dd, J=5.09, 1.57 Hz, 1H)7.99 (s, 1H) 8.03 (br. s., 1H) 8.06-8.15 (m, 2H) 8.81 (d, J=5.09 Hz, 1H)10.45 (s, 1H). LCMS (m/z) (M+H)=445.2, Rt=0.59 min.

Example 1174:3-(difluoromethyl)-N-(2′-morpholino-2-oxo-1,2-dihydro-[3,4′-bipyridin]-5-yl)benzamide

¹H NMR (400 MHz, <dmso>) δ ppm 3.53 (d, J=4.70 Hz, 4H) 3.65-3.83 (m, 4H)6.91-7.37 (m, 2H) 7.54 (br. s., 1H) 7.63-7.73 (m, 1H) 7.79 (d, J=7.43Hz, 1H) 7.98-8.24 (m, 5H) 10.28 (s, 1H). LCMS (m/z) (M+H)=427.1, Rt=0.54min.

Example 1175:6-methyl-2′-morpholino-4-oxo-N-(3-(trifluoromethyl)phenyl)-4H-[1,4′-bipyridine]-3-carboxamide

¹H NMR (400 MHz, <dmso>) δ ppm 2.15 (s, 3H) 3.51-3.54 (m, 4H) 3.65-3.73(m, 4H) 6.66 (s, 1H) 6.85-6.93 (m, 1H) 7.10 (s, 1H) 7.44 (d, J=7.83 Hz,1H) 7.58 (t, J=8.02 Hz, 1H) 7.78 (d, J=8.22 Hz, 1H) 8.23 (s, 1H) 8.31(d, J=5.09 Hz, 1H) 8.38 (s, 1H) 12.92 (s, 1H). LCMS (m/z) (M+H)=459.0,Rt=0.80 min.

The following additional compounds have been made by the methodsdescribed herein.

TABLE A

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

The activity of a compound according to the present invention can beassessed by well-known in vitro & in vivo methods. Raf inhibition dataprovided herein was obtained using the following procedures.

Example 1236. In Vitro Raf Activity Determination

The RAF enzymes and the catalytically inactive MEK1 protein substratewere all made in-house using conventional methods. CRAF cDNA wassubcloned as full length protein, with Y340E and Y341E activatingmutations, into a baculovirus expression vector for Sf9 insect cellexpression. h14-3-3 zeta cDNA was subcloned into a baculovirusexpression vector for SF9 insect cell expression. Sf9 cellsco-expressing both proteins were lysed and subjected to immobilizednickel chromatography and eluted with Imidazole. A second column(StrepII binding column) was used and eluted with desthiobiotin. ProteinTags were removed using Prescission enzyme and the protein was furtherpurified using a flowthrough step to remove tags.

C-Raf TR refers to a truncated C-Raf protein, a Δ1-324 deletion mutant.

C-Raf FL refers to the full-length C-Raf protein.

Full length MEK1 with an inactivating K97R ATP binding site mutation isutilized as a RAF substrate. The MEK1 cDNA was subcloned with anN-terminal (his)₆ tag into a vector for E. Coli expression. The MEK1substrate was purified from E. Coli lysate by nickel affinitychromatography followed by anion exchange. The final MEK1 preparationwas biotinylated (Pierce EZ-Link Sulfo-NHS-LC-Biotin) and concentrated.

Assay Materials

Assay buffer: 50 mM Tris, pH 7.5, 15 mM MgCl₂, 0.01% Bovine SerumAlbumin (BSA), 1 mM dithiothreitol (DTT)

Stop buffer: 60 mM ethylenediaminetetraacetic acid (EDTA), 0.01% Tween®20

b-Raf(V600E), active

biotinylated Mek, kinase dead

Alpha Screen detection kit (available from PerkinElmer™, #6760617R)

Anti phospho-MEK1/2 (available from Cell Signaling Technology, Inc.#9121)

384 well low volume assay plates (White Greiner® plates)

Assay Conditions

b-Raf(V600E) approximately 4 μM

c-Raf approximately 4 nM

biotinylated Mek, Kinase dead approximately 10 nM

ATP 10 μM for BRAF(V600E) and 1 uM for CRAF

Pre-incubation time with compounds 60 minutes at room temperature

Reaction time 1 or 3 hours at room temperature

Assay Protocol

Raf and biotinylated Mek, kinase dead, were combined at 2× finalconcentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl₂, 0.01%BSA and 1 mM DTT) and dispensed 5 ml per well in assay plates (Greinerwhite 384 well assay plates #781207) containing 0.25 ml of 40× of a Rafkinase inhibitor test compound diluted in 100% DMSO. The plate wasincubated for 60 minutes at room temperature.

The Raf kinase activity reaction was started by the addition of 5 mL perwell of 2×ATP diluted in assay buffer. After 3 hours (b-Raf(V600E)) or 1hour (c-Raf). The reactions were stopped and the phosphorylated productwas measured using a rabbit anti-p-MEK (Cell Signaling, #9121) antibodyand the Alpha Screen IgG (ProteinA) detection Kit (PerkinElmer#6760617R), by the addition of 10 mL to the well of a mixture of theantibody (1:2000 dilution) and detection beads (1:2000 dilution of bothbeads) in Stop/bead buffer (25 mM EDTA, 50 mM Tris, pH 7.5, 0.01%Tween20). The additions were carried out under dark conditions toprotect the detection beads from light. A lid was placed on top of theplate and incubated for 1 hour at room temperature, then theluminescence was read on a PerkinElmer Envision instrument. Theconcentration of each compound for 50% inhibition (IC₅₀) was calculatedby non-linear regression using XL Fit data analysis software.

Using the assays described above, compounds of the invention exhibitinhibitory efficacy as reported in Table 1.

TALE 1 Selected compound structures and Raf inhibition data: numberingcorresponds to the Examples above, most structures are found in theExamples. IC50's are micromolar. Ex. B-Raf C-Raf FL C-Raf TR No.Structure IC50 IC50 IC50 1 -structure and name are in the Example-0.000145 0.000144 2 -structure and name are in the Example- 0.0014160.002953 3 -structure and name are in the Example- 0.000148 4 -structureand name are in the Example- 0.000431 5 -structure and name are in theExample- 0.002996 0.000713 6 -structure and name are in the Example-0.000408 7 -structure and name are in the Example- 0.003146 0.0011830.001114 8 -structure and name are in the Example- 0.000837 0.0003890.000514 9 -structure and name are in the Example- 0.001587 0.0009490.000899 10 -structure and name are in the Example- 0.00033 0.0001030.000118 11 -structure and name are in the Example- 0.001481 0.0005420.00058 12 -structure and name are in the Example- 0.00182 0.000353 13-structure and name are in the Example- 0.002168 0.000474 0.000533 14-structure and name are in the Example- 0.002007 0.000616 0.000803 15-structure and name are in the Example- 0.002224 0.00065 16 -structureand name are in the Example- 0.001521 0.000299 17 -structure and nameare in the Example- 0.00305 0.000785 18 -structure and name are in theExample- 0.000456 0.000137 19 -structure and name are in the Example-0.001851 0.000562 20 -structure and name are in the Example- 0.0019670.000516 21 -structure and name are in the Example- 0.003433 0.000905 22-structure and name are in the Example- 0.000652 0.000202 23 -structureand name are in the Example- 0.002416 0.00086 24 -structure and name arein the Example- 0.001356 0.000328 25 -structure and name are in theExample- 0.001197 0.000352 26 -structure and name are in the Example-0.002177 0.000514 27 -structure and name are in the Example- 0.000860.00011 28 -structure and name are in the Example- 0.000585 0.000214 29-structure and name are in the Example- 0.001306 0.000421 30 -structureand name are in the Example- 0.00083 0.000322 31 -structure and name arein the Example- 0.000737 0.00021 32 -structure and name are in theExample- 0.001695 0.00051 33 -structure and name are in the Example-0.000455 0.000134 34 -structure and name are in the Example- 0.0018530.000304 35 -structure and name are in the Example- 0.003454 0.000634 36-structure and name are in the Example- 0.001277 0.000456 37 -structureand name are in the Example- 0.000773 0.000198 38 -structure and nameare in the Example- 0.001429 0.000344 39 -structure and name are in theExample- 0.000816 0.000322 40 -structure and name are in the Example-0.000601 0.000132 42 -structure and name are in the Example- 0.0004220.00009 0.000137 43 -structure and name are in the Example- 0.0016480.000388 0.000376 44 -structure and name are in the Example- 0.0028750.000637 0.000714 45 -structure and name are in the Example- 0.0056780.001392 0.001018 46 -structure and name are in the Example- 0.0021180.000433 47 -structure and name are in the Example- 0.002454 0.000356 48-structure and name are in the Example- 0.00143 0.000347 49 -structureand name are in the Example- 0.001495 0.000376 50 -structure and nameare in the Example- 0.001131 0.00025 51 -structure and name are in theExample- 0.003162 0.000661 52 -structure and name are in the Example-0.000884 0.000282 53 -structure and name are in the Example- 0.0024990.000651 54 -structure and name are in the Example- 0.00314 0.000625 55-structure and name are in the Example- 56 -structure and name are inthe Example- 0.001001 0.000191 57 -structure and name are in theExample- 0.000994 0.000179 58 -structure and name are in the Example-0.008715 0.00103 59 -structure and name are in the Example- 0.0026550.000432 60 -structure and name are in the Example- 0.006966 0.001007 61-structure and name are in the Example- 0.002273 0.000314 62 -structureand name are in the Example- 0.00108 0.000161 63 -structure and name arein the Example- 0.002553 0.000436 0.000508 64 -structure and name are inthe Example- 0.000847 65 -structure and name are in the Example-0.001142 0.000187 66 -structure and name are in the Example- 0.0030020.000711 67 -structure and name are in the Example- 0.458152 0.077922 68-structure and name are in the Example- 0.00064 0.000124 69 -structureand name are in the Example- 0.002054 0.000396 70 -structure and nameare in the Example- 0.157 0.024002 71 -structure and name are in theExample- 0.599193 0.083265 72 -structure and name are in the Example-0.639127 0.078004 73 -structure and name are in the Example- 0.0014990.00025 74 -structure and name are in the Example- 75 -structure andname are in the Example- 0.000385 0.000056 76 -structure and name are inthe Example- 0.003222 0.000765 77 -structure and name are in theExample- 0.000632 0.00013 78 -structure and name are in the Example-0.00149 0.000199 79 -structure and name are in the Example- 0.1019570.028001 80 -structure and name are in the Example- 0.030653 0.010123 81-structure and name are in the Example- 0.014017 0.001449 82 -structureand name are in the Example- 0.014469 0.001768 83 -structure and nameare in the Example- 0.002533 0.00029 84 -structure and name are in theExample- 0.002927 0.001218 85 -structure and name are in the Example-0.010918 0.001343 86 -structure and name are in the Example- 0.008430.001099 87 -structure and name are in the Example- 0.012091 0.001495 88-structure and name are in the Example- 0.037439 0.003837 89 -structureand name are in the Example- >25 7.685426 90 -structure and name are inthe Example- >25 >25 91 -structure and name are in the Example-18.594788 1.925371 92 -structure and name are in the Example- 93-structure and name are in the Example- 0.000802 0.000117 94 -structureand name are in the Example- 0.005788 0.000489 95 -structure and nameare in the Example- 0.013459 0.001829 96 -structure and name are in theExample- 0.001241 0.000182 97 -structure and name are in the Example-0.009087 0.000998 98 -structure and name are in the Example- 0.0256930.001993 99 -structure and name are in the Example- 0.00117 0.00016 100-structure and name are in the Example- 0.004089 0.000522 101 -structureand name are in the Example- 0.002183 0.000253 102 -structure and nameare in the Example- 0.028046 0.003089 103 -structure and name are in theExample- 0.018432 0.001947 104 -structure and name are in the Example-0.038535 0.005505 106 -structure and name are in the Example- 0.0017080.000359 107 -structure and name are in the Example- 0.001688 0.000363108 -structure and name are in the Example- 0.006113 0.000778 109-structure and name are in the Example- 0.005035 0.000719 110 -structureand name are in the Example- 0.002185 0.000332 111 -structure and nameare in the Example- 0.000403 112 -structure and name are in the Example-0.002384 0.0005 113 -structure and name are in the Example- 0.0011370.000465 114 -structure and name are in the Example- 0.001626 0.000285115 -structure and name are in the Example- 0.012797 0.000872 116-structure and name are in the Example- 0.010923 0.000735 117 -structureand name are in the Example- 0.002035 0.000265 118 -structure and nameare in the Example- 0.001003 0.000156 0.000308 119 -structure and nameare in the Example- 0.00027 120 -structure and name are in the Example-0.001214 0.000187 121 -structure and name are in the Example- 0.0044510.000599 122 -structure and name are in the Example- 0.003877 0.000606123 -structure and name are in the Example- 0.023164 0.004813 124-structure and name are in the Example- 0.082672 0.017977 125 -structureand name are in the Example- 0.022327 0.006383 126 -structure and nameare in the Example- 0.00107 0.000299 127 -structure and name are in theExample- 0.001667 0.00031 128 -structure and name are in the Example-0.003782 0.000873 129 -structure and name are in the Example- 0.0134410.002331 130 -structure and name are in the Example- 0.00577 0.001005131 -structure and name are in the Example- 0.000483 0.000119 132-structure and name are in the Example- 0.002708 0.000457 133 -structureand name are in the Example- 0.028875 0.001937 134 -structure and nameare in the Example- 0.00364 0.000471 135 -structure and name are in theExample- 0.003957 0.000322 136 -structure and name are in the Example-0.004173 0.000503 137 -structure and name are in the Example- 0.0037920.000527 138 -structure and name are in the Example- 0.003112 0.000652139 -structure and name are in the Example- 0.002454 0.000491 140-structure and name are in the Example- 0.0025 0.000483 141 -structureand name are in the Example- 0.034633 0.005762 142 -structure and nameare in the Example- 0.00223 0.000341 143 -structure and name are in theExample- 0.00998 0.002261 144 -structure and name are in the Example-0.013851 0.002686 145 -structure and name are in the Example- 0.0037860.000676 146 -structure and name are in the Example- 0.001918 0.000219147 -structure and name are in the Example- 0.000756 0.000103 148-structure and name are in the Example- 0.001889 0.000285 149 -structureand name are in the Example- 0.002181 0.000273 150 -structure and nameare in the Example- 0.003933 0.000562 151 -structure and name are in theExample- 0.019733 0.002897 152 -structure and name are in the Example-0.003295 0.000474 153 -structure and name are in the Example- 0.0010230.000196 154 -structure and name are in the Example- 0.007186 0.001095155 -structure and name are in the Example- 0.003831 0.000361 156-structure and name are in the Example- 0.002484 0.000415 157 -structureand name are in the Example- 0.015761 0.002134 158 -structure and nameare in the Example- 0.008383 0.000835 159 -structure and name are in theExample- 0.002618 0.000366 160 -structure and name are in the Example-0.009738 0.00089 161 -structure and name are in the Example- 0.0026480.000393 162 -structure and name are in the Example- 0.001835 0.000215163 -structure and name are in the Example- 0.00769 0.000818 164-structure and name are in the Example- 0.001575 0.000255 165 -structureand name are in the Example- 0.003127 0.000416 166 -structure and nameare in the Example- 0.006933 0.000665 167 -structure and name are in theExample- 0.106629 0.007674 168 -structure and name are in the Example-0.003139 0.000245 169 -structure and name are in the Example- 0.0007750.00018 170 -structure and name are in the Example- 0.001278 0.000263171 -structure and name are in the Example- 0.001254 0.000213 172-structure and name are in the Example- 0.002908 0.000386 173 -structureand name are in the Example- 0.0118 0.000853 174 -structure and name arein the Example- 0.010049 0.002238 175 -structure and name are in theExample- 0.001542 0.00023 176 -structure and name are in the Example-0.002474 0.000398 177 -structure and name are in the Example- 0.0007060.000122 178 -structure and name are in the Example- 0.000862 0.000172179 -structure and name are in the Example- 0.000905 0.00016 181-structure and name are in the Example- 0.002664 0.000493 182 -structureand name are in the Example- 0.021222 0.002263 184 -structure and nameare in the Example- 0.002202 0.000479 185 -structure and name are in theExample- 0.001819 0.000269 186 -structure and name are in the Example-0.002242 0.000278 189 -structure and name are in the Example- 0.0047350.000678 191 -structure and name are in the Example- 0.009525 0.001426192 -structure and name are in the Example- 0.033857 0.002507 193-structure and name are in the Example- 0.105813 0.011051 194 -structureand name are in the Example- 0.012407 0.002225 196 -structure and nameare in the Example- 0.002191 0.000403 0.000621 197 -structure and nameare in the Example- 0.006733 0.001062 198 -structure and name are in theExample- 0.000455 199 -structure and name are in the Example- 0.001292200

0.001538 0.000205 201

0.014467 0.001991 202

0.000941 0.000155 203

0.000389 0.000065 204

0.000152 0.000039 205

0.001286 0.000185 206

0.009218 0.001619 207

0.001399 0.000225 208

0.005048 0.001099 209

0.001067 0.000171 210

0.022094 0.002729 211

0.006261 0.000873 212

214

0.00483 0.000547 215

0.007267 0.000785 216

217

218

219

0.002834 0.000362 220

Additional in vitro Raf inhibition data is provided in the followingTable for compounds shown in the synthesis Examples above—compound namesand structures are in the Examples. Some of the compounds in thepreceding table are also included here, and the associated data in thefollowing table may be from a different repetition of the correspondingassay.

TABLE 2 Cmpd b-Raf IC-50 (μM) c-Raf FL IC-50 (μM) Example 1 0.000300.00010 Example 2 0.00480 0.00180 Example 3 0.00050 0.00010 Example 40.00130 0.00040 Example 5 0.00300 0.00070 Example 6 0.00130 0.00040Example 7 0.00250 0.00110 Example 8 0.00090 0.00050 Example 9 0.001500.00090 Example 10 0.00030 0.00050 Example 11 0.00150 0.00060 Example 120.00180 0.00040 Example 13 0.00220 0.00050 Example 14 0.00200 0.00070Example 15 0.00220 0.00060 Example 16 0.00150 0.00030 Example 17 0.003100.00080 Example 18 0.00050 0.00010 Example 19 0.00190 0.00060 Example 200.00200 0.00050 Example 21 0.00400 0.00090 Example 22 0.00070 0.00020Example 23 0.00240 0.00060 Example 24 0.00140 0.00030 Example 25 0.001200.00040 Example 26 0.00220 0.00050 Example 27 0.00090 0.00010 Example 280.00060 0.00020 Example 29 0.00130 0.00040 Example 30 0.00080 0.00030Example 31 0.00070 0.00020 Example 32 0.00170 0.00050 Example 33 0.000500.00010 Example 34 0.00190 0.00030 Example 35 0.00350 0.00060 Example 360.00130 0.00050 Example 37 0.00080 0.00020 Example 38 0.00140 0.00030Example 39 0.00080 0.00030 Example 40 0.00080 0.00020 Example 42 0.001600.00040 Example 43 0.00050 0.00010 Example 44 0.00290 0.00070 Example 450.00570 0.00120 Example 46 0.00210 0.00040 Example 47 0.00250 0.00040Example 48 0.00140 0.00030 Example 49 0.00150 0.00040 Example 50 0.001100.00030 Example 51 0.00320 0.00070 Example 52 0.00090 0.00030 Example 530.00250 0.00070 Example 54 0.00310 0.00060 Example 55 0.00150 0.00040Example 56 0.00100 0.00020 Example 57 0.00100 0.00020 Example 58 0.008900.00110 Example 59 0.00280 0.00040 Example 60 0.00730 0.00100 Example 610.00230 0.00030 Example 62 0.00110 0.00020 Example 63 0.00210 0.00050Example 64 0.00090 0.00080 Example 65 0.00110 0.00020 Example 66 0.003000.00070 Example 67 0.50000 0.07790 Example 68 0.00060 0.00010 Example 690.00210 0.00040 Example 70 0.20000 0.02400 Example 71 0.60000 0.08330Example 72 0.60000 0.07800 Example 73 0.00190 0.00030 Example 74 0.002800.00040 Example 75 0.00040 0.00006 Example 76 0.00320 0.00080 Example 770.00060 0.00010 Example 78 0.00150 0.00020 Example 79 0.10000 0.02800Example 80 0.03070 0.01010 Example 81 0.01400 0.00140 Example 82 0.014500.00180 Example 83 0.00250 0.00030 Example 84 0.00290 0.00120 Example 850.01090 0.00130 Example 86 0.00840 0.00110 Example 87 0.01270 0.00150Example 88 0.03740 0.00380 Example 89 25.00034 7.70000 Example 9025.00034 25.00034 Example 91 18.60000 1.90000 Example 92 0.00060 0.00060Example 93 0.00080 0.00030 Example 94 0.00580 0.00050 Example 95 0.013500.00180 Example 96 0.00120 0.00020 Example 97 0.00910 0.00100 Example 980.02570 0.00200 Example 99 0.00120 0.00020 Example 100 0.00410 0.00050Example 101 0.00220 0.00030 Example 102 0.02800 0.00310 Example 1030.01840 0.00190 Example 104 0.03850 0.00550 Example 106 0.00170 0.00040Example 107 0.00170 0.00040 Example 108 0.00610 0.00080 Example 1090.00500 0.00070 Example 110 0.00220 0.00030 Example 111 0.00050 0.00040Example 112 0.00240 0.00050 Example 113 0.00110 0.00050 Example 1140.00160 0.00030 Example 115 0.01280 0.00090 Example 116 0.01090 0.00070Example 117 0.00230 0.00040 Example 118 0.00070 0.00020 Example 1190.00040 0.00030 Example 120 0.00120 0.00020 Example 121 0.00450 0.00060Example 122 0.00390 0.00060 Example 123 0.02320 0.00480 Example 1240.08270 0.01800 Example 125 0.02230 0.00640 Example 126 0.00110 0.00030Example 127 0.00190 0.00040 Example 128 0.00380 0.00090 Example 1290.01490 0.00360 Example 130 0.00580 0.00100 Example 131 0.00180 0.00050Example 132 0.00270 0.00050 Example 133 0.02890 0.00190 Example 1340.00240 0.00070 Example 135 0.00400 0.00030 Example 136 0.00420 0.00050Example 137 0.00710 0.00070 Example 138 0.00470 0.00080 Example 1390.00250 0.00050 Example 140 0.00250 0.00050 Example 141 0.04750 0.01020Example 142 0.00220 0.00030 Example 143 0.01000 0.00230 Example 1440.01390 0.00270 Example 145 0.00300 0.00060 Example 146 0.00190 0.00020Example 147 0.00100 0.00010 Example 148 0.00190 0.00030 Example 1490.00220 0.00030 Example 150 0.00400 0.00060 Example 151 0.02000 0.00290Example 152 0.00330 0.00050 Example 153 0.00100 0.00020 Example 1540.00730 0.00110 Example 155 0.00390 0.00040 Example 156 0.00250 0.00040Example 157 0.01580 0.00210 Example 158 0.00840 0.00080 Example 1590.00260 0.00040 Example 160 0.01060 0.00090 Example 161 0.00290 0.00040Example 162 0.00180 0.00020 Example 163 0.00570 0.00070 Example 1640.00170 0.00030 Example 165 0.00310 0.00040 Example 166 0.00690 0.00070Example 167 0.05340 0.00790 Example 168 0.00310 0.00020 Example 1690.00080 0.00020 Example 170 0.00130 0.00030 Example 171 0.00130 0.00020Example 172 0.00290 0.00040 Example 173 0.00920 0.00180 Example 1740.00690 0.00150 Example 175 0.00150 0.00020 Example 176 0.00250 0.00040Example 177 0.00070 0.00010 Example 178 0.00090 0.00020 Example 1790.00090 0.00020 Example 181 0.00270 0.00050 Example 182 0.02120 0.00230Example 184 0.00310 0.00080 Example 185 0.00180 0.00030 Example 1890.00470 0.00070 Example 190 0.00220 0.00030 Example 191 0.00540 0.00110Example 192 0.03390 0.00250 Example 193 0.10000 0.01120 Example 1940.01320 0.00220 Example 196 0.00150 0.00050 Example 197 0.00670 0.00110Example 198 0.00080 0.00050 Example 199 0.00360 0.00130 Example 2150.00730 0.00080 Example 222 0.00380 0.00040 Example 223 0.00220 0.00090Example 224 0.00270 0.00090 Example 225 0.01230 0.00390 Example 2260.00190 0.00070 Example 227 0.00180 0.00040 Example 228 0.00470 0.00110Example 229 0.00070 0.00030 Example 230 0.00140 0.00040 Example 2310.00040 0.00010 Example 232 0.00080 0.00030 Example 233 0.00060 0.00020Example 234 0.00100 0.00050 Example 235 0.00100 0.00030 Example 2360.00160 0.00060 Example 237 0.00040 0.00020 Example 238 0.00090 0.00040Example 239 0.00560 0.00210 Example 240 0.01530 0.00510 Example 2410.00570 0.00200 Example 242 0.00390 0.00180 Example 243 0.00530 0.00270Example 244 0.00760 0.00360 Example 245 0.00130 0.00060 Example 2460.00120 0.00060 Example 247 0.00110 0.00060 Example 248 0.00120 0.00040Example 249 0.03650 0.00360 Example 250 0.00310 0.00080 Example 2510.00310 0.00050 Example 252 0.00310 0.00080 Example 253 0.00260 0.00070Example 254 0.00180 0.00050 Example 255 0.00560 0.00200 Example 2560.00180 0.00040 Example 257 0.01000 0.00350 Example 258 0.00830 0.00220Example 259 0.00310 0.00150 Example 260 0.00290 0.00080 Example 2610.00180 0.00050 Example 262 0.00340 0.00100 Example 263 0.00900 0.00330Example 264 0.00860 0.00240 Example 265 0.00450 0.00110 Example 2660.00190 0.00050 Example 267 0.00110 0.00030 Example 268 0.00160 0.00060Example 269 0.00240 0.00090 Example 270 0.00050 0.00020 Example 2710.00070 0.00030 Example 272 0.00630 0.00270 Example 273 0.00270 0.00110Example 274 0.00080 0.00040 Example 275 0.00050 0.00020 Example 2760.00040 0.00020 Example 277 0.00100 0.00050 Example 278 0.00840 0.00240Example 279 3.20000 0.80000 Example 280 0.00110 0.00040 Example 2810.00630 0.00160 Example 282 0.05300 0.01780 Example 283 0.00600 0.00120Example 284 0.00110 0.00040 Example 285 0.20000 0.05190 Example 2860.20000 0.05190 Example 287 0.01650 0.00400 Example 288 0.00600 0.00120Example 289 0.01560 0.00380 Example 290 0.00600 0.00140 Example 2910.00230 0.00040 Example 292 0.00380 0.00140 Example 293 0.03230 0.00660Example 294 0.01080 0.00270 Example 295 0.00360 0.00060 Example 2960.02470 0.00490 Example 297 0.01880 0.00360 Example 298 0.00390 0.00190Example 299 0.00690 0.00270 Example 300 0.01460 0.00470 Example 3010.00320 0.00090 Example 302 0.00060 0.00020 Example 303 0.10000 0.01440Example 304 0.00090 0.00030 Example 306 0.00110 0.00060 Example 3070.00060 0.00010 Example 308 0.00080 0.00020 Example 309 0.00920 0.00460Example 310 0.00180 0.00070 Example 311 0.00240 0.00090 Example 3120.00400 0.00110 Example 313 0.00700 0.00170 Example 314 0.00600 0.00160Example 315 0.00080 0.00030 Example 316 0.00310 0.00080 Example 3170.00160 0.00050 Example 318 0.00330 0.00080 Example 319 0.00120 0.00040Example 320 0.00170 0.00040 Example 321 0.02480 0.00850 Example 3220.00110 0.00050 Example 323 0.01290 0.00280 Example 324 0.00740 0.00140Example 325 0.30000 0.06230 Example 326 0.00370 0.00110 Example 3270.00390 0.00100 Example 328 0.06240 0.01730 Example 329 1.10000 0.30000Example 330 2.40000 1.30000 Example 331 0.00390 0.00040 Example 3320.02320 0.00750 Example 333 0.01140 0.00150 Example 334 0.00230 0.00070Example 335 0.00440 0.00200 Example 336 0.00550 0.00130 Example 3370.01250 0.00610 Example 338 9.00000 6.40000 Example 339 0.00180 0.00070Example 340 0.03640 0.00840 Example 341 0.00200 0.00050 Example 3440.00310 0.00050 Example 345 0.00160 0.00030 Example 346 0.00870 0.00160Example 347 0.01870 0.00330 Example 348 0.00270 0.00080 Example 3490.00620 0.00130 Example 350 0.00350 0.00040 Example 351 0.01950 0.00380Example 352 0.00220 0.00040 Example 353 0.00120 0.00020 Example 3540.00100 0.00020 Example 355 0.00250 0.00060 Example 356 0.00390 0.00080Example 357 0.00340 0.00080 Example 358 0.00730 0.00080 Example 3590.00550 0.00040 Example 360 0.00600 0.00130 Example 361 0.00280 0.00040Example 362 0.00290 0.00040 Example 363 0.00380 0.00080 Example 3640.00210 0.00050 Example 365 0.08590 0.01330 Example 366 0.10000 0.01670Example 367 0.01260 0.00300 Example 368 0.01220 0.00250 Example 3690.05310 0.01270 Example 371 0.00080 0.00020 Example 372 0.00070 0.00020Example 373 1.10000 0.20000 Example 374 3.40000 0.60000 Example 3750.20000 0.04340 Example 376 2.80000 0.70000 Example 377 0.20000 0.06190Example 379 0.00590 0.00140 Example 380 0.01250 0.00260 Example 3810.10000 0.02550 Example 382 0.90000 0.30000 Example 383 2.80000 0.20000Example 384 2.80000 0.20000 Example 389 0.06420 0.01410 Example 3900.00540 0.00140 Example 391 0.01230 0.00450 Example 392 0.01530 0.00390Example 393 0.00460 0.00130 Example 394 0.00360 0.00100 Example 3950.00980 0.00220 Example 396 0.01080 0.00500 Example 397 0.01000 0.00340Example 398 0.00840 0.00310 Example 399 0.04270 0.01480 Example 4000.03510 0.00330 Example 401 0.10000 0.01150 Example 402 0.10000 0.01230Example 403 0.06200 0.01020 Example 404 0.00430 0.00120 Example 4050.00450 0.00130 Example 406 0.00130 0.00040 Example 407 0.00140 0.00050Example 408 0.00680 0.00260 Example 409 0.00170 0.00030 Example 4100.00200 0.00040 Example 411 3.10000 4.70000 Example 412 0.00080 0.00020Example 413 0.00040 0.00009 Example 414 0.00140 0.00030 Example 41510.10000 6.20000 Example 416 1.10000 0.20000 Example 417 0.00310 0.00060Example 418 0.00350 0.00090 Example 419 0.00430 0.00120 Example 4203.60000 5.50000 Example 421 0.00100 0.00020 Example 422 0.00370 0.00090Example 423 0.00600 0.00190 Example 424 0.05040 0.01430 Example 4250.00260 0.00040 Example 426 0.00240 0.00070 Example 427 0.00600 0.00120Example 428 0.01010 0.00330 Example 429 0.03370 0.00670 Example 4300.00160 0.00060 Example 431 0.00370 0.00110 Example 432 0.09900 0.02320Example 433 0.20000 0.05580 Example 435 0.00240 0.00070 Example 4360.00380 0.00090 Example 437 0.01540 0.00490 Example 438 0.02760 0.00570Example 439 0.00630 0.00270 Example 440 0.09390 0.02250 Example 4410.03320 0.00930 Example 442 0.06870 0.02020 Example 443 0.00620 0.00170Example 444 0.04480 0.01460 Example 445 0.01200 0.00570 Example 4460.10000 0.02910 Example 451 0.08370 0.01410 Example 452 0.00230 0.00050Example 453 0.00430 0.00110 Example 454 0.00190 0.00050 Example 4550.00280 0.00070 Example 456 0.00330 0.00080 Example 457 0.03050 0.00630Example 460 0.01590 0.00310 Example 461 0.01100 0.00210 Example 4620.00370 0.00070 Example 464 0.01680 0.00210 Example 465 0.10000 0.01500Example 466 0.00550 0.00140 Example 467 0.01210 0.00240 Example 4690.00310 0.00060 Example 470 0.00450 0.00100 Example 471 0.00100 0.00020Example 472 0.00210 0.00050 Example 473 0.01210 0.00370 Example 4740.00220 0.00060 Example 475 0.00080 0.00010 Example 476 0.00060 0.00010Example 477 0.00040 0.00020 Example 478 0.00250 0.00040 Example 4790.00180 0.00030 Example 480 0.00060 0.00010 Example 481 0.00120 0.00030Example 482 0.00060 0.00020 Example 483 0.00350 0.00090 Example 4840.00040 0.00010 Example 485 0.00110 0.00040 Example 486 0.00110 0.00030Example 487 0.00280 0.00080 Example 488 0.00190 0.00040 Example 4890.00240 0.00080 Example 490 0.00250 0.00040 Example 491 0.00210 0.00040Example 492 0.00300 0.00050 Example 493 0.00410 0.00080 Example 4940.01680 0.00370 Example 495 0.00450 0.00100 Example 496 0.00090 0.00020Example 497 0.00280 0.00050 Example 498 0.00570 0.00070 Example 4990.02190 0.00350 Example 500 0.00560 0.00130 Example 501 0.03220 0.00830Example 502 0.02000 0.00540 Example 503 0.20000 0.06250 Example 5040.02100 0.00530 Example 505 0.00580 0.00140 Example 506 0.00180 0.00040Example 507 0.02060 0.00420 Example 508 0.00780 0.00270 Example 5090.01730 0.00380 Example 510 0.00750 0.00140 Example 511 0.00640 0.00130Example 512 0.05980 0.01560 Example 513 0.00240 0.00070 Example 5140.00110 0.00040 Example 515 0.00450 0.00110 Example 516 0.01770 0.00650Example 517 0.00120 0.00040 Example 518 0.07900 0.03710 Example 5190.00060 0.00010 Example 520 0.00210 0.00050 Example 521 Example 5220.00250 0.00060 Example 523 0.00370 0.00080 Example 524 0.04120 0.01360Example 525 0.00380 0.00070 Example 526 0.04970 0.00940 Example 5270.00560 0.00100 Example 528 0.01520 0.00400 Example 529 0.07610 0.02620Example 530 0.05130 0.01650 Example 531 0.00500 0.00080 Example 5320.00770 0.00120 Example 533 0.00440 0.00060 Example 534 0.00600 0.00110Example 535 0.04550 0.00410 Example 536 Example 537 0.00440 0.00060Example 538 0.00120 0.00030 Example 539 0.00280 0.00080 Example 5400.01260 0.00220 Example 541 0.00550 0.00090 Example 542 0.00770 0.00170Example 543 0.01690 0.00310 Example 544 0.00640 0.00130 Example 5400.01250 0.00210 Example 541 0.00290 0.00070 Example 542 0.00360 0.00070Example 543 0.00740 0.00130 Example 544 0.00310 0.00050 Example 5450.01650 0.00390 Example 546 0.00500 0.00080 Example 547 0.00100 0.00030Example 548 0.00110 0.00030 Example 549 0.00210 0.00050 Example 5500.00120 0.00040 Example 551 0.00120 0.00050 Example 552 0.00300 0.00080Example 553 0.00120 0.00040 Example 554 0.00120 0.00050 Example 5550.00300 0.00080 Example 556 0.00390 0.00150 Example 557 0.00540 0.00220Example 558 0.00210 0.00070 Example 559 0.00090 0.00030 Example 5600.00100 0.00030 Example 561 0.00030 0.00010 Example 562 0.00060 0.00020Example 563 0.00060 0.00020 Example 564 0.00130 0.00040 Example 5650.00130 0.00040 Example 566 0.00070 0.00020 Example 567 0.00200 0.00080Example 568 0.00070 0.00020 Example 569 0.00280 0.00080 Example 5700.00080 0.00030 Example 571 0.00250 0.00080 Example 572 0.00380 0.00100Example 573 0.00080 0.00020 Example 574 0.00220 0.00080 Example 5750.00290 0.00090 Example 576 0.00350 0.00110 Example 577 0.00060 0.00020Example 578 0.00080 0.00020 Example 579 0.00060 0.00020 Example 5800.00050 0.00010 Example 581 0.00220 0.00070 Example 582 0.00080 0.00020Example 583 0.00130 0.00030 Example 584 0.00120 0.00030 Example 5850.00140 0.00040 Example 586 0.00100 0.00020 Example 587 0.00110 0.00030Example 588 0.00220 0.00070 Example 589 0.00150 0.00040 Example 5900.00090 0.00020 Example 591 0.00210 0.00060 Example 592 0.00070 0.00020Example 593 0.00060 0.00020 Example 594 0.00080 0.00020 Example 5950.00060 0.00020 Example 596 0.00130 0.00030 Example 597 0.00050 0.00020Example 598 0.00110 0.00050 Example 599 0.00050 0.00020 Example 6000.00080 0.00030 Example 601 0.00110 0.00030 Example 602 0.00120 0.00030Example 603 0.00270 0.00090 Example 604 0.00230 0.00060 Example 6050.00270 0.00100 Example 606 0.00350 0.00130 Example 607 0.00470 0.00150Example 608 0.00490 0.00200 Example 609 0.00090 0.00030 Example 6100.00450 0.00150 Example 611 0.00130 0.00050 Example 612 0.00180 0.00070Example 613 0.01000 0.00360 Example 614 0.00420 0.00290 Example 6150.01230 0.00860 Example 616 0.00160 0.00040 Example 617 0.00350 0.00100Example 618 0.00500 0.00440 Example 619 0.00160 0.00050 Example 6200.00190 0.00050 Example 621 0.00260 0.00070 Example 622 0.00490 0.00120Example 623 0.05670 0.00930 Example 624 0.00470 0.00150 Example 6250.07680 0.01260 Example 626 0.01400 0.00380 Example 627 0.00370 0.00110Example 628 0.00180 0.00040 Example 629 0.00120 0.00040 Example 6300.00290 0.00080 Example 631 0.00270 0.00080 Example 632 0.00750 0.00180Example 633 0.00720 0.00220 Example 634 0.01710 0.00360 Example 6350.01880 0.00660 Example 636 0.00130 0.00040 Example 637 0.02490 0.00550Example 638 0.00960 0.00210 Example 639 0.00730 0.00140 Example 6400.00540 0.00110 Example 641 0.00270 0.00070 Example 642 0.00140 0.00040Example 643 0.00130 0.00030 Example 644 0.00290 0.00090 Example 6450.05340 0.00790 Example 646 0.00840 0.00310 Example 647 0.00530 0.00150Example 648 0.00450 0.00120 Example 649 0.00460 0.00120 Example 6500.00470 0.00070 Example 651 0.00690 0.00070 Example 652 0.00670 0.00050Example 653 0.00310 0.00040 Example 654 0.00170 0.00040 Example 6550.00220 0.00030 Example 656 0.00100 0.00030 Example 657 0.00110 0.00030Example 658 0.00310 0.00020 Example 659 0.00070 0.00010 Example 660Example 661 0.00430 0.00090 Example 662 0.00390 0.00130 Example 6630.00920 0.00210 Example 664 0.00290 0.00060 Example 665 0.00670 0.00210Example 666 0.00780 0.00240 Example 667 0.00340 0.00110 Example 6680.00410 0.00120 Example 669 0.01000 0.00250 Example 670 0.00280 0.00090Example 671 0.02550 0.00680 Example 672 0.01580 0.00350 Example 6730.00630 0.00270 Example 674 0.00370 0.00100 Example 675 0.00490 0.00140Example 676 0.00240 0.00070 Example 677 0.01270 0.00460 Example 6780.00640 0.00210 Example 679 0.00810 0.00270 Example 680 0.01460 0.00400Example 681 0.00310 0.00100 Example 682 0.00690 0.00220 Example 6830.01120 0.00300 Example 684 0.00290 0.00030 Example 685 0.02140 0.00190Example 686 0.00170 0.00020 Example 687 0.00080 0.00020 Example 6910.02380 0.00320 Example 694 0.00100 0.00040 Example 695 0.00400 0.00160Example 696 0.00240 0.00100 Example 697 0.00100 0.00040 Example 6980.00070 0.00020 Example 699 0.00170 0.00070 Example 700 0.00120 0.00040Example 701 0.00130 0.00030 Example 702 0.00300 0.00130 Example 7030.00130 0.00040 Example 704 0.00002 0.00008 Example 705 0.00410 0.00140Example 706 0.00080 0.00030 Example 707 0.00190 0.00070 Example 7080.00050 0.00010 Example 709 0.00340 0.00130 Example 710 0.00400 0.00160Example 711 0.00560 0.00260 Example 712 0.01210 0.00640 Example 7130.00250 0.00140 Example 714 0.00250 0.00090 Example 716 0.00130 0.00060Example 717 0.00290 0.00080 Example 718 0.00840 0.00230 Example 7190.00200 0.00050 Example 720 0.02320 0.00490 Example 721 0.00330 0.00090Example 722 0.00160 0.00040 Example 723 0.03480 0.00680 Example 7240.02050 0.00480 Example 725 0.00420 0.00120 Example 726 0.00900 0.00220Example 727 0.00850 0.00270 Example 728 0.00440 0.00080 Example 7290.01770 0.00290 Example 730 0.02720 0.00750 Example 731 0.00440 0.00150Example 732 0.00220 0.00060 Example 733 0.00080 0.00030 Example 7340.00690 0.00180 Example 735 0.00430 0.00050 Example 736 0.04780 0.00730Example 737 0.01790 0.00540 Example 738 0.03320 0.01070 Example 7390.00410 0.00140 Example 740 0.00210 0.00030 Example 741 0.00510 0.00120Example 742 0.03860 0.00460 Example 743 0.00370 0.00080 Example 7440.04270 0.00620 Example 745 0.00360 0.00070 Example 746 0.00460 0.00120Example 747 0.01900 0.00300 Example 748 0.00190 0.00040 Example 7490.00190 0.00050 Example 750 0.02240 0.00380 Example 751 0.00140 0.00040Example 752 0.00180 0.00040 Example 753 0.03090 0.00670 Example 7540.00340 0.00100 Example 755 0.01780 0.00720 Example 756 0.00420 0.00150Example 757 0.00140 0.00040 Example 758 0.00280 0.00120 Example 7590.01150 0.00470 Example 760 0.01130 0.00330 Example 761 0.00090 0.00020Example 762 0.00070 0.00020 Example 763 0.00110 0.00020 Example 7640.00340 0.00080 Example 765 0.00100 0.00020 Example 766 0.00180 0.00050Example 767 0.04740 0.01210 Example 768 0.01110 0.00280 Example 7690.01020 8.00000 Example 770 0.00530 0.00130 Example 771 0.00250 0.00080Example 772 0.00190 0.00060 Example 773 0.00170 0.00040 Example 774Example 775 0.02000 0.00460 Example 776 25.00034 10.60000 Example 7770.00020 0.00008 Example 778 0.00230 0.00090 Example 779 0.00220 0.00070Example 780 0.00210 0.00080 Example 781 0.01080 0.00270 Example 7820.02230 0.00650 Example 783 0.00630 0.00210 Example 784 0.20000 0.05100Example 785 0.00750 0.00310 Example 786 0.01490 0.00340 Example 7870.00550 0.00170 Example 788 0.20000 0.03800 Example 789 Example 7900.00350 0.00130 Example 791 0.01140 0.00260 Example 792 0.00170 0.00030Example 793 0.00130 0.00030 Example 794 0.00260 0.00080 Example 7950.00180 0.00090 Example 796 0.00070 0.00020 Example 797 0.02470 0.00790Example 798 0.00110 0.00050 Example 799 0.00150 0.00040 Example 8000.00200 0.00080 Example 801 0.00300 0.00090 Example 802 0.00310 0.00100Example 803 0.00190 0.00090 Example 804 0.00080 0.00030 Example 8050.00040 0.00020 Example 806 0.00110 0.00060 Example 807 0.00880 0.00280Example 810 0.00140 0.00030 Example 811 0.00630 0.00090 Example 8130.00270 0.00030 Example 814 0.03210 0.00310 Example 815 0.10000 0.00900Example 816 0.01740 0.00160 Example 817 0.20000 0.01320 Example 8180.01840 0.00110 Example 820 0.00140 0.00010 Example 821 0.00380 0.00040Example 822 0.00770 0.00070 Example 823 0.00940 0.00090 Example 8240.00040 0.00007 Example 825 0.00130 0.00020 Example 826 0.00500 0.00110Example 827 0.00140 0.00020 Example 828 0.00100 0.00020 Example 8290.00020 0.00004 Example 830 0.00060 0.00010 Example 831 0.00150 0.00020Example 832 1.40000 0.20000 Example 833 0.00170 0.00020 Example 8340.00060 0.00020 Example 835 0.00210 0.00060 Example 836 0.00310 0.00040Example 837 0.00020 0.00010 Example 838 0.00090 0.00030 Example 8390.00090 0.00030 Example 840 0.00060 0.00020 Example 841 0.00170 0.00040Example 842 0.00130 0.00030 Example 843 0.00080 0.00020 Example 8440.00170 0.00020 Example 845 0.00090 0.00030 Example 846 0.00060 0.00020Example 847 0.00020 0.00004 Example 848 0.00040 0.00010 Example 8490.00380 0.00090 Example 850 0.00060 0.00020 Example 851 0.00090 0.00030Example 852 0.00070 0.00020 Example 853 0.00240 0.00070 Example 8540.00080 0.00010 Example 855 0.00230 0.00040 Example 856 0.00550 0.00100Example 857 0.00040 0.00008 Example 858 0.02210 0.00270 Example 8600.01160 0.00070 Example 861 0.00250 0.00060 Example 862 0.00090 0.00030Example 863 0.00280 0.00060 Example 864 0.07020 0.02400 Example 8653.70000 7.90000 Example 866 0.00760 0.00200 Example 867 0.00140 0.00020Example 868 0.00130 0.00030 Example 869 0.00130 0.00020 Example 8700.00750 0.00150 Example 871 0.00060 0.00010 Example 873 0.00280 0.00050Example 874 0.01970 0.00340 Example 875 0.00660 0.00160 Example 8760.00240 0.00040 Example 877 0.00650 0.00140 Example 878 0.10000 0.01960Example 879 0.00610 0.00120 Example 880 0.00320 0.00060 Example 8810.03260 0.00570 Example 882 0.00810 0.00150 Example 883 0.00170 0.00040Example 884 0.01970 0.00340 Example 885 0.01230 0.00270 Example 8860.00760 0.00060 Example 887 1.30000 0.10000 Example 888 0.00160 0.00040Example 889 0.00330 0.00060 Example 899 0.00187 0.00048 Example 9000.00317 0.00078 Example 901 0.00085 0.00021 Example 902 0.00337 0.00070Example 903 0.00364 0.00082 Example 904 0.00201 0.00047 Example 9050.00233 0.00058 Example 906 0.00945 0.00238 Example 907 0.00443 0.00094Example 908 0.00688 0.00253 Example 909 0.00156 0.00032 Example 9100.00509 0.00102 Example 911 0.00358 0.00120 Example 912 0.00225 0.00065Example 913 0.00216 0.00069 Example 914 0.00195 0.00070 Example 9150.00111 0.00045 Example 916 0.00131 0.00039 Example 917 0.00080 0.00091Example 918 0.00117 0.00037 Example 919 0.00411 0.00088 Example 9200.00885 0.00199 Example 921 0.00773 0.00182 Example 923 0.00546 0.00107Example 924 0.05773 0.01099 Example 925 0.01218 0.00223 Example 9260.00213 0.00047 Example 927 0.00791 0.00353 Example 928 0.00190 0.00055Example 929 0.00105 0.00033 Example 930 0.00103 0.00031 Example 9310.00270 0.00077 Example 932 0.00689 0.00183 Example 933 0.00078 0.00022Example 934 0.00420 0.00120 Example 935 0.00204 0.00058 Example 9360.00755 0.00169 Example 937 0.00453 0.00197 Example 938 0.00236 0.00077Example 939 0.01532 0.00684 Example 940 0.00481 0.00133 Example 9410.00228 0.00067 Example 942 0.00217 0.00059 Example 943 0.00951 0.00269Example 944 0.00389 0.00153 Example 945 0.00135 0.00053 Example 9460.00236 0.00096 Example 947 0.00176 0.00061 Example 948 0.00233 0.00064Example 949 0.00363 0.00138 Example 950 0.00047 0.00021 Example 9510.00031 0.00011 Example 952 0.00198 0.00071 Example 953 0.00333 0.00136Example 954 0.00730 0.00243 Example 955 0.01815 0.00801 Example 9560.00294 0.00116 Example 957 0.00623 0.00241 Example 958 0.00915 0.00345Example 959 0.01940 0.00629 Example 960 0.00266 0.00118 Example 9610.00183 0.00070 Example 962 0.01543 0.00392 Example 963 0.00288 0.00104Example 964 0.00813 0.00317 Example 965 0.00187 0.00071 Example 9660.00135 0.00052 Example 967 0.00574 0.00215 Example 968 0.00372 0.00098Example 969 0.01803 0.00498 Example 970 0.00879 0.00234 Example 9710.00827 0.00255 Example 972 0.03704 0.01184 Example 973 0.01575 0.00560Example 974 0.00278 0.00095 Example 975 0.00181 0.00078 Example 976Example 977 0.00421 0.00177 Example 978 0.00186 0.00074 Example 9790.01358 0.00624 Example 980 0.00199 0.00078 Example 981 0.00765 0.00317Example 982 0.00244 0.00110 Example 983 0.00299 0.00143 Example 9840.00228 0.00051 Example 985 0.00201 0.00060 Example 986 0.00083 0.00028Example 987 0.00263 0.00080 Example 988 0.00583 0.00097 Example 9890.00196 0.00056 Example 990 0.00541 0.00200 Example 991 0.00236 0.00076Example 992 0.00163 0.00097 Example 993 0.00966 0.00249 Example 9940.00193 0.00066 Example 997 0.00200 0.00044 Example 998 0.00300 0.00070Example 999 0.00091 0.00019 Example 1000 0.00215 0.00051 Example 10010.00136 0.00031 Example 1002 0.00175 0.00041 Example 1003 0.004120.00116 Example 1004 0.08356 0.01395 Example 1006 0.00397 0.00114Example 1007 0.00538 0.00114 Example 1008 0.01330 0.00277 Example 10090.01482 0.00263 Example 1010 0.02889 0.00447 Example 1011 0.024470.00381 Example 1012 0.07063 0.01867 Example 1013 0.00979 0.00199Example 1014 0.01277 0.00243 Example 1015 0.02946 0.00497 Example 10160.00227 0.00070 Example 1017 0.00098 0.00035 Example 1018 0.001760.00057 Example 1019 0.00111 0.00038 Example 1020 0.00772 0.00220Example 1021 0.00260 0.00069 Example 1022 0.00149 0.00037 Example 10230.00232 0.00118 Example 1024 0.00510 0.00104 Example 1025 0.012730.00197 Example 1026 0.01294 0.00290 Example 1027 0.00848 0.00179Example 1028 0.00411 0.00160 Example 1029 0.00327 0.00156 Example 10300.00249 0.00091 Example 1031 0.00092 0.00023 Example 1032 0.002750.00076 Example 1033 0.00208 0.00059 Example 1034 0.00159 0.00046Example 1036 0.00054 0.00015 Example 1037 0.00107 0.00030 Example 10380.00286 0.00045 Example 1039 0.00504 0.00096 Example 1040 0.004350.00068 Example 1041 0.00572 0.00074 Example 1042 0.04056 0.00504Example 1043 0.02279 0.00371 Example 1044 0.03061 0.00467 Example 10450.03291 0.00818 Example 1046 0.06840 0.01062 Example 1047 0.003950.00051 Example 1048 0.00155 0.00028 Example 1049 0.00769 0.00114Example 1050 0.00131 0.00026 Example 1051 0.00819 0.00104 Example 10520.00824 0.00148 Example 1053 0.00086 0.00020 Example 1054 0.001180.00033 Example 1055 0.00117 0.00038 Example 1056 0.01118 0.00219Example 1057 0.00412 0.00081 Example 1058 0.01075 0.00177 Example 10590.00384 0.00085 Example 1060 0.00393 0.00095 Example 1061 0.003050.00065 Example 1062 0.00098 0.00025 Example 1063 0.00148 0.00025Example 1064 0.00065 0.00018 Example 1065 0.00053 0.00018 Example 10660.00058 0.00021 Example 1067 0.00060 0.00027 Example 1068 0.000720.00014 Example 1069 0.00264 0.00053 Example 1070 0.00241 0.00073Example 1071 0.00208 0.00086 Example 1072 0.00174 0.00041 Example 10730.00299 0.00055 Example 1074 0.00186 0.00057 Example 1075 0.682240.12035 Example 1076 0.00231 0.00039 Example 1077 0.00085 0.00046Example 1078 0.00067 0.00079 Example 1079 0.00464 0.00117 Example 10800.01286 0.00242 Example 1081 0.00643 0.00201 Example 1082 0.058160.01047 Example 1083 0.03519 0.00540 Example 1084 0.02330 0.00339Example 1085 0.10763 0.02762 Example 1086 0.02068 0.00329 Example 10870.02651 0.00523 Example 1088 0.00406 0.00112 Example 1089 0.071380.02035 Example 1090 0.05109 0.01271 Example 1091 1.11486 0.29498Example 1092 0.03491 0.00506 Example 1093 0.00658 0.00090 Example 10940.00384 0.00082 Example 1095 0.00111 0.00027 Example 1096 0.002000.00045 Example 1097 0.00332 0.00096 Example 1098 0.00575 0.00117Example 1099 0.01883 0.00317 Example 1100 0.00389 0.00068 Example 11010.01370 0.00264 Example 1102 0.00445 0.00085 Example 1103 0.006700.00144 Example 1104 0.00764 0.00143 Example 1105 0.00562 0.00119Example 1106 0.00859 0.00182 Example 1107 0.01345 0.00175 Example 11080.02035 0.00278 Example 1109 0.00802 0.00145 Example 1110 0.004820.00075 Example 1111 0.00209 0.00036 Example 1112 0.00083 0.00024Example 1113 0.00132 0.00037 Example 1114 0.00314 0.00068 Example 11150.00065 0.00019 Example 1116 0.00082 0.00022 Example 1117 0.001310.00030 Example 1118 0.00102 0.00030 Example 1119 0.00200 0.00035Example 1120 0.00163 0.00028 Example 1121 0.00193 0.00026 Example 11220.00331 0.00037 Example 1123 0.01085 0.00134 Example 1124 0.012110.00158 Example 1125 0.01000 0.00093 Example 1126 0.00185 0.00050Example 1127 0.00148 0.00038 Example 1128 0.00216 0.00074 Example 11290.00464 0.00126 Example 1130 0.00224 0.00067 Example 1131 0.002340.00072 Example 1132 0.26960 0.06134 Example 1133 0.00129 0.00030Example 1134 0.00499 0.00082 Example 1135 0.04295 0.00735 Example 11360.00503 0.00058 Example 1137 0.00062 0.00012 Example 1138 0.027780.00476 Example 1139 0.01434 0.00280 Example 1140 0.01345 0.00289Example 1141 0.01574 0.00371 Example 1142 0.00318 0.00110 Example 11430.00181 0.00054 Example 1144 0.00156 0.00046 Example 1145 0.001300.00040 Example 1146 0.00187 0.00032 Example 1147 0.00831 0.00152Example 1148 0.01192 0.00229 Example 1149 0.00313 0.00056 Example 11500.00160 0.00050 Example 1151 0.00060 0.00018 Example 1152 0.001250.00033 Example 1153 0.00215 0.00049 Example 1154 0.00060 0.00012Example 1155 0.00066 0.00014 Example 1156 0.00073 0.00020 Example 11570.00043 0.00009 Example 1158 0.00163 0.00037 Example 1159 0.000750.00015 Example 1160 0.00055 0.00016 Example 1161 0.00150 0.00030Example 1162 0.00038 0.00007 Example 1163 0.00112 0.00020 Example 11640.00057 0.00012 Example 1165 0.00282 0.00072 Example 1166 0.003280.00074 Example 1167 0.00762 0.00212 Example 1168 0.00456 0.00121Example 1169 0.00301 0.00060 Example 1170 0.03744 0.00384 Example 117125.00034 7.68543 Example 1172 25.00034 25.00034 Example 1173 18.594791.92537 Example 1174 25.00034 22.05985 Example 1175 0.08001 0.02036

1. A method of treating a proliferative disease, comprisingadministering to a subject in need thereof a therapeutically effectiveamount of a compound which is

or a pharmaceutically acceptable salt thereof.
 2. The method of claim 1wherein the proliferative disease is a cancer selected from solidtumors, melanoma, breast cancer, non-small cell lung cancer, lungadenocarcinoma, sarcoma, gastrointestinal stromal tumors, ovariancancer, colorectal cancer, thyroid cancer and pancreatic cancer.
 3. Themethod of claim 2 wherein the proliferative disease is melanoma.
 4. Amethod of treating a proliferative disease, comprising administering toa subject in need thereof a therapeutically effective amount of acompound which is

or a pharmaceutically acceptable salt thereof, wherein the proliferativedisease is mediated by B-Raf or C-Raf.
 5. The method of claim 4 whereinthe proliferative disease is a cancer selected from solid tumors,melanoma, breast cancer, non-small cell lung cancer, lungadenocarcinoma, sarcoma, gastrointestinal stromal tumors, ovariancancer, colorectal cancer, thyroid cancer and pancreatic cancer.
 6. Themethod of claim 5 wherein the proliferative disease is melanoma.
 7. Amethod of treating a proliferative disease, comprising administering toa subject in need thereof a therapeutically effective amount of acompound which is

or a pharmaceutically acceptable salt thereof, in combination with oneor more therapeutically active co-agents.
 8. The method of claim 7wherein the one or more therapeutically active co-agents is a RAFpathway inhibitor selected from paclitaxel, docetaxel, temozolomide,platins, doxorubicins, vinblastins, cyclophosphamide, topotecan,gemcitabine, ifosfamide, etoposide and irinotecan.
 9. The method ofclaim 8 wherein the proliferative disease is a cancer selected fromsolid tumors, melanoma, breast cancer, non-small cell lung cancer, lungadenocarcinoma, sarcoma, gastrointestinal stromal tumors, ovariancancer, colorectal cancer, thyroid cancer and pancreatic cancer.
 10. Themethod of claim 9 wherein the proliferative disease is melanoma.